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In the mid-1990s, genetic testing was introduced for two breast and ovarian cancer 
predisposition genes: BRCA1 and BRCA2. For mutation carriers, lifetime risks of breast 
and ovarian cancer approach 90%, and 54%, respectively, versus general population risks 
of 12% and 2%. Women testing positive for mutations during young adulthood face 
numerous challenges related to navigating basic life course tasks, including establishing 
permanent couple relationships, family formation, and risk-management decision-
making. These complex choices require young carriers to balance personal and family 
desires and provider recommendations for health maintenance and disease avoidance 
against their own desires/plans for personal, relationship, and family fulfillment. How 
they accomplish these tasks is significantly influenced by their experiences with cancer in 
close relatives, personal cancer risk assessment, and partner presence and support. 
Although the experience of older carriers and cancer survivors has been thoughtfully 
explored, little attention has been paid to the experiences of younger women.   
Using qualitative methods and grounded theory, I analyzed in-depth interviews 
with forty women aged 18-35 who knew themselves to be BRCA1/2-positive. Participants 
 
were recruited from: 1) an ongoing NCI Clinical Genetics Branch Breast Imaging Study; 
2) the membership of FORCE, an online support network for mutation-positive 
individuals; and 3) snowball sampling, whereby participants referred others whom they 
knew to be mutation-positive. Using a semi-structured, open-ended interview format, 
participants were asked about family relationships and background; couple relationships; 
experiences and perceptions regarding family formation; and experiences and perceptions 
related to utilization of risk management strategies over time (i.e., surveillance, 
chemoprevention, risk-reducing surgery). Questions were developed using sensitizing 
concepts from the biopsychosocial perspective on health and illness and life course 
perspective, as well as attachment and feminist theories. Interviews were conducted by 
telephone, digitally recorded and transcribed, and analyzed using QSR N-Vivo software, 
version 8. The data-driven model indicates that risk perception and management 
decisions are closely tied to family and couple relationship experiences. Young mutation 
carriers aggressively and courageously utilize agency to alter their life trajectories while 
minimizing sacrifice to their family and relationship ideals, thereby freeing themselves 
from mutation-related emotional and physical constraints, and regaining control over 
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CHAPTER 1: INTRODUCTION 
Mutations in BRCA1 and BRCA2 predispose carriers to increased risk of 
developing both breast (50-85% lifetime risk) and ovarian cancer (11-54% lifetime risk) 
(Antoniou et al., 2003; Brose et al., 2002; M. C. King, Marks, & Mandell, 2003; Suthers, 
2007); the corresponding risks in the general population are 12.8% and 1.5%, 
respectively (DevCan, 2005; Fay, 2004; Fay, Pfeiffer, Cronin, Le, & Feuer, 2003). 
Individuals with mutations in BRCA1 and BRCA2 comprise a small but notable 
proportion of all breast and ovarian cases, about seven in 100 cases of breast cancer in 
women with a family history (Ford, Easton, & Petro, 1995) and approximately 10% of all 
ovarian cancer cases, with more of these resulting from BRCA1 (about 5.7%) than 
BRCA2 (about 3.8%) (Boyd, 2003; Claus, Schildkraut, Thompson, & Risch, 1996; 
Pavelka, Li, & Karlan, 2007; Prat, Ribe, & Gallardo, 2005). However, the proportion of 
cancer cases in young women attributable to mutations in BRCA1/2 paints a very 
different picture: these mutations explain  
approximately 33% of [breast cancer] cases age 20-29 years compared with 
approximately 2% of cases age 70-79 years. The proportion of ovarian cancer 
cases predicted to be due to the susceptibility gene ranges from 14% among 
patients diagnosed in their 30s to 7% among those diagnosed in their 50s (Claus et 
al., 1996, p. 2318).   
 
The prevalence of BRCA mutations in the general population is quite low; for 
example, the gene frequency of BRCA1 as been estimated to be between 0.0006 (Ford et 
al., 1995) and 0.002 (Struewing, Lerman, Kase, Giambarresi, & Tucker, 1995); exact 
population prevalence for these genes is difficult to determine because widespread 
screening is impractical (Brody & Biesecker, 1998). While the overall carrier frequency 
for BRCA mutations is thought to be about 1 in 280, it is significantly higher in several 
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distinct populations. In the Ashkenazi Jewish population, carrier frequencies of 
approximately 1 in 40 are attributed to the prevalence of three founder mutations, two in 
BRCA1 and one in BRCA2 (Boyd, 2003). Additionally, among native Icelanders, about 
0.4% of the general population carries a specific mutation in BRCA2 (Johannesdottir et 
al., 1996). Further information regarding the historical and biological background of the 
BRCA1/2 mutations can be found in Appendix A. 
Strategies available to BRCA1/2 mutation carriers to mitigate risk include 
intensive cancer screening, chemoprevention, and risk-reducing surgery (prophylactic 
mastectomy and/or salpingo-oophorectomy) (ACS, 2007; Babb et al., 2002; Eisinger et 
al., 1997; Foster et al., 2002). These strategies vary in the extent to which they are 
effective, physically and emotionally acceptable to women at high genetic risk of cancer, 
and practical at various life-course stages. For example, with regard to ovarian cancer, 
women who have not completed childbearing and wish to have biological children are 
not candidates for risk-reducing salpingo-oophorectomy, but relying on screening 
(generally regarded as ineffective) may leave them susceptible to uncertainty and 
continued vulnerability. Carriers must also consider the risk of passing the BRCA 
mutation to their future children. BRCA1/2 are passed from parent to offspring in an 
autosomal dominant pattern; each offspring (of either sex) has a 50% chance of inheriting 
an abnormal copy of the gene from the parent (of either sex) who carries the mutation. 
Consequently, female BRCA1/2 mutation carriers may face cancer-related distress 
including worry and anxiety (Watson et al., 1999), and may have both acute and chronic 
needs related to informational, tangible, and emotional support (Appleton, Fry, Rees, 
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Rush, & Cull, 2000; Babb et al., 2002; Kenen & Peters, 2001; Koehly et al., 2008; Peters, 
Hoskins, Prindiville, Kenen, & Greene, 2006). 
These latter issues have been extensively explored, as have the bidirectional 
influences between marriage and the mutation positive experience in women of middle 
age (Manne, Audrain, Schwartz, Finch, & Lerman, 2004), and between marriage and the 
breast cancer experience of women in the same age cohort (Dorval et al., 2005; Osborne, 
Ostir, Du, Peek, & Goodwin, 2005). However, less attention has been paid to the personal 
and relationship implications of living with increased genetic risk of breast and ovarian 
cancer in early adulthood. Young female BRCA1/2 carriers face unique challenges vis-à-
vis informing partners of their risk status as new relationships develop, because they are 
less likely to be in stable relationships or to have completed childbearing when they 
undergo genetic testing (Oktay & Walter, 1991). An early literature review revealed only 
a single publication regarding the impact of being a BRCA1/2 mutation carrier on couple 
relationships (Werner-Lin, 2007); since then, additional research has elucidated the 
complex manner in which the mutation disclosure process occurs in young couples 
(Hoskins, Roy, Peters, Loud, & Greene, 2008). We still do not fully understand how 
young BRCA1/2-positive women and their partners reconcile their mutation status within 
their couple relationship over time, or how partners effectively provide support to these 
women through the myriad stressors that accompany the mutation-positive experience.   
Further, there has been little research regarding how young women living with 
increased breast/ovarian cancer risk reconcile their risk status with their plans and 
decisions regarding family formation. Werner-Lin (2008) observed a “great sense of 
urgency” (p. 428) in a group of 11 women aged 22-35 who were planning to start or 
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expand their families, largely related to their desire to have risk-reducing surgeries as 
early as possible. Young female BRCA1/2-mutation carriers may be faced with difficult 
dilemmas when, for example, their plans for having biological children are in conflict 
with physicians’ recommendations regarding the timing of pregnancies and risk-reducing 
surgeries, or when their desire to breastfeed their biological children is at odds with a 
desire or perceived need to undergo risk-reducing mastectomy (unpublished data). To 
what extent do mutation-positive women consider making use of alternatives to “natural” 
biological family formation (e.g., adoption, gamete donation, surrogacy), and what 
factors are involved in these decisions? What determines whether and how mutation-
positive women alter their plans with regard to family formation as a result of their 
knowledge of their mutation status? 
Finally, young mutation carriers face unique challenges with regard to decision-
making about risk management and/or reduction. There are significant psychological and 
physical ramifications of some risk-reduction options, and the impact of these procedures 
on young women is often very different from the impact on women in middle age. For 
example, electing to undergo risk-reducing removal of the ovaries brings about full and 
immediate menopause; doing this at age 50 would seem relatively “on time” and 
normative, while commencing menopause in one’s thirties might present challenges with 
regard to sexuality, body image, and grieving the early loss of fertility potential. 
Similarly, choosing to undergo risk-reducing prophylactic mastectomy challenges women 
and their current and/or future partners to grieve the loss of their natural breasts and the 
inherent capabilities therein; to cope with the often challenging process of surgery, 
recovery, and reconstruction; and to reacquaint themselves with their altered bodies. How 
 
 5
do women think and decide about risk-reducing surgery? How does the prospect of risk-
reducing surgery impact young mutation carriers psychologically and emotionally? How 
do they and their partners cope with this stressor as a couple unit? What is the experience 
of young female mutation carriers who are not yet in couple relationships and/or choose 
not to be?  
The current study is an attempt to elucidate this understudied area and contribute 
to our understanding of the lived experiences of women who are aware of their positive 
BRCA1/2 mutation status during young adulthood. These qualitative findings can 
contribute to the knowledge of medical, mental health, and other healthcare providers 
who work with these women throughout the mutation-positive experience, from pre-
testing through surgery and beyond, and assist them in better preparing women to 
successfully cope with the challenges and struggles they may face. 
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CHAPTER 2: REVIEW OF THE LITERATURE 
Psychosocial Issues in Breast/Ovarian Cancer Predisposition 
Cancer pre-vivorship as a newly legitimate health status. Advancements in 
medical technology have resulted in the recognition of “at-risk” as a legitimate health 
status warranting both medical and research attention. The availability of genetic testing 
and personal cancer risk assessment, combined with media reports lauding the benefits of 
genetic testing (H. T. Lynch & Lynch, 1999) has resulted in increased awareness among 
physicians and demand among consumers for testing of individuals and families with 
significant histories of cancer (Bottorff, Ratner, Johnson, & McCullum, 2000). As a 
result, there now exists a growing population of women who have never been diagnosed 
with cancer, but are aware of their own very high risk of developing breast, ovarian, and 
other cancers during their lifetime, due to an inherited mutation in BRCA1/2. These 
women are now part of an ever-expanding group of individuals who have already 
struggled with a sometimes difficult decision regarding testing, experienced a potentially 
stressful and complicated genetic testing and mutation test result disclosure, and may be 
coping with a variety of psychosocial and relational issues as a direct result of their 
membership in hereditary breast/ovarian cancer (HBOC) families and their individual 
decisions to learn their mutation statuses. For an expanded review of these complex 
issues, please refer to Appendix B. 
In an effort to highlight the unique characteristics and needs of this cancer-
unaffected, mutation-positive population, the Facing Our Risk of Cancer Empowered 
(FORCE), an online support network for BRCA1/2-positive women, has coined the term 
“cancer Pre-Vivor,” (FORCE, 2005). This term is meant to represent individuals who are 
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survivors of a predisposition to cancer. In the decade since genetic testing for BRCA1/2 
mutations became available and began to be used by members of high-risk families, a 
great deal of clinical and research energy has been focused on this group, but only a small 
subset of this research is psychosocial. Research has largely focused on the individual, 
has been largely quantitative in nature, and has targeted women in their forties and fifties. 
There is a noticeable absence of research focusing on the lived experiences of young pre-
vivors, who face an altogether different set of challenges related to their high-risk status.   
Breast and ovarian cancer risk-perception. Much of the psychosocial research 
that has been focused on women in HBOC families has examined cancer risk perception, 
and multiple studies have demonstrated that an individual’s perceived risk, rather than 
objective scientific risk, plays a significant role in decision-making regarding genetic 
testing, screening and prevention options, and other BRCA1/2-related issues. Perceived 
risk also plays a large role in the psychological ramifications of those decisions (Absetz, 
Aro, & Sutton, 2003; French, Kurczynski, Weaver, & Pituch, 1992; Klein & Stefanek, 
2007; Price, Butow, Lo, Wilson, & KConFab, 2007; Schwartz, Lerman, Miller, Daly, & 
Masny, 1995; Smerecnik, Mesters, Verweij, de Vries, & de Vries, 2009). High levels of 
cancer worry are associated with increased anxiety, depression, general emotional 
distress, family distress, and impaired role functioning for women in high-risk families 
(Audrain et al., 1997; Baider, Ever-Hadani, & Kaplan De-Nour, 1999; Lerman, Rimer, & 
Engstrom, 1991; Trask et al., 2001; Van Oostrom et al., 2003). Accurate risk perception 
is essential for women making potentially life-altering decisions regarding their breast 
and ovarian health (Hopwood, Howell, Lalloo, & Evans, 2003), and those with inaccurate 
risk perceptions may be more likely to have difficulty using empirical risk information to 
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guide decision-making regarding risk management and reduction (Kelly et al., 2005). 
Further, women with high levels of cancer risk perception may continue to experience 
negative emotional, psychological, and relationship implications of high risk perception 
even after completion of counseling, testing, and risk-reducing surgery (Lerman et al., 
1998; Lodder et al., 2001; Van Oostrom et al., 2003). 
Although several instruments, including the Claus Model, BRCAPRO, Gail 
Model, and Myriad II, have been developed to calculate scientific cancer risk based on 
family history and presence of a genetic mutation (Berry, Parmigiani, Sanchez, 
Schildkraut, & Winer, 1997; Claus, Risch, & Thompson, 1994; Pavelka, Li, & Karlan, 
2007), and although genetic counselors and other health professionals interacting with 
high-risk women use these instruments and collective knowledge about genetic risk to 
communicate scientific risk to patients, research indicates that women are commonly 
unsure about their scientific risk and/or perceive their cancer risk to be different from 
what any of these instruments would calculate (Hopwood et al., 2003). Prior to genetic 
counseling and testing, women with family histories of cancer commonly describe their 
cancer risk as above-average to high (Hopwood et al., 2003); this is consistent with 
research suggesting that individuals with family histories of cancer tend to overestimate 
their own cancer risk (Andrykowski, Munn, & Studts, 1999; Croyle & Lerman, 1993; 
Struewing et al., 1995). It is striking that fully 76% of women with family histories of 
breast and ovarian cancer (most of whom are not mutation carriers) report that they 
perceived themselves to be at significantly higher risk of cancer than women in the 
general population, and 20% of them perceived cancer as inevitable (Hallowell, Statham, 
& Murton, 1998).  
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Further, many women subscribe to relatively simple and/or illogical explanations 
about risk, such as describing risk as “fifty-fifty,” or as connected to “bad luck,” (Bottorff 
et al., 2000). Conversion of objective risk figures into categorical terms such as high/low 
or likely/unlikely has been identified as a primary way that genetic counselees simplify 
their understanding of risk by interpreting it in binary form (Lippman-Hand & Fraser, 
1979), allowing them to “mentally construct the worst-case scenario of the risk event 
occurring, and gauge the acceptability of this to themselves,” (Pilarski, 2009, p. 304). 
The extent to which individuals’ risk estimations approach actual risk after 
genetic counseling varies with method of communication and several other factors. 
Moreover, the communication of risk information is complex and involves multiple 
distinct but related pieces of information, such as lifetime risk, levels of risk that change 
with age, separate risks for different cancer sites, etc. (Hopwood et al., 2003). 
Understanding of perceived risk is vitally important because “across all genetic-testing 
domains…participants’ decisions about testing are influenced less by their actual risk 
than by subjective risk and emotional factors,” (Lerman, Croyle, Tercyak, & Hamann, 
2002, p. 792). The presence of cancer-specific worry and distress is associated with 
motivation for test use (Durfy, Bowen, McTiernan, Sporleder, & Burke, 1999; Lerman et 
al., 1997; Vernon et al., 1999), while general distress seems to reduce the likelihood of 
testing for cancer susceptibility genes (Lerman et al., 1999). 
 The common sense model “posits that individuals’ understanding of illness is 
based upon somatic symptoms and life experiences and thus may differ significantly from 
the biomedical view of illness,” (Kelly et al., 2005, p. 34). In a recent study of women at 
potentially increased risk of breast/ovarian cancer, participants indicated that their 
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perceptions of their own cancer risk were based on their understanding of the causes of 
cancer, their ability to control or cure cancer by having surgery or changing behaviors, 
and the timeline on which cancer would occur in their lifetime. The researchers argue that 
in order to better understand perceived risk and bring it in line with actual risk, genetic 
counselors and other health professionals working with high-risk women must understand 
these variables and how they fit together in the minds of women at risk (Kelly et al., 
2005). A brief review of relevant variables includes age, family cancer history, and 
personal and family myths regarding family cancer history. 
Age. Various studies have confirmed or failed to confirm the existence of an 
association between age and breast/ovarian cancer risk perception. Scientifically, cancer 
risk at both sites does increase with age (NCI, 2006, 2009) and most carriers are aware of 
this widely known fact. A study of women with significant family histories of breast 
cancer who had not yet undergone genetic testing found that older women were more 
likely to overestimate their risk (Cull et al., 1999). However, in families where breast and 
ovarian cancer are common experiences, age-related risk takes on a secondary meaning 
because individuals often associate the specific ages at which loved ones were diagnosed 
with increased risk for themselves. While simple numerical age is not always a reliable 
predictor of one’s risk perception, there is an important relationship between age and the 
awareness, fear, and worry that comes along with it, especially when at-risk women are 
acutely aware of the age at which a loved one or loved ones were diagnosed with cancer. 
Werner-Lin (2007) reported that many participants in her qualitative study of young 
BRCA mutation carriers “believed that [their] path toward cancer would mirror those of 
family members who had traveled the road before them,” (p. 342). Studies utilizing both 
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American and British samples have reported that feelings of fear, worry, and 
vulnerability increase as this age approaches for high-risk women, and that once that age 
passed the feelings would gradually subside (Appleton, Fry, Rees, Rush, & Cull, 2000; 
d'Agincourt-Canning, 2005; Werner-Lin, 2007). 
Family illness narratives. At base, the way that members of a family collectively 
understand and discuss their cancer risk is based on their knowledge of what has occurred 
in other members of their families. Thus, family breast and ovarian cancer history 
describes the set of known information about biological relatives that applies to BRCA-
related cancers. The extent to which an individual is familiar with his/her family cancer 
history is determined by levels of communication within the family group, social and 
demographic variables that determine whether or not s/he has had contact with family 
members on the relevant side of the family, and whether or not members of previous 
generations lived long enough that a natural history can be understood. 
The narratives that families develop around their understanding of cancer risk 
may be more important than the hard facts surrounding examples of cancer in the family. 
As BRCA-related cancers move through families from generation to generation, a 
powerful shared history emerges that impacts each member of that family (Rolland, 
2005). Negative images of cancer are commonly held by healthy family members as well 
as those who are personally affected by disease (Die-Trill, 2000). This shared history 
influences individuals’ current behavior and responses to new BRCA-related stressors, 
which are associated with organizational shifts and coping strategies utilized within the 
family group (Rolland, 2005). Meanings attached to illness may also directly affect 
quality of life, individual and family system-level psychological responses, and 
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interpersonal relationships throughout the pre-cancer and cancer experiences (Die-Trill, 
2000).  
Research indicates that women take family experiences with cancer, including the 
number of affected individuals, positive and negative cancer experiences, and 
interpersonal relationships with affected family members, into account in evaluating their 
own risk and making decisions about management (Kenen, Arden-Jones, & Eeles, 2003). 
Family cancer history and experience, then, is a lens through which women in high-risk 
families examine and integrate the new genetic information they receive (Emery, Kumar, 
& Smith, 1998; Mellon, Berry-Bobovski, Gold, Levin, & Tainsky, 2006). Daughters of 
breast/ovarian cancer patients who experienced their mothers’ cancer during adolescence, 
and especially daughters of women who had poor prognoses or who died as a result of 
cancer, are particularly vulnerable to high levels of cancer-related stress (Wellisch, Gritz, 
Schain, Wang, & Siam, 1992). It has been proposed that these unique challenges, 
including phobia about one’s own breasts and inability to view breasts as sexual, are 
related to the experience of puberty and breast development during the period in which 
one’s mother was experiencing and perhaps dying from breast cancer (Wellisch & 
Lindberg, 2000). In addition, women of any age who are currently dealing with cancer in 
another family member (e.g., they have recently lost a relative to cancer, have a relative 
in treatment for cancer ) are vulnerable, as they may be actively grieving and/or may 
identify more strongly with the cancer experience (Dudok de Wit et al., 1994).   
In communicating risk information to individuals with significant family histories 
of cancer, the meaning attributed to risk is impacted by both social and familial meanings 
that act together to create causal schemas in the minds of individuals (Bottorff et al., 
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2000). That is, regardless of the quality of risk information received in the healthcare 
setting, personal experiences relevant to the family history contribute to the formulation 
of a ‘fixed’ understanding of personal risk (Bottorff et al., 2000), creating a barrier in 
understanding and assimilating objective risk information (d'Agincourt-Canning, 2005). 
This is consistent with other research indicating that family cancer history is salient in 
constructing a personally meaningful explanation of one’s own level of risk (Geller et al., 
1997; McAllister, 2003). Feelings of vulnerability to cancer based on family history and 
family illness narratives shape attitudes toward behaviors that may mitigate risk, such as 
genetic testing and breast and ovarian screening (d'Agincourt-Canning, 2005). Risk 
perception is then related to the manner in which some mutation carriers create meaning 
regarding their positive mutation status and communicate with significant others, 
including partners and children (if applicable), in their lives. Breast and ovarian cancer 
risk perception is also brought to bear on women’s decision-making with regard to family 
formation and cancer risk-reduction strategies over the life course (Hoskins et al., 2008). 
In terms of a family’s handling of the stress of this shared history, maladaptive 
management of cancer-related stressors and issues may lead to an increased sense of 
vulnerability to cancer, or heightened perceived cancer risk; conversely, healthy and 
functional family coping may lend to a sense that cancer is conquerable and lower 
perceived cancer risk (Rolland, 2005). These dynamics are fluid and likely to shift over 
time as the family cancer experience continues to develop. 
Individual and family myths. Individuals and families often construct stories to 
help organize their illness experience, especially in the face of insufficient medical 
knowledge or understanding (Die-Trill, 2000; Rolland, 2005). It has been proposed that 
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such stories emerge as a result of a cultural emphasis on understanding cause and effect, 
of having a logical explanation for an event that threatens or modifies one’s status; 
further, they may fulfill a need to recover basic assumptions about life that are threatened 
by the cancer experience (Kelley, 1971). These can be shared by multiple members of a 
family system or can vary from person to person, and can have significant bearing on 
individuals’ perceptions of their risk both for being a mutation carrier and for developing 
cancer (Rolland, 2005), for decision-making with regard to prevention and treatment, for 
emotional and psychological responses, and for interpersonal relationships.  
In some cases, causal explanations of illness or high-risk status can be quite 
irrational (Die-Trill, 2000). These beliefs may be based on ideas about punishment for 
prior misdeeds committed by the affected individual or by another family member, about 
justice versus injustice, about stress, life decisions (e.g., having too many or no children), 
other physical factors, religion, heredity, homosexuality, lifestyle, or luck (Die-Trill, 
2000). Individuals have reported beliefs about the outcome of genetic testing based on 
variables such as having achieved a certain age without being diagnosed with cancer 
(e.g., “I’m 50 and I figure if I haven’t gotten it by now, I probably won’t”) and about 
having been diagnosed with another serious disease or illness (e.g., “I’m already facing 
diabetes, and I just don’t think both diabetes and cancer would happen to me”). Family 
myths and beliefs that influence one’s perceived risk of mutation-positive status and 
cancer include being raised to believe that one would eventually develop cancer and 
believing that one would inherit a cancer-predisposing mutation from a parent because 
they were physically similar to that parent (e.g., “I look like my dad, and he has the 
mutation, so I figure I will have it, too,”) (H. T. Lynch et al., 1997).   
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 These beliefs are not based in any medical fact or healthcare provider’s advice. 
Still, they may provide comfort to an individual or group of individuals within a family. 
Some family beliefs and stories may be adaptive when they “[promote] the flexible use of 
multiple biologic and psychosocial healing strategies” (Rolland, 2005, p. 2592). 
However, these beliefs may also facilitate living in denial about the actual presence of 
risk. These beliefs can also be problematic when they contribute to individual and family 
pathology by focusing on blame, shame, or guilt and therefore inhibit coping and 
adaptation (Rolland, 2005). Further, attributions that are internal have been associated 
with maladaptive coping with illness-related stressors, whereas external attributions or a 
belief that the causes of illness are unknown are more often associated with facilitative 
coping (Bearison, Sadow, Granowetter, & Winkel, 1993). 
Use of stress & coping theory in psychosocial research on HBOC. Much of the 
psychosocial research previously undertaken to examine the experiences of BRCA 
mutation carriers has used the Stress & Coping theory (Lazarus & Folkman, 1984). A 
brief review of this theory and its use with this population is appropriate because of its 
extensiveness in the current literature; however, as the stress and coping model is not the 
primary focus of the current project, it should not be considered a component of the 
project’s theoretical background. Rather, I have used a more finely-tailored theoretical 
foundation to explicitly examine the experiences of young mutation carriers.   
Briefly, stress and coping theory posits that one’s ability to cope with a threat is 
related the internal and external resources that are available to an individual (Dagan & 
Gil, 2004), including social support; and psychological and behavioral coping skills. 
Social support may be instrumental, in the form of “advice, assistance, or information,”; 
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or it may be emotional, including “moral support, sympathy, or understanding,” (Carver, 
Scheier, & Kumari Weintraub, 1989, p. 269) from close others. Although they are 
identified as separate types of support provision, it should be noted that seeking/receiving 
informational and emotional support often co-occur in practice. Receiving either type of 
support may have both positive and negative consequences. Seeking instrumental support 
can be effective when it successfully meets the informational needs of the requestor, but 
may be ineffective (even though the requestor may not realize this) if the information 
given is inaccurate, biased, or otherwise not of high quality (Carver et al., 1989). When 
effective, emotional support can help to reassure an individual and to alleviate the burden 
of a stressor, but there is also a risk that an emotionally supportive dynamic can develop 
into an outlet for venting one’s feelings, which may be counter-adaptive when it 
continues long-term and impedes adjustment (Carver et al., 1989). 
 In many ways, female members of HBOC families are uniquely qualified to 
provide both informational and emotional support to young women in various stages of 
the BRCA1/2-positive experience because they can easily empathize and can share the 
knowledge they have gained through their own processes. However, several distinct 
characteristics of HBOC families may impinge upon members’ ability to effectively 
provide support for loved ones experiencing BRCA1/2-related stressors. For example, in 
watching their younger female family members cope with the grief, fear, uncertainty and 
ambiguity that may accompany a positive mutation test result, members of older 
generations within a family may experience intense feelings of guilt for having passed a 
mutation on to a loved one, making it difficult for them to serve as sources of support. 
Furthermore, the presence of multiple cases of cancer within the family may place 
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unrealistic support demands on the family in general. At a time when there are perhaps 
several active cancer cases, unaffected mutation carriers may find it difficult to ask for or 
receive the attention they need, because the family’s support energy is being focused 
elsewhere and/or because the individuals that would otherwise be relied on for support 
are themselves coping with cancer (Dagan & Gil, 2004).  
 Findings from studies investigating the association between partner relationships 
and experiences with illness are relevant to the current study because, although BRCA1/2-
positive women are not currently ill, they are still faced with a number of unique stressors 
regarding their physical health. Like chronically ill patients, BRCA1/2-positive women 
may experience frustration about the unpredictable nature of their situation, as well as 
fears about the future (Revenson & Majerovitz, 1990). In studies related to various health 
concerns (e.g., lupus, cancer, diabetes, heart conditions) (Fekete, Parris Stephens, 
Mickelson, & Druley, 2007; Trief et al., 2003), high-quality partner support has been 
identified as having positive effects on individuals’ physical, psychological, and overall 
well-being during periods of increased stress caused by illness (Burman & Margolin, 
1992; Fekete et al., 2007; Trief et al., 2003). Specifically, having a partner has also been 
consistently associated with lower levels of distress among women at high genetic risk of 
breast and ovarian cancer and is likely associated with the increased availability of social 
and emotional support for couple members (Audrain et al., 1997; Baider, Ever-Hadani, & 
Kaplan De-Nour, 1999). The couples with the highest levels of well-being, marital 
satisfaction, and illness adjustment in the face of chronic health concerns are those who 
can effectively reciprocate each other’s support efforts (Manne et al., 2004).   
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 With regard to the experience of living with increased genetic risk of cancer in the 
context of a couple relationship, very little specific research exists. However, there is 
evidence that couples who experience high levels of distress prior to a cancer diagnosis 
are more likely to experience problems during the active phase of the disease (Northouse, 
Templin, Mood, & Oberst, 1998), and relationship distress prior to genetic counseling 
predicts higher levels of distress both during and after the counseling process (Dudok de 
Wit, Duivenvoorden, Passchier, Niermeijer, & Tibben, 1998). 
Coping with BRCA-related stressors. Various studies have highlighted a 
number of coping strategies utilized by women at high genetic risk of breast/ovarian 
cancer. A group of Scottish women who participated in a telephone focus group reported 
that they purposely shifted their focus to the present, avoided worrying about breast 
cancer cues, and thought positively about their situation by adopting an optimistic 
attitude about the future. They also reported a purposeful reassessment of their lives and 
priorities, taking on an attitude that they should maximize the potential for fullness in life 
and make their health a greater priority. They discussed the adoption of a “one-day-at-a-
time” approach, which prevented them from becoming overwhelmed by thinking about 
the negative experiences that might occur over time; this approach was also described as 
a method of combating persistent worry, varying from mild to intrusive. They engaged in 
excessive reassurance seeking from doctors, family, etc. in times of acute anxiety, in an 
apparent attempt to mitigate that emotion. They adopted significant lifestyle changes such 
as healthier diets, increasing frequency or intensity of exercise, stopping smoking, use of 
natural or herbal remedies, and various forms of stress management. They strived to pass 
along these healthier habits to other members of their family, particularly members of the 
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younger generation. These behaviors were seen as giving women some sense of control 
over their increased risk. With regard to screening, some women in this study became 
increasingly vigilant about performing breast self-exams in an effort to maximize their 
awareness of their breast tissue and health; however, others moved in the opposite 
direction, purposely avoiding breast self-exams to avoid the discomfort and anxiety 
associated with the behavior (Appleton et al., 2000).  
Denial, characterized by a refusal to acknowledge or believe that the stressor 
exists or acting as though it does not (Carver et al., 1989), is another psychological 
coping strategy, and may be effective in that it can facilitate coping if it minimizes 
distress (Appleton et al., 2000) and therefore allow the individual to shift his/her internal 
energy toward information processing and decision-making (Decruyenaere, Evers-
Kiebooms, Welkenhuysen, Denayer, & Claes, 2000). However, it may also exacerbate 
problems in the long-term if they are ignored rather than effectively dealt with and/or 
resolved (Carver et al., 1989), or if denial behavior prohibits the appropriate acquisition 
of information or prudent screening practices (Decruyenaere et al., 2000). In the context 
of a BRCA1/2-positive women, denial may be an effective coping mechanism during 
one’s late teens and early twenties if it allows her to live her life as “normal” during this 
period of relatively low risk; however, if denial behavior continues into one’s thirties and 
forties and results in failure to participate in appropriate screening and prevention 
behaviors, it may certainly be considered maladaptive and risky. To a lesser extent, 
minimization and disengagement may result in outcomes similar to those of denial. Some 
individuals may attempt to cope with distress by convincing themselves that a problem is 
not as bad as it really is (Decruyenaere et al., 2000). It is common for the need for and 
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chosen method of coping to vary based one’s level of engagement, in this case, the 
degree of cognitive and emotional involvement with one’s increased risk of developing 
cancer (McAllister, 2003). In fact, disengagement may be a result of intense emotional 
pain experienced as a result of previous engagement (McAllister, 2003), and can be 
interpreted as a method of avoidance. 
At the other end of the spectrum from denial and disengagement is acceptance, 
which may occur more frequently in response to stressors that cannot realistically be 
eliminated (Carver et al., 1989), such as carrying a BRCA1/2 mutation. Acceptance may 
also be, in some cases, a step along the route toward active behavioral coping (Carver et 
al., 1989). Finally, for BRCA-positive women, turning to religion, may be a “vehicle for 
positive reinterpretation or growth, or…a tactic of active coping with a stressor,” (Carver 
et al., 1989, p. 270). One might engage in prayer, ask others to pray about a certain topic, 
or seek comfort in passages from a religious document, among other religiously-based 
coping strategies. Given the variability in individual religious beliefs and importance of 
spirituality, it seems obvious that different people will utilize this coping strategy to 
varying degrees.   
 Some women describe seeking social support for instrumental reasons, such as for 
information, advice, or assistance in dealing with the specific demands that come along 
with a stressor (Carver et al., 1989). Women in HBOC families may ask health 
professionals for breast/ovarian cancer information, ask friends or family members to 
accompany them to doctor or mammography appointments, or ask family members for 
their opinion about BRCA1/2-related decisions. Seeking and possessing knowledge and 
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information about one’s risk status and the ramifications thereof was an oft-discussed 
topic in Appleton’s study. Specifically,  
The women commonly expressed a need for specific types of information, 
particularly up-to-date, professionally approved, detailed information on a variety 
of topics including the clinical services available (particularly genetic testing), 
scientific research (concerning breast cancer treatments, current trials and 
genetics), preventive measures (such as diet), hormone replacement therapy, the 
oral contraceptive pill and stress management, (Appleton et al., 2000, p. 517).  
 
Some of the women in that study reported that having information about their mutation 
helped them cope because they felt more able to make informed decisions about risk 
reduction and prevention, thereby decreasing anxiety; others reported that having more 
information actually added to their feelings of anxiety and distress; others sought a 
balance between having an appropriate level of knowledge to be adequately informed, 
and not getting so much so as to become overwhelmed (Appleton et al., 2000). 
Life-Course Challenges Faced by Young BRCA1/2-Positive Women  
Although the information provided by these studies is both interesting and 
informative regarding the experience of BRCA mutation carriers as a whole, it was 
collected from samples with a broad range of ages and therefore does not provide a 
focused perspective on the experiences of young carriers. Women who are aware of their 
positive mutation status during young adulthood face normative life course challenges 
that set them apart from older mutation carriers. Specifically, their positive mutation 
status may shape the manner in which they navigate couple relationships and family 
formation, and each of these may be related to women’s decision-making about use of 
risk-management and/or risk-reduction options. 
Establishing and maintaining couple relationships. Although psychosocial 
research in cancer is starting to explore issues related to couple relationships during and 
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after cancer, very few studies have examined the experiences of young adult women 
living with increased hereditary risk of cancer. Women’s experiences in dating, courtship, 
and early marriage may be profoundly shaped by the presence of a mutation in BRCA1/2, 
which may force them to consider issues related to family formation and their own 
mortality much earlier than their mutation-negative peers, putting unique stressors on 
developing couple relationships. In the limited research that has been undertaken on this 
topic, there exists some evidence that the mutation-positive experience is a relevant 
consideration in terms of context for development of early couple relationships. Women 
seeking genetic counseling and/or medical advice in research settings in which 
psychosocial issues were also attended to have reported feeling reluctant to get involved 
in relationships or attached to potential partners for fear that they will ultimately suffer 
and inflict a loss on those partners (Wellisch & Lindberg, 2000). This phenomenon, 
termed life truncation syndrome, is characterized by a seeming inability to allow life to 
progress around common commitments of adulthood, including leaving the parents’ 
home, formation of a permanent couple relationship, and forming one’s own family 
(Wellisch & Lindberg, 2000) and has been observed with varying degrees of severity in a 
number of young, high-risk women.  
Prior to developing this dissertation proposal, a qualitative pilot study was 
undertaken to explore the feasibility of conducting a large-scale qualitative dissertation 
research project focused on the experiences of young BRCA1/2-positive women (Hoskins 
et al., 2008). The results of that study provided significant insight regarding how young 
pre-marital couples and those who are newly married communicate regarding the health 
threat that accompanies a positive BRCA1/2-mutation status. Findings indicated that 
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young women in pre-marital and non-marital relationships who were aware of having a 
BRCA1/2 mutation experienced significant anxiety regarding communicating their risk 
status to their romantic partners. Some women imagined negative relationship outcomes 
resulting from such communication, and these negative experiences were a reality for a 
few. However, the majority of respondents in the pilot study reported that disclosure of 
their high-risk status to their partners was a positive experience that resulted in increased 
emotional intimacy. Further research is needed to increase our understanding of how the 
presence of a BRCA1/2 mutation continues to impact these couples over time as they 
move toward relationship permanence and confront other issues at that stage of the life 
course. In addition, knowledge about how women handle communication about their 
mutations with successive partners when early pre-marital relationships come to an end 
should be expanded through further research.   
Buried deep within the larger issue of genetic discrimination is a very subtle form 
of discrimination whereby a BRCA1/2 carrier “may find herself less welcome as a 
possible wife,” (Surbone, 2001, p. 155). This concept was confirmed by our pilot study, 
which demonstrated that although sharing information about BRCA1/2 mutations has the 
potential to bond members of young couples more closely together, it also caused tension 
and anxiety for young mutation-positive women and for their partners. Young women 
reported that they worried about being viewed differently by a partner who finds out 
about their mutation, and that some spent significant time and energy thinking about 
when and how to broach this subject in the context of a new relationship. Women also 
reported that they held specific ideals regarding how their partners should react, and 
responses outside of this ideal range were experienced as negative. That is, women 
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expected their partners to respond to the news of the mutation with enough anxiety to 
demonstrate care and concern, but not so much as to increase the women’s own anxiety 
(Hoskins et al., 2008).   
Couple dynamics with regard to communication and integration of the mutation-
positive experience into the couple relationship appear to be related to women’s cancer 
risk perception and to attachment. The familial cancer experiences that underlie high 
levels of perceived breast and ovarian cancer risk of BRCA1/2-positive women may 
contribute to attachment difficulties that make disclosure about risk to partners difficult. 
In my experience working with women from HBOC families in the CGB clinic, the 
concepts comprising attachment theory seemed particularly salient with regard to how 
BRCA1/2-positive women integrate family cancer experiences with their current methods 
of coping and communicating about cancer risk.  
Family formation. That reproductive choices may be affected by the presence of 
a BRCA1/2 mutation is widely accepted among those who study individuals and families 
at high genetic risk of cancer (Coughlin, Khoury, & Steinberg, 1999). Just as 
discrimination at the interpersonal level may lead to a woman being perceived as a less 
desirable partner, so too might this type of discrimination limit her options for 
childbearing (Surbone, 2001). Further, one’s desire to conform to societal, family, and 
relationship expectations regarding how and when family formation will occur may lead 
to stress in light of the challenges posed by positive BRCA1/2 status. Individuals may 
experience a mismatch in the roles of “mutation carrier” and “parent” when the demands 
of one role run counter to the demands of the other. For example, a woman may have to 
make difficult decisions regarding risk-reduction options at a time when she feels 
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committed to retaining fertility. The use of oral contraceptives (OCPs) is associated with 
a ~50% reduction in ovarian cancer risk (McLaughlin et al., 2007) (this is discussed in 
more detail in the chemoprevention section). If chemo-prevention via the use of OCPs 
was her chosen method of ovarian cancer risk-reduction during the pre-childbearing 
years, she will experience significant new stresses when, in order to achieve a pregnancy, 
she terminates use of OCPs and thereby increases her vulnerability to ovarian cancer. 
Ceasing chemo-prevention and relying on screening for ovarian cancer (generally 
regarded as ineffective) during one’s active childbearing years may increase cancer 
anxiety, in turn affecting a women’s psychological and emotional well-being, as well as 
her relationships with her partner, children, family of origin, healthcare team, and others. 
Individuals at high genetic risk of cancer report multiple bases for concern about 
childbearing. Concerns about the mother’s health and mortality during childbearing years 
and during children’s early lives are legitimate given the potentially very early onset of 
cancer among mutation carriers (Narod et al., 2002; K. R. Smith, Ellington, Chan, 
Croyle, & Botkin, 2004). There is also a concern regarding passing a BRCA mutation on 
to children conceived naturally (K. R. Smith et al., 2004). Finally, but perhaps of the 
greatest immediate importance, there are some concerns that pregnancy itself could serve 
as a catalyst for the development of cancer due to increased exposure to estradiol during 
pregnancy, which has been associated with tumor growth in BRCA1 carriers specifically 
(Chetkowski, Cassidy, Ma, Kagan, & Szell, 2008). 
A 2004 study investigating differences in fertility intentions among those who 
either did not know their mutation status, had tested positive, or had tested negative found 
that both women who tested positive and women who did not know their mutation status 
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were less likely than those who tested negative for a BRCA mutation to want additional 
biological children (K. R. Smith et al., 2004). This study “suggested that carriers are 5.5 
times more likely…to have altered their family planning than noncarriers because of their 
test results,” (K. R. Smith et al., 2004, p. 738).   
In the presence of a known genetic mutation, it is certainly possible that some 
individuals and couples will choose not to have biological children as a way to guarantee 
that they will not pass on a harmful genetic mutation, or to avoid the potential cancer 
risks associated with pregnancy; some of these may remain childless, while others may 
choose to adopt, use donated gametes (i.e., sperm or egg) in place of those of the 
mutation-positive parent, or employ surrogacy. Others choose to proceed with natural 
childbearing just as they would if the mutation was not an issue, and face any potential 
consequences as they arise. Others may choose to intervene in some way, in an attempt to 
“load the genetic dice” (Harmon, 2006) in their favor, using reproductive technology to 
increase the odds that they will produce a mutation-free biological child. The range of 
family formation choices available to couples in which one partner is a BRCA1/2 carrier 
includes adoption, third party reproduction (gamete donation and/or surrogacy), pre-
implantation genetic diagnosis (PGD) and pre-natal diagnosis (PND). Each of these 
strategies brings with it a unique set of considerations, and the choices faced by young 
couples are challenging and complex. However, because the current study focuses on 
how on the relationship between family formation and risk-management decision-
making, and not on the specific processes women and couples use to achieve their family 
formation goals, a detailed discussion of family formation options is beyond the scope of 
this literature review. A brief overview of these options can be found in Appendix C. 
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Breast and ovarian cancer risk management and reduction. There are three 
primary categories of cancer prevention strategies available to women at increased 
hereditary risk of breast and ovarian cancer: clinical screening/surveillance, 
chemoprevention, and risk-reducing surgery (Dowdy, Stefanek, & Hartmann, 2004). 
Each individual mutation carrier is faced with difficult choices in selecting which strategy 
or strategies to utilize at various points in her life. These decisions are made in the 
context of what is available and recommended to any given woman in the medical 
settings in which she interacts, and these settings vary widely from person to person. For 
example, some women may have annual visits with gynecologic oncologists or 
physicians who specialize in hereditary cancer risk, while others may receive their risk-
related care from general practitioners and/or obstetrician/gynecologists (Ob/Gyns) who, 
given the relatively low frequency of BRCA1/2 mutations in the general populations, may 
encounter as few as 1 BRCA1/2 mutation-positive patient every 20 years in their careers 
(de Bock et al., 2001). Clearly, these professionals are differently able to responsibly 
address the concerns and meet the needs of BRCA1/2 mutation carriers. This healthcare 
mismatch is worrisome because, for example, prior research indicates that general 
practitioners are more likely to recommend or endorse surveillance as a strategy to deal 
with increased risk than are specialists trained specifically to deal with women from 
HBOC families, who are more likely to instead recommend chemoprevention or risk-
reducing surgery (de Bock et al., 2001; Eisen, Rebbeck, Wood, & Weber, 2000).   
In making decisions regarding cancer prevention, women must take into 
consideration family cancer history, mutation status, perceived and actual cancer risk, the 
efficacy and risks associated with each prevention method, financial and insurance issues, 
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their own preferences and those of loved ones. This process is even more complicated in 
light of the inability of any strategy to provide complete protection against cancer at this 
time (Dowdy et al., 2004), leaving mutation carriers with residual vulnerability to cancer 
no matter what they choose. There is also a risk of false reassurance when women select 
a screening method and erroneously believe that they are “protected” from cancer, when 
in fact they may still be quite vulnerable (Bottorff et al., 2000). Largely for this reason, 
healthcare professionals have begun to refer to this set of options as “risk-reduction” 
options rather than “prevention” options. 
Surveillance. Risk management strategies that fall under the umbrella term 
surveillance (also referred to as “screening”) include monthly breast self-examination 
(BSE) beginning at age 18, biannual clinical breast examination (CBE), annual 
mammography and breast MRI (Brekelmans et al., 2001; NCCN, 2007; Vasen et al., 
2005), annual gynecological examinations, semi-annual serum CA-125 tests, and 
transvaginal ultrasound (TVU) (NCCN, 2007; Pavelka et al., 2007; Scheuer et al., 2002; 
Vasen et al., 2005). Generally, it is recommended that female BRCA1/2 mutation carriers 
commence surveillance at the age of 25 or 5-10 years earlier than the youngest cancer 
diagnosis in their family, whichever is earlier. The performance characteristics related to 
each of these screening procedures range from terrible (ultrasound, CA-125 for ovarian 
cancer) to good (MRI for breast cancer), and all may be accompanied by anxiety prior to 
each test, substantial risk of false-positive test results, and anxiety until definitive results 
indicating an absence of concern are in hand. It has been estimated that 40-80% of 
BRCA1/2-positive women choose to utilize screening alone to manage their risk, at least 
for some time after they complete the genetic testing process (Lerman et al., 1996). 
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Although it is frequently discussed as a risk-reduction strategy by healthcare providers 
and mutation carriers alike, screening should instead be considered a way of managing 
risk, rather than reducing it, because it does not actually alter the likelihood that cancer 
will develop. It is simply a method of detecting cancer if it is present. Choosing screening 
rather than more radical risk-reducing surgeries has advantages in that the breast or 
ovarian tissue is preserved, as is fertility and the ability to breastfeed; many women 
choose this option in the hope that new diagnostic options and treatments will emerge 
that make surgery unnecessary (Dowdy et al., 2004). 
Some researchers and practitioners have expressed worry that genetic testing for 
cancer risk may result in increased distress that may reduce adherence to screening 
(Lerman et al., 2002), and this hypothesis has been borne out in some research of 
untested high-risk women (Kash, Holland, Halper, & Miller, 1992). However, studies 
specifically examining women who have undergone testing do not support this 
hypothesis. One study failed to find a significant relationship between posttest scores on 
the State-Trait Anxiety Inventory (STAI) (Spielberger, Gorusch, & Lushene, 1970) and 
Impact of Events Scale (IES) (Horowitz, Wilner, & Alvarez, 1979) and one-year posttest 
mammography adherence in multivariate analysis (Botkin et al., 1996); another identified 
a positive correlation between BSE frequency and IES scores among carriers, but not 
among non-carriers (Lerman et al., 2000). 
Chemoprevention. The term chemoprevention in BRCA-related literature is used 
to describe a group of pharmacologic treatments, many of which alter the balance of the 
female hormones estrogen and progesterone. Both of these hormones have been 
implicated in breast and ovarian carcinogenesis (Eeles & Powles, 2000). The use of such 
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chemopreventive medications has been associated with reductions in both sporadic breast 
and ovarian cancer incidence (McLaughlin et al., 2007). Tamoxifen, for example, has 
been shown to reduce the risk of developing estrogen-receptor (ER) positive breast 
cancer among women at modestly increased risk by up to 69% (Fisher et al., 1998; 
Fisher, Powles, & Pritchard, 2000). Although data regarding the efficacy of tamoxifen in 
BRCA mutation carriers are sparse and limited by small sample size and therefore not 
definitive, the evidence is generally consistent with a protective effect (Dowdy et al., 
2004; Eisen & Weber, 2001; Johannsson et al., 1997; Karp et al., 1997; King et al., 2001; 
Vogel, 2001), though more recent research has questioned this (Temin, 2009). Raloxifene 
is a second member of the selective estrogen receptor modulator (“SERM”) drug family, 
which also has demonstrated a protective effect for sporadic, ER-positive breast cancer; it 
has not been evaluated in mutation carriers (Chlebowski, Collyar, Somerfield, & Pfister, 
1999; Temin, 2009). Ongoing trials continue to investigate the efficacy of various 
chemopreventive medications in mitigating breast cancer risk among for high-risk 
women (Palma, Ristori, Ricevuto, Giannini, & Gulino, 2006).   
Potential adverse effects of chemopreventive medications comprise a major 
barrier to the acceptance of these agents by consumers and healthcare providers alike. 
These include increased incidence of endometrial cancer, deep vein thrombosis, 
pulmonary embolism/superficial phlebitis, stroke, hot flashes, and vaginal discharge 
(Fisher et al., 1998). It has become clear that medications like those just described, which 
are readily accepted by women as part of breast cancer treatment regimens, are viewed 
with much greater skepticism and wariness by healthy (albeit at-risk) women who do not 
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have cancer. Thus, tamoxifen – a scientific triumph in the field of cancer prevention – has 
proved unacceptable to most high risk women. 
 The use of oral contraceptive pills (OCPs) has long been associated with reduced 
frequency of ovarian cancer among women in the general population (Franchesi et al., 
1991; Whittemore, Harris, Intryre, & Group, 1992). A consensus is now emerging that a 
protective effect of similar magnitude (~50% reduction) is also seen in BRCA mutation 
carriers (Bosetti et al., 2002; Franchesi et al., 1991; Lakhani et al., 2002; McLaughlin et 
al., 2007; Narod et al., 1998; Whittemore et al., 1992). Current chemoprevention research 
for ovarian cancer is focused primarily on progestational agents (Rodriguez, 2003).   
 The use of oral contraceptives as a method of reducing hereditary ovarian cancer 
risk in young women is an appealing option for several reasons. First, the treatment is 
generally well-tolerated and does not present significant side-effects for most women; 
many women of this age may be likely to use OCPs anyway as a preferred method of 
birth control, and so the risk-reduction may be seen as an added benefit of an already 
positive personal choice (Narod et al., 1998). Second, fertility can be preserved in cases 
where women wish to have biological children in the future but are not ready to do so yet. 
Third, using oral contraceptives to reduce cancer risk can be a way of “buying time” 
before more drastic measures, such as risk-reducing surgery, are deemed necessary, 
allowing women to maintain breast and ovarian tissue and function throughout early 
adulthood. However, it is important to note that OCP use has also been associated with 
increased risk of breast cancer among BRCA1 mutation carriers, especially when used for 
five years or more and when used prior to age 30 (Kaduri et al., 1999; Narod et al., 2002; 
Narod et al., 1998). This relative “tradeoff” of risks is an important component of 
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decision-making about OCP use for BRCA1 carriers (Grenader, Peretz, Lifchitz, & 
Schavit, 2005), and perceived risk of breast versus ovarian cancer (likely based on family 
history) may be an important factor in women’s decision-making regarding this risk-
reduction strategy. For BRCA1 carriers, use of OCPs may be an attractive option for 
ovarian cancer risk management after RRBM. No association between OCP use and 
breast cancer risk is noted for BRCA2 carriers. 
Risk-reducing surgery. Of the three cancer prevention strategies, risk-reducing 
(or “prophylactic”) surgery offers the highest level of protection against cancer (Karlan, 
2004). Risk-reducing bilateral mastectomy (RRBM) is the complete (or near-complete) 
removal of breast tissue in the absence of a breast cancer diagnosis. Risk-reducing 
salpingo-oophorectomy (RRSO) is the complete removal of ovarian and fallopian tube 
tissue in the absence of an ovarian cancer diagnosis. Studies of women who have chosen 
these prevention strategies suggest that RRBM reduces the risk of breast cancer by more 
than 90% in high-risk women (Esplen et al., 2004; Hartmann et al., 1999; Meijers-
Heijboer et al., 2001), while RRSO reduces the risk of ovarian cancer by 85-95%; in both 
cases, residual risk of breast or ovarian cancer is believed to be lower than population 
risk. RRSO also reduces the risk of breast cancer by 50% in pre-menopausal women 
(Kauff et al., 2002; Kramer et al., 2005; Rebbeck et al., 1999; Rebbeck et al., 2002). 
Research indicates that women who elect to undergo risk-reducing surgery “benefit both 
medically and psychologically…by the reduction of both their objective risk and their 
perceived risk of developing cancer and that this benefit is the greatest among women 
who undergo both ovarian and breast surgeries,” (Madalinska et al., 2005, p. 6897). 
These procedures are associated with high direct costs, approximately $3,100 to $4,500 
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for RRBM and $6,000 to $13,900 for RRSO (Grann, Panageas, Whang, Antman, & 
Neugut, 1998), making them inaccessible to women without insurance coverage; 
however, reports indicate that insurance companies have routinely paid for risk-reducing 
surgery for women who are confirmed BRCA1/2 mutation carriers (Eisen et al., 2000), a 
practice that is likely to become more common with time as more and more women opt 
for these procedures. 
Risk-reducing bilateral mastectomy. Originally considered controversial given its 
performance in the absence of a cancer diagnosis and the seemingly drastic nature of the 
procedure (Eisen & Weber, 1999; Fentiman, 1998; Holzgreve, Beller, Niedner, & 
Niehaus, 1989; Klijn, Janin, Corez-Funes, & Colomer, 1997), RRBM has become an 
increasingly utilized method of cancer risk reduction among BRCA mutation carriers 
(Frost et al., 2000; Hartmann et al., 1999; Hatcher, Fallowfield, & A'Hern, 2001; Meijers-
Heijboer et al., 2001). Research indicates that up to 51% of BRCA1/2-positive women 
consider risk-reducing mastectomy (Lerman et al., 1996; H. T. Lynch et al., 1997; 
Meijers-Heijboer et al., 2003; Meijers-Heijboer et al., 2000; Meiser, Butow et al., 2000; 
Meiser et al., 2003; van Dijk et al., 2003). Among those who consider the procedure, only 
about half who are eligible will actually undergo the procedure, with women who have 
children significantly more likely to undergo RRBM than those who do not (Meijers-
Heijboer et al., 2000).   
This is consistent with other research noting that many women who choose to 
undergo risk-reducing surgery are motivated to do so by a sense of obligation to their 
families (Hallowell et al., 1998), which may be a product of women’s acknowledgement 
that choosing surgery is the most effective method of preventing cancer. Women who are 
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pre-menopausal but likely finished with childbearing (aged 40-54) are more likely to 
elect RRBM than women who are under 40 or over 55; however, perhaps surprisingly, 
women between the ages of 30 and 35 (a subset of the under-40 group) were more likely 
than any of the other age groups to elect this procedure. This finding is supported by our 
pilot data, which demonstrates that some mutation-positive women in their 20s and 30s 
move quickly toward RRBM in order to bring about peace of mind prior to entering the 
parenting phase of their lives (unpublished data). One group of researchers notes that 
“combining both predictors of age and parenthood 70% (28 of 40) of women aged below 
50 years with children opted for [risk-reducing] mastectomy,” (Meijers-Heijboer et al., 
2000, p. 2018). However, none of 41 confirmed carriers in a 2000 study had undergone 
RRBM within one year following receipt of results, and only 17% were considering the 
procedure (Botkin et al., 1996). Similarly, only 3% of unaffected carriers in a separate 
study had undergone RRBM within one year of result receipt (Lerman et al., 2000). This 
suggests that women may need some time to adjust to the idea of utilizing surgical risk-
reduction, and explains the previously mentioned phenomenon whereby the vast majority 
of BRCA mutation carriers utilize surveillance for at least some period of time after 
learning about their mutation statuses. 
The decision to undergo RRBM is predicted by motherhood (Meijers-Heijboer et 
al., 2001), higher levels of breast cancer worry (Stefanek, Hartmann, & Nelson, 2001), 
the belief that surgery would significantly reduce the risk of disease, higher perceived 
risk, having had previous breast biopsies and/or genetic testing (Hatcher, Fallowfield, & 
A'Hern, 2001), older age, and positive family cancer history (Lerman et al., 2000). It is 
also of note that rates of RRBM acceptance are higher in countries with socialized 
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medicine systems (e.g., UK, Netherlands) than in the US (Dowdy et al., 2004), 
presumably because the cost barrier is eliminated for women in those countries and may 
be very present (or even insurmountable) for those in the US. 
Satisfaction with RRBM and reconstruction is generally high among women at 
high risk of cancer (Borgen et al., 1998; Frost et al., 2000; Klijn et al., 1997; Meijers-
Heijboer et al., 2000; M. E. Stefanek, 1995), but varies with reconstructive 
decisions/outcomes and by interval between surgery and measurement of satisfaction 
(Bebbington & Fallowfield, 1999). A 1998 study found that 5% of women had significant 
regrets after completion of RRBM (Borgen et al., 1998). These may be associated with 
negative outcomes such as pain during recovery, necrosis, hematoma/seroma, 
encapsulation, wrinkling, pain, asymmetry, and diminished breast sensation, which occur 
in 10 to 59% of patients (Eeles, Cole, Taylor, Lunt, & Baum, 1996; Eisen et al., 2000; 
Gabriel et al., 1997; Hopwood et al., 2000). Rates of complication may be as high as 30% 
over five years for women who chose implant reconstruction (Gabriel et al., 1997).   
In general, women who undergo RRBM generally experience positive 
psychological outcomes, as was reported in 94% of a sample of 609 women with family 
histories of breast cancer (Frost et al., 2000). Breast cancer anxiety is generally 
significantly diminished, and a majority of women report either positive changes or no 
changes with regard to emotional stability, stress, self-esteem, sexual relationships, 
femininity, and appearance. These responses were not associated with age at surgery, 
length of follow-up, level of actual family cancer risk, or type of mastectomy performed 
(i.e., total or subcutaneous) (Frost et al., 2000). Overall satisfaction with RRBM is 
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associated with satisfaction with post-surgical physical appearance, lower levels of stress, 
and the decision not to have reconstruction after RRBM. 
Possible negative emotional/psychological outcomes of RRBM include loss of 
femininity and sexuality (Eeles et al., 1996; Frost et al., 2000; Hopwood et al., 2000; 
Meijers-Heijboer et al., 2000); difficulties with body image including perceptions of 
decreased sexual and physical attractiveness, and decreased satisfaction with body 
(especially among those who elect not to have reconstruction) (Carver et al., 1998; Frost 
et al., 2000; Hopwood et al., 2000; Meijers-Heijboer et al., 2000); loss of self-esteem 
(Frost et al., 2000; Hopwood et al., 2000); unexpected difficulty accepting breast loss 
(Hopwood et al., 2000); difficulty adjusting to the appearance, feeling and/or relationship 
impact of reconstructed breasts (Carver et al., 1998; Hopwood et al., 2000); 
psychosomatic symptoms related to implants (Hopwood et al., 2000); avoidant behavior 
with respect to reconstructed breasts (i.e., avoiding intimacy or exposure) (Hopwood et 
al., 2000); negative changes in sexual relationships (Frost et al., 2000; Hopwood et al., 
2000); depression as a result of surgical complications or relationship issues following 
surgery (Hopwood et al., 2000); adverse effects in one’s level of emotional stability; and 
increased stress (Frost et al., 2000). However, most research suggests that over time, the 
procedure has no permanent detrimental effects on body image or sexuality (Borgen et 
al., 1998; Frost et al., 2000; Stefanek, Helzlsouer, Wilcox, & Houn, 1995). That said, 
there can be no doubt that the process of contemplating the possibility of RRBM, and 
then living with the consequences of that decision (regardless of what those might be), 
can be the source of an enormous amount of stress, anxiety, and interpersonal conflict. 
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Although a great deal of research has examined individual outcomes of risk-
reducing mastectomy and the process of decision-making, as outlined previously, there is 
a relative absence of research that examines these issues from the couple perspective, or 
wholly considers RRBM decisions/outcomes in the context of the couple relationship. 
One small study investigated partners’ perceptions of the outcomes of surgery, finding 
high levels of overall agreement between patients’ perceptions and partners’ perceptions; 
there were also some cases in which partners highlighted issues in adjustment to surgical 
outcome that were not identified by the patients themselves (Brereton et al., 1999). Other 
research has posited that women are reluctant to confront potential sexual problems pre-
operatively, and that this may lead to more problems in the post-operative phase (Dudok 
de Wit, Tibben, Frets et al., 1997), such as reluctance to let a partner touch or look at 
reconstructed breasts (Hopwood et al., 2000), which may present difficulties within other 
aspects of the couple relationship. Most research on RRBM in BRCA1/2 mutation carriers 
is conducted with women who are approaching surgery in the months leading up to the 
procedure; little existing research examines the thoughts and feelings of young women 
regarding risk-reducing surgery over time as they move through the mutation-positive 
experience, and this is especially true for young women. This absence leaves a significant 
gap in the research. We do not know, for example, about the experiences of women who 
are aware of their increased hereditary risk of cancer and/or undergo RRBM prior to the 
formation of a permanent couple relationship. What is their experience in explaining this 
decision and its implications to a new partner? When these women experience negative 
consequences with regard to their own sexuality and feelings of attractiveness as a result 
of an RRBM, how is this related to their desire and ability to form and/or maintain couple 
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relationships? To what extent might some women delay RRBM because they are not yet 
in a couple relationship, perhaps feeling that they will be less able to attract a partner 
without their natural breasts? Pilot data indicate that these are important considerations 
(unpublished data), and they have not yet been captured in the existing research 
 Risk-reducing salpingo-oophorectomy. Risk-reducing removal of the ovaries and 
fallopian tubes is a preferred ovarian cancer risk management strategy for many female 
BRCA1/2 carriers for several reasons. First, as previously discussed, there is no effective 
screening strategy for the early detection of ovarian cancer. Second, the majority of 
patients present with advanced disease while only a minority are cured, giving many 
carriers the (largely correct) impression that an ovarian cancer diagnosis is likely to mean 
death. Finally, RRSO leaves no visible change in bodily appearance (Palma et al., 2006). 
A growing number of health care providers strongly recommend the procedure for this 
population (Eisen & Weber, 2001). Sources of stress related to this decision include: 
• Symptoms which prove (in retrospect) to have been the harbingers of cancer 
development are vague, non-specific and common (i.e., easily confused with 
menstrual cramping or bloating); 
• Screening with CA-125 and transvaginal ultrasound is fraught with apprehension, 
worry and a high rate of false positive test results; 
• The need to make a final and irreversible decision about bringing child-bearing 
potential to an end, perhaps at an earlier point in time that it might otherwise be 
contemplated; 
• Concerns that the loss of one’s ovaries will bring a loss of femininity, particularly 
for premenopausal women; and 
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• Fears regarding the potential long-term complications of premature menopause, 
particularly with regard to cardiovascular and bone health. 
In general, patient acceptance of RRSO is high (Pavelka et al., 2007). Studies taking 
place in different countries have yielded varying results regarding the attractiveness of 
RRSO to high-risk women as well as their reasons for choosing this procedure. Various 
studies have reported that 33-76% of women at high genetic risk of breast/ovarian cancer 
consider RRSO (Hallowell et al., 1998; Lerman et al., 1996; Lynch et al., 1997), and a 
subset of those will ultimately elect to have the procedure.   
Researchers have demonstrated that RRSO is effective in reducing anxiety about 
and perceived risk of ovarian cancer for women at high genetic risk (Elit, Esplen, Butler, 
& Narod, 2001); this level of anxiety reduction is generally thought to be high enough to 
outweigh the potential adverse effects of the procedure (Tiller et al., 2002). RRSO is 
generally recommended for BRCA1/2 mutation carriers who are over 35 years of age and 
have completed childbearing (Burke et al., 1997; Dowdy et al., 2004; Pavelka et al., 
2007); this age is selected because it “represent[s] an acceptable tradeoff between cancer 
risk reduction and the preservation of hormonal function,” (Dowdy et al., 2004, p. 1115). 
Women who have not yet completed childbearing or are unsure about their desire for 
children or more children are not ideal candidates for RRSO. Since risk of ovarian cancer 
does not increase significantly until the late thirties for BRCA1 carriers (Ford, Easton, 
Bishop, Narod, & Goldgar, 1994) and the late fifties for BRCA2 carriers (M. C. King et 
al., 2003), many women are able to delay the procedure until after childbearing is 
completed (Pavelka et al., 2007). However, the beneficial effect of RRSO is greater the 
earlier it is performed, with the greatest risk-reducing effect observed among pre-
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menopausal women (Armstrong, Schwartz, Randall, Rubin, & Weber, 2004; Kramer et 
al., 2005).   
The risk-reducing benefits of RRSO include a near total elimination of risk of 
ovarian cancer (although residual risk of uterine and peritoneal cancer remains) and about 
a 60% reduction in breast cancer incidence if RRSO is completed by 35 (Rebbeck et al., 
2002), with breast cancer risk reduction benefits decreasing with age thereafter (Pavelka 
et al., 2007). With more and more women delaying childbearing into their thirties and 
forties (Arnett, 2004), BRCA1/2 carriers who delay RRSO in order to have children may 
be exposing themselves to significant levels of ovarian cancer risk and may lose some of 
the protective effect of the surgery (Kauff & Barakat, 2004). 
With regard to acceptance of RRSO, there is significant overlap with the 
predictors of RRBM. Rates of acceptance of RRSO among known BRCA1/2 mutation 
carriers may be as high as 64% (Meijers-Heijboer et al., 2000). In most studied samples, 
a majority of women aged >35 years who have completed childbearing elect to undergo 
RRSO (Kauff et al., 2002; Meijers-Heijboer et al., 2000). Cancer worry, high perceived 
risk of cancer, a belief that surgery will prevent ovarian cancer, and being aged 40 to 54 
are strong predictors of the decision to undergo RRSO (Fry et al., 2001; Meijers-Heijboer 
et al., 2000; Miller, Fang, Manne, Engstrom, & Daly, 1999); reduction of cancer worry 
seems to be the single most commonly cited motivation for undergoing RRSO (Fry, 
Rush, Busby-Earle, & Cull, 2001).     
In the Dutch study discussed previously, 60% of unaffected BRCA1/2 carriers 
elected to have RRSO, many of them at the same time as their RRBM and most within 
nine months of discovering their positive mutation status (Meijers-Heijboer et al., 2000). 
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Those most likely to elect RRSO were parents between the ages of 40 and 54. It should 
be noted that the low rate of acceptance of RRSO among women aged 55+ is likely due 
to the fact that the breast cancer-risk-reducing benefits of RRSO decrease significantly 
post-menopause, and undergoing the procedure after the age of 55 is unlikely to reduce 
breast cancer risk considerably (Kramer et al., 2005). Also, the short time between receipt 
of test results and undergoing surgery should be considered in the context of the family 
cancer histories for the women studied; many of them had been under regular 
surveillance for several years due to family history and had had ample time to consider 
risk-reducing surgery as a prevention option prior to learning of their actual mutation 
status (Meijers-Heijboer et al., 2000). 
A recent study of 359 high-risk women (120 of whom were confirmed BRCA1/2 
carriers) investigated the predictors of decision to undergo RRSO and found that older 
age, being married, lower level of education, and being postmenopausal were all 
associated with choosing RRSO. The authors note that this latter finding may be 
attributable to the decreased incidence of negative post-surgical outcomes for women 
who have already experienced natural menopause, even though the benefits of RRSO 
decrease after menopause (Madalinska et al., 2007). This study also noted that “women 
who opted for [RRSO] perceived their health as significantly worse…and reported 
significantly higher levels of worries…and intrusive thoughts…about ovarian cancer” 
than women who chose screening (p. 302). They were also less likely to perceive ovarian 
cancer as curable. Other studies of women at high familial risk of ovarian cancer 
(including BRCA1/2 mutation-carriers) have noted that older age (Fang et al., 2003; Tiller 
et al., 2002; Watson et al., 2004), greater perceived risk of ovarian cancer (Fang et al., 
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2003; Schwartz et al., 2003), higher perceived benefits of RRSO (Fang et al., 2003), 
higher levels of cancer anxiety (Meiser et al., 1999), parity (Watson et al., 2004), family 
history of ovarian cancer (Schwartz et al., 2003), and early breast tumor stage (Meijers-
Heijboer et al., 2000) are associated with electing to undergo RRSO. 
An Australian study demonstrated that desire to undergo RRSO was associated 
with high ovarian cancer anxiety, but was not associated with high objective risk (Meiser 
et al., 1999). In Britain, a study of women who had recently undergone RRSO 
categorized decision-making factors into pros and cons regarding the surgery. Pros 
included fulfilling obligations to family members and reducing ovarian cancer 
fear/anxiety; cons included not being able to fulfill social obligations, residual risk of 
cancer, upsetting the natural balance of the body, surgical complications, surgical 
menopause, and potential effects on body image/sexuality and relationships (Hallowell et 
al., 1998). Another study investigated which factors were most important for women 
considering RRSO; the top three were reducing risk of ovarian cancer, reducing cancer 
worry, and age (Fry, Rush et al., 2001). Women who chose surgery over screening placed 
higher importance on “reducing cancer worry, age, worries about effectiveness of ovarian 
screening, reducing risk of ovarian cancer, and loss of ‘periods,’” (Fry, Rush et al., 2001, 
p. 581). Premenopausal women placed higher importance on age and need for hormone 
replacement therapy than did their postmenopausal counterparts. Finally, a recent study 
examined 88 US women with a median age of 42, and was unique in that it examined 
RRSO decision-making several years after genetic testing, rather than in the 6-12 months 
immediately following disclosure as is common in previous studies. Results indicated 
that predictors of RRSO included older age at genetic testing, having children, non-
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Hispanic white race, having already had a mastectomy (either as breast cancer treatment 
or as a risk-reduction strategy), and having a family history of ovarian cancer (Bradbury 
et al., 2008) 
Regarding rates of acceptance of RRSO, one study found that only 13% of a 
sample of 29 confirmed carriers underwent RRSO within one year of receiving their 
mutation test results (Lerman et al., 2000), while a study of RRSO uptake in women who 
had known about their mutation status for several years reported uptake of 70% 
(Bradbury et al., 2008). However, it is important to note that most of the research on 
acceptance of and motivation for RRSO has been done using women in their late thirties, 
forties, and fifties as participants. We know far less about the experiences of young 
women with regard to decision-making about and planning for RRSO, and how these 
might impact other dimensions of young adulthood (e.g., expediting couple and/or family 
formation in order to proceed with RRSO by the recommended age). Pilot data indicate 
that these factors are, in fact, quite salient for young mutation carriers (unpublished data). 
Several studies have investigated post-surgical changes to quality of life, and have 
found that several improvements do result from RRSO. Beneficial effects have been 
noted with regard to cancer-specific distress and perceived cancer risk; however, they 
also note that decreases in quality of life are notable in terms of sexual functioning and 
vasomotor symptoms (i.e., “hot flashes”) (Elit et al., 2001; Robson et al., 2003; Tiller et 
al., 2002). In a study comparing women who opt for gynecological screening to manage 
their increased ovarian cancer risk with women who choose RRSO, the RRSO group 
reported significantly lower overall quality of life and reported that the surgery did not 
relieve their cancer-specific distress, nor did it worsen sexual functioning (Fry, Busby-
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Earle, Rush, & Cull, 2001). A second study comparing these groups in more detail found 
that both reported similar overall quality of life (quite high) and intrusive thoughts. 
However, the RRSO group reported lower levels of cancer worry, including worry about 
ovarian cancer for self, worry about family members, and worries affecting mood and/or 
functioning. They reported that their concern about developing both breast and ovarian 
cancer had decreased substantially as a result of surgery. They also reported more sexual 
discomfort, lower levels of pleasure and satisfaction during sexual intercourse, and more 
endocrine symptoms than the screening group (Madalinska et al., 2005); this is consistent 
with more recent research in which nearly a quarter of women who elected to undergo 
RRSO reported a worsened sex life (McArthur et al., 2007). These findings are important 
because post-surgical sexual symptomatology is one of the best predictors of satisfaction 
with RRSO (Robson et al., 2003).   
With regard to psychological outcomes, there are consistent reports of reduction 
in ovarian cancer anxiety in the years following surgery (Meiser, Tiller et al., 2000; Tiller 
et al., 2002). However, there are also reports of other, negative sequelae to PO, including 
greater interference with work functioning, interference with social activities, and both 
physical and emotional symptoms than among comparable groups of women who choose 
surveillance, especially those who are pre-menopausal at the time of decision-making 
(Fry, Busby-Earle et al., 2001). 
The majority of women who undergo RRSO are satisfied with their decision 
(Tiller et al., 2002). In one recent study comparing women who chose RRSO and those 
who chose surveillance, fully 97% of women in the RRSO group reported that they were 
satisfied with their decision, compared with 82% of women in the screening group and 
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consistent with other, similar research (McArthur et al., 2007; Meiser et al., 2000; 
Swisher, Babb, Whelan, Mutch, & Rader, 2001). Many women who have undergone 
RRSO report high levels of post-surgical satisfaction, that they would choose to do so 
again, and that they would recommend the procedure to a friend in a similar situation 
(Madalinska et al., 2005; McArthur et al., 2007; Swisher et al., 2001). 
Decision-making. As previously stated, mutation-positive women are faced with 
difficult choices in selecting a method or methods of cancer prevention across the 
lifespan, which is further complicated by the failure of any strategy to completely 
eliminate risk (Dowdy et al., 2004). Surveillance is an appealing option for young women 
who are not willing to sacrifice their fertility and/or ability to breastfeed, but leaves them 
maximally vulnerable to cancer development; use of this strategy is especially risky for 
women in families with a history of very early-onset cancer. Chemoprevention is likely to 
be used by women who wish to delay both surgical intervention and childbearing, and 
can be considered a sort of “middle ground” method of risk reduction. However, women 
who are actively engaged in family formation cannot participate in chemoprevention. 
Chemoprevention is differently efficacious for women with various mutations, and has 
differential impact on breast and ovarian cancer risk, creating a sometimes confusing 
tangle of considerations for its use. Finally, surgical risk reduction via RRBM or RRSO, 
while the most effective method of risk reduction, is also the most drastic, complicated 
(physically and, perhaps, financially), and final. Choosing to undergo a risk reducing 
surgery requires that a woman is willing to give up her ability to breastfeed or to bear 
(more) children, and because many young adult women are not ready to make this 
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sacrifice, risk-reducing surgery is not seen as an option, requiring extended reliance on 
surveillance and/or chemoprevention. 
Research suggests that women who have participated in genetic counseling are 
more likely to adhere to screening and risk-management recommendations, and that 
counseling participation is associated with use of risk-reducing surgery (Scheuer et al., 
2002). However, genetic counseling is not provided for all women who undergo testing 
for BRCA1/2, and even for those who receive it, the content and quality of services is not 
always consistent from provider to provider (Wang, Gonzalez, Milliron, Strecher, & 
Merajver, 2005). Further, as previously discussed, women who receive their BRCA1/2-
related medical care from specialists trained to address their specific needs, rather than 
from general practitioners or Ob/Gyns who may be less familiar with the options, risks, 
and recommendations for mutation carriers, may be better informed and equipped to 
make decisions over time that best meet their needs and maximally mitigate their 
breast/ovarian cancer risk (de Bock et al., 2001).    
In sum, young adult women who are aware that they carry a mutation in BRCA1 
or BRCA2 face challenges that make them unique from both non-carrier peers and older 
carriers. Young adult mutation carriers with high levels of perceived risk may find 
themselves reluctant to become involved in couple relationships due to fear of inflicting 
emotional and psychological distress on a loved one. Those who are in relationships must 
navigate the complexities of couple relationship development and communication with 
regard to their health concerns, and may face discrimination from partners and potential 
partners due to their high-risk status. In accomplishing goals related to family formation, 
these women may face complex decisions about how to go about having children, 
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including whether or not to have biological children, whether or not to attempt to reduce 
risk of passing on one’s mutation, and how to manage their own cancer risk during their 
active childbearing years. Finally, decisions about risk-management and risk-reduction 
can be especially challenging for young women, as the most effective strategies for 
reducing risk (i.e., surgeries) are often in conflict with young women’s ideals about 
physical attractiveness and sexuality, and other strategies (i.e., chemoprevention) may run 
counter to goals for family formation. 
Clearly, the complicated and sometimes conflicting considerations and research 
findings regarding methods of risk management and/or reduction create a difficult 
dilemma for female BRCA1/2 mutation carriers. This situation is confusing enough for 
women who are approaching menopause and who have completed childbearing; facing 
these decisions during young adulthood adds a considerably more complicated layer to 
the decision-making process, because these women are more likely to have to balance all 
of this information with their own desires, plans, and relationship issues regarding couple 
and family formation. To better understand this experience, we should examine it from a 
theoretical perspective. To do this, a combination of the Biopsychosocial Perspective and 
Life Course Theory will be utilized. 
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CHAPTER 3: THEORETICAL APPROACHES TO UNDERSTANDING THE 
BRCA1/2-POSITIVE EXPERIENCE 
As with most phenomena studied in the social sciences, there are many 
frameworks that might be helpful in understanding the processes by which young women 
move through the BRCA mutation positive experience. Because this research is 
positioned at the nexus of the family science and medical genetic fields, and even broader 
array of theories are applicable. A full list and description of applicable theories would 
overwhelm this project; in the interest of clarity and brevity, I select concepts from two 
primary theories and two secondary or supplemental theories. From the medical genetics 
field, the Biopsychosocial perspective, examined through the lens of attachment theory 
and anticipatory loss, will allow for exploration of the range of contexts in which 
individuals experience health-related stressors and how biology relates to the individual 
and the larger system in which she is situated. From the field of family science, Life 
Course Theory and a feminist perspective will be used to examine and understand 
process and meaning. Each of these theories was selected and prioritized because of my 
perception of their applicability to the issue at hand.  
The Biopsychosocial Perspective  
The biopsychosocial model of health and illness considers the interaction between 
individual, family, and illness development. It was first proposed by George Engel in the 
1970s, and grew out of his belief that medical and psychological issues must be 
considered in tandem in order to fully understand the human experience of disease. Engel 
believed that biochemical defects/abnormalities were only one factor in the cause of 
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disease, and that thoughts, emotions, decision-making, and relationships also play a 
significant role in disease development, coping, and recovery. He argued that  
a medical model must also take into account the patient, the social context in 
which he lives, and the complementary system devised by society to deal with the 
disruptive events of the illness, that is, the physician role and the health care 
system,” (Engel, 1977, p. 132).  
  
A biopsychosocial model is also thought to more fully absorb patient perceptions of 
themselves as “sick” or “well,” as these self-evaluations are not always based purely on 
biochemical functioning; in other words, the biopsychosocial model expands upon the 
biomedical model in that it allows for the understanding and addressing of somatic 
conditions by the physician or other healthcare professional (Engel, 1977). This 
expansion allows physicians, mental health providers, and other healthcare professionals 
who adopt a biopsychosocial view to more readily attend to general patient “stress” and 
not just to the physical causes and manifestations of illness. 
 Engel outlined the levels of the “hierarchy of natural systems” that should be 
considered as part of a holistic biopsychosocial perspective. Each system level acts both 
as an organized whole and as a component of a larger system. From narrowest to 
broadest, they are: cells, tissues, organs, nervous system, person, two-person, family, 
community, culture-subculture, society-nation, and biosphere. He noted that the person 
can be conceptualized as the bridge of two smaller hierarchies; the person is both the 
largest unit of the organismic hierarchy, and the smallest unit of the social hierarchy. 
Each level influences and is influenced by all other levels, without exception (Engel, 
1980). In this way, Engel’s biopsychosocial model is similar to Bronfenbrenner’s 
Ecological Theory (Bretherton, 2004); both consider the interactions between different, 
hierarchically-arranged levels of analysis. The biopsychosocial perspective can be 
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thought of as the “public health” version of Bronfenbrenner’s model because it expands 
upon the Ecological perspective by including relevant medical issues and context. 
 Today, more than thirty years after Engel first proposed this new lens through 
which to view human health and well-being, the biopsychosocial model has been used in 
research and practice for a wide variety of health issues and is the guiding model of the 
field of health psychology (Anderson, 1998; Suls & Rothman, 2004). Its focus on 
multiple causality has received particular attention in psychological research and 
literature, affirming the model’s contention that multiple interacting causes and 
contributing factors align to create dysphoric and disease states in humans, including 
genetic, environmental, intrapsychic, and social factors. In other words, “biological, 
psychological and social processes are integrally and interactively involved in physical 
health and illness,” (Suls & Rothman, 2004, p. 119). For example, consider an 
overweight, depressed patient being seen for diabetes and arthritis by her/his primary care 
physician. It is likely that the patient’s weight problems contribute to both the diabetes 
and the arthritis. All three may also be related to genetic susceptibility. The weight 
problems may also be exacerbated by the patient’s depression, and the depression is 
likely exacerbated by the weight problems, the arthritis, and the diabetes. The patient’s 
ability to cope with these conditions depends largely on her/his individual traits, as well 
as the relationships in which s/he is embedded (e.g., a family who is willing to support 
the patient in eating healthily will have a positive impact on disease outcome, whereas an 
unsupportive or emotionally absent family who eats unhealthily in the patient’s presence 
will have a negative impact) (Borrell-Carrio, Suchman, & Epstein, 2004). Along with this 
comes recognition of structural causality, or the belief that interventions suggested to 
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address health-related problems should be meted out hierarchically, because they have 
differential power to effect change. For example, for an individual with high blood 
pressure, cutting back on fatty foods may have a greater impact than daily meditation to 
reduce stress, (Benjamin, Flynn, Hallett, Ellis, & Booth, 2008) but not as great an impact 
as taking a blood pressure medication. 
Application of biopsychosocial perspective to young BRCA1/2 carriers. The 
biopsychosocial perspective provides a convenient lens through which to examine and 
understand the BRCA1/2 mutation-positive experience. It is inarguable that the mutation-
positive experience begins at the most basic level of analysis within Engel’s Hierarchy of 
Natural Systems (1980), in that the cells of the human biological system carry the genetic 
mutation on chromosome 17 (BRCA1) or 13 (BRCA2). This mutation is present within 
each and every cell of the body and inhibits cells from performing their natural growth 
regulation processes (more information about this can be found in Appendix A). This 
cellular change has significant implications for the tissue and organ levels of the 
hierarchy, in that women at increased risk of cancer are typically encouraged to perform 
breast self exams and to undergo frequent screening, even if they are using 
chemopreventive strategies. Further, breast or ovarian tumor development may occur and 
bring about changes to the ability of the tissues and organs to function correctly, perhaps 
affecting other tissue and organ systems and necessitating treatment (e.g., radiation, 
chemotherapy) or partial or full removal (i.e., lumpectomy, mastectomy, oophorectomy, 
hysterectomy). Women who opt for risk-reducing tissue/organ removal during young 
adulthood may acutely notice an absence of tissue and organ function if it affects, for 
example, their ability to bear or breastfeed a child (unpublished data) or feelings about 
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their bodies and sexuality (Eeles, Cole, Taylor, Lunt, & Baum, 1996; Frost et al., 2000; 
Hallowell et al., 1998; Hopwood et al., 2000; Meijers-Heijboer et al., 2000). At the 
nervous system level, locating an abnormality in one’s breast tissue during a breast self-
exam may lead to greatly increased anxiety for an individual at very high risk of cancer. 
Undergoing a surgical procedure will result in physical pain, perhaps creating negative 
emotional and psychological associations with the chromosomal mutation. All of these 
phenomena happen within the person, who in turn acts within and upon the various social 
and environmental contexts in which she exists.   
The manner in which a woman responds to these phenomena is related to her own 
psychological and emotional functioning, such as underlying levels of anxiety and 
optimism/pessimism. The person level will also be affected by various screening and 
treatment procedures across the mutation-positive experience; for example, undergoing a 
mastectomy (either for treatment or risk-reduction) will likely lead to changes is body 
image and sexuality, which may impact a woman’s overall sense of well-being and self-
perception, as discussed previously. This may have implications for the couple dyad, a 
major two-person system in which the individual patient is embedded. Other two-person 
systems of importance include the doctor-patient dyad and, where applicable, mother-
daughter, father-daughter, sister-sister, and other family relationships that may affect and 
be affected by the mutation-positive experience.   
At the family level, relationships within both the family of origin and family of 
choice are affected. The family of origin may experience issues related to grief, guilt, and 
communication about the transmission of the mutation from generation to generation and 
its result on the health of individual family members. Within the family of choice, a 
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mutation-positive individual may confront issues related to procreation, communicating 
with children about the mutation and its implications, or feelings of urgency regarding the 
formation of a family in what seems like a limited timeframe given medical 
recommendations. The community level of the hierarchy may be related to a woman’s 
ability (or perceived inability) to find similar others with whom to share her experiences, 
fears, and successes, such as through online support networks (e.g. FORCE, Bright Pink). 
Culturally, there exist issues related to the feasibility of detecting a mutation in BRCA1/2 
or the ability of the medical community to interpret the meaning of a present mutation 
that depend on one’s racial/ethnic background (e.g., Ashkenazi background increases risk 
of carriership, mutations identified in the African American population may be more 
difficult to interpret). Additionally, a subculture of BRCA-positive young women has 
developed, in which newly-identified carriers are welcomed into a sisterhood of sorts and 
guided along the path toward understanding oneself as a carrier, including learning the 
BRCA lingo and how to identify resources. At the societal level, young women’s 
experiences as mutation-positive are certainly related to popular and media 
representations of breast/ovarian cancer, intense research focus on the disease, and 
widespread beliefs about the frequency and severity of the cancers. Further, the health 
information, advice, and care they receive is largely a product of the system of laws and 
policies in the country in which they live; American women may have different options 
and face different barriers associated with a given risk-reduction option than, for 
example, women in a country with a universal healthcare policy. Finally, societal and 
cultural expectations about the role of women in young adulthood and the “right” timing 
for major events such marriage and childbearing may conflict with carriers perceived 
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needs related to risk-management, and managing these different expectations can become 
a source of stress for women in this population. 




It is important to consider, when contemplating the influence of family cancer 
history on any one individual, the simultaneous contexts of illness, individual, and family 
development. Rolland notes that  
cancer will influence the development of the affected individual and various 
family members in distinct ways, depending on several factors, including the age 
of onset of the illness, the core commitments in the affected individual and each 
family member’s life at that time, and the stage of the family life cycle (2005, p. 
2588).   
 
Notably, it is not just affected individuals who are impacted by the presence of a cancer 
diagnoses in a family; siblings, parents, children, cousins, and other family members are 
often affected as well, and the experience of growing up in a family in which breast 
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and/or ovarian cancer is a common occurrence is likely to impact young women 
significantly. 
Attachment theory and anticipatory loss. The current study necessitates a 
particularly careful examination of various interpersonal relationships, most notably the 
couple (two-person) levels of the biopsychosocial model. (The family level is also 
important to understanding the experience of young mutation carriers, but a full analysis 
of that set of relationships is outside of the scope of the current study). Adopting an 
attachment perspective can aid in understanding these relationship processes, which 
define young adulthood for many women.   
A basic tenet of attachment theory is that the experiences we have in early 
relationships with parents and other primary attachment figures play a significant role in 
shaping certain qualities of adult relationships. The extent to which relationships with 
early attachment figures are secure or insecure, and how separations and losses are 
handled in those relationships, “contribute to shaping reactions to subsequent real or 
threatened separation from or loss of important others, to whom individuals seek 
attachment in response to threat (Bowlby, 1969)” (Hoskins et al., 2008, p. 298). Further, 
“secure…relational processes steady the life course through containment of distress 
generated by threats,” (Weihs & Reiss, 2000, p. 16), which is easily applicable to women 
living with increased genetic risk of breast/ovarian cancer, as they seek and acutely notice 
the absence of supportive attachment relationships in coping with the stressors presented 
by their mutations. In a clinical context, “[a]ttachment theory…provides a framework for 
understanding patients and their different ways of dealing with emotions, the way they 
tell their story, think about themselves and their dilemma, [and] their expectations and the 
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nature of the relationships that they establish with others,” (Evans, 2006, p. 60), 
supporting the use of this perspective in qualitative research. 
 The use of Attachment Theory as a lens through which to examine the 
experiences of young couples in negotiating the presence of BRCA1/2 mutations makes 
the current study unique, as no other such studies currently exist. Predisposition to breast 
and ovarian cancer brought about by the presence of a BRCA1/2 mutation represents an 
ambiguous threat of loss within couple relationships and families. Carriers and those with 
whom they have close relationships do no know whether, when, and where cancer will 
develop, and live with uncertainty regarding the future of the life course. Weihs & Reiss 
(2000) note that “the unpredictable nature of the cancer experience [and, by extension, 
the pre-cancer period] is a threat to family function,” (p. 21), and the long-term success 
within a couple or family unit in coping with the threat presented by cancer may be 
largely dependent on the security of attachment within the relational unit. 
 My prior research supports the attachment-related ideas put forth by other 
psychosocial cancer researchers and suggests that cancer risk perception may be one 
avenue through which attachment shapes the couple and family experiences of young 
BRCA1/2 mutation carriers. Cancer risk perception is important to understanding the 
impact of positive BRCA mutation status. Significant variation in cancer risk perception 
has been observed among individuals who have tested positive for BRCA1/2 mutations 
and other cancer predisposition syndromes. Those with very strong family cancer 
histories tend to overestimate risk, even after genetic counseling, a process which seeks 
to align perceived and actual risk (McInerney-Leo et al., 2006) and which may reveal that 
risk is lower than expected (Lerman et al., 1995). Lower perceived partner support has 
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been associated with increased cancer distress (of which perceived risk is a component) 
in a study of individuals in HBOC and hereditary nonpolyposis colorectal cancer 
(HNPCC) families (van Oostrom et al., 2007). 
Cancer risk perception is directly and profoundly influenced by exposure to the 
cancer-related experiences of family members (Hallowell, 1999; Hopwood, 2000). Illness 
or death due to cancer may disrupt relationships with primary attachment figures, with 
implications for couple attachment in adulthood (Evans, 2006; Hopwood, 2000). 
Specifically, Hopwood hypothesizes that “[attachment] theory could also help to explain 
variations…in ability to communicate about risk: feeling free to talk openly about the 
loss or risk would be associated with secure attachment/realistic risk; whereas being 
preoccupied and communicating negatively would be associated with insecure 
attachment/ overestimating risk,” (2000, p. 388). Alternatively, results from our pilot 
investigation suggest that “those with higher perceived risk often [demonstrate] effective 
partner communication and [describe] healthy partner attachment,” (Hoskins et al., 2008, 
p. 312). An apparent balance is at play here, whereby individuals who have experienced a 
testing of their attachment relationships due to cancer, but not a loss, are more likely to 
report high perceived risk and healthy attachment than either those who have lost a love 
one to cancer (an attachment loss) or those who have not experienced a cancer-related 
attachment threat (e.g., a female who inherited a mutation from an unaffected father and 
did not lose any female paternal relatives to cancer). Understanding the interplay between 
perceived breast and ovarian cancer risk and partner relationships is important because 
research has demonstrated that availability of partner support is important in formulating 
accurate estimations of risk (Hopwood, 2000), and partners serve as important supporters 
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during major life stresses, including breast cancer (Shields, Travis, & Rousseau, 2000; 
Wilson & Oswald, 2005). 
Defined as “the experience of living with possible, probable, or inevitable future 
loss,” (Rolland, 2006, p. 140), anticipatory loss is certainly relevant to BRCA1/2+ women 
and those with whom they have close relationships. Anticipatory loss is characterized by 
feelings of uncertainty and fear, which may be managed through effective coping and 
adaptation (Rolland, 2006). For BRCA+ women, such stressors must be considered 
against the backdrop of family life-cycle and development (McDaniel, Rolland, Feetham, 
& Miller, 2006). The life course “arises from [the family/couple’s] particular history and 
it is guided toward the future by shared values and goals…[including] the maintenance of 
health,” (Weihs & Reiss, 2000, p. 19). For those seeking partners and forming permanent 
relationships, their life situation may trigger thoughts of threats to permanence, including 
illness or death (Weihs & Reiss, 2000). Women who are aware that they carry a BRCA1/2 
mutation are faced with a second, major non-normative stressor related to effectively 
communicating information about cancer risk to new partners, perhaps in the context of 
feeling “[vulnerable] to rejection as potentially defective,” (Rolland, 2006, p. 164).  
Our prior research has shed light on the question of whether and how young 
BRCA1/2-positive women experience anxiety regarding partners’ reactions to mutation 
disclosure. They experience concern over partners’ willingness to alter individual/family 
life cycle plans in response to women’s heightened sense of urgency to progress through 
stages to mitigate the risk of cancer and pursue risk-reducing surgery. They worry that 
partners will be unable to respond with appropriate understanding and empathy when 
they share information about their increased cancer risk (Hoskins et al., 2008). Other 
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couple relationship dynamics may also be present. Intra-family communication patterns 
regarding genetic cancer susceptibility may be established as soon as awareness of 
genetic risk exists (Rolland & Williams, 2006). Therefore, it may be challenging for new 
partners to learn to navigate successfully within established family systems and 
communication patterns during the formation of new relationships with BRCA1/2+ 
women. In permanent relationships, partners must continually navigate the challenges, 
demands, and stressors inherent in high-risk status as they move through the life course 
and make decisions ranging from jobs and health insurance to geographical location to 
how many children to have and when. 
In many ways, living with a BRCA1/2-mutation is an illness experience. Although 
young adult breast and ovarian cancer pre-vivors often may not face an immediate health 
threat, they must cope daily with the threat of future illness, and therefore with some of 
the psychosocial and relationship implications of illness. Prior research indicates that  
illness may threaten a woman’s self-worth and jeopardize her ability to form 
intimate relationships. A young woman may be pulled in toward family when she 
is trying to differentiate, and exposed to issues surrounding body image and 
sexuality that may impede relationship development. When an illness experience 
begins during courtship, couples may realign the balance of agency and 
communion, allowing mutation-positive individuals to rely on partners for 
emotional and psychological support at a time when both might expect the 
dynamic to be equitable. Disclosure of a BRCA1/2 mutation is uniquely 
ambiguous in that it prompts consideration of the possibility of eventual health 
problems for women and future children. However, parallels exist in that both 
situations force young couples to consider whether and how they can 
cooperatively manage health issues across the life-course (Hoskins et al., 2008). 
 
The biopsychosocial perspective, examined through the lenses of attachment theory and 
anticipatory loss, is exceptionally useful for explaining the range of contexts in which 
individuals experience health-related stressors. The theory explains how biology relates 
to the individual and to the larger systems in which the individual is situated. However, 
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this theory does not allow us to consider process or meaning. It tells us that biology is 
related to other system levels, but not how it is related. The theory does not explain how 
individuals adapt to their context, to the challenges presented by their biological state, 
and how they make changes over time in response to shifting demands. It also falls short 
in accounting for meaning. The question of how individuals make meaning of the 
circumstances in which they find themselves, and how that meaning-making impacts 
emotions, attitudes, and decisions, still remains. To compensate for this and to add to the 
theoretical credibility of the current study, let us now turn to the life course perspective.  
Life Course Perspective 
The life course perspective adds to the theoretical strengths of the biopsychosocial 
perspective by including consideration of process and meaning. The term “life course 
perspective” embraces a range of different frameworks, including Life Span 
Development (used primarily by psychologists) and Family Developmental Theory 
(utilized by family science professionals) (Rodgers & White, 2004). Both of these 
describe the common or typical phases that most individuals and/or families move 
through as they age and grow. They assert that there are developmental stages relatively 
common to the human experience, and that significant events occur within a relatively 
small range of ages (Settersten, 2003) and mark transitions from one phase to the next. 
Generally, the six phases of the family life course include: 1) leaving parents’ home, 2) 
joining/creating of a new family through marriage or partnership, 3) raising young 
children, 4) raising adolescents, 5) launching children and moving on, 6) retirement and 
later life (Carter & McGoldrick, 1999). Over time, families must negotiate the spectrum 
of emotional processes and boundaries (both internal and external) necessary to 
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successfully complete each phase; this task often requires significant change in 
transitioning from one phase to the next. For example, raising young children may 
require a high level of cohesion with relatively little contact outside the family, as 
opposed to raising adolescents, a phase generally characterized by increased autonomy 
for all family members and looser boundaries between the family and the outside world 
(Rolland, 2005). 
Life Course Theory is fundamentally relational in that it takes into account the 
many ways in which social interactions with others shape the experience of an 
individual’s life over time (Bengston & Allen, 2004). The theory has, at its base, several 
“paradigmatic principles” that are critical to its understanding. The first is that 
development occurs continually across the lifespan, not just during one’s early years or in 
spurts around significant transitions (Elder, Johnson, & Crosnoe, 2003). Therefore, 
human development must be conceptualized in the long-term. Not only does a life course 
perspective then accommodate the myriad changes and experiences that happen over the 
course of human life, it also accounts for the significant effects of social and 
environmental change that can and do occur during the human lifespan and which bring 
about important changes to context. 
A second principle is that of agency, which states that “individuals construct their 
own life course through the choices and actions they take within the opportunities and 
constraints of history and social circumstance,” (Elder et al., 2003, p. 11). In other words, 
at all stages of the life course, individuals make decisions given the opportunities and 
constraints with which they are presented that, over time, have significant bearing on the 
paths that their lives take.   
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A discussion of agency must be contextualized within the sociological literature 
from which the concept originated. Sociological theory holds that agency, considered 
from a life course perspective, describes “actions [that] occur with a broader sense of our 
futures involved, and these orientations are important for shaping individuals’ adaptations 
to situations,” (Hitlin & Elder, 2007, p. 182). This form of agency can also be described 
as “the self-reflective belief about one’s capacity to achieve life course goals,” (Hitlin & 
Elder, 2007, p. 182) and has social consequences; that is, a greater perception of agency 
is related to greater perseverance in the case of situational or structural obstacles (or 
constraints). Hitlin and Elder contend that although all individuals possess existential 
agency to make decisions willfully in situations, but the same is not true for this more 
nuanced form of agency that describes this ability to make decisions with a future 
orientation. Often, these occur at significant turning points in life that may or may not be 
clearly identified as such at the time. Life course agency is drawn upon in the navigation 
of context and structure, wherein expectations held at various levels of one’s social 
context (i.e., partner, family, culture) impose a set of behaviors that one “should” 
accomplish, which are not always congruent with what one wishes or is able to pursue. 
Third, the principle of time and place asserts that historical phenomena exert 
considerable influence on the life course for any given individual (Elder et al., 2003). 
Individuals born at similar points in history will be exposed to many of the same 
historical phenomenon, but will react to these in unique and individual ways, resulting in 
variation of the path through the life course from person to person. Timing, the fourth 
principle, states that “the developmental antecedents and consequences of life transitions, 
events, and behavioral patterns very according to their timing in a person’s life,” (Elder et 
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al., 2003, p. 12). That is, the same event will impact on individuals differently depending 
on their age and developmental status at the time that the event occurs. For example, 
children may be very differently affected by the divorce of their parents when the divorce 
occurs at age three than they would be if the divorce occurred at age 13. A three-year-old 
is likely to react with sadness, to have difficulty understanding what is happening, and to 
be quite resilient in the short- and long-term; in contrast, a 13-year-old may react with 
anger, more easily understand intellectually what is happening but still have difficulty 
coping with it emotionally, and may suffer from inappropriate boundaries with one or 
both parents as each attempts to align with the adolescent against the other parent by 
relating to the adolescent as an adult (Menning, 2008). 
Finally, the principle of linked lives states that because we are interdependent, 
social relationships with others are the context by which humans share the socio-
historical influences of the world in which they live (Elder et al., 2003). For example, 
children who grow up in poverty suffer not only from a lack of access to resources, but 
also may suffer from the negative psychological and emotional states of their parent(s), 
e.g., depression. Further, the addition and subtraction of relationships across the life 
course, called “turning points,” can bring about either changes or stability to behavior, 
depending on the quality of their impact (Elder et al., 2003). Surrounding oneself with 
productive and positive others is likely to lead to productivity and positivity, while 
associations with others that are counter to these may decrease one’s likelihood of 
personal progress. 
Integral to understanding family phenomena from a life-course perspective is the 
concept of on-time and off-time transitions. Cultural norms and traditions, along with 
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those that develop within families, often create dynamics whereby individuals are 
expected to accomplish specific tasks in a given order, sometimes with formal or 
informal “deadlines”. Historically, many young adults have and were expected to 
complete their education before getting married, and they are expected to marry by their 
late twenties or early thirties (Arnett, 2004). These norms are becoming more flexible 
given greater variability in recent decades, as young adults delay marriage in order to 
pursue higher education, experience a period of independence, and become established in 
a stable career (Arnett, 2004). However, many still feel social pressure to marry by a 
certain age, and this is especially true for women, who 
…believe they face a biological deadline—if they wish to have children…they 
want to have them no later than their early thirties, because the risk of infertility 
and prenatal development problems rises substantially by the late thirties. But part 
of the pressure is also social and cultural—they fear that by the time they pass age 
30 they will have missed their chance to marry because men their age will prefer 
younger women. The term ‘old maid’ may be used rarely today, but the stigma it 
represents still lingers (Arnett, 2004, p. 105).   
 
The perception that one is making a significant transition (such as from being single to 
being married) “off-time” can cause stress (Settersten Jr., 2003). Life course theorists 
generally support the notion that, from the individual psychological perspective, having 
age norms for certain behaviors allow individuals to form their own “mental maps” of the 
life course and use those to make long-term plans and preparations, thereby fulfilling 
needs for predictability and order (Hagestad & Neugarten, 1985). From a sociological 
perspective, age norms for behaviors and transitions are a method of maintaining social 
order. Societal expectations for individual progress across the life course and movement 
from stage to stage create a set of roles that individuals feel compelled to fulfill at certain 
points in their lives. Internal conflict may exist when one feels that s/he is not fulfilling 
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societal expectations appropriately, for example, by delaying marriage or childbearing in 
order to pursue further education. In other words, choosing a non-normative role over a 
normative one can cause stress. 
Application of life course perspective to the BRCA1/2 experience. Many 
elements of the BRCA1/2 mutation-positive experience present significant challenges to 
both individual and family development. Living with increased hereditary risk of cancer 
may be considered a chronic health condition; although pre-symptomatic individuals are 
not facing illness challenges per se, they are still subject to a non-normative level of 
medical attention in the form of testing and screening, worry, decision-making, etc. These 
issues are likely to vary in applicability and intensity depending on one’s location in the 
individual and family life cycle and proximity of transitions (Rolland, 2005). For 
example, a mutation-positive woman in her early thirties may be transitioning from a 
period in which she was comfortably managing her risk via chemoprevention (e.g., 
through the use of oral contraceptives), to one in which she chooses to end 
chemoprevention in order to attempt to become pregnant. During this time, she may be 
relying solely on increased surveillance as a strategy to manage her cancer risk. This life-
cycle change may, therefore, be associated with a psychologically and emotionally 
significant change in her experience as a mutation carrier, even though it would not 
necessarily be associated with development of disease. Similarly, a mutation carrier who 
has completed or decided to forego childbearing may choose to transition from 
surveillance or chemoprevention to risk-reducing surgery as a risk management strategy; 
this family life-cycle transition would then likely be associated with a reduction in cancer 
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worry as a result of the surgery, but also with an immediate increase in stress, given the 
physical, emotional, and financial challenges associated with undergoing surgery. 
Life course concepts of time and place and time are relevant to today’s young 
BRCA1/2 mutation carriers for several reasons. The mapping of the human genome and 
identification of the BRCA1 and BRCA2 mutations was a significant historical event with 
major implications for members of hereditary breast cancer families. Prior to the mid-
1990s, members of families in which many individuals had experienced breast and/or 
ovarian cancer may have had a sense that there was a hereditary component to their 
experience, but did not have any method of confirming that belief or ascertaining their 
individual risk. Today’s young female members of HBOC families are at an advantage in 
that they can choose to undergo genetic testing and therefore make relatively informed 
decisions with regard to life choices and risk management (although some uncertainty in 
these contexts remains, as discussed previously); this opportunity is afforded to them by 
virtue of the fact that they are young adults at this point in history. In addition, with 
regard to timing, we must also consider the differential impact that knowledge of positive 
BRCA1/2 mutation status will have on the lives of young women, simply because it 
occurs at this demographically dense period of the lifespan, when so many other 
important transitions are happening and roles are being fulfilled. Women who undergo 
testing in their twenties will have a very different experience of genetic testing and 
learning their results than will women in their forties, simply because this phenomenon is 
timed differently within the life course. Further, even within the young adulthood phase 
of the life cycle, issues of timing affect the context in which individuals cope with and 
make decisions about their risk. Women who learn that they are mutation positive before 
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they have completed their education or identified a permanent partner are faced with a 
different set of challenges than are present for women who learn of their mutations after 
they have married and had children. 
Another important way in which life course concepts are related to the issue of 
cancer development in BRCA1/2-mutation carriers relates to some of the relevant risk 
factors for the disease. It is well-established that breast cancer risk is related to 
cumulative exposure to active ovarian function and therefore risk increases with younger 
age at menarche, older age at first birth, lower parity, and later age at menopause (J. 
Lynch & Davey Smith, 2005). Although some of these factors are simple biological 
issues that have little to do with behaviors, factors such as older age at first birth and 
lower parity are intricately tied to life course decision making, and how those choices are 
made by any individual can be understood through the lens of life course agency. Women 
of any mutation status who delay childbearing, or who make that life course transition 
“off-time” with regard to historical expectations about appropriate roles for women 
across different ages, actually put themselves at higher risk of breast cancer. This level of 
risk is further increased for those who carry a mutation in BRCA1/2, and carriers face a 
different challenge in navigating the constraints imposed by their mutations, acting with 
agency to balance often competing demands. Similarly, lower parity is related to life 
course decision-making, as women who commence childbearing at a later age would be 
likely to have fewer children overall given the fewer available years in which the ability 
and desire to bear children overlap. Women who choose to remain childless or form a 
family by means other than biological childbearing are making decisions with 
implications for their objective cancer risk, and often doing so after careful consideration 
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and thoughtful decisions about their needs and desires related to personal/family and risk-
management goals. Both groups are increasing their breast cancer risk due to increased 
exposure to active ovarian function prior to or in the absence of first birth. 
Synthesis of Theories 
A synthesis of life course and biopsychosocial theories provides the ideal 
theoretical lens through which to understand and explain the unique challenges faced by 
women who are aware of their positive BRCA1/2 mutation status during young 
adulthood. Responsible qualitative methodology calls for consideration of process, 
context, and meaning in understanding how a given phenomenon affects members of a 
relevant population. In the current study, the biopsychosocial perspective provides a lens 
through which to understand context, while life course theory allows for understanding of 
individuals’ unique processes and the manner in which they make meaning of their 
experiences. The two theories marry nicely in their conceptualization of multiple system 
levels that influence individual behavior. A woman in the potentially lengthy, chronic 
“pre-vivor” phase of the BRCA1/2 mutation-positive experience, making decisions in 
light of knowledge of her mutation, is reacting to a significant phenomenon that is 
present at the cellular level, which influences the tissue, organ, and nervous system levels 
in her body, as discussed previously. In part, she must make life decisions concerning 
relationships, family formation, and risk management in response to the limitations and 
risks imposed on her by these intra-individual biological constraints. Her choices are 
made within the context of the various two-person, family, cultural, and societal 
environments in which she exists, and may be significantly impacted by the broader 
events that occur at the societal level during her lifetime (e.g., availability of certain 
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treatments, or medical opinion regarding the efficacy of available risk-reduction 
strategies). Choices are also influenced by the manner in which a mutation-positive 
woman and those with whom she has close relationships have navigated the crisis phase 
of the BRCA1/2 experience (discussed next), or the extent to which they have 
successfully integrated their awareness of the mutation with their identities and 
conceptualization of their lives going forward (Rolland & Williams, 2006). 
The biopsychosocial model of illness development can “provide a better link 
between the biological and psychosocial worlds, clarifying the relationship between 
chronic illness…and the family experience,” (Rolland & Williams, 2006). A key concept 
of this model is the time phase of illness, which provides insight regarding individual and 
family processes in the context of living with genetic susceptibility to cancer. 
Understanding the time phase of a health condition allows patients, families, and 
healthcare providers to recognize and plan for the changing demands of a health issue, 
and to recognize the unique challenges relevant to each phase of the illness experience. 
The three phases are the crisis phase, the chronic phase, and the terminal phase. During 
the crisis phase, affected individuals and members of the family/couple systems in which 
they are embedded are challenged with creating meaning for their health condition that 
preserves a sense of mastery. Often, they must grieve the loss of their pre-illness identity, 
reconciling their illness status with the entirety of their lives going forward. They must 
develop flexibility in order to be able to respond to the stresses of uncertainty and 
possible loss (Rolland & Williams, 2006), work to become accustomed to a new 
understanding of normality, and learn to live with illness-related treatments, symptoms, 
tests, etc. This phase is clearly applicable to young BRCA1/2-positive women in the 
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period immediately following genetic testing, during which they may struggle to create 
meaning with regard to their mutation and come to a personal understanding of why the 
mutation has affected them, and find a way to feel powerful and capable of handling the 
challenges associated with the mutation. They may deal with anger, disappointment, fear, 
loss, and other difficult emotions during this phase. For young women especially, the 
crisis phase may be characterized by a significant shifting of life plans, including long-
held ideals about when major events such as marriage and childbearing might occur. The 
current study can further our understanding of this dynamic because it includes many 
participants who are moving through the crisis phase, or have recently completed it. 
The chronic phase of illness is characterized by learning to live with the day-to-
day challenges of an illness condition and preserving or redefining one’s developmental 
goals and those of the larger system within the individual and family developmental goals 
given the limitations imposed by the illness (Rolland & Williams, 2006). This phase is 
relevant for many of the women recruited for this study. It should also be noted that for 
BRCA1/2-positive women, the “chronic” phase of this health condition may continue 
indefinitely; in fact, for those who never develop cancer, the chronic phase may last the 
rest of their lives. Therefore, the stresses, challenges, and strategies for success applicable 
to this phase may become quite “normal” and be viewed as part of everyday life by 
women in this population.   
The terminal phase of illness is related to issues of death and dying and provides 
an opportunity for acknowledging an imminent loss and saying goodbye (Rolland & 
Williams, 2006). Though this phase is not likely relevant for BRCA1/2 mutation carriers 
during young adulthood, it may be seen by some as looming on the horizon given 
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mutation positive women’s recognition of a higher risk of cancer-related mortality and a 
potentially shortened lifespan. In sum, the concept of the time phase of illness (or, in this 
case, the time phase of a health-related pre-illness condition) speaks to the challenge 
facing young women in reconciling their personal and family goals and desires with the 
constraints placed on them by the presence of a BRCA1/2 mutation (e.g., completing 
childbearing by a certain age in order to move forward with risk-reducing surgery, or 
balancing family formation with chemoprevention).   
With a focus on women’s lives and experiences, I draw on a feminist approach, 
which can further serve to link the two major theories. Gordon (1979) defined feminist 
theory as “an analysis of women’s subordination for the purpose of figuring out how to 
change it,” (p. 107). This focus necessitates attention to how gender and gender relations 
(as well as class, race, etc.) shape social experience, and how the social construction of 
differences and power relations between genders (and other groups) impact women’s 
lives. Feminist theory purports that gender is a socially constructed system, in which 
inequitable expectations of men and women shape how individuals operate within their 
relationships and broader social settings. Many variations of feminist theory exist, but all 
concur that women’s experiences, values, and activities are meaningful, important and 
deserve to be acknowledged (Acker, Barry, & Esseveld, 1983). Feminists argue that 
unequal distribution of power between genders promotes feelings of powerlessness in 
women, in which they may feel that something is intrinsically wrong with them rather 
than recognizing the cultural flaw (Osmond & Thorne, 1993).  
This clearly has application in the context of young female BRCA mutation 
carriers and in considering the impact of mutation-positive status on women’s 
 
 72
experiences in families and relationships. Women’s angst at deciding whether or not to 
disfigure their bodies to prevent cancer is largely related to their fear that they will no 
longer fit the cultural ideal of beauty, and specifically that a man (or men in general) will 
find them less attractive, challenging women’s socially constructed roles as partners and 
their perceptions of themselves as sexually desirable. They also worry about how altering 
their fertility or ability to use their breasts to nourish their children will conflict with their 
roles as mothers. Finally, BRCA1/2 mutation carriers may experience an exaggerated 
conflict over work/family balance when they are told that they must consider accelerating 
their plans for family formation in order to move forward more expeditiously with risk-
reducing surgery, likely requiring them to make sacrifices to their educational and/or 
career plans and goals. A feeling of powerlessness may be the result of believing that 
one’s choices regarding couple relationships, family, and career are being limited by the 
presence of a mutation and the changes to one’s life trajectory that it necessitates. 
An important feature of research guided by feminist theory is the inclusion of 
women’s subjective knowledge of their own lives. Capturing this requires researchers to 
incorporate the many voices of women, affording them the opportunity to articulate and 
interpret their own life experiences (Lugones & Spelman, 1999; D. Smith, 1987). 
Respecting women’s unique voices expands our understanding of their actual 
experiences, rather than relying on distorted and false constructions set forth by the male 
monopoly over accounts of women’s lives (Baber & Allen, 1992; Lugones & Spelman, 
1999). This qualitative study provides women from this understudied population with just 
such an opportunity, and gives the medical, mental health, and family science 
communities important insight about their strengths, opportunities, and challenges. 
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Feminist researchers have examined women’s decisions around health, work, and 
family, how those choices are made in the context of the cultural and structural 
expectations placed on women, and the impact of structural inequalities and differential 
access to power. Han and Moen (1999) used life course theory to describe how 
conflicting contexts of work and family intersect, and illustrate both men’s and women’s 
life trajectories are differently prioritized and altered within families when competition 
between individual and family objectives necessitates some compromise, revealing that 
women’s career objectives more often take a backseat to what their male partners wish to 
accomplish, while women often find themselves managing priorities related to home and 
children. Marks and Lambert (1998) examined the impact of marital continuity and 
change on men and women in young adulthood versus middle age, and found that 
relationship dissolution and continuing never-married status had a more significantly 
negative impact on young women than on similarly aged men, presumably due to the 
cultural pressure women feel to partner and bear children before their “biological clock” 
expires. Other, more recent work has focused on physical and mental health, and how 
both structure and physiology shape women’s choices and create gender differences in 
health (Bird & Rieker, 2008; Weber, 2006).  
Beyond these social expectations and values, the use of feminist theory as a lens 
through which to examine the BRCA-positive experience for these young women requires 
a consideration of how allocation of power and resources in institutions compete with 
women themselves for authorship over their lives. Young women in HBOC families 
comprise a wide range of life experiences, and this study describes a small subset of 
them. The highly educated, almost exclusively white, upper-middle-class participants in 
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the current study are unlikely to emphasize or even see how power works on their behalf. 
Because they have been tested for the mutation, we know they have access to information 
and to medical care. By virtue of the fact that they have learned about this study, and 
because many of them have completed or are contemplating very proactive approaches to 
managing their risk, we know that they are agentive. But a group of participants with less 
access to power might perceive structure quite differently, and recognize how 
institutions, or assumptions about class/race, have constrained their choices and agency 
and, perhaps, contributed to less positive experiences as mutation carriers.  
The feminist approach marries nicely with the life course concept of agency, in 
that BRCA1/2 positive women are actively and thoughtfully making personal decisions 
based on the information and choices available to them in their circumstance; they are not 
simply being acted upon by some outside force with no individual control over the path 
they take through the mutation-positive experience. Further, as described by Becker 
(1997), young mutation-positive women amend and navigate existing cultural ideologies 
in their own lives, sometimes finding ways and reasons to resist these structural 
“shoulds” and “musts.” They are using agency in their everyday lives and finding the 
power to create continuity after disruption. Becker states that “people’s initial concerns 
after a disruption are about the loss of personal power and how to regain that power, that 
control over their lives,” (p. 201). The data presented in Chapters Five through Nine will 
make clear that mutation-positive women acutely feel this lack of power, and will 
illustrate the multitude of ways that is dealt with by different individuals, such as by 
finding like others and taking action to alter context. Like those in Becker’s study, these 
participants use agency to “create order out of disruption” (p. 203) 
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This study can aid in understanding how young women who carry mutations in 
BRCA1/2 act with agency to create unique life paths given the opportunities and 
constraints presented to them by their status as mutation-positive – a clear link between 
the biopsychosocial perspective and life course theory. Their biological circumstance 
presents a set of significant and difficult challenges to their ability to successfully fulfill 
societal expectations about the roles of “partner,” “mother,” and “woman” at certain 
times in their lives. They must make difficult decisions when, for example, they wish to 
delay marriage and/or childbearing in order to experience a period of independence and 
autonomy or to focus on education or career development, but their doctors advise them 
to complete childbearing by the age of 35 in order to pursue risk-reducing surgery at the 
most advantageous age. The life paths of these women, then, are shaped not just by 
societal and familial expectations, not just by individual preferences and desires, but by 
the unique biological challenges and constraints presented by their mutations. Learning of 
one’s mutation demands consideration of how one might alter previously held beliefs and 
plans about the life path, roles, and timing of transitions in order to take these new 
challenges into account. What was previously considered “on-time” in terms of transition 
from one role or life stage to another may be suddenly thrown into “off-time” status by 
the knowledge of a mutation when, for example, delaying childbearing until one’s late 
thirties no longer seems like a viable or healthy option. The timing of the presence of the 
mutation in one’s life creates a maelstrom of issues and challenges at the individual, 
dyadic, and family levels. 
This unique interface between biopsychosocial and life course perspectives is on 
the leading edge of public health and behavioral genetic research. When biological 
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perspectives on life course theory have been utilized previously, researchers have 
maintained that complex interactions between biological and social forces define ranges 
of likely behaviors (Shanahan, Hofer, & Shanahan, 2003). In recent years, life course 
theorists have begun to consider biological influences on behavior across the life course, 
including that of genetics. However, most of this research and study has focused on 
“behavioral genetics,” or how specific genotypes (genetic makeup) influence behavioral 
phenotypes (the products of genes) (Shanahan et al., 2003). For example, behavioral 
genetics may contribute to our understanding of how levels of warmth and empathy 
between parent and child are created. Some children may be genetically predisposed to a 
more difficult temperament, which may or may not be similar to that of their primary 
caretakers. In response to this difficult temperament, a parent may have more or less 
difficulty successfully bonding with the child, which is at least to some extent determined 
by his or her own genetic predisposition to temperament. The product of these 
interactions is the quality of the parent-child bond which, although partially determined 
by genes, is also the product of individual decision-making and reaction to elements of 
the relational system. 
Recent research on the integration of behavioral genetics and the life course 
recognizes that “the links between genotypes and phenotypes are often heavily 
conditioned by social location and personal experiences,” (Shanahan et al., 2003, p. 611); 
that is, both genetics and individual histories of experiences, contexts and relationships 
are key in determining the set of behaviors that will be demonstrated by a person. 
Currently a major focus in the study of genetic epidemiology is on gene-environment 
interactions; life course theory can contribute to this field of research because of its utility 
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in examining shared and non-shared environmental influences over the life course (e.g., 
two siblings who share 50% of their genetic make-up and some proportion of their life 
experience). So, life course theory can help explain why two sisters with the same 
mutation in BRCA1/2 and the same family cancer history may have different outcomes 
with regard to their personal experience of cancer. It is possible that, for example, 
although they both observed and were involved to some extent with their mother’s battle 
with breast cancer, sisters’ different ages at the time of the diagnosis can create a 
differential psychological impact and a different personal conceptualization of cancer. A 
younger sister who watches her mother experience breast cancer during early puberty, at 
a time when her own breasts are just forming and she is in the process of becoming 
accustomed to breasts being part of her body and identity, may be more significantly and 
negatively impacted by her mother’s cancer (Wellisch & Lindberg, 2000) than would a 
woman whose mother had cancer when she was 22, had been finished with puberty for 
several years, and was likely away at college and somewhat removed from the family’s 
cancer experience. This may result in the younger sister taking more proactive steps to 
reduce her risk (e.g., undergoing a risk-reducing surgery at a very young age) than the 
older sister, and thereby successfully avoiding cancer while the older sister does not. 
These concepts relate to factors of attachment theory and perceived cancer risk 
development over the life course, whereby a daughter’s attachment relationship with her 
cancer-affected mother may, in some ways, set the stage for her own manner of dealing 




It is inarguable that women who are aware of their positive BRCA1/2 mutation 
status during young adulthood, although they are dealing with normative life tasks, face a 
unique set of challenges that are significantly different from the experiences of both non-
carrier peers and older female mutation-carriers. As thoroughly reviewed here, previous 
research has investigated how women in the immediate pre-menopausal years, who are 
typically finished with childbearing and for whom relationship status is relatively 
consistent, make decisions with regard to risk reduction. Only a small subset of this 
research has been psychosocial, and most has focused on women’s decisions about and 
experiences with genetic testing (Lerman et al., 1994; Lerman et al., 1997; Lodder et al., 
1999), the psychological impact of genetic testing (Dagan, 2005; Lynch et al., 1997; van 
Oostrom et al., 2007), dynamics of perceived versus actual risk (d'Agincourt-Canning, 
2005; Kelly, Senter, Leenthal, Ozakinci, & Porter, 2008; Werner-Lin, 2007), and 
decision-making about and coping with risk-reduction (Madalinska et al., 2005; 
Schwartz, 2005; Tercyak et al., 2007). However, partly because of the relative recency of 
the widespread availability of genetic testing for BRCA1/2 and the rapidly increasing 
population of young women with confirmed pre-vivor status, there has been very little 
research on the lived experiences of young adult BRCA1/2 mutation carriers. Although 
there may certainly be some overlap with the experiences of older mutation carriers, it is 
important to specifically investigate this younger subset of the BRCA1/2-positive 
population in order to understand how they face their unique challenges, so that they may 
be better served by the medical and mental health communities. 
Women in their twenties and thirties face challenges related to the transition to 
adulthood, including differentiation from family of origin, couple and family formation, 
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and career development. In the current study, I explored how young women with 
BRCA1/2 mutations cope with these normative challenges and navigate the constraints 
imposed by their cancer risk. In other words, how do women who have been identified as 
BRCA1/2 mutation carriers navigate the experience of young adulthood and, specifically, 
how can we understand the ways in which BRCA1/2 mutations and breast/ovarian cancer 
risk perception shape and are shaped by young women’s interactions in partner 
relationships, their decision-making about reproduction and/or family formation, and 
their handling of risk-reduction strategies and decisions? 
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CHAPTER 4: DESIGN AND METHODOLOGY 
Overall Strategy and Rationale 
 Rooted in the principles of symbolic interactionism, qualitative research seeks to 
richly describe the complex ways in which people in various contexts think, behave, and 
create meaning (Ambert, Adler, Adler, & Detzner, 1995; K. J. Daly, 2007; Patton, 2002). 
Unlike the positivist approach of quantitative research, which seeks to identify 
statistically significant relationships among predetermined variables, qualitative research 
uses rigorous methodologies to explore how and why particular phenomena affect 
people’s lives – data that are not always accessible from a simple survey or questionnaire 
(Creswell, 1998). Using a flexible, emergent design, qualitative researchers adapt their 
designs and inquiries through the process of data collection as their understandings of 
particular phenomena deepen or change. Adaptations may include pursuing new variables 
of interest as they emerge, including more or fewer participants based on saturation 
levels, or modifying interview questions to better explore a particular concept (Patton, 
2002). Unlike quantitative data, which represent subjects and variables numerically, 
qualitative data use words and images to create thick, detailed descriptions of people’s 
perspective and experiences (K. J. Daly, 2007; Patton, 2002). To do this, qualitative 
researchers attempt to understand and empathize with participants’ experiences to the 
degree that they are able to capture the meanings and emotions of the studied 
phenomenon (Patton, 2002). 
 The current study was conducted using qualitative methodology for three primary 
reasons. First, qualitative methods and data complement the fundamental quantitative 
methods of psychosocial research, as well as the principles of family research. The 
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knowledge gained from this study about the experiences of young BRCA1/2-positive 
women can be used to create change at the individual, family, and cultural levels (Patton, 
2002). In addition, qualitative research contributes to a deeper understanding of the 
fundamentals of family life, in terms of the diverse processes by which families create 
meaning and subjectively interpret their relationships and social environments (K. J. 
Daly, 2007; Gilgun, Daly, & Handel, 1992). 
 Second, Patton (2002) advises that qualitative research should be undertaken by 
those who believe it is the right decision personally. As a licensed marriage and family 
therapist who works with families with hereditary cancer syndromes in both therapeutic 
and research settings, I have heard young mutation carriers emphatically lament their 
perception that the healthcare providers with whom they interact do not sufficiently 
understand the unique challenges they face and wish for additional recognition of the 
perceived impossibility of their choices. I am deeply committed to understanding how 
individuals navigate the mutation-positive experience, and why they are affected in 
different ways psychologically, emotionally, and within their family and other close 
relationships; and to extending this broad understanding to other professionals with 
whom women in these populations interact. As a researcher and a clinician, I demonstrate 
this commitment through the process of hearing clients’ and patients’ stories, helping 
them to extract meaning from their experiences, and creating an environment that 
conveys respect and understanding for each person involved. As Patton (2002) notes, 
there are several principles of qualitative research that also match my personal style of 
quality therapy, which include: (1) recognizing and respecting individual differences; (2) 
collaborating with people about how they want to change rather than imposing my own 
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beliefs about what they should do; (3) being open to the perspectives and experiences of 
others; (4) allowing emotional experiences to transpire in our work together by providing 
an environment where others feel comfortable expressing their closely held thoughts and 
feelings; and (5) remaining nonjudgmental, accepting, and supportive so as to empower 
people to effect change in their own lives. The qualitative emphasis on my abilities to be 
empathic both within an interview and a therapy session brings together the research and 
clinical aspects of the proposed study. As a result, this study is uniquely positioned to 
contribute to both bodies of knowledge. 
 Third, there are no available data sets that contain quantitative information about 
the experiences of young BRCA1/2-positive women in navigating the tasks of young 
adulthood in the context of their mutation-positive status. The reason for this is that we 
do not yet know what the relevant issues are for women in this population, because no 
other researcher has yet undertaken a high-quality, exploratory qualitative investigation 
to allow these women to tell their stories and bring their challenges and successes to light. 
Therefore, a quantitative investigation into how different factors may be related is not 
possible. Qualitative research will serve the purpose of providing preliminary data about 
this topic, upon which future quantitative studies could be based, and in which variables 
identified as being of potential interest could be evaluated more formally. 
 Modified grounded theory is the qualitative approach that was used in the current 
study. Pure grounded theory, developed in 1967 by Glaser and Strauss, emphasizes the 
process of researchers suspending preconceived ideas about a specific topic or 
population, and allowing phenomena and theory to emerge from the data rather than 
strictly interpreting the data within the parameters of a pre-determined theory (K. J. Daly, 
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2007; Strauss & Corbin, 1998). Through the simultaneous use of both inductive and 
deductive analytic processes, grounded theorists listen for clues about the salience of key 
issues, which then provide direction as to the types of questions that should be asked to 
truly develop a grounded theory (K. J. Daly, 2007; Patton, 2002). Theoretical findings 
that emerge from qualitative data are subject to change, just as participants’ experiences 
and stories are expected to change over time (K. J. Daly, 2007). 
 A more recent adaptation of pure grounded theory is often referred to as modified 
grounded theory, which seeks to unite the concepts of a pre-existing theory with 
emergent theoretical concepts steeped in qualitative data. This process begins with an 
explicit theoretical perspective, which in this study is the combination of the 
biopsychosocial perspective and life course theory. This perspective is to direct the initial 
creation of the interview questions and interpretation of findings (Patton, 2002). 
Theoretical concepts from each of these perspectives (e.g., on-time/off-time progression 
through the life-cycle; partner, family, and societal expectations) serve as sensitizing 
concepts, which are ideas that suggest a direction along which to develop interview 
questions and organize and analyze the data (K. J. Daly, 2007). However, while questions 
were developed with these concepts in mind, they do not specifically ask about women’s 
perceptions of being on-time/off-time, or their perceptions of others’ expectations 
regarding their choices. Rather, open-ended questions are used to ask study participants 
to describe their previous and current plans for progression through normative 
developmental stages, or to describe various aspects of their relationships with partners, 
family members, etc. These questions were developed in such a way that the sensitizing 
concepts would emerge if they are salient to the participant, but other related or unrelated 
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concepts may unexpectedly develop that contribute to a more holistic theoretical 
understanding of the topic and population being considered. As a result, modified 
grounded theory allows the researcher to develop a substantive theory, which is a 
theoretical explanation unique to a specific empirical area of inquiry, rather than a formal 
theory that offers explanations at a broader level (K. J. Daly, 2007). Modified grounded 
theory also allows researchers to investigate if and how the formal theories initially used 
to guide the development of a study are, in fact, useful in understanding the sample and 
issue being researched. 
Participant Selection and Recruiting 
 Women aged 35 and younger who have tested positive for a deleterious mutation 
in BRCA1/2 were recruited to participate in semi-structured, open-ended telephone 
interviews. Criteria for participation included the ability to speak and understand English 
fluently; completion of genetic testing for BRCA1 and/or BRCA2 and receipt of positive 
results; and having experienced in the past or contemplating at some point in the future at 
least one of the following: (1) creation of a permanent couple relationship; (2) family 
formation through biological childbearing or any other method; or (3) risk-management 
via clinical surveillance, chemo-prevention, or mastectomy/oophorectomy. Inclusion 
criteria were determined via pre-interview screening telephone calls (see Appendix E). 
Site and Sample 
Participants were recruited through three primary sources. Fourteen were current 
or past participants in the Breast Imaging (BI) study (NCI protocol 01-C-0009). Of these, 
one was also a member of a family involved in the Hereditary Breast and Ovarian Cancer 
(HBOC) family study (NCI protocol 02-C-0212). Both the BI and HBOC studies are 
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currently being conducted by the Clinical Genetics Branch (CGB), DCEG/NCI. The 
former is a pilot study of screening breast MRI and ductal lavage in 200 women from 
BRCA mutation-positive families, who are evaluated at the NIH clinical center annually 
for four years. Women enrolled in these CGB studies are ideal interview participants for 
the current research because they have developed a long-standing relationship with CGB 
researchers and because many of them have previously met with me to complete a novel 
psychosocial tool – the Colored Eco-Genetic Relationship Map (CEGRMs) – which 
assesses the social and relationship functioning of individuals within their social 
networks, including both family and friendship relationships (Kenen & Peters, 2001; 
Peters et al., 2006). Further, six of the fourteen women recruited through existing CGB 
clinical studies had previously participated in the pilot investigation undertaken to 
prepare for the current study, in which they took part in 45-120 minute interviews about 
communication with partners relative to their mutation-positive status (Hoskins et al., 
2008). This previous research participation likely helped these women to feel comfortable 
completing a telephone interview with me, as they already knew me from a similar 
context and we have established a functional and friendly relationship.   
The HBOC study is a multidisciplinary etiologic study of 65 hereditary 
breast/ovarian cancer families, half of whom have known mutations in BRCA1 or 
BRCA2 and who have been under prospective evaluation since the late 1960s. Women 
enrolled in the HBOC study are ideal participants for the same reasons noted previously 
with regard to women in the BI study, although they have not had direct contact with me. 
These families have a long-standing relationship with CGB, having participated in 
multiple studies over the years, and are open to continued participation in future studies.   
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As a CGB staff member, I have easy access to both of these groups and was able 
to present myself to them within my role as a CGB investigator, a familiar dynamic to 
them. Because of the unexpectedly strong response received from the FORCE 
community, it was decided that we would contact only the BI participants within the 18-
35 age limit, rather than contacting both BI and HBOC groups. Therefore, each mutation-
positive BI participant aged 35 or younger as of January 1, 2009 (n=29) was contacted by 
telephone and invited to participate in the study. Fifteen were willing to participate and 
met all eligibility requirements (as measured by the telephone screening interview; see 
Appendix E). Subsequently, one participant withdrew from the study for personal reasons 
(after the screening interview but before the qualitative interview). BI participants who 
also participated in the pilot study (Hoskins et al., 2008) and who wish to be interviewed 
for the current study (n=6) were all be eligible to participate, since the topics being 
studied in the current project are a significant expansion from the previous. 
 In addition, 24 participants were recruited from the membership of Facing Our 
Risk of Cancer Empowered (FORCE), an online support and patient advocacy group 
which serves the needs of individuals at increased genetic risk of breast and ovarian 
cancer. Through my research and therapy work in the hereditary cancer field, I have 
established a relationship with Dr. Sue Friedman, the founder of FORCE. Dr. Friedman 
generously offered to allow me to use FORCE’s message boards, e-mail contact list, and 
Sue’s personal relationships with young mutation-positive women to recruit additional 
participants. A notice about the study was posted on the web page dedicated to research 
opportunities for women in HBOC families, as well as on the online discussion board 
used specifically by young pre-vivors. A link to study information was posted in the new 
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visitor survey that greets each visitor to the FORCE website. Additionally, Dr. Friedman 
sent e-mail “blasts” to young women on the mailing list with information about the study 
and how to contact me if they wish to participate; these e-mails were sent periodically 
until recruitment goals were reached (i.e., when theoretical saturation was achieved). The 
FORCE study notice can be found in Appendix D.  
   Table 1: Recruitment Sources 
________________________________________________________________________ 






Subset of BI participants who meet eligibility criteria; 
participated in 1-4 annual screening visits to NIH 
clinical center, including interviews focusing on 




Women who have voluntarily submitted contact 
information to FORCE and meet eligibility criteria.  
Invited to participate via announcements on the 





Women known to other participants and meet 
eligibility criteria. Interviewees were asked to inform 
BRCA+ acquaintances/ relatives of study and share 
researcher’s contact information. 
2 
________________________________________________________________________ 
Finally, two participants were recruited through snowball sampling, in which 
participants identified through the BI study or FORCE were asked to facilitate 
recruitment by recommending other women they know who may be eligible and willing 
to participate (Marshall & Rossman, 1999). In both cases, a participant referred her sister; 
 
 88
contact with women identified through this method was not initiated by the researcher. 
This strategy was utilized for its potential to yield new and important information as a 
result of recruiting multiple members of the same family or support network, which 
allowed for the examination of the different ways in which individuals within families 
interpret system interactions, family cancer history, traditions, etc. 
True to the nature of qualitative research, the total number of interviews that were 
conducted was unknown at the beginning of the project. Unlike quantitative research, 
which bases its decisions related to study sample size upon estimated detectable effect 
size and estimated prevalence of an outcome in a target population, qualitative research 
relies on the process of “saturation,” in which interviewing ceases when stories and 
theoretical concepts become redundant to the researcher. Daly (2007) states that 
saturation is achieved when the researcher is no longer “surprised” by what she learns 
from individual participants during interviews, because it is familiar to what has been 
heard previously. While an exact number of participants could not be pre-determined, I 
anticipated conducting 30-40 telephone interviews. According to Daly (2007), 20-25 
interviews is often a general point at which theoretical saturation is reached; however, 
because I utilized three distinct recruitment sources, allowing for a greater number of 
interviews ensured that I was able to fully capture all relevant themes and stories from 
members of all groups. The need for more interviews was evaluated throughout the data 
collection process.   
The number of responses received from members of the FORCE community to 
postings and e-mails about the study was unexpectedly high (n=82). Because future 
analyses and follow-up studies are planned as extensions to the current study, we chose to 
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maximize data collection and continue to conduct interviews beyond theoretical 
saturation. However, because theoretical saturation was indeed achieved after completion 
of approximately 40 interviews, 40 interviews (out of a total of 60 conducted) were 
included in this analysis. In order to keep the distribution of participants as even as 
possible, we included all participants recruited from the BI study, all participants 
recruited through snowball sampling, and 24 of 44 participants (54.5%) of participants 
recruited through FORCE. Participants who were related to others who completed 
interviews were automatically included in the current sample in order to maximize the 
ability to examine members of the same families. Data from the remaining 20 participants 
recruited through FORCE will be analyzed at a later date. In the remainder of the current 
document, all references to dissertation participants pertain to the 40 individuals included 
in the current analysis, rather than the entire group of 60. A summary of participant 
demographics may be found in Table 2. 
The final group of 40 participants ranged in age from 21.0 to 35.3 years at the 
time of the interview; the average age at interview was 29.8 years. All 40 participants 
self-identified as white/Caucasian, and five additionally identified themselves as Jewish. 
Participants had known about their positive BRCA1/2-mutation status for an average of 
37 months (range: 1 to 97 months). The average age at which participants learned of their 
mutations was 26.8 (range: 19.6 to 34.8). Twenty-eight women were BRCA1 mutation 
carriers, and 12 were BRCA2 carriers; among the 40 participants, 24 unique mutations 
were represented (15 in BRCA1 and nine in BRCA2), including all three Ashkenazi 
Jewish founder mutations (n = 16) and the Icelandic founder mutation (n = 1). All five 




Table 2: Participant Demographics  
______________________________________________________________________________ 
    Characteristic             BI            FORCE + Snowball      Total 
     Avg (Range)                                   (n=14)                     (n=26)       (N=40) 
______________________________________________________________________________ 
Age at Interview 31.1 (26-34) 29.3 (21-35) 29.9 (21-35) 
Age at Disclosure 25.5 (21-31) 27.4 (19-34 26.8 (19-34) 
Months since disclosure 67.2 (33-97) 21.1 (1-74) 37.3 (1-97) 
 
    Characteristic                                      BI                      FORCE + Snowball             Total 
           n (%)                                         (n=14)                          (n=26)                         (N=40) 
______________________________________________________________________________ 
Mutation:  # (%)    
   BRCA1 11 (78.6) 14 (53.8) 25 (62.5) 
   BRCA2 3 (21.4) 12 (46.2) 15 (37.5) 
   Ashkenazi mutation 9 (64.3) 7 (26.9) 16 (40.0) 
Relationship Status at Disclosure   
   Single 4 (28.6) 6 (23.1) 10 (25.0) 
   Serious relationship 8 (57.1) 5 (19.2) 13 (32.5) 
   Engaged 1 (7.1) 2 (7.7) 3 (7.5) 
   Married 1 (7.1) 13 (50.0) 14 (35.0) 
Relationship Status at Interview   
   Single 3 (21.4) 4 (15.4) 7 (17.5) 
   Serious Relationship 1 (7.1) 7 (26.9) 8 (20.0) 
   Engaged 1 (7.1) 2 (7.7) 3 (7.5) 
   Married 9 (64.3) 13 (50.0) 22 (55.0) 
Family Formation Status at Interview 
   Have kids 4 (28.6) 12 (46.2) 16 (40.0) 
   Want (more) kids 9 (64.3) 19 (73.1) 28 (70.0) 
   Pregnant 4 (28.6) 0 (0) 4 (10.0) 
Risk-Reducing Surgery Completed at Interview 
   Mastectomy 5 (35.7) 11 (42.3) 16 (40.0) 
   Oophorectomy 2 (14.3) 4 (15.4) 6 (15.0) 





the remaining 11 Ashkenazi founder mutations were carried by women who did not make 
explicit mention of an Ashkenazi Jewish background, and may or may not have been 
aware that their mutation was a founder mutation. Eight participants were related to 
another participant in the study; there were three pairs of sisters (one pair was recruited 
through the BI study; there were two pairs in which one sister was recruited through 
FORCE and then brought her sister into the study through snowball sampling) and one 
pair of first cousins among the participants (both individuals recruited through FORCE).  
With regard to relationship status, there was significant variation among 
participants. At the time they learned that they carried mutations in BRCA, ten 
participants were single (not in a relationship), 13 were in serious/long-term 
relationships, three were engaged, and 14 were married (one of these was in the process 
of getting divorced). At the time of their interviews, nine participants were single (not in 
a relationship), six were in serious/long-term relationships, three were engaged, and 22 
were married. Of those who were in relationships of any type at both times (n = 28), 24 
were with the same partner, and four were with different partners when interviewed than 
they were with when they learned of their mutations. Eight women were single when they 
learned of their mutations and remained single at the time of the interview, although 
some of these women had a relationship in the intervening months. Three women were 
single when they learned of their mutations, but had entered relationships that were 
ongoing at the time of the interview (one was in a significant relationship, one was 






















Acacia β 22, LTR 30, married 94 1 * - (M) (O)  
Annie Γ 31, single 32, LTR 13 0 + [M] (O)  
Audrey Γ 23, married 28, married 65 2 - M (O)  
Beth Γ 30, engaged 30, engaged 3 1 + (M)  
Charlotte Γ 24, LTR 26, single 21 0 + (M) © Kate 
Chris Γ 32, married 33, married 17 1 - M O  
Dawn Γ 27, married 27, married 4 2 - [M] O  
Elaine Γ 34, married 34, married 2 3 - (M) (O)  
Ellie Γ 23, single 27, LTR 44 0 + [M] (O)  
Grace β 22, LTR 31, married 97 0 * + M (O)  
Isabelle Γ 22, single 22, single 2 0 + (M) (O) § Lilly 
Jane Γ 26, married 30, married 26 1 + (O)  
Julia Γ 24, LTR 24, LTR 4 0 ? (M) (O) § Nichelle 
Kate Γ 32, marriedD 35, LTRP 36 2 + M (O) © Charlotte 
Kristy β 24, LTR 29, single 63 0 + M (O)  
Leigh Γ 33, married 35, married 22 3 - [M] [O]  
Libby Γ 31, married 32, married 11 0 + [M] (O)  
Lilly Θ 24, single 25, single 2 0 + (M) § Isabelle 
Lynn Γ 19, single 24, LTR 56 0 + M (O)  
Maelie β 28, LTR 33, married 66 3 - M O § Trixie 
Marie Γ 28, married 28, married 1 1 + (M) (O)  
Marjory Γ 24, LTR 30, LTRP 74 0 + [M] (O)  
MaryAnn Γ 26, engaged 26, engaged 2 0 + (M) (O)  
Melanie β 26, LTR 31, married 57 0 * + (M) (O)  
Monique β 21, single 26, single 61 0 ? (M)  
Nichelle Θ 20, single 21, single 2 0 + (O) § Julia 
Noelle Γ 24, LTR 26, LTR 22 0 + (M) (O)  
Pauline Γ 30, married 30, married 3 0 + [M] (O)  
Rachel Γ 30, married 33, married 42 2 - M O  
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Reina β 25, single 29, married 54 0 + (O)  
Rose Γ 29, married 30, married 6 0 + M (O)  
Ruby β 31, married 34, married 36 2 - (O)  
Rylan β 25, single 34, LTR 50 0 + M (O)  
Sadie β 28, engaged 33, married 60 0 - (M) O  
Serena β 23, single 30, single 96 0 +   
Shannon Γ 29, married 31, married 26 2 ? [M] (O)  
Sophie β 23, LTR 31, marriedP 88 0 + (O)  
Trixie β 24, LTR 27, LTRP 33 0 - M (O) § Maelie 
Valerie Γ 25, LTR 29, married 44 0 - M (O)  
Wanda β 24, LTR 32, married 86 1 * ? (O)  
________________________________________________________________________ 
Note. (1) Recruitment sources are noted by symbols following each pseudonym, whereby β = Breast 
Imaging Study, Γ = FORCE, and Θ = Snowball. (2) LTR = Long-term relationship. (3) Status at 
Disclosure: D = Divorcing (4) Status at Interview: P = Partner at interview is not the same as partner at 
disclosure. (5) Months Aware = # months between genetic testing results and interview. (6) Children: For 
each participant, the number of current children is listed, followed by either: - = no more children desired; 
+ = wants more children; ? = undecided about additional children; * = pregnant at interview. (7) M = 
mastectomy completed; (M) = considering mastectomy; [M] = mastectomy planned; O = oophorectomy 
completed; (O) = considering oophorectomy; [O] oophorectomy planned. (8) Related: § = sisters; © = first 
cousins 
 
With regard to family formation status, women varied both in terms of how many 
children they currently had, and in terms of whether and how many more children they 
were planning to have. Sixteen participants had children at the time of the interview, and 
24 did not. In response to the question, “at this time, are you considering or planning to 
have more children in the future?” ten participants responded “no;” two responded 
“probably not;” three said “maybe,” (all three of these already had at least one child); and 
25 responded “yes,” with one of these currently experiencing fertility difficulties that 
may challenge her plans. Four participants did not currently have children and reported 
that they would not or probably would not have children in the future. Eight women 
reported having completed childbearing, i.e., they already had at least one child and were 
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not planning to have any more. Four participants were pregnant at the time of the 
interview; two were expecting their first children and two were expecting their second. 
Several potentially important differences in group demographics should be noted. 
For the purposes of discussion, participants recruited through snowball sampling are 
considered together with those recruited through FORCE because a) both snowball 
recruits were referred by FORCE recruits, and b) this allows for a clinical vs. non-clinical 
comparison (i.e., a comparison of participants previously seen at the NIH Clinical Center 
vs. those who were not). Participants from the BI group tend to be older than those 
recruited through FORCE/Snowball. One-way analysis of variance (ANOVA) revealed 
that this difference in age is not statistically significant. However, there is a statistically 
significant difference between the two groups in terms of the number of months elapsed 
between mutation test disclosure and interview (α = 0.00). This makes sense when 
considered in the context of how BI study involvement fits into the life course of young 
BRCA mutation carriers. Because the BI study is a four-year process that all of the 
participants had either completed or were nearing completion, and because the vast 
majority of BI participants are aware of their mutation status at the beginning of the 
study, participants recruited from this source necessarily have known about their 
mutation longer. The range in time from disclosure to interview for women recruited 
through FORCE or snowball sampling included some who had known for as little as two 
months; this is simply not possible among women recruited through BI. Additionally, 
several women recruited through BI are members of families who have been involved in 
research studies at NIH for many years, and therefore have known about the presence of a 
BRCA mutation in the family (not necessarily in individual participants) for some time. 
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Generally, the FORCE/Snowball group was comprised of women whose families had 
learned more recently about the presence of a mutation in BRCA1 or BRCA2. 
 The proportion of participants whose mutation is one of the three Ashkenazi 
founder mutations is notably different in comparing the two groups. There are several 
possible explanations for this. One is that because the three Ashkenazi founder mutations 
are easier to test for than testing for all possible mutations in BRCA1 and BRCA2, 
members of families with Ashkenazi founder mutations may more easily access and 
afford testing. Additionally, because the increased prevalence of BRCA mutations is 
fairly well acknowledged in the Ashkenazi Jewish community, it is likely that individual 
families are more aware of the possibility that a mutation exists in the context of a family 
history of breast and ovarian cancer, and therefore more likely to seek genetic testing. 
Finally, because the NIH clinical center, where the BI study takes place, is located in a 
part of the country with a higher-than-average population of individuals with an 
Ashkenazi Jewish background, it is possible that those recruited through BI were more 
likely to have an Ashkenazi Jewish mutation that those recruited through FORCE, who 
could be from anywhere in the United States. 
The number of women who had elected to have risk-reducing surgery is notable, 
especially given the age of the participants. The number of participants who had 
undergone oophorectomy was considered in two ways: as a portion of the respective 
groups and total, and as a portion of the subset of each group who believed that they 
would not have any more children, since women who desire (additional) biological 
children do not view oophorectomy as an option. The fact that women in the BI group 
were somewhat less likely to elect surgical risk-reduction of either type may reflect their 
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involvement in an intensive screening study and a commensurate feeling that they were 
being protected via surveillance and therefore did not need to consider surgery yet.  
Table 3 provides an overview of pertinent individual and relationship 
characteristics for each participant. Narrative descriptions of each participant and her 
relational context can be found in Appendix H. 
Data Collection and Management 
After receiving IRB approval from the University of Maryland and the National 
Cancer Institute, recruitment efforts commenced. Prior to beginning the interviews, each  
participant was required to read and sign and informed consent form (see Appendix F). 
Consent forms were either e-mailed or mailed in hard copy to participants (based upon 
participants’ preferences), and the interviews did not take place until forms were signed 
and returned in hard copy. To comply with state and federal laws regarding taping of 
telephone conversations, all participants were informed that the phone interviews would 
be audio-recorded, and provided both written consent on the informed consent form and 
verbal consent on the telephone prior to the recorded interview taking place. Furthermore, 
participants were informed that they are allowed to ask questions about the study at any 
point before, during, or after the interview, and that they may withdraw from the study at 
any time without penalty and with no effect on their ability to participate in other current 
or future studies through CGB. 
 Telephone interview data were collected in 40 one-on-one, semi-structured, open-
ended interviews from February 23 to June 18, 2009. The average length of the 
interviews was 74.6 minutes (range: 30 to 160) and varied depending on participants’ 
talkativeness and how many of the issues of interest each chose to speak about and at 
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what length. In total, 2,984 minutes of recorded telephone interviews were transcribed 
and analyzed for the current study. An additional 275 minutes of recorded data were 
folded into the current study from the six BI participants who also participated in the 
earlier pilot study discussed previously; therefore, a total of 3,259 minutes of interview 
data were analyzed for the current study. Since the participants were recruited from a 
wide variety of geographic locations (participants represented 20 states and the District of 
Columbia), all interviews were conducted over the phone. Phone interviews have several 
advantages over in-person interviews, including no required travel of the interviewer and 
participant, recruitment from a larger geographic area, and the potential for participants to 
feel more open in sharing their personal stories since they are not face-to-face with the 
interviewer (K. J. Daly, 2007). Additionally, conducting interviews by telephone allowed 
me to digitally record the interviews onto an NIH computer, which later facilitated the 
transcription of the interviews and minimized time between data collection and analyses. 
The interviews were digitally recorded and process notes were taken before, during, and 
after each interview so as to capture any thoughts or reactions I may have had related to 
the content and process of the interviews, as well as to document key phrases and major 
points expressed by the participants. All recorded interviews were transcribed by a team 
of hired transcribers located on the West Coast. I personally proofread all transcriptions 
by simultaneously listening to the interview and reading the written version. 
 Qualitative methodology and modified grounded theory allows for the revision of 
recruitment strategies during the data collection process based on emergent themes. As 
previously noted, purposive sampling was used to recruit participants from three distinct 
sources: CGB’s BI study populations, FORCE membership, and through snowball 
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sampling. This varied method of sampling provided greater diversity in the sample as a 
whole, as it brought forth a wider range of prior experience and attitudes regarding 
planned behavior within the group of participants recruited through FORCE and/or 
snowball sampling, since they are not all current or past participants in a longitudinal 
screening study, as the BI participants are. Because of their participation in CGB studies, 
women in the BI group share several common experiences: (1) they have received similar 
and consistent messages regarding recommendations for fertility, risk-management, and 
risk-reduction from CGB staff; (2) they all received state-of-the-science screening during 
the period in which they actively participate in the BI study, including annual or more 
frequent clinical breast examination, mammography, MRI, transvaginal ultrasound, and 
CA-125 serum screening; (3) they were all motivated about screening enough that they 
chose to participate in this relatively intensive research study. However, women recruited 
through FORCE or snowball sampling varied more widely on each of these dimensions 
(i.e., messages received from their own healthcare providers; participation, or lack 
thereof, in various types of screening; level of monitoring with regard to their risk; length 
of family knowledge about the presence of hereditary cancer risk).  
Because qualitative research rooted in grounded theory allows for the emergence of 
whatever themes the participants introduce, and because it was unknown at the start of 
the study whether the variables listed here would prove to be important in the women’s 
stories, theoretical sampling was utilized, which means that some participants were 
recruited (or included in the current study from the larger pool of data collected) based on 
a particular idea or theme (Patton, 2002). In this case, theoretical sampling occurred in 
the selection of 24 of the 44 participants recruited through FORCE. Because age and 
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relationship status at the time of the interview proved to be important components of 
women’s thinking about risk-related choices, an effort was made to ensure diversity of 
sampling by selecting women with unique features on these dimensions (e.g., very young 
women, women who were engaged). The outcome of this was a more appropriate 
representation of the full range of experiences than might have been present if 24 
participants recruited through FORCE had been randomly selected.  
Interview protocol development. An original, standardized interview guide was 
generated specifically for the current study. Prior to beginning the interview, participants 
were informed of the purpose of this study and how the data will be used. They were 
informed that the study seeks to understand how women who have been identified as 
BRCA1/2 mutation carriers navigate the experience of young adulthood and, specifically, 
how the mutation affects their interactions in partner relationships, their decision-making 
about reproduction and/or family formation, and how they have handled or anticipate 
handling decisions about risk-reduction strategies. The data are not being used to prove a 
specific theory or hypothesis about how women are affected by their mutation-positive 
status. Rather, the data are being used to better understand individuals, couples, and 
families in which a mutation is present, and possibly to inform couple and family therapy 
treatment or other psychosocial services available to young mutation carriers. In an effort 
to build rapport and be transparent with each participant, I shared with them that I am a 
licensed marriage and family therapist who works with couples and families in a medical 
family therapy context, as well as with individuals in the context of their participation in 
the BI and HBOC studies at NCI. 
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 The interview consisted of open-ended questions that asked about the participants 
and their experiences before, during, and after they underwent genetic testing for 
BRCA1/2 (see Appendix G for complete interview protocol). The interview protocol 
consisted of six sections: 
• Section A: demographic information and participants’ personal cancer histories.   
• Section B: history of cancer in the participants’ families; questions in this section 
were developed based on systems-based sensitizing concepts of Attachment and 
family communication.   
• Section C: experience with genetic testing. 
• Section D: issues related to couple relationships, including experiences with 
disclosure of positive mutation status to past, current, and/or future partners. 
• Section E: intersection of participants’ experiences as mutation-positive and their 
plans regarding family formation.   
• Section F: questions regarding the past, current, and/or future use of cancer risk-
management and risk-reducing strategies.   
Questions in sections C through E were developed based on sensitizing concepts of 
attachment theory, on-time/off-time transitions over the life course, and the hierarchically 
interrelated nature of biopsychosocial systems, both within and outside of the individual.  
Interviewing skills. As many books on qualitative research methodology have 
explored, the skillfulness of the interviewer is an important component of research that 
should not be dismissed or minimized. Daly (2007) lists seven fundamental skills of 
interviewing that I endeavored to utilize, which include beginning the relationship, being 
attentive to the participant, staying in the present, maintaining naïveté, holding to the 
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interview protocol, monitoring personal engagement with the participant, and 
maximizing the collaborative potential of the interview. To begin and build the 
relationship, I shared a bit of information about myself and my role as a couple and 
family therapist who works with individuals and families facing medical (and specifically 
genetic) issues. While my interview questions were developed around sensitizing 
concepts of biopsychosocial, life-course, and family systems theories, I remained open to 
emergent concepts and naïve to the uniqueness of each participant’s story. Because I have 
not personally faced the challenges of living as a young BRCA1/2 mutation carrier or 
supported a friend or family member through that experience, I am already considered an 
“outsider” to the mutation-positive experience; this allows me to maintain an etic 
perspective and effectively analyze the nuances of the data. This position also affords me 
the curiosity to understand what the experience of being a young mutation carrier is like 
and to understand that through each participant’s lens, rather than imposing my own 
experiences and/or assumptions. This is in sharp contrast to the emic perspective, which 
allows the researcher to intimately share in the life and activities of the participants and 
their environments (Patton, 2002). 
 To ensure that participants perceived that their contributions are helpful and 
important, I responded to their stories from a stance of empathic neutrality, a position of 
understanding and caring that is free of judgment, while also providing support and 
recognition responses (e.g., thank you, this has been very informative so far) throughout 
the interview (Patton, 2002). 
Privacy and ethical issues. All efforts were made to protect the privacy of the 
participants and their families, as well as to maintain confidentiality of identifiable 
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information. Prior to the start of data collection, an alphanumeric code was assigned to 
each participant’s data in lieu of her name, and all paperwork containing participants’ 
names and other identifying information was kept separate from the raw data. All data 
and paperwork associated with this study are kept in a locked file cabinet in my office in 
the Clinical Genetics Branch, to which only I have access. Electronic data is stored on my 
personal drive on the CGB computer server, which is password protected and can only be 
accessed by me when logged into the secure NIH computer network. Additionally, each 
participant chose her own pseudonym to be used in writing and presenting the results. 
 As Patton (2002) notes, interviewers need an ethical framework for dealing with 
issues that may unexpectedly arise before, during, or after an interview. Since this study 
explores women’s thoughts and emotions regarding their experiences as mutation 
carriers, there was the potential for emotional hardship if the interview questions touched 
on sensitive or painful topics. Therefore, it was essential that I be prepared to handle 
situations in which participants sought therapeutic advice from me during the interview 
(given their understanding that I am a therapist). In the event that a participant expressed 
discontent as a result of her participation in the study or sought help from me for issues 
either related or unrelated to her mutation status, I was prepared to refer the participant to 
an online therapy directory where she could locate a mental health professional qualified 
to assist her in coping with those difficult emotions. In fact, several participants requested 
information about how to locate a qualified therapist in their area for assistance dealing 
with personal or relationship issues related to their mutation positive status. Furthermore, 
if a participant disclosed any information about past or present abuse of a child or 
disabled adult, expressed suicidal ideations, or expresses intent to harm someone else, I 
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was prepared to break confidentiality in order to notify appropriate authorities. 
Participants were made aware of these policies at the time they provide informed consent. 
No participants disclosed any such information, and therefore no reporting was required.  
Data Analysis 
Qualitative data are subject to both content and thematic analyses at all stages of 
the research, from the time of the first interview to the discussion of findings and 
implications. According to Daly (2007), there are four stages of analysis in grounded 
theory, which are: (1) open coding and the creation of concepts; (2) creating categories; 
(3) making linkages in the data; and (4) creating the theoretical story line. In an effort to 
organize the data in a way that would allow me to move smoothly through these four 
stages of analysis, I entered all of my raw data (i.e., transcribed interviews, transcribed 
focus group sessions) into the qualitative data management software NVivo, version 8 
(QSR, 2008). This program allowed me to organize the data and develop and modify an 
electronic codebook throughout the ongoing analysis. 
 The first stage of the analysis, open coding and the creation of concepts, involves 
breaking down the data into manageable segments through line-by-line analysis of each 
transcription. Open coding is a liberal process of openly applying labels and codes 
(naming) to data segments that are meaningful in some way (Strauss & Corbin, 1998). 
During this process, the researcher sifts through the data searching for salient words, 
phrases, sentences, concepts, and ideas that are repeatedly used by participants. For 
example, multiple participants discussed their feelings of urgency about completing 
childbearing before a cancer diagnosis or RRSO ended their fertility; these interview 
segments were coded under the common specific concept “Urgency to complete family.” 
 
 104
 As the researcher continues open coding of several transcripts, it is likely that 
similarities in participants’ stories and the related codes will emerge, thus creating a 
concept around that labeled group of data. Concepts are labels associated with the salient 
words, phrases, and sentences, and they serve as the building blocks of theory (K. J. 
Daly, 2007). It is at this point in the analysis that the researcher may rely on sensitizing 
concepts taken from the theories to guide the development of codes and concepts (Gilgun 
et al., 1992; Ragin, 1994). 
 The second stage of analysis, creating categories, refers to the ongoing process of 
open coding and bringing together related concepts under a higher level of abstraction (K. 
J. Daly, 2007). Concepts within a category may be similar or dissimilar, but somehow are 
related. For example, in addition to speaking about their urgency to complete family 
formation goals, many participants reported having thought about whether and how their 
desired family size might be impacted by their mutation statuses. While each of these 
segments would be coded separately during open coding, this second stage of analysis 
would cluster these various codes into one larger concept labeled “Timing of Family 
Formation,” because they both contain data about how participants conceptualize 
managing the timing of childbearing in the context of managing their mutation.   
Comparative analysis, in which concepts are compared in an effort to construct 
categories, serves as the primary way in which the data are organized and synthesized 
into meaningful groups during stage two of analysis (Patton, 2002). Daly (2007) warns 
researchers that this is the stage where the analysis is most complex due to the potentially 
overwhelming number of categories and related codes that can emerge. However, this 
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complexity speaks to the wide range of theoretical possibilities, and so it is important to 
allow these numerous categories to emerge. 
 The third stage of analysis, making linkages in the data, is often referred to as 
axial coding, which is a reassembly of the data after completing the open coding process 
(K. J. Daly, 2007; LaRossa, 2005). This stage of analysis involves looking at emergent 
relationships within and between the categories created in stage two. As a result, several 
categories that are somewhat similar (have the same core “axis”) may be collapsed into 
larger, more abstract concepts with new properties and dimensions. For example, during 
stage two of coding, the categories “timing of family formation,” “breastfeeding,” and 
“risk perception” all emerged as important concepts. In an attempt to examine the 
relationship between these concepts, a higher-order concept emerged that described 
women’s strategies for and decisions about controlling childbearing-related issues in 
concert with risk-management decisions. Women who have opposing desires or 
perceived needs on these issues often feel as though they must sacrifice one priority or 
the other. This new, higher-order concept was then examined among other higher-order 
concepts. As the categories became more defined and unique to the data, theoretical 
saturation of each category was achieved, such that no new information emerged from 
the interviews to deepen the meaning of each category (Patton, 2002). 
 The fourth and final stage of analysis, creating the theoretical story line, involves 
integrating and refining the theory through the analysis of participants’ stories (K. J. 
Daly, 2007). Using selective coding, data were interpreted and carefully selected to help 
tell a “story” that integrates the categories created through open and axial coding. At this 
point, I sought to weave together the data with the theories, a process known as 
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abduction, to determine the core categories that will serve as the “narrative spine” for the 
story (K. J. Daly, 2007). As expected, the story created as a product of this research 
progresses somewhat chronologically through the lifecourse, beginning with their 
perceptions of cancer risk before and after genetic testing, then addressing issues related 
to couple formation, family formation, and risk-reduction in that order. However, I 
remained open to the various ways, aside from chronologically, in which the narrative 
about women’s experiences as members of high-risk families and as mutation carriers, 
could be storied, and in fact it is the case that not all women move through mutation-
related issues in this order. For example, some women had already established couple 
relationships when they were tested for the mutation, and others had already completed 
their families at the time of testing. 
 It is important to note that movement through these stages of coding and analysis 
is not necessarily linear or consecutive. Strauss and Corbin (1990) highlight the 
significance and utility of researchers moving back and forth between stages as data 
collection and analysis simultaneously occur so as to modify and polish codes and 
categories in an effort to capture the authentic story emerging from the data. In practice, 
movement between the stages of analysis continued up to and throughout the writing 
process, whereby higher levels of abstraction were reached as new insights about 
women’s processes were discovered in the course of sifting through the data with 
different foci. In fact, many important insights about the abstract meaning of the data 
were made after having written drafts of each substantive chapter, which allowed me to 
step back and think about the story that was emerging and how different elements of that 
story were related to one another. 
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Trustworthiness and Authenticity of Qualitative Data 
The trustworthiness and authenticity of qualitative research are determined by a 
variety of methodological and analytical components throughout the research process. 
Much as quantitative research focuses on validity, reliability, and objectivity of the 
analyses, the trustworthiness of qualitative research is measured by its credibility, 
transferability, dependability, and confirmability (Lincoln & Guba, 1985). To ensure that 
this qualitative study is trustworthy and authentic, a variety of techniques were used. 
Credibility. The credibility of a qualitative study is determined by how well the 
project is designed and executed in accordance with relevant qualitative methodologies, 
as well as how accurately the participants’ stories are portrayed (K. J. Daly, 2007; 
Lincoln & Guba, 1985). Credibility has been compared with the internal validity of 
quantitative studies, which refers to the ability to show a cause-and-effect relationship 
between the independent and dependent variables. According to Daly (2007), a study’s 
credibility is strengthened by the theoretical frameworks guiding specific lines of inquiry, 
the ways in which participants are selected, how data are generated, and the extent to 
which the researcher is involved in the field. The credibility of procedures and outcomes 
of the current study are strengthened by the use of theoretical sampling, peer review and 
debriefing, triangulation, and member checking. 
 Theoretical sampling refers to the process of sampling based on specific 
information and ideas that are being sought (Patton, 2002). Since the goal of qualitative 
research is to show how theoretical concepts are related to a specific population, and not 
to generalize findings to a broader population, using a selected group of women sampled 
for specific emergent themes strengthens the researcher’s ability to accomplish this goal. 
Ensuring that the study population was as diverse as possible (i.e., recruiting women 
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across the spectrum of ages, recruiting participants who were related to one another) also 
helped to increase the credibility of the study. 
 Peer review and debriefing is an important technique that allows the researcher to 
receive constructive criticism and feedback about her/his qualitative work in an 
environment that is supportive and non-threatening (Lincoln & Guba, 1985). Requesting 
and processing colleagues’ thoughts, suggestions, and questions about one’s qualitative 
work are similar to the quantitative concept of inter-rater reliability. In the context of my 
training in the Department of Family Science at the University of Maryland, I have 
formed collegial relationships with other doctoral students who are also currently, 
previously, or soon-to-be engaged in qualitative research. These colleagues, dissertation 
chair Kevin Roy, and dissertation committee member and CGB mentor Mark H. Greene, 
were consulted throughout the study provided opportunities to ask questions, receive 
feedback, and explore topical and methodological areas of qualitative research that are 
new or challenging. These individuals read some of the interview transcripts and 
reviewed the categories and emerging theoretical framework that were developed and 
provided feedback regarding how well they represent the data and relate to each other. 
Drs. Roy and Greene were also involved in the creation and evolution of the narrative 
spine of the final document. 
 Triangulation involves utilizing a variety of data collection techniques and 
drawing from a variety of participants with the purpose of substantiating findings and 
gaining a more holistic perspective of the emergent concepts (K. J. Daly, 2007; Patton, 
2002). The four types of triangulation in qualitative research are data, investigator, 
theoretical, and methodological. For the purposes of this study, both data and theoretical 
 
 109
triangulation were utilized. Data triangulation refers to the use of multiple data sources 
throughout the study. As previously noted, study participants were recruited from three 
distinct sources: the BI study, the FORCE website, and via snowball sampling. In 
addition, the data themselves consist not only of the transcribed interviews but also of 
transcripts from focus groups conducted with young mutation-positive women at the 
FORCE 2009 Annual Conference. Further, the notes I took before, during, and after each 
interview to capture my thoughts, questions, and reactions to the interview process, as 
well as to note important points made by the participants, were referenced during the 
construction of the narrative produced from the data. These notes are considered an 
important source of supplemental data because they include qualitative information that 
is not necessarily captured during the actual interview (and subsequent transcription). 
Thus, these memos were used to triangulate the interview data and help me reach a level 
of saturation, meaning that no new themes emerge from the whole data set (interviews, 
focus groups, and memos). 
 I also used theoretical triangulation, which refers to the use of multiple theoretical 
perspectives to analyze the data from a modified grounded theory approach. As 
previously discussed, the combination of the biopsychosocial perspective and life-course 
theory, taking into consideration attachment theory and a feminist perspective, provide a 
more holistic lens through which participants’ stories were analyzed than would exist had 
only one of these theoretical perspectives been considered. 
 Member checking allows the participants to review the researcher’s analyses and 
interpretations of the data and to provide their reactions and suggestions for improvement 
(Patton, 2002). In this study, participants were asked if they would like to receive a copy 
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of some portion analyses and provide feedback; the participants who wished to do so 
were given an opportunity to provide suggestions and ask questions prior to the final 
defense of this study so that the findings and discussions could be constructed partially in 
light of their feedback. Twelve individuals from among the 40 participants were sent 
single chapters to read and asked to reflect on how accurately the chapter captured their 
experience, as well as whether they believed that the chapter conveyed a comprehensive 
description of the relevant phenomena. All twelve individuals responded positively and 
reported a high degree of enthusiasm about the manner in which their own and others’ 
experiences were woven together to comprehensively describe the issues they had faced 
as young BRCA mutation carriers.  
In addition, member checking was accomplished through the use of the FORCE 
focus group of young BRCA1/2-mutation carriers who attend the 2009 Annual Joining 
FORCEs Conference in Orlando, FL. Two groups of approximately 15 BRCA-positive 
women (some of whom were also study participants) were convened at the conference, 
and these women were asked to provide feedback about preliminary findings and themes, 
as well as to participate in a discussion of what they felt were the most relevant mutation-
related themes in their own lives at the time of the conference. This provided an 
opportunity to check these focus group findings against the findings identified through 
the analysis phase of the study.  
Transferability. Transferability, or fittingness, refers to the degree to which 
qualitative findings can be generalized to another situation or setting under similar, but 
not identical, conditions (Patton, 2002). This naturalistic term is often paralleled with the 
quantitative concept “external validity,” the extent to which the results can be generalized 
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to the larger population. According to Lincoln and Guba (1985), the degree to which 
findings may be applied to other contexts is heavily reliant on the researcher’s field notes 
which should be full of thick description (Patton, 2002). Descriptions that are thick, deep, 
and rich take the reader into the setting being described, the experiences of the researcher 
while in that setting, and the outcomes of that experience. Patton (2002) notes the 
importance of separating description from interpretation, in which descriptions should not 
explain or answer “why,” but should simply portray the experience. In the current study, 
attempts were made to create thick, rich descriptions of the interview experiences, so that 
readers will be able to decide how well these findings may transfer to other contexts. 
Dependability. Dependability is the qualitative equivalent of the quantitative 
research term, reliability, which refers to how well a study and its findings can be 
replicated. Since the hallmark of qualitative research design is flexibility and allowing 
findings to emerge within the context of interactions between researchers and 
participants, ensuring replicability is nearly impossible and not necessarily a goal of 
qualitative research. Thus, Lincoln and Guba (1985) developed the concept of inquiry 
auditing, in which the process and product of the qualitative research is tracked and 
examined for consistency by a third party. The researcher is responsible for creating an 
audit trail, which may include recorded materials, interview transcripts, interview guides, 
lists of interviewees, lists of created categories, field notes, and written guidelines of 
research procedures (Schwandt, 1997). To ensure dependability in the proposed study, a 
written record of all products and processes related to the research was kept, and ongoing 
consultations with both the dissertation chair, Dr. Kevin Roy, and colleagues with 
experience conducting qualitative research were afforded the opportunity to “audit” the 
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materials (e.g., interview transcripts, personal memoirs) in comparison with the findings 
to ensure that the process and product of the research are sound and consistent. 
Confirmability. Confirmability is concerned with how well the qualitative 
findings and interpretations are steeped in the data, and “not merely figments of the 
inquirer’s imagination” (Schwandt, 1997, p. 164). Similar to the quantitative concept of 
objectivity, interpretations of qualitative data should be as neutral as possible in spite of 
researchers’ values inherently guiding studies. To avoid the dichotomous argument of 
objective vs. subjective, Patton (2002) encourages qualitative researchers to strive for 
“empathic neutrality” (p. 50), in which the researcher may be empathic toward the 
participant but remains neutral toward the findings. This tenet of qualitative methodology 
is consistent with the adoption of a biopsychosocial perspective, the use of which in a 
clinical setting calls one to interact with patients from a position of “empathic curiosity.” 
This means that the clinician, or in this case, researcher, should be open to hearing 
unexpected things from a patient even if one believes s/he knows what to expect from an 
exchange (Borrell-Carrio et al., 2004). Adopting a stance of empathic curiosity/neutrality 
during a qualitative interview allows me to maintain openness to hearing the nuances of 
each individual’s experience as a unique phenomenon, rather than attempting to 
categorize it according to what I might already believe that I understand about an 
experience or group.  
Similar to the manner in which dependability can be accounted for in a 
quantitative study, Lincoln and Guba (1985) suggest that qualitative researchers also seek 
a confirmability audit, in which a third party attests to the neutrality of the research 
interpretations, based on an audit trail consisting of raw data, process and analysis notes 
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and memos, personal notes, and preliminary developmental information. This is different 
from an inquiry audit, in that this audit trail seeks to demonstrate the researcher’s 
neutrality in reporting the findings, as opposed to the other audit trail which seeks to track 
the analysis of data for overall consistency. In an effort to verify the neutrality of 
interpretations for the current study, a confirmability audit trail was developed and 
maintained, which consists of raw data; theoretical memos (notes about the formulation 
and evolution of theory); field notes with thick, rich descriptions; and a code book 
documenting the coding scheme as it is created and refined. All of these sources of 
information have been made available to both Dr. Roy and Dr. Greene so that findings 
and interpretations can be verified and confirmed.   
It is important to note that this project is the initial attempt to extrapolate many of 
the important concepts that exist in this data, and it is impossible to fully describe and 
discuss all of the many important issues for this population in one document. Ongoing 
analyses are planned and will provide additional opportunities to evaluate the data, along 
with similar additional data, with the ultimate goal of developing a comprehensive 
understanding of the experiences of young BRCA1/2 mutation carriers as they relate to 
navigation of young adulthood. 
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CHAPTER 5: RESULTS—EXPLANATION OF THEORETICAL MODEL 
Ellie’s Story 
 Ellie, a 27-year-old Ashkenazi Jewish carrier of a BRCA1 founder mutation who 
had known about her mutation for 3.5 years, is the oldest child of two mental health 
professionals. Confident and colorful, she was one of the most enthusiastic participants 
and had much to share about her experience in a family touched by BRCA. Ellie was 
aware of breast cancer as a part of her family legacy, but an even more powerful narrative 
in her family was that of holocaust survivorship. Several of her grandparents had lived 
through that period and were some of the only survivors from their families. Knowing 
that family story had many powerful influences on Ellie and other members of her 
family, and one of the results was that information about who did or did not get cancer 
was unavailable because so many people in her grandparents’ and great-grandparents’ 
generations did not survive the holocaust. The many missing pieces of family history 
made it difficult for Ellie and her family to develop a comprehensive understanding of 
their cancer risk. 
 Ellie’s first experience with breast cancer occurred at age eleven when her best 
friend’s mother, in her forties at the time, was diagnosed. That experience was notable for 
Ellie because it was an example of someone being diagnosed at a relatively young age. 
Sixteen years later, that woman was still living, but her cancer had metastasized and her 
prognosis was poor. Ellie’s next exposure to cancer occurred when she was 17 and both 
her maternal aunt and maternal grandmother were diagnosed around the same time. 
These diagnoses occurred in the late 1990s, only a few years after the BRCA1 and BRCA2 
mutations were identified on the human genome and several years before a mutation was 
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identified in Ellie’s family. Because they did not know that her aunt was a mutation 
carrier, doctors treated her with a lumpectomy and short course of chemo; the cancer 
quickly metastasized to her bones and brain and she passed away at the age of 49. Ellie’s 
grandmother’s cancer, however, was caught early and was less aggressive; doctors were 
able to bring her into remission and shortly after, she passed away in a car accident; this 
left an additional gap in the family cancer history because Ellie and her family could not 
know whether her grandmother’s cancer might have come back if she had lived. The 
story of how breast cancer entered the lives of Ellie and her family members is striking 
because of its suddenness and the fact that two individuals from different generations 
were impacted almost simultaneously. These two cancers seemed to come “out of 
nowhere” because nobody in the family was aware of any other cases of breast cancer in 
previous generations; however, it was unknown to them whether this would have been 
true if members of previous generations had lived normal life spans. This lack of 
information further constrained Ellie and her family members ability to fully understand 
how cancer might have impacted the family if other circumstances had not precluded the 
natural medical history of members of previous generations. 
 Another important piece of Ellie’s family narrative with respect to BRCA was the 
sense that the mutation had been identified in part because of luck: when Ellie’s mother 
visited her regular Ob/Gyn during the time that her sister and mother were both battling 
cancer, he had “put two and two together and said to her, ‘OK, young, pre-menopausal 
cancer [in] a woman who’s Ashkenazi Jewish, aggressive and doesn’t respond to 
chemo… you need to go get genetic testing.’” This was thought by the family to be lucky 
because it occurred so early in the development of knowledge about BRCA, when not all 
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doctors were yet aware of the mutations and their capacity to impact families and specific 
ethnic groups. The family encouraged Ellie’s aunt to participate in the testing, and the 
mutation was identified shortly before she passed away. Ellie’s mother and her two other 
sisters were all tested, and two of them (including Ellie’s mother) were positive; her 
grandmother was never tested, but was presumed to be a carrier. However, the mutation 
also could have come from Ellie’s maternal grandfather. 
   Figure 2: Ellie’s Cancer Genogram 
= BRCA-positive
= Breast cancer = Risk-reducing surgery = Died in Holocaust










 From there, the family narrative took a turn toward self-empowerment. Ellie’s 
mother underwent both RRBM and RRSO at the age of 39, and her other mutation-
positive aunt had RRBM several years later at about the same age. Both had remained 
cancer-free in the years since their surgeries. Ellie was armed with this knowledge as she 
approached the period in her own life in which she would begin to make risk-
management decisions. 
When Ellie was 19, her mother took her to a genetic counselor so that Ellie could 
learn about her risk of carrying the mutation and the implications for her own health if 
she was mutation-positive. Ellie recalled being exposed to conversations about BRCA and 
cancer at home, but being able to escape from thinking about it when she was away at 
college. Asked whether she felt pressured to get tested, Ellie replied,  
It wasn’t really an option. See, the way my family works, it’s not like we’re 
pressured, but she would say, “You’re too young and you should wait, but when 
you get to a certain age you really should get tested.”…If I [had] said, “You know 
what mom, I really don’t want to get tested,” my parents would have said, “Okay, 
that’s your choice,” but the expectation was that I would get tested. 
 
The time when Ellie felt ready to get tested coincided with the end of graduate school and 
her decision to move away from the city where her parents lived; she was tested at age 24 
and quickly made the decision to rely on screening for her risk-management at that time. 
She moved to a major west coast city and had trouble finding a place to get screened 
appropriately until a fortuitous coincidence occurred: 
I was working at a middle school my first year…and it was about a month after I 
moved, and the Vice Principal was dealing with ovarian cancer and recovered 
breast cancer, and I knew she was Ashkenazi Jewish, so it kind of came up that 
she had the [mutation]. So, I talked to her, and she was just so thrilled to have me, 
but sad for me at the same time. She [said], “I know this study that they’re doing 




Ellie felt fortunate to have been receiving high-level cancer screening from a program 
specifically designed for women who carry BRCA mutations, and confident that she was 
acting in the most effective way possible at that time to insure that she would not find 
herself with a late-stage cancer diagnosis and meet the same fate as her aunt. 
 Shortly after her cross-country move and entry into the cancer screening study, 
Ellie’s BRCA mutation really began to shape her couple relationships. In the first several 
years after learning that she was BRCA-positive, she disclosed her mutation liberally and 
early to several dating partners; she did not think of any of these relationships as 
potentially permanent, so telling them about her mutation was not difficult. However, 
when she met Mike, she immediately had a strong sense that he was “the one.” She chose 
to wait considerably longer to inform him about her mutation:  
I didn’t know it would work out for sure, but I just knew he met all the criteria 
and I really liked him. It wasn’t like I was trying to trap him and I was waiting for 
the right time to tell him after he loved me, like, “Oh, I’ll get him to love me and 
then I’ll tell him.” It was almost more like, “Okay, let’s find out if he’s the right 
one, and then I’ll tell him because he doesn’t need to know that information if 
he’s not the right one.” I approached it differently than the other guys I’d dated. 
 
At the same time that this relationship was developing, Ellie was beginning to think about 
RRBM. She recalled how participating in screening for several years brought a changing 
sense of its appropriateness: 
[At first] I felt like, okay, I know that my risks are higher, but I’m not going to 
deal with it for another ten years, I thought, so it’s nothing I’m even going to 
think about. I’m just going to do my surveillance. But little did I know that doing 
surveillance every few months really weighs on you, and it’s not like just a 
regular doctor exam. It’s a real heavy-duty thing, and every time you go in for 
surveillance, you start to realize that, oh, I’m not just going in to check on things, 
I’m going in to see if I got cancer. You realize, this isn’t me preventing cancer; 




Ellie began to feel that her plan to delay risk-reducing surgeries until age 35 and after 
childbearing was no longer comfortable for her because she stopped feeling confident 
that she could do so and remain cancer-free, marking a significant transition in her 
approach to risk-management. This percolating decision to undertake RRBM provided 
the impetus she needed to begin to seriously consider disclosing her mutation to Mike: 
I had to go in for surveillance and we were talking about what we were doing that 
day on the phone. I said, “Oh, I’m just going to this gynecologist and getting a 
check-up.” After that happened, I felt like I was lying to him, and I felt like I had 
to tell him soon because it was a pretty big thing. And I hadn’t decided yet when I 
was doing my surgery, but when I met him I was 25, and this was after I’d turned 
26. So I was like, okay, I’m getting into my upper 20’s, gotta get more serious 
about this. 
 
Shortly after this, Ellie and Mike went on a trip together, where Mike told Ellie that he 
loved her for the first time. Feeling sure that she loved him too, Ellie made the decision to 
tell Mike about her mutation: 
One day he came over and I’d been talking about it with my mom, and figuring 
out how I was going to the FORCE conference that year, and setting up a profile 
on the FORCE website, and I was like, “this is just too big of a thing not to 
mention. [So I said], “I need to talk to you.” He thought I was going to break up 
with him, and I said, “No, no, no; it’s not about me and you.” … He wasn’t 
expecting it, so he had no idea what I was bringing up, and I just basically started 
from the beginning. I said, “You know I told you I had an aunt that passed away,” 
and I told him how it connected to me and what I was doing now. He was just 
like, “Wow, it’s really heavy,” and he was kind of upset and he just said, “I still 
think you’re perfect.” 
 
Ellie felt strongly that one of the primary reasons she got such a positive response from 
Mike was the way that she presented information to him. She believed that her ability to 
deliver her message directly, gently, and willingly – boldly describing her feelings about 
her risk and her decisions about managing it – accounted for the positive relationship 
outcome. Because she was closely connected to other BRCA positive women through 
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both online and in-person support groups, she had discussed this with several other young 
carriers: 
People have asked me, “How are you so good about it? How do you approach it?” 
Because I’ve known girls who are in the same situation and haven’t told 
boyfriends yet, or aren’t in a relationship, and want to know how I go about it. I 
just approach it so confidently, like “This is what my situation is, it’s kind of 
sucky, it’s not the best situation, but it’s kind of making me stronger, and I’m 
taking my future seriously and I’m going to take care of it now.” I think a lot of 
men see that as a woman who is being really strong, and then they feel secure 
because they’re like, “Wow, you’re taking care of something now so you won’t 
get sick in the future,” where some women would have their head in the sand and 
ignore it, or they don’t even know they’re in my position and they’ll get sick. So 
if I said to my boyfriend, “I have this terrible gene, and I have such a high risk of 
cancer, and my kids might get cancer,” then of course the guy is going to run for 
the hills. He’d be like, “Holy crap!” But I don’t approach it that way. 
 
 Since he found out about her mutation, Mike had been a consistent source of 
emotional and instrumental support for Ellie. Mike’s ability to help Ellie think about her 
risk and participate in decision-making about risk-management created opportunities for 
closeness in the relationship. For several months Ellie considered the timing of her 
RRBM, but continued to participate in the screening study. Her mother suggested moving 
the surgery up by a few years and doing it at 32 instead of 35 as her physicians had 
recommended, but Ellie wondered,  
“Why are we picking arbitrary numbers? Why does 32 have any more 
significance than 31? … How do I know what age to pick to do this?” And then I 
just realized, I should just do it if I’m ready, and I started feeling like I’m going to 
be ready pretty soon because I don’t want to do this roller coaster ride anymore. 
 
Ellie’s realization that decisions about managing her cancer risk were up to her created a 
situation in which her choice of surgery was much more comfortable. It was her personal 
choice – not a prescription from doctors or family – that mattered most. 
Another important component of Ellie’s thinking about when major life events 
would happen was related to deciding when family formation would begin. In part, this 
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worry came from an early interaction with a healthcare provider who counseled her about 
her risk, emphasizing that she didn’t have many options: 
I just want to get one kid under my belt so I feel like I’ve started. It sounds kind of 
ridiculous, like that’s not how life should work, but I do feel that time pressure 
and I want to have one kid out of me by the time I’m 30. It’s just an idea I have in 
my head that I should do that. I think it came from knowing my risk. And also 
when I was 25 and in my study, my breast surgeon… said to me, and it’s always 
stuck with me… “You know, your risk is still low, but to be honest, if you were 
married and had 3 kids, I would tell you to get the surgery now.” It’s just hearing 
that, it was like, “Oh, wow, maybe I should get on that.” It wasn’t like he was the 
sole person that convinced me to want to do that, but statements like that, when I 
let them sink in, I’m like, “Wow, I really don’t have a lot of time to wait.” 
 
As their relationship became more serious and talk of marriage became frequent, Mike 
was one of the first people to effectively reflect what Ellie was thinking. He suggested 
that they schedule her RRBM for the upcoming summer during her break from work, 
before they were married and wanted to begin a family, so that the pressure to have the 
surgery would not be a factor during the years that they were focused on childbearing. 
Ellie decided  
that [was] a really good point, because a lot of people want to save their breasts 
until after they have a couple kids so that they can breastfeed and enjoy that, but 
… the more people I talk to and the more I talk to my mom about it, it was like I 
would rather have my kids and bottle feed them than breastfeed them and not be 
there to see them grow, and die. 
 
With Mike’s full support, Ellie had scheduled her RRBM for several months after her 
interview and was looking forward to being able to put breast surveillance behind her and 
find some relief from her worry about breast cancer; she anticipated a drastic reduction in 
breast cancer risk perception after surgery, although she noted that she would still worry 
about her ovarian cancer risk and about residual risk after RRBM because she was 
choosing to have a nipple-sparing mastectomy. However, she noted that “if I’m really 
uncomfortable and I feel stressed about it in years to come, I can always go back and take 
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them off, but if I feel better about it, then great.” Ellie’s ability to take control of her risk-
management plans and make significant changes to what she thought she would do to 
manage her risk further demonstrate her capacity to make and implement choices. Her 
story also illustrates how Ellie and Mike’s close couple bond provided them with the 
necessary resources to move past the perceived difficulties in starting a family in the face 
of a cancer risk; being able to eliminate breast cancer risk prior to family formation will 
allow Ellie and Mike to experience the early years of her children’s lives nearly free from 
worry that breast cancer will impose itself.  
Though Ellie had no doubt about whether she and Mike would continue their 
relationship, she did describe how they had negotiated an acceleration of their 
relationship to accommodate her plans for risk-management. Having resolved the 
question of when RRBM would occur, Ellie remained aware that RRSO would also need 
to be completed at some point. Because she and Mike definitely wanted to have 
biological children, RRSO had to occur after childbearing was complete.  
That’s been a compromise, because when it first came out about BRCA, I told him 
because of that, but also because I feel ready, I don’t want to have kids when I’m 
34 or 35 – I have to start sooner. So, the plan is we’re going to get married when 
I’m 28 and he’s 30, which would mean we’re supposed to get engaged pretty 
soon. So I told him if we get married when I’m 28, I’m OK with having a kid at 
29 or 30 if I can get pregnant right away. But the time we get married, we’ll have 
been together 2 ½ years, which is not so long, but if we have a baby by the time 
we’re together 3 ½ years, I don’t think that’s ridiculous at all. I don’t think that’s 
a crazy expectation, I mean, in Los Angeles, saying you’re having kids before 30 
is kind of an anomaly. Most people get married later here and I don’t hear of 
people having kids until they’re like 35, but that isn’t going to jive with me. 
 
Their ability to agree together on a plan for achieving major milestones of young 
adulthood became one of the major keys to the success of their relationship; had this not 
happened successfully, Ellie might feel much less secure about her ability to achieve both 
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her risk-management and family formation goals in the context of her relationship with 
Mike. Ellie’s experience also illustrates how young women who carry BRCA1/2 
mutations may adjust their plans in a way that does not meet with the expectations of 
their peers; living in a large west-coast city where couples often wait until well into their 
thirties to get married and have children, Ellie is choosing to move toward these 
milestones more quickly than she might if she did not feel as though waiting would be 
unwise given her health considerations. 
 Thinking about RRSO in the future, Ellie shared her thoughts about why giving 
up her ovaries might be more difficult than giving up her breasts: 
Part of me worries that I might get ovarian cancer earlier than typical, and I get 
nervous. But another part of me really doesn’t want to get my ovaries out. I’m 
actually more worried about the ovarian stuff because I don’t care about a fake set 
of boobs, but not having ovaries is a big deal to me because of the hormones.  
 
It is clear that Ellie realizes that her risk of ovarian cancer in the near future is still 
relatively low, but that she needs to be aware of the risk moving forward. Ellie sees 
ovarian cancer risk reduction as a more complicated issue than breast cancer risk 
reduction because of the multilayered effects of RRSO (i.e., hormonal changes that can 
lead to increased risk of heart disease, loss of bone density, sexual side effects). She felt 
relatively comfortable about her ovarian cancer risk in the near-term both because she 
was still quite young and because “I have been on the birth control pills for a long time, 
that was my part in protecting my ovaries for now1.” Planning an RRSO around age 40 
she noted that “there’s still a part of me that is worried that I won’t do it soon enough … 
And there’s the other part of me that doesn’t want to do it that soon because of the 
                                                 
1 Oral contraceptives reduce the risk of developing ovarian cancer in both the sporadic and the hereditary 
setting. The longer the medication is taken, the greater the protective effect. The protective effect lasts for 
20 to 30 years after use of oral contraceptives has ceased. (Collaborative Group on Epidemiological Studies 
of Ovarian Cancer, 2008) 
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shallow reasons.” Some women hesitate when they contemplate risk-reducing surgeries 
and worry that the negative effects may be very difficult to handle. This may sway some 
to postpone surgery, exposing them to longer periods of risk. 
 One of the most prominent ways in which Ellie’s story is unique is her focus on 
generativity, or creating something that will have a positive impact on others and will 
outlive oneself. Having decided to pursue RRBM, Ellie was in the process of putting 
together the necessary supports and talented collaborators to create a film documenting 
her surgery experience and filling what she saw as a gap in the information available to 
young BRCA mutation carriers. She described her thinking in making the decision to 
share her story: 
If I do it and it’s just by myself and I don’t make a film, it’s just like my own little 
personal sad story that only I know about and my friends know about. But, if I did 
this on a larger scale where people could be inspired by it, and see that I came out 
happy and positive, and not feeling lost, and not feeling indecisive, but feeling 
really empowered, then it’s not just me doing my own little sad story. … the 
surgery will be more meaningful for me if people can share and learn from it. I’ve 
been so focused on it, and the really great thing about doing this so far is that it’s 
made me feel so much more normal about doing it. Like this isn’t such a tragedy; 
some people can benefit from this. I feel so much better about it that way. 
 
Being involved in making a film had also provided an opportunity for Ellie and Mike to 
connect and work together. They were busy filming “confessionals” in which they 
captured discussions related to BRCA and surgery and the impact on their relationship for 
use in the film. Mike had also contributed his legal expertise to helping Ellie make sure 
that contracts and other legal issues were being used appropriately. 
Melanie’s Story 
 Melanie’s story provides a useful comparison to Ellie’s for several reasons. 
Specifically, both women inherited their BRCA mutations from their mothers, but 
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Melanie’s understanding of how BRCA had impacted health outcomes in her family was 
much more comprehensive because her family did not have a legacy of death from 
unnatural causes like Ellie’s. Both had mutation-positive mothers; Ellie’s was still living 
and had never had cancer, and Melanie’s had passed away after having breast cancer 
twice. Ellie’s family narrative included individuals who had chosen risk-reducing 
surgery, while nobody in Melanie’s family had yet done so. Ellie had learned about her 
BRCA mutation prior to meeting her partner, and Melanie was already in a serious 
relationship (which has since become permanent) when she learned that she was a carrier. 
Finally, the two were at slightly different developmental stages within the young 
adulthood phase of the life cycle, and were making different choices in managing their 
cancer risk. 
 As depicted in Figure 3, Melanie, 31, was the oldest of four children and was 
pregnant with her first baby when interviewed. Her family narrative included several 
examples of women who had been negatively impacted by breast cancer; the first 
occurred when Melanie was fourteen years old, and two of her mother’s sisters (the 
oldest and the youngest) were diagnosed with breast cancer at about the same time. In 
fact, the younger aunt had gone to be checked by her physician precisely because the 
older aunt was in treatment for breast cancer, and an advanced, metastasized cancer was 
detected in the younger of the two sisters. Melanie’s older aunt survived and was still 
living when Melanie was interviewed, but the younger aunt passed away at age 28. This 
created two stories of illness progression in the family: in one, breast cancer could be 
detected early and did not result in death; in the other, breast cancer struck early and 
aggressively and could be fatal. 
 
 126
Four years later, when Melanie was a freshman at a University on the other side 
of the country from where her family lived, she learned that her mother had been 
diagnosed with breast cancer. Melanie was informed of this after her mom’s treatment 
had progressed and Melanie’s parents felt confident that she would survive. This 
occurred in 1996, very shortly after the BRCA1 and BRCA2 mutations were identified,  
    Figure 3: Melanie’s Cancer Genogram 
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and Melanie’s mother made a passing comment about genetic testing; however, it was not 
pursued at that time. Five years later, when Melanie’s mother was diagnosed with breast 
cancer for a second time, Melanie learned that her breast-cancer-surviving aunt had tested 
positive for a BRCA mutation. Melanie’s mother was never tested because she passed 
away very shortly after her second diagnosis. Melanie had a strong sense that because 
there were so many cases of breast cancer in her family, it “wasn’t just random.” She 
worked with her mutation-positive aunt to construct a family history and found a 
University study that would provide genetic testing free of charge while she was in 
graduate school. In making the decision to get tested, Melanie weighed the opinions of 
both her aunt and her mother. Her aunt told her, “’Yes, I’ve had cancer twice, and yes, I 
have this [mutation], but I’m still here and there are things you can do and the screening 
is getting better.’” Conversely, she remembered her mother “saying years ago, ‘Okay, 
great, they have this test, but what do you do, do you run and get a mastectomy when you 
don’t know if you need it?’” To Melanie, her mom’s message clearly implied that she did 
not see the value in genetic testing for someone Melanie’s age. Ultimately, Melanie 
decided that she wanted to know whether or not she carried the mutation, and learned that 
she was BRCA positive at age 26. She was able to make this choice independently and 
because she believed it was the right decision for her, even though she knew that her 
mother might have disapproved. As further evidence of this, Melanie informed only her 
boyfriend and her aunt that she was being tested, choosing not to share this information 
with her father or siblings until several months after receiving her results. 
 Melanie and Connor (who was her boyfriend when she was tested and her 
husband when she was interviewed) had to confront the realities of cancer together even 
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before Melanie was aware that she was BRCA-positive. The two met about six months 
after Melanie’s mother had passed away, and he provided steady support for her as she 
coped with that significant loss. When she was deciding whether to get tested, he 
supported her by doing research about BRCA so that she could better understand what a 
positive mutation test would mean, and by “reassuring me that even if it was positive, it 
wasn’t the end of the world.” Since they learned that she is positive, Connor has 
supported Melanie by accompanying her to all of her screening appointments at the NIH 
(she was a BI participant) and helping her be diligent with her screening schedule. 
Having finished her four years in the BI study at age 29, Melanie recalled feeling nervous 
about how she would complete her screening and worrying about whether the cost of 
doing so would be covered by insurance. Her ability to feel secure about being protected 
from cancer was threatened by a change in access to medical care, magnified by the fact 
that Melanie had passed the age at which her aunt had died from breast cancer. 
Another illustration of the closeness between Melanie and her partner was present 
in Connor’s participation as an equal and engaged partner to Melanie in discussing how 
they would navigate family formation in light of her mutation status. Melanie recalled 
being frequently reminded by the healthcare provider with whom she interacted in the BI 
study that moving forward with family formation was urgent: 
After we were married, we knew that prophylactic surgery, both the ovaries and 
the breasts, are definitely an option for me. Having kids is obviously affected by 
that, so we knew we needed to get pregnant. The people at NIH said, “What are 
you waiting for, hurry up and start having kids.” So we knew that sooner was 
better than later. 
 
These strong messages about the urgency of family formation are an example of how new 
and unexpected boundaries can emerge for mutation carriers. Melanie’s plans for surgical 
 
 129
risk-reduction imposed a shortened timeline on her plans to have children, and this 
message was made crystal clear by the healthcare providers with whom she interacted. 
The potentially negative results of this were tempered by Melanie and Connor’s easy 
agreement to have their children sooner than they might have otherwise done, to 
complete their family before Melanie reached age 35 and wanted to undergo RRSO. 
 Because she was pregnant when interviewed, issues of family formation were at 
the forefront of Melanie’s thinking, and she discussed different ways that the presence of 
her mutation would arise as family formation progressed. Melanie and Connor felt 
relatively confident that they might want three children, and fitting all three of them in 
the four years before she turned 35 would require that they have children in close 
succession. Additionally, she would have to carefully time subsequent pregnancies to 
ensure proper breast and ovarian screenings could occur when she was neither pregnant 
nor nursing. Rather than being able to proceed naturally through the process of 
childbearing, Melanie was acutely aware of the extra steps she would have to take to 
ensure her ongoing health: 
I was able to have a mammogram and MRI right before I got pregnant, which 
worked out really nicely. But after that, I went and met with doctors … just to go 
over, “okay, I’m pregnant, what does this mean moving forward?” And the whole 
topic of breastfeeding came up, and what my plan is for that and what that means 
for screening for after that. What we’ve kind of decided is that I’m going to 
breastfeed … for three months, because they told me that you have to stop 
breastfeeding for six months before you can have a screening, because I guess 
you’ll light up [the MRI] because of the milk ducts and everything. So, they 
wouldn’t be able to tell if there was something there. So, if we want to have kids 
close, I’ll have to breastfeed, stop for six months, have a screening, and then try 
and get pregnant again. And because … it didn’t happen right away for us the first 




Melanie’s story beautifully illustrates how the need to continue screening, combined with 
the same concerns with achieving pregnancy that are present in the general population, 
can feel confining for young BRCA mutation carriers.  
 Another important contrast between Ellie and Melanie is in their opinions about 
risk-reducing surgeries, specifically comparing RRBM to RRSO. While Ellie found it 
relatively easy to consider giving up her breasts but struggled to reconcile the loss of her 
ovaries, Melanie’s feelings were just the opposite. She planned to undergo RRSO as soon 
as she was finished with childbearing, 
…because if I’m done with kids I don’t need them anymore, so that one is easier 
to me than mastectomy. And also, just in what I’ve read and heard, removing 
them can slightly reduce your risk of breast cancer2. Also, not producing the 
estrogen, that sort of thing, that would be kind of a first step, and the less radical 
of the two. 
 
Melanie’s belief that mastectomy would be more difficult than oophorectomy helps to 
explain why having RRBM prior to pregnancy, as Ellie was planning to do, was not an 
attractive option. These differences in gut-level reactions to the two surgical procedures 
are likely an important component of risk-management decision-making for many 
mutation carriers, and have a significant impact on whether and when women are open to 
surgical risk-reduction. These visceral negative evaluations of the surgeries become 
roadblocks to effective risk management. 
 In the years since Melanie had learned she was BRCA-positive, she recalled 
feeling bad about imposing this ongoing burden on Connor. Their ability to handle this 
experience together is another demonstration of the powerful emotional bond they shared 
I feel bad that I have it, but he just shoos that right away. … now we’re having a 
baby, I’ll say, “I really need to get life insurance, I’m the one that something 
                                                 
2 In fact, removing one’s ovaries while still premenopausal actually reduces the risk of breast cancer 
substantially, i.e., by 50 to 60%. (Rebbeck, Kauff, & Domchek, 2009) 
 
 131
might happen to,” and he’s like, “stop, I don’t want to hear that, be quiet.” He just 
shoos it off. He’s not holding it against me, obviously. … We’re very, very close 
anyway, and this is just one thing that I’ve never felt like I couldn’t talk to him 
about or make it a part of our plan for our life or anything. I don’t have to be shy 
or worry about it by myself. It’s definitely something we, from the beginning, 
have taken on together. … everything I’ve gone through with it, it’s been us going 
through it. 
 
This couple seems to have found the ideal way to share burden and convey support, 
which has allowed them to make choices with agency to feel that they will be successful 
at avoiding a cancer diagnosis. 
 Like Ellie, Melanie was generative, which she had achieved through the choices 
she made in her professional life. Having been part of a national service organization at 
the time she was tested, Melanie made a career move to a breast cancer research and 
advocacy non-profit shortly after she received test results. Asked how her job and her 
mutation status came together, she shared: 
I know that I’m doing everything I can do to help. Really, [after] losing my mom, 
I don’t know what I’d be doing professionally if I didn’t have this to fight for. It’s 
given me a lot of focus, which is kind of a blessing in disguise. … it’s nice having 
a job that’s not just a job, that it’s something I really care about, and that helps in 
my actual work because I do a lot of work with volunteers, and they know that it’s 
not just a job for me to do, I’m in it for the same reasons they are. … When you 
find out [about your mutation], it’s like, “Oh, God, when is my time going to 
happen?” And with this, you’re not just sitting around waiting for it to happen. 
Whether it’s doing the walks and raising money, or people do a million different 
things, and I’m lucky enough that my nine-to-five is that sort of thing. 
 
Melanie’s level of positive activity with regard to breast cancer and BRCA was one of the 
ways that she felt a sense of agency, and she was able to take this to the next level by 
positively impacting the lives of others as well as her own.  
Agency, Constraint, & Communion 
As Ellie and Melanie demonstrate, the process by which young female BRCA1/2 
mutation carriers make ongoing decisions about breast and ovarian cancer risk-
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management is complex and multi-faceted, influenced by and influencing a number of 
other important life events and decisions. Understanding this process is facilitated by 
considering the concepts of agency, constraint, and communion, and how each of these 
come into play for mutation carriers. Agency describes a sense of self-efficacy (McDaniel 
et al., 2006). This may be understood as the sense that one has the capacity to act 
independently and make choices freely, or to enact change upon the world and one’s 
environment. One might require a sense of agency in order to take action on a significant 
or difficult issue, or feel a sense of agency after action has successfully been taken. As 
previously stated, life course agency is drawn upon as individuals commit to a life path 
that will allow them to become who they wish to be and achieve what they wish to 
achieve. This type of agency describes “actions [that] occur with a broader sense of our 
futures involved, and these orientations are important for shaping individuals’ adaptations 
to situations,” (Hitlin & Elder, 2007, p. 182). Acting with agency is a mechanism by 
which young female mutation carriers adapt to their health status and achieve a sense of 
mastery over its stressors. Constraint is the opposing force – the sense that one is not 
fully at liberty to determine that path (or the steps that comprise it) for oneself, often 
because contextual or structural forces have imposed some limitations. Expectations on 
BRCA mutation carriers to be mothers, daughters, and partners convey a normative 
timing of progress through young adulthood, which may run counter to their preferences 
for health/wellbeing. On the other hand, the decisions they make about risk management 
can shape the timing of certain relationship family events. Finally, communion describes 
a sense of family or relationship cohesion (McDaniel et al., 2006). Communion is 
comprised of support, sharing of burden, and a sense of open communication. 
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Successfully counterbalancing feelings of constraint requires both agency and 
communion; relying too heavily on either (“unmitigated agency” or “unmitigated 
communion”) can produce negative psychosocial outcomes (Hegelson, 1994).  
Components of the Model 
 Findings from the current study were used to develop a model to contribute to a 
theoretical understanding of how BRCA1/2-mutation-positive women move through the 
major individual- and couple-level domains and processes that comprise the experience    
 
   Figure 4: Basic Theoretical Model 
 
 

































of young adulthood. This model helps to clarify how women make the mental and 
emotional journey from knowing about their mutation status and understanding family 
history, to making choices about risk-management. Note that this model is not intended 
to suggest that risk-management decisions are an endpoint to a staged process; rather, 
risk-management has been conceptualized in the current study as an important decision 
around which other model components pivot in important ways. As the data will 
demonstrate, risk management is certainly not an endpoint; rather, making a decision 
about risk-management is a significant event in the mutation-positive experience for 
young women and is shaped by other important elements of young adulthood. For many 
young mutation carriers, several risk-management decisions will be made over time as 
individual, couple, and family circumstances shift and as new knowledge and medical 
technologies become available. Further, risk-management is illustrated in an arrow that 
feeds back into the rest of the model, because women’s decisions about and experiences 
with risk-management may shape their experiences with regard to cancer risk-perception, 
disclosure to partners, mutation-related partner support, and family formation in 
important ways. 
Six core elements are present in the model: Family Cancer History & Family 
Illness Narratives, Breast and Ovarian Cancer Risk-Perception (discussed in Chapter 
Six), Mutation Disclosure to Partner (Chapter Seven), Mutation-Related Partner Support 
(Chapter Eight), Family Formation (Chapter Nine), and Risk-Management Decisions and 
Experiences. The next four chapters will discuss in detail the four identified individual 
and couple-level processes, and explain how they are related to both family cancer 
history/family illness narratives and risk management decisions and experiences.  
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Family cancer history & family illness narratives. Family cancer history 
describes the set of information about which mutation-positive individuals are aware 
regarding the legacy of BRCA-related (and perhaps -unrelated) cancer in their biological 
families. This is a relatively objective concept; it can be thought of as the “hard facts” 
surrounding how an individual understands that cancer has impacted her family. 
Knowledge about family history is influenced by many other characteristics of families 
and their histories. For example, as was illustrated in Ellie’s story, the availability of 
information about members of previous generations determines how fully family cancer 
history can be understood. Dynamics of communication on the side of one’s family from 
which the mutation was inherited are also influential; families that effectively share 
information about cancer diagnoses and treatment generally produce young female 
mutation carriers with more comprehensive understandings of their cancer history than 
families in which little information is shared (Werner-Lin & Gardner, 2009). In addition, 
women whose mutations moved down the family tree through successive males may not 
be as aware of their family cancer history as women whose mutations have been passed 
down through females, simply because men are far less likely to develop a BRCA-related 
cancer and therefore applicable cancer diagnoses occur in more distant relatives (e.g., 
second cousins, great aunts). Becoming aware of cancer diagnoses in these distant 
relatives after learning about the presence of a mutation creates new family history for 
these women. 
Family illness narratives are closely related to family cancer history. First applied 
in detail to the BRCA-positive individual by Werner-Lin and Gardner (2009), family 
illness narratives “are the stories families tell about their experiences with serious and 
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persistent illness,” (p. 201). They create a context for members of a family to give 
meaning to their illness experience. In the stories that they pass along through generations 
and adapt as new information emerges, families use illness narratives to give continuity 
and coherence to members’ understanding about “family myths or legacies that include 
beliefs about who gets sick and why, how families care for ill members, appropriate 
models of communication within the family and with outsiders, and illness outcomes,” 
(p. 201-202). Collectively, family cancer history and family illness narratives are 
represented in the model figure in one element. Family illness narratives are constantly 
evolving, and young mutation carriers can influence the family illness narratives through 
the choices they make about risk-management and in the way they approach the tasks of 
young adulthood that are related to their mutation status (i.e., partnering, family 
formation). 
In BRCA-positive families, histories of cancer and the illness narratives they 
produce are important components of women’s perceived cancer risk, and may produce 
either an optimistic or pessimistic ideal about what will happen at the individual level. If 
one’s family illness narrative says that “everybody gets cancer,” then one assumes that 
she, too, will eventually get cancer. If the family illness narrative is that cancer diagnoses 
are challenging but not life-ending, women may feel more empowered about their own 
ability to face a potential cancer diagnosis. Young women’s knowledge about cancer and 
the way it is understood by the family often bear heavily on family formation; for 
example, they may believe that they should not produce biological children because 
doing so would be akin to sentencing children to the same burdensome family legacy and 
cancer risk with which they are struggling. Family dynamics around cancer may also 
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powerfully influence one’s decision-making about risk-management. For example, 
women may feel personally empowered by family history and illness narratives that 
include examples of mutation carriers who have successfully prevented cancer diagnoses 
by undergoing risk-reducing surgery; or they may feel limited by illness narratives 
purporting that cancer cannot be controlled, and therefore risk-reducing measures are a 
waste of energy. Finally, opportunities for sharing and joining with a partner can be 
created by sharing one’s family cancer history and illness narratives with a partner and 
receiving instrumental and emotional support. 
Cancer risk perception. Development of cancer risk perception is a unique 
individual process influenced not only by one’s family history of cancer and family 
illness narratives, but by many biological and psychosocial variables as well. These 
include general levels of anxiety and depression, optimism, and recent cancer-related 
events in the individual experience (Price et al., 2007). It is “a key predictor of risk-
reduction practices, health behaviors, and processing of cancer information,” (Klein & 
Stefanek, 2007, p. 147). Data from the current project demonstrate that cancer risk 
perception can also profoundly shape the choices BRCA-positive women make with 
regard to the other elements of the proposed model. Cancer risk perception may shape 
decisions regarding disclosure of mutation to partners in couple relationships. A carrier 
who believes her risk to be very high may fear that a partner who learns about her 
mutation will choose not to continue a relationship upon learning about the mutation, and 
so might feel anxious or even scared about disclosure. Developing a sense of control 
around cancer risk can enable carriers to manage partner disclosure effectively and 
present information to their partners in a way that promotes connection.  
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Decisions about family formation may also be affected when very high cancer 
risk perception produces a belief that one’s available time for childbearing, the options 
that one may utilize to become pregnant (i.e., assisted reproduction), or one’s capacity to 
breastfeed in a way that is experienced as positive and free of risk, are limited. Women 
who are able to successfully manage their cancer risk anxiety and share their sense of 
peace with other members of their families can positively influence the family illness 
narrative. Finally, cancer risk-perception powerfully shapes decision-making about risk 
management; women with high cancer risk-perception often take more aggressive action 
to mitigate their risk (e.g., by having RRBM or RRSO at a young age) than women with 
lower perceived risk, who may opt instead to have surgery later or to rely on screening 
indefinitely. In either case, carriers’ feelings that they are taking or are able to take 
sufficient/appropriate actions to manage their risk determine whether agency or constraint 
is experienced. 
Mutation disclosure to partner. Disclosure of positive mutation status to one’s 
partner, the first of two couple-level processes in the model, occurs differently depending 
on the context of a given couple relationship, as will be illustrated in chapter six. Its 
capacity to impact other elements of the model is notable. Women’s choices about risk 
management can dramatically shape the disclosure process when the results of 
management decisions are obvious to new partners. Women may feel restricted in 
disclosing the mutation, as it impacts their partner’s willingness to have children together. 
Many participants, especially those who were single, worried that a partner would find 
the potential cancer risk to future children intolerable and choose not to participate in 
family formation; often, this was accompanied by worry about the partners’ willingness 
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to continue the relationship at all. For partnered participants, mutation disclosure in some 
cases had a constraining effect on family formation because it expanded to the partner 
carriers’ own beliefs about how family formation ideals might seem threatened and 
options might seem limited. 
Mutation disclosure is also an important actor upon mutation-related partner 
support. Disclosing one’s mutation to a partner is the only way to establish a pathway for 
effective partner support around BRCA-related issues; therefore, women who wish their 
partners to be involved in ongoing challenges and decision-making related to their BRCA-
positive status must achieve mutation disclosure first. The ability of a partner to provide 
support, or the carrier’s belief that support will be available from the partner, often 
facilitates or eases disclosure. Couples who are able to successfully share information 
about and request/provide support around BRCA-related issues experience increased 
closeness. 
Finally, an important relationship exists between mutation disclosure and risk 
management decisions. Many participants described how their decisions regarding when 
to inform their partners about their mutations were shaped either by an approaching risk 
management event (e.g., a significant screening visit or a surgery) or by the fact that they 
had already had a risk-reducing surgery and felt compelled to tell their partners about it 
before it became obvious. Women who are not actively managing their risk, or managing 
it in a way that is not noticeable to their partners, have greater flexibility and control in 




Mutation-related partner support. Discussed in detail in chapter eight, 
mutation-related partner support is a couple-level process and may be defined as the 
ability of a partner to help a mutation carrier cope (both instrumentally and emotionally) 
with the challenges that are often part of the BRCA-positive experience for young 
women. In addition to its relationship to mutation disclosure described previously, 
partner support is common in situations where partners play important roles in decision-
making about family formation and risk-management. Opportunities for closeness may 
occur when a supportive partner helps a carrier cope with her anxieties related to her high 
perceived risk of cancer, or when anxiety and decision-making with regard to family 
formation is shared. Finally, a partner’s ability to provide appropriate support and input 
about risk-management decision-making provides another opportunity for closeness and 
sharing of burden. 
Family formation. Family formation is considered both an individual- and 
couple-level process, hence its placement between these two categories in the model. 
Dynamics surrounding family formation can impact several other elements of the model, 
and the ways in which this occurs will be illustrated in chapter nine. Engaging in 
biological childbearing is considered by many women to be inherently risky because of 
their fear (often based in anecdotal experience) that the hormonal exposure that occurs 
during pregnancy and breastfeeding can contribute to carcinogenesis. When family 
formation is achieved successfully and does not result in a pregnancy- or breastfeeding-
related cancer diagnosis, it may (temporarily) mitigate cancer risk perception. When 
mutation carriers are able to successfully synchronize family formation desires with the 
perceived need to manage risk through surveillance, chemo-prevention, and/or risk-
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reducing surgery so that all needs are met, they may gain a great sense of satisfaction and 
personal control. The opposite may occur when goals related to family formation and 
those related to risk management cannot be reconciled, and sacrifices to one’s powerful 
desires must be made. All of this occurs in concert with one’s partner; among single 
participants, the needs and desires of future partners are often considered as part of 
women’s contemplation of future family formation. 
Risk management decisions. Decision-making about risk management is largely 
the product of the other five elements of the model, as described previously; however, its 
capacity to influence those model components cannot be disregarded. Risk management 
decisions that bring a sense of relief and lower cancer risk perception often create a sense 
of competence and mastery. When women perceive that their risk management decisions 
– or the risk management options available to them at a given point in their lives – are 
insufficient to protect them from cancer, they may feel limited and powerless. Risk 
management decisions may also shape the mutation disclosure process in that when a 
single woman is able to confidently explain her risk management decision-making 
process to a new partner, she may feel strong and in control of both her cancer risk and 
the way she is perceived by her partner. Conversely, risk-management decisions can 
inhibit a carrier’s ability to disclose positive mutation status to a partner in the preferred 
way or at the preferred time. 
Chapter Conclusion 
 Women who test positive for BRCA during young adulthood face complex and 
ongoing challenges in reconciling their high-risk status with the normative tasks of this 
stage of the life course. Each of the major individual- and couple-level processes outlined 
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here are intricately tied to the others, producing a confusing and tangled web of choices 
for young carriers. Women make these decisions both independently and with their 
partners and families. When this is done successfully, the process creates unique paths 
that ultimately allow each individual to feel as though she has maintained control and 
minimized sacrifices to previously held notions of how life would proceed. The proposed 
theoretical model will be used in the subsequent four chapters to illustrate how each of 







CHAPTER 6: RESULTS—RISK PERCEPTION 
 “I was sure I had two ticking time bombs strapped to my chest.” - Valerie 
 The quantitative risk of cancer among carriers of BRCA1 and BRCA2 is generally 
well-understood, and can be communicated clearly to potential and known mutation 
carriers during the genetic risk assessment, education and testing process (van Oostrom & 
Tibben, 2004). Despite this, the extent to which individual mutation carriers feel 
vulnerable to cancer is a complex dynamic influenced by information from medical 
professionals, family and family history, and peers; specific perceived vulnerabilities 
based on age, mutation type, previous cancer scares, and specific cancer type of concern; 
and other characteristics unique to each individual. These data indicate that decision-
making about risk-reduction is very much influenced by one’s perception of cancer risk, 
whereby women who feel more vulnerable to breast and ovarian cancer have a different 
experience of themselves as mutation carriers and are more apt to take early, aggressive 
steps to mitigate their risk (often by electing to undergo risk-reducing mastectomy or 
oophorectomy), whereas women who feel less anxious about their risk may be apt to rely 
on screening for a longer period of time or to believe that surgical risk-reduction is not 
necessary. For women who have already completed one or both risk-reducing surgeries, 
there is often a palpable reduction in their perceived risk. However, data indicate that the 
relationship between perceived risk and risk-management decisions is not simply direct: 
it involves the other elements of the proposed model as well. Effectively utilizing cancer 
risk perception to inform and shape decision-making and communication about various 
tasks of young adulthood is a common experience for these women, and is an important 
piece of how they take control of their lives as mutation carriers. 
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Gathering Information about Cancer Risk 
 Participants demonstrated having gathered information from a variety of sources 
and synthesizing that information to arrive at individual cancer risk perception. At the 
time of her interview, Valerie, a genetics researcher, had been aware of her mutation for 
nearly four years and had recently undergone a risk-reducing mastectomy. She recalled 
what she felt about her cancer risk shortly after receiving the news that she carried a 
BRCA mutation, and nicely illustrated the synthesis of several different sources of 
information in making decisions about her own risk management: 
I knew all along that I needed to be keeping an eye on my breasts, certainly. As 
far as I know, there’s no ovarian cancer in my family, and we’re BRCA2, so that’s 
not necessarily surprising. And also, if you [look at] where my mutation is 
[physically within the BRCA2 gene], based on the literature, it’s in the sort of 
lower risk spectrum for ovarian [cancer]. But, at the same time, ovarian cancer 
scares the hell out of me, so I’m not taking any chances. [My doctor and I] 
basically made the agreement that if anything looked fishy, they were coming out. 
So my ovaries are basically on notice. 
Valerie, 29 
Because of her education and profession, Valerie was uniquely positioned to understand 
her cancer risk. For other BRCA mutation carriers, risk information may come primarily 
from one source, or may be synthesized from several. The way that individuals come to 
understand that information and the importance they place on any one source appears to 
be an important determinant of how they approach decision making, and whether they are 
able to feel a sense of control with regard to managing their risk. 
Information from medical professionals. For most BRCA mutation carriers, the 
first substantial interaction with a medical professional in which they receive information 
about their risk of breast and ovarian cancers occurs in the context of genetic counseling, 
usually prior to submitting a blood sample for mutation testing. Sometimes, this occurs as 
part of the same appointment in which they receive their genetic test results. This 
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communication can be an intense experience for many women, especially if cancer risk is 
not something they have previously contemplated or thought of as personally relevant. 
Conversely, women whose backgrounds provide context for the information received 
from a genetic counselor may find this experience less stressful. Wanda had a doctoral 
degree in molecular biology, and therefore reached a very comprehensive understanding 
of the biological phenomenon being explained by her genetic counselor. She recalled the 
genetic counseling appointment during which she received her mutation test results: 
 I’ve always been one of those people who likes to know everything about 
everything. Sometimes they say too much knowledge isn’t necessarily a good 
thing, but in my case I felt well-informed, I think more so than somebody else 
who didn’t have a science background and had a mutation-positive test. Although 
of course genetic counselors do their best to try to explain things, patients are 
hearing, “I’m going to get cancer. I’m going to die.” With me, I was like, “Okay. 
Well, this definitely increases my risk, but there are things I can do, and now I 
know what I have to do in the future to be better prepared.” 
Wanda, 31 
Wanda’s scientific background and ability to understand what was being communicated 
by the genetic counselor allowed her to feel empowered by the information. In contrast, 
Elaine remembered being very anxious upon learning that she carried a BRCA mutation: 
 I just felt very anxious I guess. I’ve never felt that way before, but – I’m a 
[mental health professional] – I thought, “Oh my gosh, this is anxiety,” [emphasis 
added]. I felt kind of tingly and anxious, and [the genetic counselor] was going to 
give me some information and I just told him, “I have to go. I’ll call you back. I 
can’t take any information right now.” 
Elaine, 34 
Similarly, Pauline remembered: 
 I was in shock and not processing anything for a couple of minutes. [The doctor] 
came in and said some things and it was sort of like the Charlie Brown teacher 
voice, like “Wa-wa-waaaw.” And occasionally I was able to follow but he said 
something about high-risk women and that really sort of cut through the fog for 




Elaine and Pauline both felt paralyzed upon first learning that they were BRCA-positive. 
In part, this may be the product of their family histories. Elaine’s mother had died of 
ovarian cancer several years before Elaine’s genetic testing, and she lost her grandmother 
to breast cancer several years before that, so her family illness narrative was one in which 
having breast or ovarian cancer was a painful and deadly experience. For Pauline, whose 
BRCA mutation was inherited from her father, the effects of BRCA were a mystery 
because no family members with whom she had close relationships had been diagnosed. 
She felt an acute lack of insight about how the information she was hearing would play 
out in her own life. These data suggest that women’s capacity to hear and assimilate 
information from providers immediately after receiving positive mutation results may be 
low if they experience a significant amount of shock or anxiety, or if they are caught up 
in their family illness narratives. It may be helpful for physicians and genetic counselors 
who deliver results to women to find out the patient’s preference for when to discuss 
cancer risk, next steps, and risk-reduction options, so that patients can receive the 
maximum benefit from these conversations. 
Once they assimilated the information received from genetic counselors and 
began regular interactions with physicians and others involved in their ongoing care, 
participants began to receive frequent messages about their health and cancer risk from 
the doctors, nurses, and technicians with whom they interact. One frequent observation 
among participants was that once they were aware that they carried a BRCA mutation, it 
became very easy for them to access needed screening. For many, this was a notably 
different experience from what had been occurring when they attempted to access 
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screening based on family history alone (even when they knew that a BRCA mutation was 
present in their families). For example, Rose remembered that 
Once I tested positive, my ability to get in to see a doctor, my ability to get 
scheduled for an MRI just opened up immediately. I don’t know if this is true 
nationwide, but in [major city] if you try to get a mammogram it’s like an eight or 
nine month wait. It’s crazy. I couldn’t believe that. You’ve got to be kidding! But 
once I tested positive for BRCA they were like, “OK, you come in in two days.” 
Rose, 30 
The implication of this increased responsiveness from medical professionals is that they 
acknowledge a significantly elevated cancer risk in these patients, which is often 
interpreted by mutation-positive women as a confirmation that they are in a precarious 
health situation. In fact, for many women, the simple fact that they were seeing medical 
specialists for their care contributed to their perceiving themselves as being at greater risk 
of cancer; and needing care beyond what a general obstetrician/gynecologist could 
provide felt significant to many participants. 
In their interactions with medical professionals, many women lamented the fact 
that information they received from different providers was sometimes confusing and/or 
inconsistent, creating a challenge for them to select the appropriate course of action. 
These confusing interactions may begin even before women are aware that they carry a 
BRCA mutation. For example, Leigh recalled a time before she had been tested when she 
asked her physician for advice about screening as a member of a family with a strong 
history of breast cancer: 
 I sort of assumed I had a very high risk of breast cancer but I didn’t really know 
how high. A few years before our family did the genetic testing, I did ask. I told a 
gynecologist a little bit of my family history and asked if I should be receiving 
any type of screening now and she thought I was okay to wait until I was 40 to 




This interaction (which took place in about 2003) is noteworthy because, given the 
current recommendations for breast screening in young women from high-risk families, it 
is almost unthinkable for Leigh’s physician to recommend that she wait until age 40 to 
begin screening. Given current guidelines, Leigh would be advised to have 
mammograms, MRIs, and clinical breast examinations every 6 to 12 months, beginning 
at age 25. The recommendation that Leigh received likely led her to feel that her options 
for risk-management were constrained, and to feel more anxious about her cancer risk 
when she did learn of her mutation, than she would have experienced had she been 
properly screened earlier. 
 Even for known mutation carriers, there can be barriers to getting desired 
information from medical professionals. Before she enrolled in the BI study, Monique 
was receiving all of her mutation-related medical care from local physicians. Having 
been tested at age 20, she was on the very young end of the range of patients typically 
seen by physicians at high-risk breast imaging centers. Monique decided to test at an 
early age because her maternal aunt was diagnosed with breast cancer at age 20 and died 
at 22; Monique’s mother also died from breast cancer at 39 after being diagnosed at 37. 
Monique’s much older sister had already had an RRBM, and Monique was interested in 
learning whether that might also be an appropriate course of action for her: 
 I think the worst part is that they all were like, “you’re so young, you should just 
get check-ups.” I felt like I wanted more of an answer, like, what should I do? 
They didn’t really want me to have the surgery yet, like how my sister had 
surgery, just for prevention. They thought I was too young until I had a baby, so 
they were talking to me about what I should do before and after I have kids. 
Monique, 26 
Although Monique’s physicians were being honest with her about the recommended 
course of action for a mutation carrier her age, it is easy to see why Monique was 
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frustrated and felt constrained by this experience. Knowing that she was already past the 
age at which her aunt had been diagnosed, she was understandably anxious about her 
short-term cancer risk, perhaps more so than other mutation carriers who do not have a 
family history that includes a cancer diagnosis in someone as young as Monique’s aunt. 
The result of her physicians’ recommendations was that she continued to live in a state of 
high anxiety about her cancer risk, because others did not share her sense of urgency 
regarding the need to take action to mitigate her risk. Practically, there was no reason 
why Monique could not have had an RRBM if she chose to do so, with full awareness of 
the implications of that decision; therefore, her doctors’ responses to her request for 
information about her options for risk-reduction seem somewhat patriarchal. The 
assumption by the medical community that she is “too young” to make such a decision, 
that she should keep her breasts until after she has children, effectively constrains her 
choices and eliminates that option for her. Clearly, a family can be created in the absence 
of one’s natural breasts, as has been the experience of several other participants. 
Increased openness about these “alternative” progressions through the risk-reduction 
dynamic on the part of the medical professionals who care for women in this population 
would give BRCA-positive women greater freedom and more options to manage and/or 
reduce their risk in the way that seems most beneficial for them personally, and help them 
to achieve a sense of agency in making risk-management decisions that are congruent 
with their chosen path through the life course. 
 Given the enormous amount of information given to patients in medical settings 
where young BRCA mutation carriers receive their care, it is obvious that many women 
remember only certain pieces of what they hear from members of their healthcare teams. 
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When a patient does remember something, it is sometimes because it was phrased in such 
a way that it makes intuitive sense, strikes a chord, or simplifies an issue in a unique way. 
For example, Sadie’s genetic counselor used a gambling metaphor when discussing the 
odds that Sadie would develop cancer in her lifetime:  
 Mostly what I remember is the increased risk for breast cancer, that if you were 
gambling in Vegas with 80% odds, that if someone said you have an 80% chance 
of winning the jackpot, you would probably play, thinking, “Hey, that’s pretty 
good.” So I always remember that analogy and whenever I’m doubting what I’m 
doing, I sort of think, “Okay, yes. If I were gambling with those odds, I’m pretty 
much at, “’It’s a sure thing.’” 
Sadie, 33 
Sadie remembered this comparison often and had even communicated it to other mutation 
carriers in discussions with them about how to manage cancer risk. She highlighted how 
this mental checkpoint contributed to her confidence in moving forward with her decision 
to undergo RRSO at the age of 32, because she was able to return to this metaphor and 
feel confident that the choice she was making was the right one. Other participants also 
reported holding tightly to risk-related information given to them by trusted medical 
professionals. Rachel remembered that her very busy doctor 
took the time to really sit there and explain it to us. I still have the piece of paper 
that she wrote, that I had an 87% chance of having breast cancer and that I had a 
40% chance of ovarian cancer and I could do a hysterectomy or I could do an 
oophorectomy and she literally sat with us in her office and explained everything. 
Rachel, 33 
Ultimately, many women put a great deal of confidence in the opinion of their doctors 
and make decisions about risk management based largely on those recommendations. 
Asked about messages she received from physicians, Maelie recalled: 
 There were some conflicting messages, but what I held onto was what’s the most 
certain, what’s the best course of action. The majority of people, or articles, or 
anybody you talk to is if you have the surgery, you have a better guarantee. Not 
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that it’s a guarantee at all, they list all the things they can do, but surveillance isn’t 
always the best option. I think everyone is pretty unanimous on that. 
Maelie, 33 
Information from family members & family history. One of the primary 
sources of information from which women draw to arrive at their own understanding of 
their cancer risk and to make decisions about risk management is the experience of other 
family members. Like Ellie and Melanie in Chapter 5, participants reported having 
considered at what age, site, and stage relatives (usually either known or presumed 
mutation carriers) had been diagnosed with cancer as they considered whether and when 
they might be at risk themselves, as well as looking to the surgical and reconstruction 
experiences of their loved ones to help anticipate what their own experience might be 
like. When women examine their own mutation-positive experience through the lens of 
family history, feelings of either empowerment or hopelessness may result. Which of 
these occurs depends partly on what events have occurred in the family and how well 
individuals are able to imagine having an outcome different from those of family 
members. For example, Shannon, 31, began to think of herself as a person at high risk of 
breast cancer at 15, when her mother was diagnosed; after she was tested for a BRCA 
mutation years later, her sense of vulnerability to cancer did not really change, because 
she had “always felt pretty vulnerable.” Leigh, 35, reflected on both her aunt’s and her 
mother’s breast cancer and her mother’s difficult experience with surgery and 
reconstruction in deciding whether and when to have surgery, and which of the two 
surgeries to pursue. She recalled, “I guess [my mother] had a very hard time with her 
reconstruction. So it made me want to do it while I’m younger because I figured maybe I 
would have an easier time.” 
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Growing up, Dawn was aware that several women in her father’s family had died 
of breast cancer before she was born. When Dawn was three, her paternal aunt was 
diagnosed with breast cancer at age 27 and died at age 30; shortly thereafter, her paternal 
grandmother also died from the disease. Asked when she started to think of herself as a 
person at elevated risk of breast or ovarian cancer, she replied: 
 Honestly, probably really young. I’ve always known. I remember being three 
and five and six and knowing about breast cancer. Even in junior high and high 
school, I would talk to my gynecologist and ask, “Do I need to start pretty young 
getting all these tests, the [mammograms] and stuff?” And they all told me, 
“Honey, it’s on your dad’s side, you don’t need to worry.” I never really liked that 
answer because I always had a feeling that it was something that could happen to 
me, especially with everyone in my family being so young. I was so determined 
that they were all not telling me the truth. I always felt like, “Why? My dad 
passed so many genes down to me, why would he not pass this?3” 
Dawn, 27 
Though Dawn was clearly attempting to be proactive about her breast and ovarian health, 
she was inhibited by the lack of knowledge possessed by her healthcare providers. This 
was largely a product of the era in which these conversations occurred, before BRCA1 
and BRCA2 and the way they move through families was fully understood.  
Dawn and Pauline are similar in that they both inherited their BRCA mutations 
from their fathers, neither of whom have developed cancer. In contrast to Dawn’s first-
hand knowledge of family cancers, Pauline was only vaguely aware of a few cases of 
cancer in older relatives before she learned that there was a BRCA mutation in a distant 
branch of her family tree.   
 It’s really scary, though, looking at the [pedigree], because I don’t have the 
experience like a lot of women do who have these mutations, of watching their 
moms or their aunts or their grandmother go through this. …and then basing their 
recommendations on when to do things based on when their mom got sick, when 
                                                 
3 Dawn was exactly correct: BRCA1 and BRCA2 genes are inherited in an autosomal dominant fashion. One 
average, half the offspring of a mutation carrier will inherit the mutation, and the abnormal gene can be 
passed down equally well by both males and females. 
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their grandmother got sick. I don’t have that, but I look at my chart and it looks 
like everyone’s getting sick sooner and sooner. I’m seeing people who weren’t 
diagnosed with breast cancer until they were eighty-five and then two generations 
later people are getting breast cancer at thirty. I know it’s not a perfect science but 
I have two cousins who got sick at the age that I’m at right now. So that’s what I 
think about because I don’t have that experience of having watched my mom or 
grandmother go through it. 
 
Pauline went on to elucidate how, as discussed at the start of this chapter, the absence of 
first-hand experience of cancer in her family left her at something of a loss when trying to 
conceptualize and make decisions about her own risk: 
Right now, I have absolutely no idea what cancer looks like. I have no idea what 
cancer feels like. How it affects people, who it takes, who it spares. I’ve got 
nothing. I’ve got just this big fat number that the geneticist flopped in front of me 
when she gave me my status that says 87%. And so, I know it’s irrational to think 
that I have an 87% chance today, but that’s sort of how I feel to a certain extent 
because I have no sense how else to gauge it. 
Pauline, 30 
 
Other participants discussed unique circumstances in which their pervasive family 
histories of cancer still left them unsure about their own risk. Prior to being tested for a 
BRCA mutation herself, Rachel was aware that her family had a higher-than-usual 
incidence of cancer, but did not feel that she was at risk herself. She remembered: 
We didn’t really understand. Everybody on the street [we grew up on] wound up 
with some form of cancer. Mom and dad used to joke that it was something in the 
environment where they lived for so many years. That there must have been 
something in the soil, something in the water, and it literally became a joke. “We 
almost glow at night,” that kind of thing. So, we kept our faith but we also kept 
our sense of humor. It was still looked at from the standpoint that it must have had 
something to do with that neighborhood, we were quick to write it off. And in 
1998 … information [about BRCA] … definitely wasn’t … making its way to us. 
Everyone said to me, “if your mom’s already had [cancer] twice, you better be 





Rachel’s experience seems to be similar to Dawn’s, in that lack of knowledge about 
BRCA at a given point in time prevented her from fully understanding or effectively 
managing cancer risk. 
After women have assimilated perceived risk based on their family histories, what 
comes next is often a set of assumptions about what the experience of cancer would be 
like should they someday be diagnosed. Often, these cancer narratives, which can be 
either personal or shared, are based on what they witnessed in the breast and/or ovarian 
cancer treatment given to their mothers, aunts and grandmothers in years past, when 
screening for cancer was not as effective and therefore cancers were more likely to be 
detected at an advanced stage. Further, fears may be based on experiences with cancer 
treatment that occurred when medical technology was less advanced and treatments more 
physically and emotionally taxing than they are today. In the aggregate, these experiences 
may exacerbate fears about cancer that are not in line with what current medical practice 
can provide in terms of manageable treatment. Reina provided a good example of this 
when she related what it was like to watch her mom go through two difficult breast 
cancer diagnoses and treatment: 
I really had to work through it, just because my mom went through certain 
experiences doesn’t necessarily mean that I’m going to go through those same 
experiences. Whenever I think about breast cancer, I automatically associate 
everything that my mom went through and relate that to, well, God forbid if 
something were to happen to me, that’s the type of situation I would be placed in, 
which is not true. But I really had to work through that because the treatment part 
of it is so physically wearing. It’s hard. There’s always that fear of death, but I’d 
say more so the process of getting into remission, going through the treatments 
and the surgeries and all that. That weighs on my mind more heavily. 
Reina, 29 
Reina’s level of anxiety about developing cancer seemed quite high compared with many 
of the other women in the current study. It seems plausible to speculate that more 
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accurate knowledge about the experience of women whose breast cancers are caught 
early and managed effectively might have helped reduce her anxiety to a more 
manageable level and created a greater sense of agency.  
Information from peers. Discussing her cancer risk with peers might also 
provide important support and contribute to a special kind of sharing for Reina and others 
like her, and drawing support and information from peers seems to be a primary method 
of maintaining connections with other mutation carriers for young BRCA-positive 
women. Because of the low prevalence of BRCA in the general population, it is common 
for mutation carriers not to know any other carriers personally, outside of their families. 
Therefore, they often turn to the internet and other media through which young mutation 
carriers have shared their experiences. Many women mentioned their experience with 
FORCE as having been very positive and as having helped them find information that 
was lacking elsewhere. Leigh benefited from “women posting on all their experiences, 
and it’s all specific to women who have the genetic cancer risk, so that played a big part 
in terms of gathering information and dealing with everything.” Though this was clearly 
experienced by Leigh as positive and created communion with these new contacts, it 
should be noted that a possible drawback of participation in a community such as FORCE 
is that women may become saturated with negative or troubling stories posted by others 
looking for support, since those stories may be more likely to be submitted than stories 
from women who have not experienced significant problems in dealing with their 
hereditary cancer risk. This was the case for Sadie, who turned to the FORCE message 
boards for support and information soon after she learned that she was BRCA-positive: 
 When I first went to the FORCE website a couple years ago, it totally freaked me 
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out. Their message board was all about having surgeries and complications that 
people were having and whether or not they should do a hormone replacement 
therapy and what type of mastectomy they were doing. They were speaking all of 
this lingo that was so foreign to me and there are people on there who were well 
past having it done but then there are people who are about to have it done and 
were scared out of their minds, and there were people who had complications 
right after surgeries and were having trouble. I had like an anxiety attack. I was 
looking at the message boards and I was just like, “Oh my God! This is so not 
helping for me to be looking at this stuff!” 
Sadie, 33 
Although Sadie was open to information from peers when she first viewed the FORCE 
message boards, the bias toward sharing negative experiences – which makes sense, 
given that those women are also on the message boards in search of support – created an 
online environment that overwhelmed Sadie and did not provide what she was seeking at 
that time. Having real-life access to other individuals in similar situations (i.e., at a 
similar developmental point in the natural history of their BRCA-related experience) is a 
potential unmet need for young mutation carriers. This would allow them to share their 
full range of concerns, knowledge, and experiences (both positive and negative) with one 
another in a supportive and productive manner. Organizations such as FORCE and Bright 
Pink do a good job of meeting this need through annual conferences and local support 
groups, but it seems clear that some women have information and support needs beyond 
what is being provided, or simply are not finding the resources that work best for them. 
Cancer experiences of others with whom individuals have personal contact but 
who are not members of one’s family can also be a source of information about cancer 
risk. Leigh learned that she carried a BRCA mutation shortly after her mother tested 
positive. Leigh was then the mother of three small children: she experienced high levels 
of anxiety during that time, and her experience was impacted by the cancer diagnosis and 
death of the father of one of her son’s close friends: 
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 When I first found out that I had the mutation and that I was at risk now, I was 
very, very scared of developing cancer in the near term. I would still be busy 
during the day and to do whatever I have to do, but at night when I was lying 
down to put my littlest to sleep I would just be terrified of dying and being 
separated from them. I had anxiety dreams sometimes, like one where I had been 
diagnosed with cancer and had only a few months to live. It probably didn’t help 
that one of my oldest son’s friends, his father died of lung cancer, only six months 
between diagnosis and death. And he died a couple months before my mom found 
out that she was a mutation carrier. So I think that was another factor that made it 
seem very real that a parent could just easily die and leave their children behind. 
That idea really terrified me for a while.   
Leigh, 35 
Although the cancer in the father of her son’s friend was likely not genetic and was 
almost certainly unrelated to BRCA, the experience of watching a family lose a parent of 
young children had a powerful effect on Leigh and her own thinking about her health and 
her family. 
 Another vehicle through which some women have found support from peers is the 
book Pretty is What Changes (Queller, 2008). Queller’s book recounts her experience of 
her mother’s cancer diagnoses, treatments, and eventual passing; as well as Queller’s own 
process of learning about her mutation and deciding how to manage her risk. Rylan 
mentioned this book in discussing her view of her 87% lifetime risk of breast cancer and 
relating how she came to the decision to have an RRBM: 
 I had just read Jessica Queller’s book Pretty is What Changes, and I think that 
helped me make the decision. I just decided I was not worrying, but waiting to get 
cancer. … I have up to an 87% chance, and if I don’t get it, I might win the 
lottery, too, but chances are I won’t. And chances are I won’t not get cancer. To 
me it sort of became more a matter of when am I going to get it. I mean, I realize I 
have a chance of not getting it ever, but the risk statistically was so high that it 
made sense to try to avoid the risk. 
Rylan, 34 
For Rylan, it was almost as if a switch had been flipped: one day, she did not see her 87% 
lifetime risk of breast cancer as a threat worthy of her attention, and the next day, she had 
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made the decision to have surgery. Reading the detailed experience of another BRCA 
mutation carrier close to her age was a powerful catalyst for Rylan to make a confident 
decision about her own risk management. 
 Sophie was a participant in the BI study whose family cancer experience 
consisted of three fatal cases of ovarian cancer on her father’s side; nobody in her family 
had ever been diagnosed with breast cancer. Accordingly, Sophie’s perceived risk of 
ovarian cancer was quite high, while her perceived risk of breast cancer was relatively 
low. Sophie recalled how meeting other BRCA-positive women at the NIH was a 
powerful experience that became synthesized with other sources of information about 
risk, namely her family history and the documentary film In the Family (Rudnick, 2008). 
That film, with a young BRCA-positive woman named Joanna as its focus, has also 
become a source of support for many women, who have begun to look to Joanna as a peer 
and referent. For Sophie, these sources of information combined to prompt 
reconsideration about the appropriate strategy for risk management: 
 My dad made my middle sister and I sit down and watch In the Family and it was 
pretty eye-opening and depressing. It’s tough to watch. And then when I actually 
was at NIH this last time, I met a girl who is part of the study, and she was one of 
three sisters [like Sophie and one of the families in the film], and all three had the 
mutation. So that was kind of interesting to me. Even now I don’t know if a 
mastectomy would be something I would go forward with, but now it’s something 
that I would possibly consider. I think that is really extreme for me at least. I don’t 
knock anybody who does it, but for me, I think that would be the extreme and that 
movie just kind of showed that it’s something that definitely needs to be 
considered. A mastectomy really is not completely on the table, but it’s in the 
back of my head. But the oophorectomy is a done deal; I already know. I may be 
in denial about breast cancer because neither of my aunts had breast cancer. 
 Sophie, 31 
Seeing someone like herself on screen and witnessing how Joanna handled the same 
issues that Sophie was facing allowed her to see her situation from a new perspective and 
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begin to open her mind to ideas she had not previously considered seriously. Where she 
had previously felt trapped by fear and family narratives, Sophie felt empowered by this 
peer support and information. 
Specific Vulnerabilities 
Breast versus ovarian cancer risk. While the general term “cancer” certainly 
elicits feelings of anxiety in most people, women with BRCA mutations must struggle to 
balance their perceived risk of breast cancer and their perceived risk of ovarian cancer – 
these risks are not the same, and the health threats presented by the two cancers are also 
very different. Ruby recalled how learning that she carried a BRCA mutation brought 
with it a good deal of information about breast cancer risk, but left her hungry for more 
information about the risk of ovarian cancer. Unfortunately, this information has not been 
easy for Ruby to come by because Ruby’s specific mutation, like many others, is 
relatively rare, and that has influenced the way she has dealt with her high-risk status: 
 When I started looking at the information and looking at the risk, and them not 
knowing what the risk is for our family because ovarian cancer doesn’t have a big 
enough pool of people to go through … the breast cancer side and the regular risk 
is one thing. But knowing the risk was so high and so I feel like my risk was even 
higher than what was listed on the information sheets. … they don’t even know 
what the ovarian risk is …people first get breast cancer and then they get ovarian 
cancer later, but that’s not how it’s been in our family. Our mutation was not even 
on the chart. So that was spooky. They’re giving me the ratios that my risk is 60 
to 80% for breast and 40 to 60% for ovarian. But for my family, maybe it’s more. 
Ruby, 34 
The effect of this perceived lack of information was that Ruby has not felt ready or able 
to make a decision about moving forward with a risk-reducing oophorectomy, because in 
order to do so, she would need to have a solid understanding of her ovarian cancer risk. 
Pauline also illustrates this important difference when she discusses the timing of her two 
risk-reducing surgeries. When she was interviewed, she was making preparations to 
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proceed with her RRBM, which would occur at the age of 31. We discussed how she 
would know when it was time to move forward with the RRSO: 
 If I don’t have a strong impulse to do it before my fortieth birthday, then I’ll know 
as my fortieth birthday approaches that it’s time to do it. As much as I have no 
frame of reference for breast cancer, I really have no frame of reference for 
ovarian cancer. And unfortunately, the medical community doesn’t seem to have 
much of a frame of reference either because the screening techniques are so 
crappy. Ovarian cancer is such an unknown in even a bigger way to me than 
breast cancer. 
Pauline, 30 
 While most BRCA mutation carriers interviewed for this study agreed that ovarian 
cancer is more frightening than breast cancer because of how difficult it is to detect and 
treat, they also spoke emphatically about their frustration with current breast screening 
methods. In 2007, the American Cancer Society altered its breast screening 
recommendations to include annual MRIs for many high-risk groups, including BRCA 
mutation carriers of any age (Saslow et al., 2007). However, for young mutation carriers, 
even MRI screening can leave a multitude of questions and lingering uncertainty due to 
the dense structure of young women’s breasts and associated difficulty in interpreting the 
images generated by their MRIs. In relating her experience with screening immediately 
prior to her decision to undergo RRBM, Rachel recalled her frustration with her 
physician’s interpretation of her MRI: 
 An MRI on a 33-year-old is very difficult to read because of the type of tissue 
they are looking at and the fact that when they do an MRI on someone in their 
fifties, they’re not looking at the same type of material as what they are when they 
look at someone in their thirties. 
Rachel, 33 
MRI is currently believed to be the best technology available for screening for breast 
cancer in this population. However, the fact that MRIs are difficult to interpret and many 
women get called back for repeated tests lends to an increased sense of vulnerability to 
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breast cancer and constrain their ability to feel confident about relying on screening. 
Rachel’s sense of vulnerability to breast cancer was so high that she decided to proceed 
with and even completed her RRBM in the time between her initial MRI and the date on 
which a follow-up MRI would have been scheduled. Finding it intolerably uncomfortable 
to live with the ambiguity that accompanied her surveillance experience, she swiftly and 
definitively chose to use surgical risk-reduction instead and was pleased with her 
outcome and its effectiveness at reducing her perceive risk. 
As discussed previously, an important source of information for many women in 
deciphering their own risk of developing one cancer or the other is what has occurred 
with other members of their families. Although both BRCA1 and BRCA2 are associated 
with increased risk of both breast and ovarian cancer, some women feel much more 
vulnerable to one than the other because that cancer site has been more problematic for 
their family: 
 I feel like the breast cancer was more of a concern and it’s probably not good 
thinking that, but I’m not as concerned about ovarian cancer because no one in 
my family has had ovarian cancer. I know that doesn’t really make sense, but 
that’s how I think about it. We have only had so many people that we know had 
the mutation, and that doesn’t mean that we can’t get ovarian cancer or that I’m 
not also at increased risk for ovarian cancer. … I guess I’ve had so much more 
experience with breast cancer that that one seems more scary to me … 
Kristy, 29 
Charlotte also grew up in a family where breast cancer was well-known, her mother 
having been diagnosed when Charlotte was in middle school. She recalled, 
 My mom was diagnosed and beat it, but I’ve seen so many other people who 
haven’t. It became very real that people do die from this. I think when I was 
younger I saw it as one of those cancers that people beat and it wasn’t as big of a 
deal as other types of cancers. But the more people I meet in the community, and 
the more I know about it and the fact that BRCA carriers can have a more 




For both Kristy and Charlotte, this difference in perceived risk actually created a sense of 
agency in managing breast cancer risk, as they were able to contemplate surgical risk-
reduction via mastectomy early in their young adulthood rather than accepting an 
extended period of waiting to see if cancer would strike. 
Rose discussed her sense of vulnerability to ovarian cancer, which claimed the 
lives of her mother when Rose was only 13, and of her maternal grandmother before 
Rose was born. Based on her family history and long before she was aware of the 
existence of BRCA mutations, Rose was offered entry in an ovarian cancer early detection 
study at a major university near her home. Rose began a trend of taking charge of her 
high-risk status by readily accepting this; although she had a sense that her risk of ovarian 
cancer was increased, she was in grad school and did not have great insurance at the time, 
and therefore was not being screened: 
I was in my early twenties. The genetic counselor told me that there was a test, 
but probably insurance wouldn’t cover it. So I decided not to mess with it at that 
time. I was young, and had I had a positive result, I wouldn’t have acted on it, so 
it didn’t really make any sense to act at that time. I didn’t really realize that it was 
a breast cancer issue, I only thought of it as ovarian cancer, and since I tied 
ovarian cancer with having my ovaries removed, I knew I would only do that after 
I had children. I mean, I used to see people with the pink ribbons and think, “that 
has nothing to do with me. My family history is ovarian cancer.” I really 
dismissed it. Several years later, a second counselor asked me if I wanted to 
consider the test again and I was like, “why would I want to do that?” And the 
woman just said it, and I would never have thought about it had she not said it – 
she said, “Well, you’re doing all this stuff for ovarian cancer, but what if you test 
positive for this gene? You really aren’t being aggressive about breast cancer 
detection.” I didn’t really get that there was a link. I was so focused on ovarian 
cancer that it just never occurred to me. 
Rose, 30 
After she understood the link between breast and ovarian cancer susceptibility and BRCA 
mutations, Rose did not hesitate to be tested. Once she learned that she carried a 
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mutation, she moved forward with her RRBM quickly, and her surgery was complete 
within six months of receiving her test results. 
 Even among women who clearly understand the risks of both breast and ovarian 
cancer, there are often differences in perception of how negative an experience each type 
of cancer would be. Trixie had recently completed her RRBM and was midway through 
the reconstruction process when she was interviewed. Having already minimized her 
breast cancer risk as much as possible and feeling certain that she did not want children, 
Trixie had started to think about having her ovaries removed, a procedure that her older 
sister Maelie (also a participant) had recently completed. Discussing her thoughts on the 
timing of an RRSO, she stated:  
I’m scared to death of menopause. I would get my ovaries out in a second because 
ovarian cancer is really scary to me, because I can’t see it. I’ve just been afraid of 
what menopause will do to my body. 
 Trixie, 27 
Similarly, Julia expressed her intense worry about her ovarian cancer risk based on her 
unique family history. Julia’s mother, maternal aunt, and great-grandmother all had breast 
cancer, and her BRCA mutation was inherited from that side of her family; her paternal 
aunt had ovarian cancer unrelated to BRCA. All survived except her great-grandmother: 
 I think that the breast cancer is a scary thought, but ovarian probably scares me 
more than anything just because it’s already on the other [non-carrier] side of my 
family, I have a higher risk of developing it than the general population, and 
there’s really just not a lot of testing that can be done at this point for ovarian 
cancer, so I think that’s the part that really scares me more than anything. I 
actually think about having my ovaries out far before I would even think about 
having my breasts removed. 
Julia, 24 
Julia carries the same genetic mutation as the three individuals in her mother’s family 
with breast cancer, but identifies strongly with the ovarian cancer risk conveyed by her 
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paternal aunt’s diagnosis given its overlap with the risks inherent in BRCA; she was in a 
unique position in that there were relevant cancer risks on both sides of her family. It is 
striking that of the two primary cancer sites at risk in the context of a BRCA mutation, 
ovarian cancer is both harder to detect and prevented by what many women view as the 
more physically difficult risk-reducing surgery. This is an especially challenging dynamic 
for young women to navigate, as deciding about RRSO forces them to contemplate not 
only ending their ability to bear children, but altering their natural hormone levels 
decades earlier than would naturally occur, leaving them susceptible to numerous health 
challenges associated with menopause (e.g., decreases in bone density/risk of fracture, 
vascular health/risk of coronary disease and stroke, skin elasticity). 
Julia’s sentiment about the lack of effective screening for ovarian cancer is further 
reflected in what several women had to say about their confidence in the screening 
methods available for each potential cancer site (mammogram, MRI, and clinical breast 
examination for breast caner; trans-vaginal ultrasound and the CA-125 blood test for 
ovarian cancer). Almost universally, participants believed that although standard breast 
screening procedures are sufficiently effective in catching cancer early enough to be 
treated easily and successfully, current ovarian cancer screening procedures leave them 
vulnerable to this “silent killer4.” Each participant who was currently relying on 
screening for risk-management was asked how confident she felt that the screening was 
protecting them from cancer. Here are some of their answers: 
                                                 
4 Their assessment of the utility of ovarian cancer screening is entirely accurate. There is simply no 
evidence at all to suggest that screening with transvaginal ultrasound and CA-125 results in earlier 
diagnosis or, most importantly, improved cancer-related survival. Despite acknowledging that these 
screening tools are ineffective, and NIH Consensus Conference on Ovarian Cancer recommended that they 
be used in women who are at increased genetic risk of ovarian cancer. Consequently, this screening 
strategy has come to be seen as the medical “standard of care.” Health care providers therefore feel 
compelled to use it. 
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 The breast screening, very confident. The ovarian screening, not confident at all.  
Marjory, 30 
 [The breast screening] does give me reassurance that I can say, ‘If I test it, it’s 
going to be caught early and it’s a good thing that I’m doing these tests, I’m able 
to go about this proactively and catch it early. And while ovarian cancer hasn’t 
been in my family, I do worry about that a little more now because you’re not 
able to catch it as early. So I don’t have that peace of mind when I’m getting those 
tests. It’s definitely a little scary because I know if the results were to come back, 
I guess it’s more likely that it would be at an advanced stage. I don’t have that 
peace of mind that it would be caught early on.  
Charlotte, 26 
 
I’m going to play the game. I’m going to participate in the charades of ovarian 
cancer screening. I understand that it’s a little bit of smoke and mirrors. A lot of 
smoke and mirrors. But that’s what’s recommended, so I’m going to do it. 
Pauline, 30 
 
Breast cancer, yes. Ovarian cancer, I think it’s still concerning to me because the 
screening methods aren’t the best. 
Wanda, 32 
Taken together, these thoughts suggest that part of why many women feel so much more 
vulnerable to ovarian cancer than breast cancer is because they realize how inadequate 
current screening techniques for ovarian cancer are, and rightly feel that their options for 
successful ovarian cancer risk management are limited. A belief that the only effective 
method available to protect them from ovarian cancer is to undergo RRSO can feel 
inhibiting for many due to desires for childbearing. Unfortunately, this is a problem that 
can only be solved by advances in medical technology that make it easier to screen for 
ovarian cancer and detect it early, while it is still treatable; in that case, ovarian cancer 
survivability would improve and it might seem less frightening to members of this 
population. 
BRCA1 versus BRCA2 risk. Because the manifestations of BRCA1 and BRCA2 
mutations are broadly similar, they are often discussed together in publications to which 
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women turn for information about their risk. Therefore, some women are exposed to 
information about the risk differences that distinguish BRCA1 from BRCA2 that may 
mitigate or exacerbate their perceived risk of cancer. In discussing her risk, Leigh 
appeared very knowledgeable about the differences between BRCA1 and BRCA2 and 
their associated risks, having learned a good deal about her own BRCA1 mutation by 
searching for information online: 
 I think that Myriad has classified certain mutations including my own as 
deleterious as opposed to unknown or harmless, but beyond that I don’t think they 
have different gradations of deleterious. I think they’re all sort of lumped the 
same. And for my mutation they said the risk hadn’t been exactly established but 
generally for BRCA1 it’s between 64 and 87% for breast cancer. But with BRCA1, 
the cancers tend to be triple negative and those cancers tend to be more 
aggressive. BRCA2 carriers, their cancers tend to be more in line with what the 
general population would get and a little less aggressive and receptive to certain 
treatments. 
Leigh, 35 
For Leigh, the knowledge that she was a carrier of BRCA1 put her in a higher category of 
risk than she would have been if she carried a BRCA2 mutation. In other cases, making 
inappropriate distinctions between the two mutations can lead women down a path that is 
not quite in line with what is known about BRCA-related risk of cancer: 
 I’ve heard up to 85% [risk] or so for the mutation. But from the explanations I’ve 
heard how my BRCA2 is mutated but BRCA1 is there and things like the 
environment and age are what affects that and eventually could cause cancer if 
that first one kind of drops out or doesn’t start doing its job. 
Charlotte, 26 
Charlotte interpreted the mutation-specific information she was given to mean that the 
fact that she did not carry a mutation in BRCA1 was a protective factor in the context of 
her positive BRCA2 mutation status, which had the effect of erroneously reducing her 
cancer risk perception. In fact, a functional BRCA1 gene is not a protective factor in this 
situation; almost universally, individuals who have one BRCA mutation do not have the 
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other. This example highlights the need for very clear communication between medical 
professionals and mutation carriers in educating carriers about their cancer risk, as well as 
for patients to have multiple opportunities to ask questions or seek clarification about the 
information they are given. 
Specific Periods of Risk 
Risk associated with specific ages. Participants had different ways of 
conceptualizing during which parts of their lives they might be especially vulnerable to 
breast and/or ovarian cancer. Some women were able to separate the daunting 87% figure 
associated with lifetime risk of breast cancer from the lower, and therefore much more 
manageable risk estimates associated with risk of breast cancer for women in their 
twenties and thirties over shorter periods of time, e.g., the next 5 or the next 10 years. 
Rose illustrated this nicely when she stated: 
In learning some of the numbers and how you can take some of the numbers to 
mean certain things and other things, you know, like the 80% risk over the course 
of your lifetime. But that means, [I learned after talking to the doctor more], I’m 
only at 30% risk now. 
 Rose, 30 
Focusing her attention on her cancer risk during the next 5-10 years, rather than worrying 
about lifetime risk, allowed Rose to bring her risk perception down to a more manageable 
level and select a plan for risk management that would allow her to accomplish family 
formation goals comfortably; she was at home recovering from RRBM when 
interviewed, and was looking forward to starting a family soon after her recovery. For 
other women, risk perception changes in fits and starts, sometimes with entire decades 
being identified as either risky or not so. Marjory worked in a setting in which she 
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routinely encountered other BRCA mutation carriers, discussed how she managed her 
interactions with them: 
 [Patients] would tell me that one week they were fine, and the next week they had 
a diagnosis. And that was very hard for me, knowing that my risk was so high and 
I was getting into my thirties. The twenties seemed invincible and the thirties 
seemed like, well, now this could happen.   
Marjory, 30 
Similarly, Nichelle discussed how she balanced family history and knowledge of other 
cases of breast cancer in young women in deciding whether she wanted to know about 
her own mutation status after other members of her family had been tested: 
 I think the biggest reason [I decided to get tested] was, I’m in a sorority and one 
of our alumni was diagnosed with breast cancer. I want to say she’s about 25. … 
So, knowing that…I mean, I know ours typically doesn’t show up, based on 
family history, until mid- to late-forties, but I decided, “you know what? There’s 
always that chance that something could happen. And if I am positive, it could 
happen sooner than that.” So I really wanted to have that knowledge and start 
doing what’s healthiest for my lifestyle. 
Nichelle, 21 
Marjory and Nichelle provide a useful contrast: whereas Marjory discussed her 
perception of elevated age-related risk in a way that revealed a sense of doubt, Nichelle’s 
approach was focused on making positive changes to her lifestyle to address cancer risk. 
Like Nichelle, an important component of age-related individual risk perception 
for many young women is the age at which other family members were diagnosed with 
cancer. Many see the ages at which their relatives were diagnosed as “danger zones” that 
signify an elevated threat of cancer for themselves (Werner-Lin, 2007). For example, 
after finding out that she carried a BRCA mutation, Melanie thought about her aunt’s 
cancer history, remembering, “because my aunt was only 28 when she was diagnosed, it 
was scary because I was in my early twenties. But I just kind of said, ‘Okay, we know 
this – now what are we going to do about it?” For Melanie, the age at which cancer risk 
 
 169
felt more threatening was fairly low, which encouraged her to think about shifting her 
timeline for family formation in order to allow for risk-reducing surgeries (this concept is 
discussed in more detail in Chapter 9). In contrast, Serena listed the three cancer cases 
with which she was familiar in close family members: 
My grandmother is a thirty-five year survivor of breast cancer, she had it twice. 
My mom is the oldest of four and she was diagnosed with ovarian cancer twelve 
years ago now, and she’s completely in remission. Her sister next in line had 
breast cancer. The magic age in our family is forty-six. 
Serena, 30 
Serena’s experience of young adulthood thus far had been quite different from Melanie’s; 
because the age at which cancer seemed like a major threat was much later for Serena, 
she was able to navigate through her twenties and into her thirties without her BRCA 
mutation being a major stressor, and without feeling as though she needed to alter her life 
plans in any way because of it. In fact, Serena stated that “my [biological] clock is 
definitely ticking, but it’s not that loud yet. It’s not ringing in my ear right now,” 
suggesting that her risk perception and perceived need to manage risk were not 
constraining her family formation plans. 
Rylan had a somewhat dismissive attitude about her cancer risk for the first 
several years after she was tested. She attributed her recent change of heart to “being the 
age mom was. She was 31 when she was diagnosed, and her sister was 39 when she got 
it, so being in my thirties just sort of woke me up and made me start getting a little 
nervous.” Rachel recalled that the idea that specific periods of risk existed and could be 
determined based on relatives’ ages at diagnosis was reinforced by her doctors: 
What happened was all the doctors kept telling me, “you’re at risk in the 
neighborhood of ten years before your mom had it.” So, here I was, mom was 40, 
I was 29 or 30, just shy of my 30th birthday. So yeah, there was definitely a reality 
of the fact that this could be happening. Nobody tests a 30-year-old woman for 
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anything like that. So what’s to say it’s not already growing? Do you really think 
when you go in to the typical Ob/Gyn that she’s very intent and closely watching 
the breast tissue when she’s doing a hand examination on a 30-year-old? I am not 
sold on that. So I definitely had, I think, almost an undue fear of that and because 
of knowing that information. 
Rachel, 33 
Trixie was involved in the breast imaging study beginning at age 23. During the first few 
years, she remembered feeling fairly confident that screening was effective in ensuring 
that she remained healthy. However, almost immediately after her time in the study 
ended, Trixie elected to undergo RRBM at age 27. Asked about how she knew that it was 
the right time to move forward with surgery, and she stated: 
I’m 27 and my sister was 28 when she was diagnosed and I just felt like a race 
against the clock, like I wanted to get it done before 28. I know, not necessarily 
would I have gotten cancer at 28, but to me, that number stuck in my head. I want 
to see 28. I want it to come and go and I want there to be no cancer. 
Trixie, 27 
For Trixie, the experience of her older sister’s two breast cancer diagnoses and eventual 
death at age 32 served as a powerful marker which she perceived as a looming threat. 
Although her sister was uniquely vulnerable due to having two BRCA mutations (an 
extraordinarily rare situation that almost certainly resulted in her developing cancer at an 
earlier age than she would have had only one been present), Trixie’s anxiety about 
meeting a similar fate was enough to lead her to decide to have RRBM fairly early. 
Together, Trixie, Rachel and Rylan demonstrate that awareness of increased risk based 
on the ages at which family members were diagnosed with cancer can lead to a greater 
sense of urgency about risk management, and may move mutation carriers closer to 
pursuing surgical risk-reduction. 
In contrast to the women quoted previously who discussed increases in risk-
related anxiety based on proximity to ages at which other family members were 
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diagnosed, some other participants described situations in which their age-based risk 
seemed low because they were younger than the age at which other family members had 
been diagnosed with cancer. Julia, 24, was among the youngest participants in the current 
study and had not yet started screening; she was preparing for her first screening 
appointment about three months from the date of our interview. When I asked her about 
her decision-making with regard to risk-management at this point in her life, she stated 
that she had chosen screening “because I do have quite a few years before the age that my 
mom was when she had the cancer. I guess I don’t feel any immediate risk or the need to 
do anything dramatic.” Similarly, Charlotte remembered: 
When I first got [my genetic test results], I would probably rate it pretty low, but 
because my cousin had it at 37, I guess there are some people that say ten years 
out is when I should really start worrying and considering prophylactic surgery. 
And so, as I get closer to 27, I’m definitely getting more and more worried that it 
could become a reality. 
Charlotte 26 
Charlotte’s experience also nicely demonstrates the transition from a period of relatively 
low perceived risk to one of higher perceived risk, setting the stage for significant 
decision-making about risk-management. 
Risk associated with reproductive issues. As discussed previously, family 
formation is one of the major developmental events that typically occurs during young 
adulthood (Arnett, 2004; Rodgers & White, 2004). Accordingly, many of the participants 
in the current study were very much occupied with the idea of having and raising children 
as they were also learning about their own cancer risk. Dynamics related to family 
formation and risk-reduction will be detailed in Chapter 9; however, this discussion of 
specific time-related vulnerabilities would not be complete without touching on the 
subject here, because knowledge of these issues is a major source of anxiety for mutation 
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carriers. Libby found out about her BRCA mutation during a time when she was 
undergoing fertility treatments, which was specifically frightening for her because of the 
potential for increased cancer risk due to very high levels of hormone exposure: 
 I felt very vulnerable, actually. The more I read, the more freaked out I started to 
get. I had taken a round of hormones to do an artificial insemination treatment, 
because I just really wanted to get pregnant. And I was taking a really low dose of 
hormones, because the doctor knew I had the mutation. After that, I felt very 
vulnerable. I was like, “oh my God,” because it didn’t work. I thought I might 
have just put myself in a really bad situation. I felt really vulnerable also with the 
ovarian cancer, because with the fertility stuff, they track your ovaries so much. 
I’m constantly getting ultrasounds of my ovaries and I just felt really vulnerable 
in that sense. It’s good that they’re looking at them, I guess, but they’re not 
necessarily looking for cancer. 
Libby, 32 
Clearly, for Libby, the issues of cancer risk and fertility were very much intertwined. 
This was also the case for Rachel, who had had one baby with the help of fertility drugs 
before she was tested for the BRCA mutation, but wanted to have more children. In 
putting these two pieces of health information together, her risk perception was based on 
the fact that “there is still no real knowledge as to what being on the fertility drugs does 
to you. Great, they got me pregnant, but especially in a BRCA patient, is that increasing 
my risk?”  
The connection between family formation and risk perception was likely 
intensified for Libby and for Rachel because of their use of fertility treatments, but it is 
also the case that women not involved with fertility treatment feel a similar sense of 
increased vulnerability during the period in which they are attempting to get pregnant, 
while they are pregnant, and in the months (or years) following a pregnancy. Leigh was 
the mother of several young children when she learned that she carried a BRCA mutation, 
and recalled having conceptualized her risk as 
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 Very high. Also, the early onset of the ovarian cancer aspect of this was especially 
troubling. By that time I’d read on the internet of several anecdotal cases of young 
women with very young children who developed cancer while breastfeeding or 
shortly after giving birth, so I was very terrified of my immediate risk at that time. 
I thought my risk of both cancers was very high. 
Leigh, 35 
The elevated cancer risk that many women associate with reproduction is also related to 
the fact that effective screening is nearly impossible during pregnancy and while 
breastfeeding, because of the potential dangers to the fetus associated with exposure to 
radiation and hormonal-related changes in breast tissue which interfere with obtaining 
clear, interpretable mammographic images. Additionally, the normal palpable changes to 
breast tissue that occur naturally during pregnancy and while breast feeding may be seen 
as threatening to women who are already very aware of any such changes.  
Previous cancer scares. About half of the women interviewed for the current 
study had experienced at least one “cancer scare,” usually a test result that came back 
abnormal and required follow-up or biopsy. In some cases, these occurred before the 
participants knew that they carried a mutation in BRCA, and in other cases they were 
aware of their mutation when the scares occurred; still others had had multiple cancer 
scares across different stages of mutation awareness. Chris explained how, having 
already experienced two cancer scares prior to being tested for the mutation, her positive 
test results moved her to take action to reduce her risk: 
 You just kind of feel like you’re underneath a black cloud all the time, and I just 
felt like it was coming, and you just want to beat it before it gets you, pretty 
much. I mean, you kind of forget about the 13 to 20% chance that you won’t get it 
and focus on “I am going to get it.” And so, you just feel like you’re waiting for 
it. And knowing that I already had two lumps that were giving me trouble, you 
just kind of think, “Well, this is stupid. It’s stupid to sit here and dwell on that and 




Trixie further exemplifies this phenomenon. After her oldest sister was diagnosed with 
breast cancer twice within four years and passed away at the age of 32, it was discovered 
that both their mother and father carried BRCA mutations – one in BRCA1 and the other 
in BRCA2 (Trixie had inherited BRCA1 but not BRCA2). This, combined with Trixie’s 
own experience at having abnormal test results throughout her years in the BI study, 
resulted in an intense feeling of vulnerability to cancer during the years between learning 
about her mutation and having an RRBM: 
 I felt like I was definitely going to get cancer, especially because I have some 
weird spots on my MRI. And I was watching someone so young and healthy get 
cancer in my own family, and you can read varying statistics about your risks 
when you’re BRCA1, and some studies would say 50% and some would say 95% 
likelihood you’re going to have cancer. And so I tended to cling to those statistics 
just because I was watching [my sister] have cancer. 
Trixie, 27 
Soon after her involvement in the BI study ended and she no longer had that access to 
intensive breast and ovarian screening, Trixie elected to undergo RRBM.  
Trixie’s experience is another example of “screening fatigue,” in which women 
become emotionally exhausted from dealing with peaks in anxiety surrounding their 
frequent screening visits and requests for follow-up tests based on suspicious or 
ambiguous results, ultimately confirming their sense of doubt that screening is effectively 
protecting them from cancer. When asked to describe what it was like receiving abnormal 
results after her screening visits in the BI study, Grace remembered the experience as 
terrifying, because every time you get an abnormal you think, “Is this the time it’s 
cancer?” So you start mentally preparing for it. If it is [cancer], then what surgery 
option would I do, and what kind of treatment would I need…you take it to the 
next level. 
Grace, 30 
Similarly, Kristy recalled: 
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It was really sort of traumatic … having the irregular results, and I had that a 
couple of times. And I kind of got to the point where I was like, this is great that 
I’m able to get screened high-risk and the doctors are extra careful with it, but it’s 
kind of to the point where it’s just making me uncomfortable because everything 
is a red flag and everything they want to explore more and everything is just sort 
of scary, because you never know. 
Kristy, 29 
For both Grace and Kristy, and for many other participants, the repeated experience of 
having screening tests come back as inconclusive or in need of additional follow-up 
and/or tests became too much to bear, and they decided to proceed with RRBM prior to 
having their first child despite having planned to wait at least until after they had had an 
opportunity to breastfeed once (again, this will be discussed in greater detail in Chapter 
9). For Grace, this surgery occurred at age 29, and for Kristy, at age 28. In cases such as 
these, it seems that over time, the experience of screening fatigue and multiple cancer 
scares outweighs the desire to preserve one’s natural breast tissue. 
Perceived risk of other cancers. Many participants mentioned that they were 
aware of BRCA-associated risks for other cancers beyond breast and ovarian, and there 
was some variation with regard to how much this was a source of anxiety. Several 
women identified other cancers for which there was a family or personal history that 
contributed to an increased risk perception. Recall that Valerie was a genetics researcher 
and therefore had a great deal of knowledge about genetic issues in general, including 
many details about BRCA. She mentioned both melanoma and pancreatic cancer as 
specific additional risks: 
 Melanoma scares me. A lot. I’m incredibly mole-y, and that actually comes from 
my dad [from whom she had inherited her mutation]. … He and I are both very, 
very mole-y, so it scares me knowing that I come with a slightly increased risk for 
it. … I feel like that’s kind of a bad combo. So, I always knew I was going to have 
to keep an eye on my breasts and ovaries, but some of the other BRCA2 spectrum 
cancers I wasn’t even aware of. I didn’t know about melanoma. I didn’t know 
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about colon or pancreatic cancer. Unfortunately, there’s really not a lot you can 
do in terms of screening for pancreatic cancer. My doctor said it needs to be in the 
back of my mind if I have some other medical issue I can’t explain. I’m not 
necessarily enthralled with the idea of always having to go through life thinking, 
“could it be my pancreas?” 
Valerie, 29 
 
Similarly, Libby identified colon cancer as a potential future risk exacerbated by the fact 
that she had already been diagnosed with a mild case of ulcerative colitis and wondered if 
this might someday become colon cancer. She planned to monitor carefully. 
Cancer in other components of the reproductive system was also a perceived risk 
for many women. This is an interesting issue because many women describe these other 
cancers as being “in their family;” however, it is quite possible that when other 
gynecological cancers are listed as diagnoses in older family members, these may 
actually be ovarian cases that were mislabeled or misdiagnosed prior to the availability of 
medical technology accurate enough to label gynecological cancers appropriately. 
Marjory believed that even if she chose to remove her ovaries, she might still be at risk 
for cancer in other parts of her reproductive system: “I wouldn’t be worried about getting 
ovarian cancer after I had my ovaries out, but I’d be worried about the primary 
peritoneal5, because it’s in my family.” Similarly, Wanda stated that after having an 
RRSO,  
I still think I’ll need some form of screening, because I could get cancer. If I only 
have the oophorectomy done, I could still have cancer in my other reproductive 
organs, so I still want to be screened regularly. I think I’ll feel much better, but I 
think there’s still a chance that I could get, if not a reproductive cancer, I could 
get some other type of cancer, so I think I just have to be diligent about screening. 
Wanda, 32 
                                                 
5 Primary peritoneal cancer is a malignancy which strongly resembles ovarian cancer, both under the 
microscope and in its response to treatment. It is thought to arise in cells within the peritoneal lining of the 
abdomen, which are known to share a similar embryologic origin with ovarian epithelial cells. 
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For Wanda and other women like her, it seems reasonable to speculate that completing 
risk-reducing surgery might completely eliminate cancer risk or the perception of still 
being at risk with its attendant anxiety, since there is a strong belief that cancer might still 
occur at another site. The experiences of these women illustrate instances in which 
completing surgical risk-reduction might leave some carriers with lingering feelings of 
high risk perception, because of fears that risk is not limited to only breast and ovarian 
cancers6. 
Anxiety About Cancer Risk 
 There are a minority of BRCA-positive young women who seem to truly not feel 
particularly vulnerable to cancer, at least in the short term: 
 I still to this day don’t think it’s coming soon. And I hope that’s not a naïve 
attitude. I don’t think it’s something I could feel vulnerable to until I get told, 
“Noelle, you have cancer.” I think at that point, I’ll know. … right now I’m 
dealing with it and moving forward with my life. I do research, I’m up on medical 
journals, and things like that but I don’t know how real it will be until it actually 
happens. 
Noelle, 26 
It seems that Noelle has found the ideal mix of being aware and educated about her risk 
of cancer, but not letting it get the best of her or consume her life. For many women, 
however, learning that they carry mutations in BRCA is the beginning of a very stressful 
period, marked by self-doubt, intense scrutiny over any health-related challenge, and 
hyper-awareness about risk. Lilly, who had only known about her risk for about a month 
at the time of her interview, illustrated this nicely in her response to a question about how 
she thinks about her risk now as opposed to before she was tested: 
 I definitely could be worse about it, but there’s not a day that goes by that I don’t 
                                                 
6 In fact, the best available evidence suggests that neither endometrial cancer nor cervical cancer occur 
excessively in women with BRCA mutations. 
 
 178
think about the threat. At this point, I’m happy I was able to go for so long not 
really, really, really worrying about it. It always was a worry, but now I question 
everything that I put into my mouth, or every bump, every feeling, every pain. 
Lilly, 25 
Sense of inevitability and fatalism. Many women from HBOC families 
experience a phase in which they believe that breast or ovarian cancer is an inevitable 
part of their future. This may often be based on the extent to which family histories seem 
to be saturated with relatives who have been diagnosed with cancer, or at least in which 
close relatives have received diagnoses. This sense that cancer cannot be avoided may be 
problematic when it precludes recognizing that one has the capacity to take actions to 
reduce her risk. When asked about her previous beliefs about her own vulnerability to 
cancer, Leigh recalled, “after my mom and her only sister had breast cancer, I sort of 
used to think I had 100% risk of breast cancer.” Similarly, Dawn remembered that before 
she had risk-reducing surgery, she felt “a horrible feeling that I knew I was going to get it 
at some point. I would definitely get it.” For Melanie, receiving positive mutation test 
results “confirmed what I already knew. I knew that I was at a higher risk anyway, and 
you feel like you’re broken, and it’s a foregone conclusion. Like, when is my time going 
to be?” Despite knowing that the calculated risk of breast cancer was 87%, Beth believed 
that “for me it may as well be 100% because with my family history it’s just too 
prevalent.” Reina recalled how her mother’s two breast cancer diagnoses contributed to 
her own feeling that cancer was inevitable, even before she was tested for BRCA: 
 I struggled with it for many years because I always had the assumption that I was 
inevitably going to get it. It just was a part of who I was. I don’t think there was a 
day that went by where I didn’t think about it. And then when I got tested and 
found out that I was positive, then I had to revisit all of those emotions and it just 




 For some women, the threat of cancer is not only inevitable, but urgent. This 
feeling, coupled with a belief that risk is changeable through action, can move women 
toward making definitive risk-management decisions. Kate learned that she carried a 
BRCA mutation at age 32 and was from a family in which there had been six known cases 
of BRCA-associated cancers resulting in three deaths; Kate’s 39-year-old sister was in the 
middle of treatment for breast cancer when Kate was tested: 
I felt like if I didn’t do something immediately, I would get cancer right away. I 
felt like, “I’ve got to do this now, there’s no time to wait. I don’t want to take any 
chances.” Maybe because of my sister’s age, she is about seven years older than I 
am. I didn’t want to wait for it to happen. I felt like, “It’s going to happen.” I felt 
very sure that it would happen sooner rather than later.  
Kate, 35 
Valerie’s family history of breast and ovarian cancer was quite pervasive, with her 
mother, aunt, several great aunts, and great-grandfather all having been affected by breast 
cancer. She described her feeling that cancer would be coming for her next: 
Cancer always felt like it was hanging over my head … Really from my mom 
having it so much and my whole family. It seemed like we just traded off. Mom 
was sick for so long [and then she died], and then my aunt became sick, and she 
passed away. And then by that time, my great-grandparents were getting up in 
age, they were sick. And I just sort of felt like… it kind of felt inevitable. But at 
the same time, I kind of felt like, if I knew it was inevitable, I could keep an eye 
out for it. It wasn’t going to sneak up on me. But I was sure I had two ticking time 
bombs strapped to my chest.   
Valerie, 29 
Valerie’s and Kate’s recounting of their experiences nicely illustrate the pressure that 
many young BRCA carriers feel to beat cancer to the punch – when women believe that 
their risk of cancer is very high, it often comes with a belief that they must do something 
to mitigate their risk quickly - to remove the dangerous body parts before they have a 
chance to develop cancer. That is precisely what both chose to do: Valerie had an RRBM 
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at the age of 28, and felt extremely confident that she had made the right decision for 
herself; Kate was planning to have her RRBM within the year following her interview. 
 Isabelle is the younger sister of Lilly, who was quoted previously in this chapter. 
Their mother had breast cancer at 25 and again at 36. Isabelle recalled her own 
conceptualization of her breast and ovarian cancer risk prior to being tested: 
I was never really super vigilant about my own breast self-exams. I always just 
assumed that I would get breast cancer, but I’ve always had the positive outlook 
I’m going to get it, it’s going to be caught early because we’re aware of our 
family history, and I’ll be fine. I think I’m going to get it if I don’t have a 
prophylactic mastectomy. I don’t know when, I just have a feeling that I’m going 
to get it. I don’t think I’m going to die from it. I just think I’m going to get it, go 
through it, and end up healthy. 
Isabelle, 22 
Isabelle’s experience reveals another unique issue related to breast and ovarian cancer 
risk perception. While living in constant fear of a cancer diagnosis is clearly neither 
healthy nor productive, the total absence of fear – the failure to accept cancer as a 
genuine threat – may also be counterproductive if it impedes one’s ability to take the risk 
of cancer seriously and be vigilant about screening and/or risk-reduction, thus becoming 
a barrier to action.   
 Surprisingly, even some women from breast/ovarian cancer families did not fully 
appreciate the extent to which the presence of a BRCA mutation dramatically increases 
cancer risk relative to that of non-carriers. This fatalistic thinking about risk is another 
example of how dynamics of agency and constraint act on the risk-management decision-
making process of young mutation carriers. For example, Sophie stated that during the 
time before she was tested but knew there was a mutation in her family, 
 I think I thought it would be just like anybody else. You can still get breast 
cancer with or without the gene, you can still get ovarian cancer, although I think 
the risks are pretty low. But you still have all these risks. You can never be a 
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smoker and you can still get lung cancer. And I still to this day kind of think of it 
that way. You know, it could happen to anybody, my risks are just greater, but at 
least I know so I can be proactive about it. 
Sophie, 31 
Sophie’s perception of her risk does not align with her scientific risk; however, her binary 
thinking about risk is not uncommon, and has been observed in previous research 
(Pilarski, 2009).  
Given that the general culture of young women interviewed for this study is quite 
risk-reduction- and action-oriented, it is interesting to imagine the relationship 
implications for members of a family or couple in which one individual takes a fatalistic 
approach and one does not. Sadie provided some insight about this in describing her 
younger sister, also a mutation carrier: 
I think that she and I really differ in our approach to this whole thing. … I like a 
lot of scientific hard facts, and she likes religion and fate and relying on the 
cosmos and stuff like that. … She just believes the Buddhist philosophy that if it’s 
meant to be, it’s meant to be. She is just going with the flow, she lives a happy 
and full life and she has every intention that being a good person, she won’t have 
cancer. So to her, the statistics don’t really mean a whole lot. Before I went in for 
my surgery, I mentioned again to her if we were going to bet, with an 80% chance 
that you’re going to win, you would probably play all those. And her response 
was that even if the risk was 99% that you would get cancer, if she’s in the 1% 
then that’s 100% to her. So that’s really hard for me to understand. 
Sadie, 33 
The obvious differences in Sadie’s and her sister’s perception of their breast and ovarian 
cancer risk and their decisions about how to manage that risk have added a difficult 
element to their relationship and leave Sadie feeling quite frustrated in her helplessness in 
convincing her sister to take her cancer risk more seriously. Her sister’s willingness to sit 
back and wait to see what would happen is striking in contrast to the decisiveness with 
which Sadie has acted to manage her own risk, having undergone RRSO at age 32. It 
seems quite likely that this has had further implications for family harmony and 
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interpersonal dynamics between the two sisters and other members of their family, a 
dynamic that might be repeated in other HBOC families. 
 Some women may also adopt a fatalistic attitude toward their risk in considering 
the chance that they might develop cancer even after risk-reducing surgery. In this 
context, the fatalism seems to be akin to managing residual risk perception even after 
having done everything possible to mitigate the risk of cancer. Consider Maelie, 33, who 
stated, “at this point, we’ve done all the risk reduction surgeries and things that we can 
do. I feel with what I have done, if I get cancer, I’m meant to have it, because there’s 
really nothing more I can do.” Similarly, when asked how she might feel about her risk 
after completing both surgeries, Pauline stated,  
If I do get cancer after I do my surgeries, I think you’ve got to have a little bit of a 
sense of humor about it, like “Oh, this was so programmed into my body that it 
came through even though… well, at least I tried.” And if that’s really, really the 
way that I’m going to go, then I guess I can’t fix it. I don’t believe much in 
destiny, that we all have this specific predetermined plan and that we all follow it. 
But if this is my genetic destiny, if this is truly, truly how my body will expire, 
even after I have the surgeries, it’s like, “Gosh! Okay.”  
Pauline, 30 
For Pauline and Maelie and other women like them, there may be a profound comfort and 
even peace in being able to reach this state of mind. In some ways, this may be the 
optimal outcome of all available risk-reducing strategies, and is certainly preferable to 
doing everything that can be done, but continuing to worry that some stone has been left 
unturned. Instead, they have acted with agency but recognized that doing so has its limits, 
and some things simply cannot be controlled. 
Managing anxiety. Risk-related anxiety seems to shift over time, peaking in the 
weeks and months surrounding one’s genetic testing and often fading somewhat 
thereafter. For many participants, these high levels of anxiety reappear with their 
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regularly-scheduled screening appointments, as discussed earlier in this chapter. Recall 
that Leigh highlighted her high levels of worry and anxiety dreams when she realized that 
she was at very high risk of breast cancer, compounded by the recent loss of a peer to 
lung cancer. Leigh recalled having experienced these high levels of anxiety for a while, 
“until I realized that just because I have the mutation doesn’t mean I’m definitely going 
to develop cancer right now. So at some point I relaxed a little bit.” 
Some women mentioned lifestyle changes that they believed they could make in 
order to reduce the negative impact that their positive BRCA mutation status would have 
on their lives and emotional well-being. Reina had been seeing a therapist for most of the 
time since she found out she was BRCA positive. From that, she had taken away the 
message that 
It’s something you really have to make an effort, make a life change, whether it 
be eating only organic or making sure you go to yoga classes every week, or don’t 
eat out as much, try and de-stress your life – which is like a joke. All these things 
that I know can help trigger the mutation, but in the everyday environment it’s 
really hard to shift in those directions. I definitely fall into the trap of being a 
workaholic, I have a very busy job that kind of consumes me a bit. 
Reina, 29 
Reina’s experience suggests another interesting dynamic related to managing cancer risk 
anxiety, because nobody really knows that the lifestyle changes she listed truly impact the 
likelihood that a given mutation will be “triggered” and cancer will develop. However, 
thinking this way does seem logical and it provides a rational basis for making such 
changes. Perhaps some mutation carriers cope with their risk in part by developing a 
framework in which they choose to view their risk, convince themselves it is correct, and 
then set about doing all the things that framework would dictate, creating a context in 
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which they can take action and ultimately feeling that they are taking the very best care of 
themselves in the process. 
 Using humor to manage BRCA-related cancer risk anxiety may seem impossible, 
but when it is done with aplomb, this strategy can be quite effective. Pauline was one of 
the most humorous and good-natured women interviewed for this current study, and her 
consistent use of humor in navigating the mutation-positive experience was striking. This 
was her response when asked her to describe what it was like to receive an abnormal 
result on a recent MRI: 
 Well, to be honest with you, I was sort of expecting it because I had heard that 
MRIs are incredibly sensitive technology. So I wasn’t entirely surprised when I 
heard that they had seen something suspicious. I wasn’t thrilled, of course, but I 
just sort of felt in my heart that it wasn’t going to be anything big. And I sort of 
have this joke with myself that my right breast is my bad breast. That’s where I 
found the lump a few years ago and pretty much from the day I got my BRCA 
result, even a few months before that because I knew it was coming, I sort of had 
pain in that right breast. So when the radiologist called and said, “Oh, we saw 
something suspicious in your left breast,” I thought, “Oh, well then obviously 
nothing is wrong because that’s the good breast.” So I actually surprised myself at 
how well I managed the anxiety. 
Pauline, 30 
 
Ultimately, the optimum way that many women manage their cancer anxiety is by 
taking action that truly reduces their risk, producing a shift from feelings of helplessness 
or vulnerability to pride and security in having decisively taken control. At 25, Lilly was 
among the youngest women interviewed for this study, and she had only known about her 
mutation for a little over one month. Lilly’s mother had been diagnosed with breast 
cancer at age 25 and again at 36, and this was a critical point in Lilly’s concept of her 
own risk. She stated, 
I don’t deal well with risk and health. So I just said, ‘I want to get my breasts 
removed.’ I don’t have a boyfriend, I can’t spare my breasts assuming I’ll find a 
guy who will have a problem with implants or the fact that I won’t be able to 
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[breastfeed]. So I have pretty much decided that I would like to have the surgery 
to remove as much of this fear about breast cancer as possible. Then, if and when 
I get married and have kids, or if I don’t, I would like to get my ovaries removed 
as well. And if there was something to remove the other risks of other cancers as 
well, I would do that, too. I’d just like to remove as much of the anxiety and fear 
about these things as I can. 
Lilly, 25 
At the time she was interviewed, Pauline had only known about her positive mutation 
status for about two months. She was actively contemplating risk-reducing mastectomy, 
but had not yet scheduled the surgery or decided about reconstruction options. She 
recalled how she felt about her breast cancer risk upon finding out that she carried a 
BRCA mutation. 
My first thought was that my breasts are expendable. My breasts are not worth 
the anxiety that knowing that I have a super high risk of developing breast cancer 
would bring. … I have obsessive-compulsive disorder. So you can only imagine 
the idea of having four screenings a year and the attendant anxiety that comes 
with those things, especially as it relates to my personal brain chemistry. That’s 
going to be really – excuse my language – fucking hard to do. It’s going to be 
really, really hard to be anxious for maybe a week before and maybe a week after, 
four times a year. That’s like two months of my year that I’m just going to be out 
of commission eating vegan cheesecakes, sleeping, doing all the crazy stress 
things that I do. 
 
Pauline went on to explain her believe that having the risk-reducing mastectomy will 
change her quality of life by reducing her day-to-day anxiety about her risk: 
Right now I’m walking around like, “I’m BRCA2 positive, my name is Pauline.” 
It’s like my status is more important to me that my name right now. That is the 
most prominent thing about me. And after the surgery I think that I’ll be able to 
go to a place where I’m just who I am again…if I wasn’t going to have emotional 
relief from this, I wouldn’t plan on going into surgery. 
Pauline, 30 
 
 Valerie is another young mutation carrier who experienced a peak in cancer 
anxiety, followed by a feeling of relative peace connected with making the decision to 
have an RRBM. She recalled, 
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 Over time, I realized that just knowing that there’s a mutant gene there doesn’t 
mean that anything’s actually changed. I’ve had the mutant gene since I was born. 
I knew in my mind that I was positive. And when [the doctor] told me I was 
positive, it didn’t alter my mindset much, although it did – I don’t want to say that 
it was the nail in the coffin because that’s really kind of an awful way to say it. 
But that’s kind of the best analogy. It was sort of the final piece of the puzzle. I 
decided, “All right. We’ve got to get rid of them.” 
Valerie, 29 
Perceived Risk After Surgery 
 One of the major benefits of risk-reducing surgery for BRCA1/2 mutation carriers 
is that it usually brings about considerable relief with regard to perceived risk (van 
Oostrom et al., 2003). However, the transition from being a “high-risk” person to a 
person at lower risk is not always smooth or complete, and does not always feel natural 
for BRCA mutation carriers. When she was interviewed, Sadie had already completed her 
RRSO. Asked whether the surgery had affected her experience of fear and stress about 
breast and ovarian cancer (both risks are substantially reduced after RRSO), Sadie said, 
 It’s hard for me to identify with a lower risk of ovarian cancer. It’s hard for me to 
say, ‘well, I’ve had the surgery and I guess I don’t really have that risk anymore.’ 
Because there’s always that slim chance that you’re going to get some look-alike 
abdominal cancer, that it’s going to pop up that we didn’t get all of the cells, or 
that type of thing. I haven’t really felt that huge relief, I guess. Because in my 
mind, it’s like, ‘well, maybe it’s gone, but you know, it’s probably still going to 
be there.” 
Sadie, 33 
It is interesting that the completion of an RRSO does not seem to have brought Sadie any 
significant relief from anxiety related to her cancer risk. Sadie’s family is one in which 
“all the women get cancer,” and many women in her mother’s generation had opted to 
have risk-reducing surgeries even before genetic testing was available. Sadie’s mother 
had both RRBM and RRSO in her twenties and had never been diagnosed with cancer. 
Having had her own ovaries removed, Sadie believed “I’m always going to have that 
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little bit of fear. I’m always going to feel like there’s some risk there.” With regard to her 
breast cancer risk, Sadie stated, “I know intellectually that by having the ovaries 
removed, that my risk of breast cancer has diminished just a little bit. But as far as the 
overall risk, I still think that’s probably the same.” It seems that although Sadie’s 
evidence-based risk of both breast and ovarian cancer have decreased significantly after 
her RRSO, her perceived risk is relatively unchanged; going through the surgery has 
provided her with very little relief from the troubling anxiety she has experienced since 
learning about her mutation. This would likely be well-addressed by a detailed, 
thoughtful interaction with a genetics professional who might be able to help her achieve 
a more realistic assessment of her current status. 
 At the other end of the spectrum from Sadie is Kate, who had already had a risk-
reducing mastectomy but was holding off on her risk-reducing oophorectomy because 
she wanted to have more children with her second husband. In discussing her confidence 
that the mastectomy would protect her from breast cancer, she stated: 
 Oh, 100 percent. I guess from time to time, when I hear about my cousin going 
back in for a check-up, I have to re-check myself – like, “Oh, am I supposed to be 
doing anything? Oh wait, no, that’s why I had it all done. I don’t have to go.” I 
don’t have to check for lumps. I make sure that my gynecologist is aware that I 
have the [mutation], she knows about the mastectomy and she does checks. But 
during breast cancer awareness month, it doesn’t cross my mind that I could get it. 
I think, “How do I let everybody else know about it?” I don’t think of breast 
cancer as a possibility at all anymore. I know it is, still. I know there is always a 
risk because they can’t get all the tissue out. But I don’t worry about it at all. 
Kate, 35 
Other women also described their feelings after surgery as being not completely without 
risk, but at a level that was reasonable and livable. For example, Chris stated that after 
having both surgeries, 
 I feel really good about [my risk]. I feel like I’ve done everything I could possibly 
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do. I exercise, I eat pretty healthy. I keep my weight down, and I take my 
vitamins. I feel like I do everything. At first I didn’t drink any alcohol or eat any 
sugar. It’s like you try to just knock out anything that could increase your risk. 
But my God, you really have to kind of live your life! So I think my risk now is 
probably better than that of the average population. Knowing that my aunt has 
some sort of weird ovarian tissue in her uterus that has caused another cancer, I’ll 
have to give that another thought. But for me, I know that I’ve done everything 
that I can do, or that I’m willing to. I do have my uterus. I’m not willing to take 
that out. 
Chris, 33 
Chris seems both to have a realistic understanding of her residual risk of cancer and to be 
coping well with what that risk means for her own life. Like Chris, Leigh seems to be in a 
sort of middle-ground territory with regard to her feelings about cancer risk after surgery: 
Overall I feel like my risk is reduced. When I first woke up from the surgery, I 
felt a huge sense of relief that I didn’t have to worry about breast cancer anymore. 
I think from what everyone tells me that my risk is greatly reduced now. I still 
have like a 5% risk so it’s not nothing, but it’s so much less than it was. So it’s 
not going to be front and center anymore. And I guess that will be an adjustment 
in itself because I’ve been thinking about it so much for the last two years. So 
maybe that hasn’t completely sunk in yet. 
Leigh, 35 
Finally, Audrey, 28, shared her perception, after having completed both RRBM 
and while contemplating RRSO, that having surgery had been a way to “take hold and do 
something to where I feel like I have a little piece of the pie that’s leaving me in control. 
You know, ha ha ha! I’m going to get it before [cancer] does.” Each of these women has 
experienced an outcome that seems like the ideal relief from anxiety that many women 
are seeking when they act with agency and make the decision to have a risk-reducing 
surgery, freeing themselves from high cancer risk-perception and re-opening paths 




 To some extent, the relationship between cancer risk perception and risk 
management decision-making in BRCA1/2-positive young women has been thoughtfully 
explored in previous research (e.g., Antill et al., 2006; Kash et al., 1992; Neise, Rachfuss, 
Paepke, Beier, & Lichtenegger, 2001; Schwartz et al., 2004). Believing that “living with 
risk [is] an ongoing experience which [leads] over time to a subjective development of 
one’s sense of risk,” (Pilarski, 2009, p. 305), qualitative researchers studying women at 
increased familial risk of breast cancer (but who were not confirmed BRCA1/2 mutation 
carriers) have provided valuable insight regarding how risk perception is formed in this 
more nebulous situation. However, previous research has failed to richly and 
comprehensively describe how young BRCA1/2-mutation positive women gather 
information about their risk, think about specific elements of risk related to their unique 
developmental stage, and reconcile their risk-related emotional experiences with the 
demands of managing their mutation status, finding ways to act with agency in situations 
rife with constraint. The data provided here make a significant contribution to filling that 
gap. 
 Expanding upon the basic model proposed in Chapter 5, Figure 5 illustrates how 
breast and ovarian cancer risk perception is related to several other elements of the 
model. Data presented in this chapter illustrate how cancer risk-perception is powerfully 
shaped by carriers’ knowledge of their family history and family beliefs about cancer. 
Participants shared stories about how things they learned in interactions with healthcare  
providers and peers became prominent features in their understanding of their risk, as 
well as how beliefs held by providers shaped their understanding of which risk 
management options were available to them, with clear implications for cancer risk over 
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time. Finally, several participants touched on issues related to family formation and 
carriers’ worries that moving toward their family formation goals might increase their 
risk of cancer.  
 Data indicate that in HBOC families, in which legacies of cancer are often 
pervasive and quite devastating, women may begin to consider themselves “at risk” very 
  Figure 5: Role of Cancer Risk-Perception in Theoretical Model 
 
early in their development, and so experiences that contribute to one’s ongoing evolution 
of risk perception may occur across the life course and may be experienced as quite 
constraining. When this lifelong experience occurs, women appear to reach the point of 

































genetic testing with firmly held notions of what it means to be at increased hereditary risk 
of cancer, and learning about one’s mutation status is often simply a confirmation of what 
is already known to be true. However, it may be challenging for women in this situation 
to set aside their intense identification with the cancer experiences of their mothers, 
aunts, grandmothers, and sisters and their often strongly held beliefs about being 
“doomed” to meet the same fate. Participants whose family histories were saturated with 
stories of cancer-related illness and loss sometimes reported feeling overwhelmed, 
overburdened, and as though difficult diagnoses were an inevitable part of their future. 
Such feelings may preclude the ability to feel in control of one’s health because the threat 
of cancer is seen as ever-present, and messages that suggest that periods of very high risk 
are not immediate may be difficult to absorb and assimilate. This is consistent with early 
research by Chalmers, Thomson, and Degner (1996), who suggested that early in the 
development of cancer risk perception, the lived experiences of family members are the 
primary source from which women draw information. Furthermore, research attending to 
the family illness narratives present in cancer-affected families suggest that the concept 
of anticipatory loss plays heavily into the experience of being BRCA mutation positive 
(Werner-Lin & Gardner, 2009), and living with this sense of impending significant loss 
appears to be managed at least partially through behaviors that demonstrate agency, such 
as seeking and assimilating information from various sources and creating concrete plans 
for risk-reduction.  
 In the absence of information about how family members have been affected, 
some women are left with an even stronger sense of uncertainty about the meaning of 
their BRCA mutations. Participants whose mutations were inherited through unaffected 
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fathers, who did not have close relationships with the affected members of their families, 
or who simply did not have a strong family history of cancer, often reported feeling as 
though they had little personally applicable information on which to base understanding 
of their risk. This sense of being suddenly thrust into high-risk status can be alarming and 
leave women feeling as though they have only the advice of their physicians and peers 
upon which to rely in understanding their risk; the threat of impending loss becomes even 
more ambiguous, and risk-management decisions can seem impossibly confusing.  
Whichever of these two routes women take to understanding their cancer risk 
based on family history, working through presuppositions allows one to take a step back 
and consider personal cancer risk in the context of her own body, previous risk-related 
experiences (e.g., abnormal screening test results), and the historical context in which her 
at-risk years occur (i.e., at a time when science and medicine have advanced far beyond 
what was available to their mothers and grandmothers). It is in this context that 
participants frequently reported having relied heavily on information gathered from 
healthcare providers, who have a great deal of influence with regard to the choices 
mutation-positive women make about risk management. In fact, healthcare providers are 
often the very first sources from which mutation-positive women begin to gather 
objective, personal risk-related information, often in the context of genetic counseling. 
The frequency with which participants related a perceived inability to pay close attention 
and truly absorb information in this setting immediately upon learning that they carry a 
BRCA1/2 mutation suggests that providers should consider temporally separating test 
disclosure from discussions about the implications of the mutation. In order to provide 
the maximum benefit to patients, providers should be aware of the different ways in 
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which their BRCA1/2 mutation-positive patients take in and retain information; for some, 
this occurs through repetition; for others, having something concrete to take away from a 
genetic counseling appointment is key; for still a third group, a useful metaphor provides 
continuing feelings of certainty about one’s understanding of risk information. Providers 
should be conscious of these differences and attempt to deliver information in the way 
that works best for each individual patient. Connecting patients with resources such as 
FORCE, Bright Pink, and existing publications, is another way for providers to direct 
their patients toward appropriate support; however, ongoing in-person support from a 
knowledgeable, supportive healthcare provider should be available to all mutation 
carriers as they move through the ever-changing challenges presented by their mutations. 
Perceptions of variations in risk related to specific mutation (BRCA1 or BRCA2) 
different cancer sites (i.e., breast, ovarian) and developmental stages (e.g., during 
pregnancy, breastfeeding) were a major source of cancer worry for many participants; 
further biomedical research providing insight with regard to these variations in risk would 
decrease ambiguity for women in this group if, for example, better ovarian cancer 
screening techniques were available, or breast screening during lactation were reliable. 
As more individuals are identified as mutation carriers and their natural history is studied, 
the medical community will come to understand more and more about how to counsel 
women about managing their risk. In the meantime, learning to listen to the unique and 
intricate stories of today’s young women, and how they make sense of their risk given 
their own knowledge, life experience, and interpretation of both, is key to supporting and 
assisting them through the ongoing decision-making processes that come along with 
being high-risk, congruent with recommendations by d’Agincourt-Canning (2005). 
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Among participants, it seemed that those with the most desirable outcomes related 
to assimilating and making decisions about risk and risk-management were those who 
effectively came to see their breasts (and, to a lesser extent, their ovaries) as parts of their 
bodies that were not integral to their sense of self; that is, they came to understand that 
they are not defined by these body parts, bringing an easier acceptance of risk-reducing 
surgeries. Beyond this cognitive shift, some women are able to take a humor-based 
perspective on their risk, accepting that once they have done what is available to them to 
reduce their risk, the rest is out of their hands. In other words, they have found ways to 
overcome their situations and resolve some of their risk-related anxieties, but do not get 
caught up in needing to continually seek ways to act. Rather, they can take comfort in 
having done the best thing available to manage their risk. This seems to be the healthiest 
path to adaptation to the BRCA1/2 experience, and would be an effective focus of 
ongoing psychosocial support if it were routinely made available to mutation-positive 
women in the settings in which they receive their mutation-related care. 
Finally, it is important to note that risk-management should not (and in many 
cases, does not) end with surgery. Appropriate follow-up with physicians and genetic 
counselors is often necessary to help identify lingering feelings of anxiety or 
misunderstandings about risk, so that carriers have an opportunity to recognize and shift 
conceptual glitches that leave them feeling vulnerable to cancer. Ongoing screening for 
other gynecological cancers and a lifelong awareness of other BRCA related health threats 
are also necessary, but are far less intrusive and constraining than living with the very 
real and often constant threat of breast and ovarian cancer. 
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CHAPTER 7: RESULTS—MUTATION DISCLOSURE IN COUPLE 
RELATIONSHIPS 
“I expected it to be a very difficult conversation and I expected someone would be turned 
off by it.” – Kate 
 
Although BRCA mutations occur within individuals and are passed between 
biological relatives, their potential to impact and be impacted by couple relationships is 
both real and significant (Hoskins et al., 2008; Manne et al., 2004; Matloff, Barnett, & 
Bober, 2009; Werner-Lin, 2008b). Establishing, nurturing, and maintaining couple 
relationships are primary tasks for women and men in young adulthood (Arnett, 2004). 
When a female partner carries a BRCA mutation and is making ongoing decisions about 
how to manage her cancer risk, several additional relationship-related tasks become 
necessary. The presence of a BRCA mutation must be disclosed by the mutation carrier to 
her partner; this is often precipitated by a perceived need to discuss issues related to risk 
management. The timing and tenor of such discussions vary significantly with the 
longevity and depth of the relationship, and may be followed by a period of education 
(either by the carrier or through research of other sources) for the non-carrier partner. 
Couples already in serious relationships when the female partner learns that she carries a 
mutation in BRCA must adjust to a new phase of life in which the demands of managing 
the mutation must be consistently and supportively taken into consideration. Couples 
must establish bi-directional exchanges of information and support (both instrumental 
and emotional), and cooperate in decision-making about risk management. Ongoing 
discussions about the implications of a BRCA mutation for family planning and medical 




Disclosure in Dating Relationships 
 Informing one’s partner in a dating relationship about the presence of a BRCA 
mutation was described as an intimidating task by many participants, and the manner in 
which this exchange of information occurs varies depending upon, among other things, a 
woman’s choices about risk-management. Those relying upon surveillance may be 
disclosing, in addition to the presence of the mutation and risk to future children, the 
potential for future bodily changes as a result of risk-reducing surgery; however, because 
they have not yet done any risk-reducing surgeries, these women are able to choose when 
to disclose their mutation to a partner, thus having greater flexibility and control over the 
process. For women who have already completed one or both risk-reducing surgeries, 
disclosure often occurs earlier in the development of a relationship because of a belief 
that disclosure should precede any physical intimacy that would make the effects of the 
surgery obvious to the partner. This sense of obligation to disclose earlier in the 
development of a new relationship can be restraining to carriers if they feel unable to 
control how this highly personal and sensitive information is shared with a partner. 
Timing of disclosure within relationship development. For many mutation-
positive women in dating relationships, deciding when to inform a partner about their 
mutations is a delicate process. Factors that influence this decision include the perceived 
solidity of the relationship, an individual’s desire for the relationship to become 
permanent, and what actions have already been taken to mitigate risk (i.e., risk-reducing 
surgeries). In this study, the belief that disclosure of one’s mutation should occur only 
after a partner has demonstrated commitment was widespread: 
I guess I’d have to be really close to them. It would have to be a very serious 
relationship. It would not be something I’d tell somebody on the third or fourth 
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date. It’d be somebody who’s already met my family, somebody who’s already 
demonstrated commitment. 
Noelle, 26 
While many participants reported desiring some commitment prior to mutation 
disclosure, they also discussed the delicate balance between disclosing early enough to 
avoid being seen as secretive, while waiting long enough for the partner to feel 
sufficiently invested that simply ending the relationship would be less likely. As 
illustrated by Ellie in Chapter 5, Charlotte also believed that the timing of disclosure with 
a future partner could significantly impact the relationship trajectory. This derived from a 
previous experience in which a relationship had ended shortly after Charlotte and her 
partner discussed her mutation. Single when interviewed, Charlotte thought about 
disclosure to a future partner:  
I have dated a little bit and not felt like I needed to bring it up right off the bat. 
But I think probably before it got too serious, if I could tell that it was going to 
probably be an exclusive relationship or that things were going in that direction 
… if he wasn’t OK with it – I experienced that before, I wouldn’t want to be so 
involved that it was heartbreaking. So I think that I definitely would tell him 
before it got too serious, just in case it wasn’t something that he was able to 
handle at that point in his life. And it wouldn’t be so hard if it just wasn’t the right 
time for the two of us, so maybe before it got too serious. I don’t think it’s 
something that on the first date I’d need to share, but as we’re getting to know 
each other, I’d just kind of let him know my situation in case it progressed into a 
serious relationship. But I would almost feel like I was keeping a secret if I waited 
too long. I would feel like I’m not being fair, I guess. 
 
Charlotte’s plan to disclose her mutation to a future partner before the relationship had 
become serious may be a way to protect herself from the hurt she felt when her previous 
relationship ended unexpectedly after disclosure. Her acute attention to disclosing early 
enough to prevent a future partner from accusing her of being secretive—and before 
becoming too emotionally involved herself—is a testament to the gravity of this 
information. She also noted how dynamics in her family of origin, specifically with 
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regard to their worry about her, were related to the disclosure process with a future 
partner:  
I think the hardest part definitely is, I feel like I would wait until I felt close 
enough with someone. And at that point I feel like they would care about me 
obviously and I think it’ll go back to seeing my family worry about me, I feel like 
it’ll be adding another person onto that burden. Almost that this new person’s 
going to have to end up worrying about me when I don’t want anyone else to. So 
that’ll be hard. 
Charlotte, 26 
Charlotte’s concern was connected to pre-existent guilt feelings that she experiences 
when her family members worry about her, a state of mind that may be exacerbated 
because, having inherited a BRCA mutation from her father and with a mutation-negative 
sister as her only sibling, Charlotte was the sole member of her immediate family dealing 
with a very high cancer risk. Although her father was a mutation carrier, his risks (as a 
male) were much lower. Her words suggested that disclosing her BRCA-related status 
was akin to inviting her partner into this group of worriers, a perception that may account 
for her deciding to delay sharing this information until further into the relationship.  
In addition to balancing the status and demands of the relationship itself, carriers 
must also select a time for mutation disclosure based on what is happening in their lives 
with regard to the mutation itself. For many, involvement with surveillance or progress 
toward risk-reducing surgery may move them to disclose earlier than they would 
otherwise, as Ellie experienced (see Chapter 5). Trixie recounted how informing her 
partner about her yearly NIH visits, and the reason behind them, was a useful segue 
between telling him about the history of cancer in her family and about her own 
mutation: 
I told him pretty quickly about our family. You know, I had pictures and I would 
talk about different members of my family. And then … shortly after [I met him], 
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I had to go to NIH for my yearly visit. So that’s when it came up to him that that’s 
where I was going and why. He thinks it’s great that I’m involved in something, 
that I’m managing my risk. That I’m not just sitting around thinking about my 
risk, I’m doing something. So he was very supportive.  
Trixie, 27 
Disclosure prior to risk-reducing surgery. Ellie and Trixie had some flexibility to 
time their mutation disclosure because they had not yet had surgery; consequently, there 
was no outward evidence of their status. For them and for other participants who 
experienced mutation disclosure to a partner before undergoing risk-reducing surgery, 
disclosure was often focused on conveying lifetime cancer risk and the challenges of 
ongoing screening and prevention, as well as the potential risk to future children. Many, 
but not all, participants anticipated at least one risk-reducing surgery as a likely event in 
their future. Accordingly, they felt compelled to disclose this eventuality to partners in 
new relationships before they become permanent, out of a sense of obligation to inform 
their partners about an important life challenge in which the partner would be expected to 
be involved (Hoskins et al., 2008; Werner-Lin, 2008). This feeling fit with women’s 
conceptualization of the seriousness of the two surgical procedures, and suggested that 
they were aware of the demands that these procedures would put on their partners and on 
developing relationships.  
 Many participants who were not in relationships when interviewed gave 
thoughtful consideration to how to approach informing a future partner about their 
mutations and plans for subsequent risk-management. Isabelle lucidly outlined her 
strategy, which would depend upon the risk-management decisions she had made up to 
that point, as well as how the discussion would likely be influenced by her cultural 
background and that of her partner: 
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I am Jewish, Ashkenazi – there are a lot of genetic issues going on with our group 
of people. For all I know, he might have a history he wouldn’t want to bring up, 
or would want to bring up at a later point. If he’s overly caring and sensitive, it 
might just come up in conversation. If I’d already had a prophylactic mastectomy 
I would bring it up a lot sooner just to warn him what my breasts look like, but if I 
hadn’t and I’m going for surveillance, I feel like he would want to know why I’m 
going to the doctor. If it was too much for him then it would be too much for him, 
or I would take it a little bit at a time, give him little tidbits and then if he stayed 
long enough and was still interested I’d give him the whole megillah. 
Isabelle, 22 
“The whole megillah7,” to Isabelle, was comprised of her family history of cancer (i.e., 
her mother’s two very early-onset breast cancers) and their implications for her own 
health; her risk-management plans, including both risk-reducing surgeries; the 
implications of her mutation on the timing and pace of family formation; and potential 
genetic risks to future children. For Isabelle, these latter issues were confounded by the 
threat of other Ashkenazi-specific genetic health risks (e.g., Tay Sachs, Gaucher, 
Niemann-Pick diseases), which she thought might be present in her future partner’s 
family history, if he were also Jewish. Given the higher frequency of BRCA in the 
Ashkenazi Jewish population, other carriers may be similarly concerned with the 
possibility of co-occurring genetic issues within a couple considering future family 
formation. Isabelle suggests that the appropriate way to handle disclosure to a future 
partner would be to share information in pieces, ensuring that he could handle each piece 
before giving the next. 
Women’s sense of confidence about how their partners will receive mutation 
disclosure directly impacts the experience of the disclosure itself. Recall Ellie’s thinking 
(in Chapter 5) on informing her partner about her decision to undergo RRBM as 
indicative of strength, and her expectation of a positive reaction. In contrast, Annie 
                                                 
1 Megillah: a Yiddish term for a long, boring, tediously detailed account.  
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recalled disclosing her mutation and long-term risk management plans to her long-
distance boyfriend after they had been dating only a few weeks. In the same short period 
of time, she had met this partner and decided to move forward with RRBM, so disclosure 
in Annie’s case meant informing a very new partner of a significant health-related 
decision by which he would certainly be impacted if their relationship continued. Annie’s 
decision to disclose came from her sense that they were a “good fit” and had similarly 
positive ideas about moving forward together: 
It was a total mess, to be honest. We’d been dating a little under a month, and he 
had come to visit and we had spoken about how we felt about each other, and I 
just felt like before we made a commitment to each other he needed to know what 
was going on … So I just said, “Hey, this is something I want you to know,” and 
of course I started crying immediately. He goes, “What’s wrong?” and he wants 
to try to fix it and all of that. But it was very emotional for me, because there was 
a part of me that was very worried that he was gonna be like, “OK, this is a little 
more than I signed up for.” But in the end, his reaction was one of concern about 
me; he wanted to make sure I was okay versus what that meant for us. It was a 
huge relief. It was almost euphoric … like, “Did that really just happen?” … He 
took it all in stride. But I told him, “This is what I’m planning on doing. This is 
how I’m gonna manage what this means for me,” and he didn’t offer an opinion. 
He just said, “Whatever you decide. It’s your body and I’m here for you. … you 
know what you need.” So that part of it, not trying to insert his opinion, was great. 
He’s in healthcare … so I guess I was concerned he was gonna second guess the 
decisions I had already made, but instead he just had nothing but support for it. 
He’s really special and I feel fortunate in telling him and his reaction about it, that 
that’s the way it is. … even though I bumbled through telling him and trying to 
explain it, but his having a different reaction would be very devastating. 
Annie, 32 
Annie’s experience illustrates what seems to be a fundamental truth about disclosure for 
many young BRCA-positive women: they often genuinely fear that even a committed and 
seemingly wonderful partner will find the challenges presented by BRCA to be too much 
to handle, and choose to end the relationship, rather than facing the challenges together. 
Her recollection of the disclosure as “a total mess” reflected the level of emotional 
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intensity she experienced during the conversation, having found herself in tears at the 
start of the conversation because of her overwhelming fear that she would be rejected. 
Disclosure after risk-reducing surgery. As previously stated, women who have 
undergone risk-reducing surgery while single face the challenge of informing new 
partners about their risk-management decisions early in the development of new 
relationships. Kristy believed that information about her mutation would be difficult to 
hide from a new partner: 
I’m hoping that I’ll just deal with it as it comes along for whatever comes up. It’s 
not something that I think I would keep a secret for a long time, because it’s had a 
major impact on my life and obviously I have a lot of family things that are going 
on that would be hard not to talk about. I think it would come up as a result of 
that. And because I’ve had reconstruction, when I start becoming physically 
intimate with somebody, it’s going to be pretty obvious. Especially because I 
haven’t had the reconstruction finished. So it’s going to come up. 
Kristy, 29 
Kristy was in a relationship that has since ended, when she underwent RRBM. She has 
not yet had the experience of informing a new partner about her mutation and surgery. 
Lynn was the youngest study participant who had already completed RRBM, 
having done so at 23. She was in a relationship when interviewed, and had informed 
several previous partners about her situation since learning that she was a mutation 
carrier at age 19: 
I haven’t really had any bad experiences with it. Like I said, I’m really open about 
most of that information, it’s a take it or leave it sort of deal. If you don’t like it, I 
can go meet somebody else. I’m not who I am because of some guy. I am who I 
am because of me, and if they can’t understand why I’ve made a decision like 
this, then so be it, I’ll find somebody else who does. 
 
A strong sense of self, coupled with a straightforward attitude about her mutation and the 
changes it had brought in her life, were the keys to Lynn’s open communication with 
partners. She believed that diving straight into it was the best strategy; in fact, she had 
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disclosed her mutation and information about her RRBM to her current boyfriend on the 
night they met! She believed that had she not disclosed this information to this new 
partner quickly, he would have soon figured things out on his own. When they met, she 
was fitted with tissue expanders (small pouches behind each pectoral muscle) that had 
small external ports implanted in each breast through which liquid was gradually added, 
until the desired breast size is achieved, and she had no nipples. When they progressed to 
a moderate level of physical intimacy, he would have immediately recognized that 
something was amiss. Unsure whether her current relationship would become permanent, 
Lynn went on to comment about disclosure in potential future relationships: 
I think before I get married … this is something that I would tell him right off the 
bat. Not necessarily the kids part, but the BRCA mutation, the statistics that are 
added to that, what I’ve done already, what I’m going to need to have done. And 
if the relationship moves forward, I’d mention, “This is something I have to do. I 
have to remove my ovaries. I don’t need them for anything but having children. If 
I’m done having children, I expect to remove them, and all the lower parts.” And 
it might put a little bit of pressure on the time table as far as having children, but 
hopefully that person will agree with me and think that it’s a smart idea. 
Especially if I’m the person they want to have children with, they would be 
concerned about having me around to see the children grow up, and so forth. The 
more open I am about all of it, the more comfortable I am with discussing those 
things with people, and when you’re trying to find your mate for life, your 
husband, you want to be open about those things. You don’t want that to be a 
surprise, like, “Hey, we’re getting married, but by the way…” I just don’t want it 
to be one of those things. 
Lynn, 24 
Lynn’s belief was that as a mutation carrier who had already undergone RRBM, both 
facts should be disclosed very early in a new, developing relationship. Other information, 
such as the implications for children and intention to undergo RRSO in the future, could 
be appropriately held back until the relationship had progressed and was more solid.  
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 Not all participants found it as easy to be forthcoming about their mutations as 
Lynn. Kate was hesitant to share information with her new partner, after having gone 
through a divorce while she was undergoing RRBM and breast reconstruction: 
I think probably the first couple times that we went out, the thought of telling him 
about that hadn’t even crossed my mind because it had been so long since I dated. 
I was more worried about what to do on a date. But it wasn’t very long after that I 
thought, “Well, I know I like this person, and we’re going to probably continue to 
grow our relationship, I need to let him know about this.” So I brought it up like, 
“Remember how I told you my sister had cancer? It was breast cancer…” and so I 
started to tell him all these things, and I guess I expected the worst kind of 
reaction, “Oh my gosh, you have that wrong with you?!” that kind of thing. But 
he said, “Oh really? My good friend had the same thing happen to her.” So it 
ended up being remarkably easy. He knew all about the surgery, so that wasn’t a 
shock to him at all. It was totally no big deal. I was stunned that it could be that 
easy. I expected it to be a very difficult conversation and I expected someone 
would be turned off by it.  
Kate, 35 
Kate’s surprise at the ease with which her partner accepted news of her mutation and 
surgery indicate that her fears about his reaction were real. This positive outcome was 
partly facilitated by his familiarity with BRCA from his friend’s experience; clearly, most 
women who disclose BRCA-related information will not be so fortunate. 
Sense of urgency and pace of relationship development. The sense of urgency 
that some carriers feel to move forward quickly, to “fit in” all the desired tasks of young 
adulthood before their time “runs out” due to a cancer diagnosis or risk-reducing surgery, 
is another important dynamic that influences the tenor and tempo of couple relationships 
in this context. Charlotte was in a relationship when she first learned about her BRCA 
mutation, but that relationship ended shortly thereafter. Having been single for several 
months, Charlotte discussed her concerns about starting a new relationship for the first 
time with knowledge about her cancer risk: 
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When I first broke up, I was just kind of enjoying being single. But definitely 
now, I do feel a lot of pressure and just because I know my family wants me to 
have surgeries and things like that I do feel a lot of pressure and kind of like a 
ticking time bomb that I need to get married, have babies, so I can do this and not 
have to worry about it, definitely. I know that I feel emotionally ready to date 
again or be with someone again. It does almost feel like it’s something on the to-
do list, like it’s something I need to do and get done. And hopefully I’ll be able to 
take the time and really get to know someone that I care about and not just be 
doing it because I feel like, “okay, I need to get a boyfriend and get married and 
have babies and do this.” So, I think it’s definitely something that I just need to 
make sure that I’m not just doing because I feel like I need to get married, but 
because it’s someone I care about. 
Charlotte, 26 
This stress is a real threat for young female mutation carriers – differentiating the feelings 
derived from their mutations from those that might be present if the mutation were not an 
issue. Charlotte’s awareness of the risk of making rushed decisions based on needs 
imposed by her mutation is a positive sign that she can avoid this threat. 
 The sense of urgency to establish and make permanent a couple relationship may 
come not only from one’s own feeling that time is short, but also from outside sources. 
As noted by Charlotte, family members can be one source of this external pressure; 
Serena also provided a good example of this:  
I’m getting constant pressure from my mom, my dad, my grandparents, aunts, 
uncles, cousins. Everyone’s like, “Who are you dating?”, “Nobody,” “When are 
you going to date somebody?”, “When I find somebody.” It’s horrible. And it puts 
a lot of pressure. It’s hard enough to date people when you’re not under the 
pressure of “when are you going to find somebody, when are you going to get 
married, when are you going to have kids?” And it’s become internalized as well. 
It doesn’t make me happy and I know that about myself. And that is very 
frustrating because I don’t want my life to rotate or depend of me having to find a 
guy. It is hard. They want me to get married and have kids. My brother is eight 
years younger than me and he’s going to turn out a nephew any day now. My 
sister who is four years older than me has five kids. 
Serena, 30 
Unrelated medical conditions or challenges bring additional pressure on young carriers to 
progress quickly through couple relationship stages. Concurrent with discovering her 
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BRCA mutation, Monique learned that she was at high risk of cervical cancer8. This 
combination further reduced the perceived time available to have her family:  
It’s frustrating. I just want to get married, but I don’t want to just marry anyone. I 
feel like I’m forced to do this. And then I step back and I’m like, uh… it’s kind of 
frustrating, what to exactly do. You don’t want to make the wrong decision. So I 
think definitely the cervical cancer issue made it even worse. 
Monique, 26 
 Charlotte, Serena, and Monique all illuminate the experiences of young female 
mutation carriers who are not in relationships, although similar pressures exist for women 
who are in relationships as well: many experience a strong desire to make their dating 
relationships permanent. Noelle had been dating her boyfriend for several years and was 
ready to take their relationship to the next level, a plan that was not congruent with his 
timeline: 
I think he’s afraid of marriage, whether it’s because he’s too young, he owns a 
business so I know he thinks the whole business side of his life needs to be stable 
and perfect before he gets married. To me, there’s never a perfect time. … And so 
I really think he’s focusing on proving himself in the business world before he can 
dedicate himself to marriage. And he has said that he thinks being married means 
you have to have a child right away, which I thought was the silliest comment 
ever. … I was like, “Well, that works out perfectly for me and my situation here.” 
I really think I’m the backbone of this relationship in that I can deal with a lot 
more and I just think he wants problems to be other people’s problems, he wants 
kids to be other people’s kids. That’s not to say he’s not the most excited friend or 
sibling when other people are going through these major life moments. That’s 
what confuses me because there’s such a disconnect between how excited he gets 
for other people and wants to blow off that himself. 
Noelle, 26 
While Noelle was frustrated by this impasse, Kristy recalled how knowledge of her 
BRCA mutation catalyzed her relationship with her boyfriend Spencer to move more 
quickly toward permanence than it might have otherwise: 
                                                 
8 Cervical cancer is caused by persistent infection with the human papilloma virus (HPV). It is not part of 
the spectrum of BRCA1/2-related malignancies. 
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In our case, I think in some ways it kind of accelerated our relationship because 
we were pretty newly dating when I found out that I had the mutation. And I went 
to this high risk center and everybody was asking me, “When are you having 
kids? You need to have kids early and have your boobs taken out so that you 
reduce your risk.” And at that point Spencer was very supportive, and it’s 
something that we worked through together. And it kind of got to the point of, 
well, I need to get married quickly and we got along so well, and we loved each 
other. In some ways I think that news accelerated our relationship. He was very 
supportive and it brought us closer together, but in the big scheme of things it 
probably had an effect that maybe we didn’t want. 
Kristy, 29 
Ultimately, Kristy and Spencer concluded that they were not the right long-term partners 
for each other. However, Kristy was emphatic that being with a warm, supportive and 
loving partner during her mutation testing and her RRBM was very positive: she truly 
needed him then. She has no regrets about their relationship; rather, she appreciated that 
Spencer was a part of her life during such a difficult time. 
 Beth’s experience further illustrates how women’s sense of urgency complicates 
their lives. Before she knew she was BRCA-positive, Beth and her boyfriend 
unexpectedly conceived a baby, despite consistent contraceptive use. One year post-
partum, they were struggling to balance their desire to get married with issues related to 
Beth’s risk-reducing mastectomy and her sister’s ongoing breast cancer treatment. Plus, 
Beth felt compelled to complete her surgery before her son turned one, because her 
sister’s breast cancer diagnosis (which occurred one year after delivering a baby) 
dramatically exacerbated Beth’s sense of vulnerability: 
Originally we were going to get married this summer, this was before my sister’s 
[breast cancer] diagnosis. My sister’s diagnosis kind of threw a wrench in that 
because now if we do a destination wedding my sister won’t be able to go. Then I 
thought we could still do a destination wedding and just have it be the two of us, 
because I’m thinking if my sister can’t go I don’t know if I want anybody there. 
So that kind of put a wrench in it. And then me having the mutation, knowing that 
I want to have surgery, I told him I need to have the surgery before my son is one 
year old because my sister was diagnosed when her daughter was 11 months old, 
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so that feels like a ticking time bomb to me. But a wedding is just not as important 
as the surgery and getting well. So then after my sister’s diagnosis, and after 
learning about my mutation, we thought OK, she’s going to have chemo, then 
she’s going to have surgery in February, if I want to have my surgery before 
September we could still get married late spring or summer. But it just keeps 
getting pushed back because my sister’s surgery was pushed back, it’s hard 
enough to plan a wedding if you have an infant, but then throw cancer and the 
mutation into it… 
Beth, 30 
The urgency to accelerate making a couple relationship permanent was consistently 
articulated among participants who were in positive, stable dating relationships when 
they learned about their mutations. However, learning that one is a mutation carrier may 
have the opposite effect on women who are not confident that their relationships have 
long-term potential. Annie illustrated this beautifully; she was dating someone when she 
learned of her mutation, and chose to end that relationship soon after: 
I got the results and shortly after that we broke up. It wasn’t because of it, by any 
stretch. Well maybe, you know what, maybe it was, because I realized I was in a 
very casual relationship and, ultimately, I had a lot of much bigger things going 
on and wanted to focus a little bit more on myself, and wanted to find someone 
that I wanted to talk with about it and wanted to be involved in the process of it. 
Ultimately, I think that very well could have been a catalyst for me to realize, 
“I’m not really into this person and this isn’t going where I want it to.” That 
probably moved things to an end quicker than maybe I would have otherwise. 
Annie, 32 
Annie felt empowered by this decision, and commented that her experience might differ 
from other mutation carriers; rather than worrying that her mutation would make her 
undesirable to a partner, she instead viewed her mutation as a catalyst to making positive 
changes, focusing on herself, and positioning herself to meet a partner who was a better 
long-term fit. 
 Charlotte’s experience with her then-boyfriend was similar to Annie’s, although 
she did not describe it in the same way. Charlotte and her boyfriend had been dating 
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several years when Charlotte learned that her family had a BRCA mutation. That 
information was particularly difficult for her partner to cope with because a member of 
his family had a serious disability, and serious medical issues in general were a tough 
subject for him: 
He very much backed away and just wasn’t able to be a part of it and was pretty 
open that he didn’t know if he could deal with another sick person in his life. 
Even though I wasn’t getting diagnosed with cancer, the potential of having to 
deal with that was pretty hard for him, which was hard for me to hear when I 
needed the support. And so the testing process was pretty hard for him. He was 
one of the people among my friends who kept saying, “Your cousin will be 
negative. Your uncle will be negative. Your dad will be negative. You’ll be 
negative.” When it came down to my dad was positive and it was time for me to 
get tested, I asked him if he would come with me, and we actually ended up not 
talking for three days. He just said he needed some space and we were living 
together and he went and stayed somewhere else. And then he came back and he 
did apologize, but that’s when he was open about how he was feeling with all of 
it. He did come to the test with me, but it was not the kind of support that I needed 
or was looking for. After that he felt guilty because we had dated for so long, and 
he wasn’t able to be there for me. We had been growing apart after college and 
things like that. So we were just dealing with, “Is this because of this? Or is it 
because we’re just growing apart?” So it was very on-again, off-again for 
probably about nine months or so, and then that ended up just ending. 
Charlotte, 26 
Collectively, participants’ feelings of doubt about couple relationships and their 
experiences in disclosing information about their mutations and susceptibility to cancer 
are powerful illustrations of the intense emotional work that comes with the physical state 
of being BRCA1/2 mutation-positive. They also illustrate how decisions about risk 
management can have a profound impact on when and how mutation information is 
disclosed in a dating relationship. 
Fear of rejection or confirmation of commitment. It was a powerful emotion 
for several single subjects to feel that their desirability to the opposite sex was or would 
be reduced as a result of being a BRCA mutation carrier. For some, these beliefs stemmed 
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from doubts about a partner’s willingness to commit to someone whose body will likely 
change as a result of risk-reducing surgeries or cancer, or to cope with the implications of 
a BRCA mutation on family formation (e.g., risk to children, condensed timeline for 
family formation). For others, external factors, such as messages from family or societal 
beliefs about feminine attractiveness, were the source of doubt.  
Many participants who were uncertain regarding how a partner would handle 
mutation-related information were not in relationships when interviewed, but had 
considered how partner disclosure might occur someday. For example, Lilly discussed 
how she felt as she started dating several months after positive mutation testing:  
It is – pardon my potty mouth – fucking scary. It’s not a diagnosis, but who’s 
gonna want to deal with this? I mean, implants are fine and nice for strippers, but 
I don’t know too many guys who want that. I don’t know. There are just a lot of 
“ifs.” As much as I try to think it’s not, this is a big deal, and I don’t know too 
many people who are gonna want to walk into this situation. 
 
Lilly was already contemplating how a future partner might feel about her body after she 
eventually has risk-reducing surgery. In part, this feeling may stem from Lilly’s own 
uncertainty about how her body would look and feel after RRBM; she also questioned the 
ability of a future partner to deal with all of the uncertainly that comes along with being a 
mutation carrier. She then discussed her belief that the demands of her BRCA mutation 
would not align with a partner’s ideas about what young adulthood should be like: 
I can’t help but think that he’d walk. At 25, 26, 27, or even 31, 32, 33 it’s like 
you’re focused on wanting to get married or wanting to have a family. Hopefully 
someone would be able to look past [the mutation]. That’s the route that I’m 
hoping to take. But in all honesty, if the tables were turned and someone said to 





Equating the challenges presented by her BRCA mutation with those presented by a 
serious mental illness demonstrates the profound negativity with which Lilly fears a 
partner might view her mutation and its implications. This is a genuine fear for many 
young women. Nichelle, who was in a very casual relationship with a partner with whom 
she had not yet shared any information about her mutation or the presence of cancer in 
her family, illustrated this concern: 
I think that could be one of the worst things is to tell someone that you’ve tested 
positive, and then they just wouldn’t react well. Or them not being able to handle 
it and kind of removing themselves from your life. I think there’s always a fear 
that it would limit a relationship. It would possibly end a relationship because of 
finding this out. A partner not being able to handle it would be really a 
devastating thing because if it’s someone you really care about, and you tell them 
this, and they can’t handle it and would walk out of your life…that’s probably my 
biggest fear in regards to having this, just having a person walk out on me. 
Nichelle, 20 
Understanding Nichelle’s deep fear that a partner could simply walk away, it is easy to 
imagine how difficult it was for Nichelle to consider sharing this information with the 
man she was dating when interviewed. 
 Some participants had theories about partner traits that might increase the 
likelihood of his successfully coping with BRCA-related information. Most theories 
centered on his having previously experienced cancer or other medical hardships in their 
families, giving them increased capacity for empathy. Lilly suggested that a partner who 
was also from an HBOC family might be a good fit: 
After going to a lot of these [BRCA support] meetings, a lot of the women have 
sons and they say that their sons, after having a mother with cancer, are in fact 
different. It just seems like if someone has dealt with something heavy, then 
maybe they can deal with this. [Interviewer: So maybe someone who is also from 
a BRCA family would be a good match for you?] Perhaps … then again, I don’t 




Lilly’s quote also illustrates her belief that having breast or ovarian cancer in the family, 
especially when one’s mother is affected, is a truly life-altering experience that can and 
often does lead to an increased capacity to deal with the difficulties that might arise for a 
couple in which the woman is a mutation carrier. She also acknowledges the heavy 
burden that could befall the child of parents who are both mutation carriers – the “double 
whammy” to which Lilly refers would be a child who inherited two mutations, a 
potentially devastating scenario9. 
Participants’ fears that their BRCA mutations might be more than a future partner 
could handle come not just from their own imaginations, but from their loved ones as 
well. Isabelle, Lilly’s sister, shared her memories of their mother’s concern about how 
negatively both women might be perceived by potential partners; this was a topic of 
discussion in the weeks leading up to their genetic tests. Isabelle remembered: 
Going through the whole testing process, my mother’s huge concern after us 
having the mutation was, “if they do have it how are they ever going to get 
married? Who’s ever going to want to marry them if they have this huge 
possibility hanging over their heads?”  
Isabelle, 22 
Hearing this message from their mother during the time that they were deciding about 
testing was a negative experience, and doubt about their desirability as partners lingered 
long after learning that they were mutation-positive. 
 Some participants identified specific reasons upon which future partners might 
base their rejection. For Charlotte, the bodily changes created by risk-reducing surgery 
                                                 
9 Because of the rarity of BRCA1 and BRCA2 mutations in the general population (estimates range from 1 
in 280 to 1 in 1000), it is even more uncommon for two randomly mating individuals to both carry such 
mutations (except for persons of Ashkenazi Jewish heritage, in whom the mutation prevalence is 2-3 per 
100). Inheriting a BRCA1 mutation from each parent may not be compatible with fetal survival. Inheriting a 
BRCA2 mutation from each parent results in a totally different disorder - Fanconi anemia - a devastating 
disorder with susceptibility to cancer and diverse congenital anomalies. With any combination of two 
BRCA mutations, lifetime risk of BRCA-related cancers may be extraordinarily high. 
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were the biggest threat because of their incongruence with what she believed men would 
find attractive: 
 I think the biggest part will be the physical change and them having to deal with 
that. Having your breasts removed is a pretty big deal, I feel like, to a guy. That 
would be a pretty big issue in a relationship if they care about you, just having 
that worry that you could get cancer. I think that would be pretty hard for a guy. 
Charlotte, 26 
As a woman relying on surveillance for management of her cancer risk, it seems natural 
that Charlotte would view her own likely next hurdle – risk-reducing surgery – as the 
most likely threat to a future relationship. For Kristy, who had already undergone RRBM, 
the risk to future children seemed like the bigger threat: 
It’s hard to think about this because to me it’s kind of at that point where it’s just 
really not a big deal, but I know that for a potential partner it could be, especially 
considering that I have a 50% chance of passing it to my children. So I think that 
could be something that could be scary or difficult to deal with. I guess I just 
assume that if it’s a problem with him, then oh well, move on to the next person. 
And if it’s not, then great. 
Kristy, 29 
Acknowledging that a future partner might find it difficult to cope with the physical and 
psychological impact of a mutation on their children, Kristy had a realistic view of 
potential future relationship challenges. Her expectation that the “right” partner be 
willing and able to accept those challenges also seems predictive of good long-term 
coping and relationship health. This speaks to the other end of the spectrum: if the fear 
that a partner will leave the relationship because of BRCA is not confirmed, there is an 
opportunity for the relationship to be solidified by the partner’s ability to prove his 
dedication to the carrier. This was true for Marjory, who was “a little bit nervous that [her 
boyfriend] would reject” her and who felt enormously relieved when he responded in an 
enthusiastically supportive manner that did not indicate any desire to end the relationship; 
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in fact, she felt that their relationship had become considerably stronger since she told 
him about her mutation. Similarly, Reina recalled her decision to tell her then-boyfriend 
(now her husband) about her mutation fairly early in their relationship partly as a way to 
ascertain whether there was potential for the relationship to become serious and/or 
permanent: 
I guess I thought, I’m at an age now where I want to be in a serious relationship, 
something that could potentially be long-term, and if I’m going to be with 
somebody who is right for me, then I need to know that this is something he can 
handle. I need to know that this is something where this person is going to 
understand and be supportive because it’s going to be a very big part of my life. 
So I opened up to him pretty quickly, and I don’t think it’s something that he 
understood fully but something that he was very supportive about, he said he 
could only imagine how difficult something like that must be. And shortly after 
that was my first [BI] experience, and he was there for me through and through, 
110%. And I said, “Wow, this guy is a keeper.” And even my mom was like, 
“He’s somebody special.” So I kind of knew, you know, “I think this guy might 
be in it for the long run.” To deal with something of this magnitude after only 
having dated a short time, he was really there for me. 
Reina, 29 
Like Reina, Serena viewed the sharing of information about her mutation with a partner 
as a way to test the fit of the relationship: 
He asked a couple of questions, just general ones, and I answered them and he 
said, “No worries. Sounds like you’re doing everything you’re supposed to do.” 
He didn’t make a big deal out of it. And if he had, that would probably have 
ended things right there because I’m not going to date somebody who’s not going 
to understand; just like I wouldn’t date somebody that didn’t like my dog. 
Serena, 30 
Surprisingly, participant’s fears about their partners being unable to cope with the 
implications of their mutations were generally not confirmed, and most relationships not 
only survived but were strengthened by the disclosure process. However, for a few 
women, relationships devolved in the period immediately following disclosure. Although 
the breakdown of these relationships was attributed to a variety of causes, the mutation 
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was always among them. It is possible that the extra stress of a BRCA mutation on an 
already faltering relationship may push partners past their limits and bring a swifter end 
to relationships that likely would not have survived anyway. 
Disclosure to Spouse 
 The process of disclosing one’s mutation to a partner is very different for women 
who are already married when they learn about their mutations. Because married partners 
have already agreed that their relationship is permanent, the threat that a partner will 
leave the relationship is at least partially mitigated. Close, intimate relationships between 
marital partners mean that mutations are almost always disclosed immediately, and 
usually long before any risk-management decisions are pondered or reached. Almost 
universally, participants who were married when they learned about their BRCA 
mutations involved their husbands prior to even having the genetic test. However, there 
was a diversity of experience among married female mutation carriers regarding how 
openly they shared other BRCA-related information with their spouses, and regarding the 
manner in which their spouses received and handled this information.  
When interviewed, Rose had known about her mutation for six months, and was 
at home recuperating from her RRBM. She and her husband had made decisions about 
testing and risk-reduction together:  
Everything I know, he knows. We’re really open, really close. He’s absolutely my 
best friend in the entire world. It’s almost seamless. It’s hard for me to even say 
what did I know and what did I tell him and at what point did I tell him things. It’s 
just whatever happens in my life happens in his life, so it’s what we did together. 
Rose, 30 
Chris’s experience was similar to Rose’s. She recalled that after she learned her results: 
He of course asked [what the results were], and I told him. He cried. He’s pretty 
emotional when it comes to me. I unfortunately make him that way. But he cried, 
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and he told me he was sorry. And I told him I just want it all off, I just want 
everything out, I want it off. I just was ready to be done with it all. 
Chris, 33 
For Rose and Chris, there were no barriers to exchanging mutation-related information 
with their husbands. Both couples functioned as teams in making risk-management 
decisions, and this was experienced positively by both wives. In contrast, Marie’s 
husband’s was less involved in her genetic testing decision and process. Working to 
navigate the challenges of her husband’s own family history of cancer, Marie chose to 
take her brother with her to genetic counseling, leaving her husband at home. She later 
regretted this decision: 
Not taking my husband to genetic counseling was a combination of me being 
stubborn and assuming that he was feeling a certain way, and him not really 
knowing exactly what the situation is. His mom has cancer and when he gets in 
emotional, illness-related situations, he really kind of shuts down. I was assuming 
he wouldn’t want to be part of it because either he was going to freak out and shut 
himself off or get annoyed with the situation. I wanted a positive reaction from 
him and I was thinking, “If he doesn’t give me the reaction I want, I’m going to 
be really hurt. So I’m just not even going to go there.” The day I got the results, 
after the appointment when I came home and I sat down and went through with 
my husband what everything meant, he was totally shocked. He was like, “I had 
no idea it was this serious.” I was very regretful that I didn’t bring him to the 
appointment. I wished that he would have been there with me. 
Marie, 28 
Since her genetic testing, Marie and her husband have come to a better understanding 
about his desire to be involved in BRCA-related issues and her need for positive support. 
For some of the married study participants, unique family and/or health situations 
created their own dynamics with regard to BRCA-related issues. Adopted as an infant, 
Jane grew up never knowing that her biological family had a high incidence of BRCA-
related cancers. Only when she chose to contact the adoption agency as an adult (in an 
attempt to learn more about her biological family generally and not because of any 
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concerns about cancer risk) and was able to access records made available by her 
biological mother did she start to learn about the possibility of risk for herself – this 
information was a complete surprise to her. Suspecting that genetic testing might be 
appropriate, Jane consulted with her husband about next steps: 
When I learned of information from the agency I immediately shared that with 
him. I think he felt sympathetic, but I don’t think he felt super concerned about it. 
It wasn’t alarming to him, it was kind of, “OK, this is informational, it’s good for 
you to have,” and that was about the extent of it. When I talked with my doctors 
to see about getting the test done, he put it more upon me that it was my decision 
to make. 
Jane, 30 
Jane disclosed in her interview that her husband’s response was not as warm and 
supportive as she wished; although it was clear to her that he cared about her, she 
lamented that his leaving the decision completely in her hands felt isolating. 
 Like Jane, Elaine also expressed disappointment with her husband’s initial 
reaction to news that she was mutation-positive: 
I was so pissed at him. I usually work late, but I ended up coming home at like 
10:00 and just walked in the door and said, “I ended up testing positive for one of 
those mutations,” and he looked at me and said, “Oh, I’m so sorry.” And I’m like, 
“You’re so sorry?” I’m thinking, ‘I’m going to die, aren’t you sad, too?’ I was 
quite upset. But he didn’t realize what the risks were. He wasn’t making it a “we” 
thing. He was very much removed and I felt like, ‘oh my gosh, whoa, I’m your 
wife! Come on!’ He had had a little scare with cancer a couple years ago and I felt 
scared then. And I felt like he wasn’t empathizing at all! I felt like he was really 
removed. But then I told him right away. I said, “Maybe I’m PMS-ing or maybe 
I’ve just had a long day but your response really kind of hurt my feelings because 
it’s not very personal. Here I am thinking I’m going to die and you’re saying 
you’re sorry, like ‘Doesn’t that suck for you?’” I was able to vocalize it right 
away and then he responded with, “OK, well, you’ve got to quit your job. I’ll sell 
the farm.” And I’m like, OK, let’s slow down, you know… I have meaningful 
work and all. 
Elaine, 34 
Elaine’s perception that her husband’s initial response did not demonstrate enough 
concern given the gravity of the situation was similar to Jane’s; however, unlike Jane, 
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Elaine chose to address this disappointment right away and to clearly define her 
expectations, allowing her husband to alter his approach to the situation. Offering to “sell 
the farm” (a second property they owned and planned to retire to) was his attempt to 
create a financial situation in which Elaine could stop working, slow down, and enjoy life 
and their children, rather than continuing to work at her demanding mental health job. 
Although this was not exactly what Elaine wanted, it was an effective way for her 
husband to demonstrate his understanding and concern. 
 Audrey’s journey toward awareness of her BRCA-related cancer risk was 
completely unique among study participants. Rather than learning of her risk because of a 
high incidence of cancer in her family, Audrey discovered her BRCA mutation after her 
young son was diagnosed with a rare genetic disease called Fanconi Anemia (FA). In a 
very small number of FA cases, the condition is the result of a child inheriting a faulty 
BRCA2 mutation from each parent, as happened with Audrey’s son. Therefore, Audrey 
and her husband learned together in a genetic counseling session related to their son’s 
health that both of them were also BRCA-positive; each of them had one copy of an 
abnormal BRCA2 gene. She believed that their reactions to their son’s genetic diagnosis 
were unique: there was no opportunity for blame or anger at a parent who was 
“responsible” for their son’s genetically inherited disease: 
I think we just kind of looked at each other and went, “Huh. Go figure.” I know in 
most families’ situations it’s one or the other, and that wasn’t there for us to place 
blame and say, “Oh, well, it’s your fault. You’re the one who had it.” Not that it’s 
anybody’s fault anyway. But we weren’t left with any would-haves, could-haves, 
should-haves, maybes, because we didn’t know. And it was both of us, and it’s 
nothing anyone did intentionally. As far as our relationship, we don’t have 




Audrey felt that the fact that both she and her partner carried BRCA mutations eliminated 
any possibility for either partner to react negatively. 
 As a final example of spousal disclosure, Pauline’s experience came at a very 
intense time in her life and relationship. One month before their wedding, Pauline and her 
husband received an e-mail from Pauline’s father informing them that a BRCA mutation 
had been identified in one of his cousins, and that the next step was for Pauline’s father to 
get tested. He told them that if he tested positive, then Pauline should also get tested. 
Pauline and her then-fiancé had some time to ponder what this meant: 
Once we realized we were going to need to wait until my father got tested, my 
attitude was to continue to worry and start acting like [my dad] had it and I had it. 
And [Graham] was really much more positive and optimistic, saying “Oh don’t 
worry about it, neither of you have it, there’s nothing we can do right now 
anyway until we find out, so it’s not worth worrying.” I was so convinced that this 
is my destiny in some way that I was sort of like, “No, we have to pretend like I 
have it because it will make it easier for us to be able to deal with it when I do.” 
So there was a bit of tension there but not like any sort of thing that would 
escalate into a fight or a true disagreement. 
 
Ultimately, Pauline’s father and then Pauline herself received positive mutation test 
results. Looking back on that period as she approached her first anniversary and during 
the process of making a decision about RRBM, Pauline stated: 
It’s made me very, very grateful that we found out about the mutation after we 
were married. Not because I think that he would have chosen not to marry me, 
and I’ve actually wanted to be really specific with him about this, he’s been 
incredibly supportive of me. But I want him to be able to say if he’s angry that he 
married a woman who has a genetic mutation, not that he’s going to leave me. I 
know he’s not. I can separate those two things. But if he ever has anger about 
these things I think it’s appropriate to express, because I certainly have anger. If 
he says “It’s not fair,” I know that he doesn’t like me less. It’s simply the truth; 
it’s not fair.  
Pauline, 30 
Pauline insightfully acknowledges that in committed couple relationships, learning about 
the presence of a BRCA mutation is not just significant for the carrier, but for her partner 
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as well. Psychosocial intervention targeted at helping both members of a couple process 
this, both individually and as a couple unit, would likely help all couple members to do 
just as Pauline suggests – express and deal with all of the positive and negative feelings, 
including anger and fear, that come along with confronting this complicated journey 
together. 
Non-Disclosure 
 The decision not to disclose their mutation status, or to not share fully the 
consequences of their mutations, was deemed to be the best strategy for a few study 
participants, for reasons which varied from subject to subject. Sometimes, non-disclosure 
was simply a matter of circumstance, or a reflection of a participant’s progress toward 
assimilating the risk information herself. For example, Valerie recalled a previous 
significant couple relationship in which she did not disclose the presence of a BRCA 
mutation in her family or the fact that she was actively considering genetic testing: 
I was sort of the lone biologist of anybody I knew, and he was an engineer. I just 
don’t think it ever occurred to him that because my mom had cancer, and my 
grandma, and my aunt and everybody, that I might too. And I really don’t think 
we ever discussed it. I don’t remember ever actually telling him that my family 
had been tested and that I could be. 
Valerie, 29 
Valerie went on to state that the end of that relationship was just part of a natural 
evolution in her life, and did not have anything to do with her potential status as a 
mutation carrier. 
As a 20-year-old undergraduate student, Nichelle was involved in a casual 
relationship with a partner for whom she cared deeply, but she described their 
relationship as mutually “open,” and therefore not perceived as stable or potentially long-
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term. She first attributed her decision not to disclose her status to the history of cancer in 
her partner’s family, but this larger reason for not disclosing soon emerged: 
I think the biggest reason I haven’t told him is because, based on his family’s 
history that has recently developed, it’s like I don’t want to burden him with that, 
finding out someone else that he’s really close with could possibly have it. I think, 
at a younger age, it could be harder for people to process, especially if you’re 
being told that someone else at a younger age does or possibly could have 
[cancer]. I don’t know how he’ll react, so I don’t want to tell him. I’m a little 
afraid of doing that because I think that would be really hard if I did tell someone 
I truly do care about and he… [LH: So what would you need to happen in your 
dynamic with him to feel comfortable enough to tell him? What’s missing that 
you need there?] I truly think that if we were in an actual relationship, I would be 
willing to open up to him and tell him that because I’ve been very open and 
upfront with other people about it. I just think that the fact that we’re in an open 
relationship is what makes me hesitant. If we were in an actual one, I think I’d 
feel more comfortable and have faith in telling him that. It’s a fear that he’ll 
decide it’s too much to handle and say, “I can’t deal with this,” and will just kind 
of disappear out of my life. 
Nichelle, 20 
Clearly, at the core, Nichelle’s fear that her partner would be scared away by news of her 
mutation and its consequences is what kept her from sharing this information with him. 
This fear had its origin in the nature of their relationship, which was not seen as “real.” 
Annie was described earlier in this chapter as having felt compelled to end a 
relationship she did not perceive as potentially long-term after learning about her 
mutation. Here, she described what it was like to be in that relationship and not share 
information about her mutation with her then partner: 
It didn’t even cross my mind to talk with him about it, because [the relationship] 
was still something so new, and it just wasn’t serious in my mind, which probably 
should have been a sign. Rearview is 20/20, but he was very supportive when it 
came to my cousin and what was going on with her. I just never really took the 
time to explain it to him, or he didn’t want to know, or I felt like maybe he didn’t 
want to know. I think it kind of went a little bit over his head, and maybe that was 




For Annie, the instinct not to share this information with her then-partner was an 
effective internal barometer about the quality and potential longevity of their relationship; 
recognizing her hesitation in sharing this information, she understood that her heart was 
not really in the relationship and that it would probably be best to move on. 
 Although she was not in a relationship when interviewed, Monique had definitive 
ideas about whether, when, and how she would tell a future partner about her mutation. 
Because she was also at high risk of cervical cancer, she faced the challenge of informing 
a future partner about two weighty pieces of information. Describing her reasons for 
keeping this information to herself in past relationship and her plan to take her time in 
disclosing it to a future partner, Monique stated: 
It might change his outlook if I have kids with him. I don’t want someone to think 
differently of me. I just don’t even like talking about it. They just might think 
their child’s going to be almost 50% likely to have the mutation, and some people 
just don’t want that. Or even, just because I have it, am I different? No, but you 
know what I mean? If you tell someone that, you don’t want to scare them away 
either. Some people just don’t understand. I don’t usually share that kind of 
personal information yet. Until I know they’re with me for the long term. 
Monique, 26 
Monique’s perspective on mutation disclosure was reminiscent of themes discussed 
earlier in this chapter; specifically, she doubted a future partner’s willingness to continue 
their relationship given the mutation, and connected this worry with the threat to future 
children (something she worried about herself). 
 Even when disclosure occurs in couple relationships, some women are not 
particularly open with their partners about what the mutation means in their lives, or 
choose not to involve their partners in the myriad tasks and decisions that come after 
learning that one carries a BRCA mutation. Marjory recalled a previous relationship in 
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which she informed her partner about her mutation test results, but did not involve him in 
what came next: 
He knew about the testing and he knew about the result. I think he knew when I 
had my appointments, but that was about it. We didn’t really talk about it at all, 
probably because the relationship was deteriorating. We had a lot of other issues, 
so I think that just wasn’t something that was a priority to talk about. I was doing 
fine with it on my own. I didn’t really need a lot of support for that, and I think I 
avoided it because we were having issues, and if you talk about genetics, you’re 
talking about family, and I think that’s kind of why, as we got into the 
relationship, it didn’t come up as much. We were talking about marriage less, and 
so I think I protected that information a little bit more. That’s the kind of 
information I was only going to really talk about with someone who I could see 
myself having a future with, and I think there was a point when I was in grad 
school where I was questioning that. 
Marjory, 30 
Marjory’s experience suggests that, just as awareness of one’s interest in disclosing or not 
disclosing mutation status can be a barometer of relationship quality, the quality of a 
relationship is an important factor in women’s desire to involve their partners fully in 
their mutation-positive experience. Marjory’s current partner is not only aware of her 
BRCA mutation, but participates actively in supporting her through and helping her make 
decisions about the full range of BRCA related issues. 
 Finally, Sophie described the dynamic that had developed between her husband 
and herself, wherein she did not involve him fully in her BRCA-related management, but 
nonetheless reported receiving sufficient support from him: 
I don’t know exactly when I told him; it might have been a few months [into the 
relationship]. I don’t go around telling anybody and everybody, but if the 
conversation is brought up I’m not one to really shy away from it. I think it just 
came up, and again, I don’t think he really knows all that much about it. I’ve told 
him what I want to do as far as surgeries and everything like that, but I don’t think 
he really knows that much. He’s always interested in anything that has to do with 




Sophie’s more independent approach to her husband proved quite workable in the context 
of their relationship. Thus, dynamics related to exchanges of information and support 
may vary greatly between couples; while Sophie and her husband have developed a 
pattern in which he “does not really know that much,” other participants perceived such 
relationships as unsupportive. Accordingly, many study participants worked hard to 
educate their partners about the meaning and implications of a BRCA mutation, to draw 
necessary support from their relationship partners, and to engage them in BRCA-related 
decision-making. These dynamics are the focus of Chapter 8. 
Chapter Conclusion 
 Participants’ reported experiences suggest that the process of mutation disclosure 
within couple relationships is closely related to mutation-related partner support, 
relationship quality, family formation, and risk-management. Often, mutation carriers in 
non-marital relationships disclose because of their belief that a partner’s understanding 
about the issues related to BRCA will impact his ability to provide support and to make 
decisions together about family formation and management of cancer risk. Decisions 
women have already made about risk management are also highly influential in the 
disclosure process because having already completed surgery often forces young carriers 
to disclose information about the mutations to their partners very early in the 
development of new relationships, perhaps even before the feel comfortable doing so. For 
this reason, the disclosure process can look very different depending on whether or not a 
carrier has had a risk-reducing surgery (usually RRBM, since its sequelae are so much 




   Figure 6: Role of Mutation Disclosure to Partner in Theoretical Model 
 
sense of urgency to achieve important life course goals of young adulthood, such as 
solidifying relationships and completing family formation, complicate the disclosure 
process. Carriers may fear that partners will reject them because of their mutation, but in 
fact the opposite was often true among participants in this study – couple relationships 
may be solidified by partners’ responding to disclosure in a way that makes carriers feel 
unconditionally loved, cared for, understood, and as though the partner is willing to 
participate in the ongoing challenges of the mutation positive experience. 
 For participants already married when they learn of their mutations, the process of 
partner disclosure typically occurred very swiftly, and spouses were often involved in the 
genetic testing process itself. In fact, many were unable to explicitly remember the 





























process of disclosure because it had happened so naturally; they could not imagine going 
through such an experience and not sharing it with their partners. For women in this 
group, thoughts about disclosure were often focused on whether or not spouses would 
meet expectations about providing appropriate support in response to the situation. When 
this did not occur, carriers felt disappointed and they varied in their ability to discuss their 
unhappiness candidly and openly with their spouses in order to elicit a different response. 
 Participants of various relationship statuses sometimes chose not to disclose, or 
not to share fully their mutation status and what it meant, for reasons ranging from 
perceptions that partners could not handle the information or that the relationship was not 
strong enough to bear such a burden, to carriers’ own desires to be independent and 
handle mutation-related stressors without significant input from their partners. 
 Across participants, a personal focus on the next upcoming mutation-related 
challenge often created a sense of anxiety with regard to how a partner might respond. 
Once they had undergone a particular event or complication related to BRCA, and been 
forced to cope with it themselves, they often found it easier to envision that someone else 
(i.e., a partner) would find it acceptable too. Not surprisingly, it may be that women find 
scenarios that they have not yet experienced as more threatening, both to themselves and 
their partners. Overall, however, these women display remarkable courage and strength 
as they negotiate one complex situation after another and, in the process frequently 






CHAPTER 8: RESULTS—MUTATION-RELATED SUPPORT PROCESSES IN 
COUPLE RELATIONSHIPS 
 “I just simply cannot imagine taking my shirt off for another man after I have this 
surgery, and I’m really, really glad that I have to only take my shirt off for a man who 
loved me before and who I know will love me after.” - Pauline 
 
 As young female BRCA1/2 mutation carriers traverse the complicated path that 
begins when they learn that a mutation is present in their family, relationship partners are 
powerful sources of support. The type and quantity of support desired by carriers varies 
across individuals and over time. Participants who were in relationships identified various 
ways that their partners had succeeded or failed in providing support, and those who were 
single were quick to identify what they believed they might look for in a future partner 
with regard to his capacity to meet their mutation-related support needs. Interestingly, 
both single and partnered participants reported having considered the needs and desires of 
their partners in making decisions about risk management; for single women, this was 
done by imagining what a hypothetical future partner might need. Among participants, 
support was primarily viewed as directly related to the challenges imposed by a BRCA 
mutation, and as being provided by the male partner to the female mutation carrier. Some 
participants also discussed the ways in which they provided support to their male 
partners. Throughout their experiences as mutation carriers, many participants dealt with 
issues related to body image and sexuality, with clear implications for their couple 
relationships; having a loving and supportive partner was a key component of women’s 
ability to successfully manage these concerns. 
Changing Support Needs over Time 
 As noted previously, most young female BRCA mutation carriers utilize a variety 
of risk-management strategies over time. For many, this means starting out with breast 
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and ovarian cancer surveillance, which may last from only a few months to several 
decades, depending on each individual’s tolerance for the discomfort and uncertainty that 
accompanies regular screening examinations, and her willingness to take a more 
definitive step (i.e., surgical removal of the target organ[s]) to reduce her cancer risk. 
After some period of time, many BRCA-positive women ultimately elect to undergo risk-
reducing surgery. This decision is usually based on knowing that surgical risk-reduction 
is currently the most effective strategy to mitigate cancer risk. However, some women 
choose to continue surveillance indefinitely, and describe themselves as unwilling to 
remove healthy tissue from their bodies when they may never develop cancer at all. 
Regardless of women’s ultimate decisions about risk-reducing surgery, chemo-prevention 
(i.e., medications taken specifically to reduce cancer risk, such as tamoxifen for breast 
cancer, or oral contraceptives for ovarian cancer) may or may not be utilized as an 
additional risk-mitigating strategy. Across participants, our interviewees highlighted the 
role of partners, either current or future, in providing support with regard to, and making 
decisions about, cancer risk-management. Regardless of the different ways in which men 
provided support to their BRCA-positive partners, the recipients universally described 
their doing so as critically important. Opportunities to request and provide support begin 
when a woman discovers that a BRCA mutation is present in her family, and continue 
through and beyond the ongoing surveillance and/or risk-reducing surgery process. For 
this analysis, only support related to risk-management will be discussed. 
Support related to surveillance. After learning that they carried BRCA 
mutations and deciding to utilize surveillance to manage risk, many participants reported 
finding themselves in need of support in the context of regular breast/ovarian cancer 
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screening. Factors contributing to surveillance-related stress include fear that a cancer 
will be detected, pain related to the screening procedures, delays in receiving test reports, 
and the frequent occurrence of false-positive test results, which require additional testing 
to resolve. This process is often accompanied by prolonged periods of ambiguity and 
uncertainty. Shortly after she began to date the man who is now her husband, Reina 
visited the NIH for an annual BI screening appointment. An abnormal finding on one of 
her imaging tests necessitated an extra overnight stay and CAT scan the next morning, 
which frightened Reina greatly: 
I was on the phone with him and I was explaining to him what was going on, and 
he said, “I’m here for you, whatever you need, everything’s going to be okay, 
you’ll see,” just very supportive words. When I came back home, he said he was 
so relieved and so happy to hear that the news was good. I mean, I still needed 
surgery but it wasn’t cancer. And he came and visited me at my apartment with 
roses and hugged me and just said that he would always be there for me, that he 
couldn’t imagine something like this happening to me, and he said, “I knew 
everything was going to turn out fine; I just had a feeling,” and just very 
supportive in general. I think in my gut I was already feeling like he was the one, 
but this sort of sealed the deal. 
Reina, 29 
Her boyfriend’s supportive response to this BRCA-related crisis not only helped Reina 
cope; it also gave her insight about his suitability as a long-term partner. Marie, who was 
already married when she learned that she was BRCA positive, benefited from her 
husband’s willingness to come with her to her first round of screening appointments: 
When I went for my MRI, I knew that it could possibly be a scary and he came 
with me for that. I told him I really wanted him to go, and he was like, “Are you 
sure? It’s supposed to be real easy.” And I’m like, “I really want you to come, so 
let’s get a babysitter and come with me.” And thank God he came with me to that, 
because I needed him for that, for sure. 
Marie, 28 
MaryAnn, 26, reported that her fiancé supported her by insuring that she adhered to her 
recommended screening appointments schedule, stating, “…he’ll get on me because I 
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would always procrastinate before about going to doctors’ appointments and going for 
my checkups. And I don’t think he would ever let that happen anymore or let me get 
away with doing that.” 
In the previous three examples, partners of young BRCA-positive women were 
able to provide essential support during breast/ovarian cancer surveillance. However, 
support does not always flow naturally in these situations, and several women identified 
ways in which their current or former partners had been unable to meet their BRCA-
related support needs. Jane described that her husband was unsure about what his role in 
her BRCA-related care should be: 
I don’t know that he knew what to do. He was supportive. He went to a couple of 
appointments with me that I had scheduled with the gynecological oncologist, and 
then also with the breast specialist. I think he felt really uncomfortable at those 
meetings. He didn’t know what his role was or what he was supposed to do or say 
or to be. And I don’t know if they know what to do with the spouse. He’s there, 
he’s present, but I don’t know that they really made any effort to bring him into 
the process – they just didn’t have any way of including him. They weren’t rude 
or anything, but I could definitely understand that he felt that it was awkward. 
Jane, 30 
Jane’s experience suggests that some physicians and other medical professionals who 
work with couples dealing with BRCA may not have or communicate clear ideas about 
how mutation-negative male partners can be involved in meetings, screening 
appointments, and other settings in which their female partners may require support. 
Noelle noted a similar lack of fit between her needs and the support her partner provided, 
but for an altogether different reason: her boyfriend’s apparent lack of concern for the 
ongoing management of her cancer risk through surveillance: 
I would want him to say, “We can get through this.” Right now I feel like it’s my 
thing. It’s my family thing. If he were to say, “Let’s do this together, what can I 
do?” or even ask, “Hey, I know you had your blood drawn last week, did you get 
those results?” He doesn’t follow up. Or he could say, “I know you’re going in for 
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your MRI, I remember you saying last time that it was wrong or annoying or 
whatever it may be, is this going to be like that this time?,” just asking questions. 
And he doesn’t want to ask questions. 
 
Noelle missed the sense that her partner was truly interested in her problem, and that they 
would face its challenges together. Instead, he maintained emotional distance by not 
demonstrating interest in her surveillance. She went on to say: 
I haven’t asked him [to go to any appointments], but I thought that he would say, 
“Do you want me to go with you?” I have girlfriends here who are like, “Could I 
go with you? What can I do?” He’s never done that. It’s interesting because 
sometimes I go to our cancer center here in the hospital, and sometimes I see 
people and it’s just so upsetting, just to look around in the waiting room, and then 
other times I go and it’s like any other doctor’s office. So it really varies on how 
my appointment goes, whether I feel he should have come with me himself. But I 
have not asked him. I’m waiting for him to volunteer. 
 
Noelle had begun seeing a therapist to cope with the stressors related to her mutation 
status, and had recently found her sessions focusing on “how [the mutation] plays into 
my relationships.” She had repeatedly invited her boyfriend to come to therapy with her 
to talk about how her mutation had impacted them, but he refused. Her focus in therapy 
had thus shifted to  
learning how to deal with him and how people handle information differently. 
…I’m learning … to communicate in styles that he’d be responsive to. But I 
wouldn’t say it’s made our relationship stronger or brought us closer together. It’s 
taught me lessons on interpersonal communication, but that’s really it.  
Noelle, 26 
 
 The impact of breast/ovarian cancer risk-management on sexual relationships 
comprised another important theme among women relying on surveillance. For Reina, 
this manifested as a serious emotional hurdle that arose when she and her husband 
became physically intimate. She first noticed this after a particularly difficult screening 
appointment, during which she had to have a painful and humiliating ovarian ultrasound. 
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Since then, they had been struggling to come to a common understanding about this issue 
and to communicate effectively about her experience: 
I’ve had issues with my body, sort of like a disconnect. It’s something I’ve been 
working through slowly and he’s been incredibly patient with. But there have 
been some fights this year about it and I can understand from a man’s position 
that it’s very hard to truly identify. That’s been one of the hardest struggles for 
me. I don’t think he’ll truly ever know why that happens or what I feel during 
those moments, but through many, many conversations I think he understands a 
lot more than he initially did. I think he automatically thought there was 
something wrong with him, or something wrong that he was doing, or a lack of 
attraction to him, but through going to therapy and learning more about why I 
have these issues and how I can work through them, I’ve been able to 
communicate to him that there are so many different levels of reasons and 
explanations that have to do with this. It’s very deep. At one point, I had told him 
that it’s easier for me when I’m in control of the situation, when I can instigate, 
when I can have the control of when things happen because the experiences that 
I’ve had with the gene and the NIH, I’ve had absolutely no control. And I’ve 
explained to him in detail the physical aspect of the screenings, and what has 
happened in my experiences, and how I was touched, and how I felt and how I 
was naked, and all of these different things. I just try to be as open with him as 
possible in the moment if emotionally I’m having a difficult time and he can tell, 
it’s obvious, and he’ll ask me to talk about what I’m feeling and it’s very difficult, 
because sometimes I just can’t express it.  
 
Reina regretted that she was missing out on having a “normal, healthy” sex life, as she 
imagined other women her age experience, and communicating with her husband about 
how to sustain a healthy, mutually enjoyable sexual relationship had become an ongoing 
struggle. Because Reina did not view risk-reducing surgery as a viable option, these 
intimacy-related challenges will likely persist while screening continues, unless she is 
able to successfully disconnect one from the other. Reina said of her current sexual 
relationship with her husband: 
If it’s been a little longer period of time since the last time we were intimate, the 
automatic pressure is there whether it’s spoken about or not, I kind of know that at 
some point sooner or later something has to happen. And I know now that he’s 
not going to instigate, so I’m always mentally struggling with being able to get 
myself in that place where I’m OK with doing it. And it’s hard for me to stay 
there for a long period of time because it’s almost like forcing myself to only 
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think about the experience of being intimate in a positive light, only focusing on 
the feel-good part of it, allowing myself to connect with my body and allowing it 
to feel good. And it’s getting easier and it’s getting more frequent for me but it’s 
still a major struggle. The issue is not him; it’s not touching him, it’s not anything 
having to do sexually with him. It’s just me and my body. He wants that closeness 
and that’s what’s hard for me. 
Reina, 29 
As Reina continued to struggle with this issue, her husband’s consistent and gentle 
support and understanding allowed their relationship to continue to function healthily 
despite the hurdle presented by issues of sexuality. 
For women in established couple relationships, the experience of effective partner 
support during surveillance-related challenges was positive, but not without challenges. 
Marjory noticed how health-related communication with her partner had shifted since 
they learned that she was BRCA- positive: 
I’m a little more hyper-aware of things, like if I’m feeling bloated or just not 
feeling well, nauseous, or any of those things, he jumps on those more readily 
than I do. So I think maybe I hold back a little bit, and I don’t always tell him 
everything until I know for sure, because I don’t want to worry him. So that’s 
been kind of hard, if maybe I feel something in the shower, knowing I’m going to 
be getting it checked out in a month, I won’t maybe mention it to him. Whereas if 
it was something like a headache, of course I’m going to tell him. But because 
this might actually mean something, I don’t want to jump to any conclusions until 
I have to. I just don’t want to put undue worry on him. 
Marjory, 30 
Marie also noted new dynamics in her marriage as a result of ongoing communication 
about mutation-related issues: 
I feel like it’s been more challenging than anything because it’s just something 
that’s on my mind all the time and I feel like it takes over sometimes. And talking 
about it too much can definitely be pretty irritating for him, just because he is 
thinking about all these bad things that can happen to me. 
Marie, 28 
Other participants noted how being supported by a partner through surveillance had 
significant positive effects on the couple relationship, as was the case for Melanie (see 
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Chapter 5). For example, MaryAnn found that working through BRCA-related issues 
together with her fiancé reinforced her already strong belief that he was the right partner 
for her: 
I think it’s had a positive influence. Every time you go through something really 
intense with somebody else, I mean, I just think it’s been positive. I realize he will 
really be here for me no matter what. All in all, I think it’s made me realize how 
fortunate I am to have someone like that. 
MaryAnn, 26 
 As long as BRCA-positive women choose to employ surveillance for management 
of their breast and ovarian cancer risk, they will likely continue to encounter the anxiety 
and uncertainty that accompany regular screening. For some participants, this had 
become a consistent feature in couple relationships as well: 
I think it’s always on the back burner. We have our good weeks and we have our 
bad weeks. When it gets closer to screenings I get stressed. When I’ve had a very 
intense therapy session with my therapist, things get a bit more stressful with us 
just because a lot of these sessions that I have with my therapist doing a lot of this 
PTSD treatment, it’s emotionally wearing, almost like I’m not myself for the next 
day or so because my mind is just exhausted. 
Reina, 29 
Repeated, long-term involvement in preparing for, doing, and following up on each 
intervention contributed to some participants feeling like a burden to their partners. Jane, 
who previously discussed her husband not having a clear role when he accompanied her 
to screening appointments, talked about how his reaction to her reporting about screening 
visits led her to feel she was imposing on him: 
When I go in for screenings – and maybe I’m partly responsible for 
communicating it to him so much – but I just went in for a mammogram this 
month and it does make me anxious not knowing what the results are going to be, 
especially now that I’m thirty, it’s something that weighs heavily on my mind. 
And I think at times I feel guilty to ask him for support or to really tell him how I 





Like Jane, Reina reported that bringing the negative experience of BRCA to her husband 
made her feel badly, which might be related to her own anger regarding her situation and 
a way to shift her own feelings onto him: 
I think instead of it just being a burden on my shoulders, it’s a burden on both of 
our shoulders. In some ways it makes it easier, in some ways it makes it harder; 
easier in that if he can help me carry that burden a bit more then it makes it a little 
easier for me, harder in that it’s something that is going to personally affect him 
because of the decision he made to be with me for the rest of his life, something 
that he could have chosen to avoid and leave but decided to stick through with it. I 
think that in many ways he tries to stay very strong for me because he knows that 
I struggle with it deeply and if he shows any type of negativity or weakness about 
it then he kind of feels like he’s not being as strong and supportive as he should 
be. But it must be very draining for him to be like that all the time. 
Reina, 29 
Both Jane and Reina were relying on surveillance for risk management, so their support 
needs were focused on managing the anxiety and uncertainty of their regular visits for 
mammograms, MRIs, transvaginal ultrasounds, etc., each one of which contained the 
potential for a new cancer diagnosis. Their feeling like a burden during this phase of their 
management raises serious questions about their partners’ ability to cope with the more 
demanding and difficult scenarios related to risk-reducing surgery or a cancer diagnosis. 
Dealing with the ongoing uncertainty of surveillance often necessitates a real shift 
in organization and expectation for both partners. In cases where this does not happen 
effectively, real damage to the relationship can be a result, as Ruby reported: 
I think knowing that cancer could be my future, I probably focused more on the 
children, and my relationship with them, making that a priority in my life. My 
husband was working a lot, and I was really giving more to my relationships with 
my kids because they’re so cherished. It’s kind of hard. My relationship with my 
husband is kind of on life support. … Our relationship kept taking a backseat to 
his work and the kids and the stress of life, and then this. And in about February, 
he wanted to call off the marriage. And two weeks ago, we went and retained 
divorce lawyers and then he decided to go to a counselor to see if this is really 
what he wanted or not. It’s just a shock because your husband is the one who’s 
said that he would never leave you, and him saying that he wants to call it quits is 
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new to me. He’s coming up with a list of resentments this weekend, but I can only 
imagine that as I was focusing more attention on the kids than I was focusing on 
him, he probably felt not valued and he shows that to me, and then I feel not 
valued and I show it to him, and it’s a cycle. And gradually things start to happen 
that wouldn’t have been okay early in our relationship, like not talking for a day 
or two, then that goes to three or four days, then five days and then a week, and 
then two weeks and then, a month. 
Ruby, 34 
Ruby was moving toward RRSO when interviewed, and wondered whether her husband 
would continue to provide critical emotional and instrumental support during that 
process. She recognized that she might have to “supplement that support elsewhere” if 
their marriage came to an end and he was unwilling to continue in a supportive role for 
her.  
Support related to risk-reducing surgery. For some participants, discussions 
about partner support naturally focused on the time surrounding their risk-reducing 
surgeries. Partners were able to provide support to carriers in making the decision to use 
surgical risk reduction; in preparing for surgery and on the day of surgery itself; during 
recovery in the days immediately following surgery, and during potentially lengthy 
reconstruction processes; and in moving beyond surgery, both physically and 
emotionally. Pauline provided a useful example of how her partner became her primary 
support at the very beginning of her journey as a BRCA mutation carrier. They learned 
that there was a BRCA mutation in Pauline’s paternal bloodline just before their wedding, 
and learned that her father was positive shortly thereafter. Pauline quickly began to 
consider the possibility of early RRBM, because she knew herself to be intolerant of risk. 
She described her new husband as the person with whom she spoke most frequently and 
whose opinion she regarded most highly, stating: 
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I basically started thinking of myself as positive the day my dad got his results 
and I learned more about my cousin’s approach to things, which means I started 
having conversations with my husband about risk reduction even before we knew 
the test results. It was sort of like an insurance policy – if I’m not positive, then I 
can just forget all this information, but if I am, I’m not a lost individual. My 
husband was a little reluctant to go there. He said it wasn’t worth thinking about 
or talking about before we knew the results. And I would say to him, “But just in 
case, we should probably start getting comfortable with this topic.” And it turned 
out to be a good thing we did because we were able to hit the ground running 
when I actually got my results. 
Pauline, 30 
Pauline’s husband had continued to provide this crucial support over the next several 
months, as she moved toward and through her experience with RRBM. 
 Making decisions about surgery. For participants who were single when 
interviewed, thinking about a partner’s involvement in or opinion about risk management 
was a theoretical exercise and sometimes burdensome. Sisters Lilly and Isabelle, both 
single, spoke about how they envisioned discussing their desire to have an RRBM with a 
future partner. Their mother had had bilateral breast cancer, first diagnosed at age 25; this 
made cancer risk an immediate/specific, rather than somewhat distant/vague, threat for 
both women. Although their family history was identical, Lilly (the older sister) was 
more eager to pursue RRBM than Isabelle. Having turned 25 shortly before her 
interview, Lilly’s desire to pursue surgery in the near future far outweighed any concerns 
about what a future partner might think: 
I just [decided], “I want to get my breasts removed.” You know, I’m not married, 
I don’t have a boyfriend, and I can’t spare my breasts assuming that I’ll find a guy 
who will have a problem with implants, or that I won’t be able to breastfeed. I 
can’t make these decisions without having anything concrete. 
Lilly, 25 
In contrast to her sister, Isabelle planned to delay any risk-reducing surgery until after she 
had completed childbearing. Her primary concern regarding future partner’s involvement 
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in her surgery decisions were focused on how she would “sell” the procedure to her 
future partner: 
I have pretty big boobs to begin with, so I have a feeling I’m going to have a guy 
who’s going to like boobs. And [after breastfeeding] I would jokingly say, “You 
know what, they’re droopy now. If you want me around for our kids’ future, and 
if you want a new set of boobs on me, this is that we’re going to do.” I can’t see 
myself becoming the type of person who would not do it because he doesn’t want 
me to. It’s my body, my life. I’m going to do what I want. But I would definitely 
make sure that he knows everything and bring him along to doctor’s visits. I don’t 
know if I’m hoping for this Prince Charming, idealistic guy, but I’d like to think 
that somebody like that’s out there who would care enough about me to know that 
this is what I have to do, and I think at that point, because I’m that much older, 
and if I haven’t had anything until then, I have an even greater chance of 
developing breast cancer. So I would think that he would be able to understand 
that. Like, “I have to get this done even more so now. I was going to do it in my 
twenties, but I decided not to so that I could have my breasts for our children, and 
now that I had them and they got put to use I would like to get new ones so that I 
can live.” I know that there are so many different [reconstructive] options, so if he 
wants it one way as opposed to another, I would look more into that. 
Isabelle, 22 
As a final example of a single participant, Charlotte shared that among the characteristics 
she would seek in a future partner, the ability to provide strong, consistent, and definitive 
support was paramount; this would make him a unique support provider among 
Charlotte’s many very worried family members, whom Charlotte did not always find 
helpful in making tough decisions about how to manage her cancer risk: 
I would definitely want him to be supportive, probably just because my family is 
so emotional about it and so worried. I’d kind of look to him more to be a rock or 
a solid person in my life that I could go to. I think definitely because there are so 
many options out there and I tend to be indecisive by nature that I’d want 
someone that I could really talk to about different options and go to appointments 
and help me make decisions just because making decisions so permanent can be 
hard. So I think somebody that could be kind of a stronger person for me. 
 
Charlotte went on to describe how her opinions regarding the timing of risk-reducing 
surgery timing should be communicated to a partner so that he could share his input 
about whether and when that should occur: 
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I think also having to tell them about the decisions I’d have to make like having 
my breasts removed and eventually, after I have children, have the oophorectomy 
and different surgeries like that, just basically that I’ll be physically a different 
person, which is something that is a choice I feel like they’d get to make a little 
bit at that point. 
Charlotte, 26 
Partnered participants reported varied ways of involving their partners in 
decision-making about risk-management. For some, a belief that decisions about one’s 
body should be made autonomously led them to convey information about what they had 
already decided, rather than asking for a partner’s input. For example, Reina felt strongly 
that risk-reducing surgery was not an option she was interested in pursuing, and told her 
husband so: 
We had a conversation a while back about having my breasts removed, and I told 
him right off the bat, “That might be the right decision for some women; it’s 
certainly not the right decision for me.” That was one of the reality-type 
conversations that we’ve had about how to potentially tackle it head-on. I told 
him, “It’s not for me; I can’t have surgery to remove a very large part of my body 
just because one day, what if.” He supports any decision I make. He really does. 
Reina, 29 
Similarly, Shannon discussed her sense that she should inform her then-boyfriend (now 
her husband) that she intended to undergo RRBM at some point, so that he would know 
that surgery would be a part of their future, if they got married: 
I did share with him when we were dating that I had already decided to have the 
prophylactic mastectomy someday. I wasn’t quite sure when. But when I knew 
our relationship was getting serious, I wanted to make sure he knew that 
information and that that wasn’t going to be an issue for him. And he was totally 
supportive and it wasn’t an issue at all. And that’s stayed true. He’s actually, in 
the past two years, he’s wanted me to move forward with this probably quicker 
than I have myself. 
Shannon, 31 
Interestingly, Shannon demonstrated that although her informing her partner about her 
planned RRBM was initially structured to give him a passive role, he subsequently 
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became more actively engaged and is now even more enthusiastic than she is about 
moving forward with surgery.  
Trixie had also already decided to have surgery, but was pleased to find that her 
partner responded in an ideal fashion to both the news and the reality of her RRBM: 
He stood with me through the whole decision-making process about my next step. 
He had no input into the surgery because I already had my mind made up, but he 
has been so great in reassuring me that it’s me and not my breasts that he wants. 
And I think because he’s older, he has a different set of priorities, where a guy my 
age who I would meet at a club might still be more interested in my breasts than 
me. I think I was seeking somebody like that to be with.  
Trixie, 27 
Trixie illustrates that some women seek support and input from their partners regarding 
the specific type of reconstruction they will select, described as her “next step.”  
Dawn involved her partner in the decision between traditional implants (a relatively 
simple reconstruction procedure wherein a saline or silicone prosthesis is placed behind 
the pectoral [chest wall] muscle to simulate natural breast tissue) or the more complex 
autologous TRAM (transverse rectus abdominus myocutaneous) or DIEP (deep inferior 
epigastric perforator) flap procedures (wherein skin, fat, and muscle from the abdomen is 
used to reconstruct one’s breasts). The latter procedures are more difficult, complicated 
and expensive, and require a longer, more painful recovery. Despite this, some women 
choose these procedures over traditional implants because the reconstructed breasts 
formed from one’s own body tissue look and feel more like natural breasts, and age in 
concert with the rest of one’s body (breasts reconstructed with synthetic implants tend not 
to age at all) (Djohan, Gage & Bernard, 2008). Dawn recalled her husband’s position 
about the RRBM after she received an abnormal screening result and felt compelled to 
move forward with surgery: 
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When they came back with the ultrasound results and there was something there, 
he said, “You probably need to have this done. I don’t want to worry about it. 
They want to repeat in six months, that’s way too long.” So he was definitely with 
me on that one. And he’s been great, especially with the plastic surgery. He was 
like, “I don’t care if you don’t even have the reconstruction, I just want you to be 
here.” So I think that helped me make my decision just to get the implants just 
plain and simple. No 18-hour surgery to have all this plastic surgery done from 
my stomach. 
Dawn, 27 
For Dawn, the belief that her husband would accept and be happy with whatever choice 
she made allowed her to set aside her fears about having “fake” breasts and move 
forward with the simpler, less painful reconstruction process. She was scheduled for 
mastectomy exactly one month after her interview.  
Maelie reported that her husband left the decision-making about whether and 
when to have an RRBM up to her, but was invited to give input about her reconstruction: 
He really wasn’t involved in the decision-making about the surgeries. We talked 
about it, and he kind of listened and it was, “Well, whatever you want to do to 
take care of it.” He did have some say in the reconstruction part of my breasts, as 
far as if I was going to have reconstruction, what they were going to be, how they 
would look. Just because that would really be for him anyway. And he gets the 
brunt of the side effects.  
Maelie, 33 
Rachel’s husband took a different approach to post-RRBM reconstruction:  
He said, “It’s your decision. If you want to do reconstruction, do reconstruction. If 
you don’t, don’t. These are your decisions that you need to make.” And that’s an 
advantage that I had being that I was with him for 13 years and that we already 
had some obviously strongly laid foundations. 
Rachel, 33 
Rachel reported feeling that her husband’s approach was a positive experience for her. 
Their “strongly laid foundations” underlie her confidence that her husband will love and 
accept her no matter what choice she makes. 
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Wanda also noted her husband’s powerful influence in her risk-management 
decisions. Having reached full agreement about whether and when she would pursue 
RRSO, Wanda and her husband were still not quite on the same page about RRBM: 
I think we’re both pretty certain that I’m going to have my ovaries removed once 
we decide we’re done having kids. As far as the mastectomy, we’re still talking 
about that. I feel that the screening methods for breast cancer are much more 
advanced so the chances of catching it before it became something big might 
outweigh having the mastectomy. He’s like, “Just take it all out. Get new ones 
made. It’s good. It’s fine.” But that’s a much more major surgery, as opposed to 
the oophorectomy which is almost a same day procedure in some places. 
Wanda, 32 
Kristy recalled how conversations with her then-boyfriend Spencer helped her feel 
confident about and move toward RRBM: 
Spencer’s really who I had the most conversations with about that because I felt 
like it impacted him a lot, too, in terms of breastfeeding our kids, and what I 
would look like, and things like that. And he told me flat out, “I want you to have 
it done. I don’t care about you breastfeeding our kids, I just want you to be around 
to be a mother to them.” So I obviously knew that he wanted me to have it done. 
Kristy, 29 
Grace provided one of the most powerful examples of a partner’s influence over 
risk-management decision-making. Having been in the BI study for four years during her 
mid-twenties, she and her husband Jason had decided that as soon as the study was done, 
they would try to have a baby. After she breastfed, they would proceed with the RRBM 
before trying to have additional children. This compromise would allow Grace to 
experience breastfeeding one time, but would not delay her RRBM more than two or 
three years. Shortly before implementing this plan, Jason had a change of heart: 
He came to the decision before I did. He and my mom had gone to Race for the 
Cure while I was out of town, and I guess being there without me it sort of hit 
them, the reality of thinking about starting a family and what if something were to 
happen to me in the next nine months? So I got back from my trip and he sits me 
down and says, “We need to have a talk. I think the plan needs to change.” And 
he was really sweet about it but I’m like, “Why are you being so sweet and yet 
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giving me this crappy news?” And so he gave me all of these reasons that it made 
sense to do the surgery before having a baby, and he could help feed the baby at 
night and we wouldn’t have to worry. There were just a million reasons he listed. 
The next day I met with a social worker and the breast center here at the hospital, 
I was hysterical, I was bawling my eyes out all day long. She really helped me 
validate that even though I agreed with all of his reasoning, and it wasn’t like he 
was pushing me into the decision, it was just that he was a couple steps ahead of 
me in feeling more willing to accept it. And even though I knew I wanted and 
needed to accept it, I just wasn’t quite there yet. She helped me figure out how to 
just grieve about it and take the time to accept it and know that it’s the right thing. 
Grace, 30 
Ultimately, the two proceeded with Jason’s plan, and she became pregnant a few months 
post-RRBM. In retrospect, she feels confident about her choice and thankful that Jason 
foresaw that this plan would work better for them and was willing to work to bring her 
around to that perspective. 
 Rose was interviewed during her recovery from RRBM, which she had decided to 
have prior to her first pregnancy. She highlighted her husband’s role in reminding her of 
their shared priorities of family and health, especially when she found herself doubting 
her choice and wondering, in the immediate pre-surgery weeks, if she should delay the 
RRBM until after she was done having children. Her husband’s consistency allowed her 
to remain focused on getting through the RRBM so that they could put the stress of her 
breast cancer risk behind them before they tried to have their first baby: 
He was really supportive, and the part where I would stumble would be, “Well, 
wait, maybe we should have kids and I’ll do something later.” I think some of 
those stops along the way I was trying to convince myself otherwise, when deep 
down he knows how I think and that at the end of the day I want to be healthy and 
he wants me to be healthy. He supported the mastectomy from day one. There 
was no discussion really for him. It was like, “This is the right thing to do.” He 
did a ton of reading and anything I wanted to read, he wanted to read. And he’s 
always been so proud of me being part of that early detection program, so 
anything that was being proactive is something he’s the biggest cheerleader for. 




Although Marjory saw herself as the lead decision-maker with regard to her 
surgeries, her partner’s opinion was highly valued. After independently concluding that 
proceeding with RRBM was the best choice, they worked out the specifics as a team: 
For a long time, I didn’t know if I wanted to do [the mastectomy]. And then 
probably within the last year and a half, I’m almost 100%, I’m about 95% sure 
that’s something I want to do. So at that point, I had to involve him and let him 
know that’s what I was thinking. For that particular discussion, he was already 
there. It would have been harder for him to understand if I wanted to continue to 
screen, rather than have the surgery. In his mind, it was a no-brainer, like “of 
course you want to have the surgery, why would you not want to do that?” So, 
we’ve been talking about that. And we’ve been planning on when I am going to 
do it. We have appointments to meet with plastic surgery and general surgery and 
I don’t even remember who all else. I have a book that I’m reading, and then he’s 
going to read it. And we’re planning to do it maybe this fall. 
Marjory, 30 
 
Sadie’s decision to have an RRSO at age 33 came after a long, difficult, and 
ultimately unsuccessful attempt to have a baby (the details of her struggles with infertility 
and family formation decision-making will be discussed in Chapter 9). Once it became 
clear that a biological child was not in their future, Sadie and her husband began to 
discuss whether RRSO was an appropriate immediate next step. This decision was 
difficult for Sadie because she was worried about the long-term effects that this hormone-
altering surgery would have on both her physical health and her body image; she equated 
menopause with being fat, old, and ugly, and worried that she would be seen this way 
after having her ovaries removed:  
My husband was really supportive through the whole thing, and he was there and 
listened to the argument. He said, “You know what? I want you to be around. I 
want you to be here and we’re not going to be having kids. We might as well just 
go forward. I want you to be around for a really long time, and if that means 
having these surgeries, then that’s what we do.” And his argument was that a lot 
of people have their ovaries removed, his mom had it done and my mom had it 
done. He pointed out that they’re not fat, or ugly, or old, and so he was just really 
supportive through this whole thing. I ended up having the surgery about six 
weeks ago, and through the whole thing, I think for him to actually have one of 
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the surgeries done has been a big relief for him. Because for him, it’s like, “Well, 
that part of it is done, I don’t have to think about ovarian cancer anymore.” I 
mentioned before that we were talking about cancer and the diagnosis of cancer; I 
think it was in that conversation that it came up, and he said, “You know what, 
I’m really glad that you had the surgery because it’s not something that we have 
to think about anymore.” It’s like a huge relief off of his shoulders. I think for 
him, surgery has been really positive and he’s been really supportive about them. 
Sadie, 33 
Having gotten past one major risk-reduction challenge and feeling more confident that 
her ovarian cancer risk had been reduced, Sadie and her husband began to discuss 
whether and when she might have an RRBM. 
In sharp contrast to Sadie’s story, Leigh and her husband have struggled with 
regard to his supporting her. Leigh’s attempt to engage her husband in her care is 
instructive, in that she reported his having made clear that his capacity to listen was 
limited: 
Overall he would get tired of me talking about the topic after a while. Initially it 
was all-consuming after my mom found out her results, so I wanted to talk about 
it a lot and he got tired of talking about it within a week or so, and after that he 
didn’t really want to hear too much more about it and I didn’t share as much with 
him. Only if something really important came up, I would share it, but other than 
that, he wasn’t someone who I talked about it with all the time. 
 
For Leigh, her husband’s inaccessibility led her to seek the needed support from friends 
and family members. It is unclear what kept Leigh from more emphatically stating her 
need for support to her husband. A useful psychosocial intervention for couples dealing 
with BRCA might be to teach them to express their needs and communicate more 
effectively – a common challenge for all couples that may be exacerbated by the stress of 
BRCA. In addition to this challenge, Leigh found it difficult to help her husband 
understand why she feels that an RRSO is necessary. Having recently completed her 
RRBM, Leigh was scheduled for RRSO shortly after her interview, and was hopeful that 
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after she came through it successfully, her husband would accept the decision she had 
made. For this couple, effects on Leigh’s sexuality and implications for intimacy seemed 
to be primary concerns: 
The last time we talked about it, which we haven’t talked about that one as much 
recently because lately the breasts have been front and center, but he didn’t really 
understand why I wanted to do that. I have explained my reasons to him, and I 
think he’ll be OK with it, but I think we’re both afraid that I’ll be castrated like a 
cat or a dog. On the FORCE boards, most women seem to be OK with hormone 
replacement. So I’m hoping I’ll be OK and if I think I’m OK, he’ll be fine with it 
eventually. 
Leigh, 35 
Jane was also able to clearly identify support deficits in her relationship with her 
husband. Noting an overall lack of detailed communication about the implications of her 
BRCA mutation, Jane specifically noted that her husband’s tendency to leave major 
mutation-related tasks and decisions to her felt unsupportive: 
I think he wants to be supportive but I think guys kind of want to fix it, and this is 
something you can’t fix. So he just kind of puts in back on me, like “Whatever 
your decision is I’ll support you in that.” I just wish he would take more of an 
interest in understanding what this mutation means specifically to me. You know, 
if he were to say, “I found this article and it said this, and what do you think about 
that?” it would make me feel like he really cares and wants to learn more about it. 
If he had been able to help me in some of the research. And one of the things that 
I said to him in the very beginning, it was so overwhelming for me to read thing 
after thing about women getting diagnosed so young and dying and very 
aggressive cancers. And I think that raised my anxiety a lot, and so if he had been 
more helpful in that piece of it, it might have helped me to feel more supported. 
Jane, 30 
In the process of working through the decisions to have a risk-reducing surgery, 
several women recalled having important conversations with their partners about how 
they would adjust together to their altered bodies after surgery. Valerie stated: 
I’ve always had my boobs and I’d come to my peace with them. They were what 
they were and they filled out my tops or whatever. But he and I both had to start 
looking at my breasts and thinking, “how much longer are we going to keep these 
around for, and what are we going to replace them with, and how?” And we really 
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had some frank discussions about my breasts and how I feel about them and how 
he felt about them, and that’s a conversation I’m sure many people do not ever 
have. I told him that one thing I would not put up with was being lied to, and it’s 
helped me to know that he will give me the honest answer on this stuff. When I 
told him I thought it was time to do this and what did he think, he said, “Well, I’m 
thinking that I don’t know what’s bigger than a double D, but I’d like to find out.” 
And we both laughed about it, and I think we do kind of approach things that way. 
Just as honest and straightforward as we can. We’ve just had to be that way about 
things that most people don’t have to be that way about. 
Valerie, 29 
Acacia also sensed that her husband would experience a loss when she underwent 
RRBM, but highlighted how his continued involvement would help him cope: 
We talked about it and I think his initial reaction, while he is very supportive, it’s 
very scary for him and it’s obviously the part of my body that you kind of have to 
say goodbye to. Obviously he understands the whole reason behind it but it is 
definitely sad, especially being a male and looking at a feminine body like that. 
But we’ve talked about it and I think he’ll definitely go with me to the plastic 
surgeon and talk about that.  
Acacia, 30 
Beyond recognizing how issues related to body image and their own and partners’ 
feelings about their altered bodies might pose challenges in couple relationships, several 
participants described how they had reconciled these and other issues related to sexuality 
with their planning and decision-making. Libby was also concerned about how the ways 
in which she might be different after a future RRSO could be difficult for her partner: 
I’m going to have my ovaries out once I have kids, and that might pose some 
issues, just not having ovaries and stuff like that. I’m fine with it, but just afraid 
about the whole early menopause thing. He doesn’t really have much view on it at 
all.  
Libby, 32 
Recognizing the likelihood that the changes to her hormone levels precipitated by the 
oophorectomy would pose some challenges in her relationship with her husband, Libby 
had talked to him about how to handle these. She did not describe his lack of a strong 
opinion as problematic, but the fact that they have not fully decided together about how 
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they will respond to changes to her mood, physical appearance, and sexuality could set 
the stage for significant difficulties in the future. 
Pauline had given considerable thought to how her physical relationship with her 
husband might both be impacted by and be a comfort during her RRBM and recovery: 
My status has materialized for me in this physical form as the removal of my 
breasts because that’s what I’m choosing to do. That’s obviously a very intimate 
and sexual part of your body. And I just simply cannot imagine taking my shirt 
off for another man after I have this surgery, and I’m really, really glad that I have 
to only take my shirt off for a man who loved me before and who I know will love 
me after. That simple act of disrobing, it’s almost like going back to adolescence, 
being so timid about taking your clothes off or getting naked with a boy. We’re 
going to have to rediscover ourselves, probably. He’s going to have to re-learn 
about my body. I’m just really, really glad that I already know who the guy is 
that’s going to be seeing me the first time I take the bandages off, and that’s going 
to be my husband. 
Pauline, 30  
Pauline is not alone in being concerned about how her partner would respond to her body 
after her surgery, or in weighing this as part of her decision about the surgery itself. For 
example, Isabelle had already started to consider how having the surgery might impact a 
future sexual relationship, although she had only recently learned about her BRCA 
mutation and was likely years away from having either surgery: 
The first support group I went to the topic of discussion was basically sex after 
cancer, and all the hormonal changes and issues relating to sex that go along with 
going through cancer or having your ovaries removed. And after that discussion, 
I’m hoping something better comes along, because a lot of these women were just 
not happy, and I know the general stress of marriage and sex is natural. It 
dwindles after a while, but for everybody’s sake I hope they come up with 
something that doesn’t put you through what these women are going through. 
Isabelle, 22 
Beth, scheduled for her RRBM, was concerned that she would not be comfortable 
enough with her own body to allow for the desired level of intimacy with her partner: 
I’m going to have a deformed body for a while, but you know, I think when I was 
pregnant I didn’t like him to see my body because it was changing and weird. So 
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having this surgery and the idea of being kind of deformed for a while is kind of 
[difficult]. 
Beth, 30 
Marie also related her concerns about how her body would feel after surgery to her 
experience with pregnancy and childbirth: 
I just think having the mastectomy and the reconstruction, I feel like I might have 
some… I can imagine that it’ll be odd to be intimate after the surgeries have 
happened because, for example, I had a C-section with my daughter and I just 
remember that feeling of being cut open and so exposed and feeling like I didn’t 
really have any control over my body. And then down the road, I guess I always 
assume that after I have the hysterectomy, oophorectomy, that it’s going to affect 
my sex drive or something. So I think about that. It’s kind of in the back of my 
mind. 
Marie, 28 
As demonstrated previously in this chapter, many young female BRCA mutation 
carriers in this group of participants relied on their male partners to help make decisions 
about the details of their risk-reducing surgeries. For others, their partners’ reluctance 
about surgery resulted in the carrier deciding not to have surgery at all. Jane recalled her 
husband’s position with regard to surgery shortly after she learned that she was BRCA 
positive; he asked her to take her time with her risk-management decision, rather than 
rushing into the risk-reducing surgery: 
In the beginning, I had talked with my husband about a prophylactic mastectomy, 
and I think he was very put off with that idea. I think he could understand the 
reason why some women would do it, but was really concerned for me to make a 
decision so quickly after getting my results. He really wanted me to step back 
from it and not to make a decision that was totally based on fear, but that it was 
something 100% I wanted to do. And he kept saying, “Whatever you decide, I 
will support you, but you know, maybe you just need to sit on this for a minute 
and think about it.” Which I think was good advice. Because if I had made a 
decision when I first found out and had acted on that by choosing a surgery I think 
I would have an incredible amount of regret now. And then with surveillance now 
he’s supportive whenever I go in for my screenings. And when I tell him the 




Jane’s experience suggests that her husband’s advice to slow her decision-making 
process and not make it purely based on fear has worked well for her in the long run.  
Chris, who found her husband very supportive in her process of deciding whether 
to have risk-reducing surgery, became frustrated when he had different ideas than she did 
about the specific timing of her surgery: 
He was extremely supportive. I mean, he's always been very supportive of 
whatever I've wanted to do. And he just wanted me to have it done. I wanted to 
have it done as soon as possible. It was like, “Get it done!' But we have a high 
deductible insurance, of course that factors in, and he really didn't want me to do 
it at the end of the year, so we would have to pay that deductible price. He wanted 
me to wait. And then he kind of started saying, 'well, the holidays are coming, just 
kind of enjoy the holidays, and then you can do it all.' And I was angry at him at 
first for that because I thought he wasn't understanding the importance and the 
whole thing. But in hindsight, that was the best thing, because I think going 
through all that would have been really miserable. So, he definitely encouraged 
me the right way. And he's always been very encouraging with that. 
Chris, 33 
Chris’s perception that her husband’s focus on having the surgery at a time when it would 
be most logical and convenient with regard to their insurance was unsupportive highlights 
the potential conflict that arises when a carrier finally arrives at a surgical decision and 
feels compelled to move forward as quickly as possible. Like Jane, Chris was able to see 
in hindsight that her husband’s ability to see the bigger picture was useful. These 
participants provide useful examples of how members of couples in which the female 
partner carries a BRCA mutation can work together effectively (even if they do not feel as 
though they are doing so all the time) and provide balance and perspective in coping with 
the many challenges and decisions regarding breast and ovarian cancer previvorship. 
 Preparing for and experiencing surgery. Once they have made the decision to 
undergo risk-reducing surgery, mutation carriers are faced with a variety of tasks in 
preparing for and getting through the procedure(s). Undergoing risk-reducing surgery 
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brings substantial additional support needs. Surgery in this context is an intense and 
emotionally draining experience, which also brings significant physical limitations and 
reduced independence, especially during post-RRBM recovery. Bathing oneself, lifting 
almost anything, and even sitting up for any length of time are off-limits in the days 
immediately following the procedure. Partners again provide critical emotional and 
instrumental support through this part of the process.  
Beth was working on scheduling her RRBM when she was interviewed, and she 
discussed how planning for and anticipating that event had become a regular feature in 
conversations with her fiancé: 
If I talk about it he listens, he’s just a listening ear. I keep asking him, “Are you 
ready for this?” Because it’s going to be a big burden on him when I have the 
surgery and he’s like, “That’s just how it is.” He had several knee surgeries over 
the past year and a half where I’ve had to kind of wait on him hand and foot, so 
he’s like, “You did it for me, I’ll do it for you.” I hope he knows what he’s getting 
himself into. I try to tell him that my surgery is a little bit different than his – it’s a 
lot different. I’m not going to be able to lift our son, or help bathe or son or do a 
lot of stuff with our son, and he’s going to have to do everything. But I think for 
the most part he just listens. He doesn’t try to fix anything he knows he can’t fix. 
Beth, 30 
Beth appreciated her fiancé’s intuitive sense of how best to provide the appropriate level 
of pre-surgical support, i.e., by listening, rather than trying to find and impose solutions 
to the unfixable problems. Rose’s husband, however, played a more active role during her 
surgical preparations, discussing decisions with the various doctors involved in her care: 
He was the one always asking the hard questions throughout the surgery, or even 
discussing the pre-op, he was the one taking the notes and asking very 
specifically, “Is this the day that we talk about which procedure we’re doing? Will 
you do the nipple sparing? Is it going to be this kind of surgery?” And just asking 
some of those hard questions that don’t seem real, but then the surgery’s in a 




Pauline’s husband had been an active participant in her RRBM preparations, 
accompanying her to appointments and demonstrating his determination that her pain be 
well-managed during her recovery. She expected a similar level of active involvement on 
the day of surgery and during her recovery: 
I think that he will be one of the last people I see before I go under and one of the 
first people I see when I wake up. And I want it that way. I can’t imagine going 
into this without him. I imagine that he will probably take some time off work to 
be with me and take care of me. I think that he will be really, really worried about 
me. I know he already is. … his fears are seeing me in pain. So I think that he will 
be very involved. I think he’ll see the dirty gross part of it. I think that he’ll 
probably bathe me and do those sorts of things too. I think that he’s going to be 
pretty hands-on, but I know I would do the same for him, and when we’re old 
people I just hope he’ll be bathing me or I’ll be bathing him, too. 
Pauline, 30 
Pauline’s husband provided another kind of instrumental support. Knowing that her 
RRBM was scheduled for early winter, “We planned a vacation for this summer so that I 
could take my boobs away one last time.” 
The period immediately surrounding surgery is one in which some carriers 
noticed negative impacts on their partner relationships. Some felt as though they were 
putting an unfair burden on their partners in expecting such intensive support. Preparing 
for her upcoming RRBM when interviewed, Libby stated:  
It definitely caused a lot of pressure on the relationship, because now I’m having 
surgery. I have to rely on him for help. So that causes stress I think. I feel like 
maybe he feels like I’m a bad egg or something now. I mean, I’m sure he doesn’t 
feel like that, but that went through my mind. I feel bad that he has to deal with it. 
Libby, 32 
Chris, having already had both surgeries, remembered what it was like in the weeks and 
months leading up to her surgery date: 
Before the surgery, at times I was kind of angry. And so, I didn't want him to 
acknowledge my breasts or anything. It's almost like, “Can we just forget that 
they're there?” And especially when you're getting ready for the surgery. I have 
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always been really stimulated with nipples, and you're just not really sure what to 
expect after the whole thing. You kind of try to prepare and act like that's the way 
it is, like there's nothing there. That's kind of hard. 
Chris, 33 
 Elaine was swiftly moving toward both risk-reducing surgeries when interviewed. 
A busy working mom of three young kids, most of her free time was absorbed by 
thoughts about the surgeries and their impact on her and her family. She sensed that her 
husband did not understand the frequency and intensity of her mutation-related thoughts: 
I think about it all the time. For me, it’s just pervasive. We’re walking by a tattoo 
shop and he’ll say, “Hey, you want to go get a tattoo?” Well, I’ll be getting my 
nipples tattooed. I’m thinking about it all the time but I don’t think he gets that. I 
don’t want to paint him out to be self-absorbed or anything, but I think that he 
really has a hard time empathizing, not just because he’s a man but he’s not 
tremendously close with his mom and so, even with my mom dying, I don’t think 
he gets it. I don’t think he gets how it can still affect me.  
Elaine, 34 
Elaine went on to speak eloquently about how her concerns about sexual dysfunction and 
changes to her intimate relationship with her husband played into her decision to pursue 
risk-reducing surgeries and her fears as they approached: 
I’m especially concerned about sexual dysfunction. That’s the biggest concern. 
It’s already affected me sexually because my libido is so low since I learned. I 
think because I’m thinking about it a lot, and also life is just kind of hectic. You 
know, if he’s touching my breast, it’s like I’m thinking, “They’re not going to be 
there.” And my biggest concern about the oophorectomy is, “Oh, gosh, am I 
going to have sexual dysfunction?” I feel like, you know, we’ve got three kids. I 
nursed them all and was really affected with lactation and how it suppressed my 
own estrogen. I didn’t get a period for a year. So that’s probably my biggest 
concern is, “Is this what menopause is going to be like?” But I’m getting less 
worried about that. I mean part of it is that I really do feel like I don’t have a 
choice. I know I do have a choice. I mean I’m making the decision, I don’t mean 
it like that. But in my mind the choice is so simple, regardless of whether I’m 
going to have sexual dysfunction I have to go ahead and do this. And so, I’m 
worrying about it less because there’s not really a point. It’s not going to affect 
my decision. My mom’s cousin who had the oophorectomy, she ended up having 
a little bit of hormone replacement therapy that was okay for the vaginal dryness 
and so she didn’t feel like sexual dysfunction was such a big deal. So I’m just 




Elaine understood that her husband’s attitude was one of apparent confidence that any 
changes to her desire for sex would be workable within the context of their relationship, 
as they were a small tradeoff for keeping her around: 
He’s just sort of like, “Well, let’s wait and see and it’ll be fine.” He is not 
concerned about it from a selfish perspective at all. I think if we never had 
intercourse for the rest of our lives he’s be fine. I mean I’m sure he’d be a little 
sad but he’s really said, “This is no big deal, I’d rather have you alive.” 
Elaine, 34 
 Support during recovery and reconstruction. The length of the recovery and 
reconstruction process after risk-reducing surgery varies depending on which surgery a 
carrier has had and the reconstructive options she selects. Partners have an opportunity to 
provide support in a very close and intimate way during this period. Having recently 
completed her RRBM when interviewed, Valerie reflected on how integral her husband 
had been to her recovery, and pondered how difficult that phase of her life would have 
been had he not been there to rely on: 
I really do feel awful for women who have to make these decisions, and go to all 
these appointments, and have the surgery, and everything on their own. Even just 
in that week after my surgery, I don’t know what I would have done without him 
here to help me up and down the stairs and, you know, wash my armpits for me 
and everything. I mean, I’m sure if you don’t have somebody, you get through it 
because you have to, but I don’t know how I would have done it. 
Valerie, 28 
Because she chose to have her RRBM in another state, Rylan was touched that 
her then-boyfriend (now her fiancé) was willing to make the trip with her: 
When I had my surgery this past year, he came up there with me to New York 
where I had it, and stayed with me the whole nine days I was up there, and also 
was able to not have to take any vacation time, he just worked while we were 
there. That was the reason he was able to go, otherwise he’d have to take all of 
that vacation time, and we would feel like it would have been wasted because we 
like traveling and vacationing a lot. So that was nice, and he was physically and 
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emotionally supportive of me when I was recovering from that. He never 
challenged any decisions I made, or he never questioned them. 
Rylan, 34 
For Rylan, the fact that her fiancé not only chose to accompany her during surgery, but 
also arranged his work schedule so that they could still enjoy a vacation together after she 
recovered, was a powerful expression of his love for her. 
Trixie, having recently completed RRBM, reported feeling guilty at times because 
she believed “I’ve been such a burden to him for the past four months, but he assures me 
that that’s not how he’s feeling.” She discussed her appreciation of her partner’s 
willingness to ensure her comfort and facilitate a quick recovery after her RRBM: 
He does everything in his power to make me feel comfortable, which is so nice. 
He’ll prop the pillows up for me if I’m uncomfortable sleeping and make sure that 
if we go to a bar, the stools have backs on them, he’s just completely focused on 
making me comfortable and getting me through this process as quick as possible. 
Trixie, 27 
Happily, it seems that for most participants, male partners did not experience these 
support needs as burdensome; rather, they were willing and happy to provide support to 
the women they loved. 
 Though Rylan, Valerie, and Trixie’s partners were vital to their surgery and 
recovery processes, other participants reported some conflict regarding how their partners 
would fit into the team of people providing support. Kristy had been dating Spencer for 
several years when she had her RRBM; although he was present, and eager to do 
whatever he could during her recovery, Kristy’s mother was also there and they 
sometimes disagreed about who should be responsible for which tasks: 
My mom stayed for three weeks with me and it’s sort of like she and Spencer had 
to figure out their division of labor. I think that Spencer thought he was going to 
have more of a role because he was my boyfriend and he wanted to take care of 
me. But, for a lot of it I needed my mom to help me. And it caused a little bit of 
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tension in the relationship. I was very emotional because I was exhausted and I 
was on drugs. And we ended up sort of bickering a lot. I don’t even remember it. I 
would get mad at him. He would say, “You did whatever, it wasn’t very nice.” I 
was like, “Can you just get over it? I’m obviously not myself. I’m on these drugs 
and I’m going through a tough thing. Can’t you just sort of let it go?” So, in that 
way it created a tension and I think that overall it brought us together and we got 
through it, and he’s been very supportive and he’s still very supportive, but it 
definitely added some extra tension to our relationship. 
 
Kristy went on to describe how the after-effects of the tension created by her surgery 
were the beginnings of the unraveling of her relationship with Spencer; they broke up 
several months after her surgery was complete. However, Kristy felt strongly that  
it [was] something very positive, because if I wasn’t in a pretty serious 
relationship, I’m not sure that I would have had the surgery. So in that regard I 
think things happen for a reason, and I think that was one of the reasons. 
Kristy, 29 
Kristy’s experience suggests that the presence of a supportive partner, even when that 
support was not ideal, can be a powerful predictor of effective preparation and readiness 
for the challenge of undergoing a risk-reducing surgery at a young age. Because of 
Spencer’s acceptance and encouragement of her decision, Kristy was able to feel that she 
was making a good choice; she moved forward with her surgery sooner than she would 
have without him. 
Rose and her husband experienced some strong feelings about what it meant to 
them individually and as a couple to work through the process of reconstructing Rose’s 
breasts after her RRBM: 
Going through the process of mastectomy and reconstruction, it’s this really weird 
thing about seeing yourself, “does this look good, does this look good,” and that 
puts pressure on the relationship. But then there’s this chance for rebuilding my 
body. I think it puts a lot of stress on someone to have to be like, “how does this 
look? Does this look good? Is this fabulous? Now I have big beautiful boobs. Isn’t 
that awesome?” I can’t imagine how hard it is for my husband sometimes. What’s 
he supposed to say? When we’re in the doctor’s office he feels really awkward 
because he’s talking to the doctor and he [worries that the doctor’s thinking], “Is 
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he trying to get custom made boobs?” You’re going to have to readjust to the 
body image of your partner, you know? That’s a weird dynamic and something 
that doesn’t usually happen in a lifetime. I still sometimes wonder, I really want to 
know what he really thinks. I looked pretty good before, I was a very small-
chested woman, just average, like a B cup. And I just wonder. I just sometimes 
wish I could crawl in his head and really know if he thinks this is even better? 
Does this look great? It’s one of those things you kind of wonder. I’ll never know. 
Rose, 30 
Rose’s experience illustrates a likely common challenge for women who are in 
relationships when they have RRBM (and reconstruction, for most): it is impossible to 
ever truly know what one’s partner thinks about the look and feel of one’s reconstructed 
breasts. There was a sense among participants that their partners were giving up the 
breasts that were present when these partner relationships were formed, just as the 
participants themselves were giving up their natural breasts; for both, this often required a 
genuine process of grieving and accepting the loss. While this uncertainty about one’s 
partner’s opinion may turn into an ongoing source of low-level anxiety for some women, 
it is likely that in the context of a loving relationship, a post-mastectomy female mutation 
carrier would be able to feel that her partner fully accepted and even embraced her new, 
less cancer-prone body. 
 Moving past surgery. Once surgery, recovery, and reconstruction are complete, 
women may face ongoing challenges coming to peace with their altered bodies after 
surgery; this is another opportunity for male partners to provide necessary support in 
helping carriers feel confident that they are still loved and that relationships are still 
secure. Participants provided powerful examples of this:  
Sometimes we do have conversations when I’ll say I feel much more normal, or I 
feel back to myself pretty much. So it makes me a little bit stronger in some ways 
because I know that he’ll be with me through whatever. It’s almost a relief to 
think that he’s 20 years older than me, and I don’t look the same. I mean, my 
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surgery result was not perfect. And to think that I have a great husband who 
doesn’t care, it makes me feel much better about that. 
Chris, 33 
Chris suggested that her husband being older made him less concerned with physical 
attractiveness and the sexual component of their relationship, and facilitated his accepting 
the changes created by surgery. Valerie also found comfort in her husband’s acceptance 
of her post-surgery body, and highlighted how the presence of her BRCA mutation has 
added a new dimension to their relationship: 
I think that sometimes I don’t really want to lean on him. I try to be independent. 
And [BRCA] is one of those things that I get to lean on him for. So I think, to a 
degree, I’m not going to say he likes it, but I think he at least appreciates that I 
lean a little bit. I vent, I cry when I get the call that I have to come in for another 
test or a biopsy. And I let him look up stuff on PubMed for me sometimes. I don’t 
necessarily let him do that for other things. I’m fairly independent. So I think he 
likes that I let him do that for me. And he’s been very careful to tell me how much 
he likes my new boobs and that I’m still just as pretty as I was before. 
Valerie, 28 
Grace spoke powerfully about her husband’s acceptance of her post-surgery 
physique; unique among participants, Grace elected not to have breast reconstruction 
after RRBM, at age 29. Shortly after her surgery, she became pregnant, and was several 
days past her due date when interviewed. She spoke lovingly about how her husband 
shows his acceptance of her newly breastless body: 
I would say with the pregnancy – well, even before the pregnancy because I chose 
the risk-reducing option and had my prophylactic mastectomy almost a year ago, 
he’s been totally just wonderful and supportive. Each night, being nine months 
pregnant and really, all through the pregnancy, he would lotion on my scars and 
most nights he’ll kiss each side of my scar and kiss my belly each night before 
bed. And so there’s a real sweetness about his acceptance of the scars. It’s 
definitely made it way easier for me to accept it, knowing that he fully embraces 




Grace’s husband’s unconditional acceptance of her appearance made it much easier for 
her to make the bold decision to decline reconstruction, which can be a long, complicated 
and frustrating process, without a guarantee of a cosmetically pleasing outcome.  
 Negotiating or renegotiating one’s sexual relationship with a partner after risk-
reducing surgery was a challenge many participants spoke about openly. For some, this 
task was experienced as relatively straightforward; for others it presented a major hurdle. 
Having started a relationship with a new partner several months after her RRBM and 
before her reconstruction was finished, Lynn remembered: 
I was definitely nervous about it at first when we became physical and I did 
remind him. I was like, “Hey, by the way, I don’t have any nipples, don’t be 
freaked out by that.” But he didn’t care and it didn’t change our physical 
relationship at all. The only thing I miss is the nerve endings in my breasts, the 
feeling. I do miss that. 
Lynn, 24 
Lynn exemplifies how well a young mutation carrier can cope with the bodily changes 
resulting from cancer risk management. Similarly, Kate and her partner, whom she met 
after her RRBM and reconstruction were completed (sans nipple reconstruction), 
communicated effectively about their feelings about Kate’s post-surgery body: 
He thinks [nipple reconstruction] is a waste of money, since it won’t be a real 
nipple, why bother doing it? After we began our physical relationship, for a long 
time I would never take my shirt off in front of him. And he’s never said 
anything. And I asked him one time, “Is it uncomfortable? Does it bother you?” 
And he said very honestly that he doesn’t like to look at all, he doesn’t like to 
look at the scars, but it doesn’t make it impossible for him to see me naked. He 
just doesn’t look there. So he does not have a preference whether or not I keep a 
bra or a top on. He just doesn’t look in that area, and he said that works for him. 
For me, it’s a little bit sad. I mean, this is the first time since I had my surgery 
where it makes me a little sad that I did have to have a mastectomy. It doesn’t 
make me regret my choice, but it makes me sad that I had to choose it, because I 
miss – I feel okay about the fact that he doesn’t look there, but I wish that wasn’t 




Their ability to have an honest conversation about her body and what her mastectomy 
meant to their sexual relationship was an important step in moving beyond any 
awkwardness that might have been present. His avoiding looking at her bare chest, and 
the loss of her breasts as a part of their sexual relationship are clearly sad for Kate, but do 
not impede their ability to have a healthy relationship. 
 In contrast to Lynn’s and Kate’s successful adaptation to their post-mastectomy 
bodies in the context of their sexual relationships, other participants have encountered 
more significant obstacles. Recounting her sexual experiences with her husband after 
completing both risk-reducing surgeries, Chris stated: 
It's like a whole different ball game, intimacy afterwards. You don't feel your 
chest if you have expanders. I mean, how does he even get on top of you because 
of all the squishing? Plus, for me, I'm really emotionally high maintenance, and 
so, I really wanted to know that he was still attracted to me after the surgery. 
That's a big thing on the message boards that you'll see people talk about, like, 
“When did you have sex after the surgery?' So, we did -- I think it was ten days 
afterwards, I still had drains and everything. But I think it was comforting to 
know that he still found me attractive. After you have your boobs and ovaries out, 
then it like really takes it to a whole new level. You know, you don’t even have 
the hormones there. And I can go for – I mean, I was reaching my sexual peak, I 
thought I had been there for like two years, you know. So, you go from that, 
where you’re like constantly begging him for sex, to “Oh, it’s been a week? Well, 
okay.” It bothers me because I like our physical relationship and I like to be close 
with him, but I could live without sex, totally. I could definitely live without it.  
 
When interviewed, Chris and her husband were still struggling to connect intimately in a 
way that would work for both of them: 
I don’t realize when we haven’t had sex in a while, and he doesn’t say anything. 
Add onto that that he’s 20 years older than me, so sex whenever you want to is 
not always going to happen. All the stars have to be aligned. So that’s been a big 
conversation. You know, Oprah has this sex map thing on her website, and you’re 
supposed to put numbers where you like to be touched and in what order. So I 
started having problems because I’m missing a hormone now. So I went on the 
Oprah site and we did the whole sex map thing, and we talked about it. I would 
have thought he would remember, but he doesn’t. He just does his same thing. It’s 
like he just acts as though I’m still the 32-year-old with raging hormones, instead 
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of the person who’s 60 years old on the inside. I want to tell him, “You have to do 
some foreplay, you know?” It’s been terrible. I even started on testosterone to 
help a little bit with it. 
Chris, 33 
Menopausal hormone therapy (MHT) was a frequent topic in post-RRSO discussions of 
sexual relationships. Participants commented often of tension between using MHT to 
alleviate surgical menopause symptoms such as hot flashes, vaginal dryness or lack of 
libido, and the fear that doing so would increase their breast cancer risk, thus blunting the 
protective effect of RRSO.  
 Participants who had completed one or both risk-reducing surgeries were able to 
reflect on their surgery experiences and observe its impact on the partner relationship. 
Valerie believed that she had provided insufficient support for her husband in the 
preoperative weeks: 
I think, in the weeks leading up to my surgery, I know that I checked out of our 
relationship a little bit. I really just was kind of worried about me. I was worried 
about getting all my work done, and getting all my ducks in a row, and getting 
everything I needed, and getting all my tests, and, you know, everything basically. 
And I know that I was kind of distant, but not really meaning to be. I wasn’t 
necessarily pulling away from him, I just… I was always up over my head at 
work and everything. And after my surgery, he said that he was upset, but that he 
understood it needed to happen. But, you know, he kind of wished that we’d been 
able to have a few more quiet dinners at home, maybe a couple of romantic 
evenings because he knew I was going to be out of commission for a while. I do 
regret that in hindsight, not making more time for him and I right in that lead-up 
to surgery. 
Valerie, 29 
Valerie’s awareness and insight about how the pre-surgery days might have been 
different may facilitate her responding more effectively in the future, e.g., if she chooses 
to have an RRSO.  
Several participants noted the process of coming to feel closer to their partners as 
a direct result of the support they experienced in the immediate surgical aftermath. Dawn 
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believed that her relationship with her husband had only been strengthened by her BRCA-
positive experience: 
Truly, this has brought us closer. I mean, we’ve had a great relationship and – not 
to be all gushy, but – he’s my soul mate, and I think that if anything, it has 
brought us closer together and we talk more. He’s really shown me he’s there for 
me and so that has definitely brought us closer. 
Dawn, 27 
Trixie felt that her partner’s post-op physical and emotional care helped bring them closer 
together: 
I think it’s brought us closer together. I don’t see how you could go through this 
with somebody and not be … I mean, it’s not pretty right afterwards, the way I 
looked, and I was emotional. I wasn’t crying but I was mean after my surgery. 
And he stayed with me through it and understood that it wasn’t me talking, it was 
the trauma my body had just gone through, and just seeing somebody who’s able 
to take care of me when it’s not that fun to do so has brought us closer and made 
me respect him more, and made my family like him more. It’s all been great. 
Trixie, 27 
Similarly, Rylan felt that she and her fiancé had bonded through the experience of her 
surgery and recovery, and that this helped to solidify their relationship not only to them, 
but in their families’ eyes as well: 
We trust each other that we’re going to take care of each other, which is really 
important to his mom and dad. They are always telling us to take care of each 
other, no matter what. They’ve been married for thirty years now, and they want 
the same thing for him. I think this has kind of helped us do that better. It 
definitely makes you more health conscious when you’re going through 
something like this, and I think not only yourself, but your friends and family 
around you, which I think is really important. 
Rylan, 34 
Looking back on her risk-reducing surgeries, Chris noted: 
You kind of realize that obviously life isn’t forever. And I think the biggest 
impact or the change that we had to our marriage was after I had the surgery and 
how much care he gave me, and you could just tell, really, how much he cared 
about me and how much he loved me because he was so doting, and he was so 




Kristy was unique in her discussion of how experiencing RRBM with her now 
former boyfriend had brought them closer in a way that transcended the end of their 
relationship: 
Even though we’re not technically together, it’s something that has made us 
closer, especially with my family situation. Every week we have something. My 
mom calls and tells me about my aunt and it kind of gets to the point where with 
my friends, it’s kind of hard to tell them about this every week. I kind of get the 
feeling like I’m Debbie Downer. So really, Spencer is kind of in that perfect 
position where he knows my aunt and has spent time with her so I can talk to him 
about it. But he’s not so close that he’s like a family member and will get upset if 
I talk to him about my feelings. So, in that regard, it made us very close because I 
can share with him and he knows, he’s very supportive of that. And I would 
assume that with the next person it would be similar and if it’s not, then that’s 
probably not the right person for me. 
Kristy, 29 
Together, these examples illustrate the significance of partner support in the BRCA 
mutation-positive experience. When given freely and in a way that effectively meets a 
carriers’ needs, partner support can help smooth the process of surgery; when withheld or 
not given in a way that is experienced as helpful, partner support can become an added 
stressor during this difficult phase for young mutation carriers. 
Unique Ways of Supporting 
 In addition to providing support during surveillance and through the surgery, 
recovery, and reconstruction process, partners of young female BRCA mutation carriers 
provide other types of support that is specific to the unique situations surrounding each 
couple relationship. Several participants discussed the creative ways they had found to 
make something positive of their situations as carriers, and this often involved sharing 
their experiences with other (potential) carriers in some way. After the completion of her 
one-step RRBM, Rylan decided to create a blog to provide other women with information 
they might find helpful in deciding about this relatively new procedure. The product was 
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a collective effort between Rylan and her partner, Byron, and allowed Rylan to be 
generative in a way that felt powerful to her: 
We both designed it together, but he wrote all of the code for it and he has been 
teaching me HTML a little. He was pretty much willing and happy to do it, he 
was really excited about it, because he loves his job but he also thinks about doing 
projects on the side, and this became his little project. That definitely brought us 
closer together because he really has a concern about my blog and wants it to be 
the way I want it. He wants it to be functional. He tells me he’s proud of me, like 
almost every day he tells me how proud he is of me, and that helps me a lot. 
Rylan, 34 
Rylan and Byron had worked together to find a creative and educational outlet that would 
allow them both to utilize a specific expertise, and that also gave them an additional 
opportunity to share their BRCA experience with each other. Similarly, Valerie and her 
husband, both laboratory scientists, created a way to focus together on BRCA-related 
research, which Valerie has taken on as her primary focus at work: 
I’ve decided to try to get into it. It’s my first project as a post-doc, I’m going to 
start looking at BRCA1 and BRCA2. So I’ve been bouncing a lot of ideas off of 
[Jake], and he has more “out there” ideas than I do. I can think of the “A leads to 
B, which leads to C,” but then he comes up with something totally different that I 
never would have thought of. So we’ve been talking a lot about BRCA lately, in a 
research context. It’s nice to not have to feel like I’m being run by it anymore like 
I did in the weeks leading up to my surgery. I sort of felt like I was just BRCA all 
over. But we talk about it a lot lately just in terms of research. 
Valerie, 28 
 Finally, partners of some participants were uniquely positioned to provide 
emotional support when others with whom carriers had close relationships did not do so. 
MaryAnn noted that the unwillingness of some of her family members to support her 
BRCA-related decisions made her more appreciative of the support she received from her 
fiancé: 
I also think it’s important how other family members perceive your results, and 
I’ve had some interesting reactions from my sisters. One of them is vehemently 
against being tested and thought that I was being overly paranoid to go through 
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with the testing. She was negative when I told her that I got tested, and I felt like 
she was being kind of judgmental. But I think it does make me rely on my fiancé 
more just because he is supportive. 
MaryAnn, 26 
Single Carrier’s Support Needs 
 The previous sections provide many examples of both successful and 
unsuccessful provision of support by partners across various stages of the mutation-
positive experience for young female carriers. However, single participants 
acknowledged a support deficit resulting from their not being involved in a couple 
relationship. 
 Several unpartnered participants discussed characteristics they hoped would be 
present in a future partner. For Lilly, knowing that she was a BRCA mutation carrier 
made her more aware of how important it was for her future partner to possess 
compassion, in addition to the other traits she had been looking for all along: 
Before, I was looking for one type of guy, and maybe now, it might be the same 
guy, but there’s got to be a strong element of compassion there too. I always went 
for funny, sarcastic, goofy guys. To some degree I’m like a giant kid, not wanting 
to grow up and all of that, so I always went for those types of guys. Maybe I still 
would, the element of humor, but there would have to be some strong sense of a 
mature aspect of their life. 
Lilly, 25 
For Nichelle, fearing that others would believe that her abilities were limited was a major 
BRCA-related worry. Accordingly, it was important to her to have a partner who believed 
that she could have a perfectly normal life despite her mutation: 
I think just having a positive response, like, “I’m really sorry to hear that, but you 
know what? You know ahead of time and you’re going to be alright. You have 




Ultimately, for many single participants, discussions about desirable traits in a future 
partner boiled down to one crucial element: staying power. This is consistent with themes 
discussed in Chapter 7 about participant’s fears that partners might choose to end the 
relationship because they saw the mutation as too much to handle. Serena stated: 
I would want him to just be supportive. You know, try to get involved. So I would 
hope that if he was interested in something long-term, possibly marriage and kids 
and stuff that he would really support me in that way. I think that’s really all I 
would ask. I would ask for the support and the love and if something happens, 
stand by me. 
Serena, 30 
Chapter Conclusion  
In summary, effective partner support seems to be a critical component to 
successfully navigating the myriad decisions and challenges presented to young female 
BRCA carriers. Participants who did not receive the desired quantity or quality of support 
from their partners clearly noticed this deficit and were easily able to identify ways in 
which their partners could have been more supportive, and how that would have altered 
their experience. Those who did receive sufficient support highlighted the various ways 
in which that occurred and was helpful, as Marie summarized: 
He is supportive because he listens to my different things that I’m thinking about. 
And he is very logical and planful in his thinking. When I’m freaking out about 
things, he’ll always make me stop and think. He kind of makes it like it’s not as 
bad. I’ll make it like it’s really bad, but he’ll be like, “No, it’s not really that bad. 
Let’s think about it logically, and everything’s going to be OK.” So, he’s like my 
strength, my rock, my normal when I’m freaking out and being crazy. 
Marie, 28 
Effective support and cooperative decision-making about cancer risk management within 
couples can be an intense bonding experience, as was the case with many participants: 
I think it’s definitely brought us closer. I think he and I both think about our 
health a lot more, and we do that together. And it actually has facilitated us 
making decisions together a lot more. With this, there comes a lot of decision-
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making and he very much wants to be involved in every one, which is great. But 
it’s really helped us as a couple to make those decisions together. I understand 
more about what he’s thinking, what I’m thinking, whether I’m OK with it. Like, 
do I want to continue screening or do I want to look into surgery? When should 
we start having children, given time constraints and things like that. So it’s helped 
us in terms of being closer and able to talk about these issues more comfortably. I 
think in a lot of couples, if you’re not presented with serious issues, you never 
learn how to talk about them. Because we’ve had these to deal with, we’re just 
comfortable talking. There’s really not a whole lot I can’t talk about with him. It 
forced us to talk about family and if we want children, how many do we want? 
When do we want them? He’s definitely made me accountable. Those would be 
the main benefits I would say. 
Marjory, 30 
Understanding the importance of effective partner support to partnered carriers raises an 
important question: how do young female mutation carriers who are not in couple 
relationships identify and receive the needed type and quantity of emotional and 
instrumental support? This important question should be addressed in future research. 
 As illustrated in Figure 7, support from relationship partners clearly plays an 
important critical role in how women make decisions about risk management. The role of 
partner support in family formation also started to become clear in this chapter, as women 
discussed how their partners participate in making decisions that would accommodate 
both family formation and risk-management goals. This will become more evident when 
discussed in Chapter 9. With regard to risk management, participants highlighted 
different ways of inviting their partners to be a part of this process. However, a sense that 
partners (either current or future) should be involved in some way was nearly universal. 
The lack of a clear role for partners during the period in which mutation carriers rely on 
surveillance suggests that strategies aimed at helping providers recognize and respond 




   Figure 7: Role of Mutation-Related Partner Support in Theoretical Model 
 
Concerns about one’s body image and sexuality were common throughout the 
experience of moving toward, through, and beyond risk-reducing surgery, and this is 
consistent with previous research on BRCA pre-vivors (Matloff, Barnett, & Bober, 2009). 
Participants’ who reported feeling disconnected from or angry about their breasts may be 
reflecting the ambiguity that arises just before surgery, which may be part of their method 
of coping with the impending loss. Awareness of partners’ sense of loss after risk-
reducing surgery was common among participants, and anticipating this may certainly be 
a complicating factor in the process of making a decision about surgery. Couples’ 
abilities to communicate honestly about their fears and anxieties seem to facilitate 





























successful coping with women’s altered bodies, or altered feelings about their bodies, 
throughout the BRCA experience. 
Overall, the data presented in this chapter suggest that partner support is 
important to young BRCA pre-vivors, whether or not it is present. Because couple 
relationships are such an important facet of this phase of the life course, young adult 
women are acutely focused on their current or future partners and the role that those 
individuals will play in their lives. The lack of empirical research about these 
relationships, and the almost complete absence of partners’ voices in the literature, 
suggests that the medical and psychosocial communities have not effectively investigated 
or understood how best to serve this population. Physicians, genetic counselors, and 
medical professionals who are able to involve partners in a way that feels inclusive, 
welcoming, and helpful to both members of a couple may find new and effective ways to 
alleviate anxiety and help mutation carriers feel confident about their choices with regard 
to risk management. 
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CHAPTER 9: RESULTS—FAMILY FORMATION 
“It’s just this weird thing where getting testing and doing more mammograms are 
recommended all around the same time when people really start thinking about having 
kids and planning families. … God forbid … the last thing I want right now is to have 
issues with pregnancy. I’ve had enough issues with this kind of stuff.” – Rose 
 
Because breast and ovarian cancer susceptibility threatens the very parts of the 
female anatomy that are associated with procreation and nursing children, issues related 
to family formation are intimately tied to the experience of being a young female BRCA 
mutation carrier. These women often worry about how their plans for or ideals about 
family formation might be impacted by their positive mutation status (Werner-Lin, 2008). 
Some participants reported having considered family formation even in their decision 
about whether or not to undergo BRCA mutation testing. Nichelle remembered, “I’ve 
thought a lot about it prior to even test results…even just getting tested, I hope it doesn't 
limit me in having children of my own someday.” Others reported being concerned about 
their ability to have children almost immediately after receiving positive test results: 
[When I found out I was positive,] I was overwhelmed, and really anxious…you 
think you have all these plans for the future and having a family, and doing the 
things that you want to do, and for the first time I felt like that was threatened. …I 
think [learning about my mutation] created a sense of urgency to have a family. 
We had already been trying to get pregnant, even before I went through the 
testing, but I think, for the first time my fertility felt threatened. If I’d gotten a 
cancer diagnosis, if I’d gone in and had a screening and there was something there 
– I know that there were women who had gotten treatment for breast cancer and 
that sometimes they’re no longer able to have children. And, as strange as it is, 
with myself being adopted, and the complexities that I’ve been dealing with, I 
don’t know that I would want to go through adoption as a way of creating a 
family. So, that part, I felt, almost like grief in a way. I don’t know, even though it 
wasn’t like we weren’t able to get pregnant, we were, but I just felt nervous and 




Jane’s emotional experiences while she was attempting to conceive were significantly 
impacted by her feeling that her mutation could threaten highly-valued ideals about what 
the experience of forming a family would be like. 
 Contemplating how family formation and risk management goals will be 
accomplished is not an independent process, but rather one that carriers complete with 
their partners. Almost universally, participants described how current or future partners 
were or would be involved in these issues. For example, Melanie, one of four participants 
who were pregnant when interviewed, described her husband’s view of the extra 
considerations required in contemplating having a child who might be a mutation carrier: 
I feel bad that I have it, but he just shoos that away right away. He kind of doesn’t 
want to hear it. Things like, now we’re having a baby, I’ll say “We really need to 
get life insurance, I’m the one that something might happen to,” and he’s like, 
“Stop, I don’t want to hear that, be quiet.” So it’s that kind of thing. Just knowing 
that you can pass it down, and it’s me who is passing it down, but again, he just 
shoos it off. He’s not holding it against me, obviously. 
Melanie, 31 
Melanie was insistent that her husband’s attitude was a relief, and that despite having 
repeatedly checked in with him about whether he felt unfairly burdened, his message of 
acceptance and love had been consistent. 
Participants were concerned about diverse issues related to family formation, 
including whether or not to have children, the timing of family formation and completing 
one’s childbearing goals relative to desired risk-reducing surgeries, making decisions 
about family size, and whether their ability to breastfeed their children would be 
impacted by plans for surgical risk-reduction. Careful analysis of the data culled from the 
40 participants in this study suggested that a framework based on control was useful to 
conceptualize family formation data. Learning about one’s positive mutation status was 
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experienced by many young women as a threat to their closely-held ideals about how and 
when family formation will occur in the life course. Shifting family formation plans may 
be an attempt to regain some sense of control. Becoming more deliberate about family 
formation forced mutation carriers to be less flexible and to make careful choices about 
prioritizing family formation or risk-management goals. This decision was manifest in 
three major domains: timing, family size, and breastfeeding. 
Effects of Childbearing and Breastfeeding on Risk and Risk Perception 
 As women navigate the difficult decisions discussed in this chapter, they do so 
with the knowledge that the choices they make have significant implications for their risk 
of developing cancer. Although current research indicates that pregnancy and 
breastfeeding do not increase breast cancer risk in mutation carriers10, several participants 
cited a worry that this would be true for them and discussed their feelings about their risk 
given the fact that they were in their active childbearing years. For Leigh, concern about 
her cancer risk in the period immediately following childbirth came from knowledge she 
had gained through reading BRCA-related websites, and her experience demonstrates 
how misinformation can lead women to feel very differently about their risk than they 
might otherwise feel: 
The early onset of the ovarian aspects of this were especially troubling11. … I’d 
read on the internet of several anecdotal cases of young women with very young 
children who developed cancer while breastfeeding or shortly after giving birth, 
so I was very terrified of my immediate risk at that time. 
Leigh, 35 
                                                 
10 Some of this information come from studies indicating that risk of sporadic breast cancer increases 
during childbearing; however, this is attributed to a promoting effect of the altered hormonal milieu, not a 
directly carcinogenic or causative effect (i.e., cancers are already present when the patient gets pregnant, 
and then get unmasked during the pregnancy) (Jernstrom et al., 2004; Poynter et al., 2010). 
11 Age-at-onset for ovarian cancer is younger in mutation carriers (especially BRCA1) than in sporadic 
ovarian cancer, but almost never occurs prior to age 30. 
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Leigh’s sense of being at especially high-risk was amplified because the consequences of 
a cancer diagnosis for her included the possibilities of leaving her children motherless, or 
having a negative impact on their childhood as a result of her cancer treatment. Beth 
discussed how her sense of being at increased risk in the months immediately following 
childbirth influenced the timeline on which she was choosing to have her RRBM: 
Knowing that I want to have surgery, I told him that I need to have surgery before 
my son is a year old because my sister got diagnosed when her daughter was 11 
months old, so I had that ticking time bomb kind of thought… 
Beth, 30 
For Beth, this sense of increased risk came from her first-hand experience with her sister, 
not something abstract that she had read. Beth’s concern has some basis in fact, since she 
and her sister carry the exact same mutation, and members of a family are more likely to 
develop cancer at similar ages. In addition to these general concerns, some participants 
discussed specific issues related to childbearing and risk that made them feel especially 
vulnerable. 
Infertility-related challenges. Potential cancer susceptibility related to the use of 
infertility drugs/treatments is an important consideration for a minority of women who 
carry BRCA mutations. Among the participants in this study, only one had had first-hand 
experience with fertility treatments. Libby was 32 and married when interviewed. Prior to 
focusing on family formation, Libby had been aware that a BRCA mutation was present 
in her family, but was planning to wait until after she had children to get tested. She and 
her husband spent several months attempting to conceive a baby without success, and 
ultimately decided to consult a fertility specialist. Upon learning that a BRCA mutation 
was present in her family, he strongly recommended that she complete her testing sooner 
because of his concern that using fertility drugs might be dangerous if she were positive. 
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Upon learning her status, Libby chose to postpone family formation in order to complete 
RRBM so that she could use fertility drugs without worrying that doing so would 
increase her breast cancer risk. Libby recalled how she felt about her cancer risk 
immediately after completing genetic testing: 
The more you read, the more freaked out you start to get. I had taken a round of 
hormones to do an artificial insemination treatment. I just did it because I really 
wanted to get pregnant. And I was taking a really low dose of hormones, because 
the doctor knew I had the gene. After that, I felt very vulnerable. I was like, “oh 
my God,” because it didn’t work. I might have just put myself in a really bad 
situation. I felt really vulnerable also with the ovarian cancer. Because with the 
fertility stuff, they track your ovaries so much. I’m constantly getting these 
ultrasounds of my ovaries and I just felt really vulnerable in that sense. 
 
Libby’s sense of vulnerability derived from her beliefs about how hormonal exposure 
might increase cancer risk12, and her ovarian imaging studies, which kept the issue of 
cancer at the forefront of her awareness. She explained how her fertility treatment had 
changed after learning that she was BRCA positive, and how her use of assisted 
reproductive technologies influenced her decision-making about RRBM: 
I’m still having infertility issues, and they don’t really know what to do with me 
because I have the mutation. They were like, “We want to give you hormones, but 
we don’t because we’re afraid. We don’t want you to get breast cancer, or ovarian 
cancer.” They don’t want to jack me up with hormones and then leave me alone 
for nine months. They were afraid of a microscopic cancer brewing or something, 
and then giving me hormones and it just accelerating the whole time I’m pregnant 
and having a tumor by the time I give birth. They were afraid of that. So, I went to 
a couple of different doctors and I said, “I’m definitely going to have a 
mastectomy. So, when should I get it? What would you do? Would you do it after 
you have kids so that you and breastfeed? Or should I do it now?” And at first, I 
didn’t even think to do it now because I still know I’m going to have kids. I want 
to breastfeed and, to me, it seemed like it could wait. I’m only 32. My grandma 
didn’t get it until she was 38. So, that gives me five years. In my mind, it was 
going to be a risk in my late 30s. So, what happened was, the doctors all said, 
                                                 
12 The single existing study that addresses this question concluded that there is no increased cancer risk 
associated with use of fertility treatments for BRCA mutation carriers (Kotsopoulos et al., 2008). This belief 
(among carriers and providers) seems to come from reasoning by analogy – i.e., estrogen increases the risk 




“Look, if you want to be safe, get the mastectomy done now. You won’t be able 
to breastfeed, but at least you won’t get breast cancer.” And to me, that was like, 
“Breastfeeding? Alright. I’ve never done it before. I don’t even know the 
difference. I just don’t want to get cancer.” 
 
Based on her doctor’s well-intentioned but nonetheless arbitrary recommendations, and 
to mitigate her risk prior to undergoing intense fertility treatments, Libby decided that 
RRBM prior to fertility-assisted pregnancy was the best route for her. At the time of her 
interview, she was quickly approaching her RRBM surgical date: 
Now, I've stopped all treatment. They recommended IVF because they didn't want 
to do little doses of hormones over a long period of time. They just kind of 
wanted to move to the big guns, and do a lot of hormones over a short period of 
time because your chances of getting pregnant are higher. So, that's when I 
thought, let me just get this surgery over with. Then in six months, I'll start doing 
IVF treatment. So we put the baby plan on pause to take care of the surgery. 
Libby, 32 
 
Although the experience of one individual can certainly not be generalized to all BRCA-
positive women who encounter fertility issues, Libby’s story does illustrate how fertility 
difficulties can markedly complicate progression through the young adulthood phase of 
the life course, as women work to create their families. 
Surveillance during pregnancy and breastfeeding. Participants relying on 
surveillance to manage their risk during their childbearing years frequently reported 
being very worried about how they would continue effective surveillance while pregnant 
or breastfeeding. This issues is further complicated by preliminary indications that 
breastfeeding may be protective for BRCA1 carriers who breastfeed for a cumulative total 
of one year; other studies have shown no relationship and there is no association for 
BRCA2 carriers (Eitan, Michaelson-Cohen, Levavi, & Beller, 2009). In making her 
decision about when to try to become pregnant, Melanie, 31, reported that she was 
concerned with the timing of her pregnancy and ability to continue screening during the 
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months that she was breastfeeding. This concern was echoed by many other participants. 
Jane recalled her sense of relief when, upon learning that screening and pregnancy were 
not compatible, she realized that she had gotten both breast and ovarian screening 
completed just prior to becoming pregnant: 
I ended up incredibly lucky that I had had a mammogram and an MRI and a trans-
vaginal [ultrasound], all prior to getting pregnant, and then we were able to get 
pregnant. I was really glad because once I was pregnant then it dawned on me that 
I can’t get any screening done during that time. 
Jane, 30 
Jane’s realization of this after becoming pregnant suggests that some women may not be 
receiving sufficient information from their physicians about what screening should be 
completed before attempting to conceive; if this is happens, women may find themselves 
pregnant after a long gap since the last screening visit, and this may contribute to 
increased anxiety for the duration of the pregnancy and breastfeeding months. 
 For some carriers, awareness of the inability to undergo cancer screening during 
gestation/breastfeeding contributed to childbearing decision-making. Elaine indicated that 
this led her to have no additional children: 
I don’t want to take the risk. I hate the idea of being pregnant and not being able 
to have screening, and then having to choose maybe not to breastfeed because of 
wanting to have my breast MRI and stuff. I know that I don’t want to put myself 
and my husband through that, so this has kind of made our decision not to have 
any more children. Why not get [the surgery] now? I know there are risks of 
osteoporosis and heart disease and stuff like that, but I figure it’s less of a threat 
than the ovarian cancer. 
Elaine, 34 
Similarly, Leigh stated: 
Certainly, since I already had a very nice family, finding out that I had a mutation 
[was] a factor [in deciding] to not have more, because I have read of all those 
issues where breast cancer may sometimes be triggered by pregnancy, and you 
can’t screen well during breast feeding, which was always very important to me. 
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So I think it would have been a lot more stressful to have another child knowing I 
was a mutation carrier. 
Leigh, 35 
 Jane recalled her frustration at not being able to continue screening during her 
pregnancy, and the resulting anxiety: 
I breast fed my daughter for the first six months, and I think that’s something that 
was very, very, challenging to get doctors [who] are willing to do screenings 
while you’re still lactating. I was able to do a mammogram, but when I met with 
the radiologist, it was the most unprofessional experience I’ve ever had. We were 
arguing with each other, I was in my robe ready to have a mammogram done and 
she said I couldn’t have a mammogram because I was breast feeding and it wasn’t 
going to be a reliable reading because a lot of the breast tissue obviously is so 
different when you are breast feeding that it could mask a cancer that you 
wouldn’t be able to see on a mammogram. So, I think in the professional 
community, there seems to be a lot of discrepancy and uncertainty about what to 
do with lactating women who are high risk for breast cancer. 
Jane, 30 
Jane’s wish for uniformity among medical professionals regarding breast screening for 
lactating BRCA-positive women is a valid request; most doctors will not, in fact, perform 
regular breast imaging during lactation because images produced are unclear and not very 
useful; rather, they rely on self and clinical breast exams, and may recommend that 
women take this extended period of problematic imaging into consideration when 
deciding how long to breastfeed (Eitan et al., 2009).  
Beth recalled how her physician’s policy regarding lactation and screening 
interfered with her plans to undergo RRBM. She stopped breastfeeding earlier than 
planned so that she could proceed with RRBM, primarily because her older sister had 
recently been diagnosed with breast cancer and Beth’s perceived risk was quite high. She 
recalled: 
I finally stopped it and I called my doctor and I said “OK, I stopped breast feeding 
today, I want to make an appointment for imaging.” And at first, she said, “We 
want to wait until you have your period, until you’ve been done breast feeding for 
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two months before you have imaging.” And I was so mad because I knew I would 
have to wait about a month between stopping breast feeding and having imaging 
done, but I was so mad that she wanted me to have two periods because I hadn’t 
had any periods at all and I didn’t know when I was going to get it, and I didn’t 
want that to push back the surgery. So I was mad. I called her back after a couple 
weeks, I’m like, “This is ridiculous, my sister has an aggressive cancer, I don’t 
care if the imaging isn’t going to be perfect, I’m going to have this surgery no 
matter what. So, to me it doesn’t matter if the imaging is crystal clear or not … 
It’s a screening.” So they finally said OK. 
Beth, 30 
The experiences of each of these women illustrate how ambiguous expectations about 
cancer screening during breastfeeding, or a mismatch between a patient’s and doctor’s 
ideas about how to manage these competing demands, can create anxiety, frustration and 
anger. If Jane and Beth experienced a deficiency of clear information on this subject from 
their physicians, it is likely that other women have experienced this as well. 
Choices and Life Trajectories 
 Among young women in the general population, contemplating the timing of 
major life transitions, including family formation, is a common preoccupation, as they 
navigate the period during which many components of adulthood (e.g., partner, career, 
family) are becoming solidified and synthesized (Arnett, 2004). Women consider these 
decisions both independently and in the context of their ongoing relationships. BRCA 
mutation-positive women in their twenties and thirties are no exception; however, their 
decisions and the factors they must weigh in making them are complicated because of 
limits imposed by their mutations. Women who are not BRCA-positive face the likely end 
of fertility potential at the point of natural menopause13, which might allow 20-30 years 
during which biological childbearing can occur. This relatively nebulous “window of 
                                                 
13 The current average age at menopause in the US is 51.3 years, with peri-menopause beginning on 
average at age 47.5 (McKinlay, Brambilla, & Posner, 2008). 
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opportunity” for having children affords the luxury of casual decision-making, or even 
choosing not to make decisions, i.e., allowing conception and childbearing to happen 
naturally or without a great deal of planning. In contrast, BRCA mutation carriers 
navigate young adulthood aware that RRSO or ovarian cancer may end their fertility at 
age 35 or 40. This results in as few as 5-20 years of fertility potential, once they decide to 
have children.  
Werner-Lin (2008) referred to this phenomenon as the “compressed family life 
cycle,” contending that “salient issues associated with carrying a BRCA gene alteration 
shift at each stage of the life cycle. … [and] that developmental concerns play a 
significant role throughout the lifespan when considering genetic risk,” (p. 432). Data 
from the current study suggest that a more focused way to conceptualize this 
phenomenon might be to consider how awareness of positive mutation status brings about 
changes to life trajectories (Elzinga & Liefbroer, 2007). In recent years, a focus on life 
course trajectories rather than the individual or family life cycle has arisen from a 
recognition that societal changes such as cohabitation, delayed age at first marriage, and 
alternative family forms have “led to an increased de-standardization and increased 
complexity of the transition to adulthood (Elzinga & Liefbroer, 2007, p. 226). This part 
of the life course is no longer best understood as an element of a cycle that is repeated 
over generations; rather, it is a highly individual set of choices made in the context of the 
unique set of circumstances in which a given person is situated. Each person, then, must 
select his or her own paths for career, relationships, and family as they move through the 
lifecourse, and these paths may diverge, overlap, or change course at various points and 
for a wide variety of reasons. Knowledge of oneself as BRCA mutation-positive would 
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certainly qualify as a piece of this tapestry, and it is inarguable that possessing this 
knowledge necessitates decision-making about paths taken in young adulthood. Women 
who know themselves to be BRCA-positive must take this information into consideration 
as they select, create, and modify their life trajectories. 
Existing data suggest that BRCA-positive women often consider how the need for 
and timing of RRSO and/or RRBM will affect their family formation plans (Hoskins et 
al., 2008; Werner-Lin, 2008). RRSO definitively ends the ability to bear children 
naturally14, and RRBM eliminates breastfeeding (the importance of which varied among 
participants). In addition, several participants were aware that they might die prematurely 
from BRCA-related cancer, as had happened to family members. These women were 
aware that delaying childbirth might give them less time with those children.  
Several participants recalled transitioning from not relating their positive mutation 
status to concrete ideas about family formation, to a time when these two issues became 
inextricably linked. This transition often resulted from assembling information about the 
implications of their mutation from multiple sources, gradually achieving more complete 
understanding of the myriad ways in which their mutation might alter their life plans. 
This was described as a lengthy process during which realizations about needing to 
accommodate life plans to their mutation occurred at various developmental points 
throughout young adulthood. Alternatively, some participants made one seismic shift 
from their pre-BRCA to their post-BRCA lives, reorganizing all of their plans in one fell 
swoop. In either case, this shift represents a point at which mutation-positive women 
must contemplate their life trajectories, and those paths might have to be different than 
                                                 
14 Theoretically, as long as the uterus is intact, it might be possible to use assisted reproductive technologies 




what was previously planned. For example, a woman who planned to pursue several 
years of post-graduate education and focus on career development through her twenties 
and into her thirties might have envisioned herself having her first baby at age 35; when 
knowledge of her BRCA mutation elicits a desire to have RRSO by age 38, her plan may 
no longer seem workable since it would only give her three years in which to commence 
and complete childbearing. Therefore, she may have to make changes and/or sacrifices to 
her educational and career goals in order to accommodate her family formation and risk-
management priorities, or alter her family formation goals if she is not willing to change 
her educational and career plans. Ultimately, these changes create an altered path, or 
trajectory, through young adulthood. 
Messages regarding family formation urgency reached BRCA-positive women 
from multiple sources, creating a complicated backdrop against which decisions were 
made. For some women, receiving and assimilating these messages conveyed a loss of 
control or decreased agency with regard to family formation decision-making. For most 
participants, it was stressful to receive consistent directive messages from medical 
professionals regarding how they “should” address their mutation-related fertility 
concerns, but this information did influence their decisions related to timing of 
pregnancies. Annie learned of her BRCA mutation at age 31, while childless and in a 
casual relationship. Certain that she wanted to have children someday, she felt pressured 
when the connection between being a BRCA mutation carrier and having children finally 
resonated: 
[The genetic counselor] wanted me to meet with an oncologist to talk about 
preventative chemotherapy measures that were available to me. And if I decided 
to go that route, she wanted to link me up with some fertility specialists, because 
of the risks there. That’s when alarm bells really started to go off. I had never 
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really put together A to B, B to C, to start thinking about it in those terms. You 
know, at that point, I was 31, single and I’m like, “Oh, Holy cow. Here we go.” 
This is not really the way you picture things working. It was my own sensitivity, 
being in my ‘30s and not being married with kids. There’s always a little bit of, 
“Okay. I don’t need somebody else telling me to get married and have kids.” I 
want to do it, don’t get me wrong. It was kind of that stereotypical, “Oh, my God. 
I’m turning into that, I’m becoming very sensitive. Is there a huge clock over my 
head that’s ticking even louder now?” 
Annie, 32 
 
For Melanie, messages about the urgency of completing her family so that she could 
proceed with RRSO came from the researchers with whom she interacted in the BI study: 
After we were married, we knew that prophylactic surgery, both the ovaries and 
the breasts are definitely an option for me. And so having kids is obviously 
affected by that, so we knew that we needed to get pregnant. And people at NIH 
said, “What are you waiting for, hurry up and start having kids.” So we knew that 
sooner was better than later. I’ve kind of decided I want to be done by 35. 
Ovaries’ll come out, and then we’ll decide about the mastectomy. 
Melanie, 30 
Melanie’s experience also opens the issue of how best to involve partners in the 
restructuring of family formation plans. This important dynamic was highlighted by 
numerous other participants, several of whom reported that being mutation positive put 
“a little more pressure to get your family started. And, indirectly, that puts pressure on the 
other person, too,” (Marjory, 30). Rose had just completed her RRBM when interviewed; 
at age 30, she and her husband had decided to proceed with this surgery before getting 
pregnant. She described the impact her mutation status had on her family formation: 
It’s been hard for my husband and I. This affects things you do in your life, and 
timing, because these tests are done when you’re making all these big decisions 
about reproduction. I mean that in a very medical kind of way. Because now that 
I’ve had the mastectomy I won’t breast feed. And, while I’m going through the 
surgery, we certainly won’t be trying to get pregnant … because I don’t want to 
be put under or taking pain medications while pregnant. I think the timing thing 
does play a factor, because if it’s hard to conceive then we’re kind of running out 
of years. I’ll be thirty-one later this year, and I’m thinking of wanting to do the 
oophorectomy at thirty-five, so it’s kind of a compressed window of time. So, 
timing becomes very urgent in a way, especially if we have any type of problems. 
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Suddenly everything becomes very compressed. It’s just this weird thing where 
getting testing and doing more mammograms are recommended all around the 
same time when people really start thinking about having kids and planning 
families. Maybe if I had made the decision when I was younger…I could have 
done the surgery five years ago, six years ago, and then it wouldn’t have played a 
role right now. Because, God forbid, it’s the last thing I want right now is to have 
issues with pregnancy. I’ve had enough issues with this kind of stuff.  
 
Rose clearly felt enormous pressure around having a family. She was fearful that if she 
did not become pregnant quickly, her available timeline would feel stifling, and she 
would likely experience a strong sense of failure and/or injustice related to struggling 
with another complicated reproductive health issue: 
People say there’s never a good time to have kids, so you have this other added 
variable. Well, I’d better have kids now, hurry, hurry, quick get it done. And, of 
course that kind of pressure can also be bad for trying to conceive. That’s kind of 
like the next stage I’ll be going through and I really don’t know if I can be calm 
about the whole thing. That I won’t feel so pressured. 
Rose, 30 
Participants reported worrying about their ability to raise children to adulthood 
before they are affected by a future cancer diagnosis. Serena, age 30, noted the 
importance of a trend in her family in which most women were diagnosed at a specific 
age, and how that “deadline” in her head translated to her concerns about family 
formation: 
I think especially now that I have hit thirty, I would like to have them sooner than 
later. … I want have kids while I still have the energy to have them. And… if the 
magic number in our family is age forty-six, I have sixteen years which means I 
could potentially see a good portion of my son’s or daughter’s life…if and when I 
get diagnosed, the hope is that I would be able to have as much time with them as 
possible, I guess. 
Serena, 30 
In the aggregate, the experiences described by these women illustrate the phenomenally 
complicated decision-making landscape surrounding family formation as a mutation 
carrier. To manage these conflicting demands, participants reported having considered 
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altering or having actually altered family formation timing, the number of children 
planned, or the priority they placed on breastfeeding. The remainder of this chapter will 
be devoted to describing how these decisions were made and, often, negotiated between 
partners. 
Controlling the Timing of Family Formation  
Many participants had general ideas about how the timing of pregnancy would be 
shaped by ideas or recommendations regarding the optimal age for risk-reducing surgery. 
Even those who were several years away from first pregnancy were aware of the limited 
time available to have children: 
My doctor did say that by my late 30’s they probably would want my ovaries to 
be removed as a precaution with the ovarian cancer, so that’s just something to 
think about as far as the timing. Not that I need to have children now, but just 
keep that in mind if that’s something that I do decide, that there is somewhat of a 
limited window…essentially a ten year window of opportunity from now.  
 
Julia saw this “window of opportunity” as workable at the time of her interview, since 
she was in a potentially long-term relationship. However, if this relationship ended, 
leaving her single in her later twenties, she might be less optimistic. In fact, Julia and her 
boyfriend had been unable to agree about whether they would have children: 
He does not want children and I guess I am still undecided. I’m not opposed to 
them but I’m not quite sure if that’s something that I want in my future. For him, 
if it happens it happens, but he’s not somebody that actively wants to plan or 
pursue having children. And he was very up front, he said “I [really] don’t want 
kids … and I don’t think that’s something that will change.”… I’m still undecided 
and not quite sure where I fall with that decision. It’s hard for me to say…“Kids 
weren’t meant to be.” So we haven’t really gone anywhere with it.  
Julia, 24 
Considering Julia’s position as a young, unmarried female mutation carrier further 
illuminated a couples dynamic discussed in Chapter 7: for those whose childbearing 
potential is definitively limited by a surgical risk-reduction timeline, establishing and 
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maintaining a relationship may be dramatically impacted. Having to tell a dating partner 
that one needs to accelerate relationship and family progression to complete family 
formation goals by a certain time may detract from young couples’ ability to experience 
natural relationship development, as described by Kristy (see Chapter 7). 
Rylan provided an example of how some carriers carefully consider and construct 
the most workable timing of family formation within their couple relationships. Engaged 
at the time of her interview, she reported: 
We’ve already had lots of conversations about it. And I know he wants to have 
kids, for sure, and I’ve never been as gung-ho about kids as he’s been. It’s going 
to make us decide when to have kids, when to stop having kids, when I can have 
my ovaries removed, which is recommended by age 40, and I’m 34, so it kind of 
leaves me with literally a biological clock that I have to keep up with. How long 
are we going to wait to have kids, and how many are we going to have and how 
quickly will we have them, and when am I going to have my ovaries taken out, if 
at all, which I really want to do as soon as I can, but we also want kids. And I’m 
also more open to adopting, and he really isn’t as open to that, I think his 
background and culture and family have a lot to do with that. 
Rylan, 34 
Because Rylan had already completed her RRBM, her primary risk-management focus 
was the RRSO she planned for age 40. Her description of her literal biological clock was 
another powerful illustration of the intensity of this issue, and also illustrated the manner 
in which some women pulled their partners in close around BRCA-related concerns, 
making decisions at least in part based on what their partners thought or wanted. 
Once they have achieved a personal understanding of how their mutation status 
will shape their family formation decisions, participants began to make specific plans 
regarding the timing of both childbearing and risk-management interventions. For many, 
reaching these conclusions was described as the outcome of a process in which they 
absorbed as much information as they could find (or tolerate) from various sources, and 
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then identified the critical or pivotal piece of information. This was characterized as a 
gut-level sense of what “felt right” to each individual, i.e., the result of understanding 
how one feels, rather than what one rationally thinks or what the objective facts or data 
suggest is the optimal choice.  
Reorganizing one’s assumptions and plans about when biological childbearing 
will occur is a complicated and challenging task. However, doing so effectively is one 
primary way that women attain a sense of agency regarding the threat of cancer; in the 
context of a couple relationship, this may also provide an opportunity for building 
closeness between partners. In choosing which path to take, some participants allowed 
their plans for risk-management to shape their decision-making about family formation, 
while others looked to their family formation preferences to guide decision-making about 
risk-management. 
Prioritizing timing of childbearing over risk management. Represented by a 
notably small group of participants, some women concluded that the need to undergo 
risk-reducing oophorectomy would not alter their family formation plans. Noelle reported 
having always wanted to have children at a relatively young age: 
I’d love to have like two or four kids, and have them while I’m relatively young. 
I’m 26 right now and I’d like to have my first child by the time I’m 28. And then 
as soon as I could physically handle it, I’d start having the surgeries. I’m planning 
to do both surgeries, and wait until after I’m done with all of my childbearing. 
[That plan is] not any different than what I wanted before I knew about the 
mutation. The mutation just makes it more important. 
 
Noelle understood the need to implement a cancer risk management plan and how it 
would overlap with her family formation desires, but denied any intention of changing 
her pre-BRCA plans. However, her increased awareness about the urgency of completing 
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her family formation goals had created a difficult dynamic in her relationship with her 
boyfriend: 
I think this whole thing scared him, especially when I know I want to have 
children by the time I’m 30, or that I want to be pregnant for the first time by the 
time I’m 30. And I want to start having surgery when I’m 35. Those things scare 
him to think that there’s a deadline. And instead of approaching it with, “OK, well 
if there’s a deadline, let’s map it out,” he’s thinking, “Oh, my God, back off.” He 
doesn’t want to even think about it. Where to me it’s life and death, sadly to him, 
it’s something that is so upsetting he can’t even think about it. 
Noelle, 26 
Given Noelle’s relatively young age, her partner may be able to work through his 
difficulties with her compressed family formation timeline, permitting them to reach an 
agreement about how to proceed. However, if this does not occur, Noelle could face the 
difficult position of looking for a new partner when she is older, and with fewer years 
remaining prior to undergoing RRSO (planned: age 35).  
Like Noelle, Rylan felt that family formation timing decisions should take into 
account, but not be primarily driven by, RRSO timing. She described other priorities that 
she and will consider in deciding when to have children and when to undergo RRSO: 
I think both of us want to have some time with each other after marriage before 
we have children. … we haven’t made any decisions now, and I think [that]… 
would be too premature, anyway. I don’t plan that far in advance, really, in any 
area of my life, and this isn’t any different. I think we haven’t any idea of what 
things will be like a year or two or three from now, like financially, whether we’ll 
be ready for kids or not, and that’s very important to me. I want us to have a really 
stable environment for them, and we can’t know that right now… I think we’ll 
just have to cross that bridge when we get there, leave things a little up in the air 
and sort of open-ended as far as my ovarian surgery, but I think that’s just the way 
things just have to be. 
Rylan, 34 
Having already completed RRBM, Rylan’s relatively relaxed attitude about her family 
formation timeline may be related to her significantly decreased perceived risk of breast 
cancer; and the absence of ovarian cancer in her family; thus, her overall perceived 
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cancer risk was likely lower than for participants who felt high ongoing vulnerability. Her 
experience illustrates a balance of agency (ensuring reduction of personal cancer risk by 
controlling what happens to her body and when) and communion (making these decisions 
in the context of a loving and supportive relationship, with thoughtful consideration of 
her partner’s perspective). 
Prioritizing risk-management over timing of childbearing. More commonly, 
participants actively made changes to their family formation timing to accommodate their 
desire to undergo RRSO. Strategies used included having children earlier than previously 
planned, and having children in quicker succession (minimizing time between 
pregnancies). For some, this latter decision was made at the outset of family formation, 
recognizing the relatively short available time to have multiple children given perceived 
RRSO deadlines. Several participants who foresaw RRSO in their future felt a sense of 
urgency to commence or complete family formation, and pinpointed specific deadlines by 
which childbearing would be complete so they could proceed with risk-reducing surgery: 
I’m…concerned about when we’re going to have kids…we’ve already talked 
about having two kids, and ideally I would like to be done by 35. At this point it’s 
probably going to be [more] like 36 because I really want to have an 
oophorectomy as soon as possible. 
Sophie, 31 
For many participants, this sense of urgency was driven by their understanding that 
ovarian cancer screening techniques are very ineffective, making RRSO the best defense 
against cancer at that site, as discussed in Chapter 6. Reina, who had not children when 
interviewed, illustrated this: 
[Paul] and I have both had the conversation that our family will be complete 
before I’m 40 because I do have the desire to have my ovaries removed when I’m 
40. Maybe there will be a lot more changes over the next ten years, which I would 
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love to see, but at this point the screening techniques for ovarian cancer are not as 
good as for breast cancer. 
Reina, 29 
Recognizing that decision-making about family formation would be an ongoing process, 
several participants noted that conversations and negotiations around this topic would 
likely be a feature in their couple relationships for the foreseeable future:  
…Unfortunately, BRCA is the gift that keeps on giving and we’re going to have to 
stay on top of a number of things, most specifically my ovaries. And that’s going 
to be a decision that affects him very directly because of the involved choices 
about reproduction. So I think a lot of the big choices in our lives that we thought 
would happen either by mistake or with a little bit of forethought, now I’m going 
to be considering in a totally different light just given my deadline of having my 
ovaries removed by a certain age. 
Pauline, 30 
Pauline rightly expects that she and her partner will have to make careful, thoughtful 
decisions about how and when to achieve their desired family size, and that this will 
require them to continue to discuss these issues actively rather than relying on chance or 
more spontaneous choices to determine what they do. 
The decision to alter one’s family formation plans may require some juggling and 
even some tough decisions with respect to the other goals that young women wish to 
accomplish during young adulthood. This nexus is particularly evident in 21st century 
America, with women increasingly choosing to pursue higher education, be independent 
longer, and/or marry and have children later (Arnett, 2004). For MaryAnn, a conflict 
developed surrounding her educational and career goals: 
When I was younger I had always assumed that I would settle down in my late 
20’s, but now that I’m back in school that’s kind of been pushed further into the 
future. We were always waiting for the right time … so I was thinking early to 
mid-30’s would be good, I didn’t have any feeling of rush. Now, knowing that I 
have a BRCA mutation, I’ve tried imagining the future and the timing of things. 
They recommend the [RRBM] by 35, and they recommend getting your ovaries 
out by 40 if not sooner. So then you have to do the math in your head. Let’s say I 
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finish my PhD at 30 or 31, plus a really busy post-doc for two years. So that puts 
me at 32 to 33 with surgeries looming really shortly thereafter. And it’s just not a 
big window … I had to start thinking about it more. Maybe I’m going to have to 
be more flexible; maybe I shouldn’t wait. So now being in school and having a 
family at the same time, I would be open to it. In grad school, no time is an 
awesome time, but … maybe writing would be easier because I could be home 
when I do it. I wouldn’t be opposed to having kids in grad school, but I would still 
try to wait for a better time.  
MaryAnn, 26 
Changing their plans regarding when to start a family is a complex task for MaryAnn and 
her fiancé; it requires not only a shift in what MaryAnn had planned for herself 
professionally, but significant shifts for her fiancé as well. Like MaryAnn, Lynn also 
noted that the time constraints imposed by her BRCA mutation intersected with her 
educational and career goals: 
You get told these statistics, and time tables of suggestions of when you should 
have your kids by. It was a little bit stressful because it definitely put more of a 
time restriction on my life. I even joked with my mom, ‘I want to go to med 
school, I won’t be [done] until I’m 32. That’s going to give me like a three year 
window to find a husband and to have my babies.’ 
Lynn, 24 
The challenge facing Lynn may be more formidable than MaryAnn’s: although younger, 
Lynn was not in a serious relationship and therefore saw less flexibility in her options for 
accomplishing her family formation goals. Sadie also remembered that her educational 
and career goals had been in conflict with family formation plans:  
When we first got married, I had gone back to school. Our plan was … [to] be 
married for a couple years, I would get out of school, and then we would start 
having kids. And that changed overnight. Immediately, I started thinking, “Why 
are we waiting to have kids?” It was always financial … I would be out of school, 
we would have two incomes, we’d have more money, we’d be able to provide 
better. And then I started thinking, “Well, a kid doesn’t care how much money 
you have. They just care that they have parents that love them and all that stuff. 
And it’s never going to be the best time to have a kid. There’s always going to be 
something that you’re going to have to change in your life in order to make room 
for kids. Why don’t we just start making changes now?” … So I approached my 
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husband and said, “I don’t think we should wait. I think we should just start trying 
now and see what happens.” 
Sadie, 33 
These three women demonstrate that some young female BRCA mutation carriers choose 
to pursue education, career and family formation goals simultaneously, a considerable 
shift from historical notions regarding when and how these major life events would 
occur. Making this shift will likely have significant positive and negative implications, 
and create a need for ongoing navigation and balancing of priorities. 
 Telling one’s partner of the desire to alter the timing of family formation can be a 
formidable task for young BRCA mutation carriers, especially in the context of a new or 
developing relationship. This is nicely illustrated by Marjory, who described the great 
care she took in conveying her ideas to her committed partner about when to have 
children: 
I haven’t talked to him about the oophorectomy. He knows we have a limited time 
to have children, but I don’t think he realizes that I’ll have to have the surgery 
sooner than later. And so, that is something that will come up. But I don’t want to 
put too much on him at once. I’m kind of careful when we talk about this, and 
how much we talk about. I don’t want to freak him out. And so, that particular 
discussion has not happened. In general, he knows that I’ll get rid of my ovaries at 
some point, but I don’t think he realizes it could be in five or ten years. So that’s 
something in the future we’ll probably talk about. 
Marjory, 30 
Marjory’s experience conveys the perceived high stakes related to negotiating family 
formation timeline changes. Despite hers being a very solid, happy relationship, she still 
felt compelled to carefully regulate disclosing the details regarding what her risk-
management plans would mean for her fertility potential. This contrasts significantly with 




Women who were single when interviewed provided a unique perspective 
regarding the role they envisioned for future partners relative to the timing of family 
formation decisions. Lynn, in a casual relationship when interviewed, had given 
extensive thought to how she might broach this topic: 
I will let [my partner] know that [having] this mutation suggests that I have my 
kids by the time I’m 35, maybe I can stretch it out a couple extra years. I would 
just tell him, that’s the situation. I do want to have kids, and hopefully that person 
will understand. But I won’t know until I get there, and the best thing I can do is 
just be honest and up front about all that stuff. I’m only thinking I want two, 
maybe three, so there might be several years where I’m making baby after baby. 
Lynn, 24 
Lynn’s perspective at this point in her personal and relationship development was that the 
decision-making was her responsibility, while her partner should simply accept the 
decisions she has made. It is interesting to speculate regarding how Lynn’s preconceived 
notions will actually align with the preferences of the individual with whom she 
ultimately partners. Her definitive ideas about his role, if unchanged, could create a 
problematic couple dynamic, or might limit the pool of eligible partners.  
 Unique circumstances in some participants’ lives and relationships have 
significant bearing on when they will begin or complete their childbearing and undertake 
RRSO or other fertility-abrogating risk-management options. Kate had two young 
children and was getting divorced when she learned that she carried a BRCA mutation. 
Although she did not expect at that time to remarry or have additional children, she met a 
man with whom these options seemed appealing and was planning a life with him. She 
spoke about how her risk-management timeline added some unique points to navigate as 
they made decisions about how to move forward together: 
Because I am planning on having my ovaries removed when I am 40, our timeline 
is to have [a baby] sometime in the next three years, because I want to be past 
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infant stage if there are any effects of menopause that are challenging. Our 
preference is to be married first, but if it were to happen that a baby came along 
first, then that would be fine as well. Mostly because of my divorce and him 
having waited so long to get married in the first place, we’re not in a big rush to 
get married. But at the same time, being that we’re both a little older, we don’t 
want a super-prolonged dating relationship before we get married. A year or two 
and then get married, and what we have planned is that right after we get married, 
we’ll start trying to get pregnant. 
Kate, 35 
Not surprisingly, choosing to have children sooner than one might have otherwise 
done leaves some women feeling that they and their partners are taking this significant 
step forward prematurely. For example, Pauline had 
always allowed myself to imagine having children much, much later … I honestly 
did not think that we would even have the discussion about having children very 
seriously before our fifth wedding anniversary. … And so, that would have put 
me right at thirty-five. … But unfortunately, BRCA changes a lot of things having 
to do with our family planning picture. It hasn’t necessarily accelerated the desire 
for us to start a family, which is difficult because you don’t want to start before 
you’re ready. But it does put a deadline on our family planning in a way that we 
didn’t really have before. I would want to become a mother for the first time at 
forty-four … that sounds like when I’ll be ready. But a bummer of BRCA is that 
that’s no longer a possibility. So, we just started talking about it, we’re still not 
ready but instead of the five-year window … we’re thinking more like three years 
before we start … planning and trying. 
Pauline, 30 
While this might seem like a reasonable strategy for reducing the perceived time pressure 
to accomplish family formation goals, it could present other problems if the feeling of 
being “not ready” persists after children arrive. In addition, some couples may not agree 
about speeding up their timeline and having children earlier, and there is definite 
potential for this to cause relationship problems. Though she did not describe this as a 
serious problem, MaryAnn alluded to some incongruence of opinion between her fiancé 
and herself: 
My fiancé is a little bit more reluctant because he’s not ready whatsoever. I don’t 
even think I’m ready, but I mean, who is ever ready to have kids? I don’t know. I 
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still think that he feels that early 30’s would be more appropriate. So I feel more 
pressure than he does right now. 
MaryAnn, 26 
MaryAnn is certainly not alone in reporting disagreement between partners 
related to family formation planning. Marie and her husband had planned to wait until 
they were both finished with graduate school to have a second baby, but, after learning 
about her mutation, she felt strongly that she wanted to do so immediately. Asked how 
her husband felt, she stated, “I wouldn’t say he’s terribly excited. I think he knows what 
has to be done because of necessity, but it’s just so different than what we were originally 
going to do, so it’s scary. It’s all just crazy” (Marie, 28, married). Maelie also 
remembered having had some disagreement with her partner on this issue. She felt 
strongly that she wanted to have both risk-reducing surgeries as soon as possible, largely 
because her older sister had died at age 32 after two breast cancers, but still wanted a 
relatively large family: 
We definitely did have kids sooner. We had our master plan of waiting three to 
five years before we started having children, and we’re just coming up on our 
fourth wedding anniversary and we have three kids already. So it definitely sped 
that up, and we knew we wanted them, so let’s take care of it so we don’t have to 
go through the same fate that my sister and her family did. I had to do a little bit 
of pushing. My husband would have been fine to wait a couple of years, but I 
didn’t feel comfortable with that. 
Maelie, 33 
Maelie changed her family formation timeline by having children earlier than planned, 
and having them close together. Her two older children were born only 11 months apart 
and in the same calendar year. Having “pushed” her husband to begin childbearing 
sooner, she reported that they were both thrilled with the family they had created and 
happy to have been able to put both risk-reducing surgeries behind them while Maelie 
was still relatively young. 
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This complex and multifaceted decision is not an easy one to negotiate, and there 
is no one solution for all couples. Some of these difficulties are due to suboptimal skills 
in communicating about and processing the demands related to this issue. For some, 
effective psychotherapeutic care could be helpful in overcoming these challenges. 
Providing mutation carriers and their partners with access to therapists specifically 
trained to deal with these issues could pave the way for healthy and adaptive coping, and 
provide potentially critical support during a stressful decision-making process. 
Spacing between children. As previously stated, reducing the time between 
sequential pregnancies is can be a useful strategy for completing childbearing goals prior 
to undergoing RRSO. Libby had temporarily put her family formation plans on hold 
while she completed RRBM, and was anticipating using fertility treatments to 
successfully conceive. She shared her thoughts about how she and her husband would go 
about timing multiple pregnancies over the next several years: 
[After the first baby,] I would start [fertility treatments] again as soon as possible. 
I kind of want to get it done as quickly as possible, and then get my ovaries out. 
Just be free to be done with my ovaries, and then maybe get them out around 38 
or something. Some doctors have told me 40, but I don’t know. Something around 
there. Once I get started having children, I want to do it more quickly, but having 
the mutation didn’t push us to start having children sooner. 
Libby, 32 
Like Libby, Acacia reported having decided early on to have two children quite close 
together so that she could complete gestation and lactation and move forward with both 
risk-reducing surgeries: 
I think we would have probably spaced another half a year to a year out. We 
always knew that we wanted to do either zero or two [kids], so once we had our 
first daughter, we talked about having a second. The ideal situation would have 
been two-and-a-half to three years apart rather than almost two, but the mutation 




For some women, the specific decision to have children closer together was made 
because their mutation was identified after starting a family, so that commencing 
childbearing earlier was not an option. Thus, Rachel, who felt an extra sense of urgency 
about having her second baby after learning she carried a BRCA mutation because she 
had required assistance from a fertility specialist to conceive her first baby. She recalled 
discussing the timing of a second baby with her husband: 
When I told him the results, I said, “Well, if we want to have a second one, they 
want me to have these surgeries before I turn 35. If I’m going to do that, and it’s 
going to take us three years to get pregnant again, time’s ticking.” So I just sort of 
presented it that way and said, “I’m going to call the infertility doctors again and 
see if they’ll take me back,” and he’s like, “Yeah, whatever.” So I did. And we 
did. 
Rachel, 33 
Interestingly, Rachel attributed her husband’s seemingly disinterested response to his 
normal manner of handling difficult topics, and was not at all troubled by his lack of 
input. She was simply happy that he went along with the new timeline she had suggested. 
The mother of one when she learned about her mutation, Marie explained her 
decision to move her plans for a second baby up by several years, and how that idea was 
received initially by her partner: 
Our whole plan before we knew about this whole genetic thing was, we would 
probably wait until she was five or six and we would either be finished with the 
PhD or be closer to being finished. But now I don’t feel that way. I feel like I 
really want to have another baby. I’ve always wanted to have two kids. As soon 
as I got those results I told [my husband] that I’m going to stop taking birth 
control and I really want to have another baby. And he was kind of panicking 
because he is looking for a job right now … he is transitioning from finishing 
school to being in the job market. We’re pretty much completely unstable as far 
as finances and having anything concrete that you could depend on. It pretty much 
sounds like a real crazy idea, because basically I would be trying to get pregnant 
over the summer, continuing teaching, pregnant, and doing my coursework and 
everything, and doing my research. But from my recent experience of cancer and 
seeing how life is so short, I think that that’s the most important thing to do. I’m 
always talking about trying to get pregnant in this window, and it has everything 
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to do with the mutation, because that decision was made based on the results from 
the genetic tests. 
Marie, 28 
For Beth, who unexpectedly became pregnant before she was married, thinking about the 
timing of a second pregnancy overlapped significantly with her high perceived risk of 
cancer, which stemmed from her recent experience watching her older sister battle 
chemotherapy and mastectomy after a breast cancer diagnosis: 
I would want to start trying immediately after we get married. I don’t think it 
would take us a long time, but if it takes us a while to get pregnant then we’ll 
have time. Just knowing that I’m going to have to have my ovaries out… just to 
give us enough time to have a second child. I kind of do feel like I have to hurry 
up and have an oophorectomy. I just don’t want to put it off and put it off and 
then what if I get ovarian cancer when I’m 35 and I was planning on having an 
oophorectomy when I’m 35 ½? So I do feel like everything is a little more rushed 
than I would like. 
Beth, 30 
Shannon noted how her BRCA mutation was one of several factors influencing her and 
her husband to proceed with a second pregnancy soon after their first: 
[The mutation] was definitely not the only factor. It was probably more the fact 
that it took a little while to conceive my son and I didn’t want to go through that 
waiting again. That was probably the biggest factor. And then, we knew we 
wanted a second child and we were already living in a home we planned on being 
in a long time. So, as far as stability goes, we were ready to provide that. And 
then, having the additional information about the gene mutation was just an added 
factor to all of that. 
Shannon, 31 
Finally, Rachel recalled her initial belief that being a mutation carrier should not translate 
into an accelerated pace of family formation, and how that changed after she and her 
husband thought carefully about the implications of having had to use fertility drugs to 
conceive: 
It was almost, in a roundabout sort of way, a little bit of denial because I thought, 
“It’s not going to change my life right now.” But then it did, because I decided 
that with all of the information I had been presented, that perhaps we needed to 
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move our family on the fast track. And I was also referred to a gynecologist 
oncologist, and he started talking about the risks and what he wanted to do, and 
the fact that I have PCOS15 which meant that with both my babies I was on a 
significant amount of fertility drugs … there is still no real knowledge as to what 
being on the fertility drugs does to you. It’s great that they got me pregnant, but 
especially in a BRCA patient, is that increasing my risk? And we still don’t have 
the answer to that. But that was definitely something that this gynecological 
oncologist made me take a step back and think about. So with that in mind, we put 
the second baby on the fast track and when my daughter was only 51 weeks old, I 
went back into the fertility program to try to get pregnant a second time. I can tell 
you I didn’t want two kids in 20 months, which is what I had. I wanted time to 
enjoy it being my daughter and my husband and myself. I wanted time to figure 
out how you deal with having a baby. But finding out that information, I truly felt 
like I was a ticking time bomb. I decided that was something that I needed to 
move along and make it happen a little bit faster than what I had originally 
intended. 
Rachel, 33 
Rachel’s experience is analogous to women and couples choosing to proceed with family 
formation before they were ready. Rather than starting her family early, Rachel chose to 
expand her family sooner than planned, with clear implications for her relationship with 
her daughter and her idealized notion about what the early years of parenthood should be 
like. 
For some participants, having children closer together was chosen because it 
would allow them to be flexible with total family size. For example, Wanda had a clear 
age in mind at which she wanted to be finished with childbearing and proceed with 
RRSO. Unsure about whether they wanted to have two children or three, she and her 
husband chose to have the first two closer together so that there would be enough time 
remaining before the deadline age to have a third child if they decided to do so: 
I think even with the first, we knew the clock was kind of ticking. My mom was 
37 when she was diagnosed, so we want to make sure that we get our kids in 
before that. And then … between the first and the second, I think we both might 
have preferred to wait another year, but not knowing if we want to have three, we 
figured we’ve got to get them in now. [If I didn’t have the mutation], I think we’d 
                                                 
15 PCOS = poly-cystic ovary syndrome 
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have one at least, and I don’t know if we would have had the other one this soon. I 
want to have my ovaries removed when I’m like 35, is what I’m thinking now. 
And each year it gets closer and closer to that 35. I mean, obviously if we end up 
having a third, two years from now, I would breast feed and wait until I was done 
with that before I would have my ovaries removed. 
Wanda, 32 
Other participants reported not having changed their ideas about how closely to space 
subsequent pregnancies, but appreciating the benefits of having their children closer 
together as part of their pre-existing plan so that they could move forward with risk-
management strategies not conducive to ongoing childbearing. Shannon provided an 
example of this when she stated: 
We did have our two children pretty close together, but it didn’t have anything to 
do with that, per se. We were just ready to have another one. Our first child took a 
little longer than we had thought, so the second time around, we knew we wanted 
another one, so we just let it happen whenever it happened, and it happened … a 
lot quicker than the first one. But that worked out, too, because then I was able to 
start thinking more about having surgery after my kids were born. 
Shannon, 31 
All of these coping strategies illustrate how important time management became in 
making BRCA-related decisions, how pressured they felt as this process unfolded, and 
what a relief it was when there was unexpectedly more time available than they had 
estimated. Happily, participants were often able to identify positive aspects of having 
altered their family formation plans in response to the demands of their BRCA mutations, 
as Marie noted: 
I guess the only positive thing would be maybe that we are going to have another 
child soon instead of putting it off. I see other friends and couples that put it off 
because it’s not the right time, and then maybe they’ll never have a chance to 
have another child because they put it off too long. That’s kind of a blessing. No 




Independent family formation. The prospect of not finding a desirable partner 
before one’s perceived window of opportunity for childbearing closes may stimulate 
thoughts of how to get pregnant without a permanent relationship partner. This 
consideration is perhaps the most powerful manifestation of perceived need to prioritize 
managing risk over one’s preferences for family formation. Only two participants 
spontaneously discussed this topic, and their perspectives provide a useful contrast. For 
Isabelle, considering having a child without a partner was a significant departure from her 
previously held ideals about family formation, but it nonetheless was an acceptable 
option if she were still unmarried at a certain age: 
When I was much younger I always said that I wanted to be married, possibly 
pregnant by 21, because I just want to have a lot of kids. But after getting to 18, I 
realized how ridiculous that was. Now, at 22, would I have liked to have been in a 
relationship and possibly thinking about getting married? Yeah. I want to say by 
25 or 26 I would like to, if not be married, at least be in a serious relationship, or 
moving there. If not by 30, I know I would already either adopt or something, or I 
don’t know about artificial insemination, but at least on the boat to getting a kid 
on my own. 
Isabelle, 22 
Serena had also considered having a child on her own, but did not find it particularly 
appealing: 
Artificial insemination or [surrogacy] or something like that [is] a possibility. I 
don’t think I would actually do it though…because for me if I’m going to have 
kids, I want them to be a part of me and somebody else, somebody that I truly 
care for and love. So, I think that for me it would be really tough to do the 
artificial way. I don’t think I’d do it. 
Serena, 30 
It is interesting to speculate how BRCA-positive women might view these options as they 
approach the age at which they feel an RRSO should be done; perhaps the sensation of 
dwindling time for biological family formation would make independent family 
formation options such as artificial insemination or surrogacy more attractive. 
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Considering Isabelle and Serena, it is remarkable that the younger is the one who was 
open to independent childbearing; perhaps as women approach the age at which that 
choice must occur, it is a lonelier, scarier experience and therefore less appealing. 
Family Size 
 While changing or renegotiating the timeline on which family formation will 
occur is common for young women with mutations in BRCA, it is not the only strategy 
participants reported using to complete their families in an expedient manner and proceed 
to surgery. Many participants also reported having considered how the number of 
children they wished to have might be influenced by their mutation status. Participants 
who discussed decisions about family size generally approached this decision in one of 
two ways: by making their risk-management decisions in part based on their ideals about 
family size, or by regarding their plans for risk-management as urgent enough to warrant 
changes to the number of children they planned to have.  
Prioritizing family size over risk-management. As is well understood in the 
BRCA community, choosing to have risk-reducing surgery during one’s childbearing 
years has powerful implications for family formation. Young female mutation carriers are 
typically advised by their physicians to postpone RRSO until they are certain they have 
had as many children as they desire. For some women, this simplified short-term, risk 
management decision-making. Rachel recalled: 
At that point, I only had one baby, and all of these decisions were being presented 
to me, but I wasn’t ready to make a decision on any of this kind of stuff because I 
still wanted to try to have a second kid. So it was almost like, “Yeah, I’ve got the 
mutation, but I’m not doing anything about it, so carry on. I’ll go in for the six 
month checkup appointments if that’s what they feel I need to do but I’m not 
doing anything.” So in a roundabout sort of way, it was almost a little bit of 




Rachel’s certainty that having either risk-reducing surgery was inappropriate when she 
learned of her mutation was based on her choice not to have surgery before completion of 
childbearing16. Rachel also shared her thoughts about whether additional children would 
be a part of her future given the difficulties encountered in conceiving her first: 
I knew I wasn’t done trying to have kids. It was so much work to get my 
daughter, I had no idea I was going to have a second. But, I knew that I wasn’t 
ready to throw in the towel yet. 
Rachel, 33 
For some participants, making final decisions about the total number of children 
desired was the last remaining step before they could proceed with surgery. Wanda 
described her ongoing discussions with her husband about whether her current 
pregnancy, their second, would be the last: 
We’re trying to figure out how many kids we want to have, and we talk about, 
“Okay, when we’re done having kids, what are we going to do with me to make 
sure that I’m okay.” We’re pregnant with our second child right now, so we have 
been talking a little bit here and there about when we are going to decide that this 
is it, or we want one more? Because that’s about the point where we would 
probably go for the oophorectomy. 
Wanda, 32 
Like Wanda, Shannon was certain that she would eventually undergo RRSO, but was 
unclear about the timing because of lingering uncertainty about family size: 
The recommendation was before the age of 40. Or if I know that I’m done having 
kids, then do it at that time. So, it’ll definitely be before I’m 40. It’s just that 
we’re waiting to make that final decision about having another baby or not. 
Shannon, 31 
 As described in chapter three, Audrey unexpectedly learned that she was BRCA 
mutation-positive through genetic testing of her young son with Fanconi Anemia. He 
died at age two, following which Audrey and her husband struggled with whether to have 
                                                 




additional children, and how many. She shared her memories of delaying RRBM after 
unexpectedly learning that another baby was on the way: 
I was planning on doing the mastectomy after my daughter, but not the 
oophorectomy, and perhaps have more children. At that point, after my daughter 
was born, I think we were even almost done. It wasn’t even so much about not 
having any more kids. I really think that we were both getting to the point that we 
had our daughter, she was healthy, she wasn’t a carrier. …we can stop it. And 
then, about the time I got ready to say, “Okay, I’m going to start really getting 
more serious about this and what do I want to do? And how do I want to fix it?” I 
found out I was pregnant with my son. So then I was like, okay, well I’m not 
going to do anything right now. And then, after my son was born, I said, okay, 
now I’m really going to do something again. And so he’s getting ready to turn a 
year old, and I am six weeks from my prophylactic bilateral mastectomy. God 
willing, he just decided that he wasn’t finished. And gave us another son. And he 
was healthy – he was a carrier, but healthy. I guess [God] decided we just weren’t 
quite done yet. But, we definitely are now. 
Audrey, 28 
Audrey was scheduled for RRSO shortly after her interview, as part of the same 
procedure during which her breast tissue expanders were replaced with permanent 
implants. 
 Prioritizing risk-management over family size. Perhaps even more powerful 
than having one’s risk-management decisions influenced by family size, the reverse (i.e. 
having decisions about family size influenced by demands of risk-management) occurs 
for many women. Many participants experienced a time during which they questioned the 
appropriateness of having (additional) biological children, in the aftermath of genetic 
testing. Several participants cited their feelings that having more children would delay 
surgery, and this was a concern for their own health; others spoke more from a 
perspective that not having more children would permit surgery sooner. Chris wanted 
another child with her second husband, but he was significantly older than her, and this 
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desire was not congruent with his life plans. This age disparity added another 
complicating factor to Chris’s decision about whether or not to undergo RRSO: 
He said that if he was twenty years younger, he would want to have kids…he’s 
twenty years older than me. I had pushed him to get a vasectomy, and before that 
we had thought about freezing some sperm, just in case [we] changed [our] 
mind[s]. But I kind of know that he didn’t really want to have kids at his age, he 
wants to retire…It’s kind of hard because I think about having kids. I would like 
to have had another child. I knew that that wasn’t going to probably happen with 
him…But on the other hand…what if something happened? I was only thirty two. 
What if I got married again? Would I want another baby? Would I want to start 
over? Well, probably, yeah. But in the situation that I was in, married, he’s twenty 
years older than me, probably not. But, you just sort of never know, I guess, 
where life is going to take you. 
Chris, 33 
Ultimately, Chris and her husband decided that having a child was not the right choice for 
them, and Chris proceeded with both risk-reducing surgeries. Her clarity about wanting to 
start over were she to find herself in a different relationship in the future suggests that 
were that to occur, she may experience regret about having ended her fertility potential 
via RRSO. 
Sadie related a unique story about deciding whether to have children and its 
intersection with risk-reducing surgeries. After deciding to try to have a baby sooner than 
originally planned because of Sadie’s desire to have RRSO, she and her husband 
encountered significant infertility-related challenges. They tried solutions ranging from 
medical to homeopathic, and eventually: 
We had cut our losses and said, “Okay, let’s face the facts, four years, we have 
never ever gotten pregnant. This is probably it.” The idea would be that we would 
just hang out for a while, save some money and then go down the adoption road. 
 
Soon after making this decision, they realized that life without children might have its 
advantages. They focused on opportunities for travel, financial flexibility, and greater 
freedom that having children would not allow, and decided that if they subsequently 
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changed their minds, they could adopt. Making that decision allowed Sadie to move 
forward with RRSO at the age of 33, significantly younger than most BRCA-positive 
women. Sadie’s sense of fulfillment at having weathered this journey and having 
emerged with a set of decisions that truly felt like a good fit was remarkable: 
Ultimately, that feeling is just about me, really, and about coming to terms with 
that image that I’ve always swallowed hook, line and sinker my whole life is that 
in order to be a selfless person, we have to have kids and procreate and all that 
stuff. It’s been an interesting ride, definitely. But I am much more excited about 
being able to travel and see the world and spend time with my husband and be 
with him than I am about bringing in adopted kids from somewhere. And that 
may change. You know, when we get to be 40 or 50, we may be like, ‘oh, that’s 
the real meaning in life, having kids.’ And if that happens, we can adopt. There’s 
not a timeframe on that. 
Sadie, 33 
Although her sense of urgency regarding risk-reducing surgery was not the only factor in 
her decision not to have children, she clearly viewed the ability to pursue RRSO without 
regret as a positive outcome of her anguishing about family size. 
Trixie provided a final example of deciding not to have children because of one’s 
mutation status. Her decision stemmed from her experience watching her oldest sister die 
from breast cancer at age 32, four years after discovering a malignant tumor while 
breastfeeding: 
I was 20 years old and my sister was diagnosed with breast cancer out of the blue. 
She had just had a baby and they thought it was an enlarged milk duct. So, still I 
thought it was nothing. It sounded normal enough, from what my parents 
explained to me. And then it hit us like a ton of bricks when they actually came 
back and said it was cancer. We did not see it coming. 
 
Trixie then explained how her ideas about having children shifted toward remaining 




Even though I didn’t know my status, I’ve known I was high-risk since I was 20 
years old, and I really think that has played a role in my not wanting to have kids. 
I think because of my parents, the guilt that they feel and how sad they feel, I 
don’t want to feel bad. I don’t want to pass it along to anybody. I’m glad that my 
siblings have kids. I think they’re great. I love being an aunt, but myself, I just 
don’t know if I could deal with it. And then watching my parents watch their child 
die… I don’t know how people do it. And I think, subconsciously, through this 
whole process, that is what has made my mind up about kids. And [Mark] is also 
a very independent person, he’s just a take-off-and-go kind of guy. And he’s in 
his mid-40s so he has already passed that phase of his life where people normally 
have kids, and it just never happened for him. Never had the desire. 
Trixie, 27 
Trixie’s partner choice seems related to her desire to remain childless: she had selected a 
partner who was old enough to feel certain that he also did not want children. Having 
created a situation in which her decision to remain childless was not only accepted, but 
embraced, Trixie completed RRBM at age 27 and was actively considering RRSO when 
interviewed. Her relief at not having to worry about facing her sister’s fate was clear. 
 Aside from choosing not to have children, several participants reported having 
less drastically altered their ideas about how many children they would have based on 
their desires to employ surgical risk-reduction, and some participants who had not yet 
commenced family formation noted that they had considered this option. For example, 
Rylan noted that the number of children she and her fiancé ultimately decided to have 
would be an important consideration in allowing her to move forward with RRSO: 
I would love to have twins, that would be great because I do think we want to 
have two or three kids and the faster we can have them the better – then I could 
get my ovaries out. So that’ll be an issue, number of children, rate of birth, and 
adoption will be issues we might deal with in the future. We’ve talked about how 
it would be great if I could have twins and then have my ovaries out, and then if 
we decided we wanted more, we could adopt, or try to have one or two and then 
adopt more if we wanted. I think he wants at least one of his own, and then maybe 
I can negotiate with him at a later date about how many he really needs. I don’t 
really know how many kids I want right now, so I have no idea if I’m going to 




For Rylan, decision-making about family size was important not only because of her 
timeline for RRSO, but because she and her fiancé differed in their preferences: being 
from a big family, he preferred to have several children, while Rylan felt she might be 
happy with only one. 
 While Rylan was contemplating family size from the perspective of being 
childless, Jane provided insight into how decisions about family size might be impacted 
in women who have already begun childbearing. She reported that she and her husband 
might decide upon a smaller family than initially planned before learning that she was 
mutation-positive: 
When I found out about my mutation, we were already trying to get pregnant. 
Now we would like to have another child, but beyond that I don’t know that we 
will have more than one more, whereas before we might have considered having 
more than just two children. Before it was kind of open-ended, let’s see where 
we’re at with kids as we have them, and then maybe see if we want to have more. 
And now it’s kind of like, well, we’ll just have one more. And I read that the risk 
of breast cancer with BRCA2 increases with more pregnancies17, so that’s scary to 
me. And then the risk of a diagnosis is greatest within two to five years after a 
pregnancy. And I’m not sure if that’s related to hormones, or what the exact 
reasoning is for that. And then I think about whether or not to have my ovaries 
removed, and I know that the ideal is to have it before the age of 35, so that kind 
of all plays into it as well. 
Jane, 30 
Jane raised several important themes here. First, she described that her flexibility in 
family formation was reduced by being mutation-positive; rather than making ad hoc 
decisions about childbearing, Jane and her husband felt compelled to agree on total 
family size before they actually reached that goal, so that risk-reduction planning could 
begin well in advance. Second, she referred to another important dynamic surrounding 
risk perception and its connection to pregnancy and childbearing. Jane is concerned not 
only about how multiple pregnancies might increase her cancer risk, but also about 
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increasing the length of time during which she would remain at high risk if she were to 
continue having children. This will be discussed in greater detail later in this chapter. 
 Women who had completed childbearing recalled how this issue had played out 
for them. Having learned that she carried a BRCA mutation when she already had three 
children, Leigh shared her sense that the mutation was only part of her decision to have 
no more: 
If I wanted more, maybe I would have done it anyway, but it was sort of a small 
factor in favor of not having any more children. I’m pretty sure it wasn’t the 
deciding factor. Because I don’t think I could handle any more under any 
circumstances right now. 
Leigh, 35 
Similarly, Elaine’s knowledge about her mutation pushed her to decide definitively that 
she wanted no more children:  
One of the frustrating things in genetic counseling is that, over and over again, the 
genetic counselor and every provider says, “just make sure you’re done with child 
bearing before you go ahead and have an oophorectomy.” And it’s like, “Gosh, I 
was thinking if I was going to have another kid I was going to wait until my late 
thirties.” They don’t want to hear that actually this has made me decide not to 
have more children. But that’s a logical choice that I may not want to risk 
pregnancy, where your risk is just a little bit elevated, not having screening … 
Why risk it when I have three healthy kids? It’s even part of the consent, they ask 
you if you’re done with your child bearing. I understand they don’t want to take 
healthy ovaries out of a woman who may not be 100% certain, but this has made 
me certain. I wish that I didn’t have this and I wish that I could contemplate 
another child but this is a consequence of knowledge of this mutation. I think 
even before we [found out about the mutation] we were saying, “Okay, we’re not 
going to do this.” I think we were feeling like it was going to be too much. I think 
it would have been too much for my marriage and so even before I got the news, I 
had given away baby stuff. So I don’t want to make it sound like, “Oh, this made 
the decision.” It’s probably the nail in the coffin. You know, you can give away 
baby stuff but you’re still fertile. 
Elaine, 34 
Finally, making decisions about surgical risk reduction led some participants to 
doubt their pre-existing ideals about desired family size. Beth reported that what had 
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seemed like an autonomous family size choice now felt like a decision imposed by her 
BRCA mutation: 
Before this whole cancer thing I always just wanted two kids, and he just always 
wanted two kids, so that was great. Now, knowing that I’m going to have to take 
my ovaries out, and that once I do there’s never a chance to have another child, I 
keep asking him, “Are you sure you don’t want to have three kids?” And I don’t 
even know that I want three kids, per se, because of the expense and it would just 
be a lot, but just knowing that once they’re out, they’re out and there’s never 
another chance to have another kid – I’m sure that until I have that procedure 
done I’ll always ask him, “let’s have three, let’s have three.” It’s one thing if I 
have my ovaries we can both say, “We’re done, two kids is great, it’s our choice.” 
But by taking the ovaries out it’s like it’s not really my choice. It’s my genes, it’s 
the mutation, it’s the risk of cancer, the choice has been taken away from me and 
it’s all about the cancer. It’s not about what I want, or what he wants, it’s about 
the cancer. 
Beth, 30 
This is a powerful conclusion. As BRCA mutation carriers make decisions about their 
families and relationships based on cancer risk management priorities, their frustration 
over losing autonomy could be a potentially important phenomenon that might be 
usefully addressed by mental health professionals. 
Breastfeeding 
 Preferred timing of RRBM and the breastfeeding choices women make comprise 
a parallel set of problems to those just discussed. Weighing recommendations to 
complete RRBM as early as practicable against the desire to breastfeed – universally 
accepted as a gold standard for raising healthy children (Bonati & Campi, 2000; Oddy, 
2001; Scariati, Grummer-Strawn, & Fein, 1997) - creates a heart-wrenching decision for 
women who are struggling to make the best health care decisions for themselves and their 
children. The importance of breastfeeding as a unique and powerful bonding experience 
with their babies - an experience that some consider irreplaceable - cannot be denied. 
Worry about being able to provide the healthiest nourishment for their babies without the 
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ability to breastfeed was also a major concern, and this emerged most strongly from 
women who did not yet have children; they often idealized breastfeeding and powerfully 
lamented its loss. Participants typically selected one of three distinct paths: completing all 
childbearing and breastfeeding, and then proceeding with RRBM; completing RRBM 
prior to commencing childbearing; or undergoing RRBM in between pregnancies. 
Delaying RRBM until childbearing is complete. For some women, the desire to 
breastfeed clearly outweighed their urgency over mitigating breast cancer risk via 
RRBM; these women did not consider having RRBM until childbearing was complete. 
This decision seemed quite straightforward to Sophie: “I obviously don’t want to get any 
surgeries before having children.” Period. No ifs, ands or buts. Others, like Isabelle, who 
was still several years away from commencing childbearing when interviewed, discussed 
her wish to allow her breasts to fulfill their purpose before having RRBM: 
I do love my breasts, and I love them even more now, and do I really want to get 
rid of them before I get a chance to enjoy them for what they’re for? … I always 
knew that I wanted to have a lot of babies, and I know breastfeeding doesn’t 
always work for everybody, but that was always something that I wanted for me 
and my child, and would I be able to deal with the fact that I wouldn’t be able to 
do that later on in life? That’s also keeping me from rushing into prophylactic 
mastectomy. It definitely is a worry of mine. It’s like, well, God gave these to me, 
and I want them to do their job before I have to take them off. 
Isabelle, 22 
 When participants chose to complete childbearing before undergoing RRBM, they 
often did so with a sense that they were risking their own health to do so. This was 
illustrated in Chapter 5, where Melanie discussed her awareness of the limitations of 
breast surveillance during breastfeeding, and how influential that information was in how 
she would time pregnancies and decide how long to breast feed. Similarly, Shannon 
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shared her perception of her husband’s concern about these issues, and his eagerness for 
her to finish breastfeeding and move toward surgery: 
When I was breastfeeding our second child, he actually asked when I was going 
to be done with that so I could start making my doctor’s appointments. I know it 
weighs on his mind, too. And that was kind of my thought, was that I was going 
to finish breastfeeding the kids and then move forward from there. 
Shannon, 31 
Spacing between children, desire to breastfeed for as long as possible, and ability to 
screen effectively during childbearing years intertwined in Shannon’s decision-making. 
Many participants reported feeling much more confident about moving forward with 
RRBM after finishing breastfeeding. Marie, whose change in plans regarding spacing 
between children was discussed previously, described her confidence that she would be 
ready for RRBM after breastfeeding her next child: 
I think I probably talk about it every day. Because with this whole plan that I 
made for myself – which is still the same – I had said that if the results came back 
positive, I would want to have another child immediately. And then, I’m an 
adamant breast feeder so I really would want to breastfeed for a year or 14 months 
or whatever, and then get the mastectomy done. 
Marie, 28 
Rachel was several steps further down the same path; having already breastfed her two 
children for a satisfactory length of time, she described her readiness to undergo RRBM: 
I nursed both of my kids. Breastfed them both, and at the time when I was done, 
my son started to become a biter. So he actually got the breastfeeding taken away 
a little earlier than his sister did, because mommy didn’t have the patience for 
that. And once I was done nursing, I was kind of like, “What do I need them for 
anymore?” 
Rachel, 33 




Pre-pregnancy RRBM. In contrast, another group of participants preferred 
completing their RRBMs prior to their first pregnancy. Women choosing this option were 
quite heterogeneous in age and relationship status. They reported that after weighing the 
pros and cons, their sense of urgency to proceed with RRBM outweighed their desire to 
breastfeed their children. For some, this was a straightforward decision; others struggled 
to choose between these two important priorities. Monique was still actively considering 
pre-pregnancy RRBM when interviewed. With high near-term perceived breast cancer 
risk due to the very young age at which her maternal aunt was diagnosed, she discussed 
the pressure she felt from her family members to mitigate this risk by removing her 
breasts prior to having any children: 
A lot of people in family want me to have some surgery and I don’t know if I’m 
ready. You know what I mean, if I have a kid, breast feeding and stuff. So that’s 
the hardest decision, if I want to do this now or afterwards. I mean if I have to, I 
guess I will do it now, but my doctor said to wait so far. 
Monique, 26 
Like Monique, Charlotte was considering pre-pregnancy RRBM under significant family 
pressure: 
Previously, I was set on wanting to have children and wanting to be able to 
breastfeed … once I was able to do that, I would go ahead and have the 
mastectomies. Now I’m definitely getting a little stressed and tired of all the 
testing and wondering how much longer I want to do this. And there’s a little bit 
of pressure from my family, so now I’m considering doing it at a younger age and 
not necessarily having to breastfeed my children. I’ve talked about it with my 
good friend who lost her mom to cancer. It comes down to which risks I want to 
take – do I want to put myself at increasing risk every day, every year and not 
being there for my children? Or reducing the risk now being there for my 
children, but not having that breastfeeding experience? 
 
Charlotte’s inclination toward pre-pregnancy RRBM was influenced by her family, her 
desire for longevity, and escalating “screening fatigue.” This latter phenomenon, 
described in Chapter 6, is driven by cumulative experiences related to periodic breast 
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surveillance and the anxiety accompanying inconclusive results, repeated imaging and 
the occasional biopsy; this is commonly observed in young women who choose to rely on 
surveillance to manage their risk. Continuing to describe her shift in thinking, Charlotte 
went on to state: 
I look at it now as a smart choice, that I’d be reducing the risks. And I’m actually 
going to go meet with [my cousin’s] doctor in a couple of weeks … just to learn 
more about why he thinks 27 is the right age for me. So, I think if I were to lean 
toward that decision, it would just be because it seems like the smart thing to do, 
to manage my risk. But I think when it came to the point where I had children, I 
would definitely be pretty emotional that I wouldn’t be able to have that 
experience or provide that to them, because from my point of view, it can be 
healthy for them with their immune system and things like that. Going into it I 
think I would know that it would be hard at the time and maybe want to talk to 
some counselors about it or how to get through that just because I think I know 
that it would have a pretty big effect on me. 
Charlotte, 26 
Charlotte’s perspective suggests that she understands the gravity of the decision she 
faces, and is anticipating that the ramifications of pre-pregnancy RRBM might be 
difficult to deal with when she eventually has children. Her spontaneous identification of 
the need for psychosocial support suggests an unmet need for this population: 
comprehensive and specific psychosocial support from a provider who understands these 
complicated dynamics and decisions should be available to women in this population not 
just in the phases in which they are making these decisions, but also in an ongoing 
fashion as they continue to face challenges (both expected and unanticipated) brought on 
by decisions they have made in the past. 
Pauline also had not yet begun childbearing, and was contemplating pre-
pregnancy RRBM. She candidly discussed both her personal desire to breastfeed and the 
societal pressure she felt to do so: 
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The loss of the ability to breastfeed is something that has definitely crossed my 
mind. I guess most women of my education or/and social class tend to breastfeed 
their babies and tend to do it in a sort of public and very boastful way. I do regret 
that I’m not ready to have kids immediately because if I were I might have a 
baby, I might be pregnant right now, just so I could go through the experience of 
at least breastfeeding one. But that hasn’t been enough to cause me to change my 
views and my time frame that I’m comfortable with about having children. And 
you can’t really breastfeed a child if you are going through chemo or radiation or 
if you’re dead. So the functionality and the purpose of breasts in terms of 
reproduction, I’m not going to get the experience, and sure, I’m bummed, but 
that’s not going to really rule my decision. It just hard because I think that 
breastfeeding is very in vogue right now in terms of educated, upper middle class 
women. [There’s a belief that] people who don’t breast feed aren’t doing what’s 
best for their child. I sort of anticipate the moment when I’m at the play lot five 
years, ten years from now and a mother I don’t know very well says to me, “Oh, 
you don’t breastfeed?” sort of in a sneering way and I say, “Well, no I don’t 
because I had a double mastectomy,” and sort of the show-stopping quality of that 
statement. That’ll be something I confront. But I’ve been assured that women 
throughout the ages have still been able to bond with their babies even if they’ve 
been bottle-fed. If it was not in vogue right now to breastfeed, maybe I wouldn’t 
even think twice about it. But there’s just sort of this idea of good moms who eat 
organic and you know, drive safe cars, and have a graduate degrees, you know, 
they all breast feed their babies. Well, I can’t do all of those, unfortunately. But 
that also sort of allows a little bit of egalitarianism in the way that I actually wish 
to parent in the context of my relationship. If I’m not breastfeeding, my husband 
can also help me feed the baby. That’s something that I think is important for both 
the way that I hope to conduct my marriage and our co-parenting but also 
something good for [Glenn], that he could have that bonding experience as well. 
Pauline, 30 
Pauline highlights a neglected aspect of this weighty decision: women who choose pre-
pregnancy RRBM may face questions and criticisms from others regarding their risk-
management and family formation choices. Pauline’s insight that there are also parenting 
and relationship benefits to the choice that she is making is an adaptive way of coping 
with the doubts she anticipates in response to outsiders’ possible reactions to her choice. 
 While Monique, Charlotte, and Pauline provide excellent examples of women 
early in the process of deciding to complete RRBM before childbearing, other 
participants were further along this path. Marjory and her partner had decided 
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conclusively that mastectomy prior to childbearing was the right choice for them; they 
had moved on to talking about the length of time they would want to wait after RRBM to 
attempt to conceive for the first time: 
We’ll start as soon as we can. So, [early] next year. … That’s one thing that I 
have to find out about. I’ve actually been wondering about that. Obviously there’s 
some recovery time. I’ve kind of wondered, is that putting my body through too 
much in a short period of time? I know surgery is pretty major. And then, to 
become pregnant shortly thereafter that, I don’t even know what the 
recommendations are. We pretty much want to start right away. So whatever the 
recommendation is, I imagine we’ll start pretty much right after that. 
Marjory, 30 
Marjory nicely highlighted another issue that can arise for women who choose RRBM: 
when they choose to time this surgery prior to childbearing, the available remaining time 
to bear children before they reach the age at which RRSO is recommended is reduced, 
particularly if breast reconstruction is done. This may mean that although breast cancer 
risk perception is reduced post-RRBM, ovarian cancer risk perception may increase 
slightly, as a consequence of delaying RRSO.  
Rose had recently completed her surgery when interviewed. She described the 
two major components of her decision to do pre-pregnancy RRBM:  
The motivation was more two things, and the first one being that my husband and 
I are thinking of having kids in the next couple years, and there are some issues 
with monitoring [for] breast cancer and being pregnant. And, I didn’t like those 
risks and I didn’t also like the thought of having kids and then what if I got breast 
cancer when I had a kid or while I was pregnant. And the second one was timing. 
… I had a really good, long stretch of time … that just worked out for work where 
my entire building was shut down, so I knew that I wouldn’t be responsible for 
anything. And for me that is a good thing and I honestly think I healed so much 
more quickly. All I had to do was focus on myself. … And then also, the thought 
of having to do something like this in the future, what if I do put it off and then 
have kids, and do it in ten years. I don’t want to do it when I have little kids. If I 
could prevent that why wouldn’t I have the surgery now as opposed to later when 




Rylan, who had also completed her RRBM when interviewed, recalled conversations 
with her fiancé about the tradeoff between RRBM and breastfeeding 
When I told him I wanted to get the mastectomy, his first question was, “Well, 
you won’t be able to breastfeed our kids.” He was kind of concerned, he wasn’t 
happy about that. And I said, “Well, I don’t think that’s a big deal compared to 
getting cancer and possibly not being around for them, to bring them up, I think 
… breastfeeding is something I’m willing to sacrifice. We can buy breast milk 
from someone who is lactating, or we can buy the synthetic breast milk. …” And 
he said, “Yeah, but you won’t be able to hold them and the whole bonding thing.” 
And I was like, “Well, no. This kind of sucks and there are some things that aren’t 
positive about my mutation. And sacrifices will have to be made, but I think it’s 
worth being able to avoid cancer and probably save my life.” He was more 
concerned about the breastfeeding than the cosmetic thing. I think the 
breastfeeding thing is something that I’ve already gotten over. I think he’s 
accepted it, that it can’t happen now. He doesn’t understand how horrible cancer 
is to go through and the treatment, but from the things that I told him, he could 
see that, “Yeah, you’re right. It’s more important to avoid this than worry about 
being able to breastfeed or not.” 
Rylan, 34 
This is a powerful example of the remarkable manner in which some women share 
decisions about their own bodies with their partners, perhaps a unique feature of couples 
in which the female partner carries a mutation in BRCA.  
Grace’s story of decision-making about and living with pre-pregnancy RRBM is a 
similarly powerful one. She related how her ideals about commencing childbearing 
immediately upon completing the BI study were altered, and how that change resulted in 
her decision to complete the surgery – without reconstruction – before attempting to 
conceive:  
That last screening totally messed up my time frame. Our plan was to get the last 
clean bill of health with my last MRI and mammogram, and then we’d go to 
Ireland, drink a couple Guinness, and get pregnant or hope to get pregnant in 
those next months, and then have a baby, breast feed and then have prophylactic 
surgery. Instead, I got the abnormal result and they wanted to re-screen me after 
our trip to Ireland, which in my mind meant I had to put pregnancy off until I got 
that clean bill of health. And, getting that abnormal result, thinking that we 
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probably couldn’t start at having a family, or trying, reality really set in that this is 
not something to just toy with.  
 
Despite her knowing this abnormal test result might portend serious trouble, Grace was 
still focused on getting a “clean bill of health” (i.e., screening with no abnormalities) and 
proceeding with childbearing, until 
… my husband sat me down and had a little talk with me about how the plan 
needs to change and that I need to do surgery before having a baby. My initial 
reaction was to say, “Screw you.” I just was not ready for my plans to change. But 
over the course of 24 hours, I really absorbed what he was saying and why … It 
was about wanting to have me around and be healthy, and that outweighs the 
urgency to have a kid and that feeling of wanting to breast feed and wanting to 
have that experience. And, so we rearranged everything. We … did surgery and 
recovery and then a month or two after surgery, started trying to start a family… 
 
Grace shared her perspective on the impact of altering her plans:  
In hindsight, I’m so glad the surgery’s behind me before having kids and before 
going through pregnancy. The more I read about breastfeeding, the more I realize 
how difficult and challenging and painful all these things are. Even though it 
makes me sad not to be able to breast feed my baby, at the same time I know I can 
be a better parent, and even have a better pregnancy not having to worry about, 
“What is this change? Is this normal, is this cancer, is this something to worry 
about?” 
 
Three days past her due date when interviewed, Grace was uniquely able to provide 
insight into her decision to forgo breast reconstruction. She related what it was like to be 
both pregnant and breastless: 
I knew I wouldn’t look like a normal pregnant woman because I don’t have these 
large engorged breasts. [Jason is] like, “I actually think I like the breastless look 
better on pregnancy than with them, because it’s just very clean and it really 
flatters your belly.” It was just really sweet hearing him talk about that. He’s had 
no issues with the way that they look or the way that they heal. Because even 
though they’re straight lines they don’t heal evenly, the middle heals before the 
ends and stuff, but he’s been totally fine and accepting with it. 
 
In addition to her husband’s wonderful support, Grace’s realistic perspective about her 
body, and interactions with other women who reinforced that she had made wise choices, 
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reinforced her feeling good about her decisions. Asked what it was like to visit her 
doctor’s office and be surrounded by pregnant women with breasts, Grace replied: 
To me, my body isn’t this great amazing specimen that’s on display for everybody 
else. It’s a functional thing, so in some ways having gone through the surgery and 
having scars and already accepting myself as not as what’s perceived as normal, 
or socially like a normal beautiful body, I’ve been able to accept the changes with 
pregnancy a lot easier, I think, than some first-time moms that might freak out 
about the stretch marks, or the changes. The other really cool thing is I was at one 
of these support groups, and I had shared how I was really nervous about being 
pregnant without breasts and how I sort of had to redefine what’s feminine 
anyway, in my mind. I’ve got long blonde hair and I’m petite, so I’ve got that 
going for me, which is very feminine, but you just have to embrace different parts 
of yourself. And at the end of the group this woman came up to me and said, “I 
just have to tell you, you were talking about feeling feminine, there’s nothing 
more feminine than carrying a baby.” And I never thought about it that way, but 
it’s so true that, yeah, that’s what a woman’s body is built to do, and what an 
amazing experience that I get to have that. So, it just made me think about my 
pregnant body even more in a loving, accepting way than I had previously. 
 
As a final thought about not electing reconstruction, Grace stated: 
I couldn’t be happier, and [Jason]’s been really good. I mean, I think he would 
agree that not having to worry about whether there is something there, behind the 
implant, especially with pregnancy, your body’s going through so many changes 
that, you know, it’s like a clean slate. You can just look and see if there’s 
anything there, and feel it so easily. I think with reconstruction I would have had a 
lot more worry about what’s going on that I don’t see or feel. He says it’s 
aesthetically pleasing because it’s just a very clean straight line, where with 
implants sometimes you don’t really know what you’re going to get. 
Grace, 30 
Grace’s story clearly illustrates that couples can and do actively engage and debate with 
one another about how to accomplish both family formation and risk-reduction goals in 
the presence of a BRCA mutation. Allowing her husband’s opinion to be so influential in 
decision-making about such a personal and intimate decision underscores their powerful 
and intimate connection: Grace’s willingness to allow Jason to so powerfully shape her 
experience would not have been possible in a relationship that was not firmly based in 
trust, respect, and genuine love. Jason’s ongoing support of Grace and his ability to 
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consistently reaffirm her decision further exemplify the presence of appropriate 
communion in this relationship. 
RRBM between pregnancies. Some participants considered timing RRBM to 
occur between pregnancies. Often, this was described as a compromise: it permitted 
having the breastfeeding experience once, without delaying RRBM to the point of 
intolerable increases in perceived breast cancer risk. In addition, it offered a way to 
significantly reduce cancer risk without terminating fertility (as happens with RRSO). 
Acacia, who was seven months pregnant with her second and final child when 
interviewed, recalled having strongly considered RRBM between pregnancies, but 
ultimately deciding to wait: 
I’m really happy because with my first daughter, I chose to breastfeed and it’s a 
very wonderful bonding time. If I had the opportunity and I could do it where I 
felt I was still in kind of the safe age range, I wanted to try to do that. I’m pretty 
happy with my decision, thinking right now that I don’t have any big cancer 
worries. 
 
For Acacia, this decision was acceptable because she was able to alter her family 
formation timeline, both by having children sooner and having them closer together, so 
that she would complete childbearing before she reached what she perceived as the age 
when her risk would be considerably higher and require surgical risk-reduction. She 
further stated that in making the decision about the timing of her RRBM, she ultimately 
decided maybe it would be better just to bump [the second baby] up about a half 
year to a year and have everything working and then after that baby was born just 
kind of do both surgeries, get it all done together. I think we talked about it for a 
good three months or so, pretty in-depth, before we came up with a plan, but 
that’s ultimately what we decided. 
Acacia, 30 
In addition to weighing the ability to breastfeed her second baby in this decision, Acacia 
also embraced the relative convenience of having both surgeries simultaneously, thereby 
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minimizing the recovery time during which her ability to actively care for her children 
would be compromised. 
 Inter-pregnancy RRBM also creates some flexibility with regard to family size 
and timing of additional children. The decision to have RRBM after her second 
pregnancy fit nicely with the ongoing debate between Shannon and her husband about 
whether and when to have a third child: 
He’s happy with two, and that doesn’t have anything to do with the cancer risk or 
the surgery. Even before we had any children, he always thought that two would 
be a good number. I always leaned a little bit more towards three. But we agreed 
that this wasn’t a major issue for us either way. And that we’d still be willing to 
revisit it after we had the two and go from there. And then, after we had the 
second one, we both agreed that the surgery is the bigger issue right now and that 
we could think about a third after that, if I was still thinking about it. 
Shannon, 31 
Timing her RRBM at this moment allowed Shannon to keep the option of a third child 
open, while focusing on mitigating her breast cancer risk. Beth also discussed her 
decision to proceed with inter-pregnancy RRBM: 
I think not having that pressure will be nice … realistically I’m sure some of the 
emotions might come back when I have another baby and I think to myself [that] I 
won’t be able to give my baby this breast milk that everybody says is liquid gold. 
… the breast feeding community, they kind of push it and they say if you breast 
feed your child has better immunities, they won’t get sick as much. And I think 
my son has gotten sick three times in three months even though he has been 
getting milk. So, I don’t know. I think it will be a relief that I don’t have to and 
that I have a reason why I can’t. Because now people almost expect you to 
breastfeed and I can’t and this is why I can’t. And I think giving my baby formula 
and them having a mother is better than me trying to keep my breasts, giving them 
breast milk and possibly getting breast cancer, and them not having a mother. 
Beth, 30 
Shannon and Beth both spoke from the invaluable perspective of already having one 
child and knowing what it means to be a mother. This likely contributed to their clearly 
expressed and powerful concern about the well-being of their children, and their ability to 
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see RRBM between pregnancies as a way to protect their current and future children as 
well as themselves. 
Chemoprevention 
 The use of chemoprevention agents18 as a strategy to mitigate cancer risk is used 
by a minority of BRCA carriers who wish to reduce their risk during their childbearing 
years without terminating their fertility. Use of oral contraceptive pills (OCPs) (which 
reduce the risk of ovarian cancer in mutation carriers by about 50%) or the anti-estrogen 
agent tamoxifen (which reduces the risk of sporadic breast cancer by about 50%; limited 
data suggest a similar protective effect in mutation carriers) is more effective in reducing 
risk than screening (which does not actually reduce risk, but rather identifies existing 
cancers at an earlier, potentially more treatable stage), but less effective than surgical 
risk-reduction. BRCA positive women may consider this strategy either before or after 
completing childbearing; when the latter is chosen, it is typically a strategy for delaying 
surgery rather than a substitute for it.  
Several participants cited their current or past use of OCPs as useful in mitigating 
their risk of ovarian cancer during young adulthood. Other medications were viewed with 
less enthusiasm. Annie recalled believing that chemoprevention was too risky and not the 
right choice for her: 
For me, going down the whole preventative chemotherapy route and fertility and 
all that that entailed, that was just too much for me. That just wasn’t something 
that I felt would work for me at all. I thought it would be more traumatic, not only 
emotionally, I don’t know why I thought maybe even physically, that would be a 
little bit too much for me. But, I think the risk, too, of taking any kind of drug and 
ultimately not being able to have kids, [and what if] something went wrong or, I 
don’t know. There just seemed to be too many variables with that versus having a 
                                                 
18 Chemoprevention is the designation given to the use of medications to reduce the risk of cancer.  
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preventative surgery…I think just the chance of not having kids as a result of 
chemoprevention stuff, that to me is a little bit more traumatic. 
Annie, 32 
Ultimately, Annie chose to have RRBM prior to her first pregnancy rather than taking the 
chemopreventive option offered by her physicians. In contrast, Grace discussed her plan 
to employ chemoprevention (OCPs) after she was finished with childbearing, in order to 
buy a bit more time before RRSO: 
My theory is have a baby or two and then get on birth control, which I’ve never 
been on, to regulate the estrogen levels. I think that’s what’s supposed to reduce 
your risk a little bit for seven to ten years or something. And then have my ovaries 
out. I’d like to at least put it off until 45, because the issue with getting them out 
too early is worrying about bone loss and that kind of stuff. And he’s on board 
with whatever. I think he just wants me around. Especially now being a mom. 
Grace, 30 
The dual priorities of maintaining her own general health (e.g., delaying the 
cardiovascular, bone density, and vasomotor problems related to premature menopause) 
and surviving to be around for her children made chemoprevention at a later stage an 
appealing choice for Grace. 
Chapter Conclusion 
Data presented in this chapter powerfully support the notion that women’s choices 
about family formation are intricately linked to perceived risk, partner support, and risk-
management decisions, as illustrated in Figure 8. Regarding risk, mutation-positive 
women contemplate not only the risk that they might someday get cancer, but non-
oncologic components of perceived risk—e.g., the fear that they could die and leave their 
children without mothers, or simply being afraid of death. These additional risks may be 
just as powerful a motivator to intervention as simply worrying about developing a 
malignancy, and providers who can recognize these additional elements of risk and make 
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them part of the conversations they have with women in deciding about risk-management 
may be better able to counsel mutation carriers in a way that feels comprehensive.   
     Figure 8: Role of Family Formation in the Model 
 
 
These data also illustrate several examples of misunderstandings or 
misinterpretations of risk-related information by carriers. It is clear that most of these are 
the product of a medical setting in which providers (even those who are up-to-date about 
the latest research) do not have as much information as they need to make evidence-based 
recommendations. Consequently, most provider suggestions are based on “best clinical 
judgment” rather than hard data, and providers often make the same assumptions about 
what must be true on these topics, as patients do. The most effective and personally 





























relevant counseling for these women will likely come from a medical team that includes 
multiple specialties (i.e., gynecological oncologists, endocrinologists, surgeons), and 
women are unlikely to receive sufficient care from primary care physicians (or even 
ob/gyn physicians) alone. Therefore, medical teams comprised of a variety of appropriate 
specialists should be constructed and made available to young female BRCA carriers. 
 With regard to partner support, participants illustrated how their partners (either 
current or future) had been, or would someday be, involved in the decisions they made 
about how to manage their risk. Even women who were not in relationships revealed that 
they considered how their future partners might feel about decisions they were making 
while single. Mutation carriers involved their partners, to varying degrees and in different 
ways, in decisions about how to time family formation, how many children to have, and 
how to balance their desire to breastfeed with their desire to mitigate risk through RRBM. 
 The major theme that developed in analyzing data related to family formation was 
that of control: participants exercised control over the various facets of family formation 
to make way for their preferred method of family formation. There was wide variation in 
how women prioritized their risk-management and family formation goals, and women 
were most satisfied with their decisions when they identified and acted on a plan that 
resulted in minimal sacrifice to either set of goals. 
 Finally, data presented in this chapter are similar in important ways to previous 
research about “the disordered body” and how cultural discourses on femininity may 
cause women to feel inadequate when they perceive that a flaw or lack of ability would 
prevent them from accomplishing tasks such as childbearing and breastfeeding (Becker, 
1997). Becker studied women struggling with infertility and found that they “equated 
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infertility with the ability to nurture. Their ability to nurture others, and by extension their 
fertility, were central to their sense of who they were,” (p. 84). Similarly, some BRCA-
positive women in this study felt that their femininity, their identity, was threatened by 
the presence of a mutation that might render them less or differently able to bear and 
nurture children, or that they might have to sacrifice that ability in order to preserve their 
health. Prior to learning that they were mutation positive, many of these women expected 
that pregnancy and motherhood would proceed “normally,” in the manner that they had 
planned and predicted throughout their lives. Having to alter those expectations was 
jarring and difficult for some, and represented a life disruption. Some viewed themselves 
as deviating from the cultural ideal, as was illustrated by Pauline in her discussion of 
being questioned for not breastfeeding when she someday takes her infant to a park, or by 
Jane when she spoke about having her fertility threatened by her mutation. This sense 
that they are failing to live up to a cultural or structural expectation because of a 
limitation imposed by their mutation represents an additional layer of stress for young 
female mutation carriers. 
 As has been suggested previously (Werner-Lin, 2008), more research is needed to 
understand the importance of timing of genetic testing in the life course. Participants in 
this study demonstrated the very different ways that genetic information is understood, 
how meaning is made, and how decisions are shaped by awareness of one’s breast and 
ovarian cancer risk at varying points during young adulthood. Many of the women who 
were single or in casual, open, or unsteady/impermanent relationships when interviewed 
demonstrated a high degree of worry about how they would accomplish their family 
formation goals in what they saw as a limited amount of time. In many ways, the 
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strategies that are likely to lead to the best results with regard to cancer risk and 
survivability (early testing and intervention) and those that are likely to lead to the 
optimal mental health and relationship outcomes during young adulthood (waiting until 
one is in a significant relationship, and perhaps until after one has children, to test) are in 
direct opposition to one another. If these very young (i.e., 18-24) women are to continue 
to be routinely tested for BRCA mutations when they are members of families in which 
mutations are known to exist, appropriate and ongoing psychosocial care is of paramount 
importance, so that these women may have a knowledgeable, caring professional with 
whom to speak about their concerns. These providers can also be of great assistance to 
older mutation carriers and those in relationships, providing both individual- and couple-
based therapeutic services as mutation carriers move through the shifting dynamics and 
changing priorities of young adulthood. 
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CHAPTER 10: DISCUSSION 
 
 Data presented in chapters five through nine demonstrate the complex ways in 
which cancer risk perception, mutation disclosure in couple relationships, mutation-
related partner support, and family formation are connected to each other and to women’s 
decision-making about, and experience with, cancer risk management. Chapter Five 
provided two illustrative examples of women’s journeys through young adulthood as 
mutation carriers, and outlined the basic theoretical model used to understand these data. 
In Chapter Six, participants illustrated how their perceived risk of cancer was shaped by 
what they knew from their family experiences. Specifically, many discussed how family 
narratives regarding the course and behavior of cancer were integral to forming their own 
beliefs about whether and when cancer might impact them. Other participants described 
how a lack of knowledge about cancer in their families left them feeling vulnerable and 
unsure about their own risk. They shared their concerns and uncertainties about how their 
perceived risk of cancer might impact their decisions about family formation, and how 
stepping back to consider personal risk in the context of one’s own body, previous risk-
related experiences, and historical context (i.e., currently available medical knowledge 
and technology) allowed them to make risk management decisions that facilitated a sense 
of agency and regaining control over their lives from the mutation. Finally, their stories 
lend empirical support to the notion that psychosocial and genetic counseling care are 
needed throughout the mutation-positive experience, even after risk-reducing surgery. 
Patients’ ongoing interactions with these professionals can help mutation carriers stay 
informed about current research, understand their risk over time, and minimize possible 
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misunderstandings about risk that may leave them feeling more vulnerable to cancer than 
they actually are. 
 Chapter Seven, with its focus on disclosure of positive mutation status within 
couple relationships, revealed how young women’s choices about risk management shape 
their options for timing of disclosure to partners, especially in dating relationships: 
women who had already undergone one or more risk-reducing surgeries often felt 
compelled to disclose early, while those who had not yet undergone surgery had more 
flexibility in the timing of disclosure. For many participants, the act of disclosure itself 
was catalyzed by imminent risk management activities and/or the desire to have a partner 
as a source of mutation-related support. Additionally, women felt compelled to share 
information about their mutations with partners who might someday become co-parents, 
because of the obvious implications of BRCA mutations for the health of future children. 
When those already in serious relationships (long-term dating relationships or marriages) 
learned of their mutation status, disclosure often occurred as part of the normal day-to-
day conversations between partners, as male partners were typically involved throughout 
the genetic testing process. Still, many participants in this latter category reported having 
had important conversations with their partners about the implications of their mutations 
on their plans for family formation, if childbearing was not yet complete. Regardless of 
their relationship status, participants reported that they were most fearful about their 
actual or potential partners’ attitudes/responses regarding mutation-related 
decisions/interventions yet to come, while those that were fait accompli would be more 
easily accepted by partners. 
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 Mutation-related partner support, the focus of Chapter Eight, emerged as an 
important component of the successful management of high-risk status for young women. 
Partners (both current and future) played key roles in women’s decision-making about 
risk management, and in developing strategies to minimize disruption of family 
formation goals. Additionally, partners were described as advocating for carriers as they 
moved through the mutation-positive experience, encouraging them to keep up with 
screening, requesting important information from physicians, and reminding participants 
about shared priorities that necessitated some mutation-related action (e.g., have a 
mastectomy so that we can have our family without worrying about breast cancer). A 
surprising finding from these data was that a substantial subset of participants reported 
feeling that their relationships with their partners were strengthened as a result of having 
worked through BRCA-related issues together—a phenomenon likely unanticipated by 
newly-confirmed mutation carriers or their health care providers. Challenges related to 
inter-partner communication and sexuality emerged as the most prominent stumbling 
blocks related to partner support; effective psychosocial intervention to assist relationship 
partners in speaking openly about their feelings and needs would likely be of great 
benefit to both. 
 Finally, issues related to family formation were central among all participants, as 
demonstrated in Chapter Nine. Risk-related information was a frequent topic of these 
discussions, as women worked to make sense of the factual information and opinions of 
various providers, peers, and loved ones. The often confusing morass resulting from this 
process was difficult for some participants to navigate. Ultimately, most women made 
choices that allowed them to gain some control over their mutation by forging a path that 
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included their preferred course of family formation, or a close approximation of it. 
Prioritizing either risk-management or family formation on several different dimensions 
(timing of family formation, family size, and breastfeeding) was a critical strategy that 
many participants employed as they moved down this life path, often succeeding in a 
striking a balance that reconciled these conflicting goals. 
 As women reconciled all of these issues in deciding how to manage their risk, 
many of them ultimately decided that risk-reducing surgery was the best course of action; 
early RRBM was surprisingly common in this group, and my experience working with 
BRCA mutation carriers more broadly is that surgery at young ages is becoming a more 
and more common choice. Participants who had made this decision seemed to have done 
so in a way that makes sense if considered in the context of anticipatory loss: finding the 
possibility of living every day with knowledge of cancer risk and impending loss 
intolerable, they chose instead to endure a short, intense period of pain and loss (the 
surgical removal of their breasts and all that comes with that process). Even though they 
know that they could probably wait until they are done with childbearing and survive 
with their breasts intact, living with the fear of cancer is not worth that. These brave 
women choose instead to face something that most would find it difficult to conceive of, 
and in so doing free themselves from the emotional and physical constraints of their 
mutation-positive status and gain control over their genetic destiny. 
 Taken together, these four chapters provide empirical evidence to illustrate the 
complex set of decisions that BRCA-positive young women make, as illustrated in Figure 
9. For women who learn in young adulthood that they are mutation-positive, the journey 
from understanding the meaning and role of cancer in one’s family, through  
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    Figure 9: Theoretical Model of Negotiation of Health Risks for BRCA+ Young Women 
 
comprehending the implications of their carrier status for themselves as individuals, to 
making one’s own decisions about risk management, is not straightforward. Rather, it is a 
complex and unique set of interrelated compromises and considerations that require these 
young women to think hard about their relationships, priorities, and risks—and the 
different ways that those might fit together in the present or in the future—within the 
context of the relationships and societal structure in which they are embedded. 
Theoretical & Research Contributions 
As described previously, data from the current study contribute to our current 
understanding about the lived experiences of young BRCA mutation carriers in several 
important ways. The findings from this study helpfully inform each of the theories used 





























in its development. These data study sheds light on the depth of the relationship between 
intra-individual levels on Engel’s Hierarchy, illustrating how powerfully cellular-level 
phenomena can impact a person and his/her broader contexts at all levels. For example, 
participants’ knowledge of themselves as BRCA-positive was a powerful component of 
how they understood themselves, as well as how they thought about their breasts and 
ovaries and the ways that they might (or might not) use them. Experiences with breast 
and ovarian screening and knowledge of the ineffectiveness of ovarian screening 
specifically powerfully shaped women’s ideals about the long-term suitability of 
screening and their decisions about whether and when to undergo risk-reducing surgery. 
With regard to the interpersonal components of the hierarchy, participants spoke 
powerfully about their experiences in real or hypothetical couple relationships, and shed 
new light on our understanding of how these important bonds absorb and adapt to the 
BRCA mutation-positive experience. When participants had negative experiences in 
couple relationships, they demonstrated how other levels of the hierarchy are impacted 
(e.g., by relying more on peers or friends for support in the absence of a supportive 
partner). 
With regard to life course perspective, findings from this study powerfully 
illustrate how life trajectories can be altered effectively to accommodate significant and 
unexpected health demands. Consistent with feminist perspective, the life course concept 
of agency emerged as a dominant theme and effectively describes the empowering 
decision-making processes in which these young women (and their partners) engage to 
create a path through young adulthood that allows them to meet both relationship and 
health goals with minimal compromise to either. Further, women in this study often 
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found new paths that made something positive of their experiences as mutation carriers, 
such as by creating an educational or artistic product to inform other young carriers, or 
choosing to work in a field that would allow them to focus on cancer and/or cancer 
susceptibility. These experiences were universally described as empowering and 
represent creative ways of sidestepping significant constraints and limitations. 
Women’s risk-management decisions during young adulthood significantly 
inform our understanding of anticipatory loss. A striking number of participants had 
completed or were contemplating at least one risk-reducing surgery at the time of their 
interview; choosing this during one’s twenties or thirties is a courageous decision, and 
one for which many participants had no model in their families or broader social 
networks. Despite their knowledge of the potential negative effects of the surgeries 
themselves (i.e., pain, sexual side-effects, changes to body image and/or sexuality), many 
participants chose to undergo these procedures because doing so seemed like a better 
alternatives than living with the ongoing anxiety of not knowing whether, when, or at 
which site a cancer might occur. Although some risk and uncertainty always remains 
after surgery, it is much less than what would be present if no surgical intervention 
occurred. Post-surgery, many women reported being able to put their cancer risk in 
perspective and not allow it to take over so much of their consciousness, time, and 
energy, freeing them to be more fully present as partners, mothers, daughters, etc.  
Stepping back to think about the larger implications of these findings allows 
consideration of how the lessons learned here might translate to other contexts and 
phenomena. Mine is a contextual model, which describes process and contributes to our 
understanding of how individuals make meaning of significant health risk events in their 
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lives. It provides empirical evidence that elements previously known to be correlated – 
for example, cancer risk perception and family formation – are connected in unique ways. 
These data tell us how such elements are related. The model goes further to demonstrate 
the heterogeneity of experience between young BRCA mutation carriers, and suggests 
that other health risk-related phenomena may also be experienced in unique ways by 
different individuals in varying contexts.  
Participants connected the limitations imposed and challenges presented by their 
mutations to their identities as women quite differently from person to person. For some, 
the loss of breasts and/or ovaries, changes to body image and sexuality, and diminished 
freedom to engage in childbearing and nursing of children – to their minds, an important 
component of how they would be good mothers – in a manner concordant with their prior 
ideals were experienced as threats to their roles as partners and mothers. Not surprisingly, 
this view was more often voiced by unmarried women and/or those who had not 
commenced childbearing when they learned their mutation status. For those who were 
permanently partnered and/or already had children, the mutation was perceived as less of 
threat to their femininity, because those roles had already been at least partially fulfilled. 
Because of the highly feminine nature of hereditary breast and ovarian cancer, it is likely 
that this situation, more than most other health threats, brought forth such feelings. 
However, the broader concept of threats to gender-based expectations based on health 
risk likely cuts across context and gender. For example, both men and women who 
encounter infertility might feel that this circumstance threatens their ability to fulfill 
gender-specific roles. Men who face serious health threats that prevent them from 
working and earning an income to support their families may experience a sense that they 
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are failing in their role as father/provider. In both cases, the processes by which 
individuals make decisions about and manage these health challenges might be 
influenced by the same components described in the model developed here: risk 
perception, couple dynamics related to disclosure and support, and considerations about 
forming or maintaining one’s family. 
My elucidation of how individuals differently prioritize, give value to, and 
manage the various stresses that come with knowledge of serious health risk is a major 
contribution of this research. Though the 40 participants described here faced a generic 
set of challenges as a consequence of being BRCA mutation carriers, they made unique 
choices based on their own circumstances, preferences, and the opinions of those close to 
them. Understanding this heterogeneity helps to explain the wide variation in how people 
deal with real lived experiences, which cannot be as effectively captured in quantitative 
research. 
Furthermore, in keeping with the major goals of grounded theory, the model that 
emerges from this research should help us to understand other disorders or life situations. 
The product of this research represents a joining of several theories—some major “Big 
T” theories and some smaller “Little t” theories (Schneberger, Watson, & Pollard, 
2007)—to create a new model that holds potential as a mid-range conceptual framework. 
If it is a useful, portable theory, then other health challenges with analogous threats, in 
which different elements become more prominent or fade into the background, should be 
explainable using this theory. Direct expansions of the utility of this model might include 
genetic counseling or infertility; more indirect applications might be found in considering 
families’ decisions about living in dangerous or unhealthy environments, or 
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understanding the long-term impact of diethylstilbestrol (DES) on the now adult children 
of women who gave birth in the mid-20th century19. 
The proposed model could be useful in a general genetic counseling context. 
Providers might usefully consider the four components of the model in working with 
individuals, couples, and families contemplating genetic risk. Standard genetic 
counseling includes a sharp focus on perceived risk and efforts to align it with actual risk; 
issues related to family formation are also frequent topics of discussion between genetic 
counselors and their patients. Most of this interaction takes the form of genetic counselors 
conveying information about risk or family formation options to patients, whose role is to 
listen, ask questions and become informed. The experience of genetic counseling for 
patients may be seen as more beneficial if individuals are given an opportunity to speak 
about their feelings and worries, and be heard. Many women in the current study reported 
that their genetic counselors were helpful in providing medical information and 
resources, but were less successful in making them feel understood or helping them 
figure out how to deal with genetic information. A standard practice of offering referrals 
to qualified medical family therapists, or other mental health professionals who can work 
with patients in this capacity on an ongoing basis, might greatly improve the experience 
of genetic counseling clients who need to talk about their risk in a depth greater than that 
which can be accommodated in the standard (60-minute) genetic counseling appointment.  
                                                 
19 DES is a synthetic estrogen prescribed to pregnant women between 1938 and 1971 to prevent 
miscarriage and premature birth, based on the theory that those problems were caused by a deficiency of 
naturally produced estrogen. Although its utility was disproven in 1953, DES continued to be prescribed 
until 1971, when the FDA issued a bulletin alerting doctors that exposure to DES increased female’s risk of 
clear cell adenocarcinoma (CCA), a rare vaginal and cervical cancer, if they were exposed in utero. Later, it 
was discovered that DES daughters are also at risk for other reproductive abnormalities (including 
infertility) and that DES sons have elevated risk of non-cancerous epididymal cysts (Centers for Disease 
Control and Prevention, 2010). 
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Additionally, few genetic counselors have sufficient time to hear their patients’ 
family illness narratives in full, and to either help patients understand how those beliefs 
intersect with the information being provided in counseling, or to work with them to 
improve the flow of information and understanding of illness legacies within families (J. 
Green, Richards, Murton, Statham, & Hallowell, 1997). Genetic counseling experiences 
in which couple-level processes are sufficiently attended to are even less common 
(Evans, 2006). Patients are typically left to their own devices to decide how to 
communicate genetic information to partners (and others), and to identify and meet 
support needs brought about by genetic risk status. Once again, making appropriate 
referrals to mental health professionals equipped to work with couples and families in 
overcoming these challenges would build upon and greatly enhance the genetic 
counseling experience. This can only happen when genetic counselors understand the 
systems-nature of their work and recognize that individuals’ broader relationship contexts 
must be attended to therapeutically, both currently and over time. 
With regard to infertility, the proposed model can contribute to our understanding 
of how both men and women process and make meaning of the challenges they encounter 
in naturally conceiving a biological child. With regard to risk perception, fertility-
challenged individuals may experience guilt or blame if they or their partners believe that 
the cause of their difficulty getting pregnant is/was preventable, e.g., if infertility was the 
result of a previous sexually transmitted infection, drug or tobacco use. Women who 
choose to delay childbearing into their thirties and forties may perceive that they are at 
higher risk of experiencing infertility, and may question previous life choices. Couples 
may struggle with disclosure when one partner knows him- or herself to be infertile prior 
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to the start of a relationship, and who then must inform the other partner as the 
relationship becomes more serious; or, learning about fertility-related challenges in the 
context of an existing relationship might challenge intact couples to cope with this 
potentially unexpected and difficult news together. Couple support processes and patterns 
may be strained as partners struggle to realign themselves around a stressor that can 
necessitate significant renegotiations of their family formation plans, allocation of 
resources, and relationships with others outside of the couple unit. Finally, family 
formation issues are closely tied to a diagnosis of infertility; individuals and couples alike 
may be forced to consider alternative methods or timing of family formation, and 
possibly decide not to pursue having children at all. 
Moving beyond contexts of genetic medical conditions, a consideration of how 
the proposed model might apply to families living in or near hazardous environments 
elicits several interesting possibilities. For example, a low-income parent deciding 
whether or not to move her/his family to a part of a city near a power plant or sewage 
treatment facility, or even moving to an area where there is limited access to healthy food 
or clean air and water, often have valid reasons for doing so. Housing is often less 
expensive in areas where known or potential health threats are present, and jobs for 
which a low-income individual is qualified may be more readily available in these areas. 
An individual and/or parent must consider whether the advantages to her/his budget and 
ability to provide for their family warrants exposure to possible health risks. While 
dynamics around couple disclosure may be less salient in this context, access to adequate 
information from local authorities becomes more salient, and is reflective of how power 
works to obscure information around health risks – and how that shapes family dynamics. 
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Also, there are family health implications of a history of slow disclosure that emerges 
over time, and that different generations must cope with as it evolves. With regard to 
support, defining and providing couple support are likely to be relevant for those in 
relationships as they cope with the stressors inherent in living with environmental risk, or 
working to improve the family financial situation so that living in such an environment is 
no longer necessary. Family formation issues may arise when environmental health 
threats jeopardize one’s ability to have a healthy pregnancy, or when living in an 
extremely toxic environment results in severe and/or unexpected birth defects or 
complications. Individuals making these choices, and professionals addressing issues of 
low-income families in their research and policy work, might find the proposed model 
useful in conceptualizing families’ decision-making processes related to geographic 
location and housing. 
Lastly, families in which pregnant women were treated with DES to prevent 
miscarriage and premature birth (a treatment strategy employed in the US between 1938 
and 1971, but now long since abandoned) may be better understood when examined 
using the proposed model presented here. Women given DES while pregnant are at 
moderately increased risk of breast cancer. “DES sons,” or boys and men who were 
exposed to DES in the womb, are at risk of non-cancerous growths on the testicles, and 
possibly other genital abnormalities. “DES daughters” face more frequent and more 
serious risks, including reproductive tract abnormalities, clear cell adenocarcinoma 
(CCA, a rare vaginal and cervical cancer), ectopic pregnancy, premature delivery, and 
infertility. Although efforts were made to locate and inform women who had been 
prescribed DES after its health risks became known, many individuals are still unaware 
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that they are in this category (Centers for Disease Control and Prevention, 2010). 
Consequently, people are still learning that health problems they are encountering in 
adulthood are the result of drugs given to their mothers during pregnancy, and now aging 
mothers are learning or continuing to cope with the knowledge that drugs given to them 
during their pregnancy jeopardized the health of their children, creating complicated 
disclosure dynamics on multiple levels. These facts become part of ever-evolving 
narratives as intergenerational histories unfold over time within families. Individuals, 
couples, and families affected by DES move through changing phases of DES-related 
risk over successive generations, and information is still emerging regarding how the 
third generation (grandchildren of women prescribed DES) might be affected. Individuals 
must contemplate and decide how to make sense of these potential health risks, and 
reconcile their feelings about being exposed to this risk by a medical community that 
might be perceived as having failed to protect them. When cancer or fertility-related 
challenges are the result of DES exposure, individuals must go through disclosure 
processes similar to those described previously in this chapter, with the same kinds of 
variations depending on context. Couples’ support processes may require realignment to 
accommodate the challenges presented by this health phenomenon, and partners are 
likely to work together to become educated about how DES exposure might shape family 
formation. 
Overall, the model proposed here presents a new way of understanding how 
issues of family and health may be integrated, and illuminates contexts previously 
unexamined. While four additional contexts have been suggested here, it is likely that 
many other relevant situations exist. Additional research utilizing the proposed model 
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will help to refine it over time, and future quantitative investigations can clarify the 
directionality and magnitude of relationships between model elements. 
Practical Implications 
 Findings from the current study have several implications at the policy level, for 
providers who work with BRCA-positive women, and for mutation carriers themselves. 
For physicians and genetic counselors alike, a general orientation toward improving 
cancer survivability requires considering how these data might inform their ability to 
provide effective intervention. If mutation-positive women are to survive longer, they 
must be active early in the life course in working to mitigate their risk, and genetic 
testing at a young age is the essential first step. Providers ordering genetic testing for 
young women would be better able to educate and serve that population if they more 
fully understood both the complicated psychosocial implications of the BRCA-positive 
experience and the importance of initiating appropriate interventions while carriers are in 
their twenties. Understanding the unique challenges to self-perception and relationships 
for young mutation carriers would greatly facilitate providers’ ongoing interactions with 
women in this population. These well-informed providers would be better able to attend 
to carriers’ continuing need for new and updated information, and to provide informed 
guidance and resources related to risk, sexuality, pregnancy and breastfeeding, and/or 
surgery as carriers meet these different challenges along the mutation-positive path.  
        Further, a heightened awareness of how easily carriers can misinterpret information, 
receive inaccurate data, or simply not have access to appropriate resources to become 
educated about their risks and options, should incentivize providers to implement a 
medical strategy in which communication among providers and specialties is the norm, 
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and patients have access to the full range of doctors (e.g., gynecological oncologists, 
reproductive endocrinologists, ob/gyns), nurses, genetic counselors, and mental health 
professionals, working as a team, to make decisions with and in the best interest of 
patients and their loved ones. 
 Genetic counseling practice may also be informed by understanding the 
importance of a comprehensive understanding of family history for accurate risk 
assessment and risk perception. This was demonstrated by those participants who felt 
uninformed about their risk because of a lack of information about their family health 
history. While genetic counselors already focus on obtaining an accurate family history 
for quantitative risk assessment, an increased awareness of how the lived, experienced 
family narrative shapes and influences the beliefs, attitudes and decision-making of 
young mutation carriers could broaden and enrich their approach to high-risk women. 
Listening fully to the stories young women tell about how they experienced cancer and 
risk in their families provides an invaluable opportunity to reinforce that which is 
factually correct, and clarify inaccurate information, as women struggle to formulate a 
meaningful, functional understanding of their own personal risk and management 
options.  
When referral to other mental health professionals – especially medical family 
therapists – is appropriate, therapists might be optimally effective if they strive to have an 
intergenerational conversation in which the full range of individuals touched by a 
family’s cancer narrative can discuss how they understand and make meaning of this 
information. A willingness on the part of families (perhaps assisted by providers) to have 
healthy, non-threatening conversations with minor children about cancer in the family, 
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and what it means for them as a group and as individuals, could help to make BRCA a 
less intimidating threat, engender a sense of competence in handling mutation test results, 
and create a next generation of potential carriers who are well-informed and prepared to 
face challenges at this complicated stage of the life course. 
For any provider working with this population, the insights provided in this study 
could be helpful in increasing competence and confidence that they can empathize with 
young mutation carriers’ struggles. A therapeutic interaction between a BRCA mutation 
carrier and a genetic counselor, medical family therapist, physician, or nurse might occur 
when the provider can say to the patient, “I truly understand what you’re going through, 
and what difficult choices you’re facing. There is no easy answer. And, I know of some 
examples of how other women in your situation have coped. Let me share that knowledge 
with you.” A genuine sense that one is understood in the medical environment might be a 
powerful experience for many young carriers. 
 With regard to policy, health insurance issues are of vital importance for women 
contemplating testing and coping with the implications of a positive result. Though the 
passage of the Genetic Information Nondiscrimination Act (GINA) in 2008 was a major 
step forward in protecting individuals with known susceptibility to health risks from 
discrimination with respect to health insurance and employment, significant challenges 
remain relative to implementing similar protection for life insurance, and in helping the 
public become aware of their rights and feel confident that they are truly protected. 
Further, if health insurers were required to cover not only costs related to genetic testing 
and medically-indicated risk-management strategies, but also the costs of mental health 
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care (including couple and family therapy) mutation carriers’ needs could be more 
effectively met.  
Insurance coverage for assisted reproductive technology for carriers who wish to 
utilize these services would also greatly benefit this population. This is an intimately 
personal choice, and it is unfortunate that it is often decided instead by an insurance 
company’s willingness to pay for the procedure. A striking number of participants in the 
current study, as well as many other women I have encountered in my work with this 
community more broadly, have stated that they would be interested in pursuing prenatal 
genetic diagnosis (PGD) to ensure that they would have mutation-negative children, but 
that the high cost of the procedure would likely prohibit them from doing so. In the long 
run, insurance companies would likely spend less money paying for PGD than they 
would paying for genetic testing, several years of screening, risk-reducing surgeries, 
and/or cancer treatments when babies born with unknown mutation status reach young 
adulthood. Ideally, women and their partners would be able to make the choice that 
works best for them, not forced to do what best meets the needs of their insurance 
provider. 
 Finally, my results have implications for the mutation carriers themselves. The 
predominantly positive narratives provided by these participants undercut preconceptions 
that living with knowledge of oneself as BRCA-positive during young adulthood is 
“undoable.” Making data such as these available to women contemplating genetic testing, 
and to women who are newly-confirmed as carriers, might provide a roadmap for how to 
tackle BRCA at this stage of the life course. Many participants noted a perceived lack of 
access to accurate, high-quality, personally relevant information and also the opportunity 
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for social comparison at various points along their journey as mutation carriers, 
especially in the days and weeks immediately following their receipt of results. Because 
it is difficult to connect each newly-tested carrier with another young woman in a similar 
relationship and family context who lives near her, who could offer face-to-face support 
and interaction, providing salient information derived from the current study might be the 
next best thing. Knowing that others have experienced similar fears, worries, and 
challenges, and understanding how they have overcome those, would be empowering for 
some newly-aware carriers, and they should have access to this type of resource. The 
feeling that one is alone in the mutation-positive experience is troublesome, and not 
uncommon – but it does not have to be so. 
Limitations and Future Directions 
 The primary limitation of this study, as with all qualitative research, is that I was 
the sole researcher, conducting all 40 interviews and interpreting the data independently. 
My personal biases inherently shaped how the interviews were administered (e.g., 
empathy for participants, unplanned follow-up questions, knowledge of context) and how 
“emergent” themes were identified and organized. Therefore, it is likely that other 
researchers might generate different responses from the participants, and might interpret 
the data differently, as well. However, because careful measures were taken to ensure the 
trustworthiness and quality of the data (e.g., theoretical sampling, peer review and 
debriefing, member checking), as described in Chapter 3, the product of this research is 
no less valid. 
 A second important limitation is the use of women’s largely retrospective 
narratives of the periods during which they were actively contemplating issues related to 
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their mutation-positive statuses. The extent to which this may limit or bias the findings 
varies from participant to participant, as some women were newly tested and in the active 
phase of working through such issues. It is possible that women’s memories may have 
become distorted over time, or that important phenomena were not recalled. Perhaps 
some women were focused on either the positive or negative aspects of their experience, 
and unconsciously misrepresented the memories related to the other category. However, 
because women’s narratives about their experiences as mutation-positive are what 
operationally shape their current adaptation and the meaning they assign to their status, 
and because women’s stories and the way they subjectively recall their experience inform 
both their behavior and identity, these perspectives are still extremely valuable, despite 
the potential for factual distortion. That is to say, what they think they recall may be 
functionally more important than what actually occurred. Producing a record of women’s 
unique narratives and perspectives is consistent with the principles of both feminist 
thought and grounded theory methodology.  
 Another generic limitation of qualitative research is that findings cannot be 
generalized to a broader population from which respondents were drawn, in this case, to 
all young female BRCA mutation carriers. Recruitment methods were unique to this 
study, and they yielded a particular group of 40 women who produced these particular 
results. Furthermore, the issue of volunteerism creates a limitation in that women self-
selected into this study; participants recruited through FORCE and snowball sampling 
initiated contact with me to indicate their desire to participate (as opposed to participants 
recruited from the BI study, to whom I reached out directly based upon my prior research 
which targeted these women (Hoskins et al., 2008; Peters et al., 2006)). The FORCE 
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recruits tended to be younger and more likely to have recently learned their mutation 
status. A subset of the BI participants are part of a prospective NCI study which has been 
active for more than 30 years. These families had a long history of participation in 
multiple different NCI-sponsored research projects over time, and awareness of the 
family’s mutation status dates back more than 10 years for many of them. These families 
commonly had many affected family members and had made extensive use of risk-
reducing surgery before these management strategies gained widespread acceptance. 
Thus, the population described here is heterogeneous in terms of age and longevity of 
knowledge of mutation status, but relatively homogenous with regard to race, 
socioeconomic status, level of education, etc. Therefore, these findings provide little 
insight regarding how individuals who differ on these characteristics might experience 
themselves and their lives as mutation carriers. Future qualitative studies should focus on 
these other subgroups within the BRCA-positive population in order to increase our 
understanding of what kind of variation might exist. 
 A possible major deficit of this study is the absence of a wider range of negative 
experiences. This could, at least theoretically, imply that negative experiences were rare 
or uncommon. More likely, this may be another manifestation of volunteerism in which 
women with positive experiences were more likely to put themselves forward as study 
participants. Although some participants did described having struggled in a specific area 
after learning about their mutations, such narratives were rare. Instead, most participants 
were either still in the depths of the early months of their experiences and did not yet 
have either perceived successes or failures to report, or they had successfully come to 
some sort of peace with their situation over time. Anecdotally, one potential participant, 
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who happened to be the sister of another participant, indicated that she was dealing with 
some very difficult issues. In conducting her screening interview, I felt confident that her 
narrative would enrich the heterogeneity of experience among the group. Between her 
screening interview and her in-depth interview, she wrote to explain that she had decided 
not to participate in the study because she believed that doing so, and re-visiting her 
struggles in depth, would be too painful. Despite my emphasizing to her that her 
experience was very valuable and might be helpful to others coping with similar 
challenges, and despite my reassurance that we did not have to discuss things she wished 
to leave out, she remained firm in her decision not to participate. It is certainly possible 
that other young women who read the study announcement and were eligible to 
participate, chose not to do so for similar reasons. In order to reach women whose 
experiences with BRCA have been negative, recruitment efforts for future studies could 
seek referrals from genetic counselors and medical family therapists who may encounter 
such individuals in their work. A carefully worded study invitation targeted to members 
of this group and delivered by a trusted healthcare provider may be effective in 
encouraging them to participate in a future interview study more focused on issues 
pertinent to them. 
 Future qualitative studies could triangulate sources by including female mutation 
carriers’ partners, family members, and healthcare providers to better understand 
women’s experiences and relationships. Data triangulation could be folded into the 
current data to include findings from focus groups and Colored Eco-Genetic Relationship 
Maps (CEGRMS) (Peters et al., 2006) for participants who have been included in those 
other types of data collection in this and other studies to further enrich our understanding 
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of their experience. A study focusing on intra-family interactions, in which perhaps three 
women from each of ten families were interviewed both separately and as a group about 
their experiences, could provide fascinating insight into family communication, 
interpretations of family narratives, and variations in information processing and 
decision-making in the context of a shared family history. The voices of young male 
mutation carriers (and untested males in HBOC families) are still silent in existing 
literature, and a study similar to this one investigating how they experience their mutation 
status (either known or potential) would likely be both fascinating and informative. Men 
from mutation-positive families are statistically just as likely as women to be mutation 
carriers (due to BRCA1/2’s autosomal dominant mode of inheritance), they are at 
increased risks of certain specific malignancies (e.g., cancers of the male breast, 
pancreas, and prostate), and they can transmit the mutated BRCA allele to their children, 
both male and female. Finally, once qualitative data have been used to form a 
comprehensive understanding of the full range of experiences for members of this 
population, future quantitative studies might formally investigate the strength and 
direction of relationships between variables and components of the proposed model in 
order to more confidently recommend interventions and/or changes to policy. 
Conclusion 
 The current study explored how young female carriers of BRCA1/2 mutations 
coped with the normative challenges of young adulthood and navigated the constraints 
imposed by their cancer risk. Specifically, these data illustrated how breast and ovarian 
cancer risk and risk perception shaped and were shaped by young women’s interactions 
in partner relationships, their decision-making about family formation, and their handling 
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of risk-reduction strategies and decisions. My findings comprise a unique contribution to 
the literature on the diverse ways that women experience this challenging health situation 
in various developmental and relationship contexts.  
Participants’ experiences suggest that some mutation-related support services 
were not readily available, hard to find, and occasionally less than authoritative relative 
to their continued needs over time. There is a shortage of mental health professionals who 
are conversant with (let alone authoritative about) the facts and management issues 
related to BRCA1/2 and hereditary breast/ovarian cancer. This reality compromises 
providers’ ability to help mutation carriers deal with their syndrome-related consequences 
for interpersonal relationships. These results identify the need for remedies aimed at 
correcting information and experience-related deficiencies among providers, to enable 
their providing more comprehensive and ongoing services to individuals, couples and 
families affected by this and other hereditary cancer syndromes. 
  More research, both quantitative and qualitative, is needed to explore how people 
of all backgrounds experience and describe their perceived genetic risk of cancer. The 
women in the current study have demonstrated that, when given the opportunity to fully 
participate in a research project that solicits and values individual narratives and 
perspectives, the experience can be empowering and enlightening for all involved. For 
many participants, the interview afforded them the opportunity to think about their story 
in a new way or make connections that they had not previously discovered. At the end of 
her interview, Marie told me that “your questions really hit on everything that has been 
impacted for me, but it was cool to talk about all of it together – I haven’t done that 
before.” Others simply appreciated the opportunity to talk through their experience and 
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know that they were not alone, like Reina, who stated, “it’s very cathartic…and it’s a 
relief to know that other women experience similar issues.” Many women reported that 
participating in this study was a positive and generative experience, one they were happy 
to share in the hope that doing so might help others similarly affected. Rachel stated that 
she was happy to do “anything that I can do to maybe help not have somebody go 
through the same way I had to go through it.” The opportunity to share their stories, make 
sense of them, feel like part of a community, and have their experiences validated as 
meaningful and important was a powerful experience for these courageous women. I am 
forever indebted to each of my participants for sharing their stories with me. I hope that I 
have conveyed the gravity of their common challenge as well as the diversity of their 
solutions in a way that will provide comfort and insight to mutation carriers not yet 
identified and to the providers who are committed to delivering the best possible care to 
women at increased genetic risk of cancer. More importantly, I hope that I have captured 








Appendix A: Historical & Biological Background of BRCA1/2 Mutations 
The Human Genome Project, undertaken in 1990 by the National Center for 
Human Genome Research (now National Human Genome Research Institute) and the US 
Department of Energy ("Human Genome Project  Information," 2005), revolutionized our 
understanding of human genetics. Mutations in the genes BRCA1 and BRCA2 were 
implicated in hereditary breast/ovarian cancer in 1994 and 1995, respectively (Miki et al., 
1994; Wooster et al., 1995). BRCA1 is located on the long arm of chromosome 17, while 
BRCA2 is located on the long arm of chromosome 13. More than 1,640 and 1,890 distinct 
mutations have been reported in BRCA1 and BRCA2, of which 845 and 765, respectively, 
are classified as disease-causing (Lindor, McMaster, Lindor, & Greene, 2008; NHGRI, 
2007). Although the two syndromes share important fundamental similarities (e.g., the 
striking predisposition to both breast and ovarian cancer), there are unique characteristics 
of each that make the two orders dissimilar clinically. For example, the risk of developing 
ovarian cancer is significantly greater in BRCA1 than in BRCA2. The increased risks of 
male breast, prostate and pancreatic cancer are strongest in BRCA2 carriers. BRCA1-
related breast cancer is predominantly estrogen-receptor negative, and has unique 
histologic features, while BRCA2-related breast cancer more closely resembles sporadic 
breast cancer (Lindor et al., 2008). Both genes are related to DNA repair, transcription 
regulation, and cell cycle control (Boulton, 2006; Boyd, 2003; Boyd et al., 2000; Brody 
& Biesecker, 1998; Ding et al., 2004; Prat et al., 2005).   
BRCA1/2 mutations predispose carriers to a 50-87% lifetime risk of breast cancer 
(Antoniou et al., 2003; Bredart, Autier, Audisio, & Geragthy, 1998; Brody & Biesecker, 
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1998; Brose et al., 2002; Cappelli et al., 2001; Easton, Ford, & Bishop, 1995; Narod et 
al., 1998; Prat et al., 2005; Struewing et al., 1997; Suthers, 2007). Ovarian cancer risk 
among mutation carriers varies depending on which mutation is present; BRCA1 
mutations are associated with 20-60% lifetime risk of ovarian cancer, while the ovarian 
cancer risk conveyed by BRCA2 mutations ranges from 10-40% (Antoniou et al., 2003; 
Claus et al., 1996; M. C. King et al., 2003; Pavelka et al., 2007; Risch et al., 2001; 
Struewing et al., 1997; Whittemore, Gong, & Itnyre, 1997). More recent research has 
resulted in narrower risk estimates of 65%-82% for breast cancer and 39%-54% for 
ovarian cancer in BRCA1 carriers (Antoniou et al., 2003; M. C. King et al., 2003), and 
45% for breast cancer and 11-30% for ovarian cancer in BRCA2 carriers (Antoniou et al., 
2003; Boyd, 2003). There is some evidence of an ovarian cancer cluster region on exon 
11 of the BRCA2 gene; mutations occurring in this region are likely associated with 
higher risk of ovarian cancer than other BRCA2 mutations (Boyd, 2003; Gayther et al., 
1997; Gayther et al., 1995). These levels of risk are considerably higher than those 
present in the general population, about 12.8% for breast cancer and 1.5% for ovarian 
cancer (DevCan, 2005; Fay, 2004; Fay et al., 2003). Hereditary cancers also tend to occur 
at a younger age than their sporadic counterparts. For example, the mean age of onset is 
54 years for ovarian cancer in BRCA1 carriers (compared with a mean age of 63 for 
sporadic ovarian cancer) (Boyd et al., 2000; Lakhani et al., 2004), and BRCA1/2-linked 
breast cancer typically occurs before the age of 50 (Narod et al., 2002). Carriers’ risk 
level begins to increase at approximately age 25, necessitating medical screening starting 
early in the life course (Meijers-Heijboer et al., 2001). Overall, diagnosis may occur in 
the 40s for ovarian cancer (BRCA1, later for BRCA2) and in the 30s and 40s for breast 
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cancer (Boyd et al., 2000; Moslehi et al., 2000; Pavelka et al., 2007). There do not appear 
to be significant differences in histology of tissue removed for risk-reduction from 
mutation carriers versus non-carriers (Casey et al., 2000). In women who do develop 
cancers, survival rates are similar to what is observed in age-matched patients diagnosed 
with sporadic (rather than hereditary) cancers, a ten-year survival rate of approximately 
50% (Meijers-Heijboer et al., 2001). 
As previously stated, mutations in BRCA1 and BRCA2 make up a small but 
notable proportion of breast and ovarian cancer cases. Shortly after the mutations were 
identified, they were thought to explain about seven in 100 cases of breast cancer in 
women with a family history (Ford et al., 1995) and approximately 10-15% of all ovarian 
cancer cases (Pal et al., 2005; Risch et al., 2001), with more of these resulting from 
BRCA1 (about 5.7%) than BRCA2 (about 3.8%) (Boyd, 2003; Claus et al., 1996; Pavelka 
et al., 2007; Prat et al., 2005). A more recent study of 1220 women up to age 55 who 
were diagnosed with breast cancer (unselected for family history) reported that 3.8% had 
a mutation in either BRCA1 or BRCA2 (Southey et al., 1999). However, the proportion of 
cancer cases in young women attributable to mutations in BRCA1/2 paints a very 
different picture. A UK study found BRCA1/2 mutations in 5.9% of breast cancer patients 
35 and younger, and in 4.1% in those aged 36 to 45 (Peto et al., 1999). Finally, BRCA1/2 
mutations are thought to explain “approximately 33% of [breast cancer] cases age 20-29 
years,” a finding highly relevant to the proposed study (Claus et al., 1996, p. 2318).   
The prevalence of the mutations in the general population is quite small; for 
example, the gene frequency of BRCA1 as been estimated to be between 0.0006 (Ford et 
al., 1995) and 0.002 (Struewing et al., 1995); population prevalence for these genes are 
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difficult to determine because widespread screening is impractical from both logistical 
and financial perspectives (Brody & Biesecker, 1998). These numbers translate to an 
estimated overall BRCA carrier frequency of about 1 in 800, but it is significantly 
higher—about 1 in 40—in the Ashkenazi Jewish population due to the prevalence of 
three unique founder mutations, two in BRCA1 and one in BRCA2 (Boyd, 2003). 
Both BRCA1 and BRCA2 are highly but incompletely penetrant: most, but not all, 
individuals who inherit a deleterious mutation will develop cancer if no risk-reducing 
actions are taken. Whether or not cancer develops in the presence of a BRCA1/2 mutation 
is presumed to depend on the specific mutation that is present (Surbone, 2001), and on 
both gene-gene and gene-environment interactions over the lifecourse (Boyd, 2003; Eisen 
et al., 2000; Pavelka et al., 2007). Environmental influences include use of oral 
contraceptives and surgical sterilization (Narod et al., 1998; Narod et al., 2001; 
Whittemore et al., 2004), tubal ligation (Narod et al., 2001), and parity (Narod et al., 
1995).   
Breast and ovarian cancer are quite different with regard to ease of detection and 
efficacy of screening. Breast screening is widely practiced, with women in the US 
currently advised by their healthcare providers and through a wide variety of public 
service announcements to perform monthly breast self-exams (ACS, 2007). In addition, a 
clinical breast exam is a standard component of most annual Ob/Gyn and primary care 
visits (Day, 2008). Therefore, the majority of women who participate in regular medical 
care receive at least this level of breast cancer screening. However, ovarian cancer 
screening is much more difficult and less common, and is not a standard component of 
annual medical examinations aside from a standard pelvic exam (which has little if any 
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value related to early detection of ovarian cancer). Currently, the “best” available 
screening methods, serum CA-125 test and transvaginal ultrasound sonography (Pavelka 
et al., 2007) are generally regarded as ineffective, but are nonetheless offered to women 
known to be at high risk of developing ovarian cancer (Prat et al., 2005). The 
recognizable symptoms of ovarian cancer include pelvic/abdominal pain, urinary 
urgency/frequency, bloating, and early satiety occurring more than twelve days per 
month, all occurring for less than one year (Andersen et al., 2008); interestingly, 
gynecological symptoms are reported least frequently (Goff, Mandel, Melancon, & 
Muntz, 2004). Researchers have recommended that medical professionals make BRCA-
positive women aware of these symptoms (Pavelka et al., 2007), but they may be easily 
overlooked since they may be confused with pre-menstrual symptoms or other minor and 
transient health concerns.  
In addition to breast and ovarian cancer, there has been some research indicating 
that mutations in BRCA1/2 may predispose carriers to malignancies including male breast 
cancer, colorectal cancer (Ford et al., 1994; Thompson & Easton, 2002), prostate cancer 
(BCLC, 1999; Ford et al., 1994; Sigurdsson et al., 1997; Struewing et al., 1997), 
pancreatic cancer, gallbladder and bile duct cancer, stomach cancer, and malignant 
melanoma (BCLC, 1999). However, the level of risk of these cancers is significantly 
lower than the risks of breast and ovarian cancer associated with mutations in BRCA1/2, 
and for most (with the exception of prostate cancer for male carriers), normal population 
screening guidelines are recommended (Burke et al., 1997). 
Both BRCA1 and BRCA2 demonstrate an autosomal dominant inheritance pattern. 
Autosomal dominant mutations are passed with equal frequency from and to males and 
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females; that is, males and females are equally likely to inherit a mutation in BRCA1/2, 
and mutations may be inherited from either mothers or fathers. This fundamental 
characteristic of autosomal dominant Mendelian genetics is widely misunderstood in the 
context of hereditary breast/ovarian cancer, which many erroneously consider to be a 
“female disease,” thereby overlooking the important role of men in these families, both as 
carriers/transmitters of the mutations and as persons at risk of specific syndromic 
malignancies. In addition, only one mutation is needed in order for risk status to be 
achieved; therefore, individuals need only inherit one mutation, from one parent, in order 
to be considered “BRCA-positive.” Finally, an autosomal dominant inheritance pattern 
means that each offspring of an affected individual will have a fifty percent chance of 
inheriting a parent’s mutation. In other words, a parent with a mutation would statistically 
be expected to pass that mutation on to half of her/his children. 
In addition to these two identified mutations, many scientists believe that there are 
other forms of “inherited breast cancer” that are not yet fully understood. Efforts are 
underway to identify additional genetic mutations related to increased susceptibility to 
breast/ovarian cancer (e.g., BRCA3), but results thus far have not been definitive (P. 
Smith et al., 2006; Thompson & Easton, 2002). If additional genes are identified, the 
proportion of breast and ovarian cancers explained by genetic predisposition will 
continue to increase (Brody & Biesecker, 1998; Burke, Press, & Pinsky, 1999). At 
present and given the current state of knowledge about this hereditary cancer syndrome, it 
is difficult to ascertain what proportion of breast and ovarian cancer cases are due to 
genetic predisposition, or the general population carrier frequency of BRCA1/2 (Brody & 
Biesecker, 1998). However, as more and more individuals are tested and their long-term 
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Appendix B: Medical & Psychosocial Issues Related to BRCA1/2 Testing 
 Identification of HBOC families and mutation-positive individuals. In order to 
fully understand the experiences of young BRCA1/2 mutation carriers, we must first 
understand the process by which they learn of their increased risk status. Researchers 
have identified several factors which suggest the presence of hereditary breast/ovarian 
cancer (HBOC) within families, including young age of cancer onset (i.e., pre-
menopausal or <60), the presence of bilateral breast cancer, and individuals affected in 
multiple generations (Brody & Biesecker, 1998; Decruyenaere et al., 2000; Prat et al., 
2005). The official recommendation statement from the American Society of Clinical 
Oncology (ASCO) reads: 
ASCO recommends that genetic testing be offered when (1) the individual has 
personal or family history features suggestive of a genetic cancer susceptibility 
condition, (2) the test can be adequately interpreted, and (3) the results will aid in 
diagnosis or influence the medical or surgical management of the patient or 
family members at hereditary risk of cancer. ASCO recommends that genetic 
testing only be done in the setting of pre- and post-test counseling, which should 
include discussion of possible risks and benefits of cancer early detection and 
prevention modalities, (ASCO, 2003). 
 
Although these guidelines are helpful, they are open to interpretation (e.g., there is 
variability in what different healthcare professionals consider “suggestive of cancer 
susceptibility” with regard to family cancer history), and therefore some ambiguity may 
exist in decision-making about testing. 
Submission of a biological sample for genetic testing requires a blood or skin 
sample, from which individual cells are then extracted. If a BRCA1/2 mutation is 
suspected within a family, an affected member (one who has been diagnosed with breast 
of ovarian cancer) is usually tested first. This test requires “full sequencing,” or a 
complete review of the more than 3,500 distinct mutations and sequence variations that 
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have been identified in BRCA1 and BRCA2 (Van Riper & McKinnon, 2004). Of these, 
approximately 845 and 765, respectively, are known to be deleterious, or definitely 
associated with increased risk of breast/ovarian cancer; the others are missense mutations 
or variants of unknown significance, for which the level of cancer risk is not fully 
understood (NHGRI, 2007). Full sequencing is no small undertaking. The sheer number 
of possible mutations, together with their scattered distribution throughout the coding 
regions of the genes (Boyd, 2003; Prat et al., 2005) makes this a technically difficult and 
time-consuming process; hence, it is quite expensive, with the current retail cost of 
sequencing ranging from about $375 for single site testing to $3,000 for full sequencing 
of both genes (NCI, 2002; Van Riper & McKinnon, 2004). This test may or may not be 
covered by health insurance, and some insurers require that an individual be already 
affected by cancer to qualify for reimbursement. Therefore, access to pre-symptomatic 
testing may be limited to those with excellent coverage or who are able to pay for the test 
privately. Adding to this complicated dynamic, one company, Myriad Genetics, holds the 
US patents (as well as patents in at least 16 other countries) on the genetic test for 
BRCA1/2, (Balter, 2001). Therefore, all tests of US patients must be submitted to Myriad, 
which can select the price of the test relatively independently. 
 
Proband testing. There are three possible outcomes of genetic testing of a 
proband (the first person in a family to be tested) in an HBOC family. First, testing may 
identify the presence of a known pathogenic mutation; this occurs in less than half of the 
tests performed in white women, and with a significantly lower frequency in tests of 
women from racial/ethnic minorities, most notably African-Americans (Boyd, 2003). In 
cases with this testing outcome, genetic counselors and physicians who work with HBOC 
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families would be able to understand and explain a patient’s (and family members’) 
cancer risk, because risk information has been determined from other families with 
mutations in the same gene (Palma et al., 2006). However, even with the identification of 
a known mutation, it is impossible to know whether or not a person will develop cancer, 
at which site(s) a cancer or cancers may develop, or when (NCI, 2002).   
A second possible outcome of an initial genetic test within a family is the 
identification of a variant of unknown significance, a mutation in BRCA1/2 that has not 
been previously identified or for which the associated cancer risks are not yet known 
(Palma et al., 2006). This result is sometimes referred to as an ambiguous result and is 
more likely to occur when testing women from racial/ethnic minorities. In this situation, 
it is much more difficult to know whether the identified mutation is associated with 
increased cancer risk; all humans have multiple genetic mutations that occur naturally, 
and most of them are not deleterious (NCI, 2002). An ambiguous result may be 
suggestive of increased risk, but precise risk information is difficult to determine because 
the mutation has not previously been encountered.   
Finally, proband testing may yield an uninformative result when no BRCA1/2 
mutation is identified; ambiguity exists because there is a possibility that a mutation 
exists in another cancer susceptibility gene (not BRCA1/2), or that there is an undetected 
mutation in BRCA1/2. Individuals and families are left in a difficult situation, as risk 
management decisions must be made without specific guidelines (O'Neill et al., 2006). 
Subsequent testing of other family members. If an initial genetic test within a 
family results in the identification of a known mutation, testing of other family members 
is fairly straightforward. Because the location of the “family mutation” on the 
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chromosome is known, subsequent tests within the same bloodline can focus on that 
exact location to determine whether or not the mutation is present, rather than examining 
all of the potential BRCA1/2 mutation sites; hence, the level of potential ambiguity is 
reduced. This is referred to as site-specific testing. Individuals who undergo testing in this 
context will be able to more easily interpret their test results as either positive or 
negative; when a test comes back negative in this case, it is considered a “true negative” 
or “real negative,” (Palma et al., 2006). Because the prevalence of BRCA1 and BRCA2 
mutations in the general population is so low, it is extremely unlikely that an individual 
would test negative for a family mutation and actually carry another, different BRCA 
mutation (NCI, 2002). Individuals who are true negatives can assume that their risk of 
breast/ovarian cancer is the same as the risk of the general population (NCI, 2002; Palma 
et al., 2006). In certain ethnic populations in which the prevalence of BRCA mutations is 
significantly higher (e.g., individuals of Ashkenazi Jewish heritage), and in which only a 
small number of specific mutations have been linked to cancer risk (in the Ashkenazim, 
for example, there are 3 such “founder” mutations), the detection of mutations in both 
parental lineages is more likely to occur.  
 If an initial genetic test within a family produces an uninformative or ambiguous 
result, subsequent family members may also be tested for the variant of unknown 
significance. Full screening may also be used in order to ascertain whether a known 
mutation is also present, especially if there are other affected family members. Multiple 
detections of the same variant of unknown significance in members of the same family 
and across multiple families will contribute to knowledge within the field regarding the 
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implications of the variant, as time passes and the health outcomes of those individuals 
can be followed by researchers. 
 Finally, if the initial genetic test of an affected member of a family results in a 
negative result (i.e., no mutation or variant is detected), it may be considered impractical 
to test other family members unless they are also affected. However, members of HBOC 
families who do not have a mutation in BRCA1/2 can still develop breast/ovarian cancer 
since they are at standard population risk; therefore, one affected family member testing 
negative in a family with multiple affected individuals does not mean that no mutation is 
present, and further testing of other affected family members may be advisable. 
Limitations of testing. Several characteristics of genetic testing for BRCA1/2 
limit its utility and appeal to some individuals considering testing. Perhaps most 
importantly, because of the uncertainties inherent in cancer risk figures and the limited 
spectrum of proven cancer prevention strategies, even an informative genetic test (i.e., a 
true positive or true negative) leaves many lingering questions (Bredart et al., 1998), as it 
indicates only the probability, rather than certainty, that an individual will develop cancer 
(Van Riper & McKinnon, 2004). Recent data have raised the possibility that there may 
still be some residual familial risk of breast cancer even among mutation-negative women 
from mutation-positive families (Katki, Gail, & Greene, 2007). There are no guarantees 
about whether, when, or in what form cancer may develop. There are no risk-reduction or 
treatment strategies that are 100% effective; even surgical prophylaxis does not 
completely mitigate one’s risk of cancer. Therefore, regardless of the outcome of one’s 
genetic test, some level of uncertainty remains (Van Riper & McKinnon, 2004). 
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 Another significant limitation is the fact that genetic tests may miss mutations that 
truly exist, especially when those mutations are characterized by deletions or 
rearrangements of large segments of DNA (Srivastava, McKinnon, & Wood, 2001). In 
both situations, individuals may receive negative or uninformative test results, resulting 
in inappropriate, insufficient, and/or uninformed medical advice. Negative genetic test 
results are fully informative only when a known mutation has previously been identified 
within a family (Van Riper & McKinnon, 2004). 
 Because genetic conditions are inherently a family issue, the decision of one 
individual to undergo testing has implications for other family members (Bottorff et al., 
2000). It is difficult to ascertain the extent to which pressure from concerned family 
members influences testing decisions by others in the family (Murphy, 1999). For 
example, adult children may pressure one of their parents or siblings to get tested if they 
are known to have had a syndrome-related cancer, or out of a desire to share their own 
testing experience with other family members out of a sense of togetherness. However, 
family members must also be aware that it is very possible for positive tests to yield 
unwanted information including, for example, identifying an individual who has chosen 
not to be tested as an obligate carrier (e.g., a woman with a maternal family history of 
breast/ovarian cancer and an untested mother, who chooses to undergo testing herself for 
a known family mutation and learns she that is positive. Mendel’s Laws require that the 
untested mother also carry the mutation. Thus, the mother who had chosen not to be 
tested, and who may not want to know her mutation status, will nonetheless learn that she 
is a carrier) (Bottorff et al., 2000). These complicated family issues are often not fully 
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considered in the period of time leading up to a genetic test, but they are important 
factors in the process. 
 A final and important limitation of genetic testing for BRCA1/2 is that, because 
(1) mutated genes are rare in the general population, (2) the genes are very large, and (3) 
the number of reported mutations is large (i.e., more than 845 in BRCA1 alone), their 
identification in a random individual from the general population is impractical. 
Consequently, a cancer-affected person from a family with multiple cases of breast 
and/or ovarian cancer, is generally the preferred starting point for testing. If a specific 
disease-causing mutation is identified, that that specific mutation is sought in DNA 
samples of other family members. But even with this strategy, the majority of multiple-
case families do not have a detectable mutation (Murphy, 1999, p. 236). Nonetheless, 
members of such families remain at increased cancer risk simply on the basis of their 
family history, and must be managed with that knowledge in mind. 
Genetic testing is most likely to yield an informative result when an affected 
person is the first tested within a family, because that test can detect, in part, whether a 
cancer is associated with a hereditary syndrome. If an unaffected person is the first tested 
and the result is negative, there is no way of knowing whether the negative outcome is 
due to the absence of a mutation in the family or simply that the individual is a non-
carrier of a still-undetected family mutation. Therefore, in order for a family to begin the 
process of genetic testing for multiple individuals, an affected member must usually be 
willing to be the first to be tested. Although many cancer-affected individuals are often 
highly motivated to undergo genetic testing (Meiser, 2005), those who are not can inhibit 




Risks of testing. The literature elucidates several risks that come along with 
choosing to undergo genetic testing for BRCA1/2. Historically, concerns related to 
potential discrimination in employment and health/life insurance have been cited as 
reasons to be wary of genetic testing (Bredart et al., 1998), despite the fact that 
documented instances of such behavior are extraordinarily rare. At the institutional level, 
steps are being taken to mitigate these risks, including the recent passage of the Genetics 
Information Non-Discrimination Act (GINA) on May 21, 2008 (HR 493). GINA prevents 
employers and insurers from making decisions about individuals’ job or insurance status 
based on genetic information; it will take effect in May 2009 for insurance issues and 
November 2009 for employer issues. Noticeably missing from GINA are protections 
related to life, disability, and long-term care insurance, any or all of which could be 
salient concerns for those living with increased genetic risk of cancer (NHGRI, 2008). 
Although GINA is an important step forward in protecting individuals and families from 
genetic discrimination, it may not fully alleviate the fear and apprehension that some 
potential testers experience with regard to their genetic information. Additionally, GINA 
does not (and no government act or policy could) protect individuals from discrimination 
that occurs on the interpersonal level, such as, for example, being discriminated against 
as a potential romantic partner because of another person’s fear of the implications of a 
mutation. Therefore, individuals considering testing must carefully consider how 
possessing information about their genetic makeup and lifetime health risks may impact 




Another important risk of testing is that women who receive a negative or 
uninformative result could be lulled into a false sense of security regarding their risk of 
cancer, believing that because they do not have a deleterious mutation in BRCA1/2, they 
are not at risk of breast/ovarian cancer. This is certainly not the case: non-carriers are still 
subject to population risk of cancer (Bredart et al., 1998). Finally, there are significant 
risks related to negative psychological and emotional reactions to testing, including 
anxiety, depression, guilt, grief, and relational issues. These are discussed in detail in this 
appendix. 
At-Risk Populations 
As previously stated, the general population prevalence of mutations in BRCA1/2 
is thought to be relatively low, estimated at between 1/800 and 1/1000 (Brody & 
Biesecker, 1998); more recently, narrower estimates closer to 1/300 have been frequently 
reported (Boyd, 2003). However, there are some groups for which the frequency of these 
mutations is much higher, and these groups have been the focus of much intense 
examination. Among Ashkenazi Jews, three ‘founder mutations,’ two in BRCA1 and one 
in BRCA2, have been identified, carried by as many as 1 in 40 members of this 
population (Boyd, 2003). Those of Ashkenazi Jewish descent in the United States have 
been studied fairly intensely, and are considered a very high-risk group. Among 
Ashkenazi Jews, about 40% of those with ovarian cancer and 12-30% of those with 
breast cancer are also BRCA1/2-positive (Boyd, 2003; Struewing et al., 1997). Founder 
mutations have also been identified in the Icelandic population, with a gene frequency of 
one in 173 (Brody & Biesecker, 1998). Genetic testing is more frequently advised for 
members of these populations, and may be informative even when a family mutation has 
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not been identified (Brody & Biesecker, 1998). Even for probands, these tests typically 
require only site-specific testing for the mutation(s) for which the population is at-risk. 
Psychosocial Issues Related to Genetic Testing 
 Ethical issues. Genetic testing brings with it several ethical issues, and some are 
more or less relevant in the context of HBOC families. At the broadest level, ethical 
issues related to testing for BRCA1/2 lie in the communication of risks rather than 
certainties, an unavoidable consequence of incomplete penetrance of the genes, 
knowledge about the presence or absence of a BRCA mutation is individual, predictive, 
and probabilistic (Bayeritz, 1998). Such information is, by nature, easily manipulated and 
may be misunderstood by those who receive cursory or incomplete genetic education 
(Knoppers & Chadwick, 1994). This occurs in the context of rising rates of breast cancer 
among young women, mostly due to improvements in detection (Surbone, 2001). 
However, one result of such improvements has been a cultural perception of breast cancer 
as an epidemic (S. King & Schottenfeld, 1996) and as one of the most prominent and 
symbolic issues in modern women’s health (Surbone, 2001). 
There are several ethical issues related to the availability of testing and the 
manner in which testing is performed. One of the most basic is a basic respect for patient 
autonomy, which dictates that those considering genetic testing be fully informed about 
the impact that the test outcome may have on their lives. Healthcare professionals 
interacting with patients in the pre-testing phase must ascertain that each individual is 
undergoing testing to satisfy his or her own needs, and not simply to please other family 
members or healthcare providers (Kash, Dabney, Holland, Osborne, & Miller, 2000).   
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Many in the fields of genetics and genetic counseling argue that because breast 
cancer and, to a lesser extent, ovarian cancer are conditions for which screening, 
prevention, and treatment exist, genetic testing for BRCA1/2 is highly advantageous and 
should be encouraged for those who are potentially at-risk. However, it is important to 
consider personal and situational factors that may influence individuals’ and families’ 
reception of information about cancer risk, as well as potential emotional reactions; for 
example, individuals with generally high levels of anxiety may be more significantly 
disturbed or debilitated by news of a positive genetic test result (Lerman, Rimer, & 
Engstrom, 1991). Individuals have different “desires for information and control in the 
healthcare setting,” (Lerman et al., 1991, p. 1279), and these desires are likely to 
influence willingness to be tested and possess information about test results, as well as 
ability to cope with the result. Coping in the context of any result is largely facilitated by 
proper genetic counseling and education prior to and after testing, which can address both 
anticipated and actual emotional reactions and can assess and reconcile inaccurate risk 
perception (Dorval et al., 2000). However, not all individuals undergoing genetic testing 
for BRCA1/2 have access to or are required to undergo genetic counseling, as it is not yet 
a required prerequisite to testing in all contexts. 
The familial nature of genetic information brings with it a multitude of ethical 
issues, including informed consent, individuals’ rights to know or not know their own 
genetic information in light of family members’ preferences, confidentiality and privacy 
issues, and responsibility to future generations (Costalas et al., 2003; R. Green & 
Thomas, 1997; Juengst, 1999; Van Riper & McKinnon, 2004). For example, informed 
consent issues can arise when multiple members of a family undergo testing at the same 
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time and careful, individualized genetic education is not provided to all members before 
and after testing. Some individuals have even reported that they received mutation test 
results over the telephone (Van Riper & McKinnon, 2004). Further, informed consent is 
not always conceptualized as an ongoing process meant to maximize patient autonomy; 
rather, many view it as a brief communication of the technical and medical aspects of the 
testing process. Although this form of consenting may facilitate access to genetic 
counseling in areas where in-person services are unavailable and is a reasonable solution 
to the currently inadequate number of genetic counselors in the US (Jenkins et al., 2007), 
a downside is that it may fail to fully disclose the potential social and ethical implications 
(ASCO, 1996).  
Regarding individuals’ rights to know or not know, there is some debate over a 
patient’s right to self-determination and the ‘right not to know’ (ASCO, 1996; Shaw, 
1987). This ties in with feelings of responsibility to future generations, in that some seek 
genetic information not because of a personal desire to know one’s mutation status, but 
because it is useful to others, e.g., children (Rhodes, 1988). Other problems can arise 
when, for example, members of different generations do not agree on whether or not to 
pursue testing. For example, a member of a younger generation may choose to be tested 
based on knowledge that a relative other than a parent is a mutation carrier, even though 
the parent of the individual has chosen not to be tested. If the tested individual receives a 
positive result, the parent is also then known to be positive. The tested individual would 
then have information about the parent’s genetic status that the parent her/himself did not 
wish to have. Similarly, there is debate regarding, for example, whether the daughter of a 
cancer patient has a right to know her mother’s mutation status, or whether a member of a 
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high-risk family has the right to be informed of her/his risk by a health professional if 
appropriate family members refuse to share information (Surbone, 2001).   
Once genetic information is obtained via testing, there are commonly questions 
regarding with whom, when, and how to share that information. If a tested individual dies 
before sharing mutation information with her/his relatives, should that information be 
available to those family members after the death? Or is that information considered 
private and inaccessible? More rarely, information that was not being sought can be 
obtained via genetic testing for known mutations, such as chromosomal abnormalities or 
non-paternity, and such information can have serious implications for both individuals 
and families (Kash et al., 2000). Clearly, such situations have the potential to create 
complex ethical and family dilemmas. 
Decision to test. The decision to undergo genetic testing for BRCA1/2 is a 
personal one and can be difficult. Within HBOC families, there exists variation regarding 
individual decisions to test; it is certainly true that not all at-risk individuals choose to 
undergo testing (Brody & Biesecker, 1998). Further, while surveys of the general 
population indicate that interest in genetic testing for hypothetical cancer susceptibility 
genes is high (Croyle & Lerman, 1993), research regarding interest in testing among 
those with personal and/or family histories appears to be quite complex. Several 
demographic variables have been associated with the decision to undergo testing for 
mutations in BRCA1/2. Older individuals have been shown in some studies to be more 
likely to undergo testing than younger individuals (Biesecker et al., 2000; Foster et al., 
2004), while other studies have supported the opposite as true (Lerman, Daly, Masny, & 
Balshem, 1994; Pasacreta, 2003). Regarding gender, women are more likely to choose 
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testing than men (Pasacreta, 2003), especially married women; married men are more 
likely to test than unmarried men (Biesecker et al., 2000). Being a parent also appears to 
be related to choosing to undergo testing (Pasacreta, 2003). Some researchers have 
explained these associations as related to motivation to test for the sake of one’s children; 
older and married individuals are more likely to have adult children who may also wish 
to be tested, and so testing these individuals is especially informative with regard to other 
family members (Biesecker et al., 2000).  
Ethnicity appears to be associated with likelihood of testing, in that Ashkenazi 
Jewish women are more likely to choose to undergo testing than Caucasian women (due 
to the high incidence of mutations in that population, as discussed previously), who are in 
turn more likely to test than African American women (Pasacreta, 2003). One’s own 
breast cancer status appears to be unrelated to the decision to undergo testing or to follow 
through with receiving results afterward (see variation in decision to receive results) 
(Armstrong et al., 2000; Biesecker et al., 2000; Lerman et al., 1996).     
In addition to these demographic variables, research on a variety of hereditary 
cancer syndromes has identified several personality, psychological, family, and 
relationship characteristics now believed to be associated with choosing to undergo 
genetic testing. These include a tendency to cope by seeking information, a belief that 
one has a high level of control over health, low tolerance for uncertainty (Brody & 
Biesecker, 1998; Croyle, Dutson, Tran, & Sun, 1995), high family cohesion (Biesecker et 
al., 2000), higher levels of cancer worry (Durfy, Bowen, McTiernan, Sporleder, & Burke, 
1999; Foster et al., 2004), high perceived risk of cancer (Glanz, Grove, Lerman, Gotay, & 
LeMarchand, 1999; Press, Yasui, Reynolds, Durfy, & Burke, 2001; Struewing et al., 
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1995), high actual risk of cancer (Glanz et al., 1999; Lipkus, Iden, Terrenoire, & 
Feaganes, 1999), and a belief that learning about one’s cancer risk is important 
(Armstrong et al., 2000). Another study reported that women who believe that 
undergoing regular mammograms could be beneficial to health and could give at-risk 
women control over health were more likely to undergo testing (Tambor, Rimer, & 
Strigo, 1997). This is consistent with another group’s conceptualization of genetic testing 
as “a coping response that may be facilitated by disease-specific distress, if this action is 
perceived as leading to increased control over disease outcomes,” (Lerman et al., 2002, p. 
792) and with other research supporting a connection between positive views of medical 
screening as an important predictor of testing interest (Press et al., 2001).   
Brody & Biesecker (1998) reported that individuals who are optimistic are more 
likely to choose to undergo testing, but this finding contradicts another study which found 
that the reverse was true (Lerman et al., 1997). Reported intention to undergo testing at 
baseline was related to a greater likelihood of testing over time in multiple studies 
(Lerman et al., 1997; Pasacreta, 2003), suggesting that once an individual enters the 
healthcare environment in the context of an appointment with a genetic counselor or 
other health professional who can facilitate testing, the patient has already made a 
decision regarding testing. Perception of susceptibility to cancer and higher perceived 
risk of cancer are both reported to be key predictors of interest in genetic testing 
(Pasacreta, 2003). Other researchers have reported that those who perceive a large 
number of personal benefits as a result of testing, accompanied by few personal costs, are 
more likely to choose to be tested (Cappelli et al., 2001), while those with lower levels of 
cancer-specific distress are less likely to choose to undergo testing (Lerman et al., 1997). 
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Those who self-refer for genetic counseling are more likely to undergo testing than those 
who are referred by physicians (Schwartz et al., 2000). 
Multiple studies have investigated the impact of psychological distress and 
knowledge of genetics and breast cancer risk factors on intention to undergo testing and 
have not discovered a significant relationship (Pasacreta, 2003). Other factors that have 
been hypothesized to be related to the decision to test but in research appear to be 
unrelated include “family conflict, family expressivity, depression, spirituality, and self-
esteem levels,” (Biesecker et al., 2000, p. 261). 
One of the most significant predictors of interest in genetic testing for BRCA1/2 is 
perceived susceptibility to breast/ovarian cancer, whereby women who more strongly 
believe that they are susceptible to cancer are more likely to report that they are interested 
in genetic testing (Durfy et al., 1999; Pasacreta, 2003; Schwartz et al., 2000). However, 
other researchers have found no relationship between these two variables in studies of 
racial differences in interest in genetic testing that focus primarily on African-American 
women (Lerman et al., 1999; Lipkus et al., 1999). 
Variation in decision to receive results. It is interesting to note that not all 
individuals who choose to undergo genetic testing for hereditary cancer will actually 
receive their results. Some individuals choose to delay receipt of test results or change 
their mind about wanting to know about their mutation status after submitting a 
biological sample. One study of individuals from hereditary breast cancer families found 
that only 43% of members eligible for testing elected to receive their results; those who 
did so were more likely to be female, have already had cancer, have higher levels of 
education, and have health insurance (Lerman et al., 1996); there was a positive 
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correlation between receipt of test results and knowledge about BRCA testing, high 
perceived benefits of testing, and higher levels of cancer worry and distress (Lerman et 
al., 1996; 1997). 
According to the limited research that has investigated genetic testing and 
spirituality, it appears that an inverse relationship exists between spirituality and 
likelihood of receiving test results, and that this relationship is mediated by perceived risk 
of breast cancer. In a study of 290 untested female breast cancer patients with a >20% 
chance of carrying a breast cancer mutation in the Washington, DC, area, those who self-
identified as “highly spiritual” were significantly less likely to receive test results than 
those who did not identify as highly spiritual. However, this relationship only held true 
for women with low perceived breast cancer risk; there was no significant difference 
between highly spiritual and non-spiritual women in likelihood of receiving test results 
when perceived breast cancer risk was high (Schwartz et al., 2000).   
Regarding family factors, previous research has demonstrated that women are 
more likely to choose to undergo testing if a family mutation has been identified 
(Pasacreta, 2003). When family history of cancer was conceptualized as “presence of 
first-degree relatives with breast or ovarian cancer,” there was no impact on the 
likelihood of undergoing testing (Biesecker et al., 2000, p. 258). However, another study 
demonstrated a positive association between the number of first-degree relatives affected 
with breast cancer and the likelihood of requesting test results after submitting a sample 
for testing, but that this association did not hold true for the number of relatives affected 
by ovarian cancer (Lerman et al., 1996). When a group of women with one first-degree 
relative affected by breast cancer was compared with a group of women with one first-
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degree relative with ovarian cancer or more than one first-degree relative affected by 
breast cancer, the latter group had a significantly higher rate of testing (47% v. 68%) 
(Lerman et al., 1997). However, a similar study comparing similar groups did not detect a 
difference in the rate of requests for genetic test results (Schwartz et al., 2000).   
Perceived barriers to testing. A number of important barriers to testing have been 
identified in recent research, and decrease the likelihood that an at-risk individual will 
elect to undergo testing (Pasacreta, 2003). These include apprehension about the result, 
effort involved in making multiple trips to a genetics clinic, and taking time away from 
work and family to undergo testing (Foster et al., 2004). Some women predict, prior to 
testing, that they will experience an increase in anxiety level (Pasacreta, 2003) or intense 
negative emotions (Bredart et al., 1998; Patenaude et al., 1996) as a result of a positive 
test result, and these are considered barriers to testing. Some individuals are stressed by 
other medical problems, and feel that this inhibits them from pursuing genetic testing for 
BRCA (Patenaude et al., 1996). Finally, some research participants have identified fear of 
potential discrimination (e.g., obtaining or maintaining health insurance, employment) as 
a barrier, in addition to concern about potential negative impact on interpersonal 
relationships (Bredart et al., 1998; Patenaude et al., 1996). 
Motivation & perceived benefits of testing. Motivations to undergo genetic 
testing for BRCA1/2 are multiple and varied. In various studies, perceived benefits of 
testing have been shown to have a positive relationship with intention to test, or no 
relationship at all (Pasacreta, 2003). Many women report that their primary reason for 
testing is simply to know for sure whether or not they carry a mutation in BRCA1 or 
BRCA2 (Lodder et al., 1999) and become knowledgeable about one’s own level of risk 
 
 377
(Thompson et al., 2002), to inform risk management strategies and lifestyle changes 
(d'Agincourt-Canning, 2005; Thompson et al., 2002), to provide relief from the burden of 
uncertainty (Lerman et al., 1996), or to provide reassurance in the case of a negative 
result (Lerman & Croyle, 1996; Pasacreta, 2003; Patenaude et al., 1996). 
In general, individuals with children are more likely to choose to undergo genetic 
testing (Meijers-Heijboer et al., 2000). Multiple studies report that a common motivation 
to test is for the sake of children or to learn about children’s risk (Burgess & d'Agincourt-
Canning, 2001; Foster et al., 2002; J. Green et al., 1997; Lodder et al., 1999; H. T. Lynch 
et al., 1997; Patenaude et al., 1996; Tercyak, Peshkin, Brogan et al., 2007); this 
motivation is cited by as many as 90% of women with children (Pasacreta, 2003). 
Similarly, about one-third of women who do not yet have children or are considering 
having more children cite knowing risks for future children or planning important life 
decisions (e.g., future childbearing) as important motivators for genetic testing (Foster et 
al., 2002; Lodder et al., 1999; Pasacreta, 2003). Some women cite the desire to allow 
cascade testing to proceed (i.e., testing generation-by-generation from the top down) (K. 
E. Smith, West, Croyle, & Botkin, 1999) as a motivation to pursue testing (Tercyak, 
Peshkin, Brogan et al., 2007). More generally, many individuals report that the desire to 
help family members is a large component of what motivates them to undergo testing 
(Geller, Doksum, Bernhardt, & Metz, 1999; Vernon et al., 1999), or that they feel a 
responsibility to get tested out of commitment to family members (Burgess & 
d'Agincourt-Canning, 2001; Hallowell et al., 2003). 
Many women choose to undergo testing to legitimate their perceived need for 
more intense cancer screening than is accessible to members of the general population 
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(Foster et al., 2004; Pasacreta, 2003), or to more fully understand the necessity of 
intensive screening (Lodder et al., 1999; Pasacreta, 2003). That is, women are motivated 
to undergo testing so that they can use potentially positive results to demonstrate to their 
physicians why they should be screened more often or more intensely than a doctor might 
otherwise recommend. By the same token, women who test for this reason can 
legitimately alleviate their concerns about screening if their genetic test result is a true 
negative. Similarly, a large proportion of women in HBOC families report that they 
choose to undergo genetic testing in order to make decisions about risk-reducing surgery 
(Lodder et al., 1999; Patenaude et al., 1996). 
Young women frequently cite a desire to prepare for the future and alleviate 
uncertainty as important motivations to test (Decruyenaere, Evers-Kiebooms, & Van den 
Berghe, 1993; Foster et al., 2002; Messien, Mastromaura, Kiely, McNamara, & Myers, 
1991; Tibben et al., 1994; Van Asperen et al., 2002). However, due to the inability of 
genetic testing for BRCA1/2 to provide definitive information about lifetime cancer risk, 
and due to the relatively high frequency of uninformative tests, uncertainty may not be 
alleviated for women in many situations (Croyle & Lerman, 1993). This ongoing 
uncertainty may play a key role in the coping process of individuals, couples, and 
families, as feelings of uncertainty add difficulty to the already arduous task of threat 
appraisal and choosing of coping response (Lazarus & Folkman, 1984). This is especially 
true in the case of an uninformative test result, because it offers no new information to 
direct behaviors (Baum, Freidman, & Zakowski, 1997).  
Timing of genetic testing. Several researchers have investigated the timing of 
decision-making regarding genetic testing within the context of learning about the 
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possibility of genetic risk. Individuals may choose to pursue testing within several weeks, 
or may wait many years to be tested. A 1999 Dutch study found that the majority of 118 
individuals at 25% or 50% risk of having inherited a mutation in BRCA1 or BRCA2 chose 
to undergo testing within two months or receiving their test results (Lodder et al., 1999); 
however, this was likely a highly motivated population given their willingness to 
participate in the research study.  
Generally, once individuals make the decision to pursue genetic education and 
counseling, which precede testing, they will more often than not choose to be tested; that 
is, it is relatively uncommon for an individual to go through the genetic education and 
counseling process and then decide not to be tested, although this does occur in some 
cases (Botkin et al., 1996; Lerman et al., 1996). For example, 135 of 172 (78.5%), 
individuals who underwent education and counseling sessions in the context of a study of 
HBOC families enrolled in a research protocol at the National Cancer Institute 
(Struewing et al., 1995) chose to go through with testing (Biesecker et al., 2000). There 
are also some individuals who follow through with testing but choose not to learn their 
mutation status (Pasacreta, 2003). 
Family factors. In the existing research, there are some reports of individuals 
undergoing genetic testing for BRCA1/2 not because they truly wanted to, but because 
they felt obligated or coerced by their families. For example, some male research 
participants have reported that they felt obligated to undergo testing because female 
relatives wanted information regarding their own health, and as males they had no right 
to stand in the way of the pursuit of information about a hereditary syndrome that has its 
most profound effect on females (Dudok de Wit et al., 1996). 
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Psychological distress throught the testing process. There has been a 
significant amount of research regarding the psychological and emotional effects of 
genetic testing for a wide variety of medical conditions, including HBOC. Various 
studies have demonstrated that women undergoing genetic testing for BRCA1/2 
experience distress prior to testing, while they are awaiting results, and after they have 
learned their mutation status, and have investigated the implications of choosing not to be 
tested despite membership in a high-risk family. Since many women undergoing testing 
are actively experiencing or have recently experienced cancer-related issues within their 
families, it can be difficult to tease apart the distress that women feel as a result of the 
genetic testing process from that which they experience as a consequence of their 
membership in a family with many cases of cancer, which may include bereavement over 
ill or lost loved ones and fear of developing the disease oneself (Foster et al., 2002; Lobb 
et al., 2004). It has been suggested that women in hereditary cancer families may need to 
openly “discuss their feelings of loss and anxiety about the future first, to enable them to 
focus on the genetic issues,” (Lobb et al., 2004, p. 325). 
Psychological distress is also an important consideration in the context of 
adherence to screening recommendations for high-risk women (Lerman et al., 1993), and 
research illuminates the association between high levels of distress and attempts to avoid 
potentially disturbing cancer-related experiences such as screening (Bredart et al., 1998), 
and women may refuse or avoid mammography, clinical breast examination, and breast 
self-examination. This is in keeping with research on other hereditary cancer syndromes, 
such as colon cancer, in which research has identified screening avoidance as an attempt 
to mitigate distress associated with fear of cancer (Lerman & Croyle, 1996). While it is 
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interesting to assess psychological functioning on a number of different dimensions at 
unique points in the testing process, it is also necessary to consider changes across time, 
as both general and cancer-specific distress at baseline (prior to genetic education/testing) 
are highly predictive of levels of each later in the process (Esplen et al., 2004; Pasacreta, 
2003). 
 Distress prior to testing. Here, the term “prior to testing” refers to the period from 
the point at which an individual learns about the presence or possible presence of a 
hereditary cancer syndrome in her family to the point when she submits a biological 
sample for genetic testing. It includes the decision-making process, which varies in length 
and complexity from person to person, as discussed previously. At this stage of the 
testing process, women are said to be at high risk of carrying a mutation, and are 
potentially at increased genetic risk of cancer.   
It is important to note that levels of distress that are extremely low are not 
necessarily the most adaptive in this context, as they may indicate that an individual is 
engaging in denial/avoidance behavior rather than adequate mental preparation for the 
test; rather, somewhat higher levels of distress may be seen as normative among members 
of this population, as they reflect preparatory worrying during the pre-test preparation 
period (Dudok de Wit, Tibben, Duivenvoorden et al., 1997). The emotional issues raised 
by the experience of living in a hereditary breast and ovarian cancer family make the 
presence of some anxiety a part of the normative experience for members of this 
population, as they struggle to integrate fear of the illness, the threat of premature death, 
and the loss and grief experienced during other family members’ cancer struggles with 
their attempts to proceed normally through the life-course (Lobb et al., 2004). Of course, 
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very high levels of distress are potentially problematic when they interfere with an 
individual’s ability to manage everyday life. 
Multiple researchers have noted that general distress may be higher among 
women who have experienced multiple cancers within the family prior to undergoing 
genetic testing (Erblich, Bovbjerg, & Valdimarsdottir, 2000; Lerman et al., 1997; Lloyd 
et al., 1996). However, research comparing women approaching genetic testing with 
those who have one first-degree relative affected by breast cancer but are not involved in 
the genetic testing process (Lerman et al., 1997) and with members of the general 
population (Croyle, Smith, Botkin, Baty, & Nash, 1997) found no significant differences 
in either comparison on measures of depression and anxiety, but have noted that although 
mean levels of distress are similar, women in the pre-testing phase display more 
variability in distress levels (Lerman, Kash, & Stefanek, 1994; Lodder et al., 1999). 
Similarly, a study published before the identification of BRCA1/2 investigating 
psychological functioning of women with family histories of breast cancer found that 
fully 27% of them experienced levels of psychological distress high enough to warrant 
counseling (Kash et al., 1992). That study also found that psychological distress among 
women in high-risk families was associated with a greater number of perceived barriers 
to screening, having fewer social supports, and low social desirability (Kash et al., 1992). 
Relevant outcomes of higher levels of distress included poorer adherence to 
recommended screening (breast self-exam, mammography) (Lerman et al., 1993) and 
poor attendance for clinical breast examination (Kash et al., 1992), both of which could 
have dangerous long-term health implications for high-risk women. 
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When distress is present among members of this population, it often appears to be 
cancer-specific rather than general, and occurs with increased frequency just prior to 
receiving a genetic test result (Croyle et al., 1997; Foster et al., 2002; Kash et al., 1992; 
Lerman et al., 1997). Primary symptoms of cancer-specific distress in healthy women at 
high risk of cancer are heightened levels of awareness about cancer, intrusive thoughts, 
and avoidance (Zakowski et al., 1997). Studies have demonstrated that in the weeks prior 
to genetic testing for BRCA1/2, young women report higher levels of cancer-specific 
distress than older women (Foster et al., 2002; Lerman et al., 1993; Lloyd et al., 1996; 
Lodder et al., 1999), and that younger women worry about developing cancer more often 
and find this distress more disturbing than do older women (Foster et al., 2002). Concern 
about problems as a result of positive carrier status and probable consideration of risk-
reducing surgery as a cancer prevention strategy upon discovery of positive carrier status 
have been identified as predictors of cancer-specific distress prior to receipt of test results 
among women approaching genetic testing for BRCA1/2 (Lodder et al., 1999). The 
frequency of these beliefs among the study population was quite high: one-third 
anticipated that they would experience an increase in personal problems as a result of a 
positive test result, close to half reported that they intended to undergo risk-reducing 
mastectomy and/or oophorectomy if they found out they carried a mutation in BRCA1/2. 
Awareness of the potentially serious consequences of HBOC was also identified as a 
predictor of cancer-specific distress in this study. Similarly, it has been suggested that for 
women approaching genetic testing, it is not the testing process per se that causes 
distress, but rather that feelings of distress are a function of acknowledged risk (A. W. 
Smith et al., 2008).      
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In a Dutch study of 85 unaffected women at risk of carrying a mutation in 
BRCA1/2, general distress, measured by levels of anxiety and depression, was predicted 
by “pessimistic personality and not being inclined to express one’s emotions” (Lodder et 
al., 1999, p. 910). Having many affected relatives who experienced cancer onset before 
the age of 40, having young children and being under age 40 also predicted increased 
levels of anxiety, but not depression. Women who knew or had known relatives with 
metastatic breast/ovarian cancer displayed significantly higher levels of depression than 
women who had not known such relatives (Lodder et al., 1999). Other risk factors for 
cancer-specific distress include the disease having had a greater negative impact on one’s 
life prior to testing, and expecting relief in the event of a negative test result (Dudok de 
Wit, Tibben, Duivenvoorden et al., 1997).   
Because the pre-testing phase of the testing process begins as soon as an 
individual is aware of the potential presence of a cancer-related genetic mutation, some 
individuals spend many years in this stage, and it may begin well before an individual is 
old enough to pursue testing. To explore the experience of women in this situation, a 
Canadian study investigated the psychological implications for adolescent daughters of 
women with breast cancer, comparing them to adolescent females without breast cancer 
histories. Although the two groups did not differ in overall psychological functioning, the 
daughters of affected women reported significantly more worries about their future health 
and their risk of breast cancer, and significantly more of them saw themselves as 
vulnerable to breast cancer (Cappelli et al., 2005). This study demonstrates that the 
cancer specific distress experience by young women in high-risk families may begin as 
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early as adolescence, and raises additional questions about the long-term implications of 
experiencing this type of distress for such a large portion of one’s life. 
An Israeli study used the Brief Symptoms Inventory (Derogatis & Spencer, 1982) 
and Impact of Events Scale (Horowitz et al., 1979) to measure both general and cancer-
specific anxiety and distress among women with at least one first-degree relative with 
breast cancer. The 230 participants fell into three categories: 176 healthy women whose 
mothers had been affected by breast cancer, 34 healthy women whose sisters had been 
affected by breast cancer, and 20 healthy women whose mothers and sisters had both 
been affected by breast cancer. The women completed questionnaires during a one-day 
educational conference for healthy relatives of breast cancer patients; results of this study 
must be considered in this context, as the salience of breast cancer issues was likely 
higher given the concurrent involvement in this educational program. Results indicated 
that all of the subjects experienced high levels of psychological distress; over half of the 
participants fit into the very high psychological distress group, and these participants 
displayed significantly higher scores on the IES. Women in the highly-distressed group 
were also significantly less likely to be married, supporting the notion of the distress-
protective effect of having a partner. Women who had both a mother and a sister affected 
by breast cancer demonstrated consistently high IES scores across subscales, possibly 
related to even greater threat of inheriting breast cancer and increased difficulty in 
denying this threat compared with women with only one affected relative (Baider et al., 
1999). This high level of threat combined with the salience of breast cancer during a 
cancer educational conference likely explains these phenomenally high distress levels, 
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which are much higher than those observed among a similar population attending a 
cancer prevention center (Kash et al., 1992). 
A British study of 158 women assessed at the time of genetic counseling for 
hereditary breast/ovarian cancer risk and three months later indicated that 30.6% of 
participants met the criteria for psychological distress at baseline, and 26.4% met the 
criteria for psychological distress at follow-up, a statistically non-significant difference 
(Hopwood et al., 1998). At follow-up, 13.3% of the women were diagnosable with 
psychiatric disorders, including depression, anxiety, panic disorder, and adjustment 
disorder. Interestingly, none of these women reported concerns about cancer risk as the 
precipitating factors in their psychiatric problems; rather, they cited “work-related stress, 
financial problems and illness in the family (other than breast cancer)…relationship 
problems with partners…and blocked or unresolved grief…these problems were long-
standing and pre-dated the risk assessment experience,” (Hopwood et al., 1998, p. 405). 
These observations support the notion that women may benefit from increased guidance 
regarding assimilating risk information into family interaction and dealing with the 
impact of breast cancer in the family (Hopwood et al., 1998). 
In a broader study of individuals approaching testing for a range of late-onset, 
autosomal dominant, heritable disorders (e.g., Huntington’s Disease), a group of Dutch 
researchers identified predictors of pre-test distress including experience with the relevant 
disease in close family, the perception that the relatives’ disease had a significant impact 
on their lives, the expectation that a positive test result would have a significant negative 
impact on their own lives, and the expectation of relief as a result of a negative test result 
(Dudok de Wit, Tibben, Duivenvoorden et al., 1997). Results from the Intrusion and 
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Avoidance subscales of the IES also indicate that potential testers who expected an 
increase in distress and/or personal problems as a result of the test displayed higher levels 
of avoidance (i.e., increased frequency of consciously avoiding thoughts about 
breast/ovarian cancer), while those who could more readily envision and anticipate life as 
mutation carriers had higher levels of intrusion (i.e., increased frequency of thinking 
about breast/ovarian cancer when one does not want to) (Dudok de Wit, Tibben, 
Duivenvoorden et al., 1997). This has been confirmed in subsequent research, which has 
found that the majority of women approaching genetic testing for BRCA1/2 experience 
some intrusive and avoidant thoughts about developing cancer (Foster et al., 2002; 
Lodder et al., 1999; Reichelt, Dahl, Heimdal, & Moller, 1999), but that overall depression 
and anxiety scores are relatively low (Tercyak, Lerman et al., 2001). 
Distress for those who decline testing. As previously stated, not all women who 
are at significant risk of carrying a mutation in BRCA1/2 choose to undergo testing. 
Because they often end their involvement in the genetics/research component of the 
healthcare system after choosing not to be tested, very little research exits regarding the 
psychological and emotional well-being of members of this population. A study of 
individuals who either declined testing altogether or submitted biological specimens for 
genetic testing but declined receipt of their results found that there were significant 
increases in depression at six month follow-up, especially in those who had high-levels of 
stress symptoms prior to testing; in fact, “those who declined genetic testing were about 
eight times more likely to become depressed that those who were tested and found to be 
non-carriers,” (Lerman et al., 1998, p. 1653). In addition, there is evidence that 
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individuals in high-risk families who decline testing may continue to experience higher 
than normal levels of anxiety (Lerman et al., 2002). 
 Not all individuals who decline testing will remain permanently in that state. A 
variety of life-cycle triggers occurring across the lifespan may provide motivation to 
revisit the possibility of genetic testing, including a new illness in a previously tested 
individual, an impending marriage or birth, entrance of members of the younger 
generation into adulthood, or identification of additional mutation carriers within a family 
(Martin & Wilikofsky, 2004).  
Distress while awaiting results. The period of time from submission of a 
biological sample for genetic testing to receipt of results may be several weeks to several 
months, depending on whether the test involves full sequencing. A typical timeframe is 
about six to eight weeks (Lodder et al., 1999). Because women often undergo testing in a 
research context, a good deal of data has been collected regarding levels of psychological 
distress during this phase of the genetic testing process. Overall, levels of psychological 
distress seem to be comparable to that present in the general population, with only about 
7% of subjects in various studies reporting depression scores that are considered 
“borderline” or higher (Pasacreta, 2003). Some studies have concluded that women 
awaiting test results display higher than average levels of distress during this period 
(Audrain et al., 1997), and researchers have identified elevated intrusion and avoidance 
scores (Lodder et al., 1999) as well as some impairment in role and sexual functioning as 
the major issues identified in distressed women in this phase of testing (Pasacreta, 2003). 
Psychological distress prior to submission of a biological sample is highly predictive of 
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psychological distress while awaiting results (Pasacreta, 2003), as are several of the other 
predictors of distress listed in the previous section (Lodder et al., 1999; Pasacreta, 2003). 
Distress following disclosure. Breast and ovarian cancer “pre-vivorship” (the 
experience of living with increased genetic risk of cancer) (FORCE, 2005) is still a 
relatively new and unexplored situation, as it has only been a bit longer than a decade 
since the BRCA1/2 mutations were discovered and testing is still not commonplace. The 
experience of being a “mutation carrier,” therefore, is not yet fully understood, especially 
by those outside of the cancer and cancer family communities (Dagan & Gil, 2004). 
Individuals who receive positive mutation test results are plunged into this stressful 
situation and may deal with it in very different ways. 
Immediate psychological distress reactions to the testing process can have 
important implications for long-term well-being because they may interfere with 
comprehension of risk information during genetic counseling (Janis & Mann, 1977) and 
in the weeks and months following receipt of test results (Lerman & Croyle, 1996). Both 
acute and chronic psychological distress may influence comprehension of risk 
information after the formal genetic testing process, and may impact medical decision-
making as well; research indicates that highly anxious women continue to overestimate 
their risk even after genetic counseling; researchers note that “this raises concerns about 
the appropriateness of medical decisions, such as risk-reducing surgery, that may be 
based on erroneous beliefs concerning personal risk,” (Lerman & Croyle, 1996, p. 191). 
High levels of anxiety and distress also decrease adherence to clinical- and self-breast 
exams (Kash et al., 1992; Lerman & Croyle, 1996) and to mammography screening 
(Lerman & Croyle, 1996; Lerman et al., 1993).   
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In general, levels of distress among women receiving results from genetic tests for 
BRCA1/2 mutations are similar to those of a normal population; however, there is 
significant variability in distress levels (Botkin et al., 1996; Lodder et al., 1999). Not 
surprisingly, some researchers have identified higher levels of psychological distress 
among those who receive positive test results, especially immediately following receipt 
of test results (Croyle et al., 1997; Lodder et al., 2001; K. E. Smith et al., 1999; Tercyak, 
Lerman et al., 2001); in one study, fully 27% of women identified as high risk were 
distressed enough to warrant counseling (Kash et al., 1992). Another study noted that 
positive test results were associated with transient distress as measured by the IES (A. W. 
Smith et al., 2008). While consistently high levels of stress are uncommon, many women 
have reported that they experience acute negative emotional reactions such as “anxiety, 
depression, shock, surprise and feelings of neglect” (Appleton et al., 2000, p. 515) 
immediately following receipt of their mutation test results, as well as in the wake of 
trigger events such as receiving an appointment letter for a regular screening, waiting for 
a past-due appointment, having a screening test performed, and receiving the results of 
screening tests (Appleton et al., 2000; Valdimarsdottir et al., 1995). Heightened 
sensitivity to breast cancer cues, including changes in one’s own breast tissue, media 
reports, and family illnesses, prompts anxiety and/or avoidance reactions in many high-
risk women. All of this may become a part of a cycle of emotional and psychological 
highs and lows that occur over time and may coincide with the annual screening cycle 
(Appleton et al., 2000). Consistently high levels of distress have also been reported by 
women in some studies, and it is usually associated with high levels of baseline distress, 
just as low levels of baseline distress are associated with consistently low levels of 
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distress throughout the testing process (A. W. Smith et al., 2008). This further supports 
the notion that the testing process itself is not the source of stress for women in HBOC 
families, but rather that one’s response to the notion of being potentially “at-risk” occurs 
prior to testing and remains relatively constant over time. 
Most of the research that exists on the psychological impact of learning one’s 
BRCA1/2 mutation status has followed women for up to one year after result disclosure, 
representing only short-term follow-up (Appleton et al., 2000; Lerman et al., 1996). The 
bulk of this research finds that psychological problems as a result of BRCA1/2 testing are 
less frequent and less problematic than anticipated, and most individuals display levels of 
psychological disturbance within general population norms (Bredart et al., 1998; Lerman 
et al., 2002; Pasacreta, 2003). In fact, studies of both carriers and non-carriers have 
identified decreases in general distress of approximately 20% within one to two weeks 
after result disclosure, as compared with pre-test levels, with even greater reductions in 
distress at six-month follow-up (Croyle et al., 1997), and reductions in depression and 
functional impairment one month after result disclosure (Lerman et al., 1996). These 
findings may reflect the sense of relief that comes with having information about one’s 
mutation status, after a potentially lengthy period of wondering. However, distress related 
to uncertainty may re-emerge as high-risk women begin to face life as confirmed 
mutation carriers and must come to grips with a continuing sense of uncertainty and 
ambiguity about whether, when, and where cancer will develop (Lerman & Croyle, 
1996). 
Some researchers have identified levels of psychiatric morbidity in the post-
genetic testing population that are higher than population norms (e.g., Hopwood et al., 
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1998); interestingly, in the Hopwood study, women reported that the distress they were 
experiencing was not related to their genetic testing results, but rather to more universal 
stressors such as marriage, work, children, etc., common stressors for pre-menopausal 
adult women. Of those referred for psychological help, very few reported cancer concerns 
as their primary issue. Therapeutic work focused on issues of unresolved grief, loss, and 
relationship problems, often related to their positive mutation status. The researchers 
concluded that “a minority of women may need help with the impact of breast cancer in 
the family,” (Hopwood et al., 1998, p. 402). It has been proposed by some that those with 
higher levels of intrusive thoughts may be more psychologically vulnerable following 
receipt of test results (Lerman et al., 1998); this is in keeping with research demonstrating 
that individuals who underestimated the emotional impact of result receipt prior to testing 
are more likely to experience distress in the six months following receipt of results 
(Dorval et al., 2000). The limited research on long-term psychological effects of genetic 
testing suggests that a minority of individuals continue to experience cancer-related 
distress more than two years after completion of the testing process (Lloyd et al., 1996). 
Significant increases in cancer-specific distress, including sadness, guilt, and 
anger, in the period immediately following receipt of test results have been noted in 
several research studies (Brody & Biesecker, 1998; H. T. Lynch et al., 1997). Test result 
is one of the most reliable predictors of post-test psychological functioning (Esplen et al., 
2004), although individuals may experience distress in the wake of either a positive or 
negative result. Significant differences were identified between overall levels of both 
cancer-specific and general distress when comparing carriers and non-carriers (Bredart et 
al., 1998; Croyle et al., 1997), as well as in reductions in both types of distress over time, 
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with non-carriers finding more relief (Lerman et al., 1998; Lerman et al., 1996; K. E. 
Smith et al., 1999). It has been noted that the decrease in distress inherent in a negative 
test result, due to relief of worry about increased risk, is not afforded to mutation-positive 
women, who may also be more likely to experience an increase in distress (Esplen et al., 
2004).   
 Several studies have investigated at-risk individuals’ ability at pre-test to 
anticipate levels of post-test psychological distress. This is thought to be important 
because those who make an accurate appraisal of post-test emotional experience may be 
less likely to encounter unexpected difficulties after they undergo testing, and in turn may 
be more compliant with screening and prevention recommendations (Lerman et al., 
1993). Studies on anticipated reactions consistently point to anxiety and uncertainty about 
if and when cancer will develop as emotions that individuals expect to experience after 
testing (Bredart et al., 1998; Lerman & Croyle, 1996). In addition, those who have first-
degree relatives who have experienced ovarian cancer are more likely to anticipate 
anxiety (77%), depression (80%), and impaired quality of life in reaction to a positive 
mutation test result (Bredart et al., 1998), likely because they have witnessed the 
devastating experience of that cancer in a close loved one. Expectation of a negative test 
result has also been identified as a predictor of post-test psychological distress (Esplen et 
al., 2004). This is in keeping with research on stressful events suggesting that negative or 
catastrophic events are met with a greater distress response when they are unexpected 
(Lazarus & Folkman, 1984; Ortony, Clore, & Collins, 1988). 
One study identified significant differences between those affected and unaffected 
by cancer regarding how they thought they would react emotionally to their testing 
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outcomes, whereby unaffected individuals overestimated their emotional reactions and 
affected individuals underestimated these responses. Only 30% of unaffected individuals 
underestimated their emotional responses (Dorval et al., 2000). Investigators in this study 
also noted a positive association between one’s ability to accurately anticipate emotional 
response to mutation test result and one’s post-disclosure psychological adjustment, with 
underestimation associated with greatly increased psychological distress at six-month 
follow-up.  
Family cancer experience has also been repeatedly identified as an important 
factor influencing psychological distress in the genetic testing process for BRCA1/2. 
Those who have been exposed to more cases of cancer within the family are often more 
psychologically distressed by the process of genetic testing and by a positive result. The 
amount of social support one has access to, both within and outside of the family, is also 
thought to influence psychological coping (Esplen et al., 2004). 
The stress experienced as a result of learning that one is mutation-positive may 
continue in the long-term and may be present even after preventive, risk-reducing 
measures are taken. In a Dutch study comparing women who had undergone RRSO with 
women who chose screening to manage ovarian cancer risk, 10% of women in the RRSO 
group reported symptoms consistent with the presence of post-traumatic stress disorder 
(PTSD), with breast and ovarian cancer risk as an underlying factor (Madalinska et al., 
2005). This suggests that for some women, even the most extreme and effective risk 
management strategies will not be sufficient to reduce cancer-specific distress. 
 Researchers have hypothesized that an individual’s age may play an important 
role in determining one’s psychological distress in response to test results. There are 
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several factors that may influence both older and younger women’s reactions to a positive 
mutation test result. Younger women may experience more psychological distress 
because they are forced to consider the threat of cancer over a longer period of time. 
Additionally, concerns about body image may be more salient for a younger population. 
Distress in this group may be mitigated by the fact that they have a greater period of time 
remaining to create their families while their cancer risk is still relatively low, as opposed 
to women in middle age who may be facing the more imminent threat of cancer and/or 
being encouraged to undergo risk-reducing surgery even though they may not have 
achieved their ideal family size. Generational differences in the mutation-positive 
experience are also significant. For older women receiving positive mutation test results, 
a cancer diagnosis may be equated with death, due to the fact that historically, treatments 
for breast and ovarian cancer were not as good as they are now and a generation ago, 
death due to cancer was a reasonable expectation. However, for young women who have 
come of age in an era of improving medical technology and availability of excellent 
treatment and improving survivability, breast and even ovarian cancer is more likely 
viewed as a challenge that can be overcome, and so attitudes are formed in light of that 
perception (d'Agincourt-Canning, 2005). Resources that are related to and vary with age, 
such as marital status, education level, income, and access to health insurance may also 
play a role in women’s level of psychological distress as a result of genetic testing 
(Botkin et al., 1996). 
As a whole, this literature suggests that some individuals may experience a 
relatively brief (several weeks to several months) crisis response immediately after 
learning of their positive mutation status, but that the majority return to relatively normal 
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levels of psychological functioning in the weeks and months following disclosure 
(Pasacreta, 2003). The reduction of uncertainty and doubt facilitated by the completion of 
the genetic testing process is a clear psychological benefit for many women who choose 
to undergo testing, and may be present regardless of test outcome (Bredart et al., 1998). 
However, the specific types of psychological disturbance experienced by women in high-
risk families varies, and may include anxiety, depression, intrusive thoughts, guilt, and 
family stress. 
In the research context, women often report that they expect to experience 
anxiety, depression, and impaired quality of life in the aftermath of a positive genetic test 
(Bredart et al., 1998). However, these are not the only reactions that occur; rather, 
emotional, psychological, and relational experiences following positive mutation test 
results are quite varied. Specifically, researchers have examined anxiety, grief, 
depression, anger, guilt, functional health status, family stress, and family 
communication.  
Anxiety. Psychological responses to testing that take the form of anxiety may 
manifest in many different ways, including “hypervigilance, intrusive thoughts…sleep 
disturbances, confusion and somatic symptoms, and persistent worry about the future,” 
(Lerman & Croyle, 1996, p. 193) and are relatively common among women with 
significant family histories of breast/ovarian cancer (Baider et al., 1999) and among those 
who receive positive BRCA1/2 mutation-test results (Croyle et al., 1997). The 
relationship between testing and anxiety is among the most frequently studied of 
psychosocial issues in BRCA-related research; researchers have long acknowledged that 
individuals and families undergoing screening may experience this type of psychological 
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distress (Coughlin et al., 1999). Understanding of the dynamics surrounding anxiety and 
mutation test result disclosure is important because anxiety has been shown consistently 
to reduce cancer risk comprehension due to interference with information processing 
abilities (Janis & Mann, 1977; Lerman et al., 1995); this, in turn, may result in failure to 
adhere to screening or risk-reduction recommendations as women attempt to keep their 
anxiety low by avoiding cancer-related experiences, including screening (Lerman et al., 
1996). 
In longitudinal studies, baseline levels of anxiety are reliable predictors of post-
test anxiety, with carriers experiencing higher levels of distress than non-carriers (Croyle 
et al., 1997). Significant frequencies of anxiety have been identified in various BRCA1/2 
study populations (Esplen et al., 2004). In one study, a reduction in anxiety among non-
carriers was detected at one- to three-weeks post-disclosure, while levels of anxiety 
increased slightly among carriers (Lodder et al., 2001). Another study identified 
reductions in anxiety across all participants, regardless of mutation status, suggesting that 
part of the anxiety that is experienced during the pre-test and awaiting-results phases 
maybe related to uncertainty, which is relieved by receipt of test results even if they are 
positive (Croyle et al., 1997). However, researchers note that learning of a positive test 
result may represent a shift from uncertainty about whether or not one has the mutation to 
uncertainty about whether or when cancer will develop, rather than a relief from 
uncertainty altogether (Murphy, 1999), and this transition may elicit an anxiety response 
in some individuals (H. T. Lynch et al., 1997). 
Family history of cancer and the extent to which individuals have personally 
witnessed the cancer experience(s) of a loved one or loved ones has been studied with 
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regard to women at high risk of breast cancer (Gilbar & Borovik, 1998); it may also be an 
important factor in determining their psychological distress response to learning their 
mutation status (d'Agincourt-Canning, 2005). In part, this may reflect the experiences of 
those who were diagnosed with and treated for breast and ovarian cancer prior to the 
availability of successful treatments, at a time when a diagnosis was often legitimately 
equated with death (Rosenbaum & Roos, 2000). Even in the face of modern scientific 
reality, such powerful experiences may be important components of individuals’ 
processing of genetic risk information (d'Agincourt-Canning, 2005). 
A Swedish study of 87 women undergoing presymptomatic genetic testing for 
BRCA1/2 mutations concluded that as a whole, the group experienced a significant 
decrease in anxiety mean scores over time, regardless of mutation test result, with anxiety 
levels similar to population norms before testing and one-year post-test, but spiking in the 
weeks and months immediately after the test and receipt of results (Arver, Haegermark, 
Platten, Lindblom, & Brandberg, 2004). 
Several factors have been associated with increased experience of anxiety after 
receipt of mutation test results. A Canadian study of 157 women at high familial risk of 
ovarian cancer concluded that women who scored above the cutoff for clinical anxiety 
were “significantly more worried about their daughter’s future, were more likely to have 
altered plans for the future, reported greater problems with work, were more worried 
about being at risk of cancer, reported greater problems with their partner, perceived their 
partner as less supportive, and had a trend to be younger,” (Robinson et al., 1997, p. 201). 
This suggests that anxiety is related to a variety of other problems that may be present in 
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the period following testing, and that reductions in anxiety may have further benefits in 
eliminating these other symptoms and problems. 
It has been noted that anxiety is more common among those who had previously 
made unalterable life decisions based on an incorrect assumption that they were at 
increased risk (e.g., women who have undergone risk-reducing surgery prior to testing, 
only to find out that they do not carry the mutation), and among those whose distress 
levels prior to testing were higher than average (Lerman & Croyle, 1996). One study 
notes that mutation carriers who harbor an intense preoccupation with cancer “may 
experience the same emotional spectrum of cancer survivors—a sense of personal 
vulnerability and only tenuous longevity,” (Bredart et al., 1998, p. 176). 
One of the most commonly reported symptoms of anxiety among women in 
HBOC families is intrusive thoughts, usually measured by the IES. One study found that 
in the weeks following result disclosure, both carriers and non-carriers experienced a 
diminution of both intrusive thoughts and avoidant behaviors (Lodder et al., 2001); this 
suggests that the root of these intrusive thoughts and avoidant behaviors might not be just 
the phenomenon of being a potential mutation carrier, but also the uncertainty associated 
with the pre-test experience. Other research on group intervention has demonstrated that 
women who are able to discuss their feelings of uncertainty, fear, guilt grief, etc. in an 
open, authentic manner in a group environment experienced a significant reduction in 
their experience of intrusive thoughts (Esplen et al., 2004). 
Grief. Grief is a relatively common response to discovery of one’s positive 
BRCA1/2-mutation status, and may occur most intensely in the first six months after 
receipt of test results, which can be thought of as a loss experience (Ringdal, Jordhoy, 
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Ringdal, & Kaasa, 2001; Surtees & Wainwright, 1999). In discovering their positive 
mutation status, even when it has been suspected previously, women are not only forced 
to face a potentially complicated set of risks and decisions, they may also experience a re-
emergence of previously resolved feelings of grief related to the illness or loss of loved 
ones, previous cancer experiences, etc. (Bottorff et al., 2000; Clarke, Butler, & Esplen, 
2008; Hopwood et al., 1998; Lobb et al., 2004), and this merging of past and present 
cancer-related experiences can be particularly painful (Bonanno & Kaltman, 2001). 
Women may also experience a sense of loss along with the receipt of a positive mutation 
test result, which may be related to their sense of security and peace of mind being 
threatened, loss of hopefulness about the future, and/or loss of a sense of immortality. 
Women who receive negative mutation results for BRCA1/2 have also reported a sense of 
loss in their sense of connection to a deceased family member or members, as if the 
intangible bond that they once shared over cancer was been broken by the discovery of 
their non-high-risk status (Esplen et al., 2004).  
Depression. Depression may take the form of sad mood, helplessness, 
hopelessness, and reduced energy and activity levels; when depression continues long-
term, results such as drastic increase or loss of appetite, insurmountable fatigue, etc. may 
be present (Lerman & Croyle, 1996). While clinical levels of depression are not 
significantly more common among members of HBOC families than the general 
population, about one-third of individuals in one study experienced an acute period of 
sadness and crying (H. T. Lynch et al., 1997). Lodder’s 2001 study indicates that levels 
of depression after genetic testing for BRCA1/2 decrease for non-carriers, and increase 
slightly for carriers. Another study noted significantly greater reductions in depression 
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and role impairment in non-carriers as compared to carriers when comparing baseline 
scores to those at one-month post-disclosure; findings also indicate that there are 
differences in the frequency of clinical depression at one-month post-disclosure, with 
carriers demonstrating higher rates of depression than non-carriers (14% versus 8%) 
(Lerman et al., 1996). In longer-term follow-up, only non-carriers demonstrated 
significant reductions from pre-test to post-test rates of depression, while rates of 
depression among carriers actually increased over six months (Lerman et al., 1998). 
Interestingly, one British study found a reversal of these trends regarding depression, 
whereby non-carriers demonstrated a significant increase in frequency of depression 
while carriers demonstrated a non-significant decrease (Wagner et al., 2000); a similar 
finding was observed in a Swedish study, although depression scores for non-carriers in 
that study were still within the normative range (Arver et al., 2004). 
One study suggests that family experience with ovarian cancer may be 
significantly related to individuals’ experience of depression in the post-testing phase. A 
notable majority of women with ovarian cancer-affected relatives report, prior to genetic 
testing, that they believe they will experience depression if they test positive for a 
mutation in BRCA1, and almost three quarters of such women under age 45 who 
underwent testing for BRCA1 reported feeling depressed six weeks after they were tested 
(Lerman & Croyle, 1996). This finding may be related to the gravity of ovarian cancer 
and the relative frequency with which it takes the lives of those affected. 
A Canadian study of 157 women at high familial risk of ovarian cancer found that 
31.4% scored above the clinical depression cutoff point on the Center for Epidemiologic 
Studies Depression Scale (CES-D) (Radloff, 1977). Classifying participants into two 
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groups based on this cutoff point revealed significant differences between the two groups: 
those among the depressed group were “younger, currently more depressed over the 
death of a relative with ovarian cancer, more worried about being at increased risk of 
developing cancer, and more likely to have altered plans for the future [mostly about 
having children] as well as a result of their perceived risk level,” (Robinson et al., 1997, 
p. 200). The women who scored above the depression threshold were also more worried 
about future risk for their daughters than those in the non-depressed group (Robinson et 
al., 1997). These findings support the notion that young women experiencing genetic 
testing are particularly vulnerable. 
Depression is not observed only among individuals who discover that they are 
mutation carriers; interestingly, increased depression was also present in 12% of non-
carriers six weeks after testing in a kindred of 32 relatives tested for a BRCA1 mutation, 
although these levels were not above the threshold for diagnosis (H. T. Lynch et al., 
1993). As previously discussed, this psychological disturbance may be related to regret 
about irreversible surgical decisions made on the assumption of high-risk status, or may 
be related to feelings of guilt; this will be discussed further later in this appendix. 
The availability of social support has been associated with decreases in depression 
over time among women who receive positive BRCA1/2 test results (Esplen et al., 2004). 
Participation in a supportive-expressive therapy group focusing specifically on difficult 
issues associated with positive mutation status, such as guilt, fear, grief, etc., was 
associated with improvements in depression symptoms, and this improvement is thought 
to be largely due to the availability of social support associated with participation in the 
group (Esplen et al., 2004). 
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Anger. Anger is another relatively common response to receipt of a positive 
BRCA1/2 mutation-test result (Croyle et al., 1997). Individuals may experience a sort of 
“why me?” reaction to the news (Bredart et al., 1998). Anger may also result from the 
afore-mentioned transition from uncertainty about whether or not one possesses a 
BRCA1/2 mutation to uncertainty about whether and when cancer will develop, as an 
element of hope is dashed in discovering that one has not escaped the mutation (H. T. 
Lynch et al., 1997).  
Guilt. Feelings of guilt and responsibility are not uncommon among high-risk 
cancer families to begin with (Brody & Biesecker, 1998), and the testing process and 
identification of a mutation in additional family members can bring these feelings to the 
surface (Croyle et al., 1997; H. T. Lynch et al., 1997). Guilt reactions are likely to take 
different forms depending on the outcome of a genetic test. In those found to be mutation 
carriers, feelings of guilt may be related to having passed a BRCA1/2 gene on to one’s 
children, and worrying about the future health and well-being (Bredart et al., 1998; 
Lerman & Croyle, 1996). Individuals who receive negative mutation test results may 
experience “survivor guilt,” comprised of potentially invasive thoughts and questions 
about why they should be spared from the experience of carrying the mutation when their 
loved ones are enduring such stress (Lerman & Croyle, 1996). Researchers have also 
noted that this guilt manifested after the receipt of test results may play a role in 
reproductive decision-making (Frets, Verhage, & Niermeijer, 1991), discussed in further 
detail in a subsequent section. 
Functional health status. When the results of a genetic test for BRCA1/2 are at the 
forefront of one’s mind to the extent that they limit her ability to function normally, an 
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individual may experience changes in “role functioning, sexual functioning, social 
functioning, and sleep,” (Lerman & Croyle, 1996, p. 194). This type of disturbance has 
been observed in as many as 30% of women at risk of breast cancer, and is attributed to 
prominent concerns about personal risk status (Kash et al., 1992). 
Family stress. The potential for psychological and emotional disturbance as an 
outcome of genetic testing is not limited to the individual; stress may also be experienced 
at the couple and family levels. Higher than average levels of cancer-related stress and 
anxiety are likely to be present in these families even before testing as the members 
struggle with experiences of breast and ovarian cancer over time (Brody & Biesecker, 
1998). In the midst of dealing with those stressors, learning about BRCA1/2 mutations in 
one’s family may necessitate new levels and types of communication, perhaps between 
extended family members who are typically not in touch; this may bring about conflict 
and confrontation, as relatives attempt to integrate new information and engage in 
collaborative information gathering and decision-making. This may be complicated by, 
for example, a lack of consensus regarding who should be informed about the presence of 
a mutation, or who should undergo testing and when. This new dialogue also has the 
potential to bring together family members who were previously disengaged (Bottorff et 
al., 2000). Families may experience an increase in conflict and/or a decrease in cohesion 
as potential disagreements arise over testing decisions (Brody & Biesecker, 1998) and 
communicating results to younger family members, individuals and entities outside the 
family, etc. (Bottorff et al., 2000). 
Individuals within families may also vary in their experience of psychological 
distress relative to other family members, especially when there is variability in test 
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outcomes; for example, one sibling who tests positive among a group of siblings who test 
negative may experience more psychological distress related to feelings of isolation, or 
one who tests negative in a group of positives may experience high levels of survivor’s 
guilt (Esplen et al., 2004). A study specifically investigating the impact of sibling test 
result on reactions to BRCA1 test results found that  
men who received their [positive] results first and noncarrier men whose siblings 
all tested positive experienced adverse short-term psychologic reactions…carrier 
women experience elevated distress shortly after receiving their results…[and] 
women who learned their positive carrier status first report the highest levels of 
distress, (A. W. Smith et al., 2008, p. 389).   
 
These findings represent important test result/family context interactions, with significant 
differences related to gender. Relative to other hereditary cancer syndromes, HBOC may 
present more gender-specific issues and bring the issue of gender to the forefront of 
family relationships, since women are primarily affected by the increased risk (Pasacreta, 
2003). Existing gender issues within families may be magnified by the presence of a 
BRCA1/2 mutation.  
Researchers have noted that the experiences of genetic testing and result 
disclosure do not take place in isolation, but rather occur “within the context of the cancer 
histories, testing experiences and results of [one’s] relatives. Individual reactions to 
learning a relative’s mutation status may bear a relationship to the psychological sequelae 
associated with [one’s] own testing,” (Pasacreta, 2003, p. 617). 
Family communication. Once an individual has completed the genetic counseling 
and testing process, it is not atypical for him or her to take some time to come to terms 
with his/her own risk before taking on the challenge of making decisions about 
communicating mutation information to other family members (Forrest et al., 2003); 
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research indicates that carriers wait an average of four months before disclosing 
information about their carrier status to adolescent and adult offspring (Patenaude et al., 
2006), and typically view the ages of 19-25 as the ideal time to inform offspring about 
their carrier status (Segal et al., 2004). The burden of this task varies with the number of 
other tested family members, the novelty of the issue of HBOC within the family, and the 
general level of knowledge about BRCA1/2-related issues among family members. 
Furthermore, family roles, traditions, and dynamics will determine the extent to which 
one is expected and/or allowed to share information or may choose to keep it private 
(Forrest et al., 2003; Foster et al., 2004; J. Green et al., 1997).   
Researchers have noted various ways in which family context shapes the manner 
in which a family communicates about cancer. Individuals’ decisions to pursue genetic 
testing in light of new information can “destabilize family expectations and norms with 
other members feeling pulled in different directions, in terms of his/her own needs [and] 
the family’s style of coping,” (Clarke et al., 2008). The task of communicating genetic 
information to potentially affected members of a family may serve to bring together 
previously disengaged relatives, as genetically-linked but emotionally distant siblings, 
cousins, etc., trade information about the presence of disease in order to “more [precisely] 
estimate…one’s own risk,” (Forrest et al., 2003, p. 323). In contrast, decisions regarding 
testing can incite new conflict in between involved family members, adding relationship 
stress to an already stressful situation (McDaniel, 2005). Dynamics around family 
communication are complicated by the fact that genetic information about one member of 
a family has implications for multiple other family members, especially when the family 
is dealing with a first member to be tested; for example, if an individual who is the first 
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tested among her/his family is identified as a mutation carrier, a parent is automatically 
implicated as a carrier, and all of the individual’s siblings and children are suddenly at 
50% risk of also carrying mutations (Costalas et al., 2003). Therefore, those making 
decisions about genetic testing and information cannot ever act truly independently, as 
genetic information is inherently also family information. 
In general, a large proportion of individuals who undergo testing for BRCA1/2 
disclose their results to first-degree relatives within the weeks and months immediately 
following their own receipt of results. A 2006 study of 273 women who had undergone 
testing for BRCA1/2 in Boston revealed that those who received positive results disclosed 
to their mothers at a rate of 92% within four months, and at a rate of 81% to fathers 
within the same period; factors impacting disclosure of mutation status to parents 
included participant age (with younger women more likely to disclose) and father’s 
cancer status. Comparable rates of disclosure were identified for sisters (90%), brothers 
(78%), daughters 18 or older (97%), and sons 18 or older (90%) (Patenaude et al., 2008). 
Brothers were more likely to be informed if the BRCA1/2 mutation had been inherited by 
the participant from the father. Not surprisingly, telling children was related to children’s 
age (with adult children more likely to be informed than pre-adolescents) and gender 
(with daughters more likely to be informed than sons). 
Prior research indicates that individuals undergoing genetic testing for BRCA1/2 
have more trouble communicating a positive result than a negative one, likely due to 
higher levels of distress for both the speaker and listener during such an interaction 
(Costalas et al., 2003). Carriers also experience more difficulty in explaining mutation 
results to adult siblings than to adult children; this may reflect a cohort effect, in that 
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adult children would tend to be younger and more fluent in discussing issues related to 
genetics due to increased accessibility of genetic information in the form of TV, internet, 
and other outlets. In addition, women are more likely to be told about the presence of a 
BRCA1/2 mutation in the family than are men, likely because they are at much greater 
personal risk of developing cancer than are men and because it may be more difficult to 
explain issues related to breast/ovarian health to male relatives (Costalas et al., 2003; 
Julian-Reynier et al., 2003). 
A recent study of the process of disclosure of positive BRCA1/2 mutation status to 
offspring highlighted some of the pertinent issues of the proposed study (Clarke et al., 
2008). Women expressed unique concerns related to disclosing to young adult daughters, 
especially with regard to the possibility that daughters may face discrimination 
“including securing adequate insurance and finding a life partner. The concern that the 
daughter might be viewed as ‘damaged goods’” (Clarke et al., 2008, p. 799) was also 
described. Also present in this group were concerns about balancing a daughter’s right to 
know about her risk with a desire to protect her from difficult information and the 
unhappiness that might come along with it. Some women described a process whereby 
they attempted to gauge whether or not their offspring even wanted to know about the 
mutation, based on offspring’s words and actions over time (e.g., not following up on 
own genetic testing). They experienced discomfort and felt dishonest when they chose to 
withhold or delay information (even though this was based on positive intentions), and 
feared that they might disclose inadvertently, which might have a negative impact. 
Ultimately, mothers’ decisions about informing their daughters of their own carrier status 
were influenced by their perceptions that their daughters would be capable of managing 
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the psychological issues that might accompany the news (Clarke et al., 2008). The 
experience of disclosure for women in this study was often highly emotional, though 
some participants described it instead as a straightforward conveyance of honest 
information relatively free of emotionality, sometimes purposefully so as to communicate 
that the presence of the mutation was not to be interpreted by the daughter as a big deal. 
Perhaps most interestingly, women in the study described instances of being “caught off 
guard” by children’s questions, and as a result giving their children inaccurate 
information because they were not prepared to deliver the truth. It is interesting to 
consider, in these cases, how future communication about the mutation and its presence 
within the families will be received by daughters who realize that they were previously 
misled. Finally, some women in the study described a sense that by disclosing to their 
children, they were relinquishing control over how the genetic information should be 
managed; they told of struggles reconciling themselves to their children’s decisions when 
children chose paths that were not what the mothers would have desired, and to ongoing 
fears about the potential consequences of test results on their children (Clarke et al., 
2008). Certainly, the real and varied concerns and experiences of women in the Clarke et 
al. study shed light on how issues family issues may impact the process of disclosure of 
positive BRCA1/2 mutation status by mothers to their young adult daughters, changing 
the relational context in which women in the population of interest deal with their own 
testing and risk management processes. 
 A study of individuals in HBOC and Huntington’s Disease (HD) families in 
Denmark indicates that individuals often find the presence of a health professional (i.e., 
genetic counselor, physician, etc.) helpful during initial communication of information 
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about a mutation to other family members, because the professional can help reduce the 
uncertainty associated with risk information and answer family members’ questions that 
the tested individual may not be equipped to answer (Forrest et al., 2003). They also 
observed a phenomenon whereby older individuals, especially females, within a family 
were perceived as responsible for communicating risk information to members of 
younger generations, even if the younger generation were adults; this is in keeping with 
other research on mutation disclosure (Clarke et al., 2008). There are both research-based 
and anecdotal reports of frustrating experiences in which family members experience a 
great deal of frustration when the person or persons seen as “responsible” for and having 
the authority to communicate risk information to a younger member fails to do so and, for 
example, “participants felt that they could neither pass on information to relatives who 
needed to know…nor persuade those with authority…to do so,” (Forrest et al., 2003, p. 
321). 
 Researchers have noticed two distinct communication styles relevant to the 
sharing of genetic information in families. Pragmatists go about the business of 
discussing the family mutation in an active, practical fashion, while prevaricators seek 
opportunities within the context of daily life to bring up the subject. Consequently, it 
often takes much longer for prevaricators to complete the process of informing family 
members about a mutation, because they may wait weeks, months, even years for the 
“right moment” to present itself (Forrest et al., 2003). Given these two communication 
styles, it is easy to understand how families can encounter problems around the issue of 
communication; when both of these styles are present within the same family, there is 
likely to be disagreement regarding when, how, by whom, and to whom genetic risk 
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information should be communicated. The Danish study revealed that “individuals who 
wished to pass on information but felt they must defer to a relative with more 
authority…either had to keep quiet and shoulder the additional emotional burden or force 
the issue by disregarding authority or ‘blackmailing’ the prevaricating relative,” (Forrest 
et al., 2003, p. 322). 
 As discussed elsewhere in this paper, the ability to share genetic information with 
children to aid in their medical decision making is one of the most frequently cited 
motivations for genetic testing (Lerman et al., 1996; H. T. Lynch et al., 1997). However, 
the process by which this information is shared is not necessarily simple or 
straightforward. Information about mutations and cancer risk is often given to the 
younger generation at a time that is determined to be maximally helpful in terms of the 
receiver’s ability to take action to reduce risk and at which intervention is practical; in 
other words, for those in HBOC families, children might be told about the presence of a 
BRCA1/2 mutation in the family during their mid-twenties, when they may realistically 
need to begin surveillance and prevention measures. Furthermore, most health 
professionals will not administer, and professional societies generally recommend 
against, genetic testing for mutations associated with late-onset diseases (including 
BRCA1/2), until a minor has reached at least the age of consent, as there is negligible risk 
during the childhood and adolescent years and the potential medical and psychosocial 
benefits are not applicable until adulthood (ASCO, 2003; ASHG & ACMG, 1995; 
Kodish, 1999; Sharpe, 1993; Tercyak, Peshkin, DeMarco et al., 2007; Wertz, Fanos, & 
Reilly, 1994). For women in HBOC families, preventive measures (i.e., frequent 
screening, chemoprevention) are generally not recommended until an at-risk female 
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reaches the age of 25 (Burke et al., 1997; M. B. Daly et al., 2006), although some parents 
have reported that they hoped lifestyle modifications during childhood (e.g., healthier 
diet, increased physical activity) might decrease long-term cancer risk for children in 
HBOC families (Tercyak, Peshkin, DeMarco et al., 2007). In addition to these factors, the 
sense that children are old enough to understand the information is another oft-cited 
factor in decision-making about when to inform children about the presence of a mutation 
(Forrest et al., 2003). 
 A study conducted at the University of Chicago Cancer Risk Clinic investigated 
communication about the presence of BRCA1/2 mutations to children under the age of 25 
within families by analyzing 42 qualitative interviews with carriers who had a child under 
the age of 25 at the time of genetic testing. Fifty-five percent of participants discussed the 
hereditary risk of cancer in general terms (i.e., not necessarily explicitly disclosing their 
own mutation status), and approximately half informed their children of their positive 
carrier status (Bradbury et al., 2007). This is consistent with other research suggesting 
that about half of mothers who undergo testing for BRCA1/2 disclose their results to their 
minor children within one month after testing (Tercyak, Hughes et al., 2001; Tercyak, 
Peshkin, DeMarco, Brogan, & Lerman, 2002). Conversations often comprise a gradual 
process of disclosure, in which parents informed their children about the presence of a 
genetic mutation in the family and then about their personal risk and mutation status over 
time. Disclosure was associated with “older child age, female parent sex, parent history 
of [risk-reducing] surgery…and less formal parent education,” (Bradbury et al., 2007, p. 
3707), while child’s sex and parent’s history of cancer were not associated with 
disclosure (Bradbury et al., 2007; Tercyak, Hughes et al., 2001). The authors posit that 
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the association between disclosure and history of risk-reducing surgery may indicate that 
some parents choose to disclose their mutation in an attempt to explain their surgery 
decisions to their children, although this finding did not stand out from among the 
interview data collected.   
In one study of parental disclosure of BRCA1/2 presence in families to children, 
disclosure to children of all ages was generally handled independently by the mutation-
carrying parent or with a spouse, with a minority (about 5%) reporting that a genetic 
counselor had been their most important supporter during the decision-making process; 
however, 21% reported that a genetic counselor was involved in the decision, and 14% 
reported the involvement of a physician (Bradbury et al., 2007). There was a good deal of 
variation with regard to the length of time that parents waited before disclosing 
information to their children, with 30% of parents indicating that they had delayed 
disclosure to at least one of their children; length of delay varied from several months to 
six years and was chosen for the following reasons: waiting for a child to get older, 
giving self time to adjust to the information or to decide how to use the information 
personally, and waiting to share the information in person (i.e., in cases in which the 
child did not live with the parent). Interestingly, although the mean age of children of this 
set of mutation carriers who were disclosed to was close to 18, “two children younger 
than 10 were told of their parent’s BRCA mutation or the hereditary risk of cancer, one as 
young as 7,” (Bradbury et al., 2007, p. 3707). 
When parents disclosed to children under 25, they often felt that the children did 
not fully comprehend the gravity of the information with which they were being 
presented, with older child age associated with increased parental perceptions of 
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understanding. Parents reported emotional responses among offspring including 
concern/anxiety, crying, and fear; however, parents perceptions of children’s emotional 
responses were not associated with offspring age or sex. Most parents reported no effect 
(65%) or a positive effect (22%) on the parent-child relationship as a result of disclosing 
mutation information, with a small number of parents reporting that their own feelings of 
guilt post-disclosure resulting in some tension in the parent-child relationship (Bradbury 
et al., 2007). 
Certainly, there are situations in which an individual may decide not to share 
information with others, either keeping information to themselves entirely or disclosing 
only to certain family members. Declining to tell may be the result of an attempt to 
protect family members who are seen as vulnerable to discrimination or who may not be 
able to handle information about a mutation. In other cases, it may be the result of 
difficulty transcending physical and/or emotional distance or conflicts that existed before 
knowledge of the mutation was available. Finally, some individuals may decline to tell 
because they believe that certain family members do not “need” to know (e.g., an elderly 
uncle with no children may not be considered at-risk within an HBOC family) (Forrest et 
al., 2003). In sum, the motivations for withholding information from certain family 
members are varied and not necessarily negative. 
 Interestingly, despite this clearly varied experience in the process of telling family 
members about the presence of a mutation, it appears to be a moot point for some 
individuals. Many of the participants in the Danish communication study described 
having “always known” about the presence of a hereditary disease in their family, or that 
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they had come to realize this over time as more and more members of the family were 
diagnosed (Forrest et al., 2003). 
Long-term implications. The body of research that follows women beyond one-
year post-disclosure to assess their psychological functioning is quite small. One British 
qualitative study used telephone focus groups to discuss these issues with women who 
had known about their positive mutation status for at least two years. Participants’ 
responses revealed that beyond the first year post-disclosure, carriers continue to 
experience acute bouts of  
anxiety, depression, shock, surprise and feelings of neglect… triggered by risk-
related events, such as being initially informed about their risk (by a health 
professional), receiving an appointment letter, waiting for an overdue 
appointment, having a mammography or biopsy and receiving the results (even if 
they showed no signs of breast cancer), (Appleton et al., 2000, p. 515).   
 
The group also described a sense of being very sensitive to breast cancer cues, 
such as detecting changes in their own breast tissue, hearing a story about breast cancer in 
the media, or learning of a new diagnosis within their families. In response to these cues, 
they engaged in behaviors such as increased frequency of breast self exam, seeking out or 
taking greater interest in media reports, feeling anxious, or purposely trying to avoid the 
cues. The women described an ongoing cycle of emotional and cognitive fluctuations that 
coincide with their annual screening cycle and that is relatively consistent from year to 
year (Appleton et al., 2000). This is in keeping with previous research on women with 
familial risk of breast cancer who have reported that they experience distress just prior to 
routine mammography, and that this distress is relieved by a normal result 
(Valdimarsdottir et al., 1995). 
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The need for genetic counseling. In communicating about risk to patients in a 
healthcare system, it is widely acknowledged that the manner in which risk information is 
framed has significant bearing on how it is heard and the actions that will arise from it 
(Sarfati, Howden-Chapman, Woodward, & Salmond, 1998). Many researchers and 
practitioners have noted that the provision of appropriate, competent, in-person genetic 
counseling before, during, and after genetic testing and education may effectively serve 
to mitigate the risk of adverse psychological reactions (Cull et al., 1999; Lerman, Daly et 
al., 1994; Lerman et al., 1996; Offit & Brown, 1994). This includes becoming fully 
informed about the benefits and limitations of receiving genetic testing results, including 
the current limitations on options for prevention and detection of cancer (Geller et al., 
1997; Lerman & Croyle, 1996). This is further complicated by the ever-changing nature 
of genetic risk information, and health professionals and patients alike must constantly 
sift through new information to fully understand the current knowledge about risk 
(Bottorff et al., 2000). As a result of these factors, even when high-quality services are 
provided, there can be short-term negative effects on psychological functioning as a 
result of a positive BRCA1/2 mutation test result (Croyle et al., 1997). 
What is also important in the context of genetic counseling about hereditary 
cancer risk is the appropriate inclusion of family members or, at minimum, a discussion 
with the patient of whether and how other members of the family system will be 
informed of their risk. Healthcare professionals must recognize the psychosocial support 
needs of all members of the family system, including those who test negative for a 
mutation and may experience guilt, confusion, worry, etc. (Bleiker & Aaronson, 2000). 
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Appendix C: Overview of Reproductive Options for BRCA Mutation Carriers 
Adoption. Couples in which a partner carries a BRCA1/2 mutation may face 
unique challenges related to the adoption process if they choose to pursue that method of 
family formation. Should they elect to adopt through a public agency, they may be met 
with hesitation in placing a child in a family in which the risk of future cancer is 
significantly higher than average, should this information be made known; this dilemma 
may be similar to what is faced by some cancer survivors who try to adopt (Schover, 
1999). In private adoption, in which birth mothers are often allowed to personally select 
adoptive parents, it has been suggested that birth mothers may be deterred by a personal 
and/or family history of cancer, regardless of the medical facts or what measures are 
being taken to reduce one’s own risk (Schover, 1999), and may be legitimately concerned 
about the potential for adoptive parents to develop cancer in the future, which would 
certainly impact care of and relationships with the adopted child. 
Third-party reproduction. Third-party reproduction includes any method in 
which an individual outside of the couple is biologically involved in the creation or 
gestation of a child. Relevant options for couples in which the female partner is 
BRCA1/2-positive include traditional surrogacy (a surrogate is inseminated with the 
intended father’s sperm), gestational surrogacy (a surrogate is implanted with an embryo 
to which she is genetically unrelated), oocyte (egg) donation, or some combination of 
these (Schover, 1999). When gametes are donated, that may be accomplished 
anonymously (donor and recipient never know each other’s identities), through a known 
donor (donor and recipient agree to meet as part of the donation process and possibly 
beyond), or through directed donation (donor and recipient already know each other, i.e., 
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a relative or friend is the donor) (Rosen, 2005). In addition to the logistical stress of using 
this strategy, couples who select third-party reproduction may face some societal stigma 
(Braverman & Corson, 1995; Cahill, 1996). They also report fears that they will have 
trouble bonding successfully with the child(ren) produced via these strategies, or that the 
child(ren) will have unexpected psychological or health problems. Further, some parents 
are concerned about their ability to talk openly with their child(ren) in the future about 
the fact that they were created through third-party reproduction, and fear that the children 
themselves will feel stigmatized by this knowledge (Rosen, 2005). Third-party 
reproduction is still the method of choice for some of these families for several reasons. 
One partner, or perhaps both, will still have a genetic relationship with the child. Parents 
are able to exert some control over the selection of the donor (as opposed to the level of 
control possible in the case of adoption) and over their child’s prenatal care. Finally, 
parents are often able to choose this option and keep it a secret from their child (should 
they choose to do so), which is not always possible with adoption (Rosen, 2005). Use of 
this option also presents psychological and emotional challenges for mutation-positive 
women, who must come to terms with what may be a loss of a lifelong desire to 
accomplish pregnancy, childbirth, and breastfeeding (Schover, 1999). 
Reproductive technology. Currently, a limited number of interventions are 
available to reduce the risk that a BRCA1/2 mutation carrier who wishes to carry her own 
biological pregnancy will pass her mutation to offspring; specifically, parents may utilize 
Pre-implantation Genetic Diagnosis (PGD) or Prenatal Genetic Diagnosis (PND). 
Pre-implantation genetic diagnosis. The use of PGD by families with BRCA1/2 
mutations is feasible, but as yet not widely available. In this procedure, egg and sperm 
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cells are extracted from parents and brought together in a laboratory setting through a 
process called in vitro fertilization (IVF). When fertilized embryos reach 8 cells 
(approximately 3 days after fertilization), one cell from each viable embryo is extracted 
and tested for the mutation of interest. Only embryos that test negative for the mutation 
are then selected and implanted, resulting in a child (or children) that is (or are) mutation-
free. Mutation-positive and any other unused embryos are either stored, destroyed, or 
donated to research. PGD was developed to prevent pregnancies affected with serious, 
life-threatening genetic diseases, and has been used more widely for families with serious 
(often fatal), high-penetrance recessive (e.g., Cystic Fibrosis), dominant (e.g., Huntington 
Disease), and X-linked disorders (e.g., Fragile X). Its use in the setting of cancer 
predisposition syndromes has thus far been rather limited; a 2006 literature review 
identified only 55 cases of PGD and PND combined in this context, taking place at only 
13 centers; it has not yet become common practice (Offit et al., 2006) and is not 
universally available to couples in which one partner is BRCA1/2-positive. 
One major advantage of using PGD as opposed to other techniques, such as 
amniocentesis or PND (which can test for a mutation after pregnancy has been achieved 
naturally) is that it does not require parents to consider abortion in the case of a positive 
mutation test (Harmon, 2006). Another advantage is that, in cases where infertility is also 
an issue and IVF is needed regardless of the use of PGD, the cost of IVF treatment may 
be covered by insurance (Simpson, Carson, & Cisneros, 2005), which can partially 
mitigate the very high total cost of this procedure. 
The availability of PGD for testing for BRCA1/2 has come to the forefront of late, 
largely because the current cohort of interested women are the first generation to reach 
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reproductive age after their mothers developed cancer and were identified as mutation-
positive (Harmon, 2006). In light of this increased demand, some physicians and 
researchers have argued in favor of making PGD for late-onset disorders more widely 
available, arguing that availability would have a positive effect on mutation carriers of 
childbearing age because it can reduce fatalistic attitudes and make individuals more 
optimistic about starting a family (Harmon, 2006). In fact, some mutation carriers who 
proceeded with natural conception on the advice of physicians who did not recommend 
the use of PGD have reported feeling angry that they were not given the option to use 
available medical technology to reduce their children’s cancer risk; some speculate that 
physicians’ personal values stop them from informing patients about PGD, even when it 
may be desirable to the patient and allow them to stop a family legacy of illness and 
death by not passing the harmful mutation to their children (Harmon, 2006). Other 
mutation carriers take offense at the idea that new children are only desirable or selected 
for family membership if they “pass a test” by not carrying a BRCA1/2 mutation, 
implying that they themselves and others like them would not have existed had the test 
been utilized by their parents (Harmon, 2006). 
Since the use of PGD for BRCA mutation carriers was approved in the UK in 
2006, there has been some new research regarding the attitudes of patients about the 
procedure. One study found that 75% of the 53 mutation-positive women surveyed 
believed that it was acceptable to offer PGD to prevent the transmission of BRCA1/2 
mutations. Regarding personal use, 37.5% of respondents who had already completed 
their families stated that they would have considered using PGD had it been available to 
them previously; only 14% of women contemplating a future pregnancy stated that they 
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would consider using PGD. Many of the women who stated that they would not 
personally consider using PGD to prevent having a child with a BRCA1/2 mutation wrote 
emphatically about their opinions, citing the value of their own lives, the fact that a 
BRCA1/2 mutation is not a death sentence, and fear about the future of scientific 
technology. As a group, the women viewed PGD as more acceptable than PND 
(discussed later in this appendix), but expressed concerns about undergoing IVF to 
accomplish PGD, about the risk of misdiagnosis, about the low success rate associated 
with IVF, and about the inconvenience of going through the procedure (Menon et al., 
2007).   
Although we did not ask specifically about the use of reproductive technology in 
our pilot study interviews, the topic did come up spontaneously in conversations with 
some of our participants. Our data suggest that some carriers would be open to 
considering this procedure, but only if IVF were warranted for a separate reason and 
PGD could be accomplished as a sort of “add-on” procedure; in most cases, natural 
conception was still preferred (unpublished data). 
Prenatal genetic diagnosis. The other interventional option for couples in which 
one partner carries a BRCA1/2 mutation is to utilize prenatal genetic diagnosis (PND). In 
this process, cells from a growing fetus are extracted during the pregnancy, via 
amniocentesis or chorionic villus sampling (CVS) (Offit et al., 2006). Amniocentesis is 
the collection and analysis of amniotic fluid, and typically occurs at 16 to 20 weeks 
gestation. CVS is the removal and analysis of a small piece of the placenta and is usually 
performed at 10 to 12 weeks gestation. Both procedures pose some level of risk to both 
the mother and the developing fetus and are significantly uncomfortable for the mother 
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(Offit et al., 2006). Extracted materials are tested for the mutation; a positive test 
indicates that the child carries the mutation. Couples then have an option regarding 
continuation or termination of the pregnancy if they have a strong desire to avoid bearing 
children who are BRCA1/2 mutation carriers. Research suggests that rates of termination 
in the case of an identification of an abnormality are low; rather, PND is often used to 
reassure parents that their baby will not carry a mutation, or to prepare them for future 
health concerns if the baby does carry the mutation. Still, it is certainly plausible that 
some patients will choose to terminate pregnancy upon receiving a positive prenatal 
genetic test for BRCA1/2. 
A small number of studies have investigated individuals’ attitudes regarding 
termination of pregnancy based on the presence of BRCA1/2 mutations discovered via 
PND. A Dutch study asked 78 subjects, all members of families with identified BRCA1/2 
mutations, if they found termination of a pregnancy for this reason acceptable for 
themselves, for female and male fetuses. Responses of mutation-positive and mutation-
negative individuals were compared. Among carriers, none found this option acceptable, 
regardless of the sex of the fetus; among non-carriers, a minority found termination 
acceptable for female (14%) and male (10%) fetuses. The authors posit that 
…the stronger reluctance in mutation carriers than in non-mutation carriers 
towards terminating a pregnancy of a mutation carrier boy or girl may have 
several reasons. Firstly, mutation carriers may be more acutely aware of the 
burdensome emotional implications of terminating a pregnancy because of 
BRCA1/BRCA2 carriership than non-mutation carriers. Secondly, they may 
perceive terminating the pregnancy of a mutation carrier child as incompatible 
with their own existence (Lodder et al., 2000, p. 883). 
 
Similar findings were reported in a British study of adults with another hereditary cancer 
syndrome, familial adenomatous polyposis (FAP), which predisposes carriers to 
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colorectal cancer . While almost all (93%) believed that prenatal diagnosis should be 
available to affected families, a smaller percentage (64%) stated that they would 
personally use it, and only 24% would consider terminating an affected pregnancy 
(Whitelaw, Northover, & Hodgson, 1996).   
In clinical practice, demand for PND for BRCA1/2 mutations has been low and is 
expected to remain so for the foreseeable future, largely because the diseases associated 
with these mutations are survivable and carriers experience decades of healthy life before 
the onset of disease, and because of the heavy emotional burden associated with making a 
decision about termination or continuation of an existing pregnancy (Lodder et al., 2000).   
Legal and ethical issues. Laws and policies regarding the use these reproductive 
technologies to test for susceptibility to late-onset, incompletely penetrant conditions 
vary from country to country. For example, in the UK, the use of PGD for late-onset, 
low-penetrance genes like BRCA was approved in 2006 (Menon et al., 2007), while in 
Italy it has been completely banned (Harmon, 2006). US legislators have been 
surprisingly silent about the use of PGD for detecting genetic mutations such as these, 
having created no regulations thus far; hence, PGD is being used for this purpose at 
several facilities in major US cities (Harmon, 2006). The Code of Medical Ethics of the 
American Medical Association (AMA) states that the use of PGD is acceptable in some 
cases, but warns that “selection to avoid a genetic disease may not always be appropriate, 
depending on factors such as the severity of the disease, the probability of its occurrence, 
the age at onset, and the time of gestation at which selection would occur,” (American 
Medical Association Council on Ethical and Judicial Affairs, 1994). This sentiment is 
echoed by the American Society of Reproductive Medicine and by medical ethics 
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societies in Europe (Offit et al., 2006). It seems clear that the use of preimplantation 
genetic diagnosis and prenatal diagnosis could easily be seen by some as inappropriate 
under the terms of these statements. 
 Using PGD or PND to prevent the transmission of BRCA1/2 mutations raises a 
host of ethical issues. Most basically, there is the question of whether aborting a fetus or 
discarding an embryo due to the presence of a BRCA1/2 mutation is acceptable. This is 
both a broad ethical question and an individual moral one. Given that hereditary breast 
and ovarian cancer are generally late-onset, that the genes are incompletely penetrant, and 
that treatments are improving with time, there is certainly a significant chance that as a 
result of the use of PGD/PND, fetuses will be aborted or embryos discarded that may 
have never developed cancer, or for whom highly effective treatment would have been 
available by the time they reached the age of risk (Lancaster, Wiseman, & Berchuck, 
1996; Schover, 1999). At the other end of the spectrum is a question about “whether 
parents who give birth to a genetically damaged child, when they had the chance to use 
prenatal diagnosis, will be stigmatized or even denied health insurance benefits [in the 
future]” (Schover, 1999, p. 56). In a world where genetic technology is advancing faster 
than physicians, patients, and society at large can keep up with it, we must question 
whether the specter of eugenics might re-arise and result in a societal stigma against those 
born with known genetic mutations (Schover, 1999). Finally, at the family level, what are 
the implications for children who may be born with known mutations – might they be 
treated differently by parents who are aware of this risk (Schover, 1999)? 
Class issues are also related. We must recognize that, at least currently, these 
procedures are only available to those who can afford to pay for them out-of-pocket, 
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since insurance companies currently will not cover the use of PGD or PND for the 
purpose of BRCA1/2 (Schover, 1999). In the long term, this could result in the “breeding 
out” of genetic disease among the affluent while the less affluent remain at the mercy of 
chance, resulting in increasing class division and health disparities. 
As previously discussed, for couples who elect or are advised to use PND rather 
than PGD, receiving a positive result for a prenatal BRCA test leads to a choice regarding 
abortion, and some argue that this is an inappropriate use of medical knowledge and 
technology (Simpson et al., 2005; Surbone, 2001). In addition, some have expressed 
concerns regarding whether or not genetic counseling can be appropriately value-neutral 
and non-directive in counselors’ interactions with pregnant BRCA-positive women so as 
to allow them to make their own independent decisions regarding their pregnancies 
(Surbone, 2001). In its most pernicious form, forcefully communicated negative opinions 
about carrying a BRCA-positive pregnancy to term can take the form of eugenics and may 
come about as a product of movement toward patient “autonomy” or economic pressure 
within the healthcare system (Sherwin, 1992; Surbone, 2001). The availability of high-
quality, value-neutral counseling from both genetic counselors and physicians is essential 
in assuring that patients are both informed about all of their options and given the 
autonomy to make their decisions independently (Rhodes, 1988). 
 At the same time, there are several reasons that BRCA1/2-positive women may be 
particularly motivated to carry and deliver their own biological children. Both parity and 
breastfeeding are known protective factors for ovarian cancer risk in the general 
population (Modan et al., 2001; Rosenblatt & Thomas, 1996). Breastfeeding has been 
associated with reduction in breast cancer risk of BRCA1 carriers, but not BRCA2 carriers 
 
 426
(McLaughlin et al., 2007), and parity has been identified as protective for both breast and 
ovarian cancer in BRCA1 carriers and for breast cancer in BRCA2 carriers, but as a risk 
factor for ovarian cancer in BRCA2 carriers (McLaughlin et al., 2007). Other studies have 
reported that parity increases the risk of both types of cancer in BRCA2 carriers (Narod et 
al., 1998). Women who seek out information about how to influence their cancer risk 
may not always distinguish between findings that apply to the general population and 
those that apply to mutation carriers, and may believe that “recommendations” apply to 
them that actually are intended for a different group. These findings, in combination with 
recommendations from physicians and possible pressure from loved ones to proceed with 
oophorectomy before age 40, may result in women who are aware before they commence 
childbearing that they carry a mutation in BRCA1/2 feeling a sense of pressure with 
regard to reproduction. In fact, our 2008 qualitative study yielded several quotes from 
young female BRCA1/2 mutation carriers in this vein, such as “we talked about having 
children much sooner, just based on things you read, that it’s better for me to have 




Appendix D: FORCE Website Study Announcement 
NCI RESEARCHER SEEKING YOUNG FEMALE BRCA1/2 CARRIERS FOR 
INTERVIEW STUDY 
 
Researchers in the Clinical Genetics Branch (CGB) at the National Cancer Institute, in 
collaboration with the University of Maryland School of Public Health, are conducting an 
interview study of women who are aware of their positive BRCA1/2 mutation status 
during young adulthood.  Participants will be asked to take part in a 1-2 hour recorded 
telephone interview, during which they will be asked to discuss the following: 
• Personal and family history of breast/ovarian cancer; 
• Experience with genetic counseling and disclosure; 
• Previous, current, and/or future couple relationships; 
• Family formation; and  
• Previous, current and planned strategies for risk management/reduction 
 
In order to participate, women must meet all of the following criteria: 
• Currently aged 18-35 
• Tested positive for BRCA1 or BRCA2 
• Able to speak and understand English fluently 
• Have previously, are currently, or will at some point in the future contemplate a 
couple relationship, family formation, and/or risk management/reduction 
 
Interested individuals are invited to contact Lindsey M. Hoskins, MS, LGMFT via 
telephone (301-451-9732) or e-mail (hoskinsl@mail.nih.gov).  A brief telephone 
screening interview (less than 10 minutes in length) will be required to ascertain whether 
eligibility criteria are met.  If eligible, participants will be required to read, sign, and 
return NCI Informed Consent documents prior to participating in the interview. 
 
Participants and non-participants alike will have an opportunity to take part in a young 
BRCA1/2-carrier focus group at the 2009 Joining FORCEs Conference, to be held May 
15-16, 2009 in Orlando, FL. 
 
 428
Appendix E: Telephone Screening Interview 
TELEPHONE INTERVIEW FOR POTENTIAL PARTICIPANTS 
 
Hello, my name is Lindsey Hoskins and I am a pre-doctoral researcher at the National 
Cancer Institute.  I received your contact information via [FORCE, the Breast Imaging 
study, the HBOC study, your e-mail/phone call] and would like to speak with you about 
participating in my interview study.  Do you have a few minutes to talk to me and answer 
some brief screening questions? 
 
Great. I’m conducting a study of women like you, who have received positive BRCA1/2 
mutation test results during their twenties and thirties.  I’m interested in finding out how 
that event and that knowledge has shaped other parts of your life, specifically couple 
relationships, having children, and your current and future strategies for managing your 
cancer risk.  If you choose to participate, you would be asked to participate in a telephone 
interview which will probably last between one and two hours.  Does that sound like 
something you might be interested in and willing to do? 
 






Great.  Well, in order to figure out if you are eligible to participate in the study, 
I’d like to ask you a few questions.  They are just some basic pieces of 
information about you, what your life was like at the time you had genetic testing, 
and what’s going on for you now.  It should take less than five minutes.  Do you 




Participation in this study is strictly voluntary.  I have no wish to pressure 
you into doing something in which you are not interested, but are there any 
questions I might answer for you to be certain you understand what it is we 
are requesting of you? 
 
If YES: Answer the questions 
 
If NO: Thanks very much for your time.  [If speaking to an HBOC or 
BI participant] Your decision in no way affects your overall 
participation in the NCI hereditary breast/ovarian cancer study.  







1. What is your date of birth? ___/___/_____ 
 
2. When did you first learn about genetic testing for BRCA mutations? (an approximate 
date is fine) ___/___/_____ 
 
3. How old were you when you underwent genetic testing for BRCA? ____ 
 




a. Researcher calculate age at disclosure = ___ years 
 
5. Did you receive a positive (you do have the mutation) or negative (you do not have the 
mutation) test result?  ⁭ Positive   ⁭ Negative 
 
a. If positive, which mutation do you carry? 
⁭ BRCA1 
⁭ BRCA2  
 
6. What was your relationship status at the time you were tested for the BRCA mutation? 
⁭ Unmarried, not in a relationship 
⁭ Unmarried, in a casual relationship 
⁭ Unmarried, in a committed/serious relationship 
⁭ Unmarried, cohabiting with a partner 
⁭ Engaged 
⁭ Married 
⁭ Married, living apart 
⁭ Married, legally separated 
⁭ Divorced 
⁭ Widowed 
⁭ Other (specify): ______________ 
 
7. What is your relationship status now? 
⁭ Unmarried, not in a relationship 
⁭ Unmarried, in a casual relationship 
⁭ Unmarried, in a committed/serious relationship 
⁭ Unmarried, cohabiting with a partner 
⁭ Engaged 
⁭ Married 
⁭ Married, living apart 
⁭ Married, legally separated 
⁭ Divorced 
⁭ Widowed 




8. Do you currently have children? 
 ⁭ Yes 
⁭ No 
 




10. What is your current strategy for managing/reducing your breast/ovarian cancer risk? 
(check all that apply) 
⁭ Surveillance 
 ⁭ Mammography 
 ⁭ Breast MRI 
⁭ Breast Self-Exams (BSEs) 
⁭ Clinical Brest Exams 
⁭ Transvaginal Ultrasound (TVU) 
⁭ Pelvic Exams 
⁭ CA-125 test 
⁭ Other (specify): __________________________ 
⁭ Chemoprevention 
⁭ Oral contraceptive pills 
⁭ Selective estrogen receptor modulator (SERM) 
⁭ Other (specify): __________________________ 
⁭ Risk-reducing surgery 
 ⁭ Risk-reducing mastectomy 
⁭ Risk-reducing oophorectomy/salpingo-oophorectomy 
⁭ Other (specify) 
⁭ I am not currently doing anything to manage or reduce my cancer risk  
 
11. What other cancer risk management/reduction strategies have you considered or 
might you consider in the future? 
⁭ Surveillance 
 ⁭ Mammography 
 ⁭ Breast MRI 
⁭ Breast Self-Exams (BSEs) 
⁭ Clinical Brest Exams 
⁭ Transvaginal Ultrasound (TVU) 
⁭ Pelvic Exams 
⁭ CA-125 test 
⁭ Other (specify): __________________________ 
⁭ Chemoprevention 
⁭ Oral contraceptive pills 
⁭ Selective estrogen receptor modulator (SERM) 
⁭ Other (specify): __________________________ 
⁭ Risk-reducing surgery 
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 ⁭ Risk-reducing mastectomy 
⁭ Risk-reducing oophorectomy/salpingo-oophorectomy 
⁭ Other (specify) 
⁭ I have not considered any risk management/reduction strategies 
 
Great – that does it for my questions.  Do you have any questions for me about the study? 
 
Wonderful.  Well, based on the answers you have provided, it seems that you [are / are 
not] eligible for the study. 
 
 If ELIGIBLE: The next step is for you to review, sign, and return a set of 
documents providing informed consent for the interview.  Once I have those from 
you, we can schedule a time for our interview.  Would you please provide the best 
mailing address for me to send you the documents? 
 
 Address:  ___________________________________ 
 
   ___________________________________ 
 
 Wonderful, thank you.  Please expect that package within about a week.  If you 
have any questions about the materials, please do not hesitate to contact me by 
phone (301-451-9732) or e-mail (hoskinsl@mail.nih.gov).  I’m very much 
looking forward to our next conversation!  Thanks so much for your time. 
 
If INELIGIBLE: Although you’re not eligible for this particular study, I would 
love to keep your contact information on hand for participation in future studies 
for which you might be eligible.  Would that be alright with you? 
 ⁭ Yes 
⁭ No 
 




Appendix F: Interview Informed Consent Form 
 
INSTUTUTE: NCI  PRINCIPAL INVESTIGATOR: Mark H. Greene, MD 
        Chief, Clinical Genetics Branch 
 
    LEAD INVESTIGATOR: Lindsey M. Hoskins, MS, LGMFT 
         Pre-Doctoral Fellow, Clinical Genetics 
Branch 
 
STUDY TITLE: A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on 




We invite you to take part in a research study at the National Institutes of Health (NIH). 
 
First, we want you to know that: 
 Taking part in NIH research is entirely voluntary. 
 
 You may choose not to take part, or you may withdraw from the study at any time.  In either 
case, you will not lose any benefits to which you are otherwise entitled.  However, to receive 
care at the NIH, you must be taking part in a study or be under evaluation for study 
participation. 
 
 You may receive no benefit from taking part.  The research may give us knowledge that may 
help people in the future. 
 
Second, some people have personal, religious or ethical beliefs that may limit the kinds of medical or 
research treatments they would want to receive (such as blood transfusions).  If you have such beliefs, 
please discuss them with your NIH doctors or research team before you agree to the study. 
 
Now we will describe this research study.  Before you decide to take part, please take as much time as 
you need to ask any questions and discuss this study with anyone at NIH, or with family, friends or your 
personal physician or other health professional. 
 
DESCRIPTION OF RESEARCH STUDY 
 
This is a qualitative investigation, a type of research aimed at increasing understanding of important 
questions within a group of individuals by studying a few of its members in depth.  Please take the time you 
need to make your decision about taking part.  You may discuss your decision with your friends and 
family.  You can also discuss it with your health care team.  If you have any questions at any point, you can 
ask the investigator for more explanation. 
 
You are being asked to participate in this study because you have been identified as a carrier of a BRCA1 or 
BRCA2 mutation who learned of her mutation status prior to age 35. 
 
The purpose of this study is to explore the impact of receiving a positive BRCA mutation test result on 
young women’s lives and decisions, specifically with regard to couple relationships, family formation, and 
risk management/reduction.  We want to find out how things like couple communication and relationship 
development, reproductive decision-making, and planning for risk management now and in the future 
might be altered when women learn at a young age that they carry a BRCA mutation.  This research is 




Approximately 40 women will be invited to participate in this study.  As a participant, you will be asked to 
take part in a telephone interview, which may last up to two hours.  During this interview, you will be 
asked a number of open-ended questions related to your personal and family history of breast and ovarian 
cancer, your experience of genetic counseling and testing, couple relationships, family formation, and 
cancer risk management. 
 
We would like your permission to tape record this interview. Doing so will improve the accuracy of the 
information we collect, and help to make this a high-quality research study. If you agree, the tape recording 
will be transcribed into a typed document, which can then be analyzed using special computer software. 
You may choose to participate in the study, but not to have your conversation recorded. 
 
 I have been informed that the study investigator would like to tape record my 
            interview. 
  □ I agree to have my interview recorded. __________ 
                                                                                                       Initials 
  □ I choose not to have my interview recorded. __________ 
                                                                                                                Initials 
 
When you are finished with the interview, your involvement in the current study will be complete.  
However, you will be invited to participate in the analysis stage of the study if you wish to read and provide 
feedback regarding the results and early stages of analysis.  Doing so would be completely voluntary and 
would not require you to sign a new consent form. 
 
If you are interested in the outcomes of this study, but do not wish to be a part of the analysis phase, you 
may obtain a copy of the research findings after they have been analyzed and prepared for publication. 
 
You can decide to stop at any time.  Declining to participate in the study, or discontinuing your 
participation after joining, will have no effect on your remaining a member of the Breast Imaging or HBOC 
studies (if applicable), your ability to participate in future studies, or on your ability to seek advice or 
assistance from members of the Clinical Genetics Branch staff. Your participation is completely voluntary. 
 
ALTERNATIVES TO PARTICIPATION 
 
You may choose not to participate in this study.  If you choose not to participate, your decision will not 
affect your medical care, your ability to continue as a participant in the Breast Imaging or HBOC studies, 
or your ability to join future research studies conducted by the Clinical Genetics Branch.  You can still get 
your research-related medical care from our institution, if applicable. 
 
POTENTIAL BENEFITS OF PARTICIPATION 
 
Taking part in this study may or may not improve your emotional health or your understanding of changes 
in individual, relationship, and family processes as related to your status as a BRCA1/2 mutation carrier.  
We do know that the information from this study will help researchers and genetics practitioners learn more 
about the experiences of women who undergo genetic testing during young adulthood, and this information 
could improve treatment for future generations of women from hereditary breast/ovarian cancer families. 
 
You will not be paid for taking part in this study. 
 
RISKS OR DISCOMFORTS OF PARTICIPATION 
 
This study involves minimal risk to you as a research participant.  During the one hour interview, because 
you will be thinking carefully about events that have happened in your life before, during, and after your 
genetic testing and disclosure experience, it is possible that unresolved feelings of grief and/or anger may 
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resurface.  Therefore, there is a chance that you may experience emotional discomfort or anxiety related to 
the topics discussed in the interview. 
 
There is no risk of physical injury associated with participating in this study. 
 
There is no financial cost associated with taking part in this study.  When long-distance phone calls need to 
be made in order to conduct interviews, the researcher will place the telephone call to you. 
 
RESEARCH SUBJECT’S RIGHTS 
 
Taking part in this study is your choice.  You may choose either to take part or not to take part in the study.  
If you decide to take part in this study, you may leave the study at any time.  No matter what decision you 
make, there will be no penalty to you and you will not lose any of your medical benefits.  Leaving the study 
will not affect your medical care, your ability to continue as a participant in the Breast Imaging or HBOC 
studies, or your ability to join future research studies conducted by the Clinical Genetics Branch.  You can 
still get your research-related medical care from our institution. 
 
We will tell you about new information or changes in the study that may affect your health or your 
willingness to continue in the study. 
 
All information you provide will be kept confidential.  Because of the qualitative nature of this study, the 
findings will likely be published using quotations from participants that effectively illustrate emergent 
themes of the study.  However, all study participants will be referred to only by pseudonyms, so true 
identities will not be revealed. All information collected from you will be kept in either locked drawers or 
in password-protected computer files. Access to this information will be restricted to only the researchers 
involved in this study. 
 
ACCESS TO RESEARCH INFORMATION 
 
You can talk to the study investigator about any questions or concerns you have about this study.  Contact 
Lindsey Hoskins, MS, LGMFT at (301) 451-9732 or hoskinsl@mail.nih.gov. 
 
For questions about your rights while taking part in this study, call the NIH Clinical Center Patient 
Representative at (301) 496-2626. 
 
Certificate of Confidentiality 
 
This study is covered by a Certificate of Confidentiality issued by the National Cancer Institute on behalf 
of the Secretary of the Department of Health and Human Services. This Certificate provides additional 
legal protection against involuntary release of information about you collected during the course of this 
study that may identify you individually. Of course, such information can be released if you or your 
guardian requests it in writing. A Certificate of Confidentiality should prevent researchers involved in 
this project, to the full extent permitted by the Courts, from being forced to disclose your identity or any 
information about you collected in this study in any legal proceedings at the Federal, State, or local level, 
regardless of whether they are criminal, administrative, or legislative proceedings. However, this 
Certificate does not prevent the review of your research records under some legally required 
circumstances (for example, under the Federal Food, Drug, and Cosmetic Act or during the course of an 
internal program audit or evaluation). 
 
 
OTHER PERTINENT INFORMATION 
 
1. Confidentiality.  When results of an NIH research study are reported in medical journals or at 
scientific meetings, the people who take part are not named and identified.  In most cases, the NIH will 
not release any information about your research involvement without your written permission.  However, 
if you sign a release of information form, for example, for an insurance company, the NIH will give the 
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insurance company information from your medical record.  This information might affect (either 
favorably or unfavorably) the willingness of the insurance company to sell you insurance. 
 
The Federal Privacy Act protects the confidentiality of your NIH medical records.  However, you should 
know that the Act allows release of some information from your medical record without your permission, 
for example, if it is required by the Food and Drug Administration (FDA), members of Congress, law 
enforcement officials, or other authorized people. 
 
2. Policy Regarding Research-Related Injuries.  The Clinical Center will provide short-term medical 
care for any injury resulting from your participation in research here.  In general, no long-term medical 
care or financial compensation for research-related injuries will be provided by the National Institutes of 
Health, the Clinical Center, or the Federal Government.  However, you have the right to pursue legal 
remedy if you believe that your injury justifies such action. 
 
3. Payments.  The amount of payment to research volunteers is guided by the National Institutes of 
Health policies.  In general, patients are not paid for taking part in research studies at the National 
Institutes of Health. 
 
4. Problems or Questions.  If you have any problems or questions about this study, or about your 
rights as a research participant, or about any research-related injury, contact the Principal Investigator, 
Mark H. Greene, M.D., at 301-594-7642; Executive Plaza South, Room EPS 7032, Telephone: 301-435-
8062.  You may also contact the Lead Investigator, Lindsey M. Hoskins, MS, LGMFT, at 301-451-9732. 
 




5. Consent Document.  Please keep a copy of this document in case you want to read it again. 
 
COMPLETE APPROPRIATE ITEM(S) BELOW: 
A. Adult Patient’s Consent B. Parent’s Permission for Minor Patient. 
I have read the explanation about this study and have 
been given the opportunity to discuss it and to ask 
questions.  I hereby consent to take part in this study. 
I have read the explanation about this study and have 
been given the opportunity to discuss it and to ask 
questions.  I hereby give permission for my child to 
take part in this study.   
(Attach NIH 2514-2, Minor’s Assent, if applicable.) 
    
Signature of Adult Patient/Legal Representative     Date Signature of Parent(s)/Guardian                     Date 
  
C. Child’s Verbal Assent (If Applicable) 
The information in the above consent was described to my child and my child agrees to participate in the 
study. 





THIS CONSENT DOCUMENT HAS BEEN APPROVED FOR USE  
FROM [DATE] THROUGH [DATE]. 
 
    
Signature of Investigator                        Date Signature of Witness                       Date 
 
 436
Appendix G: Interview Protocol 
 
Date: ___________________ 
Location of Participant (U.S. State): ___________________ 
Interview #: ___________________ 
Recruitment Source: ___________________ 






Lindsey to the participant: Thank you so much for your willingness to participate in this 
interview study.  I’d like to tell you a bit more about the purpose of this study.  Through 
this research, I’m hoping to explore the experiences of women who learn that they carry 
BRCA1/2 mutations during young adulthood, both as an individual and within family and 
couple relationships.  I’m going to ask you to think back to the earliest time that you 
knew about the presence of breast and ovarian cancer in your family, and about how your 
family communicated about that issue.  When I say “family,” I’m not limiting this to your 
parents, but including whoever you define as family (e.g. siblings, grandparents).  I’m 
going to ask you to share your experience of genetic testing, and how that was handled in 
your family.  Then, I’d like to ask you about how you have previously or are currently 
thinking about issues of couple relationships, creating your own family, and managing 
your personal cancer risk via surveillance, chemoprevention, and/or risk-reducing 
surgery.   
 
I want to remind you that what you tell me is confidential, in that I will not use your 
name or your family members’ names or any identifying information when reporting my 
findings.  I also want to remind you that as a marriage and family therapist who works 
with families facing medical and genetic challenges, I am deeply and personally 
committed to understanding your unique and personal experience of being a young 
mutation carrier, and how that may impact other important aspects of your life.   
 
The results I generate may help inform the body of knowledge about psychosocial issues 
affecting mutation carriers, as well as the manner in which challenges faced by mutation 
carriers are understood by physicians, genetic counselors, and therapists with whom they 
interact in the physical and mental healthcare settings. 
 
Do you have any questions for me about the purpose of the study or what I hope to do 
with the results of the study?   
 
Ok, let’s get started. Please remember that if you don’t feel comfortable answering any of 






SECTION A: DEMOGRAPHICS & PERSONAL HISTORY 
 
Great.  First I’d like to get some basic demographic information from you.   
 
1. What is your date of birth? 
 
2. With what racial and ethnic group or groups do you identify? 
 
3. When did you undergo testing for BRCA1/2? 
 
4. Have you ever been diagnosed with cancer? 
a. Have you had any cancer scares?  For example, abnormal test results, 
finding a lump during a breast self-examination, etc. 20 
b. How have you dealt with these experiences? 
 
SECTION B: FAMILY CANCER HISTORY 
 
Lindsey: Okay, for the next few questions, I’d like you to think back to the time before 
you underwent genetic testing. 
 
1. Tell me about your family during your childhood. 
a. Where did you grow up? 
b. What was your childhood like? 
c. What do you remember about your family at that time? 
d. How did your family deal with health-related issues? 
e. How did your family deal with cancer-related issues during your 
childhood? 
f. To what extent did members of your family see themselves as “at-risk” for 
breast and ovarian cancer? 
g. How did these things change over time as you grew up? 
 
2. Can you tell me about the history of breast/ovarian cancer in your family? 
a. How did you experience breast/ovarian cancer in your family?  Can you 
share some of your earliest memories about it with me? 
b. What family members were affected?   
c. With which cancers? 
d. What were their health outcomes? 
e. Which cancer in your family was the most challenging for you to cope 




                                                 
20 Italicized questions are “probes,” which serve as reminders for the interviewer to gather this information; 
these items will not be directly requested unless the interviewee does not talk about them in her answer to 




SECTION C: GENETIC TESTING 
 
Lindsey: Okay, now I’d like you to share with me a little bit about how you came to the 
decision to pursue genetic testing for BRCA1/2. 
 
1. How did you first learn about genetic testing for BRCA1/2? 
a. Who told you about it? 
b. How was it presented to you? 
c. How did you feel about genetic testing when you first learned about it? 
 
2. Tell me about how you made the decision to undergo testing. 
a. What were your expectations about what testing would be like? 
b. Did you have a feeling one way or the other about what the results would 
be?  Tell me about that. 
 
Lindsey: Next I’d like to hear about what the testing process itself was like for you.   
 
1. What was your experience with genetic counseling and/or education? 
a. What type of counseling and/or education was available to you prior to 
testing? 
b. What information did you receive during the counseling and/or education 
process? 
c. How did the genetic counselor communicate with you about your risk of 
being a mutation carrier?  About your risk of developing cancer? 
 
2. Going into the test, how did you think about your breast/ovarian cancer risk? 
 
3. Tell me about what it was like waiting for your results. 
a. How long did you have to wait? 
b. What emotions did you experience during that time? 
c. How did your ideas about your chances of being a carrier change during 
that time? 
 
Lindsey: Can you remember what it was like for you to receive your results? 
 
1. How were the results communicated to you? 
 
2. To what extent did you find the results surprising or unexpected? 
 
3. What else happened during the genetic counseling session in which you received 
your results?  What else was communicated to you? 
 




Lindsey: Can you tell me about how receiving your results affected your personal sense 
of vulnerability to cancer? 
 
1. How do you currently understand your risk of developing breast and/or ovarian 
cancer at some point in your life? 
 
2. How do you assess your cancer risk compared to people who do not carry a 
BRCA1/2 mutation? 
 
Lindsey: Great, this has been very informative so far.  Do you have any questions for me 
at this point or anything else you’d like to add about what we’ve discussed up to this 
point? 
 
SECTION D: COUPLE RELATIONSHIPS 
 
Okay, next I’d like to spend some time talking with you about romantic relationships.   
 
1. I’d like to get a sense of your relationship history.  Can you tell me about the 
significant couple relationships you’ve had in your life? 
 
2. Tell me about what’s going on in your life right now in terms of relationships. 
a. Are you in a relationship? 
b. Are you where you thought you’d be at this point in your life in terms of 
relationship? Tell me about how that does or does not match up for you. 
 
If single,     If in a relationship, 
3. How has learning about your positive 
mutation status influenced your perception 
of your ability to get to where you want to 
be in terms of romantic relationships? 
3. Have you shared information about your 
mutation with your current partner? *If yes, 
skip to question 5.  If no, continue to 
question 4.   
     a. Do you think that having a mutation 
         will make it more or less difficult for 
         you to find a partner? Why? 
   
     b. How did learning about your positive 
         mutation status influence your sense 
         of a “timeline” for relationship 
         development? 
 
  
4. How do you think being a BRCA1/2 
mutation carrier has influenced the way 
that you approach relationships? 
4. Tell me about how you think about 
possibly talking to your partner about this 
in the future. *Note: May borrow questions 
from “single” category to capture 
participants’ thoughts about future 
disclosures. 
  
5. How do you think future partners will 5. Tell me about how you informed your 
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respond to learning about your mutation? current partner about your mutation. 
      a. How far into the relationship did you 
         choose to disclose your mutation to 
         your partner? 
      b. What was the nature of your 
         relationship at that time? 
     a. How do you envision telling a future 
         partner about your mutation? 
     c. How did you tell your partner about 
         your mutation? 
     b. What do you think that experience 
         will be like for you? 
     d. What was that experience like for 
         you? 
      e. How did your partner react? 
      f. Did the process of telling your partner
         about your mutation go the way that 
         you thought it would?  How was it 
         similar or different? 
     c. How do you think that sharing your 
         mutation status with a partner in the 
         future will influence the way s/he 
         views you?  The relationship? 
     g. How do you think sharing your 
         mutation status with your current 
         partner influenced the way your 
         partner views you? The way your 
         partner views the relationship? 
     d. How do you think that sharing your 
         mutation status with a partner in the 
         future will influence the relationship 
         intensity? Mutuality? Intimacy? 
         Trajectory? 
     h. How do you think that sharing your 
         mutation status with your current 
         partner influenced relationship 
         intensity? Mutuality? Intimacy? 
         Trajectory? 
  
6. What do you think the negative and 
positive effects of sharing information 
about your mutation with a future partner 
might be? 
6. Looking back, what were the negative 
and positive effects of sharing information 
about your mutation status with your 
current partner? 
  
 7. In what ways does your mutation impact 
your relationship with your partner today?  
How does it come up in the way that the 
two of you interact? 
      a. How does your partner support you 
         through the experience of being a 
         young mutation carrier? 
      b. How are current couple/relationship 
         issues related to your status as a 
         mutation carrier? 
      c. How do you see your status as a 
         mutation carrier affecting 
         couple/relationship issues in the 




 8. Have you shared information about your 
relationship with other partners prior to this 
one?  How were those experiences similar 
or different? 
  
**Note: If single individuals have been in 
significant relationships since learning 
about their mutation, applicable questions 
from the “not single” category will be 
asked to learn about their experiences in 
communicating information about the 
mutation to previous partners. 
*Note: Individuals in relationship may 
relate stories from multiple relationships 
that they have had since learning about 
their mutation, if applicable. 
 
Lindsey: Is there anything else you’d like to share about how your experience as a 
BRCA1/2 mutation carrier has intersected with your experiences in romantic 
relationships? 
 
SECTION E: FAMILY FORMATION 
 
Great.  Next I’d like to talk to you about your thoughts and feelings about having kids. 
 
1. Do you currently have children? 
 
2. Are you considering having / planning to have (more) children in the future? 
a. If no, tell me about how you came to that decision.    
 
3. How have your feelings about being a parent changed as you have moved through 
the different relationships we talked about a few minutes ago? 
 
4. Tell me about ways in which your experience as a BRCA1/2 mutation carrier has 
intersected with your experience as a (potential) parent? 
 
5. How did learning about your positive mutation status influence your ideas about 
the future with regard to having children? 
 
6. How do you understand the risk of passing your BRCA1/2 mutation on to your 
biological children? 
a. To what extent is this risk something that you spend time contemplating? 
b. How do you think that risk influences/will influence the way you make 
decisions about having kids? 
 
7. Have you considered any other methods of having children besides natural 
conception?  For example, adoption, Pre-implantation genetic diagnosis and IVF, 
donor eggs? 
a. Which of these have you considered? 
b. What are your thoughts about these alternative methods? 
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c. Is this something that you and your partner (current or previous) have 
talked about? 
d. How might you talk to a future partner about these issues? 
 
8. How does/did your positive mutation status influence the timeline in which you 
(might) have/had children? 
a. Is this something that you and your partner (current or previous) have 
talked about? 
b. How might you talk to a future partner about these issues? 
 
9. How do you think about handling BRCA-related issues with your children down 
the road? 
a. How do you think you will react if you find out that your child or children 
is/are BRCA-positive? 
b. How would you approach parenting a child who is at risk? 
c. How do you plan to communicate with a mutation-positive child about 
what the presence of a mutation means? 
d. At what age would you start communicating with your child about BRCA-
related issues? 
e. How does your current/future partner fit into this? 
 
Lindsey: Is there anything else you’d like to share with me about how your experience as 
a BRCA1/2 mutation-carrier intersects with issues of having children? 
 
SECTION F: CANCER RISK MANAGEMENT 
 
Okay, we’re down to the last section now.  This last set of questions focuses on how you 
think about managing your breast and ovarian cancer risk.   
 
1. How do you understand the implications of your mutation status on breast and 
ovarian cancer screening and prevention recommendations? 
 
2. Tell me about your experience with communicating/receiving information about 
your options for managing and/or reducing your risk. 
a. With whom have you communicated or from whom have you received this 
type of information? 
b. What sorts of messages have you received? 
c. What happens when you receive conflicting messages from different 
people? 
d. What happens when you receive messages from others (e.g., health 
professionals, family) that contradict your own plans/desires? 
 
3. What is your current method of risk management or reduction? 
a. What are your reasons for using that method at this time? 
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b. Tell me about your experience with that method of risk 
management/reduction.  How does it impact you physically?  
Emotionally? Financially? Other ways? 
c. How confident are you that your current method of managing risk is 
effective?  What is the impact of that belief? 
d. (If applicable) How has/have your current (or past) partner(s) been 
involved in the decisions you’ve made with regard to risk 
management/reduction? 
e. How is your current method of risk management/reduction related to your 
goals or plans for having children? 
 
4. What other methods of risk management/reduction do you think you might utilize 
in the future? 
a. Tell me about how you think about a plan for risk management/reduction 
as your life proceeds. 
b. Why have you selected that/those method(s) of risk 
management/reduction? 
c. (If applicable) How has/have your current (or past) partner(s) been 
involved in the decisions you’ve made with regard to risk 
management/reduction? 
d. How are your future plans for risk management/reduction related to your 
goal or plans for having children? 
 
5. Are there any other ways in which the way you manage your cancer risk has been 
or may be impacted by other important issues, such as relationships or having 
children?   
 
Lindsey: Those are all of the interview questions that I have for you. What should I have 
asked you that I didn’t think to ask?  
 
Do you have any questions for me?   
 
Thank you so much for your help.  If I have more questions for you that come up for me 
later, is it okay to contact you? And, if you think of something else that you forgot to say 
or if you just think of something else you’d like to tell me regarding your experiences as 
an adolescent, please call or email me – I’d love to hear from you. 
 
There are a few small things I wanted to check with you about before we end. First, as a 
part of this study, I am interested in talking to other women in situations like yours, and 
especially interested in talking to multiple members of the same family.  Do you have a 
sister, cousin, or other female relative who is also mutation-positive and who you think 
might also be interested in being interviewed for this study? 
 
[IF YES] Would you be willing to pass my contact information along to her so that she 




[IF YES, share contact information] 
 
Name of second contact: ______________________________ 
 
Relationship of interviewee to above person: __________________________ 
 
Great.  Second, I would like to use a pseudonym, or a different name, when writing about 
your story. This name will be used in place of your actual name so as to protect you and 
your family’s identity. Is there a specific name that you would like me to use for you?  
________________________________________________________________________ 
 
Ok, thanks. Finally, I will be emailing my study findings – my interpretations and 
conclusions – to participants to get their feedback and reactions.  Would you be willing to 




Ok, and if in the future I decide to collect some follow-up data through a survey or 




Okay, well everything you’ve told me has been very helpful, and I truly appreciate your 
taking the time to talk with me today.  I will be looking forward to talking with you again 
when the results have been analyzed, to get your feedback on my interpretation of the 
data. 
 




Appendix H: Participant Descriptions & Index 
Acacia, 30, married. (BI) As a former participant in the BI study, Acacia had been 
involved with CGB for several years and had known she was mutation positive for eight 
years. Acacia’s maternal grandmother had both breast and ovarian cancer; the latter 
resulted in her death before Acacia was born. After Acacia’s mother was diagnosed with 
breast cancer at age 39, she and both of her sisters underwent genetic testing for BRCA; 
Acacia’s mother was the only one who received a positive result. Acacia and her sister 
tested shortly afterward and were both positive as well. Acacia had been with the same 
partner since high school, and he had accompanied her through the genetic testing and 
disclosure process and helped her cope with her mom’s struggle with cancer. Acacia and 
her husband had accelerated their family formation plans to allow them to complete 
childbearing shortly after Acacia’s 30th birthday. Their first child, a girl, had been born 
about two years before our interview, and they were expecting their second and final 
baby, a boy, shortly after. Acacia was planning to undergo both surgeries after she 
finished breastfeeding her son. 
Quoted or referenced on pages: 92, 247, 295, 319 
 
Annie, 32, new relationship. (FORCE) Annie had inherited her BRCA mutation from her 
mother, who had passed away from ovarian cancer at the age of 51. Annie recalled her 
mom’s cancer as something that her mom chose not to share, and Annie regretted not 
having been more involved. The family was no aware of any other breast or ovarian 
cancer until Annie’s first cousin on her mom’s side—to whom Annie was very close—
was diagnosed with breast cancer age the age of 37. At that point, Annie, her sister, and 
their other cousin were all encouraged to pursue genetic testing, and Annie learned of her 
mutation at the age of 31. She was acutely aware of the ticking of her biological clock, 
and had decided to undergo RRBM in order to mitigate her breast cancer risk. This 
surgery was on Annie’s calendar at the time of her interview. She had just entered a new 
but very promising relationship with a man she met through mutual friends, and was 
thrilled at having just shared information about her mutation with him and being met with 
a very positive response. 
Quoted or referenced on pages: 92, 200-202, 208, 221-222, 281-282, 321-322 
 
Audrey, 28, married. (FORCE) Audrey had one of the most unique stories of all 
participants. She and her husband learned that they both carried BRCA2 mutations when 
their one-year-old son was diagnosed with a rare form of leukemia that results from 
Fanconi Anemia (FA). Although Audrey’s family had been aware of a “huge” family 
history of cancer, genetic testing had never been recommended. Three of Audrey’s great 
aunts had had breast cancer, as had three of their daughters; a male cousin had also been 
diagnosed with prostate cancer. After Audrey’s son passed away from leukemia, she and 
her husband struggled to decide whether to have additional children, because there was a 
25% chance that any child they created together would also inherit both BRCA mutations 
and would have FA. Ultimately, they chose to have another baby, but used prenatal 
genetic diagnosis (PND) to screen the fetus for FA, having decided that if the test was 
positive, they would terminate the pregnancy. Subsequently, Audrey gave birth to a 
healthy daughter (who inherited neither mutation) and a healthy son (who had inherited 
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only one mutation). They decided they were finished having children; Audrey had 
complete RRBM and was contemplating RRSO. 
Quoted or referenced on pages: 92, 188, 218-219, 302-303 
 
Beth, 30, engaged. (FORCE) The youngest of three children, Beth was one of the most 
recently tested participants, having only known about her BRCA mutation for three 
months when interviewed. Beth’s mom had passed away as a result of ovarian cancer 
when Beth was 20, and her sister, three years her elder, had become a sort of surrogate 
mother. Additional family cancer history included breast cancer in Beth’s maternal 
grandmother and pancreatic cancer in a maternal great-aunt. About a year after she had 
her second baby, Beth’s sister had been diagnosed with breast cancer, and it was that 
diagnosis—in light of the family history—that had prompted Beth’s sister’s physician to 
recommend genetic testing for BRCA. Beth was engaged and had a young son with her 
fiancé; she was urgently focused on completing her RRBM before her son reached one 
year of age because her sister was diagnosed a year after having her baby. 
Quoted or referenced on pages: 92, 178, 207-208, 248-249, 251, 273, 277-278, 297, 308-
309, 320 
 
Charlotte, 26, single. (FORCE) Charlotte’s unique family history of cancer was 
characterized by the presence of a BRCA mutation on her dad’s side of the family; 
however, Charlotte’s mother had been diagnosed with sporadic breast cancer when 
Charlotte was in middle school. Three of her father’s aunts had had breast cancer many 
years ago, but the family was not aware of the threat of cancer until Charlotte’s cousin 
(her father’s brother’s daughter) was diagnosed with breast cancer at age 37. Because of 
her mom’s breast cancer, Charlotte had been receiving “high-risk” screening, but her risk 
was considered more elevated after she received her positive mutation test result at age 
24. Charlotte’s sister had also been tested and was negative. At the time of her mutation 
testing, Charlotte was in a relationship that had been ongoing since college. Shortly after 
learning that she carried a BRCA mutation, her relationship ended, and she attributed this 
in part to her former boyfriend’s inability to cope with the challenges of her mutation and 
his heightened sensitivity to medical issues because of his own family history. Charlotte’s 
immediate family demonstrated a great deal of concern about her health, largely because 
she was the only individual living with a very high risk status. She planned to have 
RRBM at some point in the future, but not soon. Charlotte’s cousin, Kate, is also a 
participant. 
Quoted or referenced on pages: 92, 161-162, 165-166, 171, 197-198, 204-206, 208-209, 
212-213, 238-239, 312-314 
 
Chris, 33, married. (FORCE) Chris’s family history of cancer consisted of her maternal 
aunt’s diagnosis at age 30, and her mother’s diagnosis at age 50. After Chris had found 
several lumps herself, a doctor with whom she worked suggested that she talk to her 
mother about genetic testing, because an affected family member would need to be tested 
first. Chris had a strong sense that her mother and herself would be mutation positive, 
which was confirmed by the test. Having been divorced from her first husband and 
remarried to a man 20 years her senior, Chris’s positive test results forced her to consider 
whether or not she wanted to have additional children with her second husband. 
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Ultimately, they decided not to do so, and Chris underwent both risk-reducing surgeries 
within 18 months of learning that she carried the mutation. 
Quoted or referenced on pages: 92, 179, 187-188, 215-216, 250, 252-253, 258, 260-262, 
303-304 
 
Dawn, 27, married. (FORCE) Dawn had inherited her BRCA mutation from her father 
and was aware of a paternal aunt and paternal grandmother who had both died of breast 
cancer. Her aunt was diagnosed at only 27 and had died at the age of 30. In addition, 
three great aunts had died from breast cancer as well. With a history of fibrocystic 
breasts, Dawn had made and canceled several genetic counseling and testing 
appointments during college while she worked up the courage to get tested; she had a 
strong sense that she was positive. At the time of her interview, Dawn had known her 
mutation status for 4 months and had a two-year-old and a seven-month-old months; she 
had already undergone RRSO, having felt sure that she did not want any additional 
children. She had an RRBM scheduled for one week after our interview. 
Quoted or referenced on pages: 92, 152, 154, 178, 240-241, 261-262 
 
Elaine, 34, married. (FORCE). Elaine had grown up knowing that her mother had an 
intense fear of breast cancer, but her mother’s diagnosis of ovarian cancer at the age of 58 
was a surprise; after being told that 20% of individuals with her diagnosis survive one 
year, Elaine’s mother lived for seven. During that time, they discovered a heavy history 
of cancer in her mother’s family, including ten diagnoses and seven deaths. Elaine 
grandmother, great-grandmother, great-aunt, and several cousins had all had BRCA-
associated cancers. Elaine had only known her mutation status for two months when 
interviewed, and had her RRSO scheduled for the upcoming summer. She was also 
pursuing RRBM but was unsure about when that procedure would occur. Elaine’s 
primary motivation for undergoing the surgeries so quickly was to preserve her health 
and to be around for her three young children, a daughter and two sons. 
Quoted or referenced on pages: 92, 145-146, 217-218, 253-254, 276, 308 
 
Ellie, 27, serious relationship. Refer to “Ellie’s Story” in Chapter 5 for description. 
Quoted or referenced on pages: 92, 115-126, 131-133, 135, 151, 197-200 
 
Grace, 30, married. (BI). Grace’s mother was diagnosed with breast cancer when Grace 
was 14. Three of her great aunts and four of her mother’s cousins had also had breast 
cancer; of these, all but the three great aunts had survived. Her mother and several 
members of her extended family had undergone risk-reducing surgery and had avoided 
cancer. Grace learned of her positive mutation status at the age of 22 and had completed 
the four-year Breast Imaging study; during those four years, she had met Jason and gotten 
married. Originally having planned to have children before pursuing RRBM, Grace’s 
plans changed abruptly and she and Jason decided instead to complete RRBM first; she 
was the only participant who elected not to have reconstruction. At the time of her 
interview, Grace was three days past her due date to deliver her first child. She has since 
had a healthy baby boy. Grace planned to utilize chemoprevention for a few years to 
manage her cancer risk after completing childbearing, and then have RRSO near age 40. 




Isabelle, 22, single. (FORCE). Isabelle’s mother was diagnosed with breast cancer twice, 
at ages 25 and 36; the first of these occurred before Isabelle was born. Her maternal 
great-uncle had also had breast cancer, and there were several other instances of different 
types of cancer on the maternal side of her family. Isabelle learned of her mutation two 
months prior to her interview and was just getting started with high-risk surveillance. 
Because of the very young age at which her mother was diagnosed, Isabelle was already 
thinking about risk-reducing surgery and when one or both procedures might be 
appropriate for her. Isabelle’s sister, Lilly, is also a participant. 
Quoted or referenced on pages: 92, 180, 199-200, 212, 237-238, 248, 300-301, 310 
 
Jane, 30, married. (FORCE) Jane was adopted as an infant, and there was no history of 
breast or ovarian cancer in her adoptive family. She learned at age 26 that there was a 
strong history of breast cancer in her biological mother’s family, including her mother, 
aunt, and grandmother. Jane learned of her positive mutation status two years prior to her 
interview, and was relying on surveillance to manage her risk because she wanted to have 
and breastfeed more children (she already had one daughter). She was considering doing 
chemoprevention and/or risk-reducing surgery at some point in the future. 
Quoted or referenced on pages: 92, 216-217, 230, 234-235, 246, 249-250, 270-271, 276-
278, 307, 325 
 
Julia, 24, serious relationship. (FORCE). Julia had known that she was BRCA-positive 
for about four months at the time of her interview. She was very close to many 
individuals in her mother’s family because her parents had divorced when she was six.  
When Julia was 22, a maternal aunt was diagnosed with breast cancer at the age of 46 and 
because of her age, she was referred for genetic testing. One year later, Julia’s mother 
was diagnosed with breast cancer, and both women tested positive for BRCA. It later 
came to light that Julia’s grandfather’s mother had died of breast cancer, and an uncle had 
had testicular cancer. Julia was in a serious dating relationship of 2 ½ years, and her 
partner knew about her mutation but “wasn’t a worrier.” The two had talked about the 
possibility of making their relationship permanent, but had been unable to agree about 
whether or not to have children in the future. Julia was open to considering all types of 
risk-management in the future. Her younger sister, Nichelle, is also a participant. 
Quoted or referenced on pages: 92, 163-164, 171, 284 
 
Kate, 35, serious relationship. (FORCE). Kate was the youngest of three sisters and had 
inherited her BRCA mutation from her father. Kate first became aware of breast cancer in 
her family when an aunt to whom she was not biologically related developed breast 
cancer when Kate was 20. Her aunt’s cancer was caught very early and there was never 
any doubt that she would make a full recovery. This led to a perception that breast cancer 
was easily treatable and not much of a threat. More than a decade later, Kate’s sister was 
diagnosed with stage II breast cancer; when their cancer-free paternal grandmother 
learned of this, she disclosed that all three of her sisters had also had breast cancer. Kate’s 
diagnosed sister was immediately tested and was positive for BRCA, and then Kate and 
the remaining sister also got tested; Kate was positive and the third sister was negative. 
Kate had two young children and was going through a nasty divorce during this time, and 
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underwent RRBM without the support of her soon-to-be ex-husband. Since then, she had 
started a new relationship with a man whom she planned to marry and have one or two 
additional children; she then planned to have RRSO. Kate’s cousin, Charlotte, is also a 
participant. 
Quoted or referenced on pages: 92, 179-180, 187, 195, 204, 259-260, 292-293 
 
Kristy, 29, single. (BI) Kristy, a PhD student, inherited her BRCA mutation from her 
father. Her paternal aunt and grandmother had both had breast cancer, and at the time of 
our interview, Kristy’s aunt was near the end of a long struggle. Kristy learned of her 
positive mutation status at the age of 23 and had participated in the intensive BI screening 
study for the full four years before deciding to undergo RRBM at the age of 28. 
Throughout her mutation-positive experience, up to and including her surgery, she was in 
a committed partner relationship; that relationship had recently ended and she was 
adjusting to her newly-single status. Kristy believed she would undergo RRSO at some 
point in the future. 
Quoted or referenced on pages: 92, 161-162, 174-175, 202, 206-207, 213, 242, 255-256, 
263, 285 
 
Leigh, 35, married. (FORCE) Leigh had three young children ranging in age from three 
to ten and was a busy working mom. Her own mother was diagnosed with breast cancer 
at age 66 when Leigh was 23, but has since gone into full remission. Her maternal 
grandfather and aunt also had breast cancer. Leigh had known herself to be BRCA-
positive for two years at the time of her interview and was the only mutation-positive 
female in her generation of the family. After participating in surveillance for most of that 
time, she had decided to undergo RRBM and was at home recovering when interviewed. 
She also had her RRSO planned for the following summer. 
Quoted or referenced on pages: 92, 147-148, 151, 155-157, 166, 172-173, 178, 183, 188, 
245-246, 272-273, 276-277, 308 
 
Libby, 32, married. (FORCE) Libby had known that she was BRCA-positive for 11 
months at the time of her interview. The history of cancer in her family included her 
grandmother’s two breast cancer diagnoses (the first at age 38), a great aunt who died 
from ovarian cancer in her 50s when Libby was a child, and her mom’s breast cancer 
diagnosis when Libby was 28. Both her mother and grandmother had had mastectomies, 
and both women saw this as a very negative outcome because when her grandmother had 
hers, there were no reconstructive options. Libby was planning to wait until after she was 
done with childbearing to undergo testing, but when fertility challenges sent her to a 
specialist, he advised her to test earlier because the fertility drugs could be very 
dangerous if she were positive. After learning that she carried a mutation, Libby had 
decided to undergo RRBM prior to getting pregnant so that she could use the fertility 
drugs without having to worry about developing cancer while pregnant. She was 
recovering from her surgery and looking ahead to her first pregnancy at the time of her 
interview. She planned to pursue RRSO after completing childbearing. 




Lilly, 25, single. (Snowball)  Lilly remembered herself as an anxious, worried child who 
was always concerned about her health. She shared that her family viewed her as “the 
worrier” and thought that she’d gotten everybody’s share of the “worrying gene.” In fact, 
her family sometimes kept information from her because they knew how much she would 
worry about it. Lilly’s mother was diagnosed with cancer at age 25 and again at 36, and 
Lilly and her sister had always been aware of this; they remembered their mother’s 
“chicken cutlets” – their name for the breast prostheses she wore when they were 
children. At the age of 14, Lilly had informed her family that she wanted to have her 
breasts removed so that she wouldn’t have to get cancer, and she remembered her mom 
being very upset and feeling guilty about this. As an adult who could understand what 
this really meant, Lilly was still considering having the surgery, especially because she 
had just reached the age at which her mother was first diagnosed. Lilly had received her 
mutation test results just two months prior to her interview. Lilly’s sister, Isabelle, is also 
a participant. 
Quoted or referenced on pages: 92, 177-178, 247, 252, 273-275, 295 
 
Lynn, 24, casual relationship. (FORCE) Lynn learned of her positive mutation status at 
the age of 19, shortly after her mother was diagnosed with breast cancer. Other cancers in 
her family included breast cancer in two of her mother’s cousins and her maternal great-
grandmother, ovarian cancer in her maternal grandmother, and both breast and ovarian in 
a maternal great aunt. Lynn had had many abnormal test results during the years that she 
was doing surveillance, and had undergone RRBM at the age of 23; at the time of her 
interview, Lynn was nearing the end of her reconstruction process and was thrilled with 
her decision. She had been very open in sharing information about her mutation and her 
surgery with various dating partners since learning about her mutation; in fact, she had 
told her current boyfriend about her RRBM on the night they met. Lynn felt confident 
that she would also have RRSO after completing family formation. 
Quoted or referenced on pages: 92, 202-204, 259-260, 290, 292 
 
Maelie, 33, married. (BI) Maelie was an active participant in the BI study from 2005 
through 2008, along with two of her sisters. Her youngest sister, Trixie, is also a 
participant. Maelie grew up in a large family and was the second of five children (four 
girls and one boy). She was not aware of any history of breast or ovarian cancer in her 
family until her mid-twenties, when her older sister was diagnosed with breast cancer at 
the age of 28, shortly after having a baby. Because of her sister’s age, genetic testing was 
recommended and two mutations were identified: one in BRCA1 and one in BRCA2 (this 
is extraordinarily rare). Subsequently, each of Maelie’s parents was found to carry one 
mutation and the family became aware of several cancer diagnoses in distant relatives. 
After aggressive breast cancer treatment and a short remission, Maelie’s sister was 
diagnosed a second time and passed away at the age of 32, leaving behind a husband and 
two young daughters. After witnessing the swiftness with which cancer claimed her 
sister’s life, Maelie took aggressive steps to mitigate her own risk: she drastically altered 
her plans for family formation (choosing to start her family earlier and have fewer 
children closer together) and proceeded with both RRBM and RRSO only months after 
the birth of her third child. 




Marie, 28, married. (FORCE) Among all participants, Marie had known about her BRCA 
mutation for the shortest time – only one month – when interviewed. Marie came from a 
family of extremely health-conscious women: both her mother and maternal grandmother 
were conscientious eaters, exercisers, and users of holistic remedies who strove to avoid 
western medicine when possible. When Marie was a teenager, her grandmother became 
very sick and was eventually diagnosed with ovarian cancer; Marie shared a bedroom 
with her grandmother during that illness, and when her grandmother passed away Marie 
felt a great sense of loss. Several years later, after avoiding seeing a doctor for her severe 
abdominal pain until she could no longer stand it, Marie’s mother was also diagnosed 
with ovarian cancer. Her mother was still living two years later, and attributed her 
survival to healthy lifestyle and homeopathic remedies. During the first year that her 
mother was dealing with cancer, Marie also watched her best friend die from a bone 
cancer that metastasized to her lungs. Marie and her three brothers were tested for BRCA 
after their mom’s doctor suggested that she be tested and the mutation was identified. 
Although her knowledge of her mutation was still very new, Marie was already looking 
ahead to both risk-reducing surgeries. Already the mother of one young daughter, she 
was planning to accelerate her plans for a second baby so that she could move forward 
with both surgeries as early as possible. 
Quoted or referenced on pages: 92, 216, 229, 233, 249, 266, 294, 296-297, 299, 311, 348 
 
Marjory, 30, serious relationship. (FORCE) Marjory learned at age 24 that she had 
inherited her BRCA mutation from her father. She was aware of three cases of BRCA 
related cancer in her father’s family: one breast cancer (her aunt), one primary peritoneal 
cancer (her grandmother), and one ovarian cancer (a great aunt). Marjory remembered 
having known as a young child that many of her grandmother’s siblings had died of 
various types of cancer, and learned as an adolescent that her aunt had previously had 
breast cancer (Marjory was not aware of this until her aunt had been in remission for 
several years). After she graduated from college, Marjory’s parents informed her that 
based on her father’s family’s cancer history, the family had been enrolled in a study at a 
large medical research institution and a BRCA mutation had been identified, of which 
Marjory’s father was also a carrier. After meeting with a genetic counselor at age 22, 
Marjory waited two more years before deciding she was ready to be tested herself. In the 
years since she learned about her mutation, Marjory had been using surveillance to 
manage her risk; recently, she had decided to pursue RRBM in the very near future and 
planned to have an RRSO after she completed childbearing. Her partner, whom she 
planned to marry, was fully supportive of her risk management plan and open to 
developing a plan for family formation that would accommodate it. 
Quoted or referenced on pages: 92, 165, 167-168, 176, 213, 222-223, 233, 244, 267, 282, 
291, 314-315 
 
MaryAnn, 26, engaged. (FORCE) Mary Ann’s mother was diagnosed with Stage IV 
ovarian cancer when MaryAnn was 15, and died when MaryAnn was 17. Her maternal 
grandmother and great-grandmother both had breast cancer. MaryAnn learned of her 
mutation status just two months prior to her interview and had just completed her first 
round of surveillance; she and her fiancé, both PhD students, were involved in ongoing 
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discussions about how her mutation would impact other parts of their lives together, and 
when each risk-reducing surgery would be appropriate. 
Quoted or referenced on pages: 92, 229, 234, 264-265, 289-290, 293-294 
 
Melanie, 31, married. (FORCE) Refer to “Melanie’s Story” in Chapter 5 for description. 
Quoted or referenced on pages: 92, 125-133, 151, 168-169, 178, 233, 271, 275, 282, 310 
 
Monique, 26, single. (BI) Monique’s mother died from breast cancer when Monique was 
only five years old; her family history of cancer also included a diagnosis at age 20 and 
death at age 22 in Monique’s maternal aunt, and a first cousin who had survived ovarian 
cancer. Monique’s older half-sister had had both risk-reducing surgeries and remained 
cancer-free. Monique was doubly burdened because she was also at very high risk for 
cervical cancer. These two risks together had created a sense of doubt for Monique about 
whether she wanted to (or would be able to) have children. Being single exacerbated this, 
because she worried that she would have trouble finding a partner willing to accept her 
high risk status. Prior to enrolling in the BI study, Monique was interested in RRBM but 
was unable to find a physician who would do the procedure on someone so young (even 
though her family cancer history included a diagnosis at age 20). At age 26, Monique still 
envisioned RRBM as part of her future risk management. 
Quoted or referenced on pages: 92, 148-149, 209, 222, 312, 314 
 
Nichelle, 21, in an open relationship. (Snowball) The youngest participant, Nichelle had 
been tested for BRCA just prior to her 21st birthday and had known she was mutation-
positive for only two months when interviewed. Her family cancer history included 
breast cancer in her mother and maternal aunt, testicular cancer in her maternal uncle, and 
kidney cancer in her maternal grandmother; none of these were fatal. A maternal great-
grandmother had died of breast cancer, and the family was aware of several other 
potential instances of cancer in more distant relatives but did not know all of the details 
about those. Nichelle’s mother’s cancer was caught very early thanks to her knowledge 
that her sister was BRCA-positive. Nichelle and her sister Julia (also a participant) were 
referred for genetic testing shortly after their mother tested positive for BRCA, and 
Nichelle was just starting to contemplate how surveillance would be a part of her life. 
Regular screening via breast MRI, mammogram, etc. would likely be several years away 
for Nichelle because of her age. Nichelle was in an open relationship with a partner to 
whom she had not disclosed any information about her mutation or the presence of cancer 
in her family. She envisioned RRSO, but not RRBM, as part of her future. 
Quoted or referenced on pages: 92, 168, 211, 220-221, 265, 270 
 
Noelle, 26, serious relationship. (FORCE) Breast and ovarian cancer first became 
personally relevant to Noelle when her paternal aunt was diagnosed with ovarian cancer 
at age 45 when Noelle was in college. Two years later, Noelle learned that that aunt and 
then Noelle’s father had tested positive for a BRCA mutation and Noelle’s parents 
suggested that she get tested, too. The genetic counseling and testing process happened 
very quickly, and within six weeks after that conversation, Noelle received her positive 
results at age 24. The family suspected that the mutation had been passed down from 
Noelle’s paternal grandfather, but because he was an orphan, nobody had information 
 
 453
about any health history in that part of the family; Noelle’s aunt’s ovarian cancer 
diagnoses was very unexpected, and Noelle’s aunt felt very guilty for having “brought” 
this issue into the family. Other members of the family felt very lucky that Noelle’s 
aunt’s doctors had thought to recommend genetic testing based solely on the age at which 
her aunt was diagnosed, with no other relevant family history. Noelle was in a serious 
relationship that she hoped might become permanent, but was somewhat frustrated with 
her partner’s reluctance to move forward with the relationship. She believed she would 
have both risk-reducing surgeries at some point in the future. 
Quoted or referenced on pages: 92, 177, 197, 206, 230-231, 286-287 
 
Pauline, 30, married. (FORCE) Pauline’s first knowledge of breast cancer came when 
her paternal grandmother was diagnosed during Pauline’s early childhood. Her 
grandmother had a unilateral mastectomy and died many years later of unrelated causes. 
Interstingly, Pauline’s BRCA mutation came from her paternal grandfather. That man 
(who had prostate cancer) was one of nine siblings, eight of whom had some type of 
cancer, including four breast cancers, two prostate cancers, two colorectal, and one each 
of leukemia, bladder, brain, and lung cancers (some people had more than one primary). 
In addition, Pauline’s second cousin of a similar age had been diagnosed with breast 
cancer at age 30. However, Pauline was not aware of any of this cancer history except for 
her grandparents, until her father’s cousin called him one day to report that a BRCA 
mutation had been identified in this distant branch of the family tree. She shared the exact 
mutation results with Pauline’s father and suggested that he be tested; when he tested 
positive, Pauline followed suit. When interviewed, Pauline was busily gathering 
information to enable her to make concrete decisions about when and where to have 
RRBM; she completed that surgery 9 months after her interview. She and her husband 
planed to accelerate family formation by several years to enable Pauline to pursue RRSO 
in her late 30s.  
Quoted or referenced on pages: 92, 145-146, 152-153, 159-160, 165, 182, 184-185, 219-
220, 227, 236-237, 248, 252, 289, 293, 313-314, 325 
 
Rachel, 33, married. (FORCE) Rachel’s family was first touched by cancer when her 
mother was diagnosed with breast cancer during the summer that Rachel was 12. She 
recalled knowing her mom was sick because she spent days in bed, whereas usually she 
“didn’t sit still for anything.” After a lengthy remission, her mom was diagnosed again 
when Rachel was 23, and this second bout was recalled by Rachel as much more difficult 
personally: knowing what cancer treatment entailed and fearing that the difficult chemo 
and radiation treatments would not be successful, Rachel feared that her mother would 
not live to become a grandmother or to see Rachel’s younger sister get married. After a 
third diagnosis five years later, Rachel’s mom decided to have both breasts and her 
ovaries removed and did not elect to have reconstruction. The family was also aware that 
Rachel’s mom’s paternal aunt had had ovarian cancer, and based on this family history, 
genetic testing was recommended; Rachel learned that she was mutation-positive shortly 
after giving birth to her first child. Based on that information, Rachel and her husband 
decided to accelerate their plans for a second baby, and after their son was born Rachel 
underwent both RRBM and RRSO. 
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Quoted or referenced on pages: 92, 150, 153-154, 160-161, 169-170, 172-241, 296-298, 
301-302, 311, 349 
 
Reina, 29, married. (BI) Reina’s mother was first diagnosed with cancer twice when 
Reina was eleven years old, and she had vivid memories of her mom’s cancer treatments 
and the “stitches, staples, and chemo” that came along with her experience. Shortly after 
the family celebrated ten years in remission, Reina’s mother was diagnosed again; chemo 
this second time was followed by a double mastectomy and RRSO, and during this time 
her mother also tested positive for BRCA (the first in the family to undergo testing). The 
only other case of cancer Reina knew of in her family was her maternal grandmother’s 
breast cancer, which occurred after her mom’s cancer and when her grandmother was in 
her 70s. Reina struggled with a strong sense that cancer was an inevitable part of her 
future, and this belief was confirmed when Reina (and later her younger sister) also tested 
positive for BRCA. Since then, Reina has struggled to reconcile her experiences with her 
mother’s cancer with what she believes about her own future health, and has tried to 
convince herself that her fate can be different from her mom’s. She met her now-husband 
during her years in the BI study, and she is happily married and looking forward to 
starting a family within the next several years; she believes that RRSO will be her risk-
management strategy of choice after childbearing is complete. 
Quoted or referenced on pages: 93, 154-155, 178, 183, 214, 229, 231-235, 239, 288-289, 
345-349 
 
Rose, 30, married. (FORCE) Rose’s mom was diagnosed with ovarian cancer when Rose 
was 10, and died when Rose was 13. Her maternal grandmother also had and died from 
ovarian cancer before Rose was born. Rose learned of her mutation status about six 
months prior to her interview; at the time of the interview, she was recovering from 
RRBM. The primary reason she had made this decision so quickly is that she and her 
husband were ready to start a family, and she wanted to put that surgery behind her 
before she had children. She was planning to have a risk-reducing oophorectomy after 
she was done having children, no later than age 35. 
Quoted or referenced on pages: 93, 147, 162, 167, 215-216, 229, 231, 243, 251, 256-257, 
270, 282-283, 315, 351, 396 
 
Ruby, 34, married. (BI) Ruby was raised by a mother whose own mother and two 
maternal aunts had all died from ovarian cancer. The family was one of the original 
families involved in genetic studies for BRCA, and Ruby’s mom’s life (and to a lesser 
extent, her own) was permeated by the presence of this threat. Members of her mother’s 
generation were having risk-reducing surgeries even before the BRCA1 and BRCA2 
mutations were identified. Ruby was offered testing after she was finished breastfeeding 
her second child, and tested positive at the age of 31. When interviewed, Ruby was still 
actively participating in the BI study, but she planned to have RRSO after her time in the 
study was complete. A diagnosis of ovarian cancer in a distant cousin close to Ruby’s age 
had raised her anxiety about her risk in recent years. 




Rylan, 34, serious relationship. (BI) The story of breast cancer in Rylan’s immediate 
family started even before she was born; her mom was diagnosed eight years before 
Rylan was born, and then again in the opposite breast when Rylan was seven years old. 
Both of these were treated with chemotherapy and radiation, but two more diagnoses, this 
time of metastatic breast cancer, occurred when Rylan was 11 and 15 and ultimately 
resulted in her mother’s death. Ryland felt as though she had an unrealistic impression of 
what cancer was like because her mom worked so hard to hide its negative effects from 
her. The other family cancer history of which Rylan was aware was ovarian cancer in a 
great aunt and breast cancer in her maternal aunt and grandmother. Rylan had gone 
through what she referred to as a “reckless” period in which she did not pay much 
attention to her cancer risk because she felt as though, as an almost-thirty single woman, 
she was missing her chance to have a family before her time “ran out” when she reached 
the ages at which other family members had been diagnosed. After meeting her partner, 
Rylan’s attitude shifted and she had completed RRBM shortly before her interview. She 
and her partner were looking ahead to getting married soon and talking about how their 
family formation plans would fit in with her plans to complete RRSO in the relatively 
near future.  
Quoted or referenced on pages: 93, 108, 157-158, 169-170, 254-255, 262-264, 285, 287, 
306-307, 315-316 
 
Sadie, 33, married. (BI) Sadie grew up hearing the story of how her first time on an 
airplane had been at the age of two weeks when her mom flew with her to be with Sadie’s 
maternal grandmother, who was died from breast cancer while they were in the air. That 
grandmother’s twin sister also died of breast cancer, and a third sister had both breast and 
ovarian cancer and passed away when Sadie was 19, and Sadie’s great-grandmother had 
had breast cancer as well. Based on that pervasive family history, Sadie’s mother and all 
four of her sisters had all undergone RRBM and RRSO prior to the identification of the 
BRCA genes, because they believed that “everyone in our family gets cancer.” Sadie, who 
was seven when her mom had the surgeries, remembers her mother telling her, “by the 
time you’re old enough to have these surgeries, there will be a cure for cancer,” implying 
that the surgeries would therefore be unnecessary. After learning that she was mutation 
positive at 28 and during her engagement, Sadie chose to speed up her family formation 
plans so that she could complete her family and then proceed with surgery. However, she 
and her husband were unsuccessful in conceiving after several years of trying, and 
ultimately decided that they did not want to have children. Sadie had since undergone 
RRSO and was contemplating when RRBM would also be completed. 
Quoted or referenced on pages: 93, 150, 155-156, 181, 186-187, 244-245, 290-291, 304-
305 
 
Serena, 30, single. (BI) In Serena’s family, the “magic age” for cancer is 46 – her mom 
had been diagnosed with ovarian cancer at that age, and her maternal aunt and 
grandmother had both been diagnosed with breast cancer at that age. All of these women 
had survived and were in full remission. Consequently, Serena viewed cancer as 
something that would happen to her in the future (probably at age 46), and that she would 
survive, and her life would go on. She was participating in surveillance, but did not go as 
often as she should because to her thinking, cancer was still more than a decade away. 
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Serena was not planning to have any risk-reducing surgeries, but acknowledged that she 
might have to have surgery as treatment in the future. She wanted to have a family, but 
also wanted that to occur in the context of marriage and was having trouble identifying 
desirable dating partners in her area. 
Quoted or referenced on pages: 93, 169, 205-206, 214, 266, 283, 300-301 
 
Shannon, 31, married. (FORCE) Shannon first remembered being impacted by cancer 
when her maternal aunt was diagnosed shortly after giving birth. Over the next five or six 
years, her aunt had another baby, was diagnosed a second time, and passed away when 
Shannon was 11. Shannon’s maternal grandmother and her three sisters had also been 
diagnosed with breast cancer, and all but one of these passed away as a result. Shannon’s 
mother was diagnosed with breast cancer when Shannon was 15, and Shannon 
remembered that this was when she first felt that cancer was a risk for herself. Her mom’s 
cancer treatment was very aggressive, and she had been in remission ever since. Shannon 
decided early on that she would have RRBM, and was not interested in genetic testing – 
she felt as though even if she received a negative result, she would want to have the 
surgery because cancer was so pervasive in the family. However, she was unable to find a 
physician who would perform the surgery without the genetic test results, and so Shannon 
was tested at age 29. Shannon and her husband had two young children, and they were 
undecided about whether or not to have a third baby. Shannon’s RRBM was scheduled 
for several weeks after her interview, and they planned to revisit the issue of a third child 
after the surgery was complete. Once that decision was solidified, they would select an 
appropriate time for RRSO.  
Quoted or referenced on pages: 93, 151, 239, 297, 299, 302, 310-311, 320 
 
Sophie, 31, married. (BI) Sophie inherited her BRCA mutation from her father. Two of 
her paternal aunts were diagnosed with and died from ovarian cancer when Sophie was in 
her late teens; in addition, her father’s father’s mother (her great-grandmother) died from 
ovarian cancer. Sophie had been doing surveillance through the NIH for the past four 
years; to her knowledge, nobody in Sophie’s family had done any risk-reducing surgeries. 
She was planning on RRSO in her mid-30s and an RRBM at some point. Sophie’s two 
sisters were also both mutation positive. 
Quoted or referenced on pages: 93, 158-159, 180-181, 223-224, 288, 310 
 
Trixie, 27, serious relationship. (BI) Trixie was an active participant in the BI study from 
2005 through 2008, along with two of her sisters. Her oldest surviving sister, Maelie, is 
also a participant. Trixie grew up in a large family and was the youngest of five children 
(four girls and one boy). She was not aware of any history of breast or ovarian cancer in 
her family until her early-twenties, when her oldest sister was diagnosed with breast 
cancer at the age of 28, shortly after having a baby. Because of her sister’s age, genetic 
testing was recommended and two mutations were identified: one in BRCA1 and one in 
BRCA2 (this is extraordinarily rare). Subsequently, each of Trixie’s parents was found to 
carry one mutation and the family became aware of several cancer diagnoses in distant 
relatives. After aggressive breast cancer treatment and a short remission, Trixie’s sister 
was diagnosed a second time and passed away at the age of 32, leaving behind a husband 
and two young daughters. Trixie’s experience with watching her sister struggle with and 
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ultimately succumb to breast cancer was a very powerful one, and she had decided that 
she did not want to pass along that genetic legacy to a next generation; she had decided 
not to have biological children. Trixie chose to undergo RRBM shortly after finishing her 
four years in the BI study, and was contemplating when RRSO would also be appriate; 
the only thing keeping her from doing it was her worry about the long-term effects that 
the hormonal shifts associated with RRSO would have on such a young women.  
Quoted or referenced on pages: 92-93, 163, 170, 174, 198-199, 240, 255, 262, 305-306 
 
Valerie, 29, married. (FORCE) Valerie’s mom was diagnosed with breast cancer twice, 
once when Valerie was five and again when Valerie was seven; she died when Valerie 
was ten. Two of her maternal aunts had also had breast cancer, as did her great-
grandfather, as well as several other more distant relatives on that side of her family. 
Valerie learned of her mutation status at age 25 and underwent RRBM at age 28. Because 
her family was part of a large HBOC study, Valerie had been doing high-risk screening 
since she was about 20. She and her husband were both in graduate school and had 
decided almost definitely that they did not wish to have children; Valerie thought of her 
ovaries as “on notice” that if anything suspicious was detected, they would be removed 
without hesitation. 
Quoted or referenced on pages: 93, 143-144, 175-176, 179, 185-186, 220, 246-247, 254-
255, 258, 261, 264 
 
Wanda, 32, married. (BI) Wanda lost her mother to ovarian cancer when she was only 
ten years old; she remembered somehow knowing that this news was coming after her 
mom had been “more in that out” of the hospital over several months, and Wanda 
connected her knowledge that her mom’s illness was called “cancer” with her 
recollection that her cousin’s mom (not a biological aunt) had died from cancer several 
years earlier. Wanda’s mother’s sister had had ovarian cancer and cancer in both breasts, 
but was still living in remission at the time of Wanda’s interview. Wanda first learned 
about BRCA mutations during graduate school—she studied in molecular biology and 
ended up at a University with a large medical center that was running BRCA-related 
studies during her tenure there. Wanda was able to be tested and found out at age 24 that 
she was positive. Wanda felt that her educational background gave her helpful 
perspective in thinking about her mutation status not as a death sentence, but as an 
important piece of information that could inform her decision-making. Wanda was the 
mother of a two-year-old daughter and expecting a baby boy at the time of her interview. 
She and her husband were contemplating having a third baby, and believed that RRSO 
would be their risk-management strategy of choice after they felt certain that their family 
was complete. Regardless of what they decided, they wanted to be finished with 
childbearing before Wanda reached 37, the age at which her mother was first diagnosed. 
She was leaning toward not having RRBM unless a problem in one of her breasts was 
detected, believing that breast screening techniques were good enough that she would 
feel protected by continued surveillance. 





Appendix I: Codebook 
 
Level Code Label Code Description Sources References
 · · · · · · · · · · · · TREE NODES · · · · · · · · · · · · 
1 · · · · · · · · · · · · DEMOGRAPHIC INFORMATION · · · · · · · · · · · · 
Interview date/time When telephone interview 
occurred 40 40 
Date of birth/age Date of birth and age 40 40 
Race/ethnicity Self-described race and ethnicity 40 40 2 
Testing date Date on which participant learned 
of positive mutation status 40 40 
 · · · · · · · · · · · · FAMILY AND CANCER HISTORY · · · · · · · · · · · ·   
1 
Cancer Scares Abnormal screening tests, other 
events that elicited fear of cancer 
diagnosis for self 
40 42 
1 
Family History General descriptions of family 






Knowledge of breast/ovarian 





Knowledge of relatives who have 
died from breast or ovarian cancer 27 68 3 Male breast cancer Knowledge of male relatives 
diagnosed with breast cancer 4 5 
Family other cancer 
history 
Knowledge of incidence of other 
types of cancer in relatives 20 28 
Family awareness of 
cancer risk 
Description of relatives awareness 
of hereditary cancer risk 9 11 2 
Testing of relatives General knowledge of genetic 
testing experiences of relatives 32 63 
Inheritance theories Family or personal theories about 
how/why mutation was inherited  19 21 3 Inheritance hopes Hopes about their own or others’ 
mutation statuses 9 13 
Relatives’ surgeries Knowledge of risk-reducing 
surgery of family members 28 48 2 Unique family 
experiences 
(Category; descriptions below)   
Adoption Participant or close other was 
adopted 2 7 
Alcoholism Participant or close other addicted 
to alcohol 1 1 
Living overseas Participant spent part of life 
living overseas 2 2 
Loss of a parent Impact of a parent’s death 12 37 
Loss of both parents Impact of death of both parents 1 1 
3 
Cancer expert in family Member of family of origin in 
profession dealing with cancer 3 5 
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Holocaust survivors Legacy of holocaust survivorship 
in family 1 1 
Parents are first 
generation in US 
Participant’s parents are first 
generation born in US 
(grandparents immigrated) 
1 3 3 
Multiple mutations More than one BRCA mutation is 
present in the family 3 7 
4 
Fanconi Anemia Diagnosis of Fanconi Anemia in 
child resulting from presence of 2 
BRCA2 mutations 
1 11 
Serious accident Impact of a serious accident in 
family 1 1 
Mental illness Impact of diagnosis of mental 
illness in a family member 2 3 3 
Special needs child Impact of participant’s special 
needs child 1 2 
2 Non-family cancer experiences 
Exposure to cancer experiences of 
close others not in family 9 12 
1 · · · · · · · · · · · · FAMILY OF ORIGIN RELATIONSHIPS · · · · · · · · · · · · 
2 Parents Relationship with both parents 20 37 
Mom Relationship with mother 
(biological or adopted) 35 190 
Dad Relationship with father 
(biological or adopted) 32 86 
3 
Step-parents Relationship with step-parent(s) 5 6 
2 Siblings Relationship with siblings, generally 7 8 
Sisters Relationship with sister(s) 27 122 
Brothers Relationship with brother(s) 19 32 3 
Step-siblings Relationship with step-sibling(s) 1 1 
Aunts Relationship with aunt(s) 28 83 
Uncles Relationship with uncle(s) 16 22 
Grandparents Relationship with grandparent(s) 35 79 
Cousins Relationship with cousin(s) 22 44 
Great-grandparents Relationship with great-
grandparent(s) 7 9 
2 
More distant relatives Relationship with other third+ 
degree relatives 14 16 
1 · · · · · · · · · · · · GENETIC TESTING· · · · · · · · · · · · 
Awareness of BRCA in 
family 
How family members became 
aware of presence of mutation 23 32 
Awareness of testing How family members became 
aware of opportunity to be tested 28 34 
Genetic counseling Experience of genetic counseling 29 45 
Decision-making about 
testing 
How participant decided to 
undergo genetic testing 31 51 
Expectations prior to 
testing 
Belief about test result prior to 
receiving it 33 41 
2 
Waiting for results What it was like to wait for 
results of genetic testing 21 21 
 
 460
Receiving results General experience receiving 
genetic testing results 5 5 
Emotional reaction Emotional reaction to receiving 
results 30 47 
Procedural Procedural dynamics in result 
disclosure (e.g., given by phone) 29 39 3 
Support person Who was with participant when 
she received her results? 25 32 
Information provided Information provided to 
participant by person who 
disclosed results 
22 32 
Cancer risk perception Perception of cancer risk 
immediately after learning results 20 23 
Overlap with couple 
relationship 
Ways in which genetic testing 
and couple relationship issues are 
related 
17 28 
Overlap with family 
formation 
Ways in which genetic testing 




Change in access to care Noted differences in ability to 
access care after receiving results 8 10 
1 · · · · · · · · · · · · BREAST/OVARIAN CANCER RISK PERCEPTION · · · · · · · · · · · · 
General Thoughts about cancer risk 11 17 2 Anxiety Experienced anxiety about risk 14 26 
Alleviation of risk 
anxiety 
How risk anxiety has been 
alleviated 6 8 3 Anxiety-reducing 
cognitions 
Cognitive processes that lower 
anxiety 9 17 
Breast vs ovarian cancer 
risk 
Differential perception of risk at 
these two sites 16 23 
Perceived risk of other 
cancers 
Perception of risk at sites other 
than breasts or ovaries 7 10 
BRCA1 vs BRCA2 Understanding of variation of risk 
by mutation 4 5 
Sense of inevitability Belief that a cancer diagnosis is 
inevitable 15 18 
Fatalism Fatalistic views about cancer risk 3 3 
Specific periods of risk Belief that risk changes over time 14 18 
Inaccurate information Perception of risk based on 
believing inaccurate information 12 12 
2 
Does not feel vulnerable Participant does not feel 
vulnerable to cancer 1 1 
1 · · · · · · · · · · · · COUPLE RELATIONSHIPS · · · · · · · · · · · · 
General relationship 
history 
Description of general history of 
couple relationship(s) 35 56 
2 Disclosure of mutation General comments about 
disclosure of mutation status to 
partner 
2 2 
3 To spouse Experience disclosing mutation to spouse 11 16 
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To existing partner Experience disclosing mutation to 
partner in existing non-marital 
relationship 
19 27 
To new partner Experience disclosing mutation to 
partner in relationship that began 
after genetic testing 
  
Actual Lived experience of disclosure to 
new partner 18 28 
Hypothetical Imagined future experience of 
disclosure to new partner 12 25 4 
Timing within 
relationship development 
Selecting when to inform a new 
partner about mutation 7 9 
3 Non-disclosure Chose not to tell a partner (past or current) about mutation   
To past partner Chose not to tell a past partner 
about mutation 4 4 4 To current partner Chose not to tell current partner 
about mutation 1 1 
“Damaged goods” Felt that mutation is a flaw that 
others will perceive as a reason 
not to be together 
7 10 
3 Disclosure as relationship 
test 
Perceives that partner disclosure 
was/will be a test of solidity of 
relationship 
7 12 
Urgency to find LTR Felt a sense of urgency to identify 
permanent partner 13 24 2 Provision of support Partners’ provision of support to 
participants, generally 9 12 
Lack of support Felt a lack of partner support  10 14 
Support wishes Specific types of support desired 10 13 3 
Ways of supporting Specific types of support received 32 86 
Partner’s perception of 
participant 
Belief about how one is viewed 
by partner 14 18 
Partner’s emotional 
reaction 
Belief about partner’s emotional 
experience of BRCA 21 28 2 
Discussions about family 
formation 
Discussion with partner about 
family formation, generally 22 31 
Partner’s concerns about 
children 
Perception of partner’s concerns 
about health of future children 
related to BRCA 
3 4 
3 
Partner’s opinion about 
family formation 
Perception of partner’s opinion 
about family formation 22 31 
2 General impact on couple relationship 
Perception of general impact of 
BRCA on couple relationship 9 11 
Positive impact Ways that BRCA has impacted 
couple relationship positively 19 20 
Negative impact Ways that BRCA has impacted 
couple relationship negatively 20 29 3 
Pace of relationship 
development 
Impact of BRCA on pace of  
relationship development  8 12 
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Ongoing discussion about 
BRCA 
Current discourse with partner 
about BRCA 21 31 
Sexual relationship Ways that BRCA has shaped 
sexual relationship with partner(s) 9 18 
Educating partner Experience educating partner 
about BRCA 10 11 
2 
Lifestyle changes Lifestyle changes made with 
partner because of BRCA 2 2 
1 · · · · · · · · · · · · FAMILY FORMATION · · · · · · · · · · · · 
Current children Children currently in family 
(biological or adopted) 20 25 
2 Plans for (more) children Current thinking about whether 
participant will have additional 
children, generally 
17 19 
Urgency to complete 
family 
Feels a sense of urgency to 
complete childbearing quickly 22 32 
Family formation 
timeline 
Preferred or chosen timeline for 
childbearing 33 69 
Family size Preferred or chosen total family 
size 26 41 
Competing demands Description of demands that 
compete with family formation 
priorities 
17 21 
Childless by choice Does not have children by own 
choice 4 5 
Childless NOT by choice Does not have children for reason 
outside of control 1 2 
Fertility concerns Worry about ability to have 
biological children 12 17 
3 
Discussions with medical 
professionals 




2 Pregnancy Experience of pregnancy as a mutation carrier 8 11 
3 Pregnancy and cancer risk 
Concern about influence of 
pregnancy on cancer risk 8 9 
2 
Risk of passing mutation 
to child(ren) 
Thoughts about possibility of 
passing mutation to child(ren), 
generally 
14 15 
Hopes for advances in 
medical technology 
Hopes that scientific advances 





Cognitive processes that reduce 
anxiety about risk to children 14 17 
Outsiders’ perceptions Opinions of outsiders about risk 
of passing mutation to child(ren) 3 3 
3 
Willingness to accept risk Reason for belief that risk to 
children is acceptable 16 23 
1  · · · · · · · · · · · · RISK REDUCTION & MANAGEMENT · · · · · · · · · · · · 




Recommendations Advice received from providers 
about risk management 33 60 
Availability of 
information 
Access to desired information 
about risk management options 14 25 
Surveillance General thoughts about 





Ability to be reliably screened 
while pregnant 7 12 
Experience of 
surveillance 
Experience of relying on 
surveillance for risk-management 31 64 
“False positives” Experience with abnormal tests 
that did not actually indicate 
cancer 
10 14 
Confidence in protection 
with screening 
Confidence that surveillance was 
effective in protecting from 
cancer 
26 31 
Future surveillance Plans to use surveillance in the 
future 10 14 
Why chosen Reasons for choosing surveillance 
as a risk-management strategy 11 15 
Failure of surveillance to 
catch something 
Surveillance failed to detect a 
BRCA-related problem 7 7 
Surveillance for other 
cancers 
Undergoing surveillance for 
cancer other than breast or 
ovarian 
1 1 
Hopes for improvement Hopes that effectiveness of 




Access to needed 
screening 
Ability to access needed 
surveillance tests 9 11 
Chemoprevention Use of chemopreventive agents to 
manage cancer risk 15 19 2 
Risk-reducing surgery Thoughts about surgery, generally 3 3 
Which surgeries Which surgeries are desired, 
planned or completed 34 62 
Surgery timeline When surgeries will occur 33 82 3 
Interaction with providers Surgery-related interactions with 
healthcare providers 16 26 
4 Services not provided Noted deficits in services provided by healthcare system 5 6 
Reconstruction Decisions and thoughts about 
reconstruction options 27 57 
Hormone replacement Decisions and thoughts about use 
of hormone replacement therapy 7 10 
Decision-making about 
surgery 
How decisions were or will be 
made about surgeries 33 89 
3 
Preparing for surgery How carrier has prepared or will 
prepare for risk-reducing surgery 6 11 
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Grief about surgery Carrier’s feelings of grief about 
surgery 5 5 
Experience of surgery General experience of surgery 2 2 
Physical Physical experience of surgery 10 13 4 Emotional Emotional experience of surgery 12 15 
Confidence in protection 
from surgery 
Confidence that surgery will 
effectively mitigate cancer risk 23 31 
Recovery Process of recovery from risk-
reducing surgery 11 20 
Surgical menopause Experience of surgical menopause 
after RRSO 19 22 
Emotional impact Emotional impact of risk-
reducing surgery 9 17 
3 
Additional surgeries in 
future 
Plans for another surgery in the 
future 23 30 
Overlap with 
relationships 
Ways in which issues related to 
risk-management and 
relationships are related 
20 44 
2 Overlap with family 
formation 
Ways in which issues related to 
risk-management and family 
formation are related, generally 
4 10 
Breastfeeding Ways in which issues related to 
risk-management and 
breastfeeding are related 
17 24 
Fertility Ways in which issues related to 
risk-management and fertility are 
related 
18 29 
Timing Ways in which issues related to 
risk-management and timing of 
family formation are related 
25 41 
3 
Parenting during surgery 
and recovery 
Experience of parenting during 
surgery and recovery 7 9 
 · · · · · · · · · · · · FREE NODES · · · · · · · · · · · · 
Advice for other carriers Best advice for other carriers for 
successfully dealing with positive 
BRCA mutation status 
4 6 
Body image Impact of mutation on body 
image 16 24 
Burden Perception that one is a burden on 
others because of mutation 4 6 
Change in outlook on life Ways that knowledge of BRCA 
mutation has altered one’s 
outlook on life 
7 11 
Control Issues related to feeling “in 
control” 22 29 
Culture Ways in which issues related to 
mutation and culture are related 8 14 
Education and college Ways in which issues related to 





Financial and insurance issues Impact of mutation on financial 
and insurance issues 32 65 
FORCE Role of FORCE in BRCA 
experience 10 16 
Generativity Ways that participants have been 
generative with regard to their 
mutation status 
16 32 
Guilt and blame Feelings of guilt and blame in 
interpersonal relationships 16 30 
Humor Use of humor in coping with 
positive mutation status 8 19 
Interactions with medical 
community 
Notable interactions with 
healthcare providers 31 74 
Religion and spirituality Ways in which mutation status 
and religion/spirituality are 
related 
9 12 
Representation of BRCA in media Noted representation of BRCA-
related issues and experiences in 
books, magazines, news, 
television, etc. 
12 14 
Sexuality Impact of mutation on sexuality, 
not specific to sexual 
relationships 
6 10 
Study involvement Participation in research studies 
related to positive BRCA mutation 
status 
14 47 
Support Dynamics around support, 
generally 22 47 
Tension in family of origin Presence of tension in 
relationships with members of 









Absetz, P., Aro, A. R., & Sutton, S. R. (2003). Experience with breast cancer, pre-
screening perceived susceptibility and the psychological impact of screening. 
Psycho-oncology, 12, 305-318. 
Acker, J., Barry, K., & Esseveld, J. (1983). Objectivity and truth: Problems in doing 
feminist research. Women's Studies International Forum, 6, 423-435. 
ACS. (2007). Detailed guide: Breast cancer.  Can breast cancer be found early?   
Retrieved November 1, 2007, from 
http://www.cancer.org/docroot/CRI/content/CRI_2_3X_Can_breast_cancer_be_f
ound_early_5.asp 
Ambert, A., Adler, P. A., Adler, P., & Detzner, D. F. (1995). Understanding and 
evaluating qualitative research. journal of Marriage and the Family, 57, 879-893. 
American Medical Association Council on Ethical and Judicial Affairs. (1994). Ethical 
issues related to prenatal genetic testing. Archives of Family Medicine, 3, 633-
642. 
Andersen, M. R., Goff, B. A., Lowe, K. A., Scholler, N., Bergan, L., Dresher, C. W., et 
al. (2008). Combining a symptoms index with CA 125 to improve detection of 
ovarian cancer. Cancer, 113(3), 484-489. 
Anderson, N. B. (1998). Levels of analysis in health science: A framework for integrating 
sociobehavioral and biomedical research. In S. McCann & J. M. Lipton (Eds.), 
Annals of the New York Academy of Sciences (Vol. 840, pp. 563-576). New York: 
New York Academy of Sciences. 
 
 467
Andrykowski, M., Munn, R. K., & Studts, J. L. (1999). Interest in learning of personal 
genetic risk for cancer: A general population survey. Preventive Medicine, 25, 
527-536. 
Antill, Y., Reynolds, J. C., Young, M. A., Kirk, J., Tucker, K., & Boststra, T. (2006). 
Risk-reducing surgery in women with familial susceptiblity for breast and/or 
ovarian cancer. European Journal of Cancer, 42, 621-628. 
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., et 
al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 and 
BRCA2 mutations detected in case series unselected for family history: A 
combined analysis of 22 studies. American Journal of Human Genetics, 72, 1117-
1130. 
Appleton, S., Fry, A., Rees, G., Rush, R., & Cull, A. (2000). Psychosocial effects of 
living with an increased risk of breast cancer: An exploratory study using 
telephone focus groups. Psycho-oncology, 9, 511-521. 
Armstrong, K., Calzone, K., Stopfer, J., Fitzgerald, G., Coyne, J., & Weber, B. L. (2000). 
Factors associated with decisions about clinical BRCA1/2 testing. Cancer 
Epidemiology, Biomarkers & Prevention, 9, 1251-1254. 
Armstrong, K., Schwartz, J. S., Randall, T., Rubin, S. C., & Weber, B. L. (2004). 
Hormone replacement therapy and life expectancy after prophylactic 
oophorectomy in women with BRCA1/2 mutations: A decision analysis. Journal 
of Clinical Oncology, 22, 1045-1054. 
Arnett, J. J. (2004). Emerging adulthood: The winding road from the late teens through 
the twenties. New York: Oxford University Press. 
 
 468
Arver, B., Haegermark, A., Platten, U., Lindblom, A., & Brandberg, Y. (2004). 
Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian 
and colon cancer pre-disposing genes: A 12-month follow-up. Familial Cancer, 
3(2), 109-116. 
ASCO. (1996). Statement of the American Society of Clinical Oncology: Genetic testing 
for cancer susceptibility. Journal of Clinical Oncology, 14, 1730-1736. 
ASCO. (2003). American Society of Clinical Oncology policy statement update: Genetic 
testing for cancer susceptibility. Journal of Clinical Oncology, 21, 2397-2406. 
ASHG, & ACMG. (1995). American Society of Human Genetics Board of Directors and 
American College of Medical Genetics--Points to consider: Ethical, legal, and 
psychosocial implications of genetic testing in children and adolescents. American 
Journal of Human Genetics, 57, 1233-1241. 
Audrain, J., Schwartz, M. D., Lerman, C., Hughes, C., Peshkin, B. N., & Biesecker, B. 
(1997). Psychological distress in women seeking genetic counseling for breast-
ovarian cancer risk: The contributions of personality and appraisal. Annals of 
Behavioral Medicine, 19(4), 370-377. 
Babb, S. A., Swisher, E. M., Heller, H. N., Whelan, A. J., Mutch, D. G., Herzog, T. J., et 
al. (2002). Qualitative evaluation of medical information processing needs of 60 
women choosing ovarian cancer surveillance or prophylactic oophorectomy. 
Journal of Genetic Counseling, 11(2), 81-96. 
Baber, K. M., & Allen, K. R. (1992). Women & families: Feminist reconstructions. New 
York: Guilford Press. 
 
 469
Baider, L., Ever-Hadani, P., & Kaplan De-Nour, A. (1999). Psychological distress in 
healthy women with familial breast cancer: Like mother, like daughter? 
International Journal of Psychiatry in Medicine, 29(4), 411-420. 
Balter, M. (2001). Transatlatic war over BRCA1 patent. Cancer Research, 292, 1818. 
Baum, A., Freidman, A. L., & Zakowski, S. G. (1997). Stress and genetic testing for 
disease risk. Health Psychology, 16, 8-19. 
Bayeritz, K. (1998). What's special about  molecular genetic diagnostics? Journal of 
Medical Philosophy, 23, 247-254. 
BCLC. (1999). Cancer risks in BRCA2 mutation carriers. Journal of the National Cancer 
Institute, 91, 1310-1316. 
Bearison, D. J., Sadow, A. J., Granowetter, L., & Winkel, G. (1993). Patients' and 
parents' causal attributions for childhood cancer. Journal of Psychosocial 
Oncology, 11(3), 47-61. 
Bebbington, M., & Fallowfield, L. J. (1999). Psychosocial implications of prophylactic 
bilateral mastectomy. Disease Markers, 15, 154. 
Becker, G. (1997). Disrupted lives: How people create meaning in a chaotic world. 
Berkeley, CA: University of California Press. 
Bengston, V. L., & Allen, K. R. (2004). The life course perspective applied to families 
over time. In P. G. Boss, W. J. Doherty, R. LaRossa, W. R. Schumm & S. K. 
Steinmetz (Eds.), Sourcebook of family theories and methods: A contextual 
approach (pp. 469-499). New York: Springer. 
 
 470
Benjamin, C., Flynn, M., Hallett, C., Ellis, I., & Booth, K. (2008). The use of the life 
course paradigm and life course charts to explore referral for family history of 
breast cancer. International Journal of Nursing Studies, 45, 95-109. 
Biesecker, B. B., Ishibe, N., Hadley, D., Giambarresi, T. R., Kase, R. G., Lerman, C., et 
al. (2000). Psychosocial factors predicting BRCA1/BRCA2 testing decisions in 
members of hereditary breast and ovarian cancer families. American Journal of 
Medical Genetics, 93, 257-263. 
Bird, C., & Rieker, P. (2008). Gender and health: The effects of constrained choices and 
social policies. New York: Cambridge University Press. 
Bleiker, E. M. A., & Aaronson, N. K. (2000). Genetic counseling for cancer: A family 
issue. In L. Baider, C. L. Cooper & A. K. De-Nour (Eds.), Cancer and the Family 
(2 ed.). Chichester, UK: John Wiley & Sons. 
Bonanno, G., & Kaltman, S. (2001). The varieties of grief experience. Clinical 
Psychology Review, 21, 705-734. 
Bonati, M., & Campi, R. (2000). Breastfeeding and infant illness. American Journal of 
Public Health, 90(9), 1478-1479. 
Borgen, P. I., Hill, A. D. K., Tran, K. N., Van Zee, K. J., Massie, M. J., Payne, D., et al. 
(1998). Patient regrets after bilateral prophylactic mastectomy. Annals of Surgical 
Oncology, 5(7), 603-606. 
Borrell-Carrio, F., Suchman, A. L., & Epstein, R. M. (2004). The biopsychosocial model 
25 years later: Principles, practice, and scientific inquiry. Annals of Family 
Medicine, 2(6), 576-265. 
 
 471
Botkin, J. R., Croyle, R. T., Smith, K. R., Baty, B. J., Lerman, C., Goldgar, D. E., et al. 
(1996). A model protocol for evaluating the behavioral and psychosocial effects 
of BRCA1 testing. Journal of the National Cancer Institute, 88, 872-882. 
Bottorff, J. L., Ratner, P. A., Johnson, J. L., & McCullum, M. K. (2000). Communication 
of individualized cancer risk information within the family context. In L. Baider, 
C. L. Cooper & A. Kaplan De-Nour (Eds.), Cancer and the Family (2 ed., pp. 
353-372). Chichester: John Wiley & Sons. 
Boulton, S. J. (2006). Cellular functions of the BRCA tumour-suppressor proteins. 
Biochemical society transactions, 34(5), 633-645. 
Bowlby, J. (1969). Attachment and Loss (Vol. 1). London: Hogarth. 
Boyd, J. (2003). Specific keynote: Hereditary ovarian cancer: What we know. 
Gynecologic Oncology, 88, S8-S10. 
Boyd, J., Sonoda, Y., Federici, M. G., Bogomolniy, F., Rhei, E., Maresco, D. L., et al. 
(2000). Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. 
Journal of the American Medical Association, 283, 2260-2265. 
Bradbury, A. R., Dignam, J. J., Ibe, C. N., Aug, S. L., Hlubocky, F. J., Cummings, S., et 
al. (2007). How often to BRCA mutation carriers tell their young children of the 
family's risk for cancer? A study of parental disclosure of BRCA to minors and 
young adults. Journal of Clinical Oncology, 25(24), 3705-3711. 
Bradbury, A. R., Ibe, C. N., Dignam, J. J., Cummings, S. A., Verp, M., White, M. A., et 
al. (2008). Uptake and timing of bilateral prophylactic salpingo-oophorectomy 




Braverman, A. M., & Corson, S. L. (1995). Factors related to preferences in gamete 
donor sources. Fertility & Sterility, 63, 543-549. 
Bredart, A., Autier, P., Audisio, R. A., & Geragthy, J. (1998). Psycho-social aspects of 
breast cancer susceptibility testing: A literature review. European Journal of 
Cancer Care, 7, 174-180. 
Brereton, R., Hopwood, P., Baildam, A., Brain, A., Lalloo, F., Evans, D. G. R., et al. 
(1999). Prophylactic mastectomy: The partner's perspective. Psycho-oncology, 8, 
2. 
Bretherton, I. (2004). Theoretical contributions from developmental psychology. In P. G. 
Boss, W. J. Doherty, R. LaRossa, W. R. Schumm & S. K. Steinmetz (Eds.), 
Sourcebook of family theories and methods: A contextual approach. New York: 
Springer. 
Brody, L. C., & Biesecker, B. (1998). Breast cancer susceptibility genes: BRCA1 and 
BRCA2. Medicine, 77(3), 208-226. 
Brose, S., Rebbeck, T. R., Calzone, K., Stopfer, J., Nathanson, K., & Weber, B. L. 
(2002). Cancer risk estimates from BRCA1 mutation carriers identfied in risk 
evaluation program. Journal of the National Cancer Institute, 94, 1365-1372. 
Burgess, M. M., & d'Agincourt-Canning, L. (2001). Genetic testing for hereditary 
disease: Attending to relational responsibility. Journal of Clinical Ethics, 12, 361-
372. 
Burke, W., Daly, M., Garber, J. E., Botkin, J. R., Kahn, M. J., Lynch, P., et al. (1997). 
Recommendations for follow-up care of individuals with an inherited 
 
 473
predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies 
Consortium. Journal of the American Medical Association, 227(12), 997-1003. 
Burke, W., Press, N., & Pinsky, L. (1999). Editorial: BRCA1 and BRCA2: A small part 
of the puzzle. Journal of the National Cancer Institute, 91(11), 904-905. 
Burman, B., & Margolin, G. (1992). Analysis of the association between marital 
relationships and health problems: An interactional perspective. Psychological 
Bulletin, 112, 39-63. 
Cahill, L. S. (1996). Moral concerns about institutionalized gamete donation. In C. B. 
Cohen (Ed.), New ways of making babies (pp. 78-87). Bloomington, IN: Indiana 
University Press. 
Cappelli, M., Surh, L., Walker, M., Korneluk, Y., Humphreys, L., Verma, S., et al. 
(2001). Psychological and social predictors of decisions about genetic testing for 
breast cancer in high-risk women. Psychology, Health and Medicine, 6(3), 321-
333. 
Cappelli, M., Verma, S., Korneluk, Y., Hunter, A., Tomiak, E., Allanson, J., et al. (2005). 
Psychological and genetic counseling implications for adolescent daughters of 
mothers with breast cancer. Clinical Genetics, 67(6), 481-491. 
Carter, B., & McGoldrick, B. (Eds.). (1999). The expanded family life cycle: Individual, 
family, and social perspectives (3 ed.). Boston: Allyn & Bacon. 
Carver, C. S., Pozo-Kaderman, C., Price, A. A., Noriega, V., Harris, S. D., Derhagopian, 
R. P., et al. (1998). Concern about aspects of body image and adjustment to early 
stage breast cancer. Psychosomatic Medicine, 60, 168-174. 
 
 474
Carver, C. S., Scheier, M. F., & Kumari Weintraub, J. (1989). Assessing coping 
strategies: A theoretically based approach. Journal of Personality and Social 
Psychology, 56(2), 267-283. 
Casey, M. J., Bewtra, C., Hoehne, L. L., Tatpati, A. D., Lynch, H. T., & Watson, P. 
(2000). Histology of prophylactically removed ovaries from BRCA1 and BRCA2 
mutation carriers compared with noncarriers in hereditary breast ovarian cancer 
syndrome kindreds. Gynecologic Oncology, 78, 278-287. 
Centers for Disease Control and Prevention. (2010). DES Update: Consumers.   
Retrieved March 31, 2010, from 
http://www.cdc.gov/DES/consumers/about/index.html 
Chalmers, K., Thomson, K., & Degner, L. F. (1996). Information, support, and 
communication needs of women with a family history of breast cancer. Cancer 
Nursing, 19(3), 204-213. 
Chetkowski, R. J., Cassidy, M., Ma, C. P., Kagan, R., & Szell, A. Z. (2008). Novel 
adaptation of the long suppression protocol for fertility preservation in a woman 
with stage 1 receptor-positive breast cancer (BrCa) and age factor. Fertility & 
Sterility, 89(4S1), S26. 
Chlebowski, R. T., Collyar, D. E., Somerfield, M. R., & Pfister, D. G. (1999). American 
Society of Clinical Oncology technology assessment on breast cancer risk 
reduction strategies: Tamoxifen and raloxifene. Journal of Clinical Oncology, 17, 
1939-1955. 
Clarke, S. L., Butler, K., & Esplen, M. J. (2008). The phases of disclosing BRCA1/2 
genetic information to offspring. Psycho-oncology, 17, 797-803. 
 
 475
Claus, E. B., Schildkraut, J., Thompson, W. D., & Risch, N. J. (1996). The genetic 
attributable risk of breast and ovarian cancer. Cancer, 77, 2318-2324. 
Collaborative Group on Epidemiological Studies of Ovarian Cancer. (2008). Ovarian 
cancer and oral contraceptives: Collaborative reanalysis of data from 45 
epidemiological studies including 23,257 women with ovarian cancer and 87,303 
controls. Lancet, 371, 303-314. 
Costalas, J. W., Itzen, M., Malick, J., Babb, J., Bove, B., Godwin, A. K., et al. (2003). 
Communication of BRCA1 and BRCA2 results to at-risk relatives: A cancer risk 
assessment program's experience. American Journal of Medical Genetics, 119C, 
11-18. 
Coughlin, S. S., Khoury, M. J., & Steinberg, K. K. (1999). BRCA1 and BRCA2 gene 
mutations and risk of breast cancer: Public health perspectives. American Journal 
of Preventive Medicine, 16(2), 91-98. 
Creswell, J. W. (1998). Qualitative inquiry and research design: Choosing among five 
traditions. Thousand Oaks, CA: Sage Publications. 
Croyle, R. T., Dutson, D. S., Tran, V. T., & Sun, Y. C. (1995). Need for certainty and 
interest in genetic testing. Women's Health, 1, 329-339. 
Croyle, R. T., & Lerman, C. (1993). Risk communication in genetic testing for cancer 
susceptibility. journal of the National Cancer Institute Monograph, 25, 59-66. 
Croyle, R. T., Smith, K. R., Botkin, J. R., Baty, B. J., & Nash, J. (1997). Psychological 




Cull, A., Anderson, E. D. C., Campbell, S., Mackay, J., Smyth, E., & Steel, M. (1999). 
The impact of genetic counseling about breast cancer on women's risk perceptions 
and levels of distress. British Journal of Cancer, 79(3/4), 501-508. 
d'Agincourt-Canning, L. (2005). The effect of experiential knowledge on construction of 
risk perception in hereditary breast/ovarian cancer. Journal of Genetic 
Counseling, 14, 55-69. 
Dagan, E., & Gil, S. (2004). BRCA1/2 mutation carriers: Psychological distress and ways 
of coping. Journal of Psycosocial Oncology, 22(3), 93-106. 
Daly, K. J. (2007). Qualitative methods for family studies and human development. Los 
Angeles: Sage Publications. 
Daly, M. B., Axilbund, J. E., Bryand, E., Buys, S., Eng, C., Friedman, S., et al. (2006). 
Genetic/familial high-risk assessment: Breast and ovarian. Journal of the National 
Comprehensive Cancer Network, 4(2), 156-176. 
Day, N. B. (2008). The need for performance and standardization of the best clinical 
breast exam. Journal of Nurse Practitioners, 4(5), 342-349. 
de Bock, G. H., Van Asperen, C. J., de Vries, J. M., Hageman, G. C. H. A., P., S. M., & 
Kievit, J. (2001). How many women with a family history of breast cancer and 
their general practitioners act on genetic advice in general practice: Prospective 
longitudinal study. British Medical Journal, 322, 26-27. 
Decruyenaere, M., Evers-Kiebooms, G., & Van den Berghe, H. (1993). Perceptions of 
predictive testing for Huntington's disease by young women: Preferring 
uncertainty to certainty? Medical Genetics, 30, 557-561. 
 
 477
Decruyenaere, M., Evers-Kiebooms, G., Welkenhuysen, M., Denayer, L., & Claes, E. 
(2000). Cognitive representations of breast cancer, emotional distress and 
preventive health behavior: A theoretical perspective. Psycho-oncology, 9, 528-
536. 
Derogatis, L. R., & Spencer, P. M. (1982). The Brief Symptom Inventory (BSI): 
Administration, scoring, and procedures manual. Baltimore: Johns Hopkins 
University. 
DevCan. (2005). Probability of developing or dying of cancer software, version 6.2.1. In 
S. R. a. A. Branch (Ed.): National Cancer Institute. 
Die-Trill, M. (2000). Beliefs about cancer causation and their influence on family 
function. In L. Baider, C. L. Cooper & A. Kaplan De-Nour (Eds.), Cancer and the 
Family (2 ed., pp. 119-133). Chichester: John Wiley & Sons. 
Ding, S. L., Sheu, L. F., Yu, J. C., Yang, T. L., Chen, B. F., Leu, F. J., et al. (2004). 
Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, 
BRCA1 and TP53, in breast cancer is related to tumour grade. British Journal of 
Cancer, 90(10), 1995-2001. 
Dorval, M., Guay, S., Mondor, M., Masse, B., Falardeau, M., Robidoux, A., et al. (2005). 
Couples who get closer after breast cancer: Frequency and predictors in a 
prospective investigation. Journal of Clinical Oncology, 21(15), 3588-3596. 
Dorval, M., Patenaude, A. F., Schneider, K. A., Kieffer, S. A., DiGianni, L., Kalkbrenner, 
K. J., et al. (2000). Anticipated versus actual emotional reactions to disclosure of 
results of cancer susceptibility: Finding from p53 and BRCA1 testing programs. 
Journal of Clinical Oncology, 18, 2135-2142. 
 
 478
Dowdy, S. C., Stefanek, M., & Hartmann, L. C. (2004). Surgical risk reduction: 
Prophylactic salpingo-oophorectomy and prophylactic mastectomy. American 
Journal of Obstetrics and Gynecology, 191, 1113-1123. 
Dudok de Wit, A. C., Duivenvoorden, H. J., Passchier, J., Niermeijer, M. F., & Tibben, 
A. (1998). Course of distress experienced by persons at risk for an autosomal 
dominant inheritable disorder participating in a predictive testing program: An 
explorative study. Psychosomatic Medicine, 60, 543-549. 
Dudok de Wit, A. C., Meijers-Heijboer, E. J., Tibben, A., Frets, P. G., Klijn, J. G. M., 
Devilee, P., et al. (1994). Effect on a Dutch family of predictive DNA-testing for 
hereditary breast and ovarian cancer. Lancet, 344, 197. 
Dudok de Wit, A. C., Tibben, A., Duivenvoorden, H. J., Frets, P. G., Zoeteweij, M. W., 
Losekook, M., et al. (1997). Psychological distress in applicants for predictive 
DNA testing for autosomal dominant, heritable, late onset disorders. Journal of 
Medical Genetics, 34, 382-390. 
Dudok de Wit, A. C., Tibben, A., Frets, P. G., Meijers-Heijboer, E. J., Devilee, P., Klijn, 
J. G. M., et al. (1997). BRCA1 in the family: A case description of the 
psychological implications. American Journal of Medical Genetics, 71, 63-71. 
Dudok de Wit, A. C., Tibben, A., Frets, P. G., Meijers-Heijboer, E. J., Devilee, P., & 
Niermeijer, M. F. (1996). Males at-risk for the BRCA1 genet, the psychological 
impact. Psycho-oncology, 5(3), 251-257. 
Durfy, S. J., Bowen, D. J., McTiernan, A., Sporleder, J., & Burke, W. (1999). Attitudes 
and interest in genetic testing for breast and ovarian cancer susceptibility in 
 
 479
diverse gropus of women in western Washington. Cancer Epidemiology, 
Biomarkers & Prevention, 8, 369-375. 
Easton, D. F., Ford, D., & Bishop, D. T. (1995). Breast and ovarian cancer incidence in 
BRCA1-mutation carriers. American Journal of Human Genetics, 56, 265-271. 
Eeles, R., Cole, T., Taylor, R., Lunt, P., & Baum, M. (1996). Prophylactic mastectomy 
for genetic predisposition to breast cancer: The proband's study. Clinical 
Oncology, 8, 222-225. 
Eeles, R., & Powles, T. J. (2000). Chemoprevention options for BRCA1 and BRCA2 
mutation carriers. Journal of Clinical Oncology, 18(21S), 93S-99S. 
Eisen, A., Rebbeck, T. R., Wood, W. C., & Weber, B. L. (2000). Prophylactic surgery in 
women with a hereditary predisposition to breast and ovarian cancer. Journal of 
Clinical Oncology, 18, 1980-1995. 
Eisen, A., & Weber, B. L. (2001). Editorial: Prophylactic mastectomy for women with 
BRCA1 and BRCA2 mutations--facts and controversy. New England Journal of 
Medicine, 345(3), 207-208. 
Eisinger, F., Reynier, C. J., Chabal, F., Luquet, C., Moatti, J., & Sobol, H. (1997). 
Acceptable strategies for dealing with hereditary breast/ovarian cancer risk. 
Journal of the National Cancer Institute, 89(10), 731. 
Eitan, R., Michaelson-Cohen, R., Levavi, H., & Beller, U. (2009). The counseling and 
management of y oung healthy BRCA mutation carriers. International Journal of 
Gynecological Cancer, 19(7), 1156-1159. 
 
 480
Elder, G. H., Johnson, M. K., & Crosnoe, R. (2003). The emergence and development of 
Life Course Theory. In J. T. Mortimer & M. J. Shanahan (Eds.), Handbook of the 
Life Course (pp. 3-22). New York: Kluwer Academic/Plenum. 
Elit, L., Esplen, M. J., Butler, K., & Narod, S. (2001). Quality of life and psychosexual 
adjustment after prophylactic oophorectomy for a family history of ovarian 
cancer. Familial Cancer, 1, 149-156. 
Elzinga, C. H., & Liefbroer, A. C. (2007). De-standardization of family-life trajectories 
of young adults: A cross-national comparison using sequency analysis. European 
Journal of Population, 23, 225-250. 
Emery, J., Kumar, S., & Smith, H. (1998). Patient understanding of genetic principles and 
their expectations of genetic services within the NHS: A qualitative study. 
Community Genetics, 1, 78-83. 
Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. 
Science, 196(4286), 129-136. 
Engel, G. L. (1980). The clinical application of the biopsychosocial model. The American 
Journal of Psychiatry, 137(5), 535-544. 
Erblich, J., Bovbjerg, D. H., & Valdimarsdottir, H. B. (2000). Looking forward and back: 
Distress among women at familial risk for breast cancer. Annals of Behavioral 
Medicine, 22(1), 53-59. 
Esplen, M. J., Hunter, J., Leszcz, M., Warner, E., Narod, S., Metcalfe, K., et al. (2004). A 
multicenter study of supportive-expressive group therapy for women with 
BRCA1/BRCA2 mutations. Cancer, 101(10), 2327-2340. 
 
 481
Evans, C. (2006). Genetic Counseling: A Psychological Approach. Cambridge: 
Cambridge University Press. 
Fang, C. Y., Miller, S. M., Malick, J., Babb, J., Engstrom, P. F., & Daly, M. B. (2003). 
Psychosocial correlates of intention to undergo prophylactic oophorectomy 
among women with a family history of ovarian cancer. Preventive Medicine, 
37(5), 424-431. 
Fay, M. P. (2004). Estimating age conditional probability of developing disease from 
surveillance data. Population Health Metrics, 2(6), 1-9. 
Fay, M. P., Pfeiffer, R., Cronin, K. A., Le, C., & Feuer, E. J. (2003). Age-conditional 
probabilities of developing cancer. Statistics in Medicine, 22(11), 1837-1848. 
Fekete, E. M., Parris Stephens, M. A., Mickelson, K. D., & Druley, J. A. (2007). Couples' 
support provision during illness: The role of perceived emotional responsiveness. 
Families, Systems, & Health, 25(2), 204-217. 
Fisher, B., Constantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, 
W. M., et al. (1998). Tamoxifen for prevention of breast cancer: Report of the 
National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the 
National Cancer Institute, 90(18), 1371-1388. 
Fisher, B., Powles, T. J., & Pritchard, K. J. (2000). Tamoxifen for the prevention of 
breast cancer. European Journal of Cancer, 36, 142-150. 





Ford, D., Easton, D. F., Bishop, D. T., Narod, S., & Goldgar, D. E. (1994). Risks of 
cancer in BRCA1-mutation carriers.  Breast Cancer Linkage Consortium. Lancet, 
343, 692-695. 
Ford, D., Easton, D. F., & Petro, J. (1995). Estimates of the gene frequency of BRCA1 
and its contributions to breast and ovarian cancer incidence. American Journal of 
Human Genetics, 57, 1457-1462. 
Forrest, K., Simpson, S. A., Wilson, B. J., van Teijlingen, E. R., McKee, L., Haites, N., et 
al. (2003). To tell or not to tell: Barriers and facilitators in family communication 
about genetic risk. Clinical Genetics, 64, 617-326. 
Foster, C., Evans, D. G. R., Eeles, R., Eccles, D., Ashley, S., Brooks, L., et al. (2002). 
Predictive testing for BRCA1/2: Attributes, risk perception and management in a 
multi-centre clinical cohort. British Journal of Cancer, 86, 1209-1216. 
Foster, C., Evans, D. G. R., Eeles, R., Eccles, D., Ashley, S., Brooks, L., et al. (2004). 
Predictive testing for BRCA1/2: Attributes, risk perception and management in a 
multi-centre clinical cohort. British Journal of Cancer, 86, 1209-1216. 
Franchesi, S., Parazzini, F., Negri, E., Booth, M., LaVecchia, C., Beral, V., et al. (1991). 
Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: 
III: Oral contraceptive use. International Journal of Cancer, 49(1), 61-65. 
French, B. N., Kurczynski, T. W., Weaver, M. T., & Pituch, M. J. (1992). Evaluation of 
the Health Belief Model and decisionmaking regarding amniocentesis in women 
of advanced maternal age. Health Education and Behavior, 19(2), 177-186. 
 
 483
Frets, P. G., Verhage, F., & Niermeijer, M. F. (1991). Characteristics of the 
postcounseling reproductive decision-making process: An explorative study. 
American Journal of Medical Genetics, 40, 298-303. 
Frost, M. H., Schaid, D. J., Sellers, T. A., Slezak, J. M., Arnold, P. G., Woods, J. E., et al. 
(2000). Long-term satisfaction and psychological and social functioning 
following bilateral prophylactic mastectomy. Journal of the American Medical 
Association, 284, 319-324. 
Fry, A., Busby-Earle, C., Rush, R., & Cull, A. (2001). Prophylactic oophorectomy versus 
screening: Psychosocial outcomes in women at increased risk of ovarian cancer. 
Psycho-oncology, 10, 231-241. 
Fry, A., Rush, R., Busby-Earle, C., & Cull, A. (2001). Deciding about prophylactic 
oophorectomy: What is important to women at increased risk of ovarian cancer? 
Preventive Medicine, 33, 578-585. 
Gabriel, S. E., Woods, J. E., O'Fallon, W. M., Beard, C. M., Kurland, L. T., & Melton, L. 
J. I. (1997). Complications leading to surgery after breast implantation. New 
England Journal of Medicine, 336, 677-682. 
Gayther, S. A., Mangion, J., Russel, P., Seal, S., Barfoot, R., Ponder, B. A. J., et al. 
(1997). Variation of risks of breast and ovarian cancer associated with different 
germline mutations of the BRCA2 gene. Nature Genetics, 15, 103-105. 
Gayther, S. A., Warren, W., Mazoyer, S., Russel, P., Harrington, P. A., Chiano, M., et al. 
(1995). Germline mutations of the BRCA1 gene in breast and ovarian cancer 




Geller, G., Botkin, J. R., Green, M. J., Press, N., Biesecker, B., Wilfond, B., et al. (1997). 
Genetic testing for susceptibility to adult-onset cancer: The process and content of 
informed consent. journal of the American Medical Association, 277, 1467-1474. 
Geller, G., Doksum, T., Bernhardt, B. A., & Metz, S. A. (1999). Participation in breast 
cancer susceptibility testing protocols: Influence of recruitment source, altruism, 
and family involvement on women's decisions. Cancer Epidemiology, Biomarkers 
& Prevention, 8, 377-383. 
Gilbar, O., & Borovik, R. (1998). How daughters of women with breast cancer cope with 
the threat of illness. Behavioral Medicine, 24, 115-121. 
Gilgun, J. F., Daly, K. J., & Handel, G. (1992). Qualitative methods in family research. 
Newbury Park, CA: Sage Publications. 
Glanz, K., Grove, J., Lerman, C., Gotay, C., & LeMarchand, L. (1999). Correlates of 
intentions to obtain genetic counseling and colorectal cancer gene testing among 
at-risk relatives from three ethnic groups. Cancer Epidemiology, Biomarkers & 
Prevention, 8, 329-336. 
Goff, B. A., Mandel, L. S., Melancon, C. H., & Muntz, H. G. (2004). Frequency of 
symptoms of ovarian cancer in women presenting to primary care clinics. journal 
of the American Medical Association, 291(22), 2705. 
Grann, V. R., Panageas, K. S., Whang, W., Antman, K. H., & Neugut, A. I. (1998). 
Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-




Green, J., Richards, M., Murton, F., Statham, H., & Hallowell, N. (1997). Family 
communication and genetic counseling: The case of hereditary breast and ovarian 
cancer. Journal of Genetic Counseling, 6, 45-60. 
Green, R., & Thomas, A. M. (1997). Whose gene is it? A case discussion about familial 
conflict over genetic testing for breast cancer. Journal of Genetic Counseling, 6, 
645-655. 
Grenader, T., Peretz, T., Lifchitz, M., & Schavit, L. (2005). BRCA1 and BRCA2 germ-
line mutations and oral contraceptives: To use or not to use. The Breast, 14, 264-
268. 
Hagestad, G. O., & Neugarten, B. L. (1985). Age and the life course. In E. Shanas & R. 
Binstock (Eds.), Handbook of aging and the social sciences (2 ed., pp. 36-61). 
New York: Van Nostrand and Reinhold Company. 
Hallowell, N. (1999). Doing the right thing: Genetic risk and responsibility. Sociology of 
Health and Illness, 21(5), 597-621. 
Hallowell, N., Foster, C., Eeles, R., Arden-Jones, A., Murday, V., & Watson, M. (2003). 
Balancing autonomy and responsibility: The ethics of generating and disclosing 
genetic information. Journal of Medical Ethics, 29, 74-83. 
Hallowell, N., Statham, H., & Murton, F. (1998). Women's understanding of their risk of 
developing breast/ovarian cancer before and after genetic counseling. Journal of 
Genetic Counseling, 7, 345-354. 
Han, S., & Moen, P. (1999). Work and family over time: A life course approach. The 




Harmon, A. (2006, September 3, 2006). Couples cull embryos to halt heritage of cancer. 
The New York Times,  
Hatcher, M. B., Fallowfield, L., & A'Hern, R. (2001). The psychosocial impact of 
bilateral prophylactic mastectomy: Prospective study using questionnaires and 
semistructured interviews. British Medical Journal, 322, 76-81. 
Hegelson, V. S. (1994). Relation of agency and communion to well-being: Evidence and 
potential explanations. Psychological Bulletin, 116, 412-428. 
Hitlin, S., & Elder, G. H. (2007). Time, self, and the curiously abstract concept of 
agency. Sociological Theory, 25(2), 170-191. 
Hopwood, P. (2000). Breast cancer risk perception: What do we know and understand? 
Breast Cancer Research, 2, 387-391. 
Hopwood, P., Howell, A., Lalloo, F., & Evans, G. (2003). Do women understand the 
odds? Risk perceptions and recall of risk information in women with a family 
history of breast cancer. Community Genetics, 6, 214-223. 
Hopwood, P., Keeling, F., Long, A., Pool, C., Evans, G., & Howell, A. (1998). 
Psychological support needs for women at high genetic risk of breast cancer: 
Some preliminary findings. Psycho-oncology, 7, 402-412. 
Hopwood, P., Lee, A., Shenton, A., Baildam, A., Brain, A., Lalloo, F., et al. (2000). 
Clinical follow-up after bilateral risk reducing ('prophylactic') mastectomy: 
Mental health and body image outcomes. Psycho-oncology, 9, 462-472. 
Horowitz, M., Wilner, N., & Alvarez, W. (1979). Impact of Event Scale: A measure of 
subjective stress. Psychosomatic Medicine, 41(3), 209-218. 
 
 487
Hoskins, L. M., Roy, K., Peters, J., Loud, J. T., & Greene, M. H. (2008). Disclosure of 
positive BRCA1/2-mutation status in young couples: The journey from 
uncertainty to bonding through partner support. Families, Systems, & Health, 
26(3), 296-316. 
Human Genome Project  Information. (2005). Human Genome News   Retrieved March 
3, 2008, 2008, from 
http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm 
Janis, I. L., & Mann, L. (1977). Decision making: A psychological analysis of conflict, 
choice, and commitment. New York: The Free Press. 
Jenkins, J., Calzone, K., Dimond, E., Liewehr, D. J., Steinberg, S. M., Jourkiv, O., et al. 
(2007). Randomized comparison of phone versus in-person BRCA1/2 
predisposition genetic test result disclosure counseling. Genetics in Medicine, 
9(8), 487-495. 
Johannesdottir, G., Gudmundsson, J., Bergthorsson, J. T., Arason, A., Agnarson, B. A., 
Elriksdottir, G., et al. (1996). High prevalence of the 999del5 mutation in 
Icelandic breast and ovarian cancer patients. Cancer Research, 56, 3. 
Juengst, E. T. (1999). Genetic testing and the moral dynamics of family life. Public 
Understanding of Science, 8, 193-205. 
Julian-Reynier, C., Welkenhuysen, M., Hagoel, L., Decruyenaere, M., Hopwood, P., & 
CRISCOM. (2003). Risk communication strategies: State of the art and 
effectiveness in the context of cancer genetic services. European Journal of 
Human Genetics, 11(10), 725-736. 
 
 488
Karlan, B. Y. (2004). Editorial: Defining cancer risks for BRCA germline mutation 
carriers: Implications for surgical prophylaxis. Gynecologic Oncology, 92, 519-
520. 
Kash, K. M., Dabney, M. K., Holland, J. C., Osborne, M. P., & Miller, D. G. (2000). 
Familial cancer and genetics: Psychosocial and ethical aspects. In L. Baider, C. L. 
Cooper & A. Kaplan De-Nour (Eds.), Cancer and the Family (2 ed., pp. 390-403). 
Chichester, UK: John Wiley & Sons. 
Kash, K. M., Holland, J. C., Halper, M. S., & Miller, D. G. (1992). Psychological distress 
and surveillance behaviors of women with a family history of breast cancer. 
Journal of the National Cancer Institute, 84(1), 24-30. 
Katki, H. A., Gail, M. H., & Greene, M. H. (2007). Breast-cancer risk in BRCA-mutation-
negative women from BRCA-mutation-positive families. Lancet Oncology, 8(12), 
1042-1043. 
Kauff, N. D., & Barakat, R. (2004). Editorial: Surgical risk-reduction in carriers of BRCA 
mutations: Where do we go from here? Gynecologic Oncology, 93, 277-279. 
Kelley, H. H. (1971). Attribution and social interaction. Morristown, NJ: General 
Learning Process. 
Kelly, K. M., Leventhal, H., Andrykowski, M., Toppmeyer, D., Much, J., Dermody, J., et 
al. (2005). Using the common sense model to understand perceived cancer risk in 
individuals testing for BRCA1/2 mutations. Psycho-oncology, 14, 34-48. 
Kenen, R., Arden-Jones, A., & Eeles, R. (2003). Family stories and the use of heuristics: 
women from suspected hereditary breast and ovarian cancer families. Sociology of 
Health and Illness, 25(7), 838-865. 
 
 489
Kenen, R., & Peters, J. (2001). The Colored Eco-Genetic Relationship Map (CEGRM): A 
conceptual approach and tool for genetic counseling research. Journal of Genetic 
Counseling, 10(4), 289-309. 
King, M. C., Marks, J. H., & Mandell, J. B. (2003). Breast and ovarian cancer risks due 
to inherited mutations in BRCA1 and BRCA2. Science, 302, 643-646. 
King, S., & Schottenfeld, D. (1996). The 'epidemic' of breast cancer in the US -- 
Determining the factors. Oncology, 10, 453-472. 
Klein, W. M. P., & Stefanek, M. E. (2007). Cancer risk elicitation and communication: 
Lessons from the psychology of risk perception. CA: A Cancer Journal for 
Clinicians, 57, 147-167. 
Knoppers, B. M., & Chadwick, R. (1994). The human genome project: Under an 
international ethical microscope. Science, 265, 2035-2036. 
Kodish, E. D. (1999). Testing children for cancer genes: The rule of earliest onset. 
Journal of Pediatrics, 135, 390-395. 
Koehly, L. M., Peters, J., Kuhn, N., Hoskins, L., Letocha, A., Kenen, R., et al. (2008). 
Sisters in hereditary breast and ovarian cancer families: Communal coping, social 
integration, and psychological well-being. Psycho-oncology, 17(8), 812-821. 
Kotsopoulos, J., Librach, C. L., Lubinski, J., Gronwald, J., Kim-Sing, C., Ghadirian, P., 
et al. (2008). Infertility, treatment of infertility, and the risk of breast cancer 
among women with BRCA1 and BRCA2 mutations: A case-control study. Cancer 
Causes and Control, 19(10), 1111-1119. 
Kramer, J. L., Velazquez, I. A., Chen, B. E., Rosenberg, P. S., Struewing, J. P., & 
Greene, M. H. (2005). Prophylactic oophorectomy reduced breast cancer 
 
 490
penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. 
Journal of Clinical Oncology, 23, 8629-8635. 
Lakhani, S. R., Manek, S., Penault-Llorca, F., Flanagan, A., Arnout, L., Merrett, S., et al. 
(2004). Pathology of ovarian cancer in BRCA1 and BRCA2 carriers. Clinical 
Cancer Research, 10, 2473-2481. 
Lancaster, J. M., Wiseman, R. W., & Berchuck, A. (1996). An inevitable dilemma: 
Prenatal testing for mutations in the BRCA1 breast cancer susceptiblity gene. 
Obstetrics and Gynecology, 87, 306-309. 
LaRossa, R. (2005). Grounded theory methods and qualitative family research. journal of 
Marriage and Family, 67, 837-857. 
Lazarus, R. S., & Folkman, S. (1984). Stress, appraisal, and coping. New York: 
Springer. 
Lerman, C., & Croyle, R. T. (1996). Emotional and behavioral responses to genetic 
testing for susceptibility to cancer. Oncology, 10(2), 191-202. 
Lerman, C., Croyle, R. T., Tercyak, K. P., & Hamann, H. (2002). Genetic testing: 
Psychological aspects and implications. Journal of Consulting and Clinical 
Psychology, 12, 843-850. 
Lerman, C., Daly, M., Masny, A., & Balshem, A. (1994). Attitudes about genetic testing 
for breeast and ovarian cancer susceptibility. Journal of Clinical Oncology, 12, 
843-850. 
Lerman, C., Daly, M., Sands, C., Balshem, A., Lustbader, E., Heggan, T., et al. (1993). 
Mammography adherence and psychological distress among women at risk for 
breast cancer. Journal of the National Cancer Institute, 85(13), 1074-1080. 
 
 491
Lerman, C., Hughes, C., Benkendorf, J. L., Biesecker, B., Kerner, J., Willison, J., et al. 
(1999). Racial differences in testing motivation and psychological distress 
following pretest education for BRCA1 gene testing. Cancer Epidemiology, 
Biomarkers & Prevention, 8, 361-367. 
Lerman, C., Hughes, C., Croyle, R. T., Main, D., Durham, C., Snyder, C., et al. (2000). 
Prophylactic surgery decisions and surveillance practices one year following 
BRCA1/2 testing. Preventive Medicine, 31, 75-80. 
Lerman, C., Hughes, C., Lemon, S. J., Main, D., Snyder, C., Durham, C., et al. (1998). 
What you don't know can hurt you: Adverse psychologic effects in members of 
BRCA1-linked and BRCA2-linked families who decline genetic testing. Journal of 
Clinical Oncology, 16(5), 1650-1654. 
Lerman, C., Kash, K. M., & Stefanek, M. (1994). Younger women at increased risk for 
breast cancer: Perceived risk, psychological well-being, and surveillance 
behavior. Journal of the National Cancer Institute Monograph, 16, 171-176. 
Lerman, C., Lustbader, E., Rimer, B. K., Daly, M., Miller, S. M., Sands, C., et al. (1995). 
Effects of individualized breast cancer risk counseling: A randomized trial. 
Journal of the National Cancer Institute, 87, 286-292. 
Lerman, C., Narod, S., Schulman, K., Hughes, C., Gomez-Caminero, A., Bonney, G., et 
al. (1996). BRCA1 testing in families with hereditary breast-ovarian cancer.  A 
prospective study of patient decision making and outcomes. Journal of the 
American Medical Association, 275(24), 1885-1892. 
 
 492
Lerman, C., Rimer, B. K., & Engstrom, P. F. (1991). Cancer risk notification: 
Psychosocial and ethical implications. Journal of Clinical Oncology, 9(7), 1275-
1282. 
Lerman, C., Schwartz, M. D., Lin, T. H., Hughes, C., Narod, S., & Lynch, H. T. (1997). 
The influence of psychological distress on use of geneti testing for cancer risk. 
Journal of Consulting and Clinical Psychology, 65, 414-420. 
Lincoln, Y. S., & Guba, E. G. (1985). Naturalistic inquiry. Beverly Hills, CA: Sage 
Publications. 
Lindor, N., McMaster, M. L., Lindor, C. J., & Greene, M. H. (2008). Concise handbook 
of familial cancer susceptibility syndromes. Journal of the National Cancer 
Institute Monograph, 38(3), 3-93. 
Lipkus, I. M., Iden, D., Terrenoire, J., & Feaganes, J. R. (1999). Relationships among 
breast cancer concern, risk perceptions, and interest in genetic counseling for 
breast cancer susceptibility among African-American women with and without a 
family history of breast cancer. Cancer Epidemiology, Biomarkers & Prevention, 
8, 533-539. 
Lippman-Hand, A., & Fraser, F. C. (1979). Genetic counseling: Parents' responses to 
uncertainty. Birth Defects Original Article Series, XV(5C), 325-339. 
Lloyd, S. M., Watson, M., Waites, B., Meyer, L., Eeles, R., Ebbs, S., et al. (1996). 
Familial breast cancer: A controlled study of risk perception, psychological  
morbidity and health beliefs in women attending for genetic counseling. British 
Journal of Cancer, 74, 482-487. 
 
 493
Lobb, E. A., Butow, P., Barratt, A., Meiser, B., Gaff, C., Young, M. A., et al. (2004). 
Communication and information-giving in high-risk breast cancer consultations: 
Influence on patient outcomes. British Journal of Cancer, 90, 321-327. 
Lodder, L. N., Frets, P. G., Trijsburg, R. W., Meijers-Heijboer, E. J., Klijn, J. G. M., 
Duivenvoorden, H. J., et al. (1999). Presymptomatic testing for BRCA1 and 
BRCA2: How distressing are the pre-test weeks? Journal of Medical Genetics, 36, 
906-913. 
Lodder, L. N., Frets, P. G., Trijsburg, R. W., Meijers-Heijboer, E. J., Klijn, J. G. M., 
Duivenvoorden, H. J., et al. (2001). Psychological impact of receiving a 
BRCA1/2 test result. American Journal of Medical Genetics, 98, 15-24. 
Lodder, L. N., Frets, P. G., Trijsburg, R. W., Meijers-Heijboer, E. J., Klijn, J. G. M., & 
Niermeijer, M. F. (2000). Attitudes towards termination of pregnancy in subjects 
who underwent testing for the BRCA1/BRCA2 gene mutation in The Netherlands. 
Journal of Medical Genetics, 37(11), 883-884. 
Lugones, M., & Spelman, E. (1999). Have we got a theory for you! Feminist theory, 
cultural imperialism and the demand for "The woman's voice." In J. A. Kournay, 
J. P. Sterba & R. Tong (Eds.), Feminist philosophies (2nd ed., pp. 474-486). 
Upper Saddle River, NJ: Prentice Hall. 
Lynch, H. T., Lemon, S. J., Durham, C., Tinley, S. T., Connolly, C., Lynch, J. F., et al. 
(1997). A descriptive study of BRCA1 testing and reactions to disclosure of test 
results. Cancer, 79, 2219-2228. 
Lynch, H. T., & Lynch, J. F. (1999). Pros and cons of genetic screening for breast cancer. 
American Family Physician, 59, 43-45. 
 
 494
Lynch, H. T., Watson, P., Conway, T. A., Lynch, J. F., Slominski-Caster, S. M., Narod, 
S., et al. (1993). DNA screening for breast/ovarian cancer susceptibility based on 
linked markers: A family study. Archives of Internal Medicine, 153(17), 1979-
1987. 
Lynch, J., & Davey Smith, G. (2005). A Life Course Approach to Chronic Disease 
Epidemiology. Annual Review of Public Health, 26, 1-35. 
Madalinska, J. B., Hollenstein, J., Bleiker, E., van Beurden, M., Valdimarsdottir, H. B., 
Massuger, L. F., et al. (2005). Quality of life effects of prophylactic salpingo-
oophorectomy versus gynecologic screening among women at increased risk of 
hereditary ovarian cancer. Journal of Clinical Oncology, 23, 6890-6898. 
Madalinska, J. B., van Beurden, M., Bleiker, E. M. A., Valdimarsdottir, H. B., Lubsen-
Brandsma, L., Massuger, L. F., et al. (2007). Predictors of prophylactic bilateral 
salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 
mutation carriers. Journal of Clinical Oncology, 25(3), 301-307. 
Manne, S., Audrain, J., Schwartz, M. D., Finch, C., & Lerman, C. (2004). Associations 
between relationship support and psychological reactions of participants and 
partners to BRCA1 and BRCA2 testing in a clinic-based sample. Annals of 
Behavioral Medicine, 28(3), 211-225. 
Marks, N., & Lambert, J. (1998). Marital status continuity and change among young and 
midlife adults: Longitudinal effects on psychological well-being. Journal of 
Family Issues, 19, 652-686. 
Marshall, C. M., & Rossman, G. B. (1999). Designing qualitative research (3 ed.). 
Thousand Oaks, CA: Sage Publications. 
 
 495
Martin, J. R., & Wilikofsky, A. S. (2004). Genetic counseling in primary care: 
Longitudinal, psychosocial issues in genetic diagnosis and counseling. Primary 
Care: Clinics in Office Practice, 31(3), 509-524. 
McAllister, M. (2003). Personal theories of inheritance, coping strategies, risk perception 
and engagement in hereditary non-polyposis colon cancer families offered genetic 
testing. Clinical Genetics, 64, 179-189. 
McArthur, H. L., Hensley, M., Brown, C., Chi, D. S., Offit, K., Hurley, K., et al. (2007). 
Impact of risk-reducing oophorectomy on quality of life in women at risk for 
ovarian cancer. Journal of Clinical Oncology ASCO Meeting Proceedings (Post-
Meeting Edition), 25(18S), 1520. 
McDaniel, S. H. (2005). The psychotherapy of genetics. Family Process, 44, 25-44. 
McDaniel, S. H., Rolland, J. S., Feetham, S. L., & Miller, S. M. (2006). "It runs in the 
family": Family systems concepts and genetically linked disorders. In S. M. 
Miller, S. H. McDaniel, J. S. Rolland & S. L. Feetham (Eds.), Individuals, 
families, and the new era of genetics: Biopsychosocial perspectives (pp. 118-138). 
New York: W. W. Norton & Company. 
McInerney-Leo, A., Hadley, D., Kase, R. G., Giambarresi, T. R., Struewing, J. P., & 
Biesecker, B. (2006). BRCA1/2 testing in hereditary breast and ovarian cancer 
families III: Risk perception and screening. American Journal of Medical 
Genetics Part A, 140A, 2198-2206. 
McKinlay, S., Brambilla, D., & Posner, J. (2008). The normal menopause transition. 
Maturitas, 61(1), 4-16. 
 
 496
McLaughlin, J. R., Risch, H. A., Lubinski, J., Maller, P., Ghadirian, P., Lynch, H. T., et 
al. (2007). Reproductive risk factors for ovarian cancer in carriers of BRCA1 or 
BRCA2 mutations: A case-control study. Lancet Oncology, 8, 26-34. 
Meijers-Heijboer, E. J., Brekelmans, C. T. M., Menke-Pluymers, M. B. E., Seynaeve, C., 
Baalbergen, A., Burger, C., et al. (2003). Use of genetic testing and prophylactic 
mastectomy and oophorectomy in women with breast or ovarian  cancer from 
families with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 21, 
1675-1681. 
Meijers-Heijboer, E. J., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., 
Seynaeve, C., Menke-Pluymers, M. B. E., et al. (2001). Breast cancer after 
prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutations. 
New England Journal of Medicine, 345(3), 159-164. 
Meijers-Heijboer, E. J., Verhoog, L. C., Brekelmans, C. T. M., Seynaeve, C., Tilanus-
Linthorst, M. M. A., Wagner, A., et al. (2000). Presymptomatic DNA testing and 
prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet, 355, 
2015-2020. 
Meiser, B. (2005). Psychological impact of genetic testing for cancer susceptibility: An 
update of the literature. Psycho-Oncology, 14, 1060-1074. 
Meiser, B., Butow, P., Barratt, A., Friedlander, M., Gattas, M., Kirk, J., et al. (1999). 
Attitudes toward prophylactic oophorectomy and screening utilization in women 
at increased risk of developing hereditary breast/ovarian cancer. Gynecologic 
Oncology, 75, 122-129. 
 
 497
Meiser, B., Butow, P., Friedlander, M., Schnieden, V., Gattas, M., Kirk, J., et al. (2000). 
Intention to undergo prophylactic bilateral mastectomy in women at increased risk 
of developing hereditary breast cancer. Journal of Clinical Oncology, 18, 2250-
2257. 
Meiser, B., Butow, P., Price, M. A., Bennett, B., Berry, G., & Tucker, K. (2003). 
Attitudes to prophylactic surgery and chomoprevention in Australian women at 
increased risk for breast cancer. Journal of Women's Health, 12, 769-777. 
Meiser, B., Tiller, K., Gleeson, M. A., Andrews, L., Robertson, G., & Tucker, M. A. 
(2000). Psychosocial impact of prophylactic oophorectomy iin women at 
increased risk for ovarian cancer. Psycho-oncology, 9, 496-503. 
Mellon, S., Berry-Bobovski, L., Gold, R., Levin, N., & Tainsky, M. (2006). 
Communication and decision-making about seeking inherited cancer risk 
information: Findings from female survivor-relative focus groups. Psycho-
oncology, 15, 193-208. 
Menning, C. L. (2008). "I've kept it that way on purpose": Adolescents' management of 
negative parental relationship traits after divorce and separation. Journal of 
Contemporary Ethnography, 37(5), 586-618. 
Menon, U., Harper, J., Sharma, A., Fraser, L., Burnell, M., El Masry, K., et al. (2007). 
Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a 
reproductive option for hereditary breast and ovarian cancer. Human 
Reproduction, 22(6), 1573-1577. 
 
 498
Messien, G. J., Mastromaura, C. A., Kiely, D. K., McNamara, D. S., & Myers, D. S. 
(1991). Understanding the decision to take the predictive test for Huntington's 
disease. American Journal of Medical Genetics, 38, 519-526. 
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., et 
al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene 
BRCA1. Science, 266(5182), 66-71. 
Moslehi, R., Chu, W., Karlan, B. Y., Fishman, D., Risch, H. A., Fields, A., et al. (2000). 
BRCA and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with 
ovarian cancer. American Journal of Human Genetics, 66, 1259-1272. 
Murphy, A. E. (1999). Dealing with the uncertainty of developing a cancer. European 
Journal of Cancer, 8, 233-237. 
Narod, S. A., Dube, M., Klijn, J. G. M., Lubinski, J., Lynch, H. T., Ghadirian, P., et al. 
(2002). Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 
mutation carriers. Journal of the National Cancer Institute, 94(23), 1773-1779. 
Narod, S. A., Goldgar, D. E., Cannon-Albright, L., Weber, B. L., Moslehi, R., Ives, E., et 
al. (1995). Risk modifiers in carriers of brca1 mutations. International Journal of 
Cancer, 64, 394-398. 
Narod, S. A., Risch, H. A., Moslehi, R., Dorum, A., Neuhausen, S., Olsson, H., et al. 
(1998). Oral contraceptives and the risk of hereditary ovarian cancer. New 
England Journal of Medicine, 339, 424-428. 
Narod, S. A., Sun, P., Ghadirian, P., Lynch, H. T., Isaacs, C., Garber, J. E., et al. (2001). 
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 
mutations: A case-control study. Lancet, 357, 1467-1470. 
 
 499
NCI. (2002). Genetic testing for BRCA1 and BRCA2: It's your choice.   Retrieved 
February 3, 2008, from http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA 
NCI. (2006). Risk Factors. What you need to know about ovarian cancer   Retrieved 
February 3, 2010 
NCI. (2009). Risk factors. What you need to know about breast cancer   Retrieved 
February 3, 2010 
Neise, C., Rachfuss, M., Paepke, S., Beier, K., & Lichtenegger, W. (2001). Risk 
perception and psychological strain in women with a family history of breast 
cancer. Onkologie, 24, 470-475. 
NHGRI. (2007). Breast Cancer Information Core (BIC) (Publication. Retrieved October 
21, 2008, from National Institutes of Health: http://research.nhgri.nih.gov/bic/ 
NHGRI. (2008). Genetic Information Nondiscrimination Act of 2008.   Retrieved July 7, 
2008, from http://www.genome.gov/10002328#3 
Northouse, L. L., Templin, T., Mood, D., & Oberst, M. (1998). Couples' adjustment to 
breast cancer and benign breast disease: A longitudinal analysis. Psycho-
oncology, 7(1), 37-48. 
O'Neill, S. C., DeMarco, T., Peshkin, B. N., Rogers, S., Rispoli, J., Brown, K., et al. 
(2006). Tolerance for uncertainty and perceived risk among women receiving 
uninformative BRCA1/2 test results. American Journal of Medical Genetics Part 
C (Seminars in Medical Genetics), 142C, 251-259. 
Oddy, W. H. (2001). Breastfeeding protects against illness and infection in infants and 
children: A reiew of the evidence. Breastfeeding Review, 9(2), 11-18. 
 
 500
Offit, K., & Brown, K. (1994). Quantitating familial cancer risk: A resource for clinical 
oncologists. Journal of Clinical Oncology, 12, 1724-1736. 
Offit, K., Kohut, K., Clagett, B., Wadsworth, E. A., Lafaro, K. J., Cummings, S., et al. 
(2006). Cancer genetic testing and assisted reproduction. Journal of Clinical 
Oncology, 24(29), 1-8. 
Oktay, J. S., & Walter, C. A. (1991). Breast cancer in the life course: Women's 
experiences. New York: Springer. 
Ortony, C., Clore, G. L., & Collins, A. (1988). The cognitive structure of emotions. New 
York: Cambridge University Press. 
Osborne, C., Ostir, G. V., Du, X., Peek, M. K., & Goodwin, J. S. (2005). The influence of 
marital status on the stage at diagnosis, treatment, and survival of older women 
with breast cancer. Breast Cancer Research and Treatment, 93(1), 41-47. 
Osmond, M. W., & Thorne, B. (1993). Feminist theories: The social construction of 
gender in families and society. In P. G. Boss, W. J. Doherty, R. LaRossa, W. R. 
Schumm & S. K. Steinmetz (Eds.), Sourcebook of Family Theories and Methods: 
A Contextual Approach (pp. 591-625). New York: Plenum Press. 
Pal, T., Permuth-Wey, J., Betts, J. A., Krischner, J. P., Fiorica, J., Arango, H., et al. 
(2005). BRCA1 and BRCA2 mutations account for a large proportion of ovarian 
carcinoma cases. Cancer, 104(12), 2807-2816. 
Palma, M., Ristori, E., Ricevuto, E., Giannini, G., & Gulino, A. (2006). BRCA1 and 
BRCA2: The genetic testing and the current management options for mutation 
carriers. Critical Reviews in Oncology/Hematology, 57, 1-23. 
 
 501
Pasacreta, J. V. (2003). Psychosocial issues associated with genetic testing and ovarian 
cancer risk: An integrative review. Cancer Investigation, 21(4), 588-623. 
Patenaude, A. F., Dorval, M., DiGianni, L., Schneider, K. A., Chittenden, A., & Garber, 
J. E. (2006). Sharing BRCA1/2 test results with first-degree relatives: Factors 
predicting who women tell. Journal of Clinical Oncology, 24(4), 700-706. 
Patenaude, A. F., Orozco, S., Li, X., Kaelin, C. M., Gaad, M., Matory, Y., et al. (2008). 
Support needs and acceptability of peer consultation: Attitudes of 108 women 
who had undergone or were considering prophylactic mastectomy. Psycho-
oncology, 17, 831-843. 
Patenaude, A. F., Schneider, K. A., Kieffer, S. A., Calzone, K., Stopfer, J., Basili, L. A., 
et al. (1996). Acceptance of invitations for p53 and BRCA1 predisposition 
testing: Factors influencing potential utilization of cancer genetic testing. Psycho-
oncology, 5, 241-250. 
Patton, M. Q. (2002). Qualitative research & evaluation methods (3 ed.). Thousand 
Oaks, CA: Sage Publications. 
Pavelka, J. C., Li, A. J., & Karlan, B. Y. (2007). Hereditary ovarian cancer--assessing 
risk and prevention strategies. Obstetrics and Gynecology Clinics of North 
America, 34, 651-665. 
Peters, J., Hoskins, L., Prindiville, S., Kenen, R., & Greene, M. H. (2006). Evolution of 
the Colored Eco-Genetic Relationship Map (CEGRM) for assessing social 
functioning in women in hereditary breast-ovarian (HBOC) families. Journal of 
Genetic Counseling, 15(6), 477-489. 
 
 502
Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., et al. (1999). 
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset 
breast cancer. Journal of the National Cancer Institute, 91(11), 943-949. 
Pilarski, R. (2009). Risk perception among women at risk for hereditary breast and 
ovarian cancer. Journal of Genetic Counseling, 18, 303-312. 
Prat, J., Ribe, A., & Gallardo, A. (2005). Hereditary ovarian cancer. Human Pathology, 
36, 861-870. 
Press, N. A., Yasui, Y., Reynolds, S., Durfy, S. J., & Burke, W. (2001). Women's interest 
in genetic testing for breast cancer susceptibility may be based on unrealistic 
expectations. American Journal of Medical Genetics, 99, 99-110. 
Price, M. A., Butow, P. N., Lo, S. K., Wilson, J., & KConFab. (2007). Predictors of 
cancer worry in unaffected women from high risk breast cancer families: Risk 
perception is not the primary issue. Journal of Genetic Counseling, 16(16), 635-
644. 
QSR. (2008). NVivo (Version 8). Doncaster, Victoria, Australia: QSR. 
Queller, J. (2008). Pretty is what changes: Impossible choices, the breast cancer gene, 
and how I defied my destiny. New York: Spiegel & Grau. 
Radloff, L. S. (1977). The CES-D Scale: A self-report depression scale for research in the 
general population. Applied Psychological Measurement, 1, 385-403. 
Ragin, C. (1994). Constructing social research. California: Pine Forge Press. 
Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009). Meta-analysis of risk reduction 
estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or 
BRCA2 mutation carriers. Journal of the National Cancer Institute, 101, 80-87. 
 
 503
Rebbeck, T. R., Lynch, H. T., Neuhausen, S., Narod, S. A., van't Veer, L., Garber, J. E., 
et al. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 
mutations. New England Journal of Medicine, 346(21), 1616-1622. 
Reichelt, J. G., Dahl, A. A., Heimdal, K., & Moller, P. (1999). Uptake of genetic testing 
and pre-test levels of mental distress in Norweigan families with known BRCA1 
mutations. Disease Markers, 15, 139-143. 
Revenson, T. A., & Majerovitz, S. D. (1990). Spouses' support provision to chronically ill 
patients. Journal of Social and Personal Relationships, 7, 575-586. 
Rhodes, R. (1988). Genetic links, family ties, and social bonds: Rights and responsiblities 
in the face of genetic knowledge. Journal of Medicine and Philosophy, 23, 10-30. 
Ringdal, G. I., Jordhoy, M. S., Ringdal, K., & Kaasa, S. (2001). The first year of grief 
and bereavement in close family members to individuals who have died of cancer. 
Palliative Medicine, 15, 91-105. 
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Kwan, E., et al. 
(2001). Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a 
population series of 649 women with ovarian cancer. American Journal of Human 
Genetics, 68, 700-710. 
Robinson, G. E., Rosen, B., Bradley, L., Rockert, W. G., Carr, M. L., Cole, D. E. C., et 
al. (1997). Psychological impact of screening for familial ovarian cancer: 
Reactions to initial assessment. Gynecologic Oncology, 65, 197-205. 
Robson, M. E., Hensley, M., Barakat, R., Brown, C., Chi, D., Poynor, E., et al. (2003). 
Quality of life in women at risk for ovarian cancer who have undergone risk-
reducing oophorectomy. Gynecological Oncology, 89, 281-287. 
 
 504
Rodgers, R. H., & White, J. M. (2004). Family developmental theory. In P. G. Boss, W. 
J. Doherty, R. LaRossa, W. R. Schumm & S. K. Steinmetz (Eds.), Sourcebook of 
family theories and methods: A contextual approach (pp. 225-254). New York: 
Springer. 
Rodriguez, G. C. (2003). New insights regarding pharmacological approaches for ovarian 
cancer prevention. Hematology and Oncology Clinicians of North America, 17(4), 
1007-1020. 
Rolland, J. S. (2005). Cancer and the family: An integrative model. Cancer, 104(S11), 
2584-2595. 
Rolland, J. S. (2006). Living with anticiatory loss in the new era of genetics: A life cycle 
perspective. In S. M. Miller, S. H. McDaniel, J. S. Rolland & S. L. Feetham 
(Eds.), Individuals, families and the new era of genetics: Biopsychosocial 
perspectives (pp. 138-172). New York: W. W. Norton & Company. 
Rolland, J. S., & Williams, J. K. (2006). Toward a psychosocial model of the new era of 
genetics. In S. H. M. S. M. Miller, J. S. Rolland, & S. L. Freeman (Ed.), 
Individuals, families, and the new era of genetics: Biopsychosocial perspectives. 
(pp. 36-75). New York: W. W. Norton & Company. 
Rosen, A. (2005). Third party reproduction and adoption in cancer patients. Journal of 
the National Cancer Institute Monograph, 34, 91-93. 
Rosenbaum, M. E., & Roos, G. M. (2000). Women's experiences of breast cancer. In A. 
S. Kasper & S. J. Ferguson (Eds.), Breast cancer: Society shapes and epidemic 
(pp. 153-182). New York: St. Martin's Press. 
 
 505
Rudnick, J. (Writer) (2008). In the Family. In J. Rudnick, G. Quinn & B. Iams 
(Producer): Kartemquin Films. 
Sarfati, D., Howden-Chapman, P., Woodward, A., & Salmond, C. (1998). Does the frame 
affect the picture?  A study into how attitudes to screening for cancer are affected 
by the way benefits are expressed. Journal of Medical Screening, 5, 137-140. 
Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., et al. (2007). 
American Cancer Society guidelines for brest screening with MRI as an adjunct to 
mammography. CA: A Cancer Journal for Clinicians, 57(2), 17. 
Scariati, P. D., Grummer-Strawn, L. M., & Fein, S. B. (1997). A longitudinal analysis of 
infant morbidity and the extent of breastfeeding in the United States. Pediatrics, 
99(6), e5. 
Scheuer, L., Kauff, N., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., et al. (2002). 
Outcome of preventive surgery and screening for breast and ovarian cancer in 
BRCA mutation carriers. Jounal of Clinical Oncology, 20, 1260-1268. 
Schneberger, S. L., Watson, H. J., & Pollard, C. E. (2007). The efficacy of "Little T" 
theories. Paper presented at the Hawaii International Conference on System 
Sciences. 
Schover, L. R. (1999). Psychosocial aspects of infertility and decisions about 
reproduction in young cancer survivors: A review. Medical and Pediatric 
Oncology, 33, 53-59. 




Schwartz, M. D., Hughes, C., Roth, J., Main, D., Peshkin, B. N., Isaacs, C., et al. (2000). 
Spiritual faith and genetic testing among high-risk breast cancer probands. Cancer 
Epidemiology, Biomarkers & Prevention, 9, 381-385. 
Schwartz, M. D., Kaufman, E., Peshkin, B. N., Isaacs, C., Hughes, C., DeMarco, T., et al. 
(2003). Bilateral prophylactic oophorectomy and ovarian cancer screening 
following BRCA1/BRCA2 mutation testing. Journal of Clinical Oncology, 21(21), 
4034-4041. 
Schwartz, M. D., Lerman, C., Brogan, B., Peshkin, B. N., Halbert, C. H., & DeMarco, T. 
(2004). Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed 
breast cancer patients. Journal of Clinical Oncology, 22, 1823-1829. 
Schwartz, M. D., Lerman, C., Miller, S. M., Daly, S., & Masny, A. (1995). Coping 
disposition, perceived risk and psychological distress among women at increased 
risk for ovarian cancer. Health Psychology, 14, 232-253. 
Segal, J., Esplen, M. J., Toner, B., Baedorf, S., Narod, S., & Butler, K. (2004). An 
investigation of the disclosure process and support needs of BRCA1 and BRCA2 
carriers. American Journal of Medical Genetics, 125A, 267-272. 
Settersten Jr., R. A. (2003). Age structuring and the rhythm of the life course. In J. T. 
Mortimer & M. J. Shanahan (Eds.), Handbook of the Life Course (pp. 81-102). 
New York: Kluwer Academic/Plumer. 
Settersten, R. A. (2003). Age structuring and the rhythm of the life course. In J. T. 
Mortimer & M. J. Shanahan (Eds.), Handbook of the Life Course (pp. 81-102). 
New York: Kluwer Academic/Plumer. 
 
 507
Shanahan, M. J., Hofer, S. M., & Shanahan, L. (2003). Biological models of behavior and 
the life course. In J. T. Mortimer & M. J. Shanahan (Eds.), Handbook of the Life 
Course (pp. 597-622). New York: Kluwer Academic/Plenum. 
Sharpe, N. F. (1993). Presymptomatic testing for Huntington disease: Is there a duty to 
test those under the age of eighteen years? American Journal of Medical Genetics, 
26, 243-246. 
Shaw, M. W. (1987). Testing for Huntington gene: A right to know, a right not to know, 
or a duty to know. American Journal of Medical Genetics, 26, 243-246. 
Sherwin, S. (1992). No longer patient: Feminist ethics and health care. Philadelphia: 
Temple University Press. 
Shields, C. G., Travis, L. A., & Rousseau, S. L. (2000). Marital attachment and 
adjustment in older couples coping with cancer. Aging and Mental Health, 4(3), 
223-233. 
Sigurdsson, S., Thorlacius, S., Tomasson, J., Tryggvadottir, L., Benediktsdottir, K., 
Eyfjord, J. E., et al. (1997). BRCA2 mutation in Icelandic prostate cancer patients. 
Journal of Molecular Medicine, 75, 758-761. 
Simpson, J. L., Carson, S. A., & Cisneros, P. (2005). Preimplantation genetic diagnosis 
(PGD) for heritable neoplasia. Journal of the National cancer Institue 
Monograph, 34, 87-90. 
Smerecnik, C. M. R., Mesters, I., Verweij, E., de Vries, N. K., & de Vries, H. (2009). A 
systematic review of the impact of genetic counseling on risk perception 
accuracy. Journal of Genetic Counseling, 18, 217-228. 
 
 508
Smith, A. W., Dougall, A. L., Pusluszny, D. M., Somers, T. J., Rubenstein, W. S., & 
Baum, A. (2008). Psychological distress and quality of life associated with 
genetic testing for breast cancer risk. Psycho-oncology, 17, 767-773. 
Smith, D. (1987). The everyday world as problematic: A feminist sociology. Boston, MA: 
Northeastern University Press. 
Smith, K. E., West, J. A., Croyle, R. T., & Botkin, J. R. (1999). Familial context of 
genetic testing for cancer susceptiblity: Moderating effects of siblings' test results 
on psychological distress one to two weeks after BRCA 1 mutation testing. 
Cancer Epidemiology, Biomarkers & Prevention, 8, 385-392. 
Smith, K. R., Ellington, L., Chan, A. Y., Croyle, R. T., & Botkin, J. R. (2004). Fertility 
intentions following testing for BRCA1 gene mutations. Cancer Epidemiology, 
Biomarkers & Prevention, 13(5), 733-740. 
Smith, P., McGuffog, L., Easton, D. F., Mann, G. J., Pupo, G. M., Newman, B., et al. 
(2006). A genome wide linkage search for breast cancer susceptibility genes. 
Genes, Chromosomes and Cancer, 45(7), 646-655. 
Southey, M. C., Teroriero, A. A., Andersen, C. R., Jennings, K. M., Brown, S. M., Dite, 
G. S., et al. (1999). BRCA1 mutations and other sequence variants in a population-
based sample of Australian women with breast cancer. British Journal of Cancer, 
79(1), 34-39. 
Spielberger, C. D., Gorusch, R. L., & Lushene, R. D. (1970). Manual for the state-trait 




Srivastava, A., McKinnon, W. C., & Wood, M. (2001). Risk of breast and ovarian cancer 
in women with strong family histories. Oncology, 15, 889-902. 
Stefanek, M., Hartmann, L. C., & Nelson, W. (2001). Risk-reduction mastectomy: 
Clinical issues and research needs. Journal of the National Cancer Institute, 93, 
1297-1306. 
Strauss, A., & Corbin, J. (1998). Basics of Qualitative Research: Techniques and 
Procedures for Developing Grounded Theory (2 ed.). Thousand Oaks: Sage. 
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., et al. 
(1997). The risk of cancer associated with specific mutations in BRCA1 and 
BRCA2 among Ashkenazi Jews. New England Journal of Medicine, 336(20), 
1401-1408. 
Struewing, J. P., Lerman, C., Kase, R. G., Giambarresi, T. R., & Tucker, M. A. (1995). 
Anticipated uptake of genetic testing in hereditary breast and ovarian cancer 
families. Cancer Epidemiology, Biomarkers & Prevention, 4, 169-173. 
Suls, J., & Rothman, A. (2004). Evolution of the biopsychosocial model: Prospects and 
challenges for health psychology. Health Psychology, 23(2), 119-125. 
Surbone, A. (2001). Ethical implications of genetic testing for breast cancer 
susceptibility. Critical Reviews in Oncology/Hematology, 40, 149-157. 
Surtees, P., & Wainwright, N. (1999). Surviving adversity: Event decay, vulnerability 
and the onset of anxiety and depressive disorder. European Archives of Psychiatry 
and Clinical Neuroscience, 249, 86-95. 
Suthers, G. K. (2007). Cancer risks for Australian women with a brca1 or brca2 mutation. 
ANZ Journal of Surgery, 77(5), 314-319. 
 
 510
Tambor, E. S., Rimer, B. K., & Strigo, T. S. (1997). Genetic testing for breast cancer 
susceptibility: Awareness and interest among women in the general population. 
American Journal of Medical Genetics, 68, 43-49. 
Temin, S. (2009). American Society of Clinical Oncology clinical practice guideline 
update on the use of pharmacologic interventions including tamoxifen, raloxifene, 
and aromatase inhibition for breast cancer risk reduction. Gynecologic Oncology, 
115(1), 132-134. 
Tercyak, K. P., Hughes, C., Main, D., Snyder, C., Lynch, J. F., Lynch, H. T., et al. 
(2001). Parental communication of BRCA1/2 genetic test results to children. 
Patient Education and Counseling, 42, 213-224. 
Tercyak, K. P., Lerman, C., Peshkin, B. N., Hughes, C., Main, D., Isaacs, C., et al. 
(2001). Effects of coping style and BRCA1 and BRCA2 test results on anxiety 
among women participating in genetic counseling and testing for breast and 
ovarian cancer risk. Health Psychology, 20(3), 217-222. 
Tercyak, K. P., Peshkin, B. N., Brogan, B. M., DeMarco, T., Pennanen, M. F., Wiley, S. 
C., et al. (2007). Quality of life after contralateral prophylactic mastectomy in 
newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene 
testing. Journal of Clinical Oncology, 25, 285-291. 
Tercyak, K. P., Peshkin, B. N., DeMarco, T., Patenaude, A. F., Schneider, K. A., Garber, 
J. E., et al. (2007). Information needs of mothers regarding communicating 




Tercyak, K. P., Peshkin, B. N., DeMarco, T. A., Brogan, B. M., & Lerman, C. (2002). 
Parent-child factors and their effect on communicating BRCA1/2 test results to 
children. Patient Education and Counseling, 47, 145-153. 
Thompson, D., & Easton, D. F. (2002). Cancer incidence in BRCA1 mutation carriers. 
journal of the National Cancer Institute, 94, 1358-1365. 
Thompson, D., Valdimarsdottir, H. B., Duteau-Buck, C., Guevarra, J., Bovbjerg, D. H., 
Richmond-Avellaneda, C., et al. (2002). Psychosocial predictors of BRCA 
counseling and testing decisions among urban African-American women. Cancer 
Epidemiology, Biomarkers & Prevention, 11, 1579-1585. 
Tibben, A., Duivenvoorden, H. J., Niermeijer, M. F., Vegter van der Vlis, M., Roos, R. 
A., & Verhage, F. (1994). Psychological effects of presymptomatic DNA testing 
for Huntington's disease in the Dutch program. Psychosomatic Medicine, 56, 526-
532. 
Tiller, K., Meiser, B., Butow, P., Clifton, M., Thewes, B., Friedlander, M., et al. (2002). 
Psychological impact of prophylactic oophorectomy in women at increased risk of 
developing ovarian cancer: A prospective study. Gynecologic Oncology, 86, 212-
219. 
Trief, P. M., Sandberg, J., Greenberg, R. P., Graff, K., Castronove, N., Yoon, M., et al. 
(2003). Describing support: A qualitative study of couples living with diabetes. 
Families, Systems, & Health, 21, 57-67. 
Valdimarsdottir, H. B., Bovbjerg, D. H., Kash, K. M., Holland, J. C., Osborne, M. P., & 
Miller, D. G. (1995). Psychological distress in women with a familial risk of 
breast cancer. Psycho-oncology, 4, 131-144. 
 
 512
Van Asperen, C. J., Van Dijk, S., Zoeteweij, M. W., Timmermans, D. R., De Bock, G. 
H., Meijers-Heijboer, E. J., et al. (2002). What do women really want to know?  
Motives for attending familial breast cancer clinics. Journal of Medical Genetics, 
39, 410-414. 
van Dijk, S., Otten, W., Zoeteweij, M. W., Timmermans, D. R., Van Asperen, C. J., 
Breuning, M. H., et al. (2003). Genetic counseling and the intention to undergo 
prophylactic mastectomy: Effects of a breast cancer risk assessment. British 
Journal of Cancer, 88, 1675-1681. 
van Oostrom, I., Meijers-Heijboer, E. J., Duivenvoorden, H. J., Brocker-Vriends, A. H. J. 
T., van Asperen, C. J., Sihmonds, R. H., et al. (2007). Prognostic factors for 
hereditary cancer distress six months after BRCA1/2 or HNPCC genetic 
susceptibility testing. European Journal of Cancer, 43, 71-77. 
van Oostrom, I., Meijers-Heijboer, E. J., Lodder, L. N., Duivenvoorden, H. J., van Gool, 
A. R., Seynaeve, C., et al. (2003). Long-term psychological impact of carrying a 
BRCA1/2 mutation and prophylactic surgery: A 5-year follow-up study. Journal 
of Clinical Oncology, 21(20), 3867-3874. 
van Oostrom, I., & Tibben, A. (2004). A counseling model for BRCA1/2 genetic 
susceptibility testing. Hereditary Cancer in Clinical Practice, 2, 5. 
Van Riper, M., & McKinnon, W. C. (2004). Genetic testing for breast and ovarian cancer 




Vernon, S. W., Gritz, E. R., Peterson, S. K., Perz, C. A., Marani, S., Amos, C. I., et al. 
(1999). Intention to learn results of genetic testing for hereditary colon cancer. 
Cancer Epidemiology, Biomarkers & Prevention, 8, 353-360. 
Wagner, T. M. U., Moslinger, R., Langbauer, G., Ahner, R., Fleischmann, E., Auterith, 
A., et al. (2000). Attitude towards prophylactic surgery and effects of genetic 
counseling in families with BRCA mutations. British Journal of Cancer, 82, 
1249-1253. 
Wang, C., Gonzalez, R., Milliron, K. J., Strecher, V. J., & Merajver, S. D. (2005). 
Genetic counseling for BRCA1/2: A randomized controlled trial of two strategies 
to facilitate the education and counseling process. American Journal of Medical 
Genetics, 134A(1), 66-73. 
Watson, M., Foster, C., Eeles, R., Eccles, D., Ashley, S., Davidson, R., et al. (2004). 
Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic 
testing in a UK multi-centre clinical cohort. British Journal of Cancer, 91, 1787-
1794. 
Watson, M., Lloyd, S. M., Davidson, J., Meyer, L., Eeles, R., Ebbs, S., et al. (1999). The 
impact of genetic counselling on risk perception and mental health in women with 
a family history of breast cancer. British Journal of Cancer, 79, 868-874. 
Weber, L. (2006). Reconstructing the landscape of health disparities research: Promoting 
dialogue and collaboration between feminist intersectional and biomedical 
paradigms. In A. Schulz & L. Mullings (Eds.), Gender, race, class and health: 
Intersectional approaches (pp. 21-59). New York: Jossey Bass. 
 
 514
Weihs, K., & Reiss, D. (2000). Family reorganization in response to cancer: A 
developmental perspective. In L. Baider, C. L. Cooper & A. Kaplan De-Nour 
(Eds.), Cancer and the Family (2 ed., pp. 17-39). Chichester: John Wiley & Sons. 
Wellisch, D. K., Gritz, E. R., Schain, W., Wang, H., & Siam, J. (1992). Psychological 
functioning of daughters of breast cancer patients Part ii: Characterising the 
distressed daughter of the breast cancer patients. Psychosomatics, 33, 171-179. 
Wellisch, D. K., & Lindberg, N. (2000). Women at increased risk for breast cancer: 
Family issues, clinical treatment, and research findings. In L. Baider, C. L. 
Cooper & A. Kaplan De-Nour (Eds.), Cancer in the Family (2 ed., pp. 405-423). 
Chichester: John Wiley & Sons. 
Werner-Lin, A. V. (2007). Danger zones: Risk perceptions of young women from 
families with hereditary breast and ovarian cancer. Family Process, 46, 335-349. 
Werner-Lin, A. V. (2008). Beating the biological clock: The compressed family life cycle 
of young women with BRCA gene alterations. Social Work in Health Care, 47(4), 
416-437. 
Werner-Lin, A. V., & Gardner, D. S. (2009). Family illness narratives of inherited cancer 
risk: Continuity and transformation. Families, Systems, & Health, 27(3), 201-212. 
Wertz, D. C., Fanos, J. H., & Reilly, P. R. (1994). Genetic testing for children and 
adolescents: Who decides? Journal of the American Medical Association, 272, 
875-881. 
Whitelaw, S., Northover, J. M., & Hodgson, S. V. (1996). Attitudes to predictive DNA 




Whittemore, A. S., Balise, R. R., Pharoah, P. D. P., DiCioccio, R. A., kConFab, K. C. F. 
C. f. R. i. F. B. C., & Oakley-Girvan, I. (2004). Oral contraceptive use and 
ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. British 
Journal of Cancer, 91, 1911-1915. 
Whittemore, A. S., Gong, G., & Itnyre, J. (1997). Prevalence and contribution of BRCA1 
mutations in breast cancer and ovarian cancer: Results from three US population-
based case-control studies of ovarian cancer. American Journal of Human 
Genetics, 60, 496-504. 
Whittemore, A. S., Harris, R., Intryre, J., & Group, C. O. C. (1992). Characteristics 
relating to ovarian cancer risk: Collaborative analysis of 12 US case-control 
studies. II. Invasive epithelial ovarian cancers in white women. American Journal 
of Epidemiology, 136, 1184-1203. 
Wilson, C. M., & Oswald, A. J. (2005). How does marriage affect physical and 
psychological health? A survey of the longitudinal evidence. Institute of the Study 
of Labor, 1619, 1-29. 
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., et al. (1995). 
Identification of the breast cancer susceptibility gene BRCA2. Nature, 378(6559), 
789-792. 
Zakowski, S. G., Valdimarsdottir, H. B., Bovbjerg, D. H., Borgen, P. I., Holland, J. C., 
Kash, K. M., et al. (1997). Predictors of intrusive thoughts and avoidance in 
women with family histories of breast cancer. Annals of Behavioral Medicine, 
19(4), 362-369. 
 
 
 516
 
